"#",Jurisdiction,Kind,Display Key,Lens ID,Publication Date,Publication Year,Application Number,Application Date,Priority Numbers,Earliest Priority Date,Title,Abstract,Applicants,Inventors,Owners,URL,Document Type,Has Full Text,Cites Patent Count,Cited by Patent Count,Simple Family Size,Extended Family Size,Sequence Count,CPC Classifications,IPCR Classifications,US Classifications,NPL Citation Count,NPL Resolved Citation Count,NPL Resolved Lens ID(s),NPL Resolved External ID(s),NPL Citations,Legal Status
1,WO,A1,WO 2015/161799 A1,185-889-376-698-194,2015-10-29,2015,CN 2015077198 W,2015-04-22,HK 14103785 A;;HK 14110942 A,2014-04-22,A CONTAINER FOR COSMETICS,"A container (100) for use in storing cosmetics products, the container (100) including: at least one platform (130,140) configured for storing a cosmetics product; a housing including a first housing members (110) movably attached to a second housing member (120), said first and second housing members (110,120) being configured for movement relative to each other between at least a first configuration in which the at least one platform (130,140) is substantially enclosed between the first and second housing members, and, a second configuration in which the at least one platform (140) within the housing is exposed; and wherein the at least one platform (130,140) and at least one of the first and second housing members (110,120) form at least a portion of a peripheral edge surface of the container (100); wherein the peripheral edge surface is provided with convex curvature in a direction of from the first housing member (110) towards the second housing member (120); wherein a normal displacement between an axis normal to the peripheral edge surface formed by the at least one platform (130,140) and an axis normal to peripheral edge surface formed by the at least one housing member (110,120) is less than the normal displacement between the axes of the at least one platform (130,140) and the at least one of the first and second housing members (110,120).",NEWCHIC ENTPR LTD,CHENG JENNIFER,,https://lens.org/185-889-376-698-194,Patent Application,yes,7,3,2,3,0,A45D33/20;;A45D33/28;;A45D40/24;;G06Q30/02;;G06Q30/0601,A45D33/20;;A45D40/00;;G06Q30/00,,0,0,,,,PENDING
2,US,S,US D0756566 S,118-647-233-466-415,2016-05-17,2016,US 201429502711 F,2014-09-18,HK 1400522 F,2014-03-21,Container,,NEWCHIC ENTPR LTD,CHENG JENNIFER,NEWCHIC ENTERPRISES LIMITED (2014-09-17),https://lens.org/118-647-233-466-415,Design Right,no,0,2,1,1,0,,,2803;;D28/83,0,0,,,,ACTIVE
3,HK,A2,HK 1212544 A2,020-603-640-097-735,2016-06-10,2016,HK 15103889 A,2015-04-22,HK 14103785 A;;HK 14110942 A;;HK 15103889 A,2014-04-22,A CONTAINER FOR COSMETICS,,NEWCHIC ENTPR LTD,CHENG JENNIFER,,https://lens.org/020-603-640-097-735,Limited Patent,no,0,0,2,3,0,A45D33/20;;A45D33/28;;A45D40/24;;G06Q30/02;;G06Q30/0601,A45D/;;G06Q/,,0,0,,,,INACTIVE
4,HK,A2,HK 1199597 A2,057-922-467-636-328,2015-07-03,2015,HK 14103785 A,2014-04-22,HK 14103785 A,2014-04-22,A CONTAINER FOR COSMETICS,,NEWCHIC ENTPR LTD,CHENG JENNIFER,,https://lens.org/057-922-467-636-328,Limited Patent,no,0,0,1,3,0,,A45D/,,0,0,,,,INACTIVE
5,HK,A2,HK 1171614 A2,048-491-843-747-42X,2013-03-28,2013,HK 12110775 A,2012-10-29,HK 12110775 A,2012-10-29,A MULTIFUNCTIONAL COSMETIC BOX,,GLAMGIRL INTERNAT LTD,CHENG JENNIFER MAN-YUM,,https://lens.org/048-491-843-747-42X,Limited Patent,no,0,0,2,2,0,,A45D/,,0,0,,,,INACTIVE
6,US,A1,US 2020/0323992 A1,019-442-971-779-538,2020-10-15,2020,US 202016912065 A,2020-06-25,US 202016912065 A;;US 201313995415 A;;US 2011/0066510 W;;US 201061425728 P,2010-12-21,MULTI-ARM POLYMERIC PRODRUG CONJUGATES OF PEMETREXED-BASED COMPOUNDS,"Among other aspects, provided herein are multi-arm polymeric prodrug conjugates of pemetrexed-based compounds. Methods of preparing such conjugates as well as methods of administering the conjugates are also provided. Upon administration to a patient, release of the pemetrexed-based compound is achieved.",NEKTAR THERAPEUTICS,CHENG LIN;;RIGGS-SAUTHIER JENNIFER,,https://lens.org/019-442-971-779-538,Patent Application,yes,0,0,9,9,0,A61K47/60;;A61P35/00;;A61K47/60,A61K47/60,,0,0,,,,ACTIVE
7,WO,A1,WO 2012/088282 A1,000-779-280-189-591,2012-06-28,2012,US 2011/0066510 W,2011-12-21,US 201061425728 P,2010-12-21,MULTI-ARM POLYMERIC PRODRUG CONJUGATES OF PEMETREXED-BASED COMPOUNDS,"Among other aspects, provided herein are multi-arm polymeric prodrug conjugates of cabazitaxel-based compounds. Methods of preparing such conjugates as well as methods of administering the conjugates are also provided. Upon administration to a patient, release of the pemetrexed-based compound is achieved.",NEKTAR THERAPEUTICS;;CHENG LIN;;RIGGS-SAUTHIER JENNIFER,CHENG LIN;;RIGGS-SAUTHIER JENNIFER,,https://lens.org/000-779-280-189-591,Patent Application,yes,27,6,9,9,0,A61K47/60;;A61P35/00;;A61K47/60,A61K47/48;;A61P35/00,,31,12,035-433-005-944-857;;077-295-491-167-117;;000-734-409-407-897;;005-712-635-226-116;;104-335-738-580-036;;022-238-533-842-744;;093-509-508-230-620;;120-184-720-533-797;;126-128-839-153-523;;019-394-264-649-327;;063-864-581-855-676;;034-330-993-923-294,17308042;;10.1158/1535-7163.mct-06-0343;;10.1002/0471220574;;11751111;;10.1128/aac.46.1.55-61.2002;;pmc127003;;10.1002/macp.1978.021790204;;6467175;;10.1002/macp.1979.021800528;;436836;;10.1111/j.1432-1033.1979.tb12865.x;;1883529;;10.1016/0003-2697(83)90131-8;;6193731;;10.1007/bf02798546;;4026282;;10.1021/bc00023a002;;8274513;;10.1021/ma00056a005,"ORBAN E ET AL: ""Synthesis, characterization and cytostatic effect of new pemetrexed-peptide conjugates"", JOURNAL OF PEPTIDE SCIENCE; 31ST EUROPEAN PEPTIDE SYMPOSIUM (EPS), JOHN WILEY AND SONS LTD, GB; COPENHAGEN, DENMARK, vol. 16, no. Suppl. 1, 1 September 2010 (2010-09-01), pages 142 - 143, XP008148747, ISSN: 1075-2617, [retrieved on 20100901], DOI: 10.1002/PSC.1303;;S. CHATTOPADHYAY ET AL: ""Pemetrexed: biochemical and cellular pharmacology, mechanisms, and clinical applications"", MOLECULAR CANCER THERAPEUTICS, vol. 6, no. 2, 1 January 2007 (2007-01-01), pages 404 - 417, XP055019381, ISSN: 1535-7163, DOI: 10.1158/1535-7163.MCT-06-0343;;T.W. GREENE; G.M. WUTS: ""Protecting Groups in Organic Synthesis, Third Edition,"", 1999, WILEY;;P.J. KOCIENSKI: ""Protecting Groups, Third Ed.,"", 2003, THIEME CHEMISTRY;;BACCHI, ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, vol. 46, no. 1, 2002, pages 55 - 61;;WONG: ""Chemistry ofProtein Conjugation and Crosslinking"", 1991, CRC PRESS;;BRINKLEY, BIOCONJUG. CHEM., vol. 3, 1992, pages 2013;;""Chemistry and Biological Applications"", 1997, AMERICAN CHEMICAL SOCIETY, article ""Poly(ethylene glycol"";;BUCKMANN ET AL., MAKROMOI.CHEM., vol. 182, 1981, pages 1379;;ZALIPSKY ET AL., EUR. POLYM. J., vol. 19, 1983, pages 1177;;ANDRESZ ET AL., MAKROMOL. CHEM., vol. 179, 1978, pages 301;;OLSON ET AL.: ""Chemistry & Biological Applications"", 1997, ACS, article ""Poly(ethylene glycol"", pages: 170 - 181;;ABUCHOWSKI ET AL., CANCER BIOCHEM. BIOPHYS, vol. 7, 1984, pages 175;;JOPPICH ET AL., MAKROMOL. CHEM., vol. 180, 1979, pages 1381;;PITHA ET AL., EUR. J. BIOCHEM., vol. 94, 1979, pages 11;;ELLING ET AL., BIOTECH. APPL. BIOCHEM., vol. 13, 1991, pages 354;;BEAUCHAMP ET AL., ANAL. BIOCHEM., vol. 131, 1983, pages 25;;TONDELLI ET AL., J. CONTROLLED RELEASE, vol. 1, 1985, pages 251;;VERONESE ET AL., APPL. BIOCHEM. BIOTECH., vol. 11, 1985, pages 141;;SARTORC ET AL., APPL. BIOCHEM. BIOTECH., vol. 27, 1991, pages 45;;HARRIS ET AL., J. POLYM. SCI. CHEM. ED., vol. 22, 1984, pages 341;;GOODSON ET AL., BIOLTECHNOLOGY, vol. 8, 1990, pages 343;;ROMANI ET AL., CHEMISTRY UFPEPTIDES AND PROTEINS, vol. 2, 1984, pages 29;;KOGAN, SYNTHETIC COMM., vol. 22, 1992, pages 2417;;WOGHIREN ET AL., BIOCONJ. CHEM., vol. 4, 1993, pages 314;;SAWHNEY ET AL., MACROMOLECULES, vol. 26, 1993, pages 581;;""Remington: The Science & Practice of Pharmacy,19th ed.,"", 1995, WILLIAMS & WILLIAMS;;""Physician's Desk Reference,52nd ed.,"", 1998, MEDICAL ECONOMICS;;A.H. KIBBE,: ""Handbook of Pharmaceutical Excipients,"" Third Ed."", 2000, PHARMACEUTICAL PRESS;;M. B. SMITH; J. MARCH: ""March's Advanced Organic Chemistry: Reactions Mechanisms and Structure,6th Ed."", 2007, WILEY-INTERSCIENCE;;""A Comprehensive Review of the Synthetic Literature"", vol. 1-7, 1995, ELSEVIER SCIENCE, article ""Comprehensive Organic Functional Group Transformations II""",PENDING
8,EP,A1,EP 2654795 A1,132-671-003-132-505,2013-10-30,2013,EP 11806114 A,2011-12-21,US 201061425728 P;;US 2011/0066510 W,2010-12-21,MULTI-ARM POLYMERIC PRODRUG CONJUGATES OF PEMETREXED-BASED COMPOUNDS,,NEKTAR THERAPEUTICS,CHENG LIN;;RIGGS-SAUTHIER JENNIFER,,https://lens.org/132-671-003-132-505,Patent Application,yes,0,0,9,9,0,A61K47/60;;A61P35/00;;A61K47/60,A61K47/60;;A61P35/00,,0,0,,,,ACTIVE
9,EP,B1,EP 2654795 B1,100-705-793-678-319,2018-03-07,2018,EP 11806114 A,2011-12-21,US 201061425728 P;;US 2011/0066510 W,2010-12-21,MULTI-ARM POLYMERIC PRODRUG CONJUGATES OF PEMETREXED-BASED COMPOUNDS,,NEKTAR THERAPEUTICS,CHENG LIN;;RIGGS-SAUTHIER JENNIFER,,https://lens.org/100-705-793-678-319,Granted Patent,yes,5,0,9,9,0,A61K47/60;;A61P35/00;;A61K47/60,A61K47/60;;A61P35/00,,2,0,,,"ORBAN E ET AL: ""Synthesis, characterization and cytostatic effect of new pemetrexed-peptide conjugates"", JOURNAL OF PEPTIDE SCIENCE; 31ST EUROPEAN PEPTIDE SYMPOSIUM (EPS), JOHN WILEY AND SONS LTD, GB; COPENHAGEN, DENMARK, vol. 16, no. Suppl. 1, 1 September 2010 (2010-09-01), pages 142-143, XP008148747, ISSN: 1075-2617, DOI: 10.1002/PSC.1303 [retrieved on 2010-09-01];;S. CHATTOPADHYAY ET AL: ""Pemetrexed: biochemical and cellular pharmacology, mechanisms, and clinical applications"", MOLECULAR CANCER THERAPEUTICS, vol. 6, no. 2, 1 January 2007 (2007-01-01) , pages 404-417, XP55019381, ISSN: 1535-7163, DOI: 10.1158/1535-7163.MCT-06-0343",ACTIVE
10,US,S,US D0823795 S,111-990-873-320-178,2018-07-24,2018,US 201729590489 F,2017-01-11,US 201729590489 F,2017-01-11,Mobile power bank,,DATAPLUS SUPPLIES INC,HSIAO JENNIFER;;HUANG CHENG-LUN,DATAPLUS SUPPLIES INC (2016-12-15),https://lens.org/111-990-873-320-178,Design Right,no,0,1,1,1,0,,,1302;;D13/108;;D13/103,0,0,,,,ACTIVE
11,US,B2,US 11612662 B2,162-361-778-116-054,2023-03-28,2023,US 202016912065 A,2020-06-25,US 202016912065 A;;US 201313995415 A;;US 2011/0066510 W;;US 201061425728 P,2010-12-21,Multi-arm polymeric prodrug conjugates of pemetrexed-based compounds,"Among other aspects, provided herein are multi-arm polymeric prodrug conjugates of pemetrexed-based compounds. Methods of preparing such conjugates as well as methods of administering the conjugates are also provided. Upon administration to a patient, release of the pemetrexed-based compound is achieved.",NEKTAR THERAPEUTICS,CHENG LIN;;RIGGS-SAUTHIER JENNIFER,,https://lens.org/162-361-778-116-054,Granted Patent,yes,32,0,9,9,0,A61K47/60;;A61P35/00;;A61K47/60,A61K47/60,,44,18,053-074-009-249-000;;104-335-738-580-036;;005-712-635-226-116;;000-734-409-407-897;;031-087-568-760-731;;035-433-005-944-857;;120-184-720-533-797;;066-146-798-965-262;;084-334-167-693-45X;;022-238-533-842-744;;141-920-816-342-666;;007-181-598-202-221;;093-509-508-230-620;;051-315-531-263-042;;099-270-483-107-007;;019-394-264-649-327;;063-864-581-855-676;;010-030-039-052-116,10.1007/s00044-008-9144-x;;6467175;;10.1002/macp.1978.021790204;;11751111;;10.1128/aac.46.1.55-61.2002;;pmc127003;;10.1021/bc00013a001;;1616945;;17308042;;10.1158/1535-7163.mct-06-0343;;1883529;;1366535;;10.1038/nbt0490-343;;10.1002/pol.1984.170220207;;10.1002/macp.1979.021800528;;10.1080/00397919208019100;;10.1021/bk-1997-0680.ch012;;436836;;10.1111/j.1432-1033.1979.tb12865.x;;10.1007/bf02921514;;2024978;;10.1016/0168-3659(85)90001-x;;10.1007/bf02798546;;4026282;;10.1021/bc00023a002;;8274513;;10.1016/0014-3057(83)90016-2,"Tao Min, Bixin Yi, Peng Zhang, Jun Liu, Can Zhang, Huiping Zhou, Novel furoxan No-donor pemetrexed derivatives: design, synthesis, and preliminary biological evaluation, Med Chem Res (2009) 18:495-510 (Year: 2009).;;Abuchowski, et al., “Cancer Therapy with Chemically Modified Enzymes. I. Antitumor Properties of Polyethylene Glycol-Asparaginase Conjugates,” Cancer Biochem. Biophys., vol. 7, pp. 175-186, (1984).;;Andresz, et al., Chemische Synthese verzweigter Polysaccharide, 5*), Makromol. Chem., vol. 179, pp. 301-312, (1978).;;Bacchi, et al., “Novel Synthetic Polyamines Are Effective in the Treatment of Experimental Microsporidiosis, an Opportunistic AIDS-Associated Infection,” Antimicrobial Agents and Chemotherapy, vol. 46, No. 1, pp. 55-61, (2002).;;Beauchamp, et al., “A New Procedure for the Synthesis of Polyethylene Glycol-Protein Adducts; Effects on Function, Receptor Recognition, and Clearance of Superoxide Dismutase, Lactoferrin, and α2-Macroglobulin,” Analytical Biochemistry, vol. 131, pp. 25-33, (1983).;;Brinkley, “A Brief Survey of Methods for Preparing Protein Conjugates with Dyes, Haptens, and Cross-Linking Reagents,” Bioconjugate Chemistry, vol. 3, pp. 2-13, (1992).;;Buckmann, et al., “Functionalization of Poly(ethylene glycol) and Monomethoxy-Poly(ethylene glycol),” Makromol. Chem., vol. 182, pp. 1379-1384, (1981).;;Chattopadhyay, et al., “Pemetrexed: biochemical and cellular pharmacology, mechanisms, and clinical applications,” Molecular Cancer Therapeutics, vol. 6, No. 2, pp. 404-417, (2007).;;Elling, et al., “Immunoaffinity Partitioning: Synthesis and Use of Polyethylene Glycol-Oxirane for Coupling to Bovine Serum Albumin and Monoclonal Antibodies,” Biotechnology and Applied Biochemistry, vol. 13, pp. 354-362, (1991).;;Goodson, et al., “Site-Directed Pegylation of Recombinant Interleukin-2 at Its Glycosylation Site,” Bio/Technology, vol. 8, pp. 343-346, (1990).;;Harris, et al., “Synthesis and Characterization of Poly(ethylene Glycol) Derivatives,”, Journal of Polymer Science: Polymer Chemistry Edition, vol. 22, pp. 341-352, (1984).;;Joppich, et al., “Peptides Flanked by Two Polymer Chains, 1 Synthesis of Glycyl-L-tryptophylglycine Substituted by Poly(ethylene oxide) at both the Carboxy and the Amino End Groups,” Makromol. Chem., vol. 180, pp. 1381-1384, (1979).;;Kogan, “The Synthesis of Substituted Methoxy-Poly(EthyleneGlycol) Derivatives Suitable for Selective Protein Modification,” Synthetic Communications, vol. 22, No. 16, pp. 2417-2424, (1992).;;Olson, et al., “Preparation and Characterization of Poly(ethylene glycol)ylated Human Growth Hormone Antagonist,” American Chemical Society, Chapter 12 (Chapter DOI: 10.1021/bk-1997-0680.ch012), pp. 170-181, (1997).;;Orban, et al., “Synthesis, characterization and cytostatic effect of new pemetrexed-peptide conjugates,” Journal of Peptide Science; 31st European Peptide Symposium (EPS), John Wiley and Sons LTD, GB; Copenhagen, Denmark, vol. 16, No. Suppl. 1, pp. 142-143, (2010), P299. Abstract No. 195.;;Pitha, et al., “Detergents Linked to Polysaccharides: Preparation and Effects on Membranes and Cells,” Eur. J. Biochem., vol. 94, pp. 11-18, (1979).;;Romani, et al., “Synthesis of Unsymmetrical Cystine Peptides: Directed Disulfide Pairing with the Sulfenohydrazide Method,” Chemistry of Peptides and Proteins, vol. 2, pp. 29-34, (1984).;;Sartore, et al., “Enzyme Modification by MPEG with an Amino Acid or Peptide as Spacer Arms,”, Applied Biochemistry and Biotechnology, vol. 27, pp. 45-54, (1991).;;Sawhney, et al., “Bioerodible Hydrogels Based on Photopolymerized Poly(ethylene glycol)-co-poly(α-hydroxy acid) Diacrylate Macromers,” Macromolecules, vol. 26, pp. 581-587, (1993).;;Tondelli, et al., “Poly(Ethylene Glycol) Imidazolyl Formates as Oligomeric Drug-Binding Matrices,” Journal of Controlled Release, vol. 1, pp. 251-257, (1985).;;Veronese, et al., “Surface Modification of Proteins, Activation of Monomethoxy-Polyethylene Glycols by Phenylchloroformates and Modification of Ribonuclease and Superoxide Dismutase,” Applied Biochemistry and Biotechnology, vol. 11, pp. 141-152, (1985).;;Woghiren, et al., “Protected Thiol-Polyethylene Glycol: A New Activated Polymer for Reversible Protein Modification,” Bioconjugate Chem., vol. 4, pp. 314-318, (1993).;;Zalipsky, et al., “Attachment of Drugs to Polyethylene Glycols,” Eur. Polym. J., vol. 19, No. 12, pp. 1177-1183, (1983).;;PCT International Search Report and Written Opinion corresponding to PCT International Application No. PCT/US2011/066510 dated Feb. 24, 2012.;;PCT International Preliminary Report on Patentability corresponding to PCT International Application No. PCT/US2011/066510 dated Jul. 4, 2013.;;Enzon Pharmaceuticals, Macromolecular Engineering Technologies, 16 pages, (2004).;;Nektar™—Transforming Therapeutics, Nektar Molecule Engineering: Polyethylene Glycol and Derivatives for Advanced PEGylation, 24 pages, Catalog—2003, (Jul. 2003).;;Nektar™—Transforming Therapeutics, Nektar Advanced PEGylation: Polyethylene Glycol and Derivatives for Advanced PEGylation, 27 pages, Catalog—2004, (Jul. 2004).;;Nektar™—Transforming Therapeutics, Nektar Advanced PEGylation: Polyethylene Glycol and Derivatives for Advanced PEGylation, 33 pages, (Catalog 2005-2006).;;NOF Corporation, PEG Derivatives, Phospholipid and Drug Delivery Materials for Pharmaceuticals, 46 pages, Catalogue 2003-1st, (Jan. 2003).;;NOF Corporation, PEG Derivatives, Phospholipid and Drug Delivery Materials for Pharmaceuticals, 27 pages, Catalogue 2003-2nd, (Mar. 2004).;;NOF Corporation, PEG Derivatives, Phospholipids and Drug Delivery Materials for Pharmaceutical Products and Formulations, 60 pages, Catalogue Ver. 8, (Apr. 2006).;;Polypure Products, PEG amines; PEG acids and amino acids; PEG thiols and disulfides; Biotins, 5 pages, (Apr. 2004).;;Polypure Products, PEG amines; PEG acids and amino acids; PEG thiols and disulfides; Biotins, 5 pages, (Apr. 2005).;;Quanta Biodesign, Labeling, Derivatization and Crosslinking Reagents for Biological and Related Materials with dPEG™, 38 pages, (Mar. 12, 2004).;;Quanta Biodesign, Labeling, Modification and Crosslinking Reagents incorporating our unique monodispersed dPEG™ Technology, 31 pages, (Nov. 5, 2004).;;Quanta Biodesign, Ltd., Leading innovator, producer and provider of monodisperse discrete PEG™ (dPEG™) derivatives, (Product Catalog), 26 pages, (Updated: Jul. 18, 2005).;;Quanta Biodesign, Ltd., Leading innovator, producer and provider of monodisperse discrete PEG™ (dPEG™) derivatives, (Product Catalog), 26 pages, (Updated: Nov. 17, 2005).;;Shearwater Polymers, Inc., Polyethylene Glycol Derivatives, 50 pages, Catalog—(Mar. 1995).;;Shearwater Polymers, Inc., Polyethylene Glycol Derivatives, 55 pages, Catalog 1997-1998, (Jul. 1997).;;Shearwater Polymers, Inc., Polyethylene Glycol and Derivatives: Functionalized Biocompatible Polymers for Research and Pharmaceuticals, 50 pages, Catalog—(Jan. 2000).;;Shearwater Corporation, Polyethylene Glycol and Derivatives for Biomedical Applications, 20 pages, Catalog—(Jul. 2001).;;Communication pursuant to Art. 94(3) EPC in European Pat. Appl. No. 11806114.2-1453 dated Jul. 8, 2016.;;English Translation of Japanese Notice of Reasons for Rejection in Japanese Patent Application No. 2013-546374 dated Aug. 24, 2015.",ACTIVE
12,US,B2,US 10736969 B2,184-225-220-329-650,2020-08-11,2020,US 201113995415 A,2011-12-21,US 201113995415 A;;US 201061425728 P;;US 2011/0066510 W,2010-12-21,Multi-arm polymeric prodrug conjugates of pemetrexed-based compounds,"Among other aspects, provided herein are multi-arm polymeric prodrug conjugates of pemetrexed-based compounds. Methods of preparing such conjugates as well as methods of administering the conjugates are also provided. Upon administration to a patient, release of the pemetrexed-based compound is achieved.",CHENG LIN;;RIGGS-SAUTHIER JENNIFER;;NEKTAR THERAPEUTICS,CHENG LIN;;RIGGS-SAUTHIER JENNIFER,NEKTAR THERAPEUTICS (2012-02-24),https://lens.org/184-225-220-329-650,Granted Patent,yes,30,0,9,9,0,A61K47/60;;A61P35/00;;A61K47/60,A61K47/60,,43,17,104-335-738-580-036;;005-712-635-226-116;;000-734-409-407-897;;031-087-568-760-731;;035-433-005-944-857;;120-184-720-533-797;;066-146-798-965-262;;084-334-167-693-45X;;022-238-533-842-744;;141-920-816-342-666;;007-181-598-202-221;;093-509-508-230-620;;051-315-531-263-042;;099-270-483-107-007;;019-394-264-649-327;;063-864-581-855-676;;010-030-039-052-116,6467175;;10.1002/macp.1978.021790204;;11751111;;10.1128/aac.46.1.55-61.2002;;pmc127003;;10.1021/bc00013a001;;1616945;;17308042;;10.1158/1535-7163.mct-06-0343;;1883529;;1366535;;10.1038/nbt0490-343;;10.1002/pol.1984.170220207;;10.1002/macp.1979.021800528;;10.1080/00397919208019100;;10.1021/bk-1997-0680.ch012;;436836;;10.1111/j.1432-1033.1979.tb12865.x;;10.1007/bf02921514;;2024978;;10.1016/0168-3659(85)90001-x;;10.1007/bf02798546;;4026282;;10.1021/bc00023a002;;8274513;;10.1016/0014-3057(83)90016-2,"English Translation of Japanese Notice of Reasons for Rejection in Japanese Patent Application No. 2013-546374 dated Aug. 24, 2015.;;Abuchowski, et al., “Cancer Therapy with Chemically Modified Enzymes. I. Antitumor Properties of Polyethylene Glycol-Asparaginase Conjugates,” Cancer Biochem. Biophys., vol. 7, pp. 175-186, (1984).;;Andresz, et al., Chemische Synthese verzweigter Polysaccharide, 5*), Makromol. Chem., vol. 179, pp. 301-312, (1978).;;Bacchi, et al., “Novel Synthetic Polyamines are Effective in the Treatment of Experimental Microsporidiosis, an Opportunistic AIDS-Associated Infection,” Antimicrobial Agents and Chemotherapy, vol. 46, No. 1, pp. 55-61, (2002).;;Beauchamp, et al., “A New Procedure for the Synthesis of Polyethylene Glycol-Protein Adducts; Effects on Function, Receptor Recognition, and Clearance of Superoxide Dismutase, Lactoferrin, and α2-Macroglobulin,” Analytical Biochemistry, vol. 131, pp. 25-33, (1983).;;Brinkley, “A Brief Survey of Methods for Preparing Protein Conjugates with Dyes, Haptens, and Cross-Linking Reagents,” Bioconjugate Chemistry, vol. 3, pp. 2-13, (1992).;;Buckmann, et al., “Functionalization of Poly(ethylene glycol) and Monomethoxy-Poly(ethylene glycol),” Makromol. Chem., vol. 182, pp. 1379-1384, (1981).;;Chattopadhyay, et al., “Pemetrexed: biochemical and cellular pharmacology, mechanisms, and clinical applications,” Molecular Cancer Therapeutics, vol. 6, No. 2, pp. 404-417, (2007).;;Elling, et al., “Immunoaffinity Partitioning: Synthesis and Use of Polyethylene Glycol-Oxirane for Coupling to Bovine Serum Albumin and Monoclonal Antibodies,” Biotechnology and Applied Biochemistry, vol. 13, pp. 354-362, (1991).;;Goodson, et al., “Site-Directed Pegylation of Recombinant Interleukin-2 at Its Glycosylation Site,” Bio/Technology, vol. 8, pp. 345-346, (1990).;;Harris, et al., “Synthesis and Characterization of Poly(ethylene Glycol) Derivatives,”, Journal of Polymer Science: Polymer Chemistry Edition, vol. 22, pp. 341-352, (1984).;;Joppich, et al., “Peptides Flanked by Two Polymer Chains, 1 Synthesis of Glycyl-L-tryptophylglycine Substituted by Poly(ethylene oxide) at both the Carboxy and the Amino End Groups,” Makromol. Chem., vol. 180, pp. 1381-1384, (1979).;;Kogan, “The Synthesis of Substituted Methoxy-Poly(EthyleneGlycol) Derivatives Suitable for Selective Protein Modification,” Synthetic Communications, vol. 22, No. 16, pp. 2417-2424, (1992).;;Olson, et al., “Preparation and Characterization of Poly(ethylene glycol)ylated Human Growth Hormone Antagonist,” American Chemical Society, Chapter 12 (Chapter DOI: 10.1021/bk-1997-0680.ch012), pp. 170-181, (1997).;;Orban, et al., “Synthesis, characterization and cytostatic effect of new pemetrexed-peptide conjugates,” Journal of Peptide Science; 31st European Peptide Symposium (EPS), John Wiley and Sons LTD, GB; Copenhagen, Denmark, vol. 16, No. Suppl. 1, pp. 142-143, (2010), p. 299. Abstract No. 195.;;Pitha, et al., “Detergents Linked to Polysaccharides: Preparation and Effects on Membranes and Cells,” Eur. J. Biochem., vol. 94, pp. 11-18, (1979).;;Romani, et al., “Synthesis of Unsymmetrical Cystine Peptides: Directed Disulfide Pairing with the Sulfenohydrazide Method,” Chemistry of Peptides and Proteins, vol. 2, pp. 29-34, (1984).;;Sartore, et al., “Enzyme Modification by MPEG with an Amino Acid or Peptide as Spacer Arms,”, Applied Biochemistry and Biotechnology, vol. 27, pp. 45-54, (1991).;;Sawhney, et al., “Bioerodible Hydrogels Based on Photopolymerized Poly(ethylene glycol)-co-poly(α-hydroxy acid) Diacrylate Macromers,” Macromolecules, vol. 26, pp. 581-587, (1993).;;Tondelli, et al., “Poly(Ethylene Glycol) Imidazolyl Formates as Oligomeric Drug-Binding Matrices,” Journal of Controlled Release, vol. 1, pp. 251-257, (1985).;;Veronese, et al., “Surface Modification of Proteins, Activation of Monomethoxy-Polyethylene Glycols by Phenylchloroformates and Modification of Ribonuclease and Superoxide Dismutase,” Applied Biochemistry and Biotechnology, vol. 11, pp. 141-152, (1985).;;Woghiren, et al., “Protected Thiol-Polyethylene Glycol: A New Activated Polymer for Reversible Protein Modification,” Bioconjugate Chem., vol. 4, pp. 314-318, (1993).;;Zalipsky, et al., “Attachment of Drugs to Polyethylene Glycols,” Eur. Polym. J., vol. 19, No. 12, pp. 1177-1183, (1983).;;PCT International Search Report and Written Opinion corresponding to PCT International Application No. PCT/US2011/066510 dated Feb. 24, 2012.;;PCT International Preliminary Report on Patentability corresponding to PCT International Application No. PCT/US2011/066510 dated Jul. 4, 2013.;;Enzon Pharmaceuticals, Macromolecular Engineering Technologies, 16 pages, (2004).;;Nektar™—Transforming Therapeutics, Nektar Molecule Engineering: Polyethylene Glycol and Derivatives for Advanced PEGylation, 24 pages, Catalog—2003, (Jul. 2003).;;Nektar™—Transforming Therapeutics, Nektar Advanced PEGylation: Polyethylene Glycol and Derivatives for Advanced PEGylation, 27 pages, Catalog—2004, (Jul. 2004).;;Nektar™—Transforming Therapeutics, Nektar Advanced PEGylation: Polyethylene Glycol and Derivatives for Advanced PEGylation, 33 pages, (Catalog 2005-2006).;;Nof Corporation, PEG Derivatives, Phospholipid and Drug Delivery Materials for Pharmaceuticals, 46 pages, Catalogue 2003-1st, (Jan. 2003).;;Nof Corporation, PEG Derivatives, Phospholipid and Drug Delivery Materials for Pharmaceuticals, 27 pages, Catalogue 2003-2nd, (Mar. 2004).;;Nof Corporation, PEG Derivatives, Phospholipids and Drug Delivery Materials for Pharmaceutical Products and Formulations, 60 pages, Catalogue Ver. 8, (Apr. 2006).;;Polypure Products, PEG amines; PEG acids and amino acids; PEG thiols and disulfides; Biotins, 5 pages, (Apr. 2004).;;Polypure Products, PEG amines; PEG acids and amino acids; PEG thiols and disulfides; Biotins, 5 pages, (Apr. 2005).;;Quanta Biodesign, Labeling, Derivatization and Crosslinking Reagents for Biological and Related Materials with dPEG™, 38 pages, (Mar. 12, 2004).;;Quanta Biodesign, Labeling, Modification and Crosslinking Reagents incorporating our unique monodispersed dPEG™ Technology, 31 pages, (Nov. 5, 2004).;;Quanta Biodesign, Ltd., Leading innovator, producer and provider of monodisperse discrete PEG™ (dPEG™) derivatives, (Product Catalog), 26 pages, (Updated: Jul. 18, 2005).;;Quanta Biodesign, Ltd., Leading innovator, producer and provider of monodisperse discrete PEG™ (dPEG™) derivatives, (Product Catalog), 26 pages, (Updated: Nov. 17, 2005).;;Shearwater Polymers, Inc., Polyethylene Glycol Derivatives, 50 pages, Catalog—(Mar. 1995).;;Shearwater Polymers, Inc., Polyethylene Glycol Derivatives, 55 pages, Catalog 1997-1998, (Jul. 1997).;;Shearwater Polymers, Inc., Polyethylene Glycol and Derivatives: Functionalized Biocompatible Polymers for Research and Pharmaceuticals, 50 pages, Catalog—(Jan. 2000).;;Shearwater Corporation, Polyethylene Glycol and Derivatives for Biomedical Applications, 20 pages, Catalog—(Jul. 2001).;;Communication pursuant to Art. 94(3) EPC in European pat. appl. No. 11806114.2-1453 dated Jul. 8, 2016.",ACTIVE
13,US,S,US D0823794 S,072-879-981-456-162,2018-07-24,2018,US 201729590486 F,2017-01-11,US 201729590486 F,2017-01-11,Mobile power bank,,DATAPLUS SUPPLIES INC,HSIAO JENNIFER;;HUANG CHENG-LUN,DATAPLUS SUPPLIES INC (2016-12-15),https://lens.org/072-879-981-456-162,Design Right,no,0,0,1,1,0,,,1302;;D13/108;;D13/103,0,0,,,,ACTIVE
14,US,A1,US 2024/0062151 A1,040-413-296-755-417,2024-02-22,2024,US 202217889462 A,2022-08-17,US 202217889462 A,2022-08-17,SUPPLY CHAIN DISRUPTION PREDICTIONS,"Disclosed embodiments include aspects that relate to supply chain disruption predictions. An individual can identify a product. Product information associated with the product can be compiled and analyzed to determine the composition of the product. Raw material can be identified as part of the product's composition based on the product information analysis. Disruption data for a supply chain of the at least one raw material can be compiled and analyzed. A supply chain disruption can be identified based on the analysis of the disruption data. A transaction can be recommended to the customer based on the supply chain disruption, such as an optimized timing to purchase the product.",CAPITAL ONE SERVICES LLC,ZHU XIAOGUANG;;CHENG RAY;;KWOK JENNIFER,,https://lens.org/040-413-296-755-417,Patent Application,yes,0,0,1,1,0,G06Q10/087;;G06Q30/0635;;G06Q30/0206,G06Q10/08;;G06Q30/02;;G06Q30/06,,0,0,,,,PENDING
15,US,A1,US 2023/0419375 A1,036-106-792-353-025,2023-12-28,2023,US 202217846148 A,2022-06-22,US 202217846148 A,2022-06-22,DEMAND EQUILIBRIUM BASED PRICING,Disclosed aspects pertain to demand-equilibrium-based pricing. Transaction data associated with a merchant can be utilized to generate and train a pricing model. The pricing model can be invoked to determine a pricing schedule for a set of items offered by the merchant. The pricing schedule can set prices of items based on the time of day and the transaction rate of the merchant. The pricing schedule can be implemented with the merchant through a digital display. The pricing schedule can also be updated such that prices for the items offered by the merchant can change based on the time of day to achieve a target transaction rate through the merchant's business hours.,CAPITAL ONE SERVICES LLC,CHENG RAY;;KWOK JENNIFER;;ZHU XIAOGUANG,CAPITAL ONE SERVICES LLC (2022-03-25),https://lens.org/036-106-792-353-025,Patent Application,yes,0,0,1,1,0,G06Q30/0201;;G06Q30/0269;;G06Q30/0284;;G06Q30/0206;;G06Q30/0283;;G06Q30/0284;;G06Q30/0269;;G06Q30/0201,G06Q30/02,,0,0,,,,PENDING
16,CN,A,CN 102551800 A,100-708-895-948-15X,2012-07-11,2012,CN 201110373809 A,2011-11-10,US 94357210 A,2010-11-10,Method and system for displaying ultrasound data,"Methods and systems for displaying ultrasound data are provided. One method (50) includes acquiring (5) ultrasound image data and physiological monitoring data during an ultrasound imaging scan, generating (56) quantitative ultrasound data from the acquired ultrasound image data and correlating (60) the quantitative ultrasound data with the physiological monitoring data. The method also includes displaying (62) the correlated quantitative ultrasound data and physiological monitoring data time aligned on a display.",GEN ELECTRIC,JENNIFER MARTIN;;HOW NG GARY CHENG,,https://lens.org/100-708-895-948-15X,Patent Application,no,4,3,3,3,0,A61B8/4405;;A61B8/4427;;A61B8/463;;A61B8/488;;A61B8/5207;;A61B8/5223;;A61B8/5246;;A61B5/318;;A61B8/463;;A61B8/4427;;A61B8/5223;;A61B8/5207;;A61B8/4405;;A61B8/488;;A61B8/5246,A61B8/00,,0,0,,,,ACTIVE
17,CA,A1,CA 3091397 A1,031-171-932-365-669,2019-09-06,2019,CA 3091397 A,2018-07-11,US 201815909968 A;;CA 2018050843 W,2018-03-01,OLED MICROCAVITY DESIGN AND OPTIMIZATION METHOD,"Control of the emission characteristics of a light source in a light field display poses a significant benefit in the resulting 3D display quality for current and future technologies. A design system for microcavity OLEDs of any wavelength is detailed, which combines theoretical background with FDTD optimizations, permitting microcavity design of any OLED configuration. The resulting output profiles for microcavity OLEDs designed and fabricated with this method are compared to standard OLEDs and provide a reduction in spectral bandwidth, and a decrease in angular output.",AVALON HOLOGRAPHICS INC,CAMPBELL JENNIFER;;CHENG JIAQI;;PECKHAM JORDAN,,https://lens.org/031-171-932-365-669,Patent Application,no,0,0,12,12,0,G06F2111/10;;G06F30/23;;H10K50/852;;H10K50/856;;G06F30/23;;G06F2111/10;;H10K50/852;;H10K50/856;;H10K71/00;;G06F30/23;;G06F2111/10;;H10K50/852;;H10K50/856;;H10K71/00,H01L51/52;;H01L33/10;;H01L51/54;;H01L51/56,,0,0,,,,PENDING
18,US,A1,US 2022/0340683 A1,138-403-685-348-529,2022-10-27,2022,US 202117547101 A,2021-12-09,US 202117547101 A;;US 202117203650 A;;US 202063074956 P;;US 202063037374 P;;US 202062990927 P,2020-03-17,ANTI-GLYCAN ANTIBODIES AND USES THEREOF,"The present disclosure provides antibodies, or an antigen binding portion thereof, that bind to sLeA and sLeC, as well as polynucleotides, vectors, host cells, pharmaceutical compositions, and methods related thereto.",PTM THERAPEUTICS INC,PRESTA LEONARD;;LIANG TONY;;CHENG JENNIFER,PTM THERAPEUTICS INC (2021-03-18),https://lens.org/138-403-685-348-529,Patent Application,yes,0,0,10,10,19,C07K16/3076;;C07K2317/24;;C07K2317/92;;C07K2317/33;;A61K2039/505;;C07K16/3076;;A61P1/00;;C07K2317/92;;C07K2317/24;;C07K2317/33;;A61K2039/505;;A61P1/00;;A61K2039/505;;C07K16/3076;;C07K2317/24;;C07K2317/92,C07K16/30;;A61P1/00,,0,0,,,,PENDING
19,US,B2,US 11230608 B2,028-518-069-054-852,2022-01-25,2022,US 202117203650 A,2021-03-16,US 202117203650 A;;US 202062990927 P;;US 202063037374 P;;US 202063074956 P,2020-03-17,Anti-glycan antibodies and uses thereof,"The present disclosure provides antibodies, or an antigen binding portion thereof, that bind to sLeA and sLeC, as well as polynucleotides, vectors, host cells, pharmaceutical compositions, and methods related thereto.",PTM THERAPEUTICS INC,PRESTA LEONARD;;LIANG TONY;;CHENG JENNIFER,PTM THERAPEUTICS INC (2021-03-18),https://lens.org/028-518-069-054-852,Granted Patent,yes,1,0,10,10,19,C07K16/3076;;C07K2317/24;;C07K2317/92;;C07K2317/33;;A61K2039/505;;C07K16/3076;;A61P1/00;;C07K2317/92;;C07K2317/24;;C07K2317/33;;A61K2039/505;;A61P1/00;;A61K2039/505;;C07K16/3076;;C07K2317/24;;C07K2317/92,C07K16/00;;A61K39/00;;A61P1/00;;C07K16/30,,23,22,051-208-529-712-079;;051-269-283-291-575;;007-878-026-763-074;;030-193-380-221-317;;064-902-371-894-483;;008-934-157-847-366;;106-984-359-376-070;;122-664-349-677-416;;049-338-980-380-236;;005-791-137-400-140;;008-587-496-850-953;;021-335-288-836-495;;026-418-623-750-230;;028-216-202-844-164;;072-361-911-644-401;;062-073-374-849-444;;084-365-760-482-815;;021-430-782-622-770;;065-430-968-783-392;;051-940-176-386-905;;036-754-205-253-78X;;078-676-868-469-381,17981654;;10.2741/2786;;10.1016/s0065-3233(08)60488-x;;8908297;;pmc2271163;;10.1110/ps.073347208;;18359855;;11238107;;10.1182/blood.v97.6.1679;;10.1093/nar/gki460;;pmc1160221;;15980448;;10.1002/ijc.2910320305;;6885183;;20974992;;pmc3145322;;10.4049/jimmunol.1001293;;10.4049/jimmunol.1301307;;pmc4047976;;24068663;;10.1038/nrd1751;;15931257;;10.1038/nrc1649;;16069816;;886304;;10.1099/0022-1317-36-1-59;;26033938;;10.1093/glycob/cwv037;;20073133;;pmc2726606;;10.4161/mabs.1.4.9122;;10.1096/fasebj.2019.33.1_supplement.34.4;;pmc7406298;;32427587;;10.1172/jci.insight.135843;;94699;;10.1007/bf01542654;;7209516;;10.1126/science.7209516;;10.1111/j.1749-6632.1982.tb23161.x;;7046561;;10.1095/biolreprod23.1.243;;6774781;;10.1073/pnas.77.7.4216;;pmc349802;;6933469;;10.1053/j.gastro.2021.01.136;;10.1093/ibd/izaa347.090,"Almagro & Fransson, Frontiers in Bioscience 2008; 13:1619-33 (Year: 2008).;;Padlan (Advances in Protein Chemistry, 1996, 49:57-133) (Year: 1996).;;Berglund et al, Protein Science, 2008, 17:606-613 (Year: 2008).;;Corada (Blood, 2001; 97:1679-84) (Year: 2001).;;Kulkarni-Kale et al. Nucleic Acid Research, 2005, 33:W168-W171 (Year: 2005).;;Arends et al., (1983). “Monoclonal Antibody (1116 NS 19-9) Defined Monosialoganglioside (Gica) in Colorectal Carcinoma in Relation to Stage, Histopathology and DNA Flow Cytometry,” Int. J. Cancer, 32:289-293.;;Brazil et al., (2010). “Neutrophil Migration across Intestinal Epithelium: Evidence for a Role of CD44 in Regulating Detachment of Migrating Cells from the Luminal Surface,” J Immunol, 185:7026-2036.;;Brazil et al., (2013). “alpha3/4 Fucosyltransferase 3-Dependent Synthesis of Sialyl Lewis A on CD44 Variant Containing Exon 6 Mediates Polymorphonuclear Leukocyte Detachment from Intestinal Epithelium during Transepithelial Migration,” J Immunol, 191:4804-4817.;;Dube et al., (2005). “Glycans in cancer and inflammation—potential for therapeutics and diagnostics,” Nat Rev Drug Discovery, 4:477-88.;;Fuster et al., (2005). “The sweet and sour of cancer: glycans as novel therapeutic targets,” Nat Rev Cancer, 5:526-42.;;Graham et al., (1977). “Characteristics of a Human Cell Line Transformed by DNA from Human Adenovirus Type 5,” J. Gen Virol., 36:59-72.;;Haji-Ghassemi et al., (2015). “Antibody recognition of carbohydrate epitopes,” Glycobiology, 25(9):920-952.;;Jefferies et al., (2009). “Human immunoglobulin allotypes: Possible implications for immunogenicity,” MAbs, 1(4):332-338.;;Kelm et al., (Apr. 2019). “Targeting Epithelial Expressed Sialyl Lewis A Improves Intestinal Mucosal Wound Healing and Protects Against Colitis,” presented during Experimental Biology Meeting 2019, Orlando, FL, USA, 1 page.;;Kelm et al., (2020). “Targeting epithelium-expressed sialyl Lewis glycans improves colonic mucosal wound healing and protects against colitiss,” JCI Insight, 5(12):e135843, 14 pages.;;Koprowski et al., (1979). “Colorectal Carcinoma Antigens Detected by Hybridoma Antibodies,” Somatic Cell Genetics, 5:957-972.;;Magnani et al., (1981). “A Monosialoganglioside Is a Monoclonal Antibody-Defined Antigen of Colon Carcinoma,” Science, 212(3):55-56.;;Mather et al., (1982). “Culture of Testicular Cells in Hormone-Supplemented Serum-Free Medium,” Annals N.Y. Acad. Sci., 383:44-68.;;Mather, (1980). “Establishment and characterization of two distinct mouse testicular epithelial cell lines,” Biol. Reprod., 23:243-251.;;Urlaub et al., (1980). “Isolation of Chinese hamster cell mutants deficient in dihydrofolate reductase activity,” Proc. Natl. Acad. Sci. USA, 77:4216-20.;;International Search Report and Written Opinion for International Application No. PCT/US2021/022627, dated Jul. 12, 2021, 17 pages.;;Liang et al., (2021). “Validation of Hptm-001, a Humanized Candidate Therapeutic Antibody for Promoting Mucosal Wound Healing in Ibd,” Gastroenterology, 160(3):S50.;;Liang et al., (2021). “Validation of Hptm-001, a Humanized Candidate Therapeutic Antibody for Promoting Mucosal Wound Healing in Ibd,” HHS Public Access Author Manuscript, 27(1):S37, 2 pages.",ACTIVE
20,US,A1,US 2020/0287165 A1,081-280-443-090-947,2020-09-10,2020,US 202016842982 A,2020-04-08,US 202016842982 A;;US 201815909968 A;;US 201916409281 A,2018-03-01,OLED MICROCAVITY DESIGN AND OPTIMIZATION METHOD,"Control of the emission characteristics of a light source in a light field display poses a significant benefit in the resulting 3D display quality for current and future technologies. A design system for microcavity OLEDs of any wavelength is detailed, which combines theoretical background with FDTD optimizations, permitting microcavity design of any OLED configuration. The resulting output profiles for microcavity OLEDs designed and fabricated with this method are compared to standard OLEDs and provide a reduction in spectral bandwidth, and a decrease in angular output.",AVALON HOLOGRAPHICS INC,PECKHAM JORDAN;;CAMPBELL JENNIFER;;CHENG JIAQI,,https://lens.org/081-280-443-090-947,Patent Application,yes,0,4,12,12,0,G06F2111/10;;G06F30/23;;H10K50/852;;H10K50/856;;G06F30/23;;G06F2111/10;;H10K50/852;;H10K50/856;;H10K71/00;;G06F30/23;;G06F2111/10;;H10K50/852;;H10K50/856;;H10K71/00,H01L51/52;;G06F30/23;;H01L51/56,,0,0,,,,DISCONTINUED
21,KR,A,KR 20200124732 A,039-962-889-577-106,2020-11-03,2020,KR 20207027887 A,2018-07-11,US 201815909968 A;;CA 2018050843 W,2018-03-01,OLED 미세공동 설계 및 최적화 방법,"광 필드 디스플레이에서 광원의 방출 특성을 제어하면 현재와 미래의 기술을 위한 결과적인 3D 디스플레이 품질에 상당한 이점이 있다. 임의의 파장의 미세공동 OLED를 위한 설계 시스템이 상세히 설명되며, 이론적 배경과 FDTD 최적화를 결합하여 임의의 OLED 구성의 미세공동 설계를 허용한다. 이 방법으로 설계 및 제작된 미세공동 OLED의 결과 출력 프로파일은 표준 OLED와 비교되어 스펙트럼 대역폭의 감소와 각도 출력의 감소를 제공한다.",AVALON HOLOGRAPHICS INC,CAMPBELL JENNIFER;;CHENG JIAQI;;PECKHAM JORDAN,,https://lens.org/039-962-889-577-106,Patent Application,no,2,0,12,12,0,G06F2111/10;;G06F30/23;;H10K50/852;;H10K50/856;;G06F30/23;;G06F2111/10;;H10K50/852;;H10K50/856;;H10K71/00;;G06F30/23;;G06F2111/10;;H10K50/852;;H10K50/856;;H10K71/00,H01L51/52;;G06F30/23;;G06F111/10;;H01L51/56,,0,0,,,,ACTIVE
22,AU,A1,AU 2021/237566 A1,122-888-365-691-229,2022-09-29,2022,AU 2021/237566 A,2021-03-16,US 202062990927 P;;US 202063037374 P;;US 202063074956 P;;US 2021/0022627 W,2020-03-17,Anti-glycan antibodies and uses thereof,"The present disclosure provides antibodies, or an antigen binding portion thereof, that bind to sLeA and sLeC, as well as polynucleotides, vectors, host cells, pharmaceutical compositions, and methods related thereto.",PTM THERAPEUTICS INC,PRESTA LEONARD;;LIANG TONY;;CHENG JENNIFER,,https://lens.org/122-888-365-691-229,Patent Application,no,0,0,10,10,0,C07K16/3076;;C07K2317/24;;C07K2317/92;;C07K2317/33;;A61K2039/505;;C07K16/3076;;A61P1/00;;C07K2317/92;;C07K2317/24;;C07K2317/33;;A61K2039/505;;A61P1/00;;A61K2039/505;;C07K16/3076;;C07K2317/24;;C07K2317/92,C07K16/30;;A61K39/00,,0,0,,,,PENDING
23,CA,C,CA 3091397 C,009-710-346-641-686,2023-02-28,2023,CA 3091397 A,2018-07-11,US 201815909968 A;;CA 2018050843 W,2018-03-01,OLED MICROCAVITY DESIGN AND OPTIMIZATION METHOD,"Control of the emission characteristics of a light source in a light field display poses a significant benefit in the resulting 3D display quality for current and future technologies. A design system for microcavity OLEDs of any wavelength is detailed, which combines theoretical background with FDTD optimizations, permitting microcavity design of any OLED configuration. The resulting output profiles for microcavity OLEDs designed and fabricated with this method are compared to standard OLEDs and provide a reduction in spectral bandwidth, and a decrease in angular output.",AVALON HOLOGRAPHICS INC,CAMPBELL JENNIFER;;CHENG JIAQI;;PECKHAM JORDAN,,https://lens.org/009-710-346-641-686,Granted Patent,no,0,0,12,12,0,G06F2111/10;;G06F30/23;;H10K50/852;;H10K50/856;;G06F30/23;;G06F2111/10;;H10K50/852;;H10K50/856;;H10K71/00;;G06F30/23;;G06F2111/10;;H10K50/852;;H10K50/856;;H10K71/00,H10K71/00;;H01L33/10;;H10K50/81;;H10K50/82;;H10K50/852;;H10K71/60,,0,0,,,,PENDING
24,US,A1,US 2024/0020666 A1,155-669-558-806-43X,2024-01-18,2024,US 202217865503 A,2022-07-15,US 202217865503 A,2022-07-15,AUTOMATED BILL SHARING,"Disclosed embodiments pertain to automated bill sharing. An intent to pay a bill can be detected by detecting activation of a first payment application on a customer device near a point-of-sale device or by analyzing a customer conversation. A sharing model can be invoked to determine if the bill is to be shared with a party. The sharing model can be trained with a machine learning technique based on transaction history of the customer and party. A party device can be detected within proximity of the customer device to determine sharing or identify the party. A second payment application can be activated on the party device. The sharing model can be invoked to determine payment shares between the first and second payment applications. A shared payment can be completed to a point-of-sale device according to the payment shares, the first payment application, and the second payment application.",CAPITAL ONE SERVICES LLC,KWOK JENNIFER;;CHENG RAY;;CUAN LUKIIH,,https://lens.org/155-669-558-806-43X,Patent Application,yes,0,0,1,1,0,G06Q20/102;;G06Q20/14;;G06Q20/3224;;G06Q20/326;;G06Q20/327;;G06Q20/20;;G06N20/00;;G06Q20/3224;;G06Q20/14,G06Q20/14;;G06Q20/32,,0,0,,,,DISCONTINUED
25,WO,A1,WO 2019/165536 A1,044-219-202-204-638,2019-09-06,2019,CA 2018050843 W,2018-07-11,US 201815909968 A,2018-03-01,OLED MICROCAVITY DESIGN AND OPTIMIZATION METHOD,"Control of the emission characteristics of a light source in a light field display poses a significant benefit in the resulting 3D display quality for current and future technologies. A design system for microcavity OLEDs of any wavelength is detailed, which combines theoretical background with FDTD optimizations, permitting microcavity design of any OLED configuration. The resulting output profiles for microcavity OLEDs designed and fabricated with this method are compared to standard OLEDs and provide a reduction in spectral bandwidth, and a decrease in angular output.",AVALON HOLOGRAPHICS INC,CAMPBELL JENNIFER;;CHENG JIAQI;;PECKHAM JORDAN,,https://lens.org/044-219-202-204-638,Patent Application,yes,4,1,12,12,0,G06F2111/10;;G06F30/23;;H10K50/852;;H10K50/856;;G06F30/23;;G06F2111/10;;H10K50/852;;H10K50/856;;H10K71/00;;G06F30/23;;G06F2111/10;;H10K50/852;;H10K50/856;;H10K71/00,H01L51/52;;H01L33/10;;H01L51/54;;H01L51/56,,0,0,,,,PENDING
26,US,A1,US 2019/0273222 A1,101-102-054-121-748,2019-09-05,2019,US 201916409281 A,2019-05-10,US 201916409281 A;;US 201815909968 A,2018-03-01,OLED Microcavity Design and Optimization Method,"Control of the emission characteristics of a light source in a light field display poses a significant benefit in the resulting 3D display quality for current and future technologies. A design system for microcavity OLEDs of any wavelength is detailed, which combines theoretical background with FDTD optimizations, permitting microcavity design of any OLED configuration. The resulting output profiles for microcavity OLEDs designed and fabricated with this method are compared to standard OLEDs and provide a reduction in spectral bandwidth, and a decrease in angular output.",AVALON HOLOGRAPHICS INC,PECKHAM JORDAN;;CAMPBELL JENNIFER;;CHENG JIAQI,,https://lens.org/101-102-054-121-748,Patent Application,yes,0,3,12,12,0,G06F2111/10;;G06F30/23;;H10K50/852;;H10K50/856;;G06F30/23;;G06F2111/10;;H10K50/852;;H10K50/856;;H10K71/00;;G06F30/23;;G06F2111/10;;H10K50/852;;H10K50/856;;H10K71/00,H01L51/52;;G06F17/50;;H01L51/56,,0,0,,,,ACTIVE
27,EP,A1,EP 4121460 A1,174-300-650-628-751,2023-01-25,2023,EP 21720042 A,2021-03-16,US 202062990927 P;;US 202063037374 P;;US 202063074956 P;;US 2021/0022627 W,2020-03-17,ANTI-GLYCAN ANTIBODIES AND USES THEREOF,,PTM THERAPEUTICS INC,PRESTA LEONARD;;LIANG TONY;;CHENG JENNIFER,,https://lens.org/174-300-650-628-751,Patent Application,yes,0,0,10,10,0,C07K16/3076;;C07K2317/24;;C07K2317/92;;C07K2317/33;;A61K2039/505;;C07K16/3076;;A61P1/00;;C07K2317/92;;C07K2317/24;;C07K2317/33;;A61K2039/505;;A61P1/00;;A61K2039/505;;C07K16/3076;;C07K2317/24;;C07K2317/92,C07K16/30;;A61K39/00,,0,0,,,,PENDING
28,JP,A,JP 2012115665 A,024-757-652-837-777,2012-06-21,2012,JP 2011258402 A,2011-11-28,US 95779610 A,2010-12-01,METHOD AND SYSTEM FOR ULTRASOUND IMAGING,"PROBLEM TO BE SOLVED: To provide an improved ultrasound imaging system and method for guiding an instrument, such as a needle guide.SOLUTION: The ultrasound imaging system 100 includes: an ultrasound probe 106; a first sensor 122 attached to the ultrasound probe 106; a second sensor 124 attached to an instrument; a display device 118; and a processor 116. The processor 116 is configured to control the ultrasound probe 106 to acquire ultrasound data, the ultrasound data including data of a plane defined along a longitudinal axis of the instrument. The processor 116 is configured to generate an image of the plane based on the ultrasound data, and display the image of the plane on the display device 118.",GEN ELECTRIC,NG GARY CHENG HOW;;JENNIFER MARTIN,,https://lens.org/024-757-652-837-777,Patent Application,no,0,0,4,4,0,A61B10/0233;;A61B10/0233;;A61B8/0841;;A61B8/0841;;A61B8/4254;;A61B8/4254;;A61B8/4461;;A61B8/4461;;A61B8/4477;;A61B8/4477;;A61B8/481;;A61B8/481;;A61B8/483;;A61B8/483;;A61B8/485;;A61B8/485;;A61B8/488;;A61B8/488;;A61B18/1477;;A61B18/1477;;A61B90/361;;A61B90/361;;A61B2017/3413;;A61B2017/3413;;A61B2034/2051;;A61B2034/2051;;A61B2090/378;;A61B2090/378,A61B8/00,,0,0,,,,PENDING
29,US,A1,US 2012/0143055 A1,118-139-429-153-84X,2012-06-07,2012,US 95779610 A,2010-12-01,US 95779610 A,2010-12-01,METHOD AND SYSTEM FOR ULTRASOUND IMAGING,"A method and system for ultrasound imaging includes tracking the position and orientation of an ultrasound probe. The method and system includes tracking the position and orientation of an instrument while moving the instrument. The method and system includes acquiring ultrasound data of a plane defined along a longitudinal axis of the instrument, where the position of the plane is determined based on the position and orientation of the ultrasound probe and the position and orientation of the instrument. The method and system includes generating a plurality of images of the plane based on the ultrasound data and displaying the plurality of images of the plane as part of a dynamic image.",NG GARY CHENG HOW;;MARTIN JENNIFER;;GEN ELECTRIC,NG GARY CHENG HOW;;MARTIN JENNIFER,GENERAL ELECTRIC COMPANY (2010-11-23),https://lens.org/118-139-429-153-84X,Patent Application,yes,1,55,4,4,0,A61B10/0233;;A61B10/0233;;A61B8/0841;;A61B8/0841;;A61B8/4254;;A61B8/4254;;A61B8/4461;;A61B8/4461;;A61B8/4477;;A61B8/4477;;A61B8/481;;A61B8/481;;A61B8/483;;A61B8/483;;A61B8/485;;A61B8/485;;A61B8/488;;A61B8/488;;A61B18/1477;;A61B18/1477;;A61B90/361;;A61B90/361;;A61B2017/3413;;A61B2017/3413;;A61B2034/2051;;A61B2034/2051;;A61B2090/378;;A61B2090/378,A61B8/14,600/439,0,0,,,,DISCONTINUED
30,WO,A1,WO 2021/188591 A1,123-360-900-183-447,2021-09-23,2021,US 2021/0022627 W,2021-03-16,US 202062990927 P;;US 202063037374 P;;US 202063074956 P,2020-03-17,ANTI-GLYCAN ANTIBODIES AND USES THEREOF,"The present disclosure provides antibodies, or an antigen binding portion thereof, that bind to sLeA and sLeC, as well as polynucleotides, vectors, host cells, pharmaceutical compositions, and methods related thereto.",PTM THERAPEUTICS INC,PRESTA LEONARD;;LIANG TONY;;CHENG JENNIFER,,https://lens.org/123-360-900-183-447,Patent Application,yes,1,1,10,10,19,C07K16/3076;;C07K2317/24;;C07K2317/92;;C07K2317/33;;A61K2039/505;;C07K16/3076;;A61P1/00;;C07K2317/92;;C07K2317/24;;C07K2317/33;;A61K2039/505;;A61P1/00;;A61K2039/505;;C07K16/3076;;C07K2317/24;;C07K2317/92,C07K16/30;;A61K39/00,,14,13,122-664-349-677-416;;028-216-202-844-164;;078-676-868-469-381;;036-754-205-253-78X;;005-791-137-400-140;;049-338-980-380-236;;021-335-288-836-495;;026-418-623-750-230;;008-587-496-850-953;;065-430-968-783-392;;021-430-782-622-770;;051-940-176-386-905;;122-664-349-677-416,10.4049/jimmunol.1301307;;pmc4047976;;24068663;;10.1096/fasebj.2019.33.1_supplement.34.4;;10.1093/ibd/izaa347.090;;10.1053/j.gastro.2021.01.136;;10.1038/nrc1649;;16069816;;10.1038/nrd1751;;15931257;;26033938;;10.1093/glycob/cwv037;;20073133;;pmc2726606;;10.4161/mabs.1.4.9122;;886304;;10.1099/0022-1317-36-1-59;;10.1095/biolreprod23.1.243;;6774781;;10.1111/j.1749-6632.1982.tb23161.x;;7046561;;10.1073/pnas.77.7.4216;;pmc349802;;6933469;;10.4049/jimmunol.1301307;;pmc4047976;;24068663,"JENNIFER C. BRAZIL ET AL: ""[alpha]3/4 Fucosyltransferase 3-Dependent Synthesis of Sialyl Lewis A on CD44 Variant Containing Exon 6 Mediates Polymorphonuclear Leukocyte Detachment from Intestinal Epithelium during Transepithelial Migration"", THE JOURNAL OF IMMUNOLOGY, vol. 191, no. 9, 25 September 2013 (2013-09-25), US, pages 4804 - 4817, XP055639105, ISSN: 0022-1767, DOI: 10.4049/jimmunol.1301307;;ANONYMOUS: ""Targeting Epithelial Expressed Sialyl Lewis A Improves Intestinal Mucosal Wound Healing and Protects Against Colitis - Kelm - 2019 - The FASEB Journal - Wiley Online Library"", 1 January 2019 (2019-01-01), XP055820734, Retrieved from the Internet <URL:https://faseb.onlinelibrary.wiley.com/doi/10.1096/fasebj.2019.33.1_supplement.34.4> [retrieved on 20210702];;LIANG TONY ET AL: ""Validation of Hptm-001, a Humanized Candidate Therapeutic Antibody for Promoting Mucosal Wound Healing in Ibd"", HHS PUBLIC ACCESS AUTHOR MANUSCRIPT, vol. 27, no. Supplement_1, 21 January 2021 (2021-01-21), US, pages S37 - S37, XP055820626, ISSN: 1078-0998, Retrieved from the Internet <URL:http://academic.oup.com/ibdjournal/article-pdf/27/Supplement_1/S37/35931907/izaa347.090.pdf> DOI: 10.1093/ibd/izaa347.090;;LIANG TONY ET AL: ""VALIDATION OF HPTM-001, A HUMANIZED CANDIDATE THERAPEUTIC ANTIBODY FOR PROMOTING MUCOSAL WOUND HEALING IN IBD"", GASTROENTEROLOGY, ELSEVIER INC, US, vol. 160, no. 3, 1 February 2021 (2021-02-01), XP086489354, ISSN: 0016-5085, DOI: 10.1053/J.GASTRO.2021.01.136;;FUSTER, NAT REV CANCER, vol. 5, 2005, pages 526 - 42;;DUBE, NAT REV DRUG DISCOVERY, vol. 4, 2005, pages 477 - 88;;GHASSEMI, GLYCOBIOLOGY, vol. 25, no. 9, September 2015 (2015-09-01), pages 920 - 952;;JEFFERIESLEFRANC, MABS, vol. 1, no. 4, July 2009 (2009-07-01), pages 332 - 338;;GRAHAM ET AL., J. GEN VIROL., vol. 36, 1977, pages 59;;MATHER, BIOL. REPROD., vol. 23, 1980, pages 243 - 251;;MATHER ET AL., ANNALS N.Y. ACAD. SCI., vol. 383, 1982, pages 44 - 68;;URLAUB ET AL., PROC. NATL. ACAD. SCI. USA, vol. 77, 1980, pages 4216;;""Remington, The Science and Practice of Pharmacy"", 2000, MACK PUBLISHING;;BRAZIL, J IMMUNOL, vol. 191, 2013, pages 4804 - 4817",PENDING
31,US,B2,US 10651424 B2,166-059-865-014-097,2020-05-12,2020,US 201916409281 A,2019-05-10,US 201916409281 A;;US 201815909968 A,2018-03-01,OLED microcavity design and optimization method,"Control of the emission characteristics of a light source in a light field display poses a significant benefit in the resulting 3D display quality for current and future technologies. A design system for microcavity OLEDs of any wavelength is detailed, which combines theoretical background with FDTD optimizations, permitting microcavity design of any OLED configuration. The resulting output profiles for microcavity OLEDs designed and fabricated with this method are compared to standard OLEDs and provide a reduction in spectral bandwidth, and a decrease in angular output.",AVALON HOLOGRAPHICS INC,PECKHAM JORDAN;;CAMPBELL JENNIFER;;CHENG JIAQI,,https://lens.org/166-059-865-014-097,Granted Patent,yes,2,0,12,12,0,G06F2111/10;;G06F30/23;;H10K50/852;;H10K50/856;;G06F30/23;;G06F2111/10;;H10K50/852;;H10K50/856;;H10K71/00;;G06F30/23;;G06F2111/10;;H10K50/852;;H10K50/856;;H10K71/00,H01L51/52;;G06F30/23;;G06F111/10;;H01L51/56,,0,0,,,,ACTIVE
32,DE,A1,DE 102011055828 A1,081-841-205-171-722,2012-06-06,2012,DE 102011055828 A,2011-11-29,US 95779610 A,2010-12-01,Verfahren und System zur Ultraschallbildgebung,"Ein Ultraschall-Bildgebungssystem (100) enthält eine Ultraschallsonde (106), einen an der Ultraschallsonde (106) angebrachten ersten Sensor (122), einen an einem Instrument (304) angebrachten zweiten Sensor (124), eine Anzeigeeinrichtung (118) und einen Prozessor (116). Der Prozessor (116) ist dafür eingerichtet, erste Daten aus dem ersten Sensor (122) zu empfangen, wobei die ersten Daten Positions- und Ausrichtungsinformation für die Ultraschallsonde (106) enthalten. Der Prozessor (116) ist dafür eingerichtet, zweite Daten aus dem zweiten Sensor (124) zu empfangen, wobei die zweiten Daten Positions- und Ausrichtungsinformation für das Instrument enthalten. Der Prozessor (116) ist dafür eingerichtet, die Ultraschallsonde (106) zum Erfassen von Ultraschalldaten zu steuern, wobei die Ultraschalldaten Daten einer entlang einer Längsachse (127) des Instrumentes definierten Ebene enthalten. Der Prozessor (116) ist dafür eingerichtet, ein Bild der Ebene auf der Basis der Ultraschalldaten zu erzeugen und das Bild der Ebene auf der Anzeigeeinrichtung (118) darzustellen.",GEN ELECTRIC,NG GARY CHENG HOW;;MARTIN JENNIFER,,https://lens.org/081-841-205-171-722,Patent Application,no,0,0,4,4,0,A61B10/0233;;A61B10/0233;;A61B8/0841;;A61B8/0841;;A61B8/4254;;A61B8/4254;;A61B8/4461;;A61B8/4461;;A61B8/4477;;A61B8/4477;;A61B8/481;;A61B8/481;;A61B8/483;;A61B8/483;;A61B8/485;;A61B8/485;;A61B8/488;;A61B8/488;;A61B18/1477;;A61B18/1477;;A61B90/361;;A61B90/361;;A61B2017/3413;;A61B2017/3413;;A61B2034/2051;;A61B2034/2051;;A61B2090/378;;A61B2090/378,A61B19/00;;A61B8/00;;A61B10/02,,0,0,,,,DISCONTINUED
33,CN,A,CN 102525558 A,135-645-816-944-498,2012-07-04,2012,CN 201110417609 A,2011-12-01,US 95779610 A,2010-12-01,Method and system for ultrasound imaging,"The invention provides a method and a system for ultrasound imaging. The ultrasound imaging system (100) includes an ultrasound probe (106), a first sensor (122) attached to the ultrasound probe (106), a second sensor (124) attached to an instrument, a display device (118) and a processor (116). The processor (116) is configured to receive first data from the first sensor (122), the first data including position and orientation information for the ultrasound probe (106), and the processor (116) is configured to receive second data from the second sensor (124), the second data including position and orientation information for the instrument. The processor (116) is configured to control the ultrasound probe (106) to acquire ultrasound data, the ultrasound data including data of a plane defined along a longitudinal axis (127) of the instrument. The processor (116) is configured to use the first data and the second data when acquiring the ultrasound data. The processor (116) is configured to generate an image of the plane based on the ultrasound data and display the image of the plane on the display device (118).",GEN ELECTRIC,HOW NG GARY CHENG;;JENNIFER MARTIN,,https://lens.org/135-645-816-944-498,Patent Application,no,4,11,4,4,0,A61B10/0233;;A61B10/0233;;A61B8/0841;;A61B8/0841;;A61B8/4254;;A61B8/4254;;A61B8/4461;;A61B8/4461;;A61B8/4477;;A61B8/4477;;A61B8/481;;A61B8/481;;A61B8/483;;A61B8/483;;A61B8/485;;A61B8/485;;A61B8/488;;A61B8/488;;A61B18/1477;;A61B18/1477;;A61B90/361;;A61B90/361;;A61B2017/3413;;A61B2017/3413;;A61B2034/2051;;A61B2034/2051;;A61B2090/378;;A61B2090/378,A61B8/00,,0,0,,,,DISCONTINUED
34,CA,A1,CA 3170434 A1,044-585-074-972-746,2021-09-23,2021,CA 3170434 A,2021-03-16,US 202062990927 P;;US 202063037374 P;;US 202063074956 P;;US 2021/0022627 W,2020-03-17,ANTI-GLYCAN ANTIBODIES AND USES THEREOF,"The present disclosure provides antibodies, or an antigen binding portion thereof, that bind to sLeA and sLeC, as well as polynucleotides, vectors, host cells, pharmaceutical compositions, and methods related thereto.",PTM THERAPEUTICS INC,PRESTA LEONARD;;LIANG TONY;;CHENG JENNIFER,,https://lens.org/044-585-074-972-746,Patent Application,no,0,0,10,10,0,C07K16/3076;;C07K2317/24;;C07K2317/92;;C07K2317/33;;A61K2039/505;;C07K16/3076;;A61P1/00;;C07K2317/92;;C07K2317/24;;C07K2317/33;;A61K2039/505;;A61P1/00;;A61K2039/505;;C07K16/3076;;C07K2317/24;;C07K2317/92,C07K16/30,,0,0,,,,PENDING
35,US,A1,US 2021/0292432 A1,141-181-457-830-281,2021-09-23,2021,US 202117203650 A,2021-03-16,US 202117203650 A;;US 202062990927 P;;US 202063037374 P;;US 202063074956 P,2020-03-17,ANTI-GLYCAN ANTIBODIES AND USES THEREOF,"The present disclosure provides antibodies, or an antigen binding portion thereof, that bind to sLeA and sLeC, as well as polynucleotides, vectors, host cells, pharmaceutical compositions, and methods related thereto.",PTM THERAPEUTICS INC,PRESTA LEONARD;;LIANG TONY;;CHENG JENNIFER,PTM THERAPEUTICS INC (2021-03-18),https://lens.org/141-181-457-830-281,Patent Application,yes,0,0,10,10,19,C07K16/3076;;C07K2317/24;;C07K2317/92;;C07K2317/33;;A61K2039/505;;C07K16/3076;;A61P1/00;;C07K2317/92;;C07K2317/24;;C07K2317/33;;A61K2039/505;;A61P1/00;;A61K2039/505;;C07K16/3076;;C07K2317/24;;C07K2317/92,C07K16/30;;A61P1/00,,0,0,,,,ACTIVE
36,KR,A,KR 20220155333 A,136-527-226-339-334,2022-11-22,2022,KR 20227035436 A,2021-03-16,US 202062990927 P;;US 202063037374 P;;US 202063074956 P;;US 2021/0022627 W,2020-03-17,항-글리칸 항체 및 이의 용도,"본 개시내용은 sLeA 및 sLeC에 결합하는 항체, 또는 이의 항원 결합부, 뿐만 아니라 폴리뉴클레오티드, 벡터, 숙주 세포, 약학적 조성물, 및 이와 관련된 방법을 제공한다.",PTM THERAPEUTICS INC,PRESTA LEONARD;;LIANG TONY;;CHENG JENNIFER,,https://lens.org/136-527-226-339-334,Patent Application,no,0,0,10,10,38,C07K16/3076;;C07K2317/24;;C07K2317/92;;C07K2317/33;;A61K2039/505;;C07K16/3076;;A61P1/00;;C07K2317/92;;C07K2317/24;;C07K2317/33;;A61K2039/505;;A61P1/00;;A61K2039/505;;C07K16/3076;;C07K2317/24;;C07K2317/92,C07K16/30;;A61K39/00;;A61P1/00,,0,0,,,,PENDING
37,US,A1,US 2012/0116218 A1,148-941-558-288-35X,2012-05-10,2012,US 94357210 A,2010-11-10,US 94357210 A,2010-11-10,METHOD AND SYSTEM FOR DISPLAYING ULTRASOUND DATA,"Methods and systems for displaying ultrasound data are provided. One method includes acquiring ultrasound image data and physiological monitoring data during an ultrasound imaging scan, generating quantitative ultrasound data from the acquired ultrasound image data and correlating the quantitative ultrasound data with the physiological monitoring data. The method also includes displaying the correlated quantitative ultrasound data and physiological monitoring data time aligned on a display.",MARTIN JENNIFER;;NG GARY CHENG HOW,MARTIN JENNIFER;;NG GARY CHENG HOW,GENERAL ELECTRIC COMPANY (2010-11-08),https://lens.org/148-941-558-288-35X,Patent Application,yes,3,25,3,3,0,A61B8/4405;;A61B8/4427;;A61B8/463;;A61B8/488;;A61B8/5207;;A61B8/5223;;A61B8/5246;;A61B5/318;;A61B8/463;;A61B8/4427;;A61B8/5223;;A61B8/5207;;A61B8/4405;;A61B8/488;;A61B8/5246,A61B8/00,600/437,0,0,,,,DISCONTINUED
38,DE,T2,DE 60038154 T2,021-823-355-353-657,2009-02-26,2009,DE 60038154 T,2000-06-01,US 32336699 A;;US 0015014 W,1999-06-01,THERMISCH INHIBIERTE STÄRKE HERGESTELLT IN GEGENWART VON OLIGOSACCHARIDEN,"The present invention is directed to a process of preparing thermally inhibited starches using the low molecular weight carbohydrates to improve the rate of inhibition. The resulting starch/low molecular weight carbohydrate blends have improved cold storage stability and may be used in a variety of products, particularly food products.",NAT STARCH CHEM INVEST,SHI YONG-CHENG;;GOODALL JENNIFER;;JEFFCOAT ROGER,"BRUNOB II B.V., ARNHEM, NL (2009-06-18)",https://lens.org/021-823-355-353-657,Granted Patent,no,0,0,15,15,0,A21D2/181;;A21D2/186;;C08B30/12;;C08B30/14;;C08B30/18;;C08L3/02;;C08L3/12;;A23L29/219;;C08B30/18;;A21D2/181;;C08B30/14;;C08B30/12;;A21D2/186;;C08L3/12;;C08L3/02;;A23L29/219,A01K1/015;;C08B30/12;;A21D2/18;;A21D13/08;;A23L1/0522;;A61K8/73;;A61K8/96;;A61K47/36;;A61Q5/00;;A61Q5/02;;C08B30/14;;C08B30/18;;C08L3/02;;C08L3/12,,0,0,,,,EXPIRED
39,MX,A,MX 2012003775 A,191-107-196-923-305,2012-06-12,2012,MX 2012003775 A,2010-09-29,US 24693109 P;;US 2010/0050761 W,2009-09-29,OLIGOMER-CALCIMIMETIC CONJUGATES AND RELATED COMPOUNDS.,"The invention relates to a conjugate comprising a calcimimetic, including cinacalcet, covalently attached via a linkage to a water-soluble, non-peptidic oligomer or polymer, preferably to poly (ethylene glycol).",NEKTAR THERAPEUTICS,RIGGS-SAUTHIER JENNIFER;;CHENG LIN;;MARTIN DAVID,,https://lens.org/191-107-196-923-305,Patent Application,no,0,0,18,22,0,A61K47/60;;A61P13/02;;A61P13/12;;A61P3/14;;A61P5/18;;A61K47/60;;A61K9/20;;A61K9/48;;C07F3/04,A61K47/48,,0,0,,,,ACTIVE
40,AU,A1,AU 2010/315805 A1,085-593-220-305-552,2012-03-15,2012,AU 2010/315805 A,2010-09-29,US 24693109 P;;US 2010/0050761 W,2009-09-29,Oligomer-calcimimetic conjugates and related compounds,"The invention relates to a conjugate comprising a calcimimetic, including cinacalcet, covalently attached via a linkage to a water-soluble, non-peptidic oligomer or polymer, preferably to poly (ethylene glycol).",NEKTAR THERAPEUTICS,RIGGS-SAUTHIER JENNIFER;;CHENG LIN;;MARTIN DAVID,,https://lens.org/085-593-220-305-552,Patent Application,no,0,0,18,22,0,A61K47/60;;A61P13/02;;A61P13/12;;A61P3/14;;A61P5/18;;A61K47/60;;A61K9/20;;A61K9/48;;C07F3/04,A61K47/48,,0,0,,,,ACTIVE
41,EP,B1,EP 2482855 B1,118-512-772-271-969,2017-12-27,2017,EP 10810996 A,2010-09-29,US 24693109 P;;US 2010/0050761 W,2009-09-29,OLIGOMER-CALCIMIMETIC CONJUGATES AND RELATED COMPOUNDS,,NEKTAR THERAPEUTICS,RIGGS-SAUTHIER JENNIFER;;CHENG LIN;;MARTIN DAVID,NEKTAR THERAPEUTICS (2017-12-20),https://lens.org/118-512-772-271-969,Granted Patent,yes,3,0,18,22,0,A61K47/60;;A61P13/02;;A61P13/12;;A61P3/14;;A61P5/18;;A61K47/60;;A61K9/20;;A61K9/48;;C07F3/04,A61K47/60,,2,0,,,"MARCUS YONIT ET AL: ""Turning low-molecular-weight drugs into prolonged acting prodrugs by reversible pegylation: A study with gentamicin"", JOURNAL OF MEDICINAL CHEMISTRY, vol. 51, no. 14, July 2008 (2008-07), pages 4300-4305, XP002636000, ISSN: 0022-2623, DOI: 10.1021/JM8002558;;UREÑA PABLO ET AL: ""Calcimimetic agents: review and perspectives."", KIDNEY INTERNATIONAL. SUPPLEMENT JUN 2003, vol. 63, no. 85, June 2003 (2003-06), pages S91-S96, XP002636001, ISSN: 0098-6577",ACTIVE
42,MX,B,MX 341690 B,134-401-553-913-712,2016-08-29,2016,MX 2012003775 A,2010-09-29,US 24693109 P;;US 2010/0050761 W,2009-09-29,OLIGOMER-CALCIMIMETIC CONJUGATES AND RELATED COMPOUNDS.,"The invention relates to a conjugate comprising a calcimimetic, including cinacalcet, covalently attached via a linkage to a water-soluble, non-peptidic oligomer or polymer, preferably to poly (ethylene glycol).",NEKTAR THERAPEUTICS,RIGGS-SAUTHIER JENNIFER;;CHENG LIN;;MARTIN DAVID,,https://lens.org/134-401-553-913-712,Granted Patent,no,0,0,18,22,0,A61K47/60;;A61P13/02;;A61P13/12;;A61P3/14;;A61P5/18;;A61K47/60;;A61K9/20;;A61K9/48;;C07F3/04,A61K47/48;;A61K47/00,,0,0,,,,ACTIVE
43,US,A1,US 2012/0238621 A1,042-322-240-049-424,2012-09-20,2012,US 201213433100 A,2012-03-28,US 201213433100 A;;US 2010/0050761 W;;US 24693109 P;;US 201261597663 P,2009-09-29,Oligomer-Calcimimetic Conjugates and Related Compounds,"The invention relates to (among other things) oligomer-calcimimetic conjugates and related compounds. A conjugate of the invention, when administered by any of a number of administration routes, exhibits advantages over previously administered compounds.",RIGGS-SAUTHIER JENNIFER;;CHENG LIN;;MARTIN DAVID;;NEKTAR THERAPEUTICS,RIGGS-SAUTHIER JENNIFER;;CHENG LIN;;MARTIN DAVID,NEKTAR THERAPEUTICS (2012-05-02),https://lens.org/042-322-240-049-424,Patent Application,yes,0,3,4,22,0,A61K47/60;;A61K47/60;;A61P5/10;;A61P5/20;;C07B2200/11;;C07B2200/11;;C07C211/30;;C07C211/30;;C07C271/14;;C07C271/14,C07C271/14;;A61K31/137;;A61K31/27;;A61P5/20;;C07C211/31,514/481;;560/28;;564/374;;514/654,0,0,,,,ACTIVE
44,US,A1,US 2014/0323565 A1,040-181-328-149-295,2014-10-30,2014,US 201414223572 A,2014-03-24,US 201414223572 A;;US 201213433100 A;;US 2010/0050761 W;;US 24693109 P;;US 201261597663 P,2009-09-29,Oligomer-Calcimimetic Conjugates and Related Compunds,"The invention relates to (among other things) oligomer-calcimimetic conjugates and related compounds. A conjugate of the invention, when administered by any of a number of administration routes, exhibits advantages over previously administered compounds.",NEKTAR THERAPEUTICS,RIGGS-SAUTHIER JENNIFER;;CHENG LIN;;MARTIN DAVID,,https://lens.org/040-181-328-149-295,Patent Application,yes,0,0,4,22,0,A61K47/60;;A61K47/60;;A61P5/10;;A61P5/20;;C07B2200/11;;C07B2200/11;;C07C211/30;;C07C211/30;;C07C271/14;;C07C271/14,A61K47/48,514/481;;560/28;;564/196;;514/626,0,0,,,,ACTIVE
45,CN,A,CN 102573921 A,095-196-957-504-496,2012-07-11,2012,CN 201080043400 A,2010-09-29,US 2010/0050761 W;;US 24693109 P,2009-09-29,Oligomer-calcimimetic conjugates and related compounds,"The invention relates to (among other things) oligomer-calcimimetic conjugates and related compounds. A conjugate of the invention, when administered by any of a number of administration routes, exhibits advantages over previously administered compounds.",NEKTAR THERAPEUTICS,JENNIFER RIGGS-SAUTHIER;;LIN CHENG;;DAVID MARTIN,,https://lens.org/095-196-957-504-496,Patent Application,no,2,1,18,22,0,A61K47/60;;A61P13/02;;A61P13/12;;A61P3/14;;A61P5/18;;A61K47/60;;A61K9/20;;A61K9/48;;C07F3/04,A61K47/48,,2,2,011-328-347-291-336;;037-957-737-402-076,12753275;;10.1046/j.1523-1755.63.s85.22.x;;18578475;;10.1021/jm8002558,"PABLO URENA AND JOAO M. FRAZAO: ""Calcimimetic agents： review and perspectives"", 《KIDNEY INTERNATIONAL》, vol. 63, no. 85, 30 June 2003 (2003-06-30), pages 91 - 96, XP002636001, DOI: doi:10.1046/j.1523-1755.63.s85.22.x;;YONIT MARCUS ET AL.: ""Tuning Low-Molecular-Weight Drugs into Prolonged Acting Prodrugs by Reversible Pegylation: A study with gentamicin"", 《JOURNAL OF MEDICINAL CHEMISTRY》, vol. 51, no. 14, 25 June 2008 (2008-06-25), pages 4300 - 4305, XP002636000, DOI: doi:10.1021/JM8002558",ACTIVE
46,WO,A2,WO 2011/056325 A2,102-433-470-697-220,2011-05-12,2011,US 2010/0050761 W,2010-09-29,US 24693109 P,2009-09-29,OLIGOMER-CALCIMIMETIC CONJUGATES AND RELATED COMPOUNDS,"The invention relates to (among other things) oligomer-calcimimetic conjugates and related compounds. A conjugate of the invention, when administered by any of a number of administration routes, exhibits advantages over previously administered compounds.",NEKTAR THERAPEUTICS;;RIGGS-SAUTHIER JENNIFER;;CHENG LIN;;MARTIN DAVID,RIGGS-SAUTHIER JENNIFER;;CHENG LIN;;MARTIN DAVID,,https://lens.org/102-433-470-697-220,Patent Application,yes,12,2,18,22,0,A61K47/60;;A61P13/02;;A61P13/12;;A61P3/14;;A61P5/18;;A61K47/60;;A61K9/20;;A61K9/48;;C07F3/04,A61K31/785,,5,2,077-295-491-167-117;;058-789-596-477-892,10.1002/0471220574;;11674697;;10.1021/jo990620m,"T.W. GREENE; G.M. WUTS: ""Protecting Groups in Organic Synthesis"", 1999, WILEY;;CHCN Y.; BAKER, G.L., J. ORG. CHEM., 1999, pages 6870 - 6873;;""Remington: The Science & Practice of Pharmacy"", 1995;;""Medical Economics"", 1998, article ""Physician's Desk Reference"";;KIBBE, A.H.: ""Handbook of Pharmaceutical Excipients"", 2000, AMERICAN PHARMACEUTICAL ASSOCIATION",PENDING
47,KR,A,KR 20120090961 A,122-824-243-910-961,2012-08-17,2012,KR 20127005885 A,2010-09-29,US 24693109 P;;US 2010/0050761 W,2009-09-29,OLIGOMER-CALCIMIMETIC CONJUGATES AND RELATED COMPOUNDS,,NEKTAR THERAPEUTICS,RIGGS SAUTHIER JENNIFER;;CHENG LIN;;MARTIN DAVID,,https://lens.org/122-824-243-910-961,Patent Application,no,0,0,18,22,0,A61K47/60;;A61P13/02;;A61P13/12;;A61P3/14;;A61P5/18;;A61K47/60;;A61K9/20;;A61K9/48;;C07F3/04,A61K47/48;;A61P13/02;;A61P13/12;;C07F3/04,,0,0,,,,ACTIVE
48,DE,D1,DE 60038154 D1,026-597-013-426-202,2008-04-10,2008,DE 60038154 T,2000-06-01,US 32336699 A;;US 0015014 W,1999-06-01,THERMISCH INHIBIERTE STÄRKE HERGESTELLT IN GEGENWART VON OLIGOSACCHARIDEN,"The present invention is directed to a process of preparing thermally inhibited starches using the low molecular weight carbohydrates to improve the rate of inhibition. The resulting starch/low molecular weight carbohydrate blends have improved cold storage stability and may be used in a variety of products, particularly food products.",NAT STARCH CHEM INVEST,SHI YONG-CHENG;;GOODALL JENNIFER;;JEFFCOAT ROGER,"BRUNOB II B.V., ARNHEM, NL (2009-06-18)",https://lens.org/026-597-013-426-202,Granted Patent,no,0,0,15,15,0,A21D2/181;;A21D2/186;;C08B30/12;;C08B30/14;;C08B30/18;;C08L3/02;;C08L3/12;;A23L29/219;;C08B30/18;;A21D2/181;;C08B30/14;;C08B30/12;;A21D2/186;;C08L3/12;;C08L3/02;;A23L29/219,A01K1/015;;C08B30/12;;A21D2/18;;A21D13/08;;A23L1/0522;;A61K8/73;;A61K8/96;;A61K47/36;;A61Q5/00;;A61Q5/02;;C08B30/14;;C08B30/18;;C08L3/02;;C08L3/12,,0,0,,,,EXPIRED
49,AT,T1,AT E387462 T1,137-140-989-575-853,2008-03-15,2008,AT 00939446 T,2000-06-01,US 32336699 A,1999-06-01,THERMISCH INHIBIERTE STÄRKE HERGESTELLT IN GEGENWART VON OLIGOSACCHARIDEN,"The present invention is directed to a process of preparing thermally inhibited starches using the low molecular weight carbohydrates to improve the rate of inhibition. The resulting starch/low molecular weight carbohydrate blends have improved cold storage stability and may be used in a variety of products, particularly food products.",NAT STARCH CHEM INVEST,SHI YONG-CHENG;;GOODALL JENNIFER;;JEFFCOAT ROGER,,https://lens.org/137-140-989-575-853,Granted Patent,no,0,0,15,15,0,A21D2/181;;A21D2/186;;C08B30/12;;C08B30/14;;C08B30/18;;C08L3/02;;C08L3/12;;A23L29/219;;C08B30/18;;A21D2/181;;C08B30/14;;C08B30/12;;A21D2/186;;C08L3/12;;C08L3/02;;A23L29/219,A01K1/015;;A21D2/18;;A23L1/0522;;A61K8/73;;A61K8/96;;A61K47/36;;A61Q5/00;;A61Q5/02;;C08B30/12;;C08B30/14;;C08B30/18;;C08L3/02;;C08L3/12,,0,0,,,,EXPIRED
50,EP,B1,EP 1102792 B1,167-329-076-136-319,2008-02-27,2008,EP 00939446 A,2000-06-01,US 0015014 W;;US 32336699 A,1999-06-01,THERMALLY-INHIBITED STARCH PREPARED WITH OLIGOSACCHARIDES,"The present invention is directed to a process of preparing thermally inhibited starches using the low molecular weight carbohydrates to improve the rate of inhibition. The resulting starch/low molecular weight carbohydrate blends have improved cold storage stability and may be used in a variety of products, particularly food products.",NAT STARCH CHEM INVEST,SHI YONG-CHENG;;GOODALL JENNIFER;;JEFFCOAT ROGER,"CORN PRODUCTS DEVELOPMENT, INC., BR (2014-09-23);;CORN PRODUCTS DEVELOPMENT INC., WESTCHESTER, US (2012-07-02);;CORN PRODUCTS DEVELOPMENT INC., 60154 WESTCHES, US (2012-07-02)",https://lens.org/167-329-076-136-319,Granted Patent,yes,7,0,15,15,0,A21D2/181;;A21D2/186;;C08B30/12;;C08B30/14;;C08B30/18;;C08L3/02;;C08L3/12;;A23L29/219;;C08B30/18;;A21D2/181;;C08B30/14;;C08B30/12;;A21D2/186;;C08L3/12;;C08L3/02;;A23L29/219,A01K1/015;;C08B30/12;;A21D2/18;;A21D13/08;;A23L1/0522;;A61K8/73;;A61K8/96;;A61K47/36;;A61Q5/00;;A61Q5/02;;C08B30/14;;C08B30/18;;C08L3/02;;C08L3/12,,2,0,,,"HIPPLEHEUSER A L ET AL: ""A SYSTEM APPROACH TO FORMULATING A LOW-FAT MUFFIN PREGELATINIZED DULL WAXY CORN STARCHES MAY BE USED TO REDUCE FAT IN BAKERY PRODUCTS"" FOOD TECHNOLOGY,US,INSTITUTE OF FOOD TECHNOLOGISTS. CHICAGO, vol. 49, no. 3, 1 March 1995 (1995-03-01), pages 92-96, XP000495808 ISSN: 0015-6639;;DATABASE CHEMICAL ABSTRACTS [Online] Chemical Abstracts Service,Columbus, Ohio, USA; Vol. 118, no. 11, Abstract No. 100631 , 1992 K. KATSUTA ET AL.: ""Effects of saccharides on stabilities of rice starch gels"" XP002146735 & FOOD COLLOIDS, vol. 6, no. 4, 1992, pages 387-398,",EXPIRED
51,AU,B2,AU 2010/315805 B2,012-052-202-223-393,2015-09-17,2015,AU 2010/315805 A,2010-09-29,US 24693109 P;;US 2010/0050761 W,2009-09-29,Oligomer-calcimimetic conjugates and related compounds,"The invention relates to a conjugate comprising a calcimimetic, including cinacalcet, covalently attached via a linkage to a water-soluble, non-peptidic oligomer or polymer, preferably to poly (ethylene glycol).",NEKTAR THERAPEUTICS,RIGGS-SAUTHIER JENNIFER;;CHENG LIN;;MARTIN DAVID,,https://lens.org/012-052-202-223-393,Granted Patent,no,3,0,18,22,0,A61K47/60;;A61P13/02;;A61P13/12;;A61P3/14;;A61P5/18;;A61K47/60;;A61K9/20;;A61K9/48;;C07F3/04,A61K47/48,,0,0,,,,ACTIVE
52,CA,A1,CA 2773353 A1,018-787-433-406-483,2011-05-12,2011,CA 2773353 A,2010-09-29,US 24693109 P;;US 2010/0050761 W,2009-09-29,OLIGOMER-CALCIMIMETIC CONJUGATES AND RELATED COMPOUNDS,"The invention relates to a conjugate comprising a calcimimetic, including cinacalcet, covalently attached via a linkage to a water-soluble, non-peptidic oligomer or polymer, preferably to poly (ethylene glycol).",NEKTAR THERAPEUTICS,RIGGS-SAUTHIER JENNIFER;;CHENG LIN;;MARTIN DAVID,,https://lens.org/018-787-433-406-483,Patent Application,no,0,0,18,22,0,A61K47/60;;A61P13/02;;A61P13/12;;A61P3/14;;A61P5/18;;A61K47/60;;A61K9/20;;A61K9/48;;C07F3/04,A61K47/48;;A61P3/14;;A61P5/18,,0,0,,,,ACTIVE
53,CA,A1,CA 2339177 A1,071-724-510-703-478,2000-12-07,2000,CA 2339177 A,2000-06-01,US 32336699 A;;US 0015014 W,1999-06-01,THERMALLY-INHIBITED STARCH PREPARED WITH OLIGOSACCHARIDES,"The present invention is directed to a process of preparing thermally inhibited starches using oligosaccharides to improve the rate of inhibition. The resulting starch/oligosaccharide blends have improved cold storage stability and may be used in a variety of products, particularly food produc ts.",NAT STARCH CHEM INVEST,SHI YONG-CHENG;;GOODALL JENNIFER;;JEFFCOAT ROGER,,https://lens.org/071-724-510-703-478,Patent Application,no,0,0,15,15,0,A21D2/181;;A21D2/186;;C08B30/12;;C08B30/14;;C08B30/18;;C08L3/02;;C08L3/12;;A23L29/219;;C08B30/18;;A21D2/181;;C08B30/14;;C08B30/12;;A21D2/186;;C08L3/12;;C08L3/02;;A23L29/219,A01K1/015;;A21D2/18;;A23L1/0522;;A61K8/73;;A61K8/96;;A61K47/36;;A61Q5/00;;A61Q5/02;;C08B30/12;;C08B30/14;;C08B30/18;;C08L3/02;;C08L3/12,,0,0,,,,EXPIRED
54,AU,B2,AU 772968 B2,085-832-718-610-613,2004-05-13,2004,AU 2000/054530 A,2000-06-01,US 32336699 A;;US 0015014 W,1999-06-01,Thermally-inhibited starch prepared with oligosaccharides,"The present invention is directed to a process of preparing thermally inhibited starches using the low molecular weight carbohydrates to improve the rate of inhibition. The resulting starch/low molecular weight carbohydrate blends have improved cold storage stability and may be used in a variety of products, particularly food products.",NAT STARCH CHEM INVEST,SHI YONG-CHENG;;GOODALL JENNIFER;;JEFFCOAT ROGER,,https://lens.org/085-832-718-610-613,Granted Patent,no,2,0,15,15,0,A21D2/181;;A21D2/186;;C08B30/12;;C08B30/14;;C08B30/18;;C08L3/02;;C08L3/12;;A23L29/219;;C08B30/18;;A21D2/181;;C08B30/14;;C08B30/12;;A21D2/186;;C08L3/12;;C08L3/02;;A23L29/219,A01K1/015;;A21D2/18;;A23L1/0522;;A61K8/73;;A61K8/96;;A61K47/36;;A61Q5/00;;A61Q5/02;;C08B30/12;;C08B30/14;;C08B30/18;;C08L3/02;;C08L3/12,,0,0,,,,EXPIRED
55,CA,C,CA 2773353 C,125-812-301-317-914,2018-02-27,2018,CA 2773353 A,2010-09-29,US 24693109 P;;US 2010/0050761 W,2009-09-29,OLIGOMER-CALCIMIMETIC CONJUGATES AND RELATED COMPOUNDS,"The invention relates to a conjugate comprising a calcimimetic, including cinacalcet, covalently attached via a linkage to a water-soluble, non-peptidic oligomer or polymer, preferably to poly (ethylene glycol).",NEKTAR THERAPEUTICS,RIGGS-SAUTHIER JENNIFER;;CHENG LIN;;MARTIN DAVID,,https://lens.org/125-812-301-317-914,Granted Patent,no,0,0,18,22,0,A61K47/60;;A61P13/02;;A61P13/12;;A61P3/14;;A61P5/18;;A61K47/60;;A61K9/20;;A61K9/48;;C07F3/04,A61K47/60;;A61P3/14;;A61P5/18,,0,0,,,,ACTIVE
56,EP,A1,EP 1102792 A1,025-282-203-869-650,2001-05-30,2001,EP 00939446 A,2000-06-01,US 0015014 W;;US 32336699 A,1999-06-01,THERMALLY-INHIBITED STARCH PREPARED WITH OLIGOSACCHARIDES,"The present invention is directed to a process of preparing thermally inhibited starches using the low molecular weight carbohydrates to improve the rate of inhibition. The resulting starch/low molecular weight carbohydrate blends have improved cold storage stability and may be used in a variety of products, particularly food products.",NAT STARCH CHEM INVEST,SHI YONG-CHENG;;GOODALL JENNIFER;;JEFFCOAT ROGER,"CORN PRODUCTS DEVELOPMENT, INC., BR (2014-09-23);;CORN PRODUCTS DEVELOPMENT INC., WESTCHESTER, US (2012-07-02);;CORN PRODUCTS DEVELOPMENT INC., 60154 WESTCHES, US (2012-07-02)",https://lens.org/025-282-203-869-650,Patent Application,yes,0,7,15,15,0,A21D2/181;;A21D2/186;;C08B30/12;;C08B30/14;;C08B30/18;;C08L3/02;;C08L3/12;;A23L29/219;;C08B30/18;;A21D2/181;;C08B30/14;;C08B30/12;;A21D2/186;;C08L3/12;;C08L3/02;;A23L29/219,A01K1/015;;A21D2/18;;A23L1/0522;;A61K8/73;;A61K8/96;;A61K47/36;;A61Q5/00;;A61Q5/02;;C08B30/12;;C08B30/14;;C08B30/18;;C08L3/02;;C08L3/12,,0,0,,,,EXPIRED
57,US,B2,US 8722732 B2,045-363-380-712-494,2014-05-13,2014,US 201213433100 A,2012-03-28,US 201213433100 A;;US 2010/0050761 W;;US 24693109 P;;US 201261597663 P,2009-09-29,Oligomer-calcimimetic conjugates and related compounds,"The invention relates to (among other things) oligomer-calcimimetic conjugates and related compounds. A conjugate of the invention, when administered by any of a number of administration routes, exhibits advantages over previously administered compounds.",RIGGS-SAUTHIER JENNIFER;;CHENG LIN;;MARTIN DAVID;;NEKTAR THERAPEUTICS,RIGGS-SAUTHIER JENNIFER;;CHENG LIN;;MARTIN DAVID,NEKTAR THERAPEUTICS (2012-05-02),https://lens.org/045-363-380-712-494,Granted Patent,yes,25,1,4,22,0,A61K47/60;;A61K47/60;;A61P5/10;;A61P5/20;;C07B2200/11;;C07B2200/11;;C07C211/30;;C07C211/30;;C07C271/14;;C07C271/14,A61P5/10;;A61K31/137;;A61K31/27;;C07C271/14,514/481;;514/654;;560/28;;564/374,33,12,000-734-409-407-897;;031-087-568-760-731;;058-789-596-477-892;;037-957-737-402-076;;011-328-347-291-336;;000-055-258-100-593;;093-496-833-263-469;;027-230-470-821-73X;;059-775-367-221-34X;;049-145-179-244-094;;067-739-378-974-664;;072-196-496-138-563,11751111;;10.1128/aac.46.1.55-61.2002;;pmc127003;;10.1021/bc00013a001;;1616945;;11674697;;10.1021/jo990620m;;18578475;;10.1021/jm8002558;;12753275;;10.1046/j.1523-1755.63.s85.22.x;;10.1021/bc700333s;;18370417;;10.1056/nejmoa031633;;15071126;;8255296;;10.1038/366575a0;;18004298;;10.1038/sj.ki.5002675;;14593085;;10.1124/jpet.103.057273;;pmc19959;;9520489;;10.1073/pnas.95.7.4040;;10.1152/ajprenal.00302.2004;;15507543,"Bacchi, et al., ""Novel Synthetic Polyamines Are Effective in the Treatment of Experimental Microsporidiosis, an Opportunistic AIDS-Associated Infection"", Antimicrobial Agents and Chemotherapy, vol. 46, No. 1, pp. 55-61, (Jan. 2002).;;Brinkley, ""A Brief Survey of Methods for Preparing Protein Conjugates with Dyes, Haptens, and Cross-Linking Reagents"", Bioconjugate Chem., vol. 3, pp. 2-13, (1992).;;Chen, et al., ""Synthesis and Properties of ABA Amphiphiles"", J. Org. Chem., vol. 64, pp. 6870-6873, (1999).;;Marcus, et al., ""Turning Low-Molecular-Weight Drugs into Prolonged Acting Prodrugs by Reversible Pegylation: A Study with Gentamicin"", Journal of Medicinal Chemistry, vol. 51, No. 14, pp. 4300-4305, (2008).;;Urena, et al., ""Calcimimetic agents: Review and perspectives"", Kidney International, vol. 63, Supplement No. 85, pp. S91-S96, (2003).;;Zhao, et al., ""Novel Prodrugs of SN38 Using Multiarm Poly(ethylene glycol) Linkers"", Bioconjugate Chem., vol. 19, pp. 849-859, (2008).;;PCT International Search Report corresponding to PCT Application No. PCT/US2010/050761 date of mailing May 20, 2011.;;PCT International Preliminary Report on Patentability and Written Opinion corresponding to PCT Application No. PCT/US2010/050761 dated of mailing Apr. 12, 2012.;;Enzon Pharmaceuticals, Macromolecular Engineering Technologies, 16 pages, (2004).;;Nektar(TM)-Transforming Therapeutics, Nektar Molecule Engineering: Polyethylene Glycol and Derivatives for Advanced PEGylation, 24 pages, Catalog-2003, (Jul. 2003).;;Nektar(TM)-Transforming Therapeutics, Nektar Advanced PEGylation: Polyethylene Glycol and Derivatives for Advanced PEGylation, 27 pages, Catalog-2004, (Jul. 2004).;;Nektar(TM)-Transforming Therapeutics, Nektar Advanced PEGylation: Polyethylene Glycol and Derivatives for Advanced PEGylation, 33 pages, (Catalog 2005-2006).;;NOF Corporation, PEG Derivatives, Phospholipid and Drug Delivery Materials for Pharmaceuticals, 46 pages, Catalogue 2003-1st, (Jan. 2003).;;NOF Corporation, PEG Derivatives, Phospholipid and Drug Delivery Materials for Pharmaceuticals, 27 pages, Catalogue 2003-2nd, (Mar. 2004).;;NOF Corporation, PEG Derivatives, Phospholipids and Drug Delivery Materials for Pharmaceutical Products and Formulations, 60 pages, Catalogue Ver. 8, (Apr. 2006).;;Polypure Products, PEG amines; PEG acids and amino acids; PEG thiols and disulfides; Biotins, 5 pages, (Apr. 2004).;;Polypure Products, PEG amines; PEG acids and amino acids; PEG thiols and disulfides; Biotins, 5 pages, (Apr. 2005).;;Quanta Biodesign, Labeling, Derivatization and Crosslinking Reagents for Biological and Related Materials with dPEG(TM), 38 pages, (Mar. 12, 2004).;;Quanta Biodesign, Labeling, Modification and Crosslinking Reagents incorporating our unique monodispersed dPEG(TM) Technology, 31 pages, (Nov. 5, 2004).;;Quanta Biodesign, Ltd., Leading innovator, producer and provider of monodisperse discrete PEG(TM) (dPEG(TM)) derivatives, (Product Catalog), 26 pages, (Updated: Jul. 18, 2005).;;Quanta Biodesign, Ltd., Leading innovator, producer and provider of monodisperse discrete PEG(TM) (dPEG(TM)) derivatives, (Product Catalog), 26 pages, (Updated: Nov. 17, 2005).;;Shearwater Polymers, Inc., Polyethylene Glycol Derivatives, 50 pages, Catalog-(Mar. 1995).;;Shearwater Polymers, Inc., Polyethylene Glycol Derivatives, 55 pages, Catalog 1997-1998, (Jul. 1997).;;Shearwater Polymers, Inc., Polyethylene Glycol and Derivatives: Functionalized Biocompatible Polymers for Research and Pharmaceuticals, 50 pages, Catalog-(Jan. 2000).;;Shearwater Corporation, Polyethylene Glycol and Derivatives for Biomedical Applications, 20 pages, Catalog-(Jul. 2001).;;Block, et al., ""Cinacalcet for Secondary Hyperparathyroidism in Patients Receiving Hemodialysis"", N. Engl. J. Med., vol. 350, No. 15, pp. 1516-1525, (Apr. 2004).;;Brown, et al., ""Cloning and Characterization of an Extracellular Ca2+-Sensing Receptor from Bovine Parathyroid"", Nature, vol. 366, pp. 575-580, (Dec. 1993).;;Lopez, et al., ""The Effect of Calcitriol, Paricalcitol, and a Calcimimetic on Extraosseous Calcifications in Uremic Rats"", Kidney International, vol. 73, pp. 300-307, (2008).;;Nemeth, et al., ""Pharmacodynamics of the Type II Calcimimetic Compound Cinacalcet HCI"", Journal of Pharmacology and Experimental Therapeutics, vol. 308, No. 2, pp. 627-635, (2004).;;Nemeth, et al., ""Calcimimetics with Potent and Selective Activity on the Parathyroid Calcium Receptor"", Proc. Natl. Acad. Sci. USA, vol. 95, pp. 4040-4045, (Mar. 1998).;;Rodriguez, et al., ""The Calcium-Sensing Receptor: a Key Factor in the Pathogenesis of Secondary Hyperparathyroidism"", Am. J. Physiol. Renal Physiol., vol. 288, pp. F253-F264, (Feb. 2005).;;Chinese First Office Action corresponding to Chinese Patent Application No. 201080043400.0 dated Feb. 28, 2013.;;European Office Action corresponding to European Patent Application No. 10 810 996.8-1453 dated Jun. 17, 2013.",ACTIVE
58,US,B2,US 9421275 B2,129-963-172-304-52X,2016-08-23,2016,US 201414223572 A,2014-03-24,US 201414223572 A;;US 201213433100 A;;US 2010/0050761 W;;US 24693109 P;;US 201261597663 P,2009-09-29,Oligomer-calcimimetic conjugates and related compunds,"The invention relates to (among other things) oligomer-calcimimetic conjugates and related compounds. A conjugate of the invention, when administered by any of a number of administration routes, exhibits advantages over previously administered compounds.",NEKTAR THERAPEUTICS,RIGGS-SAUTHIER JENNIFER;;CHENG LIN;;MARTIN DAVID,,https://lens.org/129-963-172-304-52X,Granted Patent,yes,27,0,4,22,0,A61K47/60;;A61K47/60;;A61P5/10;;A61P5/20;;C07B2200/11;;C07B2200/11;;C07C211/30;;C07C211/30;;C07C271/14;;C07C271/14,A61P5/10;;A61K31/137;;A61K31/27;;A61K47/48;;C07C211/30;;C07C271/14,,40,12,000-734-409-407-897;;093-496-833-263-469;;031-087-568-760-731;;027-230-470-821-73X;;058-789-596-477-892;;059-775-367-221-34X;;037-957-737-402-076;;067-739-378-974-664;;049-145-179-244-094;;072-196-496-138-563;;011-328-347-291-336;;000-055-258-100-593,11751111;;10.1128/aac.46.1.55-61.2002;;pmc127003;;10.1056/nejmoa031633;;15071126;;10.1021/bc00013a001;;1616945;;8255296;;10.1038/366575a0;;11674697;;10.1021/jo990620m;;18004298;;10.1038/sj.ki.5002675;;18578475;;10.1021/jm8002558;;pmc19959;;9520489;;10.1073/pnas.95.7.4040;;14593085;;10.1124/jpet.103.057273;;10.1152/ajprenal.00302.2004;;15507543;;12753275;;10.1046/j.1523-1755.63.s85.22.x;;10.1021/bc700333s;;18370417,"Bacchi, et al., ""Novel Synthetic Polyamines Are Effective in the Treatment of Experimental Microsporidiosis, an Opportunistic AIDS-Associated Infection"", Antimicrobial Agents and Chemotherapy, vol. 46, No. 1, pp. 55-61, (Jan. 2002).;;Block, et al., ""Cinacalcet for Secondary Hyperparathyroidism in Patients Receiving Hemodialysis"", N. Engl. J. Med., vol. 350, No. 15, pp. 1516-1525, (Apr. 2004).;;Brinkley, ""A Brief Survey of Methods for Preparing Protein Conjugates with Dyes, Haptens, and Cross-Linking Reagents"", Bioconjugate Chem., vol. 3, pp. 2-13, (1992).;;Brown, et al., ""Cloning and Characterization of an Extracellular Ca2+-Sensing Receptor from Bovine Parathyroid"", Nature, vol. 366, pp. 575-580, (Dec. 1993).;;Chen, et al., ""Synthesis and Properties of ABA Amphiphiles"", J. Org. Chem., vol. 64, pp. 6870-6873, (1999).;;Lopez, et al., ""The Effect of Calcitriol, Paricalcitol, and a Calcimimetic on Extraosseous Calcifications in Uremic Rats"", Kidney International, vol. 73, pp. 300-307, (2008).;;Marcus, et al., ""Turning Low-Molecular-Weight Drugs into Prolonged Acting Prodrugs by Reversible Pegylation: A Study with Gentamicin"", Journal of Medicinal Chemistry, vol. 51, No. 14, pp. 4300-4305, (2008).;;Nemeth, et al., ""Calcimimetics with Potent and Selective Activity on the Parathyroid Calcium Receptor"", Proc. Natl. Acad. Sci. USA, vol. 95, pp. 4040-4045, (Mar. 1998).;;Nemeth, et al., ""Pharmacodynamics of the Type II Calcimimetic Compound Cinacalcet HCI"", Journal of Pharmacology and Experimental Therapeutics, vol. 308, No. 2, pp. 627-635, (2004).;;Rodriguez, et al., ""The Calcium-Sensing Receptor: a Key Factor in the Pathogenesis of Secondary Hyperparathyroidism"", Am. J. Physiol. Renal Physiol., vol. 288, pp. F253-F264, (Feb. 2005).;;Urena, et al., ""Calcimimetic agents: Review and perspectives"", Kidney International, vol. 63, Supplement No. 85, pp. S91-S96, (2003).;;Zhao, et al., ""Novel Prodrugs of SN38 Using Multiarm Poly(ethylene glycol) Linkers"", Bioconjugate Chem., vol. 19, pp. 849-859, (2008).;;PCT International Search Report corresponding to PCT Application No. PCT/US2010/050761 date of mailing May 20, 2011.;;PCT International Preliminary Report on Patentability and Written Opinion corresponding to PCT Application No. PCT/US2010/050761 date of mailing Apr. 12, 2012.;;Enzon Pharmaceuticals, Macromolecular Engineering Technologies, 16 pages, (2004).;;NEKTAR(TM)-Transforming Therapeutics, Nektar Molecule Engineering: Polyethylene Glycol and Derivatives for Advanced PEGylation, 24 pages, Catalog-2003, (Jul. 2003).;;NEKTAR(TM)-Transforming Therapeutics, Nektar Advanced PEGylation: Polyethylene Glycol and Derivatives for Advanced PEGylation, 27 pages, Catalog-2004, (Jul. 2004).;;NEKTAR(TM)-Transforming Therapeutics, Nektar Advanced PEGylation: Polyethylene Glycol and Derivatives for Advanced PEGylation, 33 pages, (Catalog 2005-2006).;;NOF Corporation, PEG Derivatives, Phospholipid and Drug Delivery Materials for Pharmaceuticals, 46 pages, Catalogue 2003-1st, (Jan. 2003).;;NOF Corporation, PEG Derivatives, Phospholipid and Drug Delivery Materials for Pharmaceuticals, 27 pages, Catalogue 2003-2nd, (Mar. 2004).;;NOF Corporation, PEG Derivatives, Phospholipids and Drug Delivery Materials for Pharmaceutical Products and Formulations, 60 pages, Catalogue Ver. 8, (Apr. 2006).;;Polypure Products, PEG amines; PEG acids and amino acids; PEG thiols and disulfides; Biotins, 5 pages, (Apr. 2004).;;Polypure Products, PEG amines; PEG acids and amino acids; PEG thiols and disulfides; Biotins, 5 pages, (Apr. 2005).;;Quanta Biodesign, Labeling, Derivatization and Crosslinking Reagents for Biological and Related Materials with dPEG(TM), 38 pages, (Mar. 12, 2004).;;Quanta Biodesign, Labeling, Modification and Crosslinking Reagents incorporating our unique monodispersed dPEG(TM) Technology, 31 pages, (Nov. 5, 2004).;;Quanta Biodesign, Ltd., Leading innovator, producer and provider of monodisperse discrete PEG(TM) (dPEG(TM)) derivatives, (Product Catalog), 26 pages, (Updated: Jul. 18, 2005).;;Quanta Biodesign, Ltd., Leading innovator, producer and provider of monodisperse discrete PEG(TM) (dPEG(TM)) derivatives, (Product Catalog), 26 pages, (Updated: Nov. 17, 2005).;;Shearwater Polymers, Inc., Polyethylene Glycol Derivatives, 50 pages, Catalog-(Mar. 1995).;;Shearwater Polymers, Inc., Polyethylene Glycol Derivatives, 55 pages, Catalog 1997-1998, (Jul. 1997).;;Shearwater Polymers, Inc., Polyethylene Glycol and Derivatives: Functionalized Biocompatible Polymers for Research and Pharmaceuticals, 50 pages, Catalog-(Jan. 2000).;;Shearwater Corporation, Polyethylene Glycol and Derivatives for Biomedical Applications, 20 pages, Catalog-(Jul. 2001).;;Chinese First Office Action corresponding to Chinese Patent Application No. 201080043400.0 dated Feb. 28, 2013.;;European Office Action corresponding to European Patent Application No. 10 810 996.8-1453 dated Jun. 17, 2013.;;Chinese Second Office Action corresponding to Chinese Patent Application No. 201080043400.0 dated Nov. 25, 2013.;;Australian Patent Examination Report No. 1 in Australian Patent Application No. 2010315805 dated Sep. 10, 2014.;;English translation of Chinese Third Office Action in Chinese Patent Application No. 201080043400.0 dated Jun. 4, 2014.;;English translation of Chinese Fourth Office Action in Chinese Patent Application No. 201080043400.0 dated Feb. 3, 2015.;;English translation of Israeli First Substantive Examination Report in Israeli Patent Application No. 218869 dated Jan. 25, 2015.;;English translation of Japanese Notice of Reasons for Rejection in Japanese Patent Application No. 2012-531124 mailed Oct. 30, 2014.;;English Translation of Israeli Substantive Examination Report in Israeli Patent Application No. 218869 dated Jun. 30, 2015.",ACTIVE
59,CA,C,CA 2339177 C,062-330-030-324-040,2006-03-21,2006,CA 2339177 A,2000-06-01,US 32336699 A;;US 0015014 W,1999-06-01,THERMALLY-INHIBITED STARCH PREPARED WITH OLIGOSACCHARIDES,"The present invention is directed to a process of preparing thermally inhibited starches using oligosaccharides to improve the rate of inhibition. The resulting starch/oligosaccharide blends have improved cold storage stability and may be used in a variety of products, particularly food products.",NAT STARCH CHEM INVEST,JEFFCOAT ROGER;;SHI YONG-CHENG;;GOODALL JENNIFER,,https://lens.org/062-330-030-324-040,Granted Patent,no,0,0,15,15,0,A21D2/181;;A21D2/186;;C08B30/12;;C08B30/14;;C08B30/18;;C08L3/02;;C08L3/12;;A23L29/219;;C08B30/18;;A21D2/181;;C08B30/14;;C08B30/12;;A21D2/186;;C08L3/12;;C08L3/02;;A23L29/219,A01K1/015;;C08L3/02;;A21D2/18;;A23L1/0522;;A61K8/73;;A61K8/96;;A61K47/36;;A61Q5/00;;A61Q5/02;;C08B30/12;;C08B30/14;;C08B30/18;;C08L3/12,,0,0,,,,EXPIRED
60,BR,B1,BR 0006170 B1,100-893-347-228-298,2011-09-20,2011,BR 0006170 A,2000-06-01,US 32336699 A;;US 0015014 W,1999-06-01,processo de preparação de uma mistura de amido termicamente inibido/oligossacarìdeos e mistura de amido termicamente inibido/oligossacarìdeos.,"The present invention is directed to a process of preparing thermally inhibited starches using the low molecular weight carbohydrates to improve the rate of inhibition. The resulting starch/low molecular weight carbohydrate blends have improved cold storage stability and may be used in a variety of products, particularly food products.",,SHI YONG-CHENG;;GOODALL JENNIFER;;JEFFCOAT ROGER,,https://lens.org/100-893-347-228-298,Granted Patent,no,0,0,15,15,0,A21D2/181;;A21D2/186;;C08B30/12;;C08B30/14;;C08B30/18;;C08L3/02;;C08L3/12;;A23L29/219;;C08B30/18;;A21D2/181;;C08B30/14;;C08B30/12;;A21D2/186;;C08L3/12;;C08L3/02;;A23L29/219,A01K1/015;;C08B30/12;;A21D2/18;;A23L1/0522;;A61K8/73;;A61K8/96;;A61K47/36;;A61Q5/00;;A61Q5/02;;C08B30/14;;C08B30/18;;C08L3/02;;C08L3/12,,0,0,,,,EXPIRED
61,AU,A,AU 2000/054530 A,026-417-392-001-499,2000-12-18,2000,AU 2000/054530 A,2000-06-01,US 32336699 A;;US 0015014 W,1999-06-01,Thermally-inhibited starch prepared with oligosaccharides,"The present invention is directed to a process of preparing thermally inhibited starches using the low molecular weight carbohydrates to improve the rate of inhibition. The resulting starch/low molecular weight carbohydrate blends have improved cold storage stability and may be used in a variety of products, particularly food products.",CORN PRODUCTS DEVELOPMENT INC,SHI YONG-CHENG;;GOODALL JENNIFER;;JEFFCOAT ROGER,,https://lens.org/026-417-392-001-499,Patent Application,no,0,0,15,15,0,A21D2/181;;A21D2/186;;C08B30/12;;C08B30/14;;C08B30/18;;C08L3/02;;C08L3/12;;A23L29/219;;C08B30/18;;A21D2/181;;C08B30/14;;C08B30/12;;A21D2/186;;C08L3/12;;C08L3/02;;A23L29/219,A01K1/015;;A21D2/18;;A23L1/0522;;A61K8/73;;A61K8/96;;A61K47/36;;A61Q5/00;;A61Q5/02;;C08B30/12;;C08B30/14;;C08B30/18;;C08L3/02;;C08L3/12,,0,0,,,,EXPIRED
62,WO,A3,WO 2011/056325 A3,024-173-164-285-660,2011-09-29,2011,US 2010/0050761 W,2010-09-29,US 24693109 P,2009-09-29,OLIGOMER-CALCIMIMETIC CONJUGATES AND RELATED COMPOUNDS,"The invention relates to a conjugate comprising a calcimimetic, including cinacalcet, covalently attached via a linkage to a water-soluble, non-peptidic oligomer or polymer, preferably to poly (ethylene glycol).",NEKTAR THERAPEUTICS;;RIGGS-SAUTHIER JENNIFER;;CHENG LIN;;MARTIN DAVID,RIGGS-SAUTHIER JENNIFER;;CHENG LIN;;MARTIN DAVID,,https://lens.org/024-173-164-285-660,Search Report,yes,3,0,18,22,0,A61K47/60;;A61P13/02;;A61P13/12;;A61P3/14;;A61P5/18;;A61K47/60;;A61K9/20;;A61K9/48;;C07F3/04,A61K47/48,,2,2,037-957-737-402-076;;011-328-347-291-336,18578475;;10.1021/jm8002558;;12753275;;10.1046/j.1523-1755.63.s85.22.x,"MARCUS YONIT ET AL: ""Turning low-molecular-weight drugs into prolonged acting prodrugs by reversible pegylation: A study with gentamicin"", JOURNAL OF MEDICINAL CHEMISTRY, vol. 51, no. 14, July 2008 (2008-07-01), pages 4300 - 4305, XP002636000, ISSN: 0022-2623, DOI: 10.1021/JM8002558;;UREÑA PABLO ET AL: ""Calcimimetic agents: review and perspectives."", KIDNEY INTERNATIONAL. SUPPLEMENT JUN 2003, vol. 63, no. 85, June 2003 (2003-06-01), pages S91 - S96, XP002636001, ISSN: 0098-6577",PENDING
63,WO,A1,WO 2000/073353 A1,047-095-005-694-874,2000-12-07,2000,US 0015014 W,2000-06-01,US 32336699 A,1999-06-01,THERMALLY-INHIBITED STARCH PREPARED WITH OLIGOSACCHARIDES,"The present invention is directed to a process of preparing thermally inhibited starches using oligosaccharides to improve the rate of inhibition. The resulting starch/oligosaccharide blends have improved cold storage stability and may be used in a variety of products, particularly food products.",NAT STARCH CHEM INVEST,SHI YONG-CHENG;;GOODALL JENNIFER;;JEFFCOAT ROGER,,https://lens.org/047-095-005-694-874,Patent Application,yes,7,10,15,15,0,A21D2/181;;A21D2/186;;C08B30/12;;C08B30/14;;C08B30/18;;C08L3/02;;C08L3/12;;A23L29/219;;C08B30/18;;A21D2/181;;C08B30/14;;C08B30/12;;A21D2/186;;C08L3/12;;C08L3/02;;A23L29/219,A01K1/015;;A21D2/18;;A23L1/0522;;A61K8/73;;A61K8/96;;A61K47/36;;A61Q5/00;;A61Q5/02;;C08B30/12;;C08B30/14;;C08B30/18;;C08L3/02;;C08L3/12,,2,0,,,"HIPPLEHEUSER A L ET AL: ""A SYSTEM APPROACH TO FORMULATING A LOW-FAT MUFFIN PREGELATINIZED DULL WAXY CORN STARCHES MAY BE USED TO REDUCE FAT IN BAKERY PRODUCTS"", FOOD TECHNOLOGY,US,INSTITUTE OF FOOD TECHNOLOGISTS. CHICAGO, vol. 49, no. 3, 1 March 1995 (1995-03-01), pages 92 - 96, XP000495808, ISSN: 0015-6639;;DATABASE CHEMICAL ABSTRACTS Chemical Abstracts Service,Columbus, Ohio, USA; 1992, K. KATSUTA ET AL.: ""Effects of saccharides on stabilities of rice starch gels"", XP002146735",PATENTED
64,BR,A,BR 0006170 A,029-350-450-496-369,2001-12-04,2001,BR 0006170 A,2000-06-01,US 32336699 A;;US 0015014 W,1999-06-01,Amido inibido termicamente preparado comoligossacarìdeos,"The present invention is directed to a process of preparing thermally inhibited starches using the low molecular weight carbohydrates to improve the rate of inhibition. The resulting starch/low molecular weight carbohydrate blends have improved cold storage stability and may be used in a variety of products, particularly food products.",NAT STARCH CHEM INVEST,SHI YONG-CHENG;;GOODALL JENNIFER;;JEFFCOAT ROGER,,https://lens.org/029-350-450-496-369,Patent Application,no,0,0,15,15,0,A21D2/181;;A21D2/186;;C08B30/12;;C08B30/14;;C08B30/18;;C08L3/02;;C08L3/12;;A23L29/219;;C08B30/18;;A21D2/181;;C08B30/14;;C08B30/12;;A21D2/186;;C08L3/12;;C08L3/02;;A23L29/219,A01K1/015;;A21D2/18;;A23L1/0522;;A61K8/73;;A61K8/96;;A61K47/36;;A61Q5/00;;A61Q5/02;;C08B30/12;;C08B30/14;;C08B30/18;;C08L3/02;;C08L3/12,,0,0,,,,EXPIRED
65,US,B1,US 6277186 B1,152-602-563-144-797,2001-08-21,2001,US 32336699 A,1999-06-01,US 32336699 A,1999-06-01,Thermally-inhibited starch prepared with oligosaccharides,"The present invention is directed to a process of preparing thermally inhibited starches using the low molecular weight carbohydrates to improve the rate of inhibition. The resulting starch/low molecular weight carbohydrate blends have improved cold storage stability and may be used in a variety of products, particularly food products.",NAT STARCH CHEM INVEST,SHI YONG-CHENG;;GOODALL JENNIFER;;JEFFCOAT ROGER,CORN PRODUCTS DEVELOPMENT INC (2011-12-19);;BRUNOB II B.V (2008-04-01);;NATIONAL STARCH AND CHEMICAL INVESTMENT HOLDING CORPORATION (1999-08-05),https://lens.org/152-602-563-144-797,Granted Patent,yes,13,27,15,15,0,A21D2/181;;A21D2/186;;C08B30/12;;C08B30/14;;C08B30/18;;C08L3/02;;C08L3/12;;A23L29/219;;C08B30/18;;A21D2/181;;C08B30/14;;C08B30/12;;A21D2/186;;C08L3/12;;C08L3/02;;A23L29/219,A01K1/015;;A21D2/18;;A23L1/0522;;A61K8/73;;A61K8/96;;A61K47/36;;A61Q5/00;;A61Q5/02;;C08B30/12;;C08B30/14;;C08B30/18;;C08L3/02;;C08L3/12,106/205.72;;106/215.5,3,2,015-781-143-657-288;;006-446-103-242-059,10.1002/star.19870390306;;10.1002/star.19890410306,"Theander, et al., ""Studies on Chemical Modifications in Heat-Processed Starch and Wheat Flour"" Starke 39 (1987) No Month Provided Nr. 3, S. 88-93.;;Siljestrom et al., ""Transglycosidation Reactions following Heat Treatment of Starch-Effects on Enzymic Digestibility"" Starke 41 (1989) No Month Provided Nr. 3, S. 95-100.;;Hippleheuser A. L. et. al., ""A System Approach to Formulating A Low-Fat Muffin Pregelatinized Dull Waxy Corn Starches May be Used To Reduce Fat In Bakery Products"", Food Technology, US, Instittue of Food Technologists. vol. 49, No. 3, Mar. 1, 1995, pp. 92-96 XP000495808 SSN: 0015-6639 p. 93, Left-hand column; table 1.",EXPIRED
66,EP,A2,EP 2482855 A2,161-102-078-175-069,2012-08-08,2012,EP 10810996 A,2010-09-29,US 24693109 P;;US 2010/0050761 W,2009-09-29,OLIGOMER-CALCIMIMETIC CONJUGATES AND RELATED COMPOUNDS,,NEKTAR THERAPEUTICS,RIGGS-SAUTHIER JENNIFER;;CHENG LIN;;MARTIN DAVID,NEKTAR THERAPEUTICS (2017-12-20),https://lens.org/161-102-078-175-069,Patent Application,yes,0,0,18,22,0,A61K47/60;;A61P13/02;;A61P13/12;;A61P3/14;;A61P5/18;;A61K47/60;;A61K9/20;;A61K9/48;;C07F3/04,A61K47/60,,0,0,,,,ACTIVE
67,US,A1,US 2015/0250894 A1,052-005-284-954-796,2015-09-10,2015,US 201314428816 A,2013-09-17,US 201314428816 A;;US 201261702088 P;;US 2013/0060179 W,2012-09-17,Oligomer-Containing Benzamide-Based Compounds,The invention relates to (among other things) oligomer-containing benzamide-based compounds. A compound of the invention exhibits one or more advantages over corresponding compounds lacking the oligomer.,NEKTAR THERAPEUTICS,CHENG LIN;;RIGGS-SAUTHIER JENNIFER;;ANAND NEEL K,NEKTAR THERAPEUTICS (2015-02-23),https://lens.org/052-005-284-954-796,Patent Application,yes,0,2,11,11,0,C07C237/44;;A61K31/166;;A61K47/60;;A61P1/04;;C07C237/44;;A61K31/166;;C07C231/12;;A61K47/60;;A61K47/59,A61K47/48;;A61K31/166;;C07C231/12;;C07C237/44,,0,0,,,,ACTIVE
68,US,A1,US 2018/0185499 A1,119-886-676-500-381,2018-07-05,2018,US 201815908286 A,2018-02-28,US 201815908286 A;;US 201615164607 A;;US 201514428816 A;;US 2013/0060179 W;;US 201261702088 P,2012-09-17,OLIGOMER-CONTAINING BENZAMIDE-BASED COMPOUNDS,The invention relates to (among other things) oligomer-containing benzamide-based compound compounds. A compound of the invention exhibits one or more advantages over corresponding compounds lacking the oligomer.,NEKTAR THERAPEUTICS,CHENG LIN;;RIGGS-SAUTHIER JENNIFER;;ANAND NEEL K,,https://lens.org/119-886-676-500-381,Patent Application,yes,0,0,11,11,0,C07C237/44;;A61K31/166;;A61K47/60;;A61P1/04;;C07C237/44;;A61K31/166;;C07C231/12;;A61K47/60;;A61K47/59,A61K47/59;;A61K31/166;;C07C231/12;;C07C237/44,,0,0,,,,ACTIVE
69,US,A1,US 2014/0235261 A1,187-646-428-488-540,2014-08-21,2014,US 201414263919 A,2014-04-28,US 201414263919 A;;US 84513110 A,2010-07-28,FEMTOCELL SERVICE THROUGH A SECONDARY CONNECTION,"System(s), apparatus(es), and method(s) are provided to for providing femtocell service through a secondary connection to a network gateway node that is part of a service provider network. The secondary connection can be established in response to at least one telecommunication performance condition of a primary connection to the network gateway node; the at least one performance condition includes connectivity state of the primary connection or quality of traffic delivery through the primary connection. The secondary connection can be established, in part, via a home gateway node that is alternative to a home gateway node associated with a femtocell access point (AP) that enables, in part, the femtocell wireless service. The main home gateway node or the femtocell AP can initiate establishment of the secondary connection. Home gateway node(s) or femtocell AP(s) that can provide femtocell service through the secondary connection can manage connectivity with the network gateway node.",AT & T IP I LP,FAN JAMES;;LAM JENNIFER K;;LIU CHENG P,AT&T INTELLECTUAL PROPERTY I L.P (2010-07-24),https://lens.org/187-646-428-488-540,Patent Application,yes,1,18,6,6,0,H04W24/00;;H04W84/045;;H04W88/16;;H04W76/20;;H04W76/10;;H04W40/02;;H04W24/04;;H04W8/30;;H04W84/045;;H04W88/16;;H04W76/20;;H04W76/10;;H04W72/52;;H04W28/0289,H04W72/04,455/452.1,0,0,,,,ACTIVE
70,US,A1,US 2011/0307932 A1,029-289-032-774-012,2011-12-15,2011,US 81400110 A,2010-06-11,US 81400110 A,2010-06-11,INTEGRATING VIDEO SHARE AND TEXT MESSAGING WITH SET-TOP BOX AND ACCESS POINT,"System(s), method(s), and device(s) providing converged wireline and wireless services in part by employing a set-top box (STB) with machine-to-machine (M2M) communication are presented. The STB, associated with an access point, such as a femtocell, can be used to send/receive messages, including video, to/from user equipment (UE) via a core network. A monitoring system includes a sensor component that is triggered under specified conditions, and the STB records events in response to the trigger, where a recorded event can be sent as a message to the UE. The STB or associated remote control can indicate a received message to a user, who can view the message on the STB, remote control, or associated television. A meter component is associated with the STB via the femtocell or other desired connection. The STB can receive and store utility meter readings for validation or dispute by the user.",FAN JAMES;;LAM JENNIFER K;;LIU CHENG P;;AT & T IP I LP,FAN JAMES;;LAM JENNIFER K;;LIU CHENG P,AT&T INTELLECTUAL PROPERTY I L.P (2010-06-10),https://lens.org/029-289-032-774-012,Patent Application,yes,4,78,6,6,0,G01D4/004;;H04N21/4788;;H04N21/4788;;H04N21/2547;;H04N21/2547;;H04N21/4131;;H04N21/4786;;H04N21/4786;;H04N21/488;;H04N21/8126;;Y02B90/20;;Y04S20/30,H04N7/173,725/110,0,0,,,,INACTIVE
71,US,B2,US 9942783 B2,175-113-148-853-411,2018-04-10,2018,US 201615293238 A,2016-10-13,US 201615293238 A;;US 201414263919 A;;US 84513110 A,2010-07-28,Femtocell service through a secondary connection,"Femtocell service is provided through a secondary connection to a network gateway node that is part of a service provider network. The secondary connection can be established in response to at least one telecommunication performance condition of a primary connection to the network gateway node; the at least one performance condition includes connectivity state of the primary connection or quality of traffic delivery through the primary connection. The secondary connection can be established, in part, via a home gateway node that is alternative to a home gateway node associated with a femtocell access point (AP) that enables, in part, the femtocell wireless service. The main home gateway node or the femtocell AP can initiate establishment of the secondary connection. Home gateway node(s) or femtocell AP(s) that can provide femtocell service through the secondary connection can manage connectivity with the network gateway node.",AT & T IP I LP,FAN JAMES;;LAM JENNIFER K;;LIU CHENG P,AT&T INTELLECTUAL PROPERTY I L.P (2010-07-24),https://lens.org/175-113-148-853-411,Granted Patent,yes,9,5,6,6,0,H04W24/00;;H04W84/045;;H04W88/16;;H04W76/20;;H04W76/10;;H04W40/02;;H04W24/04;;H04W8/30;;H04W84/045;;H04W88/16;;H04W76/20;;H04W76/10;;H04W72/52;;H04W28/0289,H04W8/30;;H04W24/00;;H04W24/04;;H04W28/02;;H04W40/02;;H04W72/04;;H04W84/04;;H04W88/16,,4,0,,,"Office Action dated Jul. 23, 2012 for U.S. Appl. No. 12/845,131, 17 pages.;;Office Action dated Dec. 17, 2012 for U.S. Appl. No. 12/845,131, 17 pages.;;Office Action dated Jul. 29, 2013 for U.S. Appl. No. 12/845,131, 24 pages.;;Office Action dated Feb. 4, 2016 for U.S. Appl. No. 14/263,919, 16 pages.",ACTIVE
72,US,A1,US 2016/0100223 A1,057-285-275-163-993,2016-04-07,2016,US 201514970476 A,2015-12-15,US 201514970476 A;;US 201514752597 A;;US 81400110 A,2010-06-11,INTEGRATING VIDEO SHARE AND TEXT MESSAGING WITH SET-TOP BOX AND ACCESS POINT,"Techniques provide for converged wireline and wireless services in part by employing a set-top box (STB) with machine-to-machine (M2M) communication. The STB, associated with an access point, such as a femtocell, can be used to send/receive messages, including video, to/from user equipment (UE) via a core network. A monitoring system includes a sensor component that is triggered under specified conditions, and the STB records events in response to the trigger, where a recorded event can be sent as a message to the UE. The STB or associated remote control can indicate a received message to a user, who can view the message on the STB, remote control, or associated television. A meter component is associated with the STB via the femtocell or other desired connection. The STB can receive and store utility meter readings for validation or dispute by the user.",AT & T IP I LP,FAN JAMES;;LAM JENNIFER K;;LIU CHENG P,AT&T INTELLECTUAL PROPERTY I L.P (2010-06-10),https://lens.org/057-285-275-163-993,Patent Application,yes,0,4,6,6,0,G01D4/004;;H04N21/4788;;H04N21/4788;;H04N21/2547;;H04N21/2547;;H04N21/4131;;H04N21/4786;;H04N21/4786;;H04N21/488;;H04N21/8126;;Y02B90/20;;Y04S20/30,H04N21/4788;;H04N21/2547;;H04N21/41;;H04N21/4786;;H04N21/488;;H04N21/81,,0,0,,,,ACTIVE
73,US,A1,US 2017/0034718 A1,156-165-833-513-365,2017-02-02,2017,US 201615293238 A,2016-10-13,US 201615293238 A;;US 201414263919 A;;US 84513110 A,2010-07-28,FEMTOCELL SERVICE THROUGH A SECONDARY CONNECTION,"Femtocell service is provided through a secondary connection to a network gateway node that is part of a service provider network. The secondary connection can be established in response to at least one telecommunication performance condition of a primary connection to the network gateway node; the at least one performance condition includes connectivity state of the primary connection or quality of traffic delivery through the primary connection. The secondary connection can be established, in part, via a home gateway node that is alternative to a home gateway node associated with a femtocell access point (AP) that enables, in part, the femtocell wireless service. The main home gateway node or the femtocell AP can initiate establishment of the secondary connection. Home gateway node(s) or femtocell AP(s) that can provide femtocell service through the secondary connection can manage connectivity with the network gateway node.",AT & T IP I LP,FAN JAMES;;LAM JENNIFER K;;LIU CHENG P,AT&T INTELLECTUAL PROPERTY I L.P (2010-07-24),https://lens.org/156-165-833-513-365,Patent Application,yes,2,8,6,6,0,H04W24/00;;H04W84/045;;H04W88/16;;H04W76/20;;H04W76/10;;H04W40/02;;H04W24/04;;H04W8/30;;H04W84/045;;H04W88/16;;H04W76/20;;H04W76/10;;H04W72/52;;H04W28/0289,H04W24/04;;H04W28/02;;H04W40/02;;H04W76/02,,0,0,,,,ACTIVE
74,US,B2,US 9474076 B2,185-146-700-971-459,2016-10-18,2016,US 201414263919 A,2014-04-28,US 201414263919 A;;US 84513110 A,2010-07-28,Femtocell service through a secondary connection,"System(s), apparatus(es), and method(s) are provided to for providing femtocell service through a secondary connection to a network gateway node that is part of a service provider network. The secondary connection can be established in response to at least one telecommunication performance condition of a primary connection to the network gateway node; the at least one performance condition includes connectivity state of the primary connection or quality of traffic delivery through the primary connection. The secondary connection can be established, in part, via a home gateway node that is alternative to a home gateway node associated with a femtocell access point (AP) that enables, in part, the femtocell wireless service. The main home gateway node or the femtocell AP can initiate establishment of the secondary connection. Home gateway node(s) or femtocell AP(s) that can provide femtocell service through the secondary connection can manage connectivity with the network gateway node.",AT & T IP I LP,FAN JAMES;;LAM JENNIFER K;;LIU CHENG P,AT&T INTELLECTUAL PROPERTY I L.P (2010-07-24),https://lens.org/185-146-700-971-459,Granted Patent,yes,7,6,6,6,0,H04W24/00;;H04W84/045;;H04W88/16;;H04W76/20;;H04W76/10;;H04W40/02;;H04W24/04;;H04W8/30;;H04W84/045;;H04W88/16;;H04W76/20;;H04W76/10;;H04W72/52;;H04W28/0289,H04W8/30;;H04W24/00;;H04W24/04;;H04W40/02;;H04W72/04;;H04W76/02;;H04W76/04;;H04W84/04;;H04W88/16,,3,0,,,"Office Action dated Jul. 23, 2012 for U.S. Appl. No. 12/845,131, 17 pages.;;Office Action dated Dec. 17, 2012 for U.S. Appl. No. 12/845,131, 17 pages.;;Office Action dated Jul. 29, 2013 for U.S. Appl. No. 12/845,131, 24 pages.",ACTIVE
75,WO,A1,WO 2014/043707 A1,100-045-917-831-207,2014-03-20,2014,US 2013/0060179 W,2013-09-17,US 201261702088 P,2012-09-17,OLIGOMER-CONTAINING BENZAMIDE-BASED COMPOUNDS,The invention relates to (among other things) oligomer-containing benzamide-based compounds. A compound of the invention exhibits one or more advantages over corresponding compounds lacking the oligomer.,NEKTAR THERAPEUTICS,CHENG LIN;;RIGGS-SAUTHIER JENNIFER;;ANAND NEEL K,,https://lens.org/100-045-917-831-207,Patent Application,yes,4,0,11,11,0,C07C237/44;;A61K31/166;;A61K47/60;;A61P1/04;;C07C237/44;;A61K31/166;;C07C231/12;;A61K47/60;;A61K47/59,A61K31/66;;C07C237/34;;C07C237/44,,2,2,101-301-788-189-938;;003-748-871-796-171,10.1021/ja00153a029;;10.1021/ja00174a037,"MRKSICH M ET AL: ""BIOSPECIFIC ADSORPTION OF CARBONIC ANHYDRASE TO SELF-ASSEMBLED MONOLAYERS OF ALKANETHIOLATES THAT PRESENT BENZENESULFONAMIDE GROUPS ON GOLD"", JOURNAL OF THE AMERICAN CHEMICAL SOCIETY, ACS PUBLICATIONS, US, vol. 117, 1 January 1995 (1995-01-01), XP001093945, ISSN: 0002-7863, DOI: 10.1021/JA00153A029;;V. JOHN JASYS ET AL: ""Isolation , structure elucidation and synthesis of novel hydroxylamine-containing polyamines from the venom of the Agelenopsis aperta spider"", JOURNAL OF THE AMERICAN CHEMICAL SOCIETY., vol. 112, 1990, USAMERICAN CHEMICAL SOCIETY, WASHINGTON, DC., pages 6696 - 6704, XP002717232, ISSN: 0002-7863",PENDING
76,EP,A1,EP 2895457 A1,165-280-348-795-506,2015-07-22,2015,EP 13770766 A,2013-09-17,US 201261702088 P;;US 2013/0060179 W,2012-09-17,OLIGOMER-CONTAINING BENZAMIDE-BASED COMPOUNDS,,NEKTAR THERAPEUTICS,CHENG LIN;;RIGGS-SAUTHIER JENNIFER;;ANAND NEEL K,,https://lens.org/165-280-348-795-506,Patent Application,yes,0,0,11,11,0,C07C237/44;;A61K31/166;;A61K47/60;;A61P1/04;;C07C237/44;;A61K31/166;;C07C231/12;;A61K47/60;;A61K47/59,C07C237/34;;A61K31/66;;C07C237/44,,0,0,,,,ACTIVE
77,US,A1,US 2016/0339108 A1,033-557-951-392-472,2016-11-24,2016,US 201615164607 A,2016-05-25,US 201615164607 A;;US 201514428816 A;;US 2013/0060179 W;;US 201261702088 P,2012-09-17,OLIGOMER-CONTAINING BENZAMIDE-BASED COMPOUNDS,The invention relates to (among other things) oligomer-containing benzamide-based compound compounds. A compound of the invention exhibits one or more advantages over corresponding compounds lacking the oligomer.,NEKTAR THERAPEUTICS,CHENG LIN;;RIGGS-SAUTHIER JENNIFER;;ANAND NEEL K,,https://lens.org/033-557-951-392-472,Patent Application,yes,0,1,11,11,0,C07C237/44;;A61K31/166;;A61K47/60;;A61P1/04;;C07C237/44;;A61K31/166;;C07C231/12;;A61K47/60;;A61K47/59,A61K47/48;;A61K31/166;;C07C237/44,,0,0,,,,ACTIVE
78,EP,B1,EP 2895457 B1,125-949-405-366-013,2020-05-20,2020,EP 13770766 A,2013-09-17,US 201261702088 P;;US 2013/0060179 W,2012-09-17,OLIGOMER-CONTAINING BENZAMIDE-BASED COMPOUNDS,,NEKTAR THERAPEUTICS,CHENG LIN;;RIGGS-SAUTHIER JENNIFER;;ANAND NEEL K,,https://lens.org/125-949-405-366-013,Granted Patent,yes,0,0,11,11,0,C07C237/44;;A61K31/166;;A61K47/60;;A61P1/04;;C07C237/44;;A61K31/166;;C07C231/12;;A61K47/60;;A61K47/59,C07C237/34;;A61K31/66;;A61K47/60;;C07C237/44,,1,1,042-615-858-045-58X,11310669;;10.1248/cpb.49.424,"SAKAGUCHI J ET AL: ""SYNTHESIS AND GASTROINTESTINAL PROKINETIC ACTIVITY OF NOVEL BENZAMIDE DERIVATIVES WITH AMPHOTERIC SIDE CHAINS"", CHEMICAL AND PHARMACEUTICAL BULLETIN, PHARMACEUTICAL SOCIETY OF JAPAN, JP, vol. 49, no. 4, 1 April 2001 (2001-04-01), pages 424 - 436, XP001074012, ISSN: 0009-2363, DOI: 10.1248/CPB.49.424",ACTIVE
79,US,A1,US 2015/0296265 A1,182-177-475-059-22X,2015-10-15,2015,US 201514752597 A,2015-06-26,US 201514752597 A;;US 81400110 A,2010-06-11,INTEGRATING VIDEO SHARE AND TEXT MESSAGING WITH SET-TOP BOX AND ACCESS POINT,"Techniques provide for converged wireline and wireless services in part by employing a set-top box (STB) with machine-to-machine (M2M) communication. The STB, associated with an access point, such as a femtocell, can be used to send/receive messages, including video, to/from user equipment (UE) via a core network. A monitoring system includes a sensor component that is triggered under specified conditions, and the STB records events in response to the trigger, where a recorded event can be sent as a message to the UE. The STB or associated remote control can indicate a received message to a user, who can view the message on the STB, remote control, or associated television. A meter component is associated with the STB via the femtocell or other desired connection. The STB can receive and store utility meter readings for validation or dispute by the user.",AT & T IP I LP,FAN JAMES;;LAM JENNIFER K;;LIU CHENG P,AT&T INTELLECTUAL PROPERTY I L.P (2010-06-10),https://lens.org/182-177-475-059-22X,Patent Application,yes,3,4,6,6,0,G01D4/004;;H04N21/4788;;H04N21/4788;;H04N21/2547;;H04N21/2547;;H04N21/4131;;H04N21/4786;;H04N21/4786;;H04N21/488;;H04N21/8126;;Y02B90/20;;Y04S20/30,H04N21/4788;;G01D4/00;;H04N21/41;;H04N21/488;;H04N21/81,,0,0,,,,ACTIVE
80,EP,B1,EP 3386583 B1,199-420-215-752-970,2022-11-23,2022,EP 16816155 A,2016-12-09,US 201562265086 P;;US 2016/0065757 W,2015-12-09,SURGICAL TOOLS FOR DELIVERING A NEUROSTIMULATOR INTO THE PTERYGOPALATINE FOSSA,,AUTONOMIC TECH INC,LUHRS TOM;;CHENG ALAN;;POWELL RYAN;;TENG JENNIFER,,https://lens.org/199-420-215-752-970,Granted Patent,yes,2,0,8,8,0,A61B17/3468;;A61N1/0551;;A61N1/36075;;A61N1/0526;;A61N1/37205;;A61N1/0551;;A61N1/36075;;A61B17/3468;;A61N1/0526;;A61N1/3605;;A61N1/37205,A61N1/05;;A61B17/34;;A61N1/36;;A61N1/372,,1,0,,,"ASSAF A T ET AL: ""Technical and surgical aspects of the sphenopalatine ganglion (SPG) microstimulator insertion procedure"", INTERNATIONAL JOURNAL OF ORAL AND MAXILLOFACIAL SURGERY, vol. 45, no. 2, 7 November 2015 (2015-11-07), pages 245-254, XP029387411, ISSN: 0901-5027, DOI: 10.1016/J.IJOM.2015.09.023",ACTIVE
81,US,A1,US 2017/0165482 A1,007-282-351-125-888,2017-06-15,2017,US 201615373698 A,2016-12-09,US 201615373698 A;;US 201562265086 P,2015-12-09,SURGICAL TOOLS AND METHODS FOR DELIVERING A NEUROSTIMULATOR INTO THE PTERYGOPALATINE FOSSA,"One aspect of the present disclosure includes a delivery tool configured to deliver a neurostimulator into a pterygopalatine fossa of a subject. The neurostimulator can include a body connected to an integral stimulation lead having one or more stimulating electrodes. The delivery tool can comprise a handle, an elongated shaft extending from the handle, a hub portion, and a double barrel sheath. The hub portion can be located between the shaft and a spine member that extends axially away from the hub portion. The hub portion can be sized and dimensioned to releasably mate with the neurostimulator. The double barrel sheath can be connected to the spine member. A central lumen can extend through at least a portion of the shaft and the hub portion. The central lumen can be adapted to receive a lead ejector for selective deployment of the stimulation lead from the double barrel sheath.",AUTONOMIC TECH INC,LUHRS TOM;;CHENG ALAN;;POWELL RYAN;;TENG JENNIFER,UNITY HA LLC (2019-12-20);;AUTONOMIC (ASSIGNMENT FOR THE BENEFIT OF CREDITORS) LLC (2019-04-10);;AUTONOMIC TECHNOLOGIES INC (2016-08-17),https://lens.org/007-282-351-125-888,Patent Application,yes,1,0,8,8,0,A61B17/3468;;A61N1/0551;;A61N1/36075;;A61N1/0526;;A61N1/37205;;A61N1/0551;;A61N1/36075;;A61B17/3468;;A61N1/0526;;A61N1/3605;;A61N1/37205,A61N1/36;;A61N1/05;;A61N1/372,,0,0,,,,DISCONTINUED
82,US,A1,US 2023/0111536 A1,074-092-789-300-807,2023-04-13,2023,US 202217933950 A,2022-09-21,US 202217933950 A;;US 202016736004 A;;US 201615373698 A;;US 201562265086 P,2015-12-09,Surgical Tools and Methods for Delivering a Neurostimulator into the Pterygopalatine Fossa,"One aspect of the present disclosure includes a delivery tool configured to deliver a neurostimulator into a pterygopalatine fossa of a subject. The neurostimulator can include a body connected to an integral stimulation lead having one or more stimulating electrodes. The delivery tool can comprise a handle, an elongated shaft extending from the handle, a hub portion, and a double barrel sheath. The hub portion can be located between the shaft and a spine member that extends axially away from the hub portion. The hub portion can be sized and dimensioned to releasably mate with the neurostimulator. The double barrel sheath can be connected to the spine member. A central lumen can extend through at least a portion of the shaft and the hub portion. The central lumen can be adapted to receive a lead ejector for selective deployment of the stimulation lead from the double barrel sheath.",REALEVE LLC,LUHRS TOM;;CHENG ALAN;;POWELL RYAN;;TENG JENNIFER,REALEVE LLC (2019-12-20);;AUTONOMIC (ASSIGNMENT FOR THE BENEFIT OF CREDITORS) LLC (2019-04-10);;AUTONOMIC TECHNOLOGIES INC (2016-08-17),https://lens.org/074-092-789-300-807,Patent Application,yes,3,0,8,8,0,A61B17/3468;;A61N1/0551;;A61N1/36075;;A61N1/0526;;A61N1/37205;;A61N1/0551;;A61N1/36075;;A61B17/3468;;A61N1/0526;;A61N1/3605;;A61N1/37205,A61N1/36;;A61B17/34;;A61N1/05;;A61N1/372,,0,0,,,,PENDING
83,US,A1,US 2013/0149741 A1,154-932-607-900-975,2013-06-13,2013,US 201213538755 A,2012-06-29,US 201213538755 A;;US 201161502796 P,2011-06-29,METHODS FOR IMPROVED PRODUCTION OF BIOACTIVE WNT PROTEINS,"Methods and compositions for protein expression are provided. In particular, cells producing efficient and reliable amounts of functional Wnt protein are provided.",GREEN JENNIFER L;;WAHL GEOFFREY;;LI YAO-CHENG;;SALK INST FOR BIOLOGICAL STUDI,GREEN JENNIFER L;;WAHL GEOFFREY;;LI YAO-CHENG,SALK INSTITUTE FOR BIOLOGICAL STUDIES (2014-02-27),https://lens.org/154-932-607-900-975,Patent Application,yes,0,3,1,1,6,C12P21/02;;C12P21/005;;C12N2510/02;;C12P21/00;;C12P21/02;;C12P21/005;;C12N2510/02,C12P21/00,435/69.1;;435/325,3,1,058-498-145-258-834,10.1038/nature01611;;12717451,"Wong et al., Nucleic Acids Research, 2005, Vol. 33, pages 1-13;;Willert et al., Nature, 2003, Vol. 423, pages 448-452;;WNT3A, GenBank Record, 2006, accessed 8/26/2013 from:http://www.ncbi.nlm.nih.gov/nucleotide/74353514?report=genbank&log$=nuclalign&blast_rank=1&RID=1PEP2J6E01R",DISCONTINUED
84,US,B2,US 10434181 B2,078-052-410-006-427,2019-10-08,2019,US 201815908286 A,2018-02-28,US 201815908286 A;;US 201615164607 A;;US 201514428816 A;;US 2013/0060179 W;;US 201261702088 P,2012-09-17,Oligomer-containing benzamide-based compounds,The invention relates to (among other things) oligomer-containing benzamide-based compound compounds. A compound of the invention exhibits one or more advantages over corresponding compounds lacking the oligomer.,NEKTAR THERAPEUTICS,CHENG LIN;;RIGGS-SAUTHIER JENNIFER;;ANAND NEEL K,,https://lens.org/078-052-410-006-427,Granted Patent,yes,29,1,11,11,0,C07C237/44;;A61K31/166;;A61K47/60;;A61P1/04;;C07C237/44;;A61K31/166;;C07C231/12;;A61K47/60;;A61K47/59,C07C237/44;;A61K31/166;;A61K47/59;;A61K47/60;;C07C231/12,,26,6,058-789-596-477-892;;022-687-167-620-52X;;033-673-878-395-885;;003-748-871-796-171;;019-315-852-279-483;;101-301-788-189-938,11674697;;10.1021/jo990620m;;10.1021/jm000942e;;11020286;;pmc1910004;;8012715;;10.1111/j.1476-5381.1994.tb14064.x;;10.1021/ja00174a037;;10.1023/a:1015040217741;;10554091;;10.1021/ja00153a029,"Chen, et al., “Synthesis and Properties of ABA Amphiphiles”, J. Org. Chem., vol. 64, pp. 6870-6873, (1999).;;Ertl, et al., “Fast Calculation of Molecular Polar Surface Area as a Sum of Fragment-Based Contributions and Its Application to the Prediction of Drug Transport”, J. Med. Chem., vol. 43, pp. 3714-3717, (2000).;;Gale, et al., “GR113808: a novel, selective antagonist with high affinity at the 5-HT4 receptor”, Br. J. Pharmacol. vol. 111, pp. 332-338, (1994).;;Jasys, et al., “Isolation, Structure Elucidation, and Synthesis of Novel Hydroxylamine-Containing Polyamines from the Venom of the Agelenopsis aperta Spider”, J. Am. Chem. Soc., vol. 112, pp. 6696-6704, (1990).;;Kelder, et al., “Polar Molecular Surface as a Dominating Determinant for Oral Absorption and Brain Penetration of Drugs”, Pharmaceutical Research, vol. 16, No. 10, pp. 1514-1519, (1999).;;Mrksich, et al., “Biospecific-Adsorption of Carbonic Anhydrase to Self-Assembled Monolayers of Alkanethiolates That Present Benzenesulfonamide Groups on Gold”, J. Am. Chem. Soc., vol. 117, pp. 12009-12010, (1995).;;PCT International Search Report and Written Opinion corresponding to PCT Application No. PCT/US2013/060179 dated Dec. 13, 2013.;;PCT International Preliminary Report on Patentability corresponding to PCT Application No. PCT/US2013/060179 dated Mar. 26, 2015.;;Enzon Pharmaceuticals, Macromolecular Engineering Technologies, 16 pages, (2004).;;NEKTAR™—Transforming Therapeutics, Nektar Molecule Engineering: Polyethylene Glycol and Derivatives for Advanced PEGylation, 24 pages, Catalog—2003, (Jul. 2003).;;NEKTAR™—Transforming Therapeutics, Nektar Advanced PEGylation: Polyethylene Glycol and Derivatives for Advanced PEGylation, 27 pages, Catalog—2004, (Jul. 2004).;;NEKTAR™—Transforming Therapeutics, Nektar Advanced PEGylation: Polyethylene Glycol and Derivatives for Advanced PEGylation, 33 pages, (Catalog 2005-2006).;;NOF Corporation, PEG Derivatives, Phospholipid and Drug Delivery Materials for Pharmaceuticals, 46 pages, Catalogue 2003-1st, (Jan. 2003).;;NOF Corporation, PEG Derivatives, Phospholipid and Drug Delivery Materials for Pharmaceuticals, 27 pages, Catalogue 2003-2nd, (Mar. 2004).;;NOF Corporation, PEG Derivatives, Phospholipids and Drug Delivery Materials for Pharmaceutical Products and Formulations, 60 pages, Catalogue Ver. 8, (Apr. 2006).;;Polypure Products, PEG amines; PEG acids and amino acids; PEG thiols and disulfides; Biotins, 5 pages, (Apr. 2004).;;Polypure Products, PEG amines; PEG acids and amino acids; PEG thiols and disulfides; Biotins, 5 pages, (Apr. 2005).;;Quanta Biodesign, Labeling, Derivatization and Crosslinking Reagents for Biological and Related Materials with dPEG™, 38 pages, (Mar. 12, 2004).;;Quanta Biodesign, Labeling, Modification and Crosslinking Reagents incorporating our unique monodispersed dPEG™ Technology, 31 pages, (Nov. 5, 2004).;;Quanta Biodesign, Ltd., Leading innovator, producer and provider of monodisperse discrete PEG™ (dPEG™) derivatives, (Product Catalog), 26 pages, (Updated: Jul. 18, 2005).;;Quanta Biodesign, Ltd., Leading innovator, producer and provider of monodisperse discrete PEG™ (dPEG™) derivatives, (Product Catalog), 26 pages, (Updated: Nov. 17, 2005).;;Shearwater Polymers, Inc., Polyethylene Glycol Derivatives, 50 pages, Catalog—(Mar. 1995).;;Shearwater Polymers, Inc., Polyethylene Glycol Derivatives, 55 pages, Catalog 1997-1998, (Jul. 1997).;;Shearwater Polymers, Inc., Polyethylene Glycol and Derivatives: Functionalized Biocompatible Polymers for Research and Pharmaceuticals, 50 pages, Catalog—(Jan. 2000).;;Shearwater Corporation, Polyethylene Glycol and Derivatives for Biomedical Applications, 20 pages, Catalog—(Jul. 2001).;;English Translation of Notice of Reasons for Rejection in Japanese Patent Application No. 2015-532149 dated Jun. 14, 2017.",ACTIVE
85,US,B2,US 9712880 B2,111-917-170-914-69X,2017-07-18,2017,US 201514970476 A,2015-12-15,US 201514970476 A;;US 201514752597 A;;US 81400110 A,2010-06-11,Integrating video share and text messaging with set-top box and access point,"Techniques provide for converged wireline and wireless services in part by employing a set-top box (STB) with machine-to-machine (M2M) communication. The STB, associated with an access point, such as a femtocell, can be used to send/receive messages, including video, to/from user equipment (UE) via a core network. A monitoring system includes a sensor component that is triggered under specified conditions, and the STB records events in response to the trigger, where a recorded event can be sent as a message to the UE. The STB or associated remote control can indicate a received message to a user, who can view the message on the STB, remote control, or associated television. A meter component is associated with the STB via the femtocell or other desired connection. The STB can receive and store utility meter readings for validation or dispute by the user.",AT & T IP I LP,FAN JAMES;;LAM JENNIFER K;;LIU CHENG P,AT&T INTELLECTUAL PROPERTY I L.P (2010-06-10),https://lens.org/111-917-170-914-69X,Granted Patent,yes,5,0,6,6,0,G01D4/004;;H04N21/4788;;H04N21/4788;;H04N21/2547;;H04N21/2547;;H04N21/4131;;H04N21/4786;;H04N21/4786;;H04N21/488;;H04N21/8126;;Y02B90/20;;Y04S20/30,H04N7/173;;G01D4/00;;H04N21/2547;;H04N21/41;;H04N21/4786;;H04N21/4788;;H04N21/488;;H04N21/81,,7,0,,,"“M2M smart metering: where are we now?” <http://blogs.orange-business.com/live/2009/11/m2m-smart-metering-where-are-we-now.html> Accessed Sep. 10, 2010. 4 pages.;;“The NES System Components” <http://www.echelon.com/metering/nes—system—components.htm> Accessed Sep. 10, 2010. 2 pages.;;“The NES Smart Metering System” <http://www.echelon.com/metering/datasheets/SmartMetering—System—IEC—Fall09.pdf> Accessed Sep. 10, 2010. 6 pages.;;Final Office Action mailed Jun. 19, 2013 for U.S. Appl. No. 12/814,001, 24 pages.;;Office Action mailed Sep. 11, 2012 for U.S. Appl. No. 12/814,001, 25 pages.;;Office Action mailed Dec. 17, 2014 for U.S. Appl. No. 12/814,001, 27 pages.;;Notice of Allowance mailed Sep. 25, 2015 for U.S. Appl. No. 14/752,597, 26 pages.",ACTIVE
86,US,B2,US 11478641 B2,084-860-611-584-322,2022-10-25,2022,US 202016736004 A,2020-01-07,US 202016736004 A;;US 201615373698 A;;US 201562265086 P,2015-12-09,Surgical tools and methods for delivering a neurostimulator into the pterygopalatine fossa,"One aspect of the present disclosure includes a delivery tool configured to deliver a neurostimulator into a pterygopalatine fossa of a subject. The neurostimulator can include a body connected to an integral stimulation lead having one or more stimulating electrodes. The delivery tool can comprise a handle, an elongated shaft extending from the handle, a hub portion, and a double barrel sheath. The hub portion can be located between the shaft and a spine member that extends axially away from the hub portion. The hub portion can be sized and dimensioned to releasably mate with the neurostimulator. The double barrel sheath can be connected to the spine member. A central lumen can extend through at least a portion of the shaft and the hub portion. The central lumen can be adapted to receive a lead ejector for selective deployment of the stimulation lead from the double barrel sheath.",REALEVE LLC,LUHRS TOM;;CHENG ALAN;;POWELL RYAN;;TENG JENNIFER,REALEVE LLC (2019-12-20);;AUTONOMIC (ASSIGNMENT FOR THE BENEFIT OF CREDITORS) LLC (2019-04-10);;AUTONOMIC TECHNOLOGIES INC (2016-08-17),https://lens.org/084-860-611-584-322,Granted Patent,yes,3,0,8,8,0,A61B17/3468;;A61N1/0551;;A61N1/36075;;A61N1/0526;;A61N1/37205;;A61N1/0551;;A61N1/36075;;A61B17/3468;;A61N1/0526;;A61N1/3605;;A61N1/37205,A61N1/36;;A61B17/34;;A61N1/05;;A61N1/372,,2,1,001-270-142-225-771,26559753;;10.1016/j.ijom.2015.09.023,"PCT International Search Report and Written Opinion for corresponding International Application Serial No. PCT/US2016/065757, pp. 1-16, dated Mar. 21, 2017.;;Assaf, A. T., et al. “Technical and surgical aspects of the sphenopalatine ganglion (SPG) microstimulator insertion procedure.” International journal of oral and maxillofacial surgery 45.2 (2016): 245-254.",ACTIVE
87,US,B2,US 9100707 B2,119-476-300-339-620,2015-08-04,2015,US 81400110 A,2010-06-11,US 81400110 A,2010-06-11,Integrating video share and text messaging with set-top box and access point,"System(s), method(s), and device(s) providing converged wireline and wireless services in part by employing a set-top box (STB) with machine-to-machine (M2M) communication are presented. The STB, associated with an access point, such as a femtocell, can be used to send/receive messages, including video, to/from user equipment (UE) via a core network. A monitoring system includes a sensor component that is triggered under specified conditions, and the STB records events in response to the trigger, where a recorded event can be sent as a message to the UE. The STB or associated remote control can indicate a received message to a user, who can view the message on the STB, remote control, or associated television. A meter component is associated with the STB via the femtocell or other desired connection. The STB can receive and store utility meter readings for validation or dispute by the user.",FAN JAMES;;LAM JENNIFER K;;LIU CHENG P;;AT & T IP I LP,FAN JAMES;;LAM JENNIFER K;;LIU CHENG P,AT&T INTELLECTUAL PROPERTY I L.P (2010-06-10),https://lens.org/119-476-300-339-620,Granted Patent,yes,5,4,6,6,0,G01D4/004;;H04N21/4788;;H04N21/4788;;H04N21/2547;;H04N21/2547;;H04N21/4131;;H04N21/4786;;H04N21/4786;;H04N21/488;;H04N21/8126;;Y02B90/20;;Y04S20/30,H04N7/173;;H04N21/2547;;H04N21/4786;;H04N21/4788,,3,0,,,"""M2M smart metering: where are we now?"" Accessed Sep. 10, 2010. 4 pages.;;""The NES System Components"" Accessed Sep. 10, 2010. 2 pages.;;""The NES Smart Metering System"" Accessed Sep. 10, 2010. 6 pages.",INACTIVE
88,WO,A1,WO 2019/125923 A1,088-739-127-404-669,2019-06-27,2019,US 2018/0065586 W,2018-12-14,US 201715849020 A,2017-12-20,THREE DIMENSIONAL GRAPHENE FOAM REINFFORCED COMPOSITIE COATING AND DEICING SYSTEMS THEREFROM,An efficient deicing system is a silicone-graphene foam composite connected to a source of electrical energy for current promoted heating of the silicone-graphene foam composite. The deicing system can be constructed by infusion and curing a silicone resin infused into the graphene foam attached to electrical contacts. The deicing system can be attached to surfaces of an aircraft for rapid deicing of the aircraft.,THE FLORIDA INTERNATIONAL UNIV BOARD OF TRUSTEES,AGARWAL ARVIND;;BOESL BENJAMIN;;BUSTILLOS JENNIFER;;ZHANG CHENG,,https://lens.org/088-739-127-404-669,Patent Application,yes,6,1,4,4,0,F05D2300/224;;F05D2300/612;;F03D80/40;;F05B2230/90;;F01D25/02;;F02C7/047;;B64D15/14;;B64C2001/0072;;Y02P70/50;;Y02T50/40;;Y02T50/60;;Y02E10/72;;B64D15/20;;B64D15/14;;F01D25/02;;B64D2033/0233;;C08J9/35;;C01B32/182;;F02C7/047;;F05B2230/90;;F05D2300/224;;B64C2001/0072;;F03D80/40;;F05D2300/612,B64D15/12;;C08K3/04;;C08K7/24;;C08L83/00;;C23C26/00,,0,0,,,,PENDING
89,EP,A1,EP 3386583 A1,095-098-215-894-422,2018-10-17,2018,EP 16816155 A,2016-12-09,US 201562265086 P;;US 2016/0065757 W,2015-12-09,SURGICAL TOOLS AND METHODS FOR DELIVERING A NEUROSTIMULATOR INTO THE PTERYGOPALATINE FOSSA,,AUTONOMIC TECH INC,LUHRS TOM;;CHENG ALAN;;POWELL RYAN;;TENG JENNIFER,,https://lens.org/095-098-215-894-422,Patent Application,yes,0,0,8,8,0,A61B17/3468;;A61N1/0551;;A61N1/36075;;A61N1/0526;;A61N1/37205;;A61N1/0551;;A61N1/36075;;A61B17/3468;;A61N1/0526;;A61N1/3605;;A61N1/37205,A61N1/05;;A61B17/34;;A61N1/36,,0,0,,,,ACTIVE
90,US,B2,US 9375486 B2,043-268-792-630-294,2016-06-28,2016,US 201314428816 A,2013-09-17,US 201314428816 A;;US 201261702088 P;;US 2013/0060179 W,2012-09-17,Oligomer-containing benzamide-based compounds,The invention relates to (among other things) oligomer-containing benzamide-based compounds. A compound of the invention exhibits one or more advantages over corresponding compounds lacking the oligomer.,NEKTAR THERAPEUTICS,CHENG LIN;;RIGGS-SAUTHIER JENNIFER;;ANAND NEEL K,NEKTAR THERAPEUTICS (2015-02-23),https://lens.org/043-268-792-630-294,Granted Patent,yes,18,1,11,11,0,C07C237/44;;A61K31/166;;A61K47/60;;A61P1/04;;C07C237/44;;A61K31/166;;C07C231/12;;A61K47/60;;A61K47/59,C07C231/12;;A61K31/166;;A61K47/48;;C07C237/44,,25,6,058-789-596-477-892;;022-687-167-620-52X;;033-673-878-395-885;;003-748-871-796-171;;019-315-852-279-483;;101-301-788-189-938,11674697;;10.1021/jo990620m;;10.1021/jm000942e;;11020286;;pmc1910004;;8012715;;10.1111/j.1476-5381.1994.tb14064.x;;10.1021/ja00174a037;;10.1023/a:1015040217741;;10554091;;10.1021/ja00153a029,"Chen, et al., ""Synthesis and Properties of ABA Amphiphiles"", J. Org. Chem., vol. 64, pp. 6870-6873, (1999).;;Ertl, et al., ""Fast Calculation of Molecular Polar Surface Area as a Sum of Fragment-Based Contributions and Its Application to the Prediction of Drug Transport"", J. Med. Chem., vol. 43, pp. 3714-3717, (2000).;;Gale, et al., ""GR113808: a novel, selective antagonist with high affinity at the 5-HT4 receptor"", Br. J. Pharmacol. vol. 111, pp. 332-338, (1994).;;Jasys, et al., ""Isolation, Structure Elucidation, and Synthesis of Novel Hydroxylamine-Containing Polyamines from the Venom of the Agelenopsis aperta Spider"", J. Am. Chem. Soc., vol. 112, pp. 6696-6704, (1990).;;Kelder, et al., ""Polar Molecular Surface as a Dominating Determinant for Oral Absorption and Brain Penetration of Drugs"", Pharmaceutical Research, vol. 16, No. 10, pp. 1514-1519, (1999).;;Mrksich, et al., ""Biospecific-Adsorption of Carbonic Anhydrase to Self-Assembled Monolayers of Alkanethiolates That Present Benzenesulfonamide Groups on Gold"", J. Am. Chem. Soc., vol. 117, pp. 12009-12010, (1995).;;PCT International Search Report and Written Opinion corresponding to PCT Application No. PCT/US2013/060179 date of mailing Dec. 13, 2013.;;PCT International Preliminary Report on Patentability corresponding to PCT Application No. PCT/US2013/060179 date of mailing Mar. 26, 2015.;;ENZON Pharmaceuticals, Macromolecular Engineering Technologies, 16 pages, (2004).;;NEKTAR(TM)-Transforming Therapeutics, Nektar Molecule Engineering: Polyethylene Glycol and Derivatives for Advanced PEGylation, 24 pages, Catalog-2003, (Jul. 2003).;;NEKTAR(TM)-Transforming Therapeutics, Nektar Advanced PEGylation: Polyethylene Glycol and Derivatives for Advanced PEGylation, 27 pages, Catalog-2004, (Jul. 2004).;;NEKTAR(TM)-Transforming Therapeutics, Nektar Advanced PEGylation: Polyethylene Glycol and Derivatives for Advanced PEGylation, 33 pages, (Catalog 2005-2006).;;NOF Corporation, PEG Derivatives, Phospholipid and Drug Delivery Materials for Pharmaceuticals, 46 pages, Catalogue 2003-1st, (Jan. 2003).;;NOF Corporation, PEG Derivatives, Phospholipid and Drug Delivery Materials for Pharmaceuticals, 27 pages, Catalogue 2003-2nd, (Mar. 2004).;;NOF Corporation, PEG Derivatives, Phospholipids and Drug Delivery Materials for Pharmaceutical Products and Formulations, 60 pages, Catalogue Ver. 8, (Apr. 2006).;;POLYPURE Products, PEG amines; PEG acids and amino acids; PEG thiols and disulfides; BIOTINS, 5 pages, (Apr. 2004).;;POLYPURE Products, PEG amines; PEG acids and amino acids; PEG thiols and disulfides; BIOTINS, 5 pages, (Apr. 2005).;;Quanta Biodesign, Labeling, Derivatization and Crosslinking Reagents for Biological and Related Materials with dPEG(TM), 38 pages, (Mar. 12, 2004).;;Quanta Biodesign, Labeling, Modification and Crosslinking Reagents incorporating our unique monodispersed dPEG(TM) Technology, 31 pages, (Nov. 5, 2004).;;Quanta Biodesign, Ltd., Leading innovator, producer and provider of monodisperse discrete PEG(TM) (dPEG(TM)) derivatives, (Product Catalog), 26 pages, (Updated: Jul. 18, 2005).;;Quanta Biodesign, Ltd., Leading innovator, producer and provider of monodisperse discrete PEG(TM) (dPEG(TM)) derivatives, (Product Catalog), 26 pages, (Updated: Nov. 17, 2005).;;Shearwater Polymers, Inc., Polyethylene Glycol Derivatives, 50 pages, Catalog-(Mar. 1995).;;Shearwater Polymers, Inc., Polyethylene Glycol Derivatives, 55 pages, Catalog 1997-1998, (Jul. 1997).;;Shearwater Polymers, Inc., Polyethylene Glycol and Derivatives: Functionalized Biocompatible Polymers for Research and Pharmaceuticals, 50 pages, Catalog-(Jan. 2000).;;Shearwater Corporation, Polyethylene Glycol and Derivatives for Biomedical Applications, 20 pages, Catalog-(Jul. 2001).",ACTIVE
91,WO,A1,WO 2017/100530 A1,065-300-260-607-312,2017-06-15,2017,US 2016/0065757 W,2016-12-09,US 201562265086 P,2015-12-09,SURGICAL TOOLS AND METHODS FOR DELIVERING A NEUROSTIMULATOR INTO THE PTERYGOPALATINE FOSSA,"One aspect of the present disclosure includes a delivery tool configured to deliver a neurostimulator into a pterygopalatine fossa of a subject. The neurostimulator can include a body connected to an integral stimulation lead having one or more stimulating electrodes. The delivery tool can comprise a handle, an elongated shaft extending from the handle, a hub portion, and a double barrel sheath. The hub portion can be located between the shaft and a spine member that extends axially away from the hub portion. The hub portion can be sized and dimensioned to releasably mate with the neurostimulator. The double barrel sheath can be connected to the spine member. A central lumen can extend through at least a portion of the shaft and the hub portion. The central lumen can be adapted to receive a lead ejector for selective deployment of the stimulation lead from the double barrel sheath.",AUTONOMIC TECH INC,LUHRS TOM;;CHENG ALAN;;POWELL RYAN;;TENG JENNIFER,,https://lens.org/065-300-260-607-312,Patent Application,yes,5,0,8,8,0,A61B17/3468;;A61N1/0551;;A61N1/36075;;A61N1/0526;;A61N1/37205;;A61N1/0551;;A61N1/36075;;A61B17/3468;;A61N1/0526;;A61N1/3605;;A61N1/37205,A61N1/05;;A61B17/34;;A61N1/36,,1,1,001-270-142-225-771,26559753;;10.1016/j.ijom.2015.09.023,"ASSAF A T ET AL: ""Technical and surgical aspects of the sphenopalatine ganglion (SPG) microstimulator insertion procedure"", INTERNATIONAL JOURNAL OF ORAL AND MAXILLOFACIAL SURGERY, vol. 45, no. 2, 7 November 2015 (2015-11-07), pages 245 - 254, XP029387411, ISSN: 0901-5027, DOI: 10.1016/J.IJOM.2015.09.023",PENDING
92,US,A1,US 2012/0026865 A1,194-218-743-024-060,2012-02-02,2012,US 84513110 A,2010-07-28,US 84513110 A,2010-07-28,FEMTOCELL SERVICE THROUGH A SECONDARY CONNECTION,"System(s), apparatus(es), and method(s) are provided to for providing femtocell service through a secondary connection to a network gateway node that is part of a service provider network. The secondary connection can be established in response to at least one telecommunication performance condition of a primary connection to the network gateway node; the at least one performance condition includes connectivity state of the primary connection or quality of traffic delivery through the primary connection. The secondary connection can be established, in part, via a home gateway node that is alternative to a home gateway node associated with a femtocell access point (AP) that enables, in part, the femtocell wireless service. The main home gateway node or the femtocell AP can initiate establishment of the secondary connection. Home gateway node(s) or femtocell AP(s) that can provide femtocell service through the secondary connection can manage connectivity with the network gateway node.",FAN JAMES;;LAM JENNIFER K;;LIU CHENG P;;AT & T IP I LP,FAN JAMES;;LAM JENNIFER K;;LIU CHENG P,AT&T INTELLECTUAL PROPERTY I L.P (2010-07-24),https://lens.org/194-218-743-024-060,Patent Application,yes,6,98,6,6,0,H04W24/00;;H04W84/045;;H04W88/16;;H04W76/20;;H04W76/10;;H04W40/02;;H04W24/04;;H04W8/30;;H04W84/045;;H04W88/16;;H04W76/20;;H04W76/10;;H04W72/52;;H04W28/0289,G06F11/00,370/225,0,0,,,,ACTIVE
93,US,B2,US 9937266 B2,025-253-581-700-585,2018-04-10,2018,US 201615164607 A,2016-05-25,US 201615164607 A;;US 201514428816 A;;US 2013/0060179 W;;US 201261702088 P,2012-09-17,Oligomer-containing benzamide-based compounds,The invention relates to (among other things) oligomer-containing benzamide-based compound compounds. A compound of the invention exhibits one or more advantages over corresponding compounds lacking the oligomer.,NEKTAR THERAPEUTICS,CHENG LIN;;RIGGS-SAUTHIER JENNIFER;;ANAND NEEL K,,https://lens.org/025-253-581-700-585,Granted Patent,yes,27,0,11,11,0,C07C237/44;;A61K31/166;;A61K47/60;;A61P1/04;;C07C237/44;;A61K31/166;;C07C231/12;;A61K47/60;;A61K47/59,C07C231/12;;A61K31/166;;C07C237/44,,26,6,058-789-596-477-892;;022-687-167-620-52X;;033-673-878-395-885;;003-748-871-796-171;;019-315-852-279-483;;101-301-788-189-938,11674697;;10.1021/jo990620m;;10.1021/jm000942e;;11020286;;pmc1910004;;8012715;;10.1111/j.1476-5381.1994.tb14064.x;;10.1021/ja00174a037;;10.1023/a:1015040217741;;10554091;;10.1021/ja00153a029,"Chen, et al., “Synthesis and Properties of ABA Amphiphiles”, J. Org. Chem., vol. 64, pp. 6870-6873, (1999).;;Ertl, et al., “Fast Calculation of Molecular Polar Surface Area as a Sum of Fragment-Based Contributions and Its Application to the Prediction of Drug Transport”, J. Med. Chem., vol. 43, pp. 3714-3717, (2000).;;Gale, et al., “GR113808: a novel, selective antagonist with high affinity at the 5-HT4 receptor”, Br. J. Pharmacol. vol. 111, pp. 332-338, (1994).;;Jasys, et al., “Isolation, Structure Elucidation, and Synthesis of Novel Hydroxylamine-Containing Polyamines from the Venom of the Agelenopsis aperta Spider”, J. Am. Chem. Soc., vol. 112, pp. 6696-6704, (1990).;;Kelder, et al., “Polar Molecular Surface as a Dominating Determinant for Oral Absorption and Brain Penetration of Drugs”, Pharmaceutical Research, vol. 16, No. 10, pp. 1514-1519, (1999).;;Mrksich, et al., “Biospecific-Adsorption of Carbonic Anhydrase to Self-Assembled Monolayers of Alkanethiolates That Present Benzenesulfonamide Groups on Gold”, J. Am. Chem. Soc., vol. 117, pp. 12009-12010, (1995).;;PCT International Search Report and Written Opinion corresponding to PCT Application No. PCT/US2013/060179 dated Dec. 13, 2013.;;PCT International Preliminary Report on Patentability corresponding to PCT Application No. PCT/US2013/060179 dated Mar. 26, 2015.;;Enzon Pharmaceuticals, Macromolecular Engineering Technologies, 16 pages, (2004).;;NEKTAR™—Transforming Therapeutics, Nektar Molecule Engineering: Polyethylene Glycol and Derivatives for Advanced PEGylation, 24 pages, Catalog—2003, (Jul. 2003).;;NEKTAR™—Transforming Therapeutics, Nektar Advanced PEGylation: Polyethylene Glycol and Derivatives for Advanced PEGylation, 27 pages, Catalog—2004, (Jul. 2004).;;NEKTAR™—Transforming Therapeutics, Nektar Advanced PEGylation: Polyethylene Glycol and Derivatives for Advanced PEGylation, 33 pages (Catalog 2005-2006).;;NOF Corporation, PEG Derivatives, Phospholipid and Drug Delivery Materials for Pharmaceuticals, 46 pages, Catalogue 2003-1st, (Jan. 2003).;;NOF Corporation, PEG Derivatives, Phospholipid and Drug Delivery Materials for Pharmaceuticals, 27 pages, Catalogue 2003-2nd, (Mar. 2004).;;NOF Corporation, PEG Derivatives, Phospholipids and Drug Delivery Materials for Pharmaceutical Products and Formulations, 60 pages, Catalogue Ver. 8, (Apr. 2006).;;Polypure Products, PEG amines; PEG acids and amino acids; PEG thiols and disulfides; BIOTINS, 5 pages, (Apr. 2004).;;Polypure Products, PEG amines; PEG acids and amino acids; PEG thiols and disulfides; BIOTINS, 5 pages, (Apr. 2005).;;Quanta Biodesign, Labeling, Derivatization and Crosslinking Reagents for Biological and Related Materials with dPEG™, 38 pages, (Mar. 12, 2004).;;Quanta Biodesign, Labeling, Modification and Crosslinking Reagents incorporating our unique monodispersed dPEG™ Technology, 31 pages, (Nov. 5, 2004).;;Quanta Biodesign, Ltd., Leading innovator, producer and provider of monodisperse discrete PEG™ (dPEG™) derivatives, (Product Catalog), 26 pages, (Updated: Jul. 18, 2005).;;Quanta Biodesign, Ltd., Leading innovator, producer and provider of monodisperse discrete PEG™ (dPEG™) derivatives, (Product Catalog), 26 pages, (Updated: Nov. 17, 2005).;;Shearwater Polymers, Inc., Polyethylene Glycol Derivatives, 50 pages, Catalog—(Mar. 1995).;;Shearwater Polymers, Inc., Polyethylene Glycol Derivatives, 55 pages, Catalog 1997-1998, (Jul. 1997).;;Shearwater Polymers, Inc., Polyethylene Glycol and Derivatives: Functionalized Biocompatible Polymers for Research and Pharmaceuticals, 50 pages, Catalog—(Jan. 2000).;;Shearwater Corporation, Polyethylene Glycol and Derivatives for Biomedical Applications, 20 pages, Catalog—(Jul. 2001).;;English Translation of Notice of Reasons for Rejection in Japanese Patent Application No. 2015-532149 dated Jun. 14, 2017.",ACTIVE
94,US,A1,US 2020/0197697 A1,072-415-745-771-114,2020-06-25,2020,US 202016736004 A,2020-01-07,US 202016736004 A;;US 201615373698 A;;US 201562265086 P,2015-12-09,SURGICAL TOOLS AND METHODS FOR DELIVERING A NEUROSTIMULATOR INTO THE PTERYGOPALATINE FOSSA,"One aspect of the present disclosure includes a delivery tool configured to deliver a neurostimulator into a pterygopalatine fossa of a subject. The neurostimulator can include a body connected to an integral stimulation lead having one or more stimulating electrodes. The delivery tool can comprise a handle, an elongated shaft extending from the handle, a hub portion, and a double barrel sheath. The hub portion can be located between the shaft and a spine member that extends axially away from the hub portion. The hub portion can be sized and dimensioned to releasably mate with the neurostimulator. The double barrel sheath can be connected to the spine member. A central lumen can extend through at least a portion of the shaft and the hub portion. The central lumen can be adapted to receive a lead ejector for selective deployment of the stimulation lead from the double barrel sheath.",AUTONOMIC TECH INC,LUHRS TOM;;CHENG ALAN;;POWELL RYAN;;TENG JENNIFER,REALEVE LLC (2019-12-20);;AUTONOMIC (ASSIGNMENT FOR THE BENEFIT OF CREDITORS) LLC (2019-04-10);;AUTONOMIC TECHNOLOGIES INC (2016-08-17),https://lens.org/072-415-745-771-114,Patent Application,yes,0,1,8,8,0,A61B17/3468;;A61N1/0551;;A61N1/36075;;A61N1/0526;;A61N1/37205;;A61N1/0551;;A61N1/36075;;A61B17/3468;;A61N1/0526;;A61N1/3605;;A61N1/37205,A61N1/36;;A61B17/34;;A61N1/05;;A61N1/372,,0,0,,,,ACTIVE
95,US,B2,US 8750098 B2,112-976-881-336-474,2014-06-10,2014,US 84513110 A,2010-07-28,US 84513110 A,2010-07-28,Femtocell service through a secondary connection,"System(s), apparatus(es), and method(s) are provided to for providing femtocell service through a secondary connection to a network gateway node that is part of a service provider network. The secondary connection can be established in response to at least one telecommunication performance condition of a primary connection to the network gateway node; the at least one performance condition includes connectivity state of the primary connection or quality of traffic delivery through the primary connection. The secondary connection can be established, in part, via a home gateway node that is alternative to a home gateway node associated with a femtocell access point (AP) that enables, in part, the femtocell wireless service. The main home gateway node or the femtocell AP can initiate establishment of the secondary connection. Home gateway node(s) or femtocell AP(s) that can provide femtocell service through the secondary connection can manage connectivity with the network gateway node.",FAN JAMES;;LAM JENNIFER K;;LIU CHENG P;;AT & T IP I LP,FAN JAMES;;LAM JENNIFER K;;LIU CHENG P,AT&T INTELLECTUAL PROPERTY I L.P (2010-07-24),https://lens.org/112-976-881-336-474,Granted Patent,yes,6,11,6,6,0,H04W24/00;;H04W84/045;;H04W88/16;;H04W76/20;;H04W76/10;;H04W40/02;;H04W24/04;;H04W8/30;;H04W84/045;;H04W88/16;;H04W76/20;;H04W76/10;;H04W72/52;;H04W28/0289,H04L1/00;;H04L12/26,370/225,0,0,,,,ACTIVE
96,EP,A1,EP 4201471 A1,156-707-041-406-629,2023-06-28,2023,EP 22208433 A,2016-12-09,US 201562265086 P;;EP 16816155 A;;US 2016/0065757 W,2015-12-09,SURGICAL TOOLS FOR DELIVERING A NEUROSTIMULATOR INTO THE PTERYGOPALATINE FOSSA,"One aspect of the present disclosure includes a delivery tool configured to deliver a neurostimulator into a pterygopalatine fossa of a subject. The neurostimulator can include a body connected to an integral stimulation lead having one or more stimulating electrodes. The delivery tool can comprise a handle, an elongated shaft extending from the handle, a hub portion, and a double barrel sheath. The hub portion can be located between the shaft and a spine member that extends axially away from the hub portion. The hub portion can be sized and dimensioned to releasably mate with the neurostimulator. The double barrel sheath can be connected to the spine member. A central lumen can extend through at least a portion of the shaft and the hub portion. The central lumen can be adapted to receive a lead ejector for selective deployment of the stimulation lead from the double barrel sheath.
",AUTONOMIC TECH INC,LUHRS TOM;;CHENG ALAN;;POWELL RYAN;;TENG JENNIFER,,https://lens.org/156-707-041-406-629,Patent Application,yes,6,0,8,8,0,A61B17/3468;;A61N1/0551;;A61N1/36075;;A61N1/0526;;A61N1/37205;;A61N1/0551;;A61N1/36075;;A61B17/3468;;A61N1/0526;;A61N1/3605;;A61N1/37205,A61N1/05;;A61B17/34;;A61N1/36;;A61N1/372,,1,1,001-270-142-225-771,26559753;;10.1016/j.ijom.2015.09.023,"ASSAF A T ET AL: ""Technical and surgical aspects of the sphenopalatine ganglion (SPG) microstimulator insertion procedure"", INTERNATIONAL JOURNAL OF ORAL AND MAXILLOFACIAL SURGERY, vol. 45, no. 2, 7 November 2015 (2015-11-07), pages 245 - 254, XP029387411, ISSN: 0901-5027, DOI: 10.1016/J.IJOM.2015.09.023",PENDING
97,US,B2,US 9247307 B2,199-823-750-608-504,2016-01-26,2016,US 201514752597 A,2015-06-26,US 201514752597 A;;US 81400110 A,2010-06-11,Integrating video share and text messaging with set-top box and access point,"Techniques provide for converged wireline and wireless services in part by employing a set-top box (STB) with machine-to-machine (M2M) communication. The STB, associated with an access point, such as a femtocell, can be used to send/receive messages, including video, to/from user equipment (UE) via a core network. A monitoring system includes a sensor component that is triggered under specified conditions, and the STB records events in response to the trigger, where a recorded event can be sent as a message to the UE. The STB or associated remote control can indicate a received message to a user, who can view the message on the STB, remote control, or associated television. A meter component is associated with the STB via the femtocell or other desired connection. The STB can receive and store utility meter readings for validation or dispute by the user.",AT & T IP I LP,FAN JAMES;;LAM JENNIFER K;;LIU CHENG P,AT&T INTELLECTUAL PROPERTY I L.P (2010-06-10),https://lens.org/199-823-750-608-504,Granted Patent,yes,5,1,6,6,0,G01D4/004;;H04N21/4788;;H04N21/4788;;H04N21/2547;;H04N21/2547;;H04N21/4131;;H04N21/4786;;H04N21/4786;;H04N21/488;;H04N21/8126;;Y02B90/20;;Y04S20/30,H04N7/173;;G01D4/00;;H04N21/41;;H04N21/4788;;H04N21/488;;H04N21/81,,6,0,,,"""M2M smart metering: where are we now?"" Accessed Sep. 10, 2010. 4 pages.;;""The NES System Components"" Accessed Sep. 10, 2010. 2 pages.;;""The NES Smart Metering System"" Accessed Sep. 10, 2010. 6 pages.;;Final Office Action mailed Jun. 19, 2013 for U.S. Appl. No. 12/814,001, 24 pages.;;Office Action mailed Sep. 11, 2012 for U.S. Appl. No. 12/814,001, 25 pages.;;Office Action mailed Dec. 17, 2014 for U.S. Appl. No. 12/814,001, 27 pages.",ACTIVE
98,AU,B2,AU 2012/397816 B2,020-969-858-997-791,2017-03-09,2017,AU 2012/397816 A,2012-12-31,US 2012/0072327 W,2012-12-31,"Sourceless density determination apparatus, methods, and systems","In some embodiments, an apparatus and a system, as well as a method and an article, may operate to determine a compressional velocity (CV) of a geological formation, to determine a reflection coefficient (RC) associated with the geological formation, and to determine a density of the geological formation based on the CV and the RC. The CV and RC may be determined from values associated with sonic and ultrasonic velocity measurements. Additional apparatus, systems, and methods are described.",HALLIBURTON ENERGY SERVICES INC,BATAKRISHNA MANDAL;;CHENG ARTHUR;;CLEGG NIGEL;;MARKET JENNIFER ANNE,,https://lens.org/020-969-858-997-791,Granted Patent,no,1,0,13,13,0,G01V1/306;;G01V1/50;;G01V1/50;;G01V1/306;;G01V1/306;;G01V1/44;;G01V1/44;;G01V2210/622;;G01V2210/6222;;G01V2210/6222;;G01V2210/6224;;G01V2210/6224;;G01V2210/6224,G01V1/44;;G01V1/50,,0,0,,,,INACTIVE
99,US,A1,US 2005/0005244 A1,058-611-596-175-554,2005-01-06,2005,US 91009004 A,2004-08-02,US 91009004 A;;US 68632800 A,2000-10-11,Scripted text discussion system,"A text discussion script data structure is stored on a computer-readable medium in association with a real-time computer discussion. The text discussion script data structure is specified by an author to guide a real-time, multi-user, text discussion or “chat.” The text discussion script includes one or more successive scenes having roles for each of one or more discussion participants. For each scene and role, the author provides instructions and background information that guide the discussion participants, but do not provide the explicit text of the real-time discussion. Accordingly, the text discussion script is adapted to guide real-time computer discussions or chats in a scalable, replicable way, while allowing participants to generate the actual discussion dialog. The text discussion script data structure may be specified by markup language tags that, together, form a markup language tag schema.",MICROSOFT CORP,CHESLEY HARRY R;;CHENG LILI;;SEBAN SUZANA;;LANDAU JENNIFER,MICROSOFT TECHNOLOGY LICENSING LLC (2014-10-14),https://lens.org/058-611-596-175-554,Patent Application,yes,3,15,2,2,0,H04L12/1831;;H04L12/1831,G09G5/00;;H04L12/18,715/751;;715/733;;715/755;;715/758,0,0,,,,DISCONTINUED
100,BR,A2,BR 112015011872 A2,065-963-000-086-650,2017-07-11,2017,BR 112015011872 A,2012-12-31,US 2012/0072327 W,2012-12-31,"sistema, método implementado por processador e artigo","resumo “sistema, método implementado por processador e artigo” em algumas modalidades, um aparato e um sistema, assim como um método e um artigo, podem operar para determinar uma velocidade de compressão (cv) de uma formação geológica, para determinar um coeficiente de reflexão (rc) associado à formação geológica, e para determinar uma densidade da formação geológica com base na cv e no rc. a cv e o rc podem ser determinados a partir de valores associados a medições de velocidade sônica e ultrassônica. aparatos, sistemas e métodos adicionais são divulgados.",HALLIBURTON ENERGY SERVICES INC,ARTHUR CHENG;;JENNIFER ANNE MARKET;;MANDAL BATAKRISHNA;;NIGEL CLEGG,,https://lens.org/065-963-000-086-650,Patent Application,no,0,0,13,13,0,G01V1/306;;G01V1/50;;G01V1/50;;G01V1/306;;G01V1/306;;G01V1/44;;G01V1/44;;G01V2210/622;;G01V2210/6222;;G01V2210/6222;;G01V2210/6224;;G01V2210/6224;;G01V2210/6224,G01V1/44;;G01V1/50,,0,0,,,,DISCONTINUED
101,US,A1,US 2021/0118259 A1,030-347-146-324-464,2021-04-22,2021,US 202016857054 A,2020-04-23,US 202016857054 A;;US 201962923264 P,2019-10-18,VISUAL METER PROGRESSION ON SYMBOL,"Some methods involve receiving user input for initiation of an instance of a slot game, determining a game outcome that includes corresponding display symbols and an award determination, controlling a display system to display the display symbols at a plurality of display symbol positions and controlling the display system to present award effects corresponding to the award determination. The display symbol positions may be arranged in display symbol rows and display symbol columns. At least one of the display symbols may be a metamorphic display symbol that includes a metamorphic image. A state of the first metamorphic image may correspond to a level of progress towards attaining a goal. Progress towards the goal may be based, at least in part, in the number of occurrences of the metamorphic display symbol.",ARISTOCRAT TECH INC,MIZZI JENNIFER;;CHING ERICK;;WASIELEWSKI PETER;;LIN TSUNG-CHENG,ARISTOCRAT TECHNOLOGIES INC (2020-04-22),https://lens.org/030-347-146-324-464,Patent Application,yes,0,2,5,5,0,G07F17/3213;;G07F17/3244;;G07F17/3267;;G07F17/3213;;G07F17/3267;;G07F17/34,G07F17/32,,0,0,,,,ACTIVE
102,US,A,US 6111416 A,072-560-714-094-182,2000-08-29,2000,US 92056197 A,1997-08-29,US 92056197 A;;US 85947897 A;;US 73909996 A;;US 1884496 P,1996-05-31,Electro-optical and magneto-optical sensing apparatus and method for characterizing free-space electromagnetic radiation,"Apparatus and methods for characterizing free-space electromagnetic energy, and in particular, apparatus/method suitable for real-time two-dimensional far-infrared imaging applications are presented. The sensing technique is based on a non-linear coupling between a low-frequency electric (or magnetic) field and a laser beam in an electro-optic (or magnetic-optic) crystal. In addition to a practical counter-propagating sensing technique, a co-linear approach is described which provides longer radiated field-optical beam interaction length, thereby making imaging applications practical.",RENSSELAER POLYTECH INST,ZHANG XI-CHENG;;RIORDAN JENNIFER ANN;;SUN FENG-GUO,RENSSELAER POLYTECHNIC INSTITUTE (1997-08-26),https://lens.org/072-560-714-094-182,Granted Patent,yes,14,85,8,12,0,G01R29/0885;;G01R29/0885;;G01N21/3581;;G01N21/3581;;G02F1/09;;G02F1/09;;G02F1/3515;;G02F1/3515;;G02F1/353;;G02F1/353;;G02F2202/10;;G02F2202/10;;G02F2202/101;;G02F2202/101;;G02F2203/13;;G02F2203/13,G01R33/032;;G01J4/00;;G01N21/21;;G01N21/35;;G01R29/08;;G01R31/302,324/753;;324/96,10,8,030-371-164-666-652;;039-540-350-030-828;;046-849-358-382-640;;073-848-427-903-337;;069-478-175-123-018;;010-375-779-099-941;;147-378-737-246-394;;022-845-299-601-487,10.1063/1.114909;;19862134;;10.1364/ol.20.001716;;10.1063/1.116130;;10.1109/101.485909;;10.1063/1.103299;;10.1063/1.105268;;10.1063/1.115665;;10.1063/1.116356,"Wu et al., Free Space Electro Optic Sampling of Terhertz Beams, Appl. Phys. Lett., Vo. 67, No. 24, pp. 1 3, Dec. 1995.;;Jespen et al., Detection of High Power THz Pulses by Phase Retardation in an Electro Optic Crystal, International Symposium on Ultra Fast Processes In Spectroscopy, Trieste, Italy Oct. 30 Nov. 3, 1995, pp. 1 7.;;Hu et al., Imaging with Terahertz Waves, Optic Letters, vol. 20, No. 16, pp. 1716 1719, May 1995.;;A Lauren Publication Biophotonics, Bell Labs T rays Provide Unique Images With a Variety of Potential Applications, Biophotonics International, pp. 58 59, Jul./Aug. 1995.;;Nahata et al., Coherent Detection of Freely Propagating Terhertz Radiation by Electro Optic Sampling, Appl. Phys. Lett., vol. 68, No. 2, pp. 150 152, Jan. 1996.;;Nuss, Martin C., Chemistry is Right for T Ray Imaging, IEEE Circuits and Devices, pp. 25 29, Mar. 1996.;;Hu, B.B., Zhang, X. C., Auston, D.H. and Smith, P.R., Free Space Radiation From Electro Optic Crystals , 1990 American Institute of Physics, Appl Phys, Lett. 56(6), Feb. 5, 1990 (pp. 506 508).;;Green, B.I., Federici, J.F., Dykaar, D.R., Jones, R.R. and Bucksbaum, P.H., Interferometric Characterization of 160 fs Far Infrared Light Pulses , 1991 American Institute of Physics, Appl. Phys. Lett. 59(8), Aug. 19, 1991 (pp. 893 895).;;Wu, Q. and Zhang, X. C., Ultrafast Electro Optic Field Sensors , 1996 American Institute of Physics, Appl. Phys. Lett. 698(12), Mar. 18, 1996 (pp. 1604 1606).;;Wu, Q., Litz, M. and Zhang, X. C., Broadband Detection Capability of ZnTe Electro Optic Field Detectors , 1996 American Institute of Physics, Appl. Phys. Lett. 68(21), May 20, 1996 (2924 2926).",EXPIRED
103,US,A1,US 2022/0189240 A1,046-581-467-743-383,2022-06-16,2022,US 202217652894 A,2022-02-28,US 202217652894 A;;US 202016857054 A;;US 201962923264 P,2019-10-18,VISUAL METER PROGRESSION ON SYMBOL,"Some methods involve receiving user input for initiation of an instance of a slot game, determining a game outcome that includes corresponding display symbols and an award determination, controlling a display system to display the display symbols at a plurality of display symbol positions and controlling the display system to present award effects corresponding to the award determination. The display symbol positions may be arranged in display symbol rows and display symbol columns. At least one of the display symbols may be a metamorphic display symbol that includes a metamorphic image. A state of the first metamorphic image may correspond to a level of progress towards attaining a goal. Progress towards the goal may be based, at least in part, in the number of occurrences of the metamorphic display symbol.",ARISTOCRAT TECH INC,MIZZI JENNIFER;;CHING ERICK;;WASIELEWSKI PETER;;LIN TSUNG-CHENG,ARISTOCRAT TECHNOLOGIES INC (2020-04-22),https://lens.org/046-581-467-743-383,Patent Application,yes,2,2,5,5,0,G07F17/3213;;G07F17/3244;;G07F17/3267;;G07F17/3213;;G07F17/3267;;G07F17/34,G07F17/32;;G07F17/34,,0,0,,,,ACTIVE
104,WO,A1,WO 2014/105088 A1,096-297-004-179-953,2014-07-03,2014,US 2012/0072327 W,2012-12-31,US 2012/0072327 W,2012-12-31,"SOURCELESS DENSITY DETERMINATION APPARATUS, METHODS, AND SYSTEMS","In some embodiments, an apparatus and a system, as well as a method and an article, may operate to determine a compressional velocity (CV) of a geological formation, to determine a reflection coefficient (RC) associated with the geological formation, and to determine a density of the geological formation based on the CV and the RC. The CV and RC may be determined from values associated with sonic and ultrasonic velocity measurements. Additional apparatus, systems, and methods are described.",HALLIBURTON ENERGY SERV INC,BATAKRISHNA MANDAL;;CHENG ARTHUR;;CLEGG NIGEL;;MARKET JENNIFER ANNE,,https://lens.org/096-297-004-179-953,Patent Application,yes,5,2,13,13,0,G01V1/306;;G01V1/50;;G01V1/50;;G01V1/306;;G01V1/306;;G01V1/44;;G01V1/44;;G01V2210/622;;G01V2210/6222;;G01V2210/6222;;G01V2210/6224;;G01V2210/6224;;G01V2210/6224,G01V1/44;;G01V1/50,,1,0,,,See also references of EP 2932309A4,PENDING
105,US,B2,US 11401599 B2,111-997-560-230-050,2022-08-02,2022,US 201916444701 A,2019-06-18,US 201916444701 A;;US 201862686409 P,2018-06-18,Erosion resistant metal silicate coatings,"Disclosed are rare earth metal containing silicate coatings, coated articles (e.g., heaters and susceptors) or bodies of articles and methods of coating such articles with a rare earth metal containing silicate coating.",APPLIED MATERIALS INC,HE XIAO-MING;;CHOU CHENG-HSUAN;;SUN JENNIFER Y,APPLIED MATERIALS INC (2018-09-17),https://lens.org/111-997-560-230-050,Granted Patent,yes,18,0,3,3,0,C23C16/401;;C23C16/4404;;C23C16/45529;;C23C16/45531;;C23C14/08;;C23C16/45525;;C23C16/0281;;C23C14/046;;C23C14/34;;C23C16/401;;C23C16/405;;B23B2228/10;;Y10T428/2949;;B23B2228/36,C23C16/40;;C23C14/04;;C23C14/08;;C23C14/34;;C23C16/02;;C23C16/455,,1,1,009-194-328-202-710,10.1179/1743280414y.0000000033,"Sun, et al., “Recent progress on synthesis, multi-scale structure, and properties of Y—Si—O oxides,” International Materials Reviews, 2014, vol. 59, No. 7, pp. 357-383, Maney.",ACTIVE
106,US,B2,US 11288914 B2,140-085-151-410-974,2022-03-29,2022,US 202016857054 A,2020-04-23,US 202016857054 A;;US 201962923264 P,2019-10-18,Visual meter progression on symbol,"Some methods involve receiving user input for initiation of an instance of a slot game, determining a game outcome that includes corresponding display symbols and an award determination, controlling a display system to display the display symbols at a plurality of display symbol positions and controlling the display system to present award effects corresponding to the award determination. The display symbol positions may be arranged in display symbol rows and display symbol columns. At least one of the display symbols may be a metamorphic display symbol that includes a metamorphic image. A state of the first metamorphic image may correspond to a level of progress towards attaining a goal. Progress towards the goal may be based, at least in part, in the number of occurrences of the metamorphic display symbol.",ARISTOCRAT TECH INC,MIZZI JENNIFER;;CHING ERICK;;WASIELEWSKI PETER;;LIN TSUNG-CHENG,ARISTOCRAT TECHNOLOGIES INC (2020-04-22),https://lens.org/140-085-151-410-974,Granted Patent,yes,23,0,5,5,0,G07F17/3213;;G07F17/3244;;G07F17/3267;;G07F17/3213;;G07F17/3267;;G07F17/34,G07F17/34;;G07F17/32,,0,0,,,,ACTIVE
107,US,A1,US 2019/0382880 A1,172-694-118-641-396,2019-12-19,2019,US 201916444701 A,2019-06-18,US 201916444701 A;;US 201862686409 P,2018-06-18,EROSION RESISTANT METAL SILICATE COATINGS,"Disclosed are rare earth metal containing silicate coatings, coated articles (e.g., heaters and susceptors) or bodies of articles and methods of coating such articles with a rare earth metal containing silicate coating.",APPLIED MATERIALS INC,HE XIAO-MING;;CHOU CHENG-HSUAN;;SUN JENNIFER Y,APPLIED MATERIALS INC (2018-09-17),https://lens.org/172-694-118-641-396,Patent Application,yes,0,8,3,3,0,C23C16/401;;C23C16/4404;;C23C16/45529;;C23C16/45531;;C23C14/08;;C23C16/45525;;C23C16/0281;;C23C14/046;;C23C14/34;;C23C16/401;;C23C16/405;;B23B2228/10;;Y10T428/2949;;B23B2228/36,C23C14/08;;C23C14/04;;C23C14/34;;C23C16/02;;C23C16/40;;C23C16/455,,0,0,,,,ACTIVE
108,US,B1,US 6795093 B1,130-576-498-287-809,2004-09-21,2004,US 68632800 A,2000-10-11,US 68632800 A,2000-10-11,Scripted text discussion system,"
    A text discussion script data structure is stored on a computer-readable medium in association with a real-time computer discussion. The text discussion script data structure is specified by an author to guide a real-time, multi-user, text discussion or chat. The text discussion script includes one or more successive scenes having roles for each of one or more discussion participants. For each scene and role, the author provides instructions and background information that guide the discussion participants, but do not provide the explicit text of the real-time discussion. Accordingly, the text discussion script is adapted to guide real-time computer discussions or chats in a scalable, replicable way, while allowing participants to generate the actual discussion dialog. The text discussion script data structure may be specified by markup language tags that, together, form a markup language tag schema. 
",MICROSOFT CORP,CHESLEY HARRY R;;CHENG LILI;;SEBAN SUZANA;;LANDAU JENNIFER,MICROSOFT TECHNOLOGY LICENSING LLC (2014-10-14),https://lens.org/130-576-498-287-809,Granted Patent,yes,7,11,2,2,0,H04L12/1831;;H04L12/1831,G09G5/00;;H04L12/18,345/751;;345/733;;345/753;;345/755;;345/758,0,0,,,,EXPIRED
109,US,S,US D0721672 S,165-762-742-662-666,2015-01-27,2015,US 201429482493 F,2014-02-19,US 201429482493 F,2014-02-19,Handset,,NOKIA CORP,DEARSLEY SIMON;;CICHOCKI ASHLEY;;CHENG XIN XU;;CHEN JENNIFER,MICROSOFT MOBILE OY (2014-04-25);;NOKIA CORPORATION (2014-11-13);;MICROSOFT CORPORATION (2017-08-30),https://lens.org/165-762-742-662-666,Design Right,no,0,2,3,3,0,,,1403;;D14138AA,0,0,,,,ACTIVE
110,TW,S,TW D171278 S,172-634-514-911-242,2015-10-21,2015,TW 103304883 F,2014-08-19,US 201429482493 F,2014-02-19,手機,【物品用途】;本設計係提供一種手機，特別是指外觀圓潤精巧，具和諧對稱之設計美感，可作程式運算處理及訊號傳遞接收之手機造型新設計。;【設計說明】;本設計為一直立造型之手機，從立體圖及前後視圖可看出，本設計之手機造形大致為長方形體，其正面上方設有一大型螢幕，下方並設有複數輸出輸入功能鍵；背面則設有一圓形鏡頭及功能元件，以極簡化設計予人乾淨大方之意象。;另，請參閱左、右視圖及俯、仰視圖，可明顯看出本設計手機之側面及背面皆採圓弧設計，可增加手機背面與手掌之接觸面積，達到穩定握持效果；此外，如俯視圖所示，本設計之手機在頂部位置設有複數基本功能元件；整體而言，本設計之手機跳脫以往設計概念，將所有操作元件集中於手機之頂部、正面與背面(請參前後視圖、俯視圖)，方便使用者可迅速學習功能之操作，側面及背面周緣的圓弧設計，提供使用者舒適握感並能夠一手掌握。;綜上所述，本設計之手機整體造形予人和諧之對稱美感，同;時兼具人體工學設計與極簡化視感，確為新穎首創，符合設計專利要件，爰依法提出專利申請。,微軟移動設備有限公司;;MICROSOFT MOBILE OY,DEARSLEY SIMON;;CICHOCKI ASHLEY;;XU CHENG XIN;;CHEN JENNIFER,,https://lens.org/172-634-514-911-242,Design Right,no,0,0,3,3,0,,,14-03,0,0,,,,ACTIVE
111,US,B1,US 7882484 B1,088-739-815-428-63X,2011-02-01,2011,US 5340708 A,2008-03-21,US 5340708 A,2008-03-21,Generating a design-specific input/output model document,A method of creating a design-specific I/O model document can include reading a plurality of I/O pin models corresponding to available I/O pin profiles on a target device ( 355 ) and identifying I/O pins of the target device that are used by a circuit design ( 325 ). An I/O pin profile for each I/O pin of the target device that is used by the circuit design can be determined ( 345 ). An I/O pin model can be selected from the plurality of I/O pin models for each I/O pin of the target device that is used by the circuit design according to the I/O pin profiles ( 355 ). The design-specific I/O model document for the circuit design can be generated by including each selected I/O pin model within the design-specific I/O model document ( 365 ). The design-specific I/O model document can be output ( 380 ).,XILINX INC,BALDWIN JENNIFER D;;CHENG PAUL;;GARRAULT PHILIPPE;;DEVANATH HARI,XILINX INC (2008-03-18),https://lens.org/088-739-815-428-63X,Granted Patent,yes,3,6,1,1,0,G06F30/30;;G06F2113/18;;G06F30/30;;G06F2113/18,G06F17/50,716/115;;716/116,0,0,,,,ACTIVE
112,CA,C,CA 2895025 C,147-057-022-893-62X,2019-12-31,2019,CA 2895025 A,2012-12-31,US 2012/0072327 W,2012-12-31,"SOURCELESS DENSITY DETERMINATION APPARATUS, METHODS, AND SYSTEMS","In some embodiments, an apparatus and a system, as well as a method and an article, may operate to determine a compressional velocity (CV) of a geological formation, to determine a reflection coefficient (RC) associated with the geological formation, and to determine a density of the geological formation based on the CV and the RC. The CV and RC may be determined from values associated with sonic and ultrasonic velocity measurements. Additional apparatus, systems, and methods are described.",HALLIBURTON ENERGY SERVICES INC,BATAKRISHNA MANDAL;;CHENG ARTHUR;;CLEGG NIGEL;;MARKET JENNIFER ANNE,,https://lens.org/147-057-022-893-62X,Granted Patent,no,0,0,13,13,0,G01V1/44;;G01V1/306;;G01V2210/6222;;G01V2210/6224;;G01V1/50;;G01V1/306;;G01V2210/622;;G01V2210/6224;;G01V1/306;;G01V2210/6222;;G01V2210/6224;;G01V1/44;;G01V1/50,G01V1/44;;G01V1/50,,0,0,,,,INACTIVE
113,CA,A1,CA 2895025 A1,080-086-749-486-885,2014-07-03,2014,CA 2895025 A,2012-12-31,US 2012/0072327 W,2012-12-31,"SOURCELESS DENSITY DETERMINATION APPARATUS, METHODS, AND SYSTEMS","In some embodiments, an apparatus and a system, as well as a method and an article, may operate to determine a compressional velocity (CV) of a geological formation, to determine a reflection coefficient (RC) associated with the geological formation, and to determine a density of the geological formation based on the CV and the RC. The CV and RC may be determined from values associated with sonic and ultrasonic velocity measurements. Additional apparatus, systems, and methods are described.",HALLIBURTON ENERGY SERVICES INC,BATAKRISHNA MANDAL;;CHENG ARTHUR;;CLEGG NIGEL;;MARKET JENNIFER ANNE,,https://lens.org/080-086-749-486-885,Patent Application,no,0,0,13,13,0,G01V1/306;;G01V1/50;;G01V1/50;;G01V1/306;;G01V1/306;;G01V1/44;;G01V1/44;;G01V2210/622;;G01V2210/6222;;G01V2210/6222;;G01V2210/6224;;G01V2210/6224;;G01V2210/6224,G01V1/44;;G01V1/50,,0,0,,,,INACTIVE
114,US,B2,US 9753170 B2,169-054-809-664-526,2017-09-05,2017,US 201214650808 A,2012-12-31,US 2012/0072327 W,2012-12-31,"Sourceless density determination apparatus, methods, and systems","In some embodiments, an apparatus and a system, as well as a method and an article, may operate to determine a compressional velocity (CV) of a geological formation, to determine a reflection coefficient (RC) associated with the geological formation, and to determine a density of the geological formation based on the CV and the RC. The CV and RC may be determined from values associated with sonic and ultrasonic velocity measurements. Additional apparatus, systems, and methods are described.",HALLIBURTON ENERGY SERVICES INC,MANDAL BATAKRISHNA;;CHENG ARTHUR;;CLEGG NIGEL;;MARKET JENNIFER ANNE,HALLIBURTON ENERGY SERVICES INC (2013-01-21),https://lens.org/169-054-809-664-526,Granted Patent,yes,17,0,13,13,0,G01V1/306;;G01V1/50;;G01V1/50;;G01V1/306;;G01V1/306;;G01V1/44;;G01V1/44;;G01V2210/622;;G01V2210/6222;;G01V2210/6222;;G01V2210/6224;;G01V2210/6224;;G01V2210/6224,G01V1/30;;G01V1/44;;G01V1/50,,15,0,,,"“Australian Application Serial No. 2012397816, First Examiner Report mailed Mar. 17, 2016”, 2 pgs.;;“Canadian Application Serial No. 2,895,025, Office Action mailed Jun. 6, 2016”, 3 pgs.;;“European Application Serial No. 12891140.1, Extended European Search Report mailed Jul. 21, 2016”, 8 pgs.;;“European Application Serial No. 12891140.1, Office Action mailed Jul. 24, 2015”, 2 pgs.;;“European Application Serial No. 12891140.1, Reply mailed Oct. 8, 2015 to Office Action mailed Jul. 24, 2015”, 8 pgs.;;“International Application Serial No. PCT/US2012/072327, Response filed Oct. 23, 2014 to Written Opinion mailed Sep. 2, 2013”, 2 pgs.;;“Russian Federation Application Serial No. 2015122489, Office Action mailed Mar. 28, 2016”, (w/ English Translations), 21 pgs.;;“Russian Federation Application Serial No. 2015122489, Response filed Aug. 11, 2016 to Office Action mailed Mar. 28, 2016”, (w/ English Translation of Claims), 11 pgs.;;“International Application Serial No. PCT/US2012/072327, International Preliminary Report on Patentability mailed Mar. 4, 2015”, 6 pgs.;;“International Application Serial No. PCT/US2012/072327, International Search Report mailed Sep. 2, 2013”, 3 pgs.;;“International Application Serial No. PCT/US2012/072327, Written Opinion mailed Sep. 2, 2013”, 5 pgs.;;Quijada, M. F., et al., “Density estimations using density-velocity relations and seismic inversion”, CREWES Research Report . vol. 19, (2007), 1-20.;;“Canadian Application Serial No. 2,895,025, Office Action mailed Jan. 10, 2017”, 3 pages.;;“Chinese Application Serial No. 201280077537.7, Office Action mailed Aug. 18, 2016.”, 6 pages (15 pages total w/English translation).;;“Chinese Application Serial No. 201280077537.7, Office Action mailed Apr. 24, 2017.”, 3 pages.",ACTIVE
115,CN,A,CN 104903748 A,182-611-527-338-28X,2015-09-09,2015,CN 201280077537 A,2012-12-31,US 2012/0072327 W,2012-12-31,"Sourceless density determination apparatus, methods, and systems","In some embodiments, an apparatus and a system, as well as a method and an article, may operate to determine a compressional velocity (CV) of a geological formation, to determine a reflection coefficient (RC) associated with the geological formation, and to determine a density of the geological formation based on the CV and the RC. The CV and RC may be determined from values associated with sonic and ultrasonic velocity measurements. Additional apparatus, systems, and methods are described.",HALLIBURTION ENERGY SERVICES INC,BATAKRISHNA MANDAL;;CHENG ARTHUR;;CLEGG NIGEL;;MARKET JENNIFER ANNE,,https://lens.org/182-611-527-338-28X,Patent Application,no,6,2,13,13,0,G01V1/306;;G01V1/50;;G01V1/50;;G01V1/306;;G01V1/306;;G01V1/44;;G01V1/44;;G01V2210/622;;G01V2210/6222;;G01V2210/6222;;G01V2210/6224;;G01V2210/6224;;G01V2210/6224,G01V1/44;;G01V1/50,,2,0,,,"张学东等: ""准中地区高精度合成地震记录的制作"", 《新疆地质》;;王树理等: ""井下超声波成像提取岩层节理产状信息"", 《现代地质》",INACTIVE
116,US,A1,US 2022/0349041 A1,139-526-004-607-326,2022-11-03,2022,US 202217864745 A,2022-07-14,US 202217864745 A;;US 201916444701 A;;US 201862686409 P,2018-06-18,EROSION RESISTANT METAL SILICATE COATINGS,"Disclosed are rare earth metal containing silicate coatings, coated articles (e.g., heaters and susceptors) or bodies of articles and methods of coating such articles with a rare earth metal containing silicate coating.",APPLIED MATERIALS INC,HE XIAO-MING;;CHOU CHENG-HSUAN;;SUN JENNIFER Y,APPLIED MATERIALS INC (2018-09-17),https://lens.org/139-526-004-607-326,Patent Application,yes,0,0,3,3,0,C23C16/401;;C23C16/4404;;C23C16/45529;;C23C16/45531;;C23C14/08;;C23C16/45525;;C23C16/0281;;C23C14/046;;C23C14/34;;C23C16/401;;C23C16/405;;B23B2228/10;;Y10T428/2949;;B23B2228/36,C23C14/08;;C23C14/04;;C23C14/34;;C23C16/02;;C23C16/40;;C23C16/455,,0,0,,,,PENDING
117,EP,A1,EP 2932309 A1,173-973-820-112-185,2015-10-21,2015,EP 12891140 A,2012-12-31,US 2012/0072327 W,2012-12-31,"SOURCELESS DENSITY DETERMINATION APPARATUS, METHODS, AND SYSTEMS",,HALLIBURTON ENERGY SERVICES INC,BATAKRISHNA MANDAL;;CHENG ARTHUR;;CLEGG NIGEL;;MARKET JENNIFER ANNE,HALLIBURTON ENERGY SERVICES INC. (2019-06-19),https://lens.org/173-973-820-112-185,Patent Application,yes,0,0,13,13,0,G01V1/306;;G01V1/50;;G01V1/50;;G01V1/306;;G01V1/306;;G01V1/44;;G01V1/44;;G01V2210/622;;G01V2210/6222;;G01V2210/6222;;G01V2210/6224;;G01V2210/6224;;G01V2210/6224,G01V1/44;;G01V1/30;;G01V1/50,,0,0,,,,DISCONTINUED
118,AU,A1,AU 2020/239808 A1,190-918-583-163-804,2021-05-06,2021,AU 2020/239808 A,2020-09-25,US 202016857054 A;;US 201962923264 P,2019-10-18,VISUAL METER PROGRESSION ON SYMBOL,"Aristocrat Ref. P05993USP IUI Some methods involve receiving user input for initiation of an instance of a slot game, determining a game outcome that includes corresponding display symbols and an award determination, controlling a display system to display the display symbols at a plurality of display symbol positions and controlling the display system to present award effects corresponding to the award determination. The display symbol positions may be arranged in display symbol rows and display symbol columns. At least one of the display symbols may be a metamorphic display symbol that includes a metamorphic image. A state of the first metamorphic image may correspond to a level of progress towards attaining a goal. Progress towards the goal may be based, at least in part, in the number of occurrences of the metamorphic display symbol. 16572316 1 (GHMatters) P114455.AU Receiving, by a control system of a gaming device, user input for 605 initiation of an instance of a wagering game, the wagering game comprising a slot game Determining, via the control system, a game outcome and corresponding display symbols, the game outcome comprising an 610 award determination, wherein at least one of the display symbols is a first metamorphic display symbol comprising a first metamorphic image, a state of the first metamorphic image corresponding to a level of progress towards attaining a goal Controlling, via the control system, a display system to display the display symbols at a plurality of display symbol positions on a display 615 device of the display system, wherein the plurality of display symbol positions are arranged in a plurality of display symbol rows and display symbol columns Controlling, via the control system, the display system to present award effects corresponding to the award determination",ARISTOCRAT TECHNOLOGIES INC,MIZZI JENNIFER;;CHING ERICK;;WASIELEWSKI PETER;;LIN TSUNG-CHENG,,https://lens.org/190-918-583-163-804,Patent Application,no,0,0,5,5,0,G07F17/3213;;G07F17/3244;;G07F17/3267;;G07F17/3213;;G07F17/3267;;G07F17/34,G07F17/32,,0,0,,,,PENDING
119,EP,A4,EP 2932309 A4,184-411-836-364-656,2016-08-24,2016,EP 12891140 A,2012-12-31,US 2012/0072327 W,2012-12-31,"SOURCELESS DENSITY DETERMINATION APPARATUS, METHODS, AND SYSTEMS",,HALLIBURTON ENERGY SERVICES INC,BATAKRISHNA MANDAL;;CHENG ARTHUR;;CLEGG NIGEL;;MARKET JENNIFER ANNE,HALLIBURTON ENERGY SERVICES INC. (2019-06-19),https://lens.org/184-411-836-364-656,Search Report,no,5,0,13,13,0,G01V1/306;;G01V1/50;;G01V1/50;;G01V1/306;;G01V1/306;;G01V1/44;;G01V1/44;;G01V2210/622;;G01V2210/6222;;G01V2210/6222;;G01V2210/6224;;G01V2210/6224;;G01V2210/6224,G01V1/44;;G01V1/30;;G01V1/50,,1,0,,,See also references of WO 2014105088A1,DISCONTINUED
120,US,B2,US 11915543 B2,100-856-501-821-784,2024-02-27,2024,US 202217652894 A,2022-02-28,US 202217652894 A;;US 202016857054 A;;US 201962923264 P,2019-10-18,Visual meter progression on symbol,"Some methods involve receiving user input for initiation of an instance of a slot game, determining a game outcome that includes corresponding display symbols and an award determination, controlling a display system to display the display symbols at a plurality of display symbol positions and controlling the display system to present award effects corresponding to the award determination. The display symbol positions may be arranged in display symbol rows and display symbol columns. At least one of the display symbols may be a metamorphic display symbol that includes a metamorphic image. A state of the first metamorphic image may correspond to a level of progress towards attaining a goal. Progress towards the goal may be based, at least in part, in the number of occurrences of the metamorphic display symbol.",ARISTOCRAT TECH INC,MIZZI JENNIFER;;CHING ERICK;;WASIELEWSKI PETER;;LIN TSUNG-CHENG,ARISTOCRAT TECHNOLOGIES INC (2020-04-22),https://lens.org/100-856-501-821-784,Granted Patent,yes,25,0,5,5,0,G07F17/3213;;G07F17/3244;;G07F17/3267;;G07F17/3213;;G07F17/3267;;G07F17/34,G07F17/34;;G07F17/32,,2,0,,,"Office Action dated Jun. 15, 2021 for U.S. Appl. No. 16/857,054 (pp. 1-16).;;Office Action (Notice of Allowance and Fees Due (PTOL-85)) dated Nov. 22, 2021 for U.S. Appl. No. 16/857,054 (pp. 1-8).",ACTIVE
121,AU,A1,AU 2012/397816 A1,160-394-344-596-917,2015-06-11,2015,AU 2012/397816 A,2012-12-31,US 2012/0072327 W,2012-12-31,"Sourceless density determination apparatus, methods, and systems","In some embodiments, an apparatus and a system, as well as a method and an article, may operate to determine a compressional velocity (CV) of a geological formation, to determine a reflection coefficient (RC) associated with the geological formation, and to determine a density of the geological formation based on the CV and the RC. The CV and RC may be determined from values associated with sonic and ultrasonic velocity measurements. Additional apparatus, systems, and methods are described.",HALLIBURTON ENERGY SERVICES INC,BATAKRISHNA MANDAL;;CHENG ARTHUR;;CLEGG NIGEL;;MARKET JENNIFER ANNE,,https://lens.org/160-394-344-596-917,Patent Application,no,0,0,13,13,0,G01V1/306;;G01V1/50;;G01V1/50;;G01V1/306;;G01V1/306;;G01V1/44;;G01V1/44;;G01V2210/622;;G01V2210/6222;;G01V2210/6222;;G01V2210/6224;;G01V2210/6224;;G01V2210/6224,G01V1/44;;G01V1/50,,0,0,,,,INACTIVE
122,EP,B1,EP 3841202 B1,032-753-079-591-947,2023-10-04,2023,EP 19851177 A,2019-08-20,US 201862720014 P;;US 2019/0047239 W,2018-08-20,NUCLEOTIDE SEQUENCE GENERATION BY BARCODE BEAD-COLOCALIZATION IN PARTITIONS,,BIO RAD LABORATORIES INC,LEBOFSKY RONALD;;KOHLWAY ANDREW;;CHEW JENNIFER;;BURKETT ZACHARY;;CHENG MAN,,https://lens.org/032-753-079-591-947,Granted Patent,yes,7,0,10,10,0,G16B40/10;;G16B30/10;;C12Q1/6869;;C12Q1/6869;;G16B40/10;;C12Q2563/185;;C12Q2563/155;;G16B30/10,C12N5/10;;C12Q1/68;;C12Q1/6869;;C40B20/04,,1,0,,,"LAREAU CALEB A ET AL: ""Droplet-based combinatorial indexing for massive-scale single-cell chromatin accessibility"", NATURE BIOTECHNOLOGY, NATURE PUBLISHING GROUP US, NEW YORK, vol. 37, no. 8, 24 June 2019 (2019-06-24), pages 916-924, XP036849994, ISSN: 1087-0156, DOI: 10.1038/S41587-019-0147-6 [retrieved on 2019-06-24]",ACTIVE
123,WO,A1,WO 2020/041293 A1,060-960-551-498-138,2020-02-27,2020,US 2019/0047239 W,2019-08-20,US 201862720014 P,2018-08-20,NUCLEOTIDE SEQUENCE GENERATION BY BARCODE BEAD-COLOCALIZATION IN PARTITIONS,Comparison of common sequencing reads from sequencing based on partition-based barcoding can be used to improve sequencing results. Increased loading of barcodes per partition can also improve sequencing results.,BIO RAD LABORATORIES,LEBOFSKY RONALD;;KOHLWAY ANDREW;;CHEW JENNIFER;;BURKETT ZACHARY;;CHENG MAN,,https://lens.org/060-960-551-498-138,Patent Application,yes,113,0,10,10,9,G16B40/10;;G16B30/10;;C12Q1/6869;;C12Q1/6869;;G16B40/10;;C12Q2563/185;;C12Q2563/155;;G16B30/10,C12N5/10;;C12Q1/68;;C12Q1/6869;;C40B20/04,,26,22,010-639-981-123-294;;104-015-228-687-308;;053-572-201-729-030;;051-979-084-434-779;;000-404-332-410-390;;040-128-403-822-230;;020-844-141-136-135;;020-844-141-136-135;;067-123-677-365-353;;017-426-489-915-543;;062-534-143-598-528;;050-400-165-665-489;;104-497-647-494-695;;103-261-559-380-762;;029-319-148-139-066;;161-864-238-595-646;;161-864-238-595-646;;006-415-294-038-875;;043-895-385-051-167;;104-989-663-398-661;;016-159-010-515-549;;068-891-509-412-163,24302831;;pmc3831736;;10.4103/0975-7406.120066;;10.1016/0168-9525(90)90186-a;;18680433;;10.1146/annurev.genet.42.110807.091656;;12603728;;10.1046/j.1365-2958.2003.03382.x;;9516433;;10.1074/jbc.273.13.7367;;289456;;10.1101/sqb.1979.043.01.046;;pmc4409979;;10.1038/ng.3119;;25326703;;pmc4409979;;10.1038/ng.3119;;25326703;;12895469;;10.1016/s0003-2697(03)00291-4;;10.1126/science.327.5970.1190;;20203024;;10.1038/nature03959;;16056220;;pmc1464427;;10.1517/14622416.6.4.373;;16004555;;10.1038/76469;;10835600;;10.1093/nar/28.20.e87;;pmc110803;;11024189;;10.1373/clinchem.2008.112789;;19246620;;19287448;;19287448;;16448145;;10.1021/ja057123+;;10.1073/pnas.0710982105;;pmc2234111;;18216253;;10.1038/nmeth.4396;;10.1101/181206;;pmc5623106;;28846090;;19451168;;10.1093/bioinformatics/btp324;;pmc2705234;;pmc2592715;;18798982;;10.1186/gb-2008-9-9-r137,"SAMBROOK ET AL.: ""MOLECULAR CLONING: A LABORATORY MANUAL"", 1989, COLD SPRING HARBOR LABORATORY PRESS;;FAKRUDDIN ET AL., J. PHARM BIOALLIED SCI., vol. 5, no. 4, 2013, pages 245 - 252;;""PCR Protocols: A Guide to Methods and Applications"", 1990;;REZNIKOFFWS., ANNU REV GENET, vol. 42, 2008, pages 269 - 286;;REZNIKOFF WS., MOL MICROBIOL, vol. 47, 2003, pages 1199 - 1206;;GORYSHIN IYREZNIKOFFWS, JBIOL CHEM, vol. 273, 1998, pages 7367 - 7374;;SCHALLER H, COLD SPRING HARB SYMP QUANT BIOL, vol. 43, 1979, pages 401 - 408;;AMINI ET AL., NATURE GENETICS, vol. 46, 2014, pages 1343 - 1349;;AMINI ET AL., NATURE GENETICS, vol. 46, no. 12, pages 1343 - 1349;;BUENROSTRO ET AL., CURR PROTOCMOLBIOL., vol. 109, 2015, pages 1 - 9;;GENOMICS, vol. 92, 2008, pages 255;;MITRA ET AL., ANALYTICAL BIOCHEMISTRY, vol. 320, 2003, pages 55 - 65;;SHENDURE ET AL., SCIENCE, vol. 327, no. 5970, 2010, pages 1190 - 1732;;MARGULIES ET AL., NATURE, vol. 437, 2005, pages 376 - 380;;BENNETT ET AL., PHARMACOGENOMICS, vol. 6, 2005, pages 373 - 382;;BRENNER ET AL., NAT. BIOTECHNOL., vol. 18, 2000, pages 630 - 634;;ADESSI ET AL., NUCLEIC ACID RES., vol. 28, 2000, pages E87;;VOELKERDING ET AL., CLINICAL CHEM., vol. 55, 2009, pages 641 - 658;;MACLEAN ET AL., NATURE REV. MICROBIOL., vol. 7, pages 287 - 296;;MACLEAN ET AL., NATURE REV. MICROBIAL., vol. 7, pages 287 - 296;;ASTIER ET AL., J. AM. CHEM. SOC., vol. 128, no. 5, 8 February 2006 (2006-02-08), pages 1705 - 10;;MACLEAN ET AL., NATURE REV. MICROBIAL, vol. 7, pages 287 - 296;;KORLACH ET AL.: ""Selective aluminum passivation for targeted immobilization of single DNA polymerase molecules in zero-mode waveguide nanostructures"", PNAS, vol. 105, no. 4, 2008, pages 1176 - 81, XP002632441, DOI: 10.1073/PNAS.0710982105;;CORCES ET AL., NATURE METHODS, 2017;;LI H.DURBIN R.: ""Fast and accurate short read alignment with Burrows-Wheeler Transform"", BIOINFORMATICS, vol. 25, 2009, pages 1754 - 60, XP055553969, DOI: 10.1093/bioinformatics/btp324;;ZHANG Y ET AL.: ""Model-based Analysis of ChIP-Seq (MACS"", GENOME BIOLOGY, vol. 9, no. 9, 2008, pages R137, XP021046980, DOI: 10.1186/gb-2008-9-9-r137",PENDING
124,EP,A3,EP 4249651 A3,097-159-639-930-959,2023-10-18,2023,EP 23172531 A,2019-08-20,US 201862720014 P;;EP 19851177 A;;US 2019/0047239 W,2018-08-20,NUCLEOTIDE SEQUENCE GENERATION BY BARCODE BEAD-COLOCALIZATION IN PARTITIONS,Comparison of common sequencing reads from sequencing based on partition-based barcoding can be used to improve sequencing results. Increased loading of barcodes per partition can also improve sequencing results.,BIO RAD LABORATORIES INC,LEBOFSKY RONALD;;KOHLWAY ANDREW;;CHEW JENNIFER;;BURKETT ZACHARY;;CHENG MAN,,https://lens.org/097-159-639-930-959,Search Report,yes,2,0,10,10,0,G16B40/10;;G16B30/10;;C12Q1/6869;;C12Q1/6869;;G16B40/10;;C12Q2563/185;;C12Q2563/155;;G16B30/10,C12N5/10;;C12Q1/68;;C12Q1/6869;;C40B20/04,,1,1,031-771-179-679-906,10.1038/s41587-019-0147-6;;pmc10299900;;31235917,"LAREAU CALEB A ET AL: ""Droplet-based combinatorial indexing for massive-scale single-cell chromatin accessibility"", NATURE BIOTECHNOLOGY, NATURE PUBLISHING GROUP US, NEW YORK, vol. 37, no. 8, 24 June 2019 (2019-06-24), pages 916 - 924, XP036849994, ISSN: 1087-0156, [retrieved on 20190624], DOI: 10.1038/S41587-019-0147-6",PENDING
125,WO,A1,WO 2001/011680 A1,163-641-686-983-479,2001-02-15,2001,US 0006598 W,2000-03-13,US 37149899 A,1999-08-10,METHOD AND APPARATUS FOR CHARACTERIZING A SEMICONDUCTOR DEVICE,"A method and apparatus are provided for providing characterization data for semiconductor devices. A first data set containing measured results obtained from wafer electrical tests performed on the semiconductor device during the fabrication process is compared (S216) to a second data set containing values corresponding to design characteristics for the semiconductor device. Based on this comparison, semiconductor devices having valid and invalid performance characteristics are identified. The characterization results data are subsequently (S220) generated for the identified semiconductor devices.",ADVANCED MICRO DEVICES INC,PUTNAM GARY GENE;;CHENG JENNIFER MENG-TSU;;SUN CHIN-YANG,,https://lens.org/163-641-686-983-479,Patent Application,yes,4,2,6,6,0,G01R31/2831;;H01L22/20;;H01L22/00;;H01L22/20;;G01R31/2831,G01R31/28;;H01L21/02;;H01L21/66,,2,0,,,"RAMAKRISHNAN V ET AL: ""IC PERFORMANCE PREDICTION SYSTEM"", PROCEEDINGS OF THE INTERNATIONAL TEST CONFERENCE (ITC),US,NEW YORK, IEEE, 1995, pages 336 - 344, XP000552836, ISBN: 0-7803-2992-9;;SACK E A: ""GLOBAL YIELD ENGINEERING FOR IC PRODUCTION"", SOLID STATE TECHNOLOGY,US,COWAN PUBL.CORP. WASHINGTON, vol. 41, no. 12, 1 December 1998 (1998-12-01), pages 81 - 85, XP000791654, ISSN: 0038-111X",PENDING
126,US,A1,US 2020/0056231 A1,065-545-304-520-936,2020-02-20,2020,US 201916545611 A,2019-08-20,US 201916545611 A;;US 201862720014 P,2018-08-20,NUCLEOTIDE SEQUENCE GENERATION BY BARCODE BEAD-COLOCALIZATION IN PARTITIONS,Comparison of common sequencing reads from sequencing based on partition-based barcoding can be used to improve sequencing results. Increased loading of barcodes per partition can also improve sequencing results.,BIO RAD LABORATORIES,LEBOFSKY RONALD;;KOHLWAY ANDREW;;CHEW JENNIFER;;BURKETT ZACHARY;;CHENG MAN,BIO-RAD LABORATORIES INC (2018-08-21),https://lens.org/065-545-304-520-936,Patent Application,yes,0,4,10,10,0,G16B40/10;;G16B30/10;;C12Q1/6869;;C12Q1/6869;;G16B40/10;;C12Q2563/185;;C12Q2563/155;;G16B30/10,C12Q1/6869;;G16B30/10;;G16B40/10,,0,0,,,,ACTIVE
127,EP,A2,EP 4249651 A2,036-802-427-586-25X,2023-09-27,2023,EP 23172531 A,2019-08-20,US 201862720014 P;;EP 19851177 A;;US 2019/0047239 W,2018-08-20,NUCLEOTIDE SEQUENCE GENERATION BY BARCODE BEAD-COLOCALIZATION IN PARTITIONS,Comparison of common sequencing reads from sequencing based on partition-based barcoding can be used to improve sequencing results. Increased loading of barcodes per partition can also improve sequencing results.,BIO RAD LABORATORIES INC,LEBOFSKY RONALD;;KOHLWAY ANDREW;;CHEW JENNIFER;;BURKETT ZACHARY;;CHENG MAN,,https://lens.org/036-802-427-586-25X,Patent Application,yes,108,0,10,10,0,G16B40/10;;G16B30/10;;C12Q1/6869;;C12Q1/6869;;G16B40/10;;C12Q2563/185;;C12Q2563/155;;G16B30/10,C40B20/04,,28,23,010-639-981-123-294;;104-015-228-687-308;;053-572-201-729-030;;051-979-084-434-779;;000-404-332-410-390;;040-128-403-822-230;;020-844-141-136-135;;020-844-141-136-135;;067-123-677-365-353;;085-676-611-860-928;;062-534-143-598-528;;050-400-165-665-489;;104-497-647-494-695;;103-261-559-380-762;;029-319-148-139-066;;161-864-238-595-646;;161-864-238-595-646;;006-415-294-038-875;;017-426-489-915-543;;043-895-385-051-167;;104-989-663-398-661;;016-159-010-515-549;;068-891-509-412-163,24302831;;pmc3831736;;10.4103/0975-7406.120066;;10.1016/0168-9525(90)90186-a;;18680433;;10.1146/annurev.genet.42.110807.091656;;12603728;;10.1046/j.1365-2958.2003.03382.x;;9516433;;10.1074/jbc.273.13.7367;;289456;;10.1101/sqb.1979.043.01.046;;pmc4409979;;10.1038/ng.3119;;25326703;;pmc4409979;;10.1038/ng.3119;;25326703;;12895469;;10.1016/s0003-2697(03)00291-4;;10.1126/science.1117389;;16081699;;10.1038/nature03959;;16056220;;pmc1464427;;10.1517/14622416.6.4.373;;16004555;;10.1038/76469;;10835600;;10.1093/nar/28.20.e87;;pmc110803;;11024189;;10.1373/clinchem.2008.112789;;19246620;;19287448;;19287448;;16448145;;10.1021/ja057123+;;10.1126/science.327.5970.1190;;20203024;;10.1073/pnas.0710982105;;pmc2234111;;18216253;;10.1038/nmeth.4396;;10.1101/181206;;pmc5623106;;28846090;;19451168;;10.1093/bioinformatics/btp324;;pmc2705234;;pmc2592715;;18798982;;10.1186/gb-2008-9-9-r137,"SAMBROOK ET AL.: ""MOLECULAR CLONING: A LABORATORY MANUAL"", 1989, COLD SPRING HARBOR LABORATORY PRESS;;FAKRUDDIN ET AL., J. PHARM BIOALLIED SCI., vol. 5, no. 4, 2013, pages 245 - 252;;""PCR Protocols: A Guide to Methods and Applications"", 1990;;REZNIKOFF WS., ANNU REV GENET, vol. 42, 2008, pages 269 - 286;;REZNIKOFF WS., MOL MICROBIOL, vol. 47, 2003, pages 1199 - 1206;;GORY SHIN IYREZNIKOFF WS, JBIOL CHEM, vol. 273, 1998, pages 7367 - 7374;;SCHALLER H, COLD SPRING HARB SYMP QUANT BIOL, vol. 43, 1979, pages 401 - 408;;AMINI ET AL., NATURE GENETICS, vol. 46, 2014, pages 1343 - 1349;;AMINI ET AL., NATURE GENETICS, vol. 46, no. 12, pages 1343 - 1349;;BUENROSTRO ET AL., CURR PROTOC MOL BIOL, vol. 109, 2015, pages 1 - 9;;GENOMICS, vol. 92, 2008, pages 255;;BIRREN ET AL., GENOME ANALYSIS: ANALYZING DNA, vol. 1;;MITRA ET AL., ANALYTICAL BIOCHEMISTRY, vol. 320, 2003, pages 55 - 65;;SHENDURE ET AL., SCIENCE, vol. 309, 2005, pages 1728 - 1732;;MARGULIES ET AL., NATURE, vol. 437, 2005, pages 376 - 380;;BENNETT ET AL., PHARMACOGENOMICS, vol. 6, 2005, pages 373 - 382;;BRENNER ET AL., NAT. BIOTECHNOL., vol. 18, 2000, pages 630 - 634;;ADESSI ET AL., NUCLEIC ACID RES., vol. 28, 2000, pages E87;;VOELKERDING ET AL., CLINICAL CHEM., vol. 55, 2009, pages 641 - 658;;MACLEAN ET AL., NATURE REV. MICROBIOL., vol. 7, pages 287 - 296;;MACLEAN ET AL., NATURE REV. MICROBIAL., vol. 7, pages 287 - 296;;ASTIER ET AL., J. AM. CHEM. SOC., vol. 128, no. 5, 8 February 2006 (2006-02-08), pages 1705 - 10;;MACLEAN ET AL., NATURE REV. MICROBIAL, vol. 7, pages 287 - 296;;SCIENCE, vol. 327, no. 5970, 2010, pages 1190;;KORLACH ET AL.: ""Selective aluminum passivation for targeted immobilization of single DNA polymerase molecules in zero-mode waveguide nanostructures"", PNAS, vol. 105, no. 4, 2008, pages 1176 - 81, XP002632441, DOI: 10.1073/PNAS.0710982105;;CORCES ET AL., NATURE METHODS, 2017;;LI H.DURBIN R.: ""Fast and accurate short read alignment with Burrows-Wheeler Transform"", BIOINFORMATICS, vol. 25, 2009, pages 1754 - 60, XP055553969, DOI: 10.1093/bioinformatics/btp324;;ZHANG Y ET AL.: ""Model-based Analysis of ChIP-Seq (MACS"", GENOME BIOLOGY, vol. 9, no. 9, 2008, pages R137, XP021046980, DOI: 10.1186/gb-2008-9-9-r137",PENDING
128,EP,A4,EP 3841202 A4,120-062-407-489-368,2022-06-08,2022,EP 19851177 A,2019-08-20,US 201862720014 P;;US 2019/0047239 W,2018-08-20,NUCLEOTIDE SEQUENCE GENERATION BY BARCODE BEAD-COLOCALIZATION IN PARTITIONS,,BIO RAD LABORATORIES,LEBOFSKY RONALD;;KOHLWAY ANDREW;;CHEW JENNIFER;;BURKETT ZACHARY;;CHENG MAN,,https://lens.org/120-062-407-489-368,Search Report,no,2,0,10,10,0,G16B40/10;;G16B30/10;;C12Q1/6869;;C12Q1/6869;;G16B40/10;;C12Q2563/185;;C12Q2563/155;;G16B30/10,C12N5/10;;C12Q1/68;;C12Q1/6869;;C40B20/04,,1,1,031-771-179-679-906,10.1038/s41587-019-0147-6;;pmc10299900;;31235917,"LAREAU CALEB A ET AL: ""Droplet-based combinatorial indexing for massive-scale single-cell chromatin accessibility"", NATURE BIOTECHNOLOGY, NATURE PUBLISHING GROUP US, NEW YORK, vol. 37, no. 8, 24 June 2019 (2019-06-24), pages 916 - 924, XP036849994, ISSN: 1087-0156, [retrieved on 20190624], DOI: 10.1038/S41587-019-0147-6",ACTIVE
129,US,B2,US 9265845 B2,141-494-203-758-117,2016-02-23,2016,US 201314028348 A,2013-09-16,US 201314028348 A;;US 41837609 A;;US 2007/0021218 W;;US 84925906 P,2006-10-04,Imaging methods using engineered integrin binding peptides,"Engineered peptides that bind with high affinity (low equilibrium dissociation constant (Kd)) to the cell surface receptors of fibronectin (α 5 β 1 ) or vitronectin (α v β 3 and α v β 5 integrins) are disclosed as useful as imaging tissue. These peptides are based on a molecular scaffold into which a subsequence containing the RGD integrin-binding motif has been inserted. The subsequence (RGD mimic) comprises about 9-13 amino acids, and the RGD contained within the subsequence can be flanked by a variety of amino acids, the sequence of which was determined by sequential rounds of selection (in vitro evolution). The molecular scaffold is preferably based on a knottin, e.g., EETI (Trypsin inhibitor 2 (Trypsin inhibitor II) (EETI-II) [Ecballium elaterium (Jumping cucumber)], AgRP (Agouti-related protein), and Agatoxin IVB, which peptides have a rigidly defined three-dimensional conformation. It is demonstrated that EETI tolerates mutations in other loops and that the present peptides may be used as imaging agents.",UNIV LELAND STANFORD JUNIOR,COCHRAN JENNIFER R;;KIMURA RICHARD;;GAMBHIR SANJIV S;;CHENG ZHEN,THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (2009-05-07),https://lens.org/141-494-203-758-117,Granted Patent,yes,30,3,11,11,138,C07K14/47;;A61K38/06;;A61K38/08;;A61K38/1709;;C07K14/47;;A61K49/0056;;A61K51/082;;G01N33/57492;;A61K38/06;;A61K38/08;;A61K38/1709;;A61K45/06,A61K49/00;;A61K38/08;;A61K51/08;;C07K14/47;;G01N33/53;;G01N33/574,,35,33,135-885-932-173-38X;;030-788-898-683-850;;154-408-963-605-779;;027-668-288-438-829;;033-015-593-167-286;;017-483-212-418-625;;034-177-209-038-665;;004-095-161-627-112;;073-833-128-125-836;;046-020-355-273-612;;081-402-899-282-026;;045-793-765-211-13X;;004-850-538-888-993;;038-527-559-639-375;;152-686-974-320-813;;040-610-210-109-805;;068-561-655-460-372;;052-137-570-101-385;;023-705-104-791-025;;135-885-932-173-38X;;092-237-305-361-249;;038-690-982-758-195;;105-303-933-941-415;;001-578-827-425-486;;006-309-725-971-597;;021-251-150-686-588;;018-426-519-141-734;;003-753-910-647-483;;005-004-812-299-918;;063-640-832-834-034;;023-301-052-611-166;;054-358-792-874-801;;070-749-505-956-790,16702041;;10.1080/09537100500436663;;10.1094/mpmi.1999.12.1.16;;9885189;;pmc308750;;14681383;;10506290;;10.1093/protein/12.9.797;;11747427;;10.1021/bi0117192;;10.2210/pdb2mfn/pdb;;10.2210/pdb1mfn/pdb;;9533887;;10.1006/jmbi.1998.1616;;10.1074/jbc.m210492200;;12482862;;10.1016/s0021-9258(18)94206-7;;2521482;;9150551;;10.1177/030098589703400113;;10.1038/ni0706-681;;16785881;;10.1021/mp060049x;;17009846;;10.1002/1099-1352(200007/08)13:4<167::aid-jmr502>3.0.co;2-9;;10931555;;10.1002/1099-1352(200007/08)13:4<167::aid-jmr502>3.3.co;2-0;;10.1042/0264-6021:3560011;;11336631;;10.1042/bj3560011;;pmc1221807;;pmc2242358;;16373474;;10.1110/ps.051817606;;10.1006/jmbi.1997.1621;;9514763;;10.1016/s0021-9258(18)54041-2;;8419314;;10.1074/jbc.270.28.16660;;7542651;;10.1073/pnas.95.11.6037;;pmc27581;;9600913;;10.1073/pnas.86.11.4022;;pmc287380;;2726764;;16702041;;10.1080/09537100500436663;;pmc2833353;;19276378;;10.1158/0008-5472.can-08-2495;;10409654;;10.1074/jbc.274.30.21037;;10.1038/nbt0395-265;;9634769;;10.1126/science.7512751;;7512751;;2654042;;10.1111/j.1399-3011.1989.tb00210.x;;10.1073/pnas.89.16.7384;;1380156;;pmc49714;;10319765;;7529494;;pmc1137422;;10.1042/bj3040929;;10.1126/science.290.5491.471;;11183771;;10631780;;10.1016/s0167-7799(99)01398-0;;10.1126/science.257.5073.1078;;1509259;;pmc2143563;;9336839;;10.1002/pro.5560061011;;12646694;;10.1093/proeng/gzg002,"Reiss et al. Inhibition of platelet aggregation by grafting RGD and KGD sequences on the structural scaffold of small disulfide-rich proteins. Platelets 17(3), 153-157 (2006). Platelets 17(3):153-157, 2006.;;Ana Segura, et al., ""Snakin-1, a peptide from potato that is active against plant pathogens,"" MPMI, 1999, vol. 12, 16-23.;;Jean-Christophe Gelly, et al., ""The Knottin website and database: a new information system dedicated to the knottin scaffold,"" Nucleic Acids Research, 2004, vol. 32, D156-D159.;;Andreas Christmann, et al., ""The cystine knot of a squash-type protease inhibitor as a structural scaffold for Escherichia coli cell surface display of conformationally constrained peptides,"" Protein Engineering, 1999, vol. 12, 797-806.;;FlowJo, Data analysis software for flow cytometry, User Documentation tutorial, Version 3.4, Apr. 2001.;;Joseph C. McNulty, et al., ""High-resolution NMR structure of the chemically-synthesized melanocortin receptor binding domain AGRP(87-132) of the agouti-related protein,"" Biochemistry, 2001, vol. 40, 15520-15527.;;Valerie Copie, et al., ""Solution structure and dynamics of linked cell attachment modules of mouse fibronectin containing the RGD and synergy regions: comparison with the human fibronectin crystal structure,"" J. Mol. Biol., 1998, vol. 277, 663-682.;;Norelle L. Daly, et al., ""Disulfide folding pathways of cystine know proteins,"" J. Biol. Chem., 2003, vol. 278, 6314-6322.;;Aarno Hautanen, et al., ""Effects of modifications of the RGD sequence and its context on recognition by the fibronectin receptor,"" J. Biol. Chem., 1989, vol. 264, 1437-1442.;;C. S. Elangbam, et al., ""Cell adhesion molecules-update,"" Vet Pathol, 1997, 34,61-73.;;Leonore A. Herzenberg, et al., ""Intepreting flow cytometry data: a guide for the perplexed,"" Nature Immunology, 2006, vol. 7, 681-685.;;Shuang Liu, ""Radiolabeled multimeric cyclic RGD peptides as integrin alphavbeta3 targeted radiotracers for tumor imaging,"" Molecular Pharmaceutics, 2006, vol. 3, 472-487.;;Arne Skerra, ""Engineered protein scaffolds for molecular recognition,"" J. Mol. Recognition, 2000, vol. 13, 167-187.;;Beth Wattam, et al., ""Arg-Tyr-Asp (RYD) and Arg-Cys-Asp (RCD) motifs in dendroaspin promote selective inhibition of beta1 and beta3 integrins,"" Biochem. J., 2001, vol. 356, 11-17.;;Ralf J. Hosse, et al., ""A new generation of protein display scaffolds for molecular recognition,"" Protein Science, 2006, vol. 15, 14-27.;;Geoffrey P. Smith, et al., ""Small binding proteins selected from a combinatorial repertoire of knottins displayed on phage,"" J. Mol. Biol., 1998, vol. 277, 317-332.;;Robert M. Scarborough, et al., ""Characterization of the integrin specificities of disintegrins isolated from american pit viper venoms,"" J. Biol. Chem., 1993, vol. 268, 1058-1065.;;Thomas J. Kunicki, et al., ""The exchange of Arg-Gly-Asp (RGD) and Arg-Tyr-Asp (RYD) binding sequences in a recombinant murine Fab fragment specific for the integrin alphallbbeta3 does not alter integrin recognition,"" J. Biol. Chem., 1995, vol. 270, 16660-16665.;;Herren Wu, et al., ""Stepwise in vitro affinity maturation of vitaxin, an alphavbeta3-specific humanized mAb,"" PNAS, 1998, vol. 95, 6037-6042.;;Victor M. Garsky, et al., ""Chemical synthesis of echistatin, a potent inhibitor of platelet aggregation from Echis carinatus: synthesis and biological activity of selected analogs,"" PNAS, 1989, vol. 86, 4022-4026.;;Sandy Reiss, et al., ""Inhibition of platelet aggregation by grafting RGD and KGD sequences on the structural scaffold of small disulfide-rich proteins,"" Platelets, 2006, vol. 17, 153-157.;;Richard H. Kimura, et al., ""Engineered knottin peptides: A new class of agents for imaging integrin expression in living subjects,"" Cancer Research, 2009, vol. 69, 2435-2442.;;Alexander Wentzel, et al., ""Sequence requirements of the GPNG beta-turn of the Ecballium elaterium trypsin inhibitor II explored by combinatorial library screening,"" J. Biol. Chem., 1999, vol. 274, 21037-21043.;;Erkki Koivunen, et al., ""Phage libraries displaying cyclic peptides with different ring sizes: ligand specificities of the RGD-directed integrins,"" Nature Biotechnology, 1995, vol. 13, 265-270.;;Peter C. Brooks, et al., ""Requirement of vascular integrin alphavbeta3 for angiogenesis,"" Science, 1994, vol. 264, 569-571.;;A. Favel, et al., ""Protease inhibitors from Ecballium elaterium seeds,"" Int. J. Peptide Protein Res., 1989, vol. 33, 202-208.;;Timothy HLA, et al., ""Human cyclooxygenase-2 cDNA,"" PNAS, 1992, vol. 89, 7384-7388.;;PCT International Search Report for application PCT/US 07/21218 dated May 29, 2008.;;Koivunen, et al., ""Identification of receptor ligands with phage display peptide libraries"", J. Nucl. Med.; 40:883-888, 1999.;;Lu, et al., ""Preferential antagonism of the interactions of the integrin alpha Ilb beta 3 with immobilized glycoprotein ligands by snake-venom RGD (Arg-Gly-Asp) proteins . . . snake-venom RGD proteins"", 1994, Biochem J 304: 929-936.;;Attwood, ""Genomics. The Babel of bioinformatics"", Science. 290(5491):471-473, 2000.;;Skolnick, et al., ""From genes to protein structure and function: novel applications of computational approaches in the genomic era,"" Trends Biotechnol. 18(1):34-9, 2000.;;Kuntz, ""Structure-based strategies for drug design and discovery,"" Science, 1992, 257(5073):1078-1082.;;Miller, et al., ""Ligand binding to proteins: the binding landscape model"", Protein Sci. Oct. 1997:6(10):2166-79.;;Li, et al., ""Use of phage display to probe the evolution of binding specificity and affinity in integrins"", Protein Engineering vol. 16, No. 1, pp. 65-72, 2003.",ACTIVE
130,US,A1,US 2002/0065236 A1,080-925-796-504-972,2002-05-30,2002,US 54099100 A,2000-03-31,US 54099100 A;;US 39246299 A;;US 9958398 P,1998-09-09,CpG reduced plasmids and viral vectors,"
   Unmethylated plasmid DNA vectors are a major contributor to the inflammatory response associated with gene delivery. Results of clinical studies where CF subjects were subjected to either aerosolized liposomes alone or cationic lipid:DNA complexes indicated that bacterial derived plasmid DNA may be inflammatory. Additionally, unmethylated CpG dinucleotides have been shown to be immunostimulatory and are present at a much higher frequency in bacterially-derived plasmid DNA compared to vertebrate DNA. The invention provides for methods of modulating the immunostimulatory response to gene delivery by modifying the plasmid delivered to the cell. The plasmid is modified to reduce or eliminate the immunostimulatory response in order to preserve the efficacy of gene transfer but reduce the associated toxicity. In a preferred embodiment, the invention provides for a method of reducing inflammatory response to gene delivery by methylating CpG motifs of the plasmid vector and/or removing CpG motifs of the plasmid vector. 
",YEW NELSON S.;;ZHAO HONGMEI;;TOUSIGNANT JENNIFER;;CHENG SENG H.,YEW NELSON S;;ZHAO HONGMEI;;TOUSIGNANT JENNIFER;;CHENG SENG H,GENZYME CORPORATION (2000-04-20),https://lens.org/080-925-796-504-972,Patent Application,yes,0,63,6,6,0,A61K48/00;;A61K48/00;;C12N15/88;;C12N15/88;;C12N15/63;;C12N15/63;;C12N2799/021;;C12N2799/021;;C12P19/34;;C12P19/34,A61K48/00;;C12N15/63;;C12N15/88;;C12P19/34,514/44;;435/91.1;;435/91.4;;435/458;;536/23.1,0,0,,,,DISCONTINUED
131,US,A1,US 2014/0010757 A1,151-392-711-118-920,2014-01-09,2014,US 201314028348 A,2013-09-16,US 201314028348 A;;US 41837609 A;;US 2007/0021218 W;;US 84925906 P,2006-10-04,IMAGING METHODS USING ENGINEERED INTEGRIN BINDING PEPTIDES,"Engineered peptides that bind with high affinity (low equilibrium dissociation constant (Kd)) to the cell surface receptors of fibronectin (α 5 β 1 ) or vitronectin (α v β 3 and α v β 5 integrins) are disclosed as useful as imaging tissue. These peptides are based on a molecular scaffold into which a subsequence containing the RGD integrin-binding motif has been inserted. The subsequence (RGD mimic) comprises about 9-13 amino acids, and the RGD contained within the subsequence can be flanked by a variety of amino acids, the sequence of which was determined by sequential rounds of selection (in vitro evolution). The molecular scaffold is preferably based on a knottin, e.g., EETI (Trypsin inhibitor 2 (Trypsin inhibitor II) (EETI-II) [Ecballium elaterium (Jumping cucumber)], AgRP (Agouti-related protein), and Agatoxin IVB, which peptides have a rigidly defined three-dimensional conformation. It is demonstrated that EETI tolerates mutations in other loops and that the present peptides may be used as imaging agents.",UNIV LELAND STANFORD JUNIOR,COCHRAN JENNIFER R;;KIMURA RICHARD;;GAMBHIR SANJIV S;;CHENG ZHEN,THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (2009-05-07),https://lens.org/151-392-711-118-920,Patent Application,yes,1,9,11,11,138,C07K14/47;;A61K38/06;;A61K38/08;;A61K38/1709;;C07K14/47;;A61K49/0056;;A61K51/082;;G01N33/57492;;A61K38/06;;A61K38/08;;A61K38/1709;;A61K45/06,A61K51/08;;A61K38/08;;A61K49/00;;G01N33/574,424/1.69;;424/9.6;;435/7.23,1,1,135-885-932-173-38X,16702041;;10.1080/09537100500436663,"Reiss et al. Inhibition of platelet aggregation by grafting RGD and KGD sequences on the structural scaffold of small disulfide-rich proteins. Platelets 17(3), 153-157 (2006). Platelets 17(3):153-157, 2006.",ACTIVE
132,US,B2,US 10721265 B2,028-730-849-185-560,2020-07-21,2020,US 201715610160 A,2017-05-31,US 201715610160 A,2017-05-31,User device profiling using integrated vibration mechanism,A system for user device profiling that includes operations such requesting an acoustic profile from a user device. Receiving the acoustic profile from the user device and comparing the received acoustic profile with a stored acoustic profile.,PAYPAL INC,TIAN CHENG;;ERICSON BRADEN;;VYAS ADHISH N;;DELANEY JENNIFER ESMERALDA,PAYPAL INC (2017-05-24),https://lens.org/028-730-849-185-560,Granted Patent,yes,9,5,2,2,0,G10L17/04;;H04L63/1441;;H04L63/1441;;H04L63/102;;H04L63/102;;H04M1/2155,G10L17/04;;H04L29/06;;H04M1/215,,0,0,,,,ACTIVE
133,EP,A1,EP 1208591 A1,035-221-374-316-720,2002-05-29,2002,EP 00916313 A,2000-03-13,US 0006598 W;;US 37149899 A,1999-08-10,METHOD AND APPARATUS FOR CHARACTERIZING A SEMICONDUCTOR DEVICE,,ADVANCED MICRO DEVICES INC,PUTNAM GARY GENE;;CHENG JENNIFER MENG-TSU;;SUN CHIN-YANG,"GLOBALFOUNDRIES, INC. (2009-12-23)",https://lens.org/035-221-374-316-720,Patent Application,yes,0,0,6,6,0,G01R31/2831;;H01L22/20;;H01L22/00;;H01L22/20;;G01R31/2831,G01R31/28;;H01L21/02;;H01L21/66,,0,0,,,,DISCONTINUED
134,EP,A1,EP 3841202 A1,099-391-419-965-673,2021-06-30,2021,EP 19851177 A,2019-08-20,US 201862720014 P;;US 2019/0047239 W,2018-08-20,NUCLEOTIDE SEQUENCE GENERATION BY BARCODE BEAD-COLOCALIZATION IN PARTITIONS,,BIO RAD LABORATORIES,LEBOFSKY RONALD;;KOHLWAY ANDREW;;CHEW JENNIFER;;BURKETT ZACHARY;;CHENG MAN,,https://lens.org/099-391-419-965-673,Patent Application,yes,0,0,10,10,9,G16B40/10;;G16B30/10;;C12Q1/6869;;C12Q1/6869;;G16B40/10;;C12Q2563/185;;C12Q2563/155;;G16B30/10,C12N5/10;;C12Q1/68;;C12Q1/6869;;C40B20/04,,0,0,,,,ACTIVE
135,US,B1,US 6319737 B1,191-120-645-252-137,2001-11-20,2001,US 37149899 A,1999-08-10,US 37149899 A,1999-08-10,Method and apparatus for characterizing a semiconductor device,"A method and apparatus are provided for providing characterization data for semiconductor devices. A first data set containing measured results obtained from wafer electrical tests performed on the semiconductor device during the fabrication process is compared to a second data set containing values corresponding to design characteristics for the semiconductor device. Based on this comparison, semiconductor devices having valid and invalid performance characteristics are identified. The characterization results data are subsequently generated for the identified semiconductor devices.",ADVANCED MICRO DEVICES INC,PUTNAM GARY GENE;;CHENG JENNIFER MENG-TZU;;SUN CHIN-YANG,ADVANCED MICRO DEVICES INC (1999-08-09);;GLOBALFOUNDRIES INC (2009-06-30),https://lens.org/191-120-645-252-137,Granted Patent,yes,10,30,6,6,0,G01R31/2831;;H01L22/20;;H01L22/00;;H01L22/20;;G01R31/2831,G01R31/28;;H01L21/02;;H01L21/66,438/17;;439/622;;29/25.01,3,0,,,"""IC Performance Prediction System"", V. Ramakrishnan et al., Proceedings of the International Test Conference (ITC), New York, IEEE, Oct. 21, 1995, p. 336-344.;;""Global Yield Engineering for IC Production"", E.A. Sack, Solid State Technology, Cowan Publ. Corp., Washington, vol. 41, No. 12, Dec. 1, 1998, p. 81-85.;;International Search Report.",EXPIRED
136,US,B2,US 11479816 B2,186-335-420-667-89X,2022-10-25,2022,US 201916545611 A,2019-08-20,US 201916545611 A;;US 201862720014 P,2018-08-20,Nucleotide sequence generation by barcode bead-colocalization in partitions,Comparison of common sequencing reads from sequencing based on partition-based barcoding can be used to improve sequencing results. Increased loading of barcodes per partition can also improve sequencing results.,BIO RAD LABORATORIES INC,LEBOFSKY RONALD;;KOHLWAY ANDREW;;CHEW JENNIFER;;BURKETT ZACHARY;;CHENG MAN,BIO-RAD LABORATORIES INC (2018-08-21),https://lens.org/186-335-420-667-89X,Granted Patent,yes,8,0,10,10,9,G16B40/10;;G16B30/10;;C12Q1/6869;;C12Q1/6869;;G16B40/10;;C12Q2563/185;;C12Q2563/155;;G16B30/10,C12Q1/6869;;G16B30/10;;G16B40/10,,3,1,031-771-179-679-906,10.1038/s41587-019-0147-6;;pmc10299900;;31235917,"International Search Report and Written Opinion from PCT Application PCT/US2019/047239 dated Nov. 21, 2019; 15 pages.;;Extended European Search Report in EP Appln. 19851177.6 dated May 6, 2022; 6 pages.;;Lareau, C.A. et al.; “Droplet-based combinatorial indexing for massive-scale single-cell chromatin accessibility”; Nature Biotechnology; Nature Publishing Group US, New York; vol. 37, No. 8; Jun. 24, 2019; pp. 916-924.",ACTIVE
137,US,A1,US 2023/0012786 A1,050-697-065-483-442,2023-01-19,2023,US 202217944758 A,2022-09-14,US 202217944758 A;;US 201916545611 A;;US 201862720014 P,2018-08-20,NUCLEOTIDE SEQUENCE GENERATION BY BARCODE BEAD-COLOCALIZATION IN PARTITIONS,Comparison of common sequencing reads from sequencing based on partition-based barcoding can be used to improve sequencing results. Increased loading of barcodes per partition can also improve sequencing results.,BIO RAD LABORATORIES INC,LEBOFSKY RONALD;;KOHLWAY ANDREW;;CHEW JENNIFER;;BURKETT ZACHARY;;CHENG MAN,,https://lens.org/050-697-065-483-442,Patent Application,yes,0,0,10,10,0,G16B40/10;;G16B30/10;;C12Q1/6869;;C12Q1/6869;;G16B40/10;;C12Q2563/185;;C12Q2563/155;;G16B30/10,C12Q1/6869;;G16B30/10;;G16B40/10,,0,0,,,,PENDING
138,US,A1,US 2018/0351994 A1,128-043-272-349-794,2018-12-06,2018,US 201715610160 A,2017-05-31,US 201715610160 A,2017-05-31,USER DEVICE PROFILING USING INTEGRATED VIBRATION MECHANISM,A system for user device profiling that includes operations such requesting an acoustic profile from a user device. Receiving the acoustic profile from the user device and comparing the received acoustic profile with a stored acoustic profile.,PAYPAL INC,TIAN CHENG;;ERICSON BRADEN;;VYAS ADHISH N;;DELANEY JENNIFER ESMERALDA,PAYPAL INC (2017-05-24),https://lens.org/128-043-272-349-794,Patent Application,yes,9,3,2,2,0,G10L17/04;;H04L63/1441;;H04L63/1441;;H04L63/102;;H04L63/102;;H04M1/2155,H04L29/06,,0,0,,,,ACTIVE
139,US,A1,US 2009/0257952 A1,191-388-314-386-154,2009-10-15,2009,US 41837609 A,2009-04-03,US 41837609 A;;US 2007/0021218 W;;US 84925906 P,2006-10-04,Engineered Integrin Binding Peptides,"Engineered peptides that bind with high affinity (low equilibrium dissociation constant (Kd)) to the cell surface receptors of fibronectin (α 5 β 1 ) or vitronectin (α v β 3 and α v β 5 integrins) are disclosed. These peptides are based on a molecular scaffold into which a subsequence containing the RGD integrin-binding motif has been inserted. The subsequence (RGD mimic) comprises about 9-13 amino acids, and the RGD contained within the subsequence can be flanked by a variety of amino acids, the sequence of which was determined by sequential rounds of selection (in vitro evolution). The molecular scaffold is preferably based on a knottin, e.g., EETI (Trypsin inhibitor 2 (Trypsin inhibitor II) (EETI-II) [ Ecballium elaterium (Jumping cucumber)], AgRP (Agouti-related protein), and Agatoxin IVB, which peptides have a rigidly defined three-dimensional conformation. It is demonstrated that EETI tolerates mutations in other loops and that the present peptides may be used as imaging agents.",UNIV LELAND STANFORD JUNIOR,COCHRAN JENNIFER R;;KIMURA RICHARD;;LEVIN ARON M;;SILVERMAN ADAM;;GAMBHIR SANJIV S;;CHENG ZHEN;;LAHTI JENNIFER,THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (2009-05-07),https://lens.org/191-388-314-386-154,Patent Application,yes,29,55,11,11,138,C07K14/47;;A61K38/06;;A61K38/08;;A61K38/1709;;C07K14/47;;A61K49/0056;;A61K51/082;;G01N33/57492;;A61K38/06;;A61K38/08;;A61K38/1709;;A61K45/06,A61K38/16;;A61K38/08;;A61K49/00;;A61K51/08;;C07H21/00;;C07K2/00;;C12N5/10;;C12N15/63,424/1.69;;514/12;;530/324;;435/320.1;;424/9.1;;536/23.1;;435/325,0,0,,,,ACTIVE
140,WO,A1,WO 2021/081219 A1,116-784-864-893-446,2021-04-29,2021,US 2020/0056883 W,2020-10-22,US 201962924938 P;;US 202017072301 A,2019-10-23,HAFNIUM ALUMINUM OXIDE COATINGS DEPOSITED BY ATOMIC LAYER DEPOSITION,"Embodiments of the present disclosure relate to articles, coated articles, and methods of coating such articles with a corrosion resistant coating. The corrosion resistant coating can comprise hafnium aluminum oxide. The corrosion resistant coating may be deposited by a nonline of sight deposition, such as atomic layer deposition. Articles that may be coated may include chamber components, such as gas lines.",APPLIED MATERIALS INC,FENWICK DAVID;;SUN JENNIFER Y;;CHOU CHENG-HSUAN;;HE XIAO-MING,,https://lens.org/116-784-864-893-446,Patent Application,yes,5,1,6,6,0,H01J37/32477;;C23C16/40;;C23C16/45531;;C23C16/45553;;C23C16/40;;C23C16/45529;;C23C16/45553;;C23C16/40;;C23C16/45553;;C23C16/45529;;C23C16/45555;;C23C16/45531;;C23C16/4404;;H01J37/32495;;C23C16/45565;;C23C16/40;;C23C16/505;;C23C16/45553;;C23C16/45565;;C23C16/45529;;C23C16/45536,C23C16/40;;C23C16/44;;C23C16/455;;H01J37/32,,0,0,,,,PENDING
141,EP,A2,EP 1272625 A2,173-585-714-808-360,2003-01-08,2003,EP 01920894 A,2001-04-02,US 0110309 W;;US 54099100 A,2000-03-31,CpG REDUCED PLASMIDS AND VIRAL VECTORS,,GENZYME CORP,YEW NELSON S;;ZHAO HONGMEI;;TOUSIGNANT JENNIFER D;;CHENG SENG H,,https://lens.org/173-585-714-808-360,Patent Application,yes,0,1,6,6,0,A61K48/00;;A61K48/00;;C12N15/88;;C12N15/88;;C12N15/63;;C12N15/63;;C12N2799/021;;C12N2799/021;;C12P19/34;;C12P19/34,A61K48/00;;C12N15/63;;C12N15/88;;C12P19/34,,1,0,,,See references of WO 0175092A3,DISCONTINUED
142,WO,A1,WO 2013/184561 A1,061-201-271-351-931,2013-12-12,2013,US 2013/0043862 W,2013-06-03,US 201261655117 P,2012-06-04,SYSTEM AND METHOD FOR MICRO-AERATION BASED FERMENTATION,"A method and apparatus for micro-aeration of large scale fermentation systems is provided. The micro-aeration system includes a fermentation reactor, a sparging apparatus, and a micro-aeration gas mixture delivered to the fermentation reactor via the sparging apparatus. The micro-aeration gas mixture is a very low oxygen concentration mixture comprising an oxygen containing gas and an inert carrier gas that is preferably recycled through the fermentation reactor. The inert carrier gas is preferably nitrogen whereas the oxygen containing gas is oxygen or and is introduced to the fermentation reactor at a minimum superficial velocity of about 0.02 m/sec to produce a uniform dispersion of the oxygen/air throughout the fermentation broth while concurrently mixing the entire fermentation broth. The micro-aeration method and apparatus further comprises a controller operatively coupled to one or more control valves for regulating the micro-aeration conditions in the fermentation reactor.",PRAXAIR TECHNOLOGY INC,CHENG ALAN T;;ZHOU YING;;BELANGER PAUL W;;BUGAYONG JENNIFER G,,https://lens.org/061-201-271-351-931,Patent Application,yes,4,4,4,4,0,C12M27/00;;C12M29/06;;C12M41/32;;C12M41/34;;C12M21/12;;C12M29/24;;C12M29/24;;C12M29/06;;C12M41/34;;C12M27/00;;C12M41/32;;C12M21/12;;C12M41/48,C12M1/00;;C12M1/02;;C12M1/34,,2,2,059-062-029-772-27X;;065-334-474-359-727,10.1016/s0961-9534(99)00037-9;;10.1263/jbb.103.350;;17502277,"TANGO: ""Amelioration of lactic acid production from cheese whey using micro-aeration"", 1 January 1999 (1999-01-01), pages 221 - 238, XP055075968, Retrieved from the Internet <URL:http://ac.els-cdn.com/S0961953499000379/1-s2.0-S0961953499000379-main.pdf?_tid=31f6c394-0a5e-11e3-8b3c-00000aab0f6c&acdnat=1377088723_8d4b448e8e9663482fa7929994b33a49> [retrieved on 20130821];;OKUDA ET AL: ""Microaeration enhances productivity of bioethanol from hydrolysate of waste house wood using ethanologenic Escherichia coli KO11"", JOURNAL OF BIOSCIENCE AND BIOENGINEERING, ELSEVIER, AMSTERDAM, NL, vol. 103, no. 4, 1 April 2007 (2007-04-01), pages 350 - 357, XP022071903, ISSN: 1389-1723, DOI: 10.1263/JBB.103.350",PENDING
143,WO,A2,WO 2001/075092 A2,153-019-301-996-699,2001-10-11,2001,US 0110309 W,2001-04-02,US 54099100 A,2000-03-31,CpG REDUCED PLASMIDS AND VIRAL VECTORS,"Unmethylated plasmid DNA vectors are a major contributor to the inflammatory response associated with gene delivery. Results of clinical studies where CF subjects were subjected to either aerosolized liposomes alone or cationic lipid:DNA complexes indicated that bacterial derived plasmid DNA may be inflammatory. Additionally, unmethylated CpG dinucleotides have been shown to be immunostimulatory and are present at a much higher frequency in bacterially-derived plasmid DNA compared to vertebrate DNA. The invention provides for methods of modulating the immunostimulatory response to gene delivery by modifying the plasmid delivered to the cell. The plasmid is modified to reduce or eliminate the immunostimulatory response in order to preserve the efficacy of gene transfer but reduce the associated toxicity. In a preferred embodiment, the invention provides for a method of reducing inflammatory response to gene delivery by methylating CpG motifs of the plasmid vector and/or removing CpG motifs of the plasmid vector.",GENZYME CORP,YEW NELSON S;;ZHAO HONGMEI;;TOUSIGNANT JENNIFER D;;CHENG SENG H,,https://lens.org/153-019-301-996-699,Patent Application,yes,0,26,6,6,7,A61K48/00;;A61K48/00;;C12N15/88;;C12N15/88;;C12N15/63;;C12N15/63;;C12N2799/021;;C12N2799/021;;C12P19/34;;C12P19/34,A61K48/00;;C12N15/63;;C12N15/88;;C12P19/34,,0,0,,,,PENDING
144,US,A1,US 2013/0323714 A1,034-522-340-784-932,2013-12-05,2013,US 201313908462 A,2013-06-03,US 201313908462 A;;US 201261655117 P,2012-06-04,SYSTEM AND METHOD FOR MICRO-AERATION BASED FERMENTATION,"A method and apparatus for micro-aeration of large scale fermentation systems is provided. The micro-aeration system includes a fermentation reactor, a sparging apparatus, and a micro-aeration gas mixture delivered to the fermentation reactor via the sparging apparatus. The micro-aeration gas mixture is a very low oxygen concentration mixture comprising an oxygen containing gas and an inert carrier gas that is preferably recycled through the fermentation reactor. The inert carrier gas is preferably nitrogen whereas the oxygen containing gas is oxygen or and is introduced to the fermentation reactor at a minimum superficial velocity of about 0.02 m/sec to produce a uniform dispersion of the oxygen/air throughout the fermentation broth while concurrently mixing the entire fermentation broth. The micro-aeration method and apparatus further comprises a controller operatively coupled to one or more control valves for regulating the micro-aeration conditions in the fermentation reactor.",CHENG ALAN T;;ZHOU YING;;BELANGER PAUL W;;BUGAYONG JENNIFER G,CHENG ALAN T;;ZHOU YING;;BELANGER PAUL W;;BUGAYONG JENNIFER G,PRAXAIR TECHNOLOGY INC (2013-06-06),https://lens.org/034-522-340-784-932,Patent Application,yes,3,25,4,4,0,C12M27/00;;C12M29/06;;C12M41/32;;C12M41/34;;C12M21/12;;C12M29/24;;C12M29/24;;C12M29/06;;C12M41/34;;C12M27/00;;C12M41/32;;C12M21/12;;C12M41/48,C12M1/00,435/3;;435/300.1;;435/287.1;;435/286.6,0,0,,,,DISCONTINUED
145,WO,A3,WO 2001/075092 A3,140-807-160-036-840,2002-06-27,2002,US 0110309 W,2001-04-02,US 54099100 A,2000-03-31,CpG REDUCED PLASMIDS AND VIRAL VECTORS,"Unmethylated plasmid DNA vectors are a major contributor to the inflammatory response associated with gene delivery. Results of clinical studies where CF subjects were subjected to either aerosolized liposomes alone or cationic lipid:DNA complexes indicated that bacterial derived plasmid DNA may be inflammatory. Additionally, unmethylated CpG dinucleotides have been shown to be immunostimulatory and are present at a much higher frequency in bacterially-derived plasmid DNA compared to vertebrate DNA. The invention provides for methods of modulating the immunostimulatory response to gene delivery by modifying the plasmid delivered to the cell. The plasmid is modified to reduce or eliminate the immunostimulatory response in order to preserve the efficacy of gene transfer but reduce the associated toxicity. In a preferred embodiment, the invention provides for a method of reducing inflammatory response to gene delivery by methylating CpG motifs of the plasmid vector and/or removing CpG motifs of the plasmid vector.",GENZYME CORP,YEW NELSON S;;ZHAO HONGMEI;;TOUSIGNANT JENNIFER D;;CHENG SENG H,,https://lens.org/140-807-160-036-840,Search Report,yes,2,0,6,6,0,A61K48/00;;A61K48/00;;C12N15/88;;C12N15/88;;C12N15/63;;C12N15/63;;C12N2799/021;;C12N2799/021;;C12P19/34;;C12P19/34,A61K48/00;;C12N15/63;;C12N15/88;;C12P19/34,,3,3,014-237-804-991-764;;105-363-896-520-535;;013-980-560-568-461,9770537;;pmc22882;;10.1073/pnas.95.21.12631;;9103425;;10.4049/jimmunol.158.8.3635;;10.1016/s0966-842x(97)01145-1;;9481820,"KRIEG ARTHUR M ET AL: ""Sequence motifs in adenoviral DNA block immune activation by stimulatory CpG motifs"", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF USA, NATIONAL ACADEMY OF SCIENCE. WASHINGTON, US, vol. 95, no. 21, 13 October 1998 (1998-10-13), pages 12631 - 12636, XP002161301, ISSN: 0027-8424;;KLINMAN D M ET AL: ""Contribution of CpG motifs to the immunogenicity of DNA vaccines"", JOURNAL OF IMMUNOLOGY, THE WILLIAMS AND WILKINS CO. BALTIMORE, US, vol. 158, 1997, pages 3635 - 3639, XP002108454, ISSN: 0022-1767;;KRIEG A M ET AL: ""THE ROLE OF CPG DINUCLEOTIDES IN DNA VACCINES"", TRENDS IN MICROBIOLOGY, ELSEVIER SCIENCE LTD., KIDLINGTON, GB, vol. 6, no. 1, January 1998 (1998-01-01), pages 23 - 26, XP000857633, ISSN: 0966-842X",PENDING
146,US,A1,US 2023/0262081 A1,033-783-829-149-335,2023-08-17,2023,US 202318303307 A,2023-04-19,US 202318303307 A;;US 202217724770 A;;US 202117156035 A,2021-01-22,INTELLIGENT ALERT CUSTOMIZATION IN A BACKUP AND RECOVERY ACTIVITY MONITORING SYSTEM,"Embodiments for generating user customized alert notifications for application operations and activities based on monitored performance metrics. Key performance indicators for the application and user behavior are defined, and a monitor process collects behavior statistics of the application for each user with respect to data assets for each of the key performance indicators. Anomaly detection policies are provided to define anomalous behavior of the users with respect to data assets of the computer network. An anomaly detection process detects anomalous user behavior and an alert notification is sent to administrative or security personnel upon each detected instance of abnormal user behavior. The alert notification rules are defined by the user based on operation severity, asset type, operation, and defined metrics to tailor and minimize the number of alerts sent to the user.",DELL PRODUCTS LP,MALAMUT MARK;;MINARIK JENNIFER M;;CHENG KEVIN D;;FREEMAN BRIAN E,DELL PRODUCTS L.P (2023-04-11),https://lens.org/033-783-829-149-335,Patent Application,yes,0,2,1,6,0,G06F11/1464;;G06F11/3034;;G06F11/3082;;G06F11/327;;G06F11/3409;;G06F11/3438;;H04L41/142;;H04L41/22;;H04L41/5009;;H04L43/0817;;H04L43/16;;H04L63/1425;;H04L43/045;;G06F11/1453;;G06F11/1469;;H04L63/1425,H04L9/40,,0,0,,,,PENDING
147,US,A1,US 2021/0123143 A1,001-844-316-817-903,2021-04-29,2021,US 202017072301 A,2020-10-16,US 202017072301 A;;US 201962924938 P,2019-10-23,HAFNIUM ALUMINUM OXIDE COATINGS DEPOSITED BY ATOMIC LAYER DEPOSITION,"Embodiments of the present disclosure relate to articles, coated articles, and methods of coating such articles with a corrosion resistant coating. The corrosion resistant coating can comprise hafnium aluminum oxide. The corrosion resistant coating may be deposited by a non-line of sight deposition, such as atomic layer deposition. Articles that may be coated may include chamber components, such as gas lines.",APPLIED MATERIALS INC,FENWICK DAVID;;SUN JENNIFER Y;;CHOU CHENG-HSUAN;;HE XIAO-MING,APPLIED MATERIALS INC (2020-01-07),https://lens.org/001-844-316-817-903,Patent Application,yes,4,2,6,6,0,H01J37/32477;;C23C16/40;;C23C16/45531;;C23C16/45553;;C23C16/40;;C23C16/45529;;C23C16/45553;;C23C16/40;;C23C16/45553;;C23C16/45529;;C23C16/45555;;C23C16/45531;;C23C16/4404;;H01J37/32495;;C23C16/45565;;C23C16/40;;C23C16/505;;C23C16/45553;;C23C16/45565;;C23C16/45529;;C23C16/45536,C23F11/02;;C23C16/40;;C23C16/455;;C23C16/505;;C23F11/18,,0,0,,,,PENDING
148,US,A1,US 2022/0385798 A1,189-898-778-612-250,2022-12-01,2022,US 202017636078 A,2020-08-21,US 202017636078 A;;US 201962890657 P;;US 2020/0047398 W,2019-08-23,SYSTEMS AND METHODS FOR IMAGING USING RECONFIGURABLE PARTICLE ASSEMBLIES,"An imaging system includes a scattering assembly with a scattering medium positioned a first distance from an object to be imaged. The scattering medium includes a plurality of particles suspended in a suspension medium and at least one field source generating an electromagnetic field to manipulate an orientation, concentration, spatial distribution, and/or other properties of the plurality of particles. The imaging system further includes a detector including a plurality of detector elements positioned a second distance from the scattering medium and an image processing system configured to reconstruct an image of the object from an object image signal detected by the detector using object light scattered by the scattering medium and incident on the detector.",PENN STATE RES FOUND,LIU ZHIWEN;;KEATING CHRISTINE D;;WANG CHENG-YU;;MILLER JENNIFER R,THE PENN STATE RESEARCH FOUNDATION (2021-07-02),https://lens.org/189-898-778-612-250,Patent Application,yes,2,1,2,2,0,G01N21/17;;G01N2021/1765;;G02B5/0242;;H04N23/72;;H04N23/56;;H04N23/71,H04N5/235;;G02B5/02;;H04N5/225,,0,0,,,,PENDING
149,TW,A,TW 202130849 A,119-412-350-855-76X,2021-08-16,2021,TW 109136783 A,2020-10-23,US 201962924938 P;;US 202017072301 A,2019-10-23,Hafnium aluminum oxide coatings deposited by atomic layer deposition,"Embodiments of the present disclosure relate to articles, coated articles, and methods of coating such articles with a corrosion resistant coating. The corrosion resistant coating can comprise hafnium aluminum oxide. The corrosion resistant coating may be deposited by a non-line of sight deposition, such as atomic layer deposition. Articles that may be coated may include chamber components, such as gas lines.",APPLIED MATERIALS INC,FENWICK DAVID;;SUN JENNIFER Y;;CHOU CHENG-HSUAN;;HE XIAO-MING,,https://lens.org/119-412-350-855-76X,Patent of Addition,no,0,0,6,6,0,H01J37/32477;;C23C16/40;;C23C16/45531;;C23C16/45553;;C23C16/40;;C23C16/45529;;C23C16/45553;;C23C16/40;;C23C16/45553;;C23C16/45529;;C23C16/45555;;C23C16/45531;;C23C16/4404;;H01J37/32495;;C23C16/45565;;C23C16/40;;C23C16/505;;C23C16/45553;;C23C16/45565;;C23C16/45529;;C23C16/45536,C23C16/40;;C23C16/44;;C23C16/455;;H01J37/32,,0,0,,,,PENDING
150,KR,A,KR 20220084395 A,085-646-597-961-599,2022-06-21,2022,KR 20227017134 A,2020-10-22,US 201962924938 P;;US 202017072301 A;;US 2020/0056883 W,2019-10-23,원자층 증착에 의해 증착된 하프늄 알루미늄 산화물 코팅들,"본 개시의 구현예들은 물품들, 코팅된 물품들, 및 이러한 물품들을 내부식성 코팅으로 코팅하는 방법들에 관한 것이다. 내부식성 코팅은 하프늄 알루미늄 산화물을 포함할 수 있다. 내부식성 코팅은 비가시선(non-line of sight) 증착, 예를 들어, 원자층 증착에 의해 증착될 수 있다. 코팅될 수 있는 물품들은 챔버 구성요소들, 예를 들어, 가스 라인들을 포함할 수 있다.",APPLIED MATERIALS INC,FENWICK DAVID;;SUN JENNIFER Y;;CHOU CHENG HSUAN;;HE XIAO MING,,https://lens.org/085-646-597-961-599,Patent Application,no,0,0,6,6,0,H01J37/32477;;C23C16/40;;C23C16/45531;;C23C16/45553;;C23C16/40;;C23C16/45529;;C23C16/45553;;C23C16/40;;C23C16/45553;;C23C16/45529;;C23C16/45555;;C23C16/45531;;C23C16/4404;;H01J37/32495;;C23C16/45565;;C23C16/40;;C23C16/505;;C23C16/45553;;C23C16/45565;;C23C16/45529;;C23C16/45536,C23C16/40;;C23C16/44;;C23C16/455;;H01J37/32,,0,0,,,,DISCONTINUED
151,AU,A,AU 2001/047902 A,199-527-441-708-767,2001-10-15,2001,AU 2001/047902 A,2001-04-02,US 54099100 A;;US 0110309 W,2000-03-31,Cpg reduced plasmids and viral vectors,,GENZYME CORP,YEW NELSON S;;ZHAO HONGMEI;;TOUSIGNANT JENNIFER D;;CHENG SENG H,,https://lens.org/199-527-441-708-767,Patent Application,no,0,0,6,6,0,A61K48/00;;A61K48/00;;C12N15/88;;C12N15/88;;C12N15/63;;C12N15/63;;C12N2799/021;;C12N2799/021;;C12P19/34;;C12P19/34,A61K48/00;;C12N15/63;;C12N15/88;;C12P19/34,,0,0,,,,PENDING
152,WO,A1,WO 2021/041212 A1,102-341-787-427-378,2021-03-04,2021,US 2020/0047398 W,2020-08-21,US 201962890657 P,2019-08-23,SYSTEMS AND METHODS FOR IMAGING USING RECONFIGURABLE PARTICLE ASSEMBLIES,"An imaging system includes a scattering assembly with a scattering medium positioned a first distance from an object to be imaged. The scattering medium includes a plurality of particles suspended in a suspension medium and at least one field source generating an electromagnetic field to manipulate an orientation, concentration, spatial distribution, and/or other properties of the plurality of particles. The imaging system further includes a detector including a plurality of detector elements positioned a second distance from the scattering medium and an image processing system configured to reconstruct an image of the object from an object image signal detected by the detector using object light scattered by the scattering medium and incident on the detector.",PENN STATE RES FOUND,LIU ZHIWEN;;KEATING CHRISTINE D;;WANG CHENG-YU;;MILLER JENNIFER R,,https://lens.org/102-341-787-427-378,Patent Application,yes,4,0,2,2,0,G01N21/17;;G01N2021/1765;;G02B5/0242;;H04N23/72;;H04N23/56;;H04N23/71,G01N21/47;;A61B5/00;;G01N21/17;;G01N21/49;;G01N21/51,,0,0,,,,PENDING
153,US,A1,US 2004/0053870 A1,010-791-980-333-755,2004-03-18,2004,US 35160303 A,2003-01-27,US 35160303 A;;US 54099100 A;;US 39246299 A;;US 9958398 P,1998-09-09,CpG reduced plasmids and viral vectors,"
   Unmethylated plasmid DNA vectors are a major contributor to the inflammatory response associated with gene delivery. Results of clinical studies where CF subjects were subjected to either aerosolized liposomes alone or cationic lipid:DNA complexes indicated that bacterial derived plasmid DNA may be inflammatory. Additionally, unmethylated CpG dinucleotides have been shown to be immunostimulatory and are present at a much higher frequency in bacterially-derived plasmid DNA compared to vertebrate DNA. The invention provides for methods of modulating the immunostimulatory response to gene delivery by modifying the plasmid delivered to the cell. The plasmid is modified to reduce or eliminate the immunostimulatory response in order to preserve the efficacy of gene transfer but reduce the associated toxicity. In a preferred embodiment, the invention provides for a method of reducing inflammatory response to gene delivery by methylating CpG motifs of the plasmid vector and/or removing CpG motifs of the plasmid vector. 
",GENZYME CORP,YEW NELSON S;;ZHAO HONGMEI;;TOUSIGNANT JENNIFER D;;CHENG SENG H,,https://lens.org/010-791-980-333-755,Patent Application,yes,0,25,6,6,7,A61K48/00;;A61K48/00;;C12N15/88;;C12N15/88;;C12N15/63;;C12N15/63;;C12N2799/021;;C12N2799/021;;C12P19/34;;C12P19/34,A61K48/00;;C12N15/63;;C12N15/88;;C12P19/34,514/44,0,0,,,,DISCONTINUED
154,US,A1,US 2010/0068671 A1,089-384-473-469-699,2010-03-18,2010,US 28356708 A,2008-09-12,US 28356708 A,2008-09-12,Dental appliance with resilient portion,"Methods and devices utilizing a dental appliance having a resilient portion are disclosed. One such appliance is a removable dental positioning appliance that includes, a plurality of shell portions each having one or more cavities shaped therein to receive one or more teeth and wherein each of the plurality of shell portions is formed to be separate from each of the other plurality of shell portions; a resilient component attached to a side of at least two shell portions; and wherein at least one of, the resilient component and one or more of the shell portions, provides one or more forces to reposition one or more teeth from a first orientation to a successive orientation.",KAKAVAND ALI;;MATOV VADIM;;CHEN JENNIFER C;;MOSS JON F;;CHENG JIHUA,KAKAVAND ALI;;MATOV VADIM;;CHEN JENNIFER C;;MOSS JON F;;CHENG JIHUA,ALIGN TECHNOLOGY INC (2008-08-14),https://lens.org/089-384-473-469-699,Patent Application,yes,18,52,2,2,0,A61C7/08;;A61C7/08,A61C7/08,433/6,0,0,,,,ACTIVE
155,CN,A,CN 108348307 A,170-168-225-036-041,2018-07-31,2018,CN 201680066445 A,2016-11-09,US 201514939252 A;;IB 2016056734 W,2015-11-12,Dental attachment formation structures,"The present disclosure provides methods, computing device readable medium, devices, and systems having a dental attachment formation structures. One dental appliance includes a body having a first surface shaped to abut an exterior surface of a tooth and a well portion of the first surface shaped to form an attachment that is to be attached to the exterior surface of the tooth, a release layer formed over a surface of the well to allow the attachment to be removed from the well, and a curable material that is used to form the attachment positioned within the well.",ALIGN TECHNOLOGY INC,WEBBER PETER;;CHEN JENNIFER;;CHEN YAN;;CHENG JIHUA;;PESENTI BASTIEN;;LI CHUNHUA,,https://lens.org/170-168-225-036-041,Patent Application,no,5,0,7,7,0,A61C19/003;;A61C7/16;;A61B1/0002;;A61C7/08;;A61B1/00039;;A61B1/24;;A61C7/146;;A61B1/00045;;A61C2202/01;;A61C7/08;;A61C7/146;;A61C7/16;;A61C2202/01;;A61C2202/01;;A61C7/08;;A61C7/16;;A61C7/146;;A61B1/0002;;A61B1/00045;;A61B1/24;;A61C19/003;;A61N2005/063;;A61N2005/0661,A61C7/08;;A61C7/14;;A61C7/16,,0,0,,,,ACTIVE
156,EP,B1,EP 3373847 B1,042-620-880-142-040,2022-03-02,2022,EP 16798820 A,2016-11-09,US 201514939252 A;;IB 2016056734 W,2015-11-12,DENTAL ATTACHMENT FORMATION APPARATUS,,ALIGN TECHNOLOGY INC,WEBBER PETER;;CHEN JENNIFER;;CHEN YAN;;CHENG JIHUA;;PESENTI BASTIEN;;LI CHUNHUA,,https://lens.org/042-620-880-142-040,Granted Patent,yes,6,0,7,7,0,A61C19/003;;A61C7/16;;A61B1/0002;;A61C7/08;;A61B1/00039;;A61B1/24;;A61C7/146;;A61B1/00045;;A61C2202/01;;A61C7/08;;A61C7/146;;A61C7/16;;A61C2202/01;;A61C2202/01;;A61C7/08;;A61C7/16;;A61C7/146;;A61B1/0002;;A61B1/00045;;A61B1/24;;A61C19/003;;A61N2005/063;;A61N2005/0661,A61C7/08;;A61C7/14;;A61C7/16,,0,0,,,,ACTIVE
157,US,B1,US 6268202 B1,068-054-904-769-826,2001-07-31,2001,US 11323198 A,1998-07-10,US 11323198 A;;US 5227897 P,1997-07-11,Strains of coniothyrium minitans having beta-glucanase activity,"Strains of the aerobic mycoparasitic fungus Coniothyrium minitans having high levels of .beta.-glucanase activity have been obtained. Preferred strains have been deposited at the American Type Culture Collection under accession numbers 74415, 74416, 74417, 74418, 74419, 74435 and 74436. Methods for mutagenizing C. minitans 74415 and obtaining strains having .beta.-glucanase activity are provided.",UNITED KINGDOM GOVERNMENT,HUANG HUNG CHANG;;CHENG KUO JOAN;;ZANTINGE JENNIFER L;;LAROCHE ANDRE J,HER MAJESTY THE QUEEN IN RIGHT OF CANADA AS REPRESENTED BY THE DEPARTMENT OF AGRICULTURE AND AGRI-FOOD CANADA (1998-07-24),https://lens.org/068-054-904-769-826,Granted Patent,yes,5,3,5,5,6,C12Y302/01004;;C12Y302/01006;;C12Y302/01039;;C12Y302/01058;;C12Y302/01073;;Y10S435/911;;C12N9/244;;C12R2001/645;;C12N1/145;;C12Y302/01039;;C12Y302/01073;;C12Y302/01004;;C12Y302/01058;;C12Y302/01006;;Y10S435/911;;C12N9/244;;C12N1/145;;C12R2001/645,C12N9/24;;C12N9/42,435/254.1;;435/911;;424/93.5,13,9,053-210-668-113-91X;;002-900-296-075-673;;085-128-528-193-629;;000-726-092-447-291;;046-014-572-372-827;;067-754-187-601-465;;028-972-565-521-907;;110-910-560-145-146;;096-619-466-971-40X,10.1111/j.1439-0434.1988.tb04460.x;;10.1111/j.1439-0434.1984.tb00716.x;;4476212;;10.1042/bj1400047;;pmc1167969;;10.1038/224287a0;;10.1080/07060668109501352;;10.1139/b76-039;;10.1139/b77-039;;10.1139/b87-337;;10.1016/s0953-7562(09)80588-1,"Huang et al., ""Penetration of Hyphae of Sclerotinia sclerotiorum by Coniothyrium minitans Without the Formation of Appressoria,"" (1988) J. Phytopathology 123:133-39.;;Tu et al., ""Mycoparasitism by Coniothyrium minitans on Sclerotinia sclerotiorum sclerotiorum and its effect on Sclerotinia Germination,"" (1984) Phytopath.Z 109:261-268.;;Jones, D., Gordon, A.H., and Bacon, J.S.D. 1974. Cooperative action by endo- and exo-beta- (1,3) -glucanases from parasitic fungi in the degradation of cell-wall glucans of Sclerotinia sclerotiorum. (Lib.) de Bary, Biochem. J. 140:47-55.;;Jones, D. and Watson, D. 1969. Parasitism and lysis by soil fungi of Sclerotinia sclerotiorum (Lib.) de Bary, a Phytopathogenic Fungus. Nature 24:287-288.;;Domsch, K.H., Gams, W., and Anderson, T.H. (eds.) 1980, Coniothyrium corda 1840 emend. Sacc. 1880 (nomen conservadum). In: Compendium of Soil Fungi. Academic Press, New York. vol. 1:228-231.;;Sesan, T. and Baicu, T. 1993. New aspects of the biology of the hyperparasitic fungus Coniothyrium minitans Campbell. In: Revue Roumaine de Biologie. vol. 38 (No. 2) :132-137.;;Huang, H.C. 1981. Distribution of Coniothyrium minitans in Manitoba sunflower fields. Can. J. Plant Pathol. 3:219-222.;;Huang, H.C. and Hoes, J.A. 1976. Penetration and infection of Sclerotinia sclerotiorum by Coniothyrium minitans. Can. J. Bot. 54:406-410.;;Huang, H.C. 1977. Importance of Coniothyrium minitans in survival of sclerotia of Sclerotinia sclerotiorum in wilted sunflower. Can. J. Bot. 55:289-295.;;Huang, H.C. 1980. Control of sclerotinia wilt of sunflower by hyperparasites. Can. J. Plant Pathol. 2:26-32.;;Huang, H.C. and Kokko, E.G. 1987. Ultrastructure of hyperparasitism of Coniothyrium minitans on sclerotia of Sclerotinia sclerotiorum. Can. J. Bot. 65:2483-2489.;;Whipps, J.M. and Gerlagh, M. 1992. Biology of Coniothyrium minitans and its potential for use in disease biocontrol. Myco. Rs. 96 (II):897-907.;;Rai, J. N., et al. 1978. Lysis of Sclerotia of Sclerotinia sclerotiorum and Its Possible Relation with Chitinase Activity. Indian J. Mycology and Plant Pathology. 8:103-107.",EXPIRED
158,WO,A1,WO 2017/081616 A1,199-503-924-397-901,2017-05-18,2017,IB 2016056734 W,2016-11-09,US 201514939252 A,2015-11-12,DENTAL ATTACHMENT FORMATION STRUCTURES,"The present disclosure provides methods, computing device readable medium, devices, and systems having a dental attachment formation structures. One dental appliance includes a body having a first surface shaped to abut an exterior surface of a tooth and a well portion of the first surface shaped to form an attachment that is to be attached to the exterior surface of the tooth, a release layer formed over a surface of the well to allow the attachment to be removed from the well, and a curable material that is used to form the attachment positioned within the well.",ALIGN TECHNOLOGY INC,WEBBER PETER;;CHEN JENNIFER;;CHEN YAN;;CHENG JIHUA;;PESENTI BASTIEN;;LI CHUNHUA,,https://lens.org/199-503-924-397-901,Patent Application,yes,5,1,7,7,0,A61C19/003;;A61C7/16;;A61B1/0002;;A61C7/08;;A61B1/00039;;A61B1/24;;A61C7/146;;A61B1/00045;;A61C2202/01;;A61C7/08;;A61C7/146;;A61C7/16;;A61C2202/01;;A61C2202/01;;A61C7/08;;A61C7/16;;A61C7/146;;A61B1/0002;;A61B1/00045;;A61B1/24;;A61C19/003;;A61N2005/063;;A61N2005/0661,A61C7/08;;A61C7/14;;A61C7/16,,0,0,,,,PENDING
159,AU,A,AU 1998/083278 A,096-926-830-381-511,1999-02-08,1999,AU 1998/083278 A,1998-07-10,CA 9800668 W;;US 5227897 P,1997-07-11,"Strains of (coniothyrium minitans) having 1,3 and 1,4 beta-glucanase activity",,HER MAJESTY THE QUEEN IN RIGHT OF CANADA AS REPRESENTED BY THE DEPT OF AGRICULTURE AND AGRI FOOD CAN,HUANG HUNG CHANG;;CHENG KUO JOAN;;ZANTINGE JENNIFER L;;LAROCHE ANDRE J,,https://lens.org/096-926-830-381-511,Patent Application,no,0,0,5,5,0,C12Y302/01004;;C12Y302/01006;;C12Y302/01039;;C12Y302/01058;;C12Y302/01073;;Y10S435/911;;C12N9/244;;C12R2001/645;;C12N1/145;;C12Y302/01039;;C12Y302/01073;;C12Y302/01004;;C12Y302/01058;;C12Y302/01006;;Y10S435/911;;C12N9/244;;C12N1/145;;C12R2001/645,C12N9/24;;C12N9/42,,0,0,,,,DISCONTINUED
160,WO,A1,WO 1999/002662 A1,135-811-446-231-167,1999-01-21,1999,CA 9800668 W,1998-07-10,US 5227897 P,1997-07-11,"STRAINS OF CONIOTHYRIUM MINITANS HAVING 1,3 AND 1,4 BETA-GLUCANASE ACTIVITY","Strains of the aerobic mycoparasitic fungus Coniothyrium minitans having high levels of β-glucanase activity have been obtained. Preferred strains have been deposited at the American Type Culture Collection under accession numbers 74415, 74416, 74417, 74418, 74419, 74435 and 74436. Methods for mutagenizing C. minitans 74415 and obtaining strains having β-glucanase activity are provided.",CA MINISTER AGRICULTURE & FOOD;;HUANG HUNG CHANG;;CHENG KUO JOAN;;ZANTINGE JENNIFER L;;LAROCHE ANDRE J,HUANG HUNG CHANG;;CHENG KUO JOAN;;ZANTINGE JENNIFER L;;LAROCHE ANDRE J,,https://lens.org/135-811-446-231-167,Patent Application,yes,3,3,5,5,6,C12Y302/01004;;C12Y302/01006;;C12Y302/01039;;C12Y302/01058;;C12Y302/01073;;Y10S435/911;;C12N9/244;;C12R2001/645;;C12N1/145;;C12Y302/01039;;C12Y302/01073;;C12Y302/01004;;C12Y302/01058;;C12Y302/01006;;Y10S435/911;;C12N9/244;;C12N1/145;;C12R2001/645,C12N9/24;;C12N9/42,,2,2,096-619-466-971-40X;;085-128-528-193-629,10.1016/s0953-7562(09)80588-1;;4476212;;10.1042/bj1400047;;pmc1167969,"WHIPP, J.M. ET AL.: ""Biology of Coniothyrium minitans and its potential for use in disease control."", MYCOLOGICAL RESEARCH, vol. 96, no. 11, 1992, pages 897 - 907, XP002085829;;JONES, D. ET AL.: ""Co-operative action by endo- and exo-beta-(1->3)-glucanases from parasitic fungi in the degradation of cell-wall glucans of sclerotina sclerotiorum (Lib.) de Bary."", BIOCHEMICAL JOURNAL, vol. 140, no. 1, April 1974 (1974-04-01), pages 47 - 55, XP002085830",PENDING
161,EP,A1,EP 3373847 A1,143-083-026-704-121,2018-09-19,2018,EP 16798820 A,2016-11-09,US 201514939252 A;;IB 2016056734 W,2015-11-12,DENTAL ATTACHMENT FORMATION STRUCTURES,,ALIGN TECHNOLOGY INC,WEBBER PETER;;CHEN JENNIFER;;CHEN YAN;;CHENG JIHUA;;PESENTI BASTIEN;;LI CHUNHUA,,https://lens.org/143-083-026-704-121,Patent Application,yes,0,2,7,7,0,A61C19/003;;A61C7/16;;A61B1/0002;;A61C7/08;;A61B1/00039;;A61B1/24;;A61C7/146;;A61B1/00045;;A61C2202/01;;A61C7/08;;A61C7/146;;A61C7/16;;A61C2202/01;;A61C2202/01;;A61C7/08;;A61C7/16;;A61C7/146;;A61B1/0002;;A61B1/00045;;A61B1/24;;A61C19/003;;A61N2005/063;;A61N2005/0661,A61C7/08;;A61C7/14;;A61C7/16,,0,0,,,,ACTIVE
162,US,B1,US 8375450 B1,189-773-027-953-848,2013-02-12,2013,US 57330009 A,2009-10-05,US 57330009 A,2009-10-05,Zero day malware scanner,"A training model for malware detection is developed using common substrings extracted from known malware samples. The probability of each substring occurring within a malware family is determined and a decision tree is constructed using the substrings. An enterprise server receives indications from client machines that a particular file is suspected of being malware. The suspect file is retrieved and the decision tree is walked using the suspect file. A leaf node is reached that identifies a particular common substring, a byte offset within the suspect file at which it is likely that the common substring begins, and a probability distribution that the common substring appears in a number of malware families. A hash value of the common substring is compared (exact or approximate) against the corresponding substring in the suspect file. If positive, a result is returned to the enterprise server indicating the probability that the suspect file is a member of a particular malware family.",TREND MICRO INC;;OLIVER JONATHAN JAMES;;HOU CHENG-LIN;;DIAO LILI;;LIANG YIFUN;;RIHN JENNIFER,OLIVER JONATHAN JAMES;;HOU CHENG-LIN;;DIAO LILI;;LIANG YIFUN;;RIHN JENNIFER,TREND MICRO INC (2009-12-01),https://lens.org/189-773-027-953-848,Granted Patent,yes,3,107,1,1,0,G06F21/564;;H04L63/1416;;G06F21/565;;G06F21/567;;H04L63/1416;;G06F21/564;;G06F21/567;;G06F21/565,G06F21/00,726/24;;726/22;;726/23;;713/181;;713/187;;713/188,0,0,,,,ACTIVE
163,WO,A1,WO 2023/021285 A1,068-150-668-333-499,2023-02-23,2023,GB 2022052131 W,2022-08-16,GB 202111734 A,2021-08-16,HYPERPOLARISATION METHOD AND PRODUCT,"In a method for preparing a hyperpolarised sample, for example for a magnetic resonance procedure, a starting solution comprising alpha-ketoglutaric acid and 13C-labelled molecules is frozen to form a frozen solution. The solution is irradiated with ultraviolet and/or visible radiation, to generate free radicals. The frozen solution is then hyperpolarised by applying a magnetic field to the solution while irradiating it with frequency-modulated microwave radiation.",CAMBRIDGE ENTPR LTD,COMMENT ARNAUD;;GAUNT ADAM;;LEWIS JENNIFER SUNARI;;MARCO-RIUS IRENE;;CHENG TIAN,,https://lens.org/068-150-668-333-499,Patent Application,yes,5,0,2,2,0,G01R33/282;;G01R33/62;;G01N24/12;;G01R33/5601;;G01R33/46,G01R33/28;;G01N24/12;;G01R33/46;;G01R33/56;;G01R33/62,,5,5,030-750-994-779-429;;117-708-696-333-934;;022-146-000-801-546;;005-760-614-268-161;;008-808-461-402-460,10.1016/j.cplett.2014.04.013;;10.1007/s10334-020-00894-w;;33185800;;34852925;;10.1016/j.pnmrs.2021.04.002;;10.1021/jacs.8b09326;;30346733;;pmc6217999;;10.1002/anie.201810522;;pmc6531289;;30515929,"BORNET AURÉLIEN ET AL: ""Microwave frequency modulation to enhance Dissolution Dynamic Nuclear Polarization"", CHEMICAL PHYSICS LETTERS, ELSEVIER BV, NL, vol. 602, 18 April 2014 (2014-04-18), pages 63 - 67, XP028665006, ISSN: 0009-2614, DOI: 10.1016/J.CPLETT.2014.04.013;;PINON ARTHUR C ET AL: ""Hyperpolarization via dissolution dynamic nuclear polarization: new technological and methodological advances"", MAGNETIC RESONANCE MATERIALS IN PHYSICS, BIOLOGY AND MEDICINE, vol. 34, no. 1, 13 November 2020 (2020-11-13), pages 5 - 23, XP037382865, ISSN: 0968-5243, DOI: 10.1007/S10334-020-00894-W;;ELLIOTT STUART J ET AL: ""Practical dissolution dynamic nuclear polarization"", PROGRESS IN NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY, PERGAMON PRESS, OXFORD, GB, vol. 126, 21 May 2021 (2021-05-21), pages 59 - 100, XP086881416, ISSN: 0079-6565, [retrieved on 20210521], DOI: 10.1016/J.PNMRS.2021.04.002;;I. MARCO-RIUS ET AL., J. AM. CHEM. SOC., vol. 140, 2018, pages 14455;;CAPOZZI ET AL., ANGEWANDTE CHEMIE, vol. 58, 2019, pages 1334",PENDING
164,US,B2,US 8517726 B2,191-855-976-790-13X,2013-08-27,2013,US 28356708 A,2008-09-12,US 28356708 A,2008-09-12,Dental appliance with resilient portion,"Methods and devices utilizing a dental appliance having a resilient portion are disclosed. One such appliance is a removable dental positioning appliance that includes, a plurality of shell portions each having one or more cavities shaped therein to receive one or more teeth and wherein each of the plurality of shell portions is formed to be separate from each of the other plurality of shell portions; a resilient component attached to a side of at least two shell portions; and wherein at least one of, the resilient component and one or more of the shell portions, provides one or more forces to reposition one or more teeth from a first orientation to a successive orientation.",KAKAVAND ALI;;MATOV VADIM;;CHEN JENNIFER C;;MOSS JON F;;CHENG JIHUA;;ALIGN TECHNOLOGY INC,KAKAVAND ALI;;MATOV VADIM;;CHEN JENNIFER C;;MOSS JON F;;CHENG JIHUA,ALIGN TECHNOLOGY INC (2008-08-14),https://lens.org/191-855-976-790-13X,Granted Patent,yes,18,125,2,2,0,A61C7/08;;A61C7/08,A61C7/08,433/6;;433/8;;433/18,0,0,,,,ACTIVE
165,TW,A,TW 200507092 A,194-411-642-836-048,2005-02-16,2005,TW 92122199 A,2003-08-13,TW 92122199 A,2003-08-13,Method for controlling cmp process,"A method for controlling a CMP process is described, which is suitably applied to a CMP process within a damascene process. In this method, a test run is firstly performed using several test wafers, and then the erosion amounts of the dielectric layer or the thickness of the metal layer on the test wafers are measured. Thereafter, the polishing time for each wafer in the first lot is calculated from the polishing time and the dielectric erosion amount or the metal thickness of the test wafers, a dielectric erosion target or a metal thickness target, and the erosion rate or polishing rate of the polishing pad. Each wafer of the first lot is then polished for the calculated polishing time. Moreover, the polishing time required for each wafer in any lot after the first lot is calculated from the dielectric erosion amounts or the metal thickness of the wafers in a previous lot.",PROMOS TECHNOLOGIES INC,CHENG CHUN-LUNG;;HSU LILLIAN;;CHON HON-HONG;;SU SHUI-CHIN;;CHEN JENNIFER,,https://lens.org/194-411-642-836-048,Patent of Addition,no,0,4,2,2,0,,H01L21/304,,0,0,,,,EXPIRED
166,WO,A1,WO 2009/149456 A1,041-972-445-979-754,2009-12-10,2009,US 2009/0046632 W,2009-06-08,US 5951808 P,2008-06-06,VEIN THERAPY DEVICE AND METHOD,"A vapor delivery and insulation device is provided that may include any of a number of features. One feature of the device is that it can deliver vapor to the veins of a patient. The vapor can be generated within the device, in a handle of the device, or external to the device. Another feature of the device is that it can actively insulate the vapor to minimize heat transfer from a vapor delivery lumen of the device to an exterior surface of the device. The active insulation can be a vacuum or a flowing gas. Methods associated with use of the device are also covered.",VARIX MEDICAL CORP;;GLAZE GRANT MICHAEL;;CHENG JENNIFER;;JACKSON JEROME;;TARTAGLIA JOSEPH MICHAEL;;TREBOTICH STEVEN H,GLAZE GRANT MICHAEL;;CHENG JENNIFER;;JACKSON JEROME;;TARTAGLIA JOSEPH MICHAEL;;TREBOTICH STEVEN H,,https://lens.org/041-972-445-979-754,Patent Application,yes,4,4,7,7,0,A61B18/04;;A61B18/04;;A61B17/00008;;A61B17/00008;;A61B17/12045;;A61B17/12045;;A61B17/12109;;A61B17/12109;;A61B17/12136;;A61B17/12136;;A61B2017/12127;;A61B2017/12127;;A61B2018/00023;;A61B2018/00023;;A61B2018/048;;A61B2018/048,A61B17/00,,0,0,,,,PENDING
167,CA,A1,CA 2727035 A1,172-380-452-609-47X,2009-12-10,2009,CA 2727035 A,2009-06-08,US 5951808 P;;US 2009/0046632 W,2008-06-06,VEIN THERAPY DEVICE AND METHOD,"A vapor delivery and insulation device is provided that may include any of a number of features. One feature of the device is that it can deliver vapor to the veins of a patient. The vapor can be generated within the device, in a handle of the device, or external to the device. Another feature of the device is that it can actively insulate the vapor to minimize heat transfer from a vapor delivery lumen of the device to an exterior surface of the device. The active insulation can be a vacuum or a flowing gas. Methods associated with use of the device are also covered.",VARIX MEDICAL CORP,GLAZE GRANT MICHAEL;;CHENG JENNIFER;;JACKSON JEROME;;TARTAGLIA JOSEPH MICHAEL;;TREBOTICH STEVEN H,,https://lens.org/172-380-452-609-47X,Patent Application,no,0,0,7,7,0,A61B18/04;;A61B18/04;;A61B17/00008;;A61B17/00008;;A61B17/12045;;A61B17/12045;;A61B17/12109;;A61B17/12109;;A61B17/12136;;A61B17/12136;;A61B2017/12127;;A61B2017/12127;;A61B2018/00023;;A61B2018/00023;;A61B2018/048;;A61B2018/048,A61B17/00,,0,0,,,,DISCONTINUED
168,AU,A1,AU 2009/255933 A1,115-904-148-031-244,2009-12-10,2009,AU 2009/255933 A,2009-06-08,US 5951808 P;;US 2009/0046632 W,2008-06-06,Vein therapy device and method,,VENITI INC,TARTAGLIA JOSEPH MICHAEL;;GLAZE GRANT MICHAEL;;JACKSON JEROME;;CHENG JENNIFER;;TREBOTICH STEVEN H,"VENITI, INC. (2011-06-16)",https://lens.org/115-904-148-031-244,Patent Application,no,0,0,7,7,0,A61B18/04;;A61B18/04;;A61B17/00008;;A61B17/00008;;A61B17/12045;;A61B17/12045;;A61B17/12109;;A61B17/12109;;A61B17/12136;;A61B17/12136;;A61B2017/12127;;A61B2017/12127;;A61B2018/00023;;A61B2018/00023;;A61B2018/048;;A61B2018/048,A61B17/00,,0,0,,,,DISCONTINUED
169,CN,A,CN 102112063 A,129-745-297-893-131,2011-06-29,2011,CN 200980129899 A,2009-06-08,US 2009/0046632 W;;US 5951808 P,2008-06-06,Vein therapy device and method,"A vapor delivery and insulation device is provided that may include any of a plurality of features. One feature of the device is that it can deliver vapor to the veins of a patient. The vapor can be generated within the device, in a handle of the device, or external to the device. Another feature of the device is that it can actively insulate the vapor to minimize heat transfer from a vapor delivery lumen of the device to an exterior surface of the device. The active insulation can be a vacuum or a flowing gas. Methods associated with use of the device are also covered.",VARIX MEDICAL CORP,MICHAEL GLAZE GRANT;;JENNIFER CHENG;;JEROME JACKSON;;MICHAEL TARTAGLIA JOSEPH;;TREBOTICH STEVEN H,,https://lens.org/129-745-297-893-131,Patent Application,no,0,2,7,7,0,A61B18/04;;A61B18/04;;A61B17/00008;;A61B17/00008;;A61B17/12045;;A61B17/12045;;A61B17/12109;;A61B17/12109;;A61B17/12136;;A61B17/12136;;A61B2017/12127;;A61B2017/12127;;A61B2018/00023;;A61B2018/00023;;A61B2018/048;;A61B2018/048,A61B17/00,,0,0,,,,DISCONTINUED
170,US,A1,US 2017/0135793 A1,086-041-401-796-451,2017-05-18,2017,US 201514939252 A,2015-11-12,US 201514939252 A,2015-11-12,DENTAL ATTACHMENT FORMATION STRUCTURES,"The present disclosure provides methods, computing device readable medium, devices, and systems having a dental attachment formation structures. One dental appliance includes a body having a first surface shaped to abut an exterior surface of a tooth and a well portion of the first surface shaped to form an attachment that is to be attached to the exterior surface of the tooth, a release layer formed over a surface of the well to allow the attachment to be removed from the well, and an attachment material that is used to form the attachment positioned within the well.",ALIGN TECHNOLOGY INC,WEBBER PETER;;CHEN YAN;;CHENG JIHUA;;PESENTI BASTIEN;;LI CHUNHUA;;CHEN JENNIFER C,ALIGN TECHNOLOGY INC (2015-11-02),https://lens.org/086-041-401-796-451,Patent Application,yes,51,95,7,7,0,A61C19/003;;A61C7/16;;A61B1/0002;;A61C7/08;;A61B1/00039;;A61B1/24;;A61C7/146;;A61B1/00045;;A61C2202/01;;A61C7/08;;A61C7/146;;A61C7/16;;A61C2202/01;;A61C2202/01;;A61C7/08;;A61C7/16;;A61C7/146;;A61B1/0002;;A61B1/00045;;A61B1/24;;A61C19/003;;A61N2005/063;;A61N2005/0661,A61C13/15;;A61B1/00;;A61B1/24,,0,0,,,,PENDING
171,EP,A1,EP 2296556 A1,012-124-976-279-964,2011-03-23,2011,EP 09759614 A,2009-06-08,US 2009/0046632 W;;US 5951808 P,2008-06-06,VEIN THERAPY DEVICE AND METHOD,,VARIX MEDICAL CORP,GLAZE GRANT MICHAEL;;CHENG JENNIFER;;JACKSON JEROME;;TARTAGLIA JOSEPH MICHAEL;;TREBOTICH STEVEN H,"VENITI, INC. (2011-09-14)",https://lens.org/012-124-976-279-964,Patent Application,yes,0,0,7,7,0,A61B18/04;;A61B18/04;;A61B17/00008;;A61B17/00008;;A61B17/12045;;A61B17/12045;;A61B17/12109;;A61B17/12109;;A61B17/12136;;A61B17/12136;;A61B2017/12127;;A61B2017/12127;;A61B2018/00023;;A61B2018/00023;;A61B2018/048;;A61B2018/048,A61B17/00,,1,0,,,See references of WO 2009149456A1,DISCONTINUED
172,US,B2,US 10463452 B2,030-724-661-373-560,2019-11-05,2019,US 201715684775 A,2017-08-23,US 201715684775 A;;US 201662379199 P,2016-08-24,Method to visualize and manufacture aligner by modifying tooth position,Orthodontic systems and related methods are disclosed for designing and providing improved or more effective tooth moving systems for eliciting a desired tooth movement and/or repositioning teeth into a desired arrangement. Methods and orthodontic systems include the generation of an overcorrection in the tooth-receiving cavities of an appliance worn in the dentition. The overcorrection may provide an improved and more accurately applied force or moment applied to a tooth. The overcorrected force or moment can move a tooth closer to a desired position than if not overcorrected as sufficient force can still applied to the tooth as it gets closer to the desired position. The overcorrected force or moment may also better target the root of the tooth where the biological response to tooth movement occurs. The overcorrection may be calculated in various ways as described herein.,ALIGN TECHNOLOGY INC,MATOV VADIM;;WU FUMING;;CHENG JIHUA;;CHEN JENNIFER;;LI CHUNHUA;;PESENTI BASTIEN;;KVASOV IGOR,ALIGN TECHNOLOGY INC (2017-09-08),https://lens.org/030-724-661-373-560,Granted Patent,yes,190,100,13,13,0,A61C7/002;;A61C7/08;;B33Y80/00;;G16H20/40;;G16H50/50;;G06F30/00;;A61C7/002;;A61C7/08,A61C7/00;;A61C7/08;;G06F17/50,,156,79,066-282-335-791-995;;025-616-909-029-765;;012-349-279-389-292;;012-109-303-347-357;;107-771-608-717-858;;062-739-307-619-727;;059-588-461-518-39X;;005-024-996-709-894;;052-731-758-553-641;;081-328-802-841-096;;009-638-995-800-030;;008-744-219-127-384;;083-235-787-432-859;;006-548-225-912-257;;008-400-662-682-578;;008-334-069-985-364;;106-143-739-919-771;;041-946-650-568-904;;026-672-240-066-566;;010-426-032-640-987;;082-594-697-736-865;;114-408-402-448-688;;007-458-121-098-163;;048-527-821-955-377;;052-763-059-483-265;;048-656-201-606-564;;042-727-167-432-165;;109-794-479-707-999;;158-570-183-388-081;;046-112-675-259-076;;046-223-741-691-636;;053-649-857-143-596;;053-005-861-291-15X;;011-087-626-493-243;;007-221-538-620-409;;021-018-768-707-650;;000-494-525-786-513;;034-464-951-348-782;;013-689-140-672-656;;150-267-339-118-983;;006-370-362-381-143;;099-384-176-695-780;;056-064-135-529-61X;;054-749-861-626-632;;136-362-268-202-528;;002-943-783-913-03X;;002-001-653-775-549;;049-270-017-771-054;;114-349-043-008-578;;027-822-397-122-973;;138-684-123-834-414;;056-383-866-369-582;;123-028-396-811-269;;112-073-423-851-594;;021-881-631-200-08X;;043-213-859-914-534;;058-953-285-075-855;;004-945-615-972-614;;007-791-552-338-375;;036-191-696-513-286;;025-329-363-440-138;;006-539-396-314-679;;129-709-346-949-085;;051-296-399-382-894;;069-298-082-055-441;;021-507-277-374-529;;053-048-658-252-470;;031-271-546-068-031;;049-407-482-660-143;;042-526-631-078-104;;027-754-365-457-953;;030-427-969-872-795;;064-378-232-278-762;;046-665-331-726-574;;055-477-823-513-100;;027-316-381-573-41X;;000-788-861-492-825;;055-418-850-870-066;;088-958-363-169-71X,10.1117/12.7972842;;10.1117/12.957387;;2686338;;10.3109/00016358909007713;;4511478;;6943954;;10.1043/0003-3219(1981)051<0252:acsfta>2.0.co;2;;10.1016/0266-4356(84)90080-9;;6235838;;10.1043/0003-3219(1970)040<0028:cdsas>2.0.co;2;;5262685;;10.1016/0002-9416(72)90076-0;;4501183;;10.1109/tip.2004.826093;;15376602;;10.1177/00220345860650031101;;3457048;;6937139;;10.1016/0002-9416(81)90310-9;;298295;;298302;;2089065;;4064420;;6935222;;5248055;;10.1016/s0002-9416(69)90171-7;;2021892;;10356486;;3714886;;10.1097/00006534-198606000-00001;;1022792;;10.1016/0021-9290(76)90187-1;;1777659;;3058771;;10.14219/jada.archive.1988.0096;;298289;;15419274;;10.1016/0002-9416(50)90076-5;;3479893;;10.1016/0889-5406(87)90229-0;;3476699;;10.1016/0278-2391(87)90195-9;;6960008;;2613889;;3333504;;2277050;;10.1016/0021-9290(90)90008-q;;8617829;;6584438;;9563366;;10.1016/s0889-5406(98)80024-3;;10.1179/bjo.16.2.85;;2673344;;271471;;10.1016/0002-9416(78)90100-8;;10.2334/josnusd1959.26.11;;6589367;;6956677;;10.2334/josnusd1959.24.1;;6594373;;10.1177/00220345840630110901;;21027613;;10.1016/0096-6347(46)90053-1;;10.1016/0096-6347(45)90101-3;;10356517;;10.1145/964965.808575;;10.1016/0141-9382(94)90007-8;;10.1016/s0889-5406(96)70036-7;;8876485;;10.1109/42.97596;;18222848;;2738247;;10.14219/jada.archive.1989.0156;;10.14219/jada.archive.1989.0240;;2918147;;3862671;;3911387;;2132100;;10.2334/josnusd1959.19.93;;294475;;10.1109/iecon.1998.724103;;5276727;;10.1016/0002-9416(71)90099-6;;10.1016/s0889-5406(00)70049-7;;10672223;;1591643;;10.1016/0022-3913(87)90285-x;;3312586;;1783723;;10.14219/jada.archive.1991.0205;;10.1109/10.133223;;1855790;;10.1093/ejo/14.2.125;;1582457;;10.1016/0889-5406(87)90412-4;;3477086;;10.1093/ejo/3.4.279;;7028491;;1539546;;10.1016/0889-5406(92)70089-s;;10.1001/archotol.1988.01860160082026;;3348899;;10.1016/0002-9416(71)90006-6;;5280427;;2269115;;1452058;;4504704;;10.1177/00220345720510042301;;4504700;;10.1177/00220345720510041901;;20830889;;10.1016/s0010-4485(96)00054-1;;9874310;;10.1109/42.736056;;2718969;;10.1016/0889-5406(89)90300-4;;2639882;;5272402;;10.1016/0002-9416(70)90106-5;;3553441;;3473186;;10.1109/4233.924800;;11420997;;2486752,"AADR. American Association for Dental Research, Summary of Activities, Mar. 20-23, 1980, Los Angeles, CA, p. 195.;;Alcaniz, et al., “An Advanced System for the Simulation and Planning of Orthodontic Treatments,” Karl Heinz Hohne and Ron Kikinis (eds.), Visualization in Biomedical Computing, 4th Intl. Conf., VBC '96, Hamburg, Germany, Sep. 22-25, 1996, Springer-Verlag, pp. 511-520.;;Alexander et al., “The DigiGraph Work Station Part 2 Clinical Management,” JCO, pp. 402-407 (Jul. 1990).;;Altschuler, “3D Mapping of Maxillo-Facial Prosthesis,” AADR Abstract #607, 2 pages total, (1980).;;Altschuler et al., “Analysis of 3-D Data for Comparative 3-D Serial Growth Pattern Studies of Oral-Facial Structures,” AADR Abstracts, Program and Abstracts of Papers, 57th General Session, IADR HP Annual Session, Mar. 29, 1979-Apr. 1, 1979, New Orleans Marriot, Journal of Dental Research, vol. 58, Jan. 1979, Special Issue A, p. 221.;;Altschuler et al., “Laser Electro-Optic System for Rapid Three-Dimensional (3D) Topographic Mapping of Surfaces,” Optical Engineering, 20(6):953-961 (1981).;;Altschuler et al., “Measuring Surfaces Space-Coded by a Laser-Projected Dot Matrix,” SPIE Imaging Applications for Automated Industrial Inspection and Assembly, vol. 182, p. 187-191 (1979).;;Andersson et al., “Clinical Results with Titanium Crowns Fabricated with Machine Duplication and Spark Erosion,” Acta. Odontol. Scand., 47:279-286 (1989).;;Andrews, The Six Keys to Optimal Occlusion Straight Wire, Chapter 3, pp. 13-24 (1989).;;Bartels, et al., An Introduction to Splines for Use in Computer Graphics and Geometric Modeling, Morgan Kaufmann Publishers, pp. 422-425 (1987).;;Baumrind, “A System for Craniofacial Mapping Through the Integration of Data from Stereo X-Ray Films and Stereo Photographs,” an invited paper submitted to the 1975 American Society of Photogram Symposium on Close-Range Photogram Systems, University of Ill., Aug. 26-30, 1975, pp. 142-166.;;Baumrind et al., “A Stereophotogrammetric System for the Detection of Prosthesis Loosening in Total Hip Arthroplasty,” NATO Symposium on Applications of Human Biostereometrics, Jul. 9-13, 1978, SPIE, vol. 166, pp. 112-123.;;Baumrind et al., “Mapping the Skull in 3-D,” reprinted from J. Calif. Dent. Assoc., 48(2), 11 pages total, (1972 Fall Issue).;;Baumrind, “Integrated Three-Dimensional Craniofacial Mapping: Background, Principles, and Perspectives,” Semin. in Orthod., 7(4):223-232 (Dec. 2001).;;Begole et al., “A Computer System for the Analysis of Dental Casts,” The Angle Orthod., 51(3):253-259 (Jul. 1981).;;Bernard et al.,“Computerized Diagnosis in Orthodontics for Epidemiological Studies: A Progress Report,” Abstract, J. Dental Res. Special Issue, vol. 67, p. 169, paper presented at International Association for Dental Research 66th General Session, Mar. 9-13, 1988, Montreal, Canada.;;Bhatia et al., “A Computer-Aided Design for Orthognathic Surgery,” Br. J. Oral Maxillofac. Surg., 22:237-253 (1984).;;Biggerstaff, “Computerized Diagnostic Setups and Simulations,” Angle Orthod., 40(1):28-36 (Jan. 1970).;;Biggerstaff et al., “Computerized Analysis of Occlusion in the Postcanine Dentition,” Am. J. Orthod., 61(3): 245-254 (Mar. 1972).;;Biostar Opeation & Training Manual. Great Lakes Orthodontics, Ltd. 199 Fire Tower Drive, Tonawanda, New York. 14150-5890, 20 pages total (1990).;;Blu, et al., “Linear interpolation revitalized”, IEEE Trans. Image Proc., 13(5):710-719 (May 2004.;;Bourke, “Coordinate System Transformation,” (Jun. 1996), p. 1, retrieved from the Internet Nov. 5, 2004, URL< http://astronomy.swin.edu.au/—pbourke/prolection/coords>.;;Boyd et al., “Three Dimensional Diagnosis and Orthodontic Treatment of Complex Malocclusions With the Invisalipn Appliance,” Semin. Orthod., 7(4):274-293 (Dec. 2001).;;Brandestini et al., “Computer Machined Ceramic Inlays: In Vitro Marginal Adaptation,” J. Dent. Res. Special Issue, Abstract 305, vol. 64, p. 208 (1985).;;Brook et al., “An Image Analysis System for the Determination of Tooth Dimensions from Study Casts: Comparison with Manual Measurements of Mesio-distal Diameter,” J. Dent. Res., 65(3):428-431 (Mar. 1986).;;Burstone et al., Precision Adjustment of the Transpalatal Lingual Arch: Computer Arch Form in Predetermination, Am, Journal of Orthodontics, vol. 79, No. 2 (Feb. 1981), pp. 115-133.;;Burstone (interview), “Dr. Charles J. Burstone on the Uses of the Computer in Orthodontic Practice (Part 1),” J. Clin. Orthod., 13(7):442-453 (Jul. 1979).;;Burstone (interview), “Dr. Charles J. Burstone on the Uses of the Computer in Orthodontic Practice (Part 2),” J. Clin. Orthod., 13(8):539-551 (Aug. 1979).;;Cardinal Industrial Finishes, Powder Coatings information posted at<http://www.cardinalpaint.com> on Aug. 25, 2000, 2 pages.;;Carnaghan, “An Alternative to Holograms for the Portrayal of Human Teeth,” 4th Int'l. Conf. on Holographic Systems, Components and Applications, Sep. 15, 1993, pp. 228-231.;;Chaconas et al., “The DigiGraph Work Station, Part 1, Basic Concepts,” JCO, pp. 360-367 (Jun. 1990).;;Chafetz et al., “Subsidence of the Femoral Prosthesis, A Stereophotogrammetric Evaluation,” Clin. Orthop. Relat. Res., No. 201, pp. 60-67 (Dec. 1985).;;Chiappone, (1980). Constructing the Gnathologic Setup and Positioner, J. Clin. Orthod, vol. 14, pp. 121-133.;;Co-pending U.S. Appl. No. 15/051,364, filed Feb. 23, 2016.;;Cottingham, (1969). Gnathologic Clear Plastic Positioner, Am. J. Orthod, vol. 55, pp. 23-31.;;Crawford, “CAD/CAM in the Dental Office: Does It Work?”, Canadian Dental Journal, vol. 57, No. 2, pp. 121-123 (Feb. 1991).;;Crawford, “Computers in Dentistry: Part 1 CAD/CAM: The Computer Moves Chairside, Part 2 F. Duret—A Man with a Vision, Part 3 The Computer Gives New Vision—Literally, Part 4 Bytes 'N Bites—The Computer Moves from the Front Desk to the Operatory,” Canadian Dental Journal, vol. 54 (9), pp. 661-666 (1988).;;Crooks, “CAD/CAM Comes to USC,” USC Dentistry, pp. 14-17 (Spring 1990).;;Cureton, Correcting Malaligned Mandibular Incisors with Removable Retainers, J. Clin. Orthod, vol. 30, No. 7 (1996) pp. 390-395.;;Curry et al., “Integrated Three-Dimensional Craniofacial Mapping at the Craniofacial Research Instrumentation Laboratory/University of the Pacific,” Semin. Orthod., 7(4):258-265 (Dec. 2001).;;Cutting et a/., “Three-Dimensional Computer-Assisted Design of Craniofacial Surgical Procedures: Optimization and Interaction with Cephalometric and CT-Based Models,” Plast. 77(6):877-885 (Jun. 1986).;;DCS Dental AG, “The CAD/CAM ‘DCS Titan System’ for Production of Crowns/Bridges,” DSC Production AG, pp. 1-7 (Jan. 1992.;;Definition for gingiva. Dictionary.com p. 1-3. Retrieved from the internet Nov. 5, 2004<http://reference.com/search/search?q=gingiva>.;;Defranco et al., “Three-Dimensional Large Displacement Analysis of Orthodontic Appliances,” J. Biomechanics, 9:793-801 (1976).;;Dental Institute University of Zurich Switzerland, Program for International Symposium JD on Computer Restorations: State of the Art of the CEREC-Method, May 1991, 2 pages total.;;Dentrac Corporation, Dentrac document, pp. 4-13 (1992).;;Dent-X posted on Sep. 24, 1998 at< http://www.dent-x.com/DentSim.htm>, 6 pages.;;Doyle, “Digital Dentistry,” Computer Graphics World, pp. 50-52, 54 (Oct. 2000).;;DuraClearTM product information, Allesee Orthodontic Appliances-Pro Lab, 1 page (1997).;;Duret et al., “CAD/CAM Imaging in Dentistry,” Curr. Opin. Dent., 1:150-154 (1991).;;Duret et al, “CAD-CAM in Dentistry,” J. Am. Dent. Assoc. 117:715-720 (Nov. 1988).;;Duret, “The Dental CAD/CAM, General Description of the Project,” Hennson International Product Brochure, 18 pages total, Jan. 1986.;;Duret,“Vers Une Prosthese Informatisee,” (English translation attached), Tonus, vol. 75, pp. 55-57 (Nov. 15, 1985).;;Economides, “The Microcomputer in the Orthodontic Office,” JCO, pp. 767-772 (Nov. 1979).;;Elsasser, Some Observations on the History and Uses of the Kesling Positioner, Am. J. Orthod. (1950) 36:368-374.;;English translation of Japanese Laid-Open Publication No. 63-11148 to inventor T. Ozukuri (Laid-Open on Jan. 18, 1998) pp. 1-7.;;Felton et al., “A Computerized Analysis of the Shape and Stability of Mandibular Arch Form,” Am. J. Orthod. Dentofacial Orthop., 92(6):478-483 (Dec. 1987).;;Friede et al., “Accuracy of Cephalometric Prediction in Orthognathic Surgery,” Abstract of Papers, J. Dent. Res., 70:754-760 (1987).;;Futterling et a/., “Automated Finite Element Modeling of a Human Mandible with Dental Implants,” JS WSCG '98—Conference Program, retrieved from the Internet:<http://wscg.zcu.cz/wscg98/papers98/Strasser 98.pdf>, 8 pages.;;Gao et al., “3-D element Generation for Multi-Connected Complex Dental and Mandibular Structure,” Proc. Intl Workshop on Medical Imaging and Augmented Reality, pp. 267-271 (Jun. 12, 2001).;;Gim-Alldent Deutschland, “Das DUX System: Die Technik,” 2 pages total (2002).;;Gottleib et al., “JCO Interviews Dr. James A. McNamura, Jr., on the Frankel Appliance: Part 2: Clinical 1-1 Management,” J. Clin. Orthod., 16(6):390-407 (Jun. 1982).;;Grayson, “New Methods for Three Dimensional Analysis of Craniofacial Deformity, Symposium: JW Computerized Facial Imaging in Oral and Maxiiofacial Surgery,” AAOMS, 3 pages total, (Sep. 13, 1990).;;Guess et al., “Computer Treatment Estimates in Orthodontics and Orthognathic Surgery,” JCO, pp. 262-28 (Apr. 1989).;;Heaven et a/., “Computer-Based Image Analysis of Artificial Root Surface Caries,” Abstracts of Papers, J. Dent. Res., 70:528 (Apr. 17-21, 1991).;;Highbeam Research, “Simulating Stress Put on Jaw,” Tooling & Production [online], Nov. 1996, n pp. 1-2, retrieved from the Internet on Nov. 5, 2004, URL http://static.highbeam.com/t/toolingampproduction/november011996/simulatingstressputonfa . . . >.;;Hikage, “Integrated Orthodontic Management System for Virtual Three-Dimensional Computer Graphic Simulation and Optical Video Image Database for Diagnosis and Treatment Planning”, Journal of Japan KA Orthodontic Society, Feb. 1987, English translation, pp. 1-38, Japanese version, 46(2), pp. 248-269 (60 pages total).;;Hoffmann, et al., “Role of Cephalometry for Planning of Jaw Orthopedics and Jaw Surgery Procedures,” (Article Summary in English, article in German), Informatbnen, pp. 375-396 (Mar. 1991).;;Hojjatie et al., “Three-Dimensional Finite Element Analysis of Glass-Ceramic Dental Crowns,” J. Biomech., 23(11):1157-1166 (1990).;;Huckins, “CAD-CAM Generated Mandibular Model Prototype from MRI Data,” AAOMS, p. 96 (1999).;;Important Tip About Wearing the Red White & Blue Active Clear Retainer System, Allesee Orthodontic Appliances-Pro Lab, 1 page 1998).;;JCO Interviews, Craig Andreiko , DDS, MS on the Elan and Orthos Systems, JCO, pp. 459-468 (Aug. 1994).;;JCO Interviews, Dr. Homer W. Phillips on Computers in Orthodontic Practice, Part 2, JCO. 1997; 1983:819-831.;;Jerrold, “The Problem, Electronic Data Transmission and the Law,” AJO-DO, pp. 478-479 (Apr. 1988).;;Jones et al., “An Assessment of the Fit of a Parabolic Curve to Pre- and Post-Treatment Dental Arches,” Br. J. Orthod., 16:85-93 (1989).;;JP Faber et al., “Computerized Interactive Orthodontic Treatment Planning,” Am. J. Orthod., 73(1):36-46 (Jan. 1978).;;Kamada et.al., Case Reports on Tooth Positioners Using LTV Vinyl Silicone Rubber, J. Nihon University School of Dentistry (1984) 26(1): 11-29.;;Kamada et.al., Construction of Tooth Positioners with LTV Vinyl Silicone Rubber and Some Case KJ Reports, J. Nihon University School of Dentistry (1982) 24(1):1-27.;;Kanazawa et al., “Three-Dimensional Measurements of the Occlusal Surfaces of Upper Molars in a Dutch Population,” J. Dent Res., 63(11):1298-1301 (Nov. 1984).;;Kesling, Coordinating the Predetermined Pattern and Tooth Positioner with Conventional Treatment, KN Am. J. Orthod. Oral Surg. (1946) 32:285-293.;;Kesling et al., The Philosophy of the Tooth Positioning Appliance, American Journal of Orthodontics and Oral surgery. 1945; 31:297-304.;;Kleeman et al., The Speed Positioner, J. Clin. Orthod. (1996) 30:673-680.;;Kochanek, “Interpolating Splines with Local Tension, Continuity and Bias Control,” Computer Graphics, ri 18(3):33-41 (Jul. 1984). KM Oral Surgery (1945) 31 :297-30.;;Kunii et al., “Articulation Simulation for an Intelligent Dental Care System,” Displays 15:181-188 (1994).;;Kuroda et al., Three-Dimensional Dental Cast Analyzing System Using Laser Scanning, Am. J. Orthod. Dentofac. Orthop. (1996) 110:365-369.;;Laurendeau, et al., “A Computer-Vision Technique for the Acquisition and Processing of 3-D Profiles of 7 KR Dental Imprints: An Application in Orthodontics,” IEEE Transactions on Medical Imaging, 10(3):453-461 (Sep. 1991.;;Leinfelder, et al., “A New Method for Generating Ceramic Restorations: a CAD-CAM System,” J. Am. 1-1 Dent. Assoc., 118(6):703-707 (Jun. 1989).;;Manetti, et al., “Computer-Aided Cefalometry and New Mechanics in Orthodontics,” (Article Summary in English, article in German), Fortschr Kieferorthop. 44, 370-376 (Nr. 5), 1983.;;McCann, “Inside the ADA,” J. Amer. Dent. Assoc., 118:286-294 (Mar. 1989).;;McNamara et al., “Invisible Retainers,” J. Cfin. Orthod., pp. 570-578 (Aug. 1985).;;McNamara et al., Orthodontic and Orthopedic Treatment in the Mixed Dentition, Needham Press, pp. 347-353 (Jan. 1993).;;Moermann et al., “Computer Machined Adhesive Porcelain Inlays: Margin Adaptation after Fatigue Stress,” IADR Abstract 339, J. Dent. Res., 66(a):763 (1987).;;Moles, “Correcting Mild Malalignments—As Easy As One, Two, Three,” AOA/Pro Corner, vol. 11, No. 1, 2 pages (2002).;;Mormann et al., “Marginale Adaptation von adhasuven Porzellaninlays in vitro,” Separatdruck aus: Schweiz. Mschr. Zahnmed. 95: 1118-1129, 1985.;;Nahoum, “The Vacuum Formed Dental Contour Appliance,” N. Y. State Dent. J., 30(9):385-390 (Nov. 1964).;;Nash, “CEREC CAD/CAM Inlays: Aesthetics and Durability in a Single Appointment,” Dent. Today, 9(8):20, 22-23 (Oct. 1990).;;Nishiyama et al., “A New Construction of Tooth Repositioner by LTV Vinyl Silicone Rubber,” J. Nihon Univ. Sch. Dent., 19(2):93-102 (1977).;;Paul et al., “Digital Documentation of Individual Human Jaw and Tooth Forms for Applications in Orthodontics, Oral Surgery and Forensic Medicine” Proc. of the 24th Annual Conf. of the IEEE Industrial Electronics Society (IECON '98), Sep. 4, 1998, pp. 2415-2418.;;Pinkham, “Foolish Concept Propels Technology,” Dentist, 3 pages total, Jan./Feb. 1989.;;Pinkham, “Inventors CAD/CAM May Transform Dentistry,” Dentist, 3 pages total, Sep. 1990.;;Ponitz, “Invisible Retainers,” Am. J. Orthod., 59(3):266-272 (Mar. 1971).;;PROCERA Research Projects, “PROCERA Research Projects 1993—Abstract Collection,” pp. 3-7; 28 (1993).;;Proffit et al., Contemporary Orthodontics, (Second Ed.), Chapter 15, Mosby Inc., pp. 470-533 (Oct. 1993.;;Raintree Essix & ARS Materials, Inc., Raintree Essix, Technical Magazine Table of contents and Essix Appliances,< http:// www.essix.com/magazine/defaulthtml> Aug. 13, 1997.;;Redmond et al., “Clinical Implications of Digital Orthodontics,” Am. J. Orthod. Dentofacial Orthop., 117(2):240-242 (2000).;;Rekow, “A Review of the Developments in Dental CAD/CAM Systems,” (contains references to Japanese efforts and content of the papers of particular interest to the clinician are indicated with a one line summary of their content in the bibliography), Curr. Opin. Dent., 2:25-33 (Jun. 1992).;;Rekow, “CAD/CAM in Dentistry: A Historical Perspective and View of the Future,” J. Can. Dent. Assoc., 58(4):283, 287-288 (Apr. 1992).;;Rekow, “Computer-Aided Design and Manufacturing in Dentistry: A Review of the State of the Art,” J. Prosthet. Dent., 58(4):512-516 (Oct. 1987).;;Rekow, “Dental CAD-CAM Systems: What is the State of the Art'?”, J. Amer. Dent. Assoc., 122:43-48 1991.;;Rekow et al., “CAD/CAM for Dental Restorations—Some of the Curious Challenges,” IEEE Trans. Biomed. Eng., 38(4):314-318 (Apr. 1991).;;Rekow et al., “Comparison of Three Data Acquisition Techniques for 3-D Tooth Surface Mapping,” Annual International Conference of the IEEE Engineering in Medicine and Biology Society, 13(1):344-345 1991.;;Rekow, “Feasibility of an Automated System for Production of Dental Restorations, Ph.D. Thesis,” Univ. of Minnesota, 244 pages total, Nov. 1988.;;Richmond et al., “The Development of a 3D Cast Analysis System,” Br. J. Orthod., 13(1):53-54 (Jan. 1986).;;Richmond et al., “The Development of the PAR Index (Peer Assessment Rating): Reliability and Validity,” Eur. J. Orthod., 14:125-139 (1992).;;Richmond, “Recording The Dental Cast in Three Dimensions,” Am. J. Orthod. Dentofacial Orthop., 92(3):199-206 (Sep. 1987).;;Rudge, “Dental Arch Analysis: Arch Form, A Review of the Literature,” Eur. J. Orthod., 3(4):279-284 1981.;;Sakuda et al., “Integrated Information-Processing System in Clinical Orthodontics: An Approach with Use of a Computer Network System,” Am. J. Orthod. Dentofacial Orthop., 101(3): 210-220 (Mar. 1992).;;Schellhas et al., “Three-Dimensional Computed Tomography in Maxillofacial Surgical Planning,” Arch. Otolamp!. Head Neck Sur9., 114:438-442 (Apr. 1988).;;Schroeder et al., Eds. The Visual Toolkit, Prentice Hall PTR, New Jersey (1998) Chapters 6, 8 & 9, (pp. 153-210,309-354, and 355-428, respectively.;;Shilliday, (1971). Minimizing finishing problems with the mini-positioner, Am. J. Orthod. 59:596-599.;;Siemens, “CEREC—Computer-Reconstruction,” High Tech in der Zahnmedizin, 14 pages total (2004).;;Sinclair, “The Readers' Corner,” J. Clin. Orthod., 26(6):369-372 (Jun. 1992).;;Sirona Dental Systems GmbH, CEREC 3D, Manuel utiiisateur, Version 2.0X (in French), 2003,114 pages total.;;Stoll et al., “Computer-aided Technologies in Dentistry,” (article summary in English, article in German), Dtsch Zahna'rztl Z 45, pp. 314-322 (1990).;;Sturman, “Interactive Keyframe Animation of 3-D Articulated Models,” Proceedings Graphics Interface '84, May-Jun. 1984, pp. 35-40.;;The Choice Is Clear: Red, White & Blue . . . The Simple, Affordable, No-Braces Treatment, Allesee HI Orthodontic Appliances-Pro Lab product information for doctors. http://ormco.com/aoa/appliancesservices/RWB/doctorhtml>, 5 pages (May 19, 2003).;;The Choice is Clear: Red, White & Blue . . . The Simple, Affordable, No-Braces Treatment, Allesee HJ Orthodontic Appliances-Pro Lab product information for patients,< http://ormco.com/aoa/appliancesservices/RWB/patients.html>, 2 pages (May 19, 2003).;;The Choice Is Clear: Red, White & Blue . . . The Simple, Affordable, No-Braces Treatment, Allesee Orthodontic Appliances-Pro Lab product information, 6 pages (2003).;;The Red, White & Blue Way to Improve Your Smile! Allesee Orthodontic Appliances-Pro Lab product information for patients, 2 pages 1992.;;Truax L., “Truax Clasp-Less(TM) Appliance System,” Funct. Orthod., 9(5):22-4, 26-8 (Sep.-Oct. 1992).;;Tru-Tain Orthodontic & Dental Supplies, Product Brochure, Rochester, Minnesota 55902, 16 pages total (1996).;;U.S. Department of Commerce, National Technical Information Service, “Automated Crown Replication Using Solid Photography SM,” Solid Photography Inc., Melville NY, Oct. 1977, 20 pages total.;;U.S. Department of Commerce, National Technical Information Service, “Holodontography: An Introduction to Dental Laser Holography,” School of Aerospace Medicine Brooks AFB Tex, Mar. 1973, 37 pages total.;;U.S. Appl. No. 60/050342, filed Jun. 20,1997, 41 pages total.;;Van Der Linden, “A New Method to Determine Tooth Positions and Dental Arch Dimensions,” J. Dent. Res., 51(4):1104 (Jul.-Aug. 1972).;;Van Der Linden et al., “Three-Dimensional Analysis of Dental Casts by Means of the Optocom,” J. Dent. Res., p. 1100 (Jul.-Aug. 1972).;;Van Der Zel, “Ceramic-Fused-to-Metal Restorations with a New CAD/CAM System,” Quintessence Int., 24(11):769-778 (1993.;;Varady et al., “Reverse Engineering of Geometric Models—An Introduction,” Computer-Aided Design, 29(4):255-268,1997.;;Verstreken et al., “An Image-Guided Planning System for Endosseous Oral Implants,” IEEE Trans. Med. Imaging, 17(5):842-852 (Oct. 1998).;;Warunek et al., Physical and Mechanical Properties of Elastomers in Orthodonic Positioners, Am J. Orthod. Dentofac. Orthop, vol. 95, No. 5, (May 1989) pp. 399-400.;;Warunek et.al., Clinical Use of Silicone Elastomer Applicances, JCO (1989) XXIII(10):694-700.;;Wells, Application of the Positioner Appliance in Orthodontic Treatment, Am. J. Orthodont. (1970) 58:351-366.;;Williams, “Dentistry and CAD/CAM: Another French Revolution,” J. Dent. Practice Admin., pp. 2-5 (Jan./Mar. 1987).;;Williams, “The Switzerland and Minnesota Developments in CAD/CAM,” J. Dent. Practice Admin., pp. 50-55 (Apr./Jun. 1987.;;Wishan, “New Advances in Personal Computer Applications for Cephalometric Analysis, Growth Prediction, Surgical Treatment Planning and Imaging Processing,” Symposium: Computerized Facial Imaging in Oral and Maxilofacial Surgery Presented on Sep. 13, 1990.;;WSCG'98—Conference Program, “The Sixth International Conference in Central Europe on Computer Graphics and Visualization '98,” Feb. 9-13, 1998, pp. 1-7, retrieved from the Internet on Nov. 5, 2004, URL<http://wscg.zcu.cz/wscg98/wscg98.h>.;;Xia et al., “Three-Dimensional Virtual-Reality Surgical Planning and Soft-Tissue Prediction for Orthognathic Surgery,” IEEE Trans. Inf. Technol. Biomed., 5(2):97-107 (Jun. 2001).;;Yamamoto et al., “Optical Measurement of Dental Cast Profile and Application to Analysis of Three-Dimensional Tooth Movement in Orthodontics,” Front. Med. Biol. Eng., 1(2):119-130 (1988).;;Yamamoto et al., “Three-Dimensional Measurement of Dental Cast Profiles and Its Applications to Orthodontics,” Conf. Proc. IEEE Eng. Med. Biol. Soc., 12(5):2051-2053 (1990).;;Yamany et al., “A System for Human Jaw Modeling Using Intra-Oral Images,” Proc. of the 20th Annual Conf. of the IEEE Engineering in Medicine and Biology Society, Nov. 1, 1998, vol. 2, pp. 563-566.;;Yoshii, “Research on a New Orthodontic Appliance: The Dynamic Positioner (D.P.); I. The D.P. Concept and Implementation of Transparent Silicone Resin (Orthocon),” Nippon Dental Review, 452:61-74 (Jun. 1980).;;Yoshii, “Research on a New Orthodontic Appliance: The Dynamic Positioner (D.P.); II. The D.P. Manufacturing Procedure and Clinical Applications,” Nippon Dental Review, 454:107-130 (Aug. 1980).;;Yoshii, “Research on a New Orthodontic Appliance: The Dynamic Positioner (D.P.); III. The General Concept of the D.P. Method and Its Therapeutic Effect, Part 1, Dental and Functional Reversed Occlusion Case Reports,” Nippon Dental Review, 457:146-164 (Nov. 1980).;;Yoshii, “Research on a New Orthodontic Appliance: The Dynamic Positioner (D.P.); III.—The General Concept of the D.P. Method and Its Therapeutic Effect, Part 2. Skeletal Reversed Occlusion Case Reports,” Nippon Dental Review, 458:112-129 (Dec. 1980).;;You May Be a Candidate for This Invisible No-Braces Treatment, Allesee Orthodontic Appliances-Pro Lab product information for patients, 2 pages (2002).;;International search report with written opinion dated Dec. 5, 2017 for PCT/US2017/048275.",ACTIVE
173,TW,A,TW 200505279 A,003-718-816-422-719,2005-02-01,2005,TW 92120288 A,2003-07-24,TW 92120288 A,2003-07-24,Organic light emitting diode containing a novel ir complex as a phosphorescent emitter,"This invention relates to an organic light emitting diode containing a novel Ir complex as a phosphorescent emitter. The invented phosphorescent Ir complex has the following structure (I) or (II), in which X is any monoanionic bidentate ligand, Z is any atom group forming the nitrogen containing heterocyclic group, R1 is a substituent on the nitrogen containing heterocyclic group, m is 0 or a positive integer, R2 and R3 are independently H, halogen, C1-C6 alkyl group, halogen substituted C1-C6 alkyl group, C1-C6 alkoxy group, phenyl C1-C6 alkyl group, amino group, aryl group and hetero nuclei aromatic substituent.",CHENG CHIEN-HONG,CHENG CHIEN-HONG;;DUAN JIUN-PEY;;RAYABARAPU DINESH KUMAR;;JENNIFER BETTY MARIE S P,,https://lens.org/003-718-816-422-719,Patent of Addition,no,0,0,8,8,0,C09K11/06;;C09K2211/1029;;C09K2211/185;;H05B33/14;;Y10S428/917;;C09K11/06;;C09K11/06;;C09K2211/1029;;C09K2211/185;;H05B33/14;;Y10S428/917,H01L51/50;;C09K11/06;;H05B33/14;;H05B33/20;;H05B33/22,,0,0,,,,EXPIRED
174,JP,A,JP 2005044802 A,009-421-663-968-905,2005-02-17,2005,JP 2004211837 A,2004-07-20,TW 92120288 A,2003-07-24,ORGANIC LIGHT EMITTING DIODE,"<P>PROBLEM TO BE SOLVED: To provide an organic light emitting diode having high intensity, high external quantum efficiency, high current efficiency and excellent CIE coordinates. <P>SOLUTION: This organic light emitting diode comprises an anode + on a base material 100, an electroluminescent medium 400 on the anode(+), and a cathode(-) on the electroluminescent medium 400. The electroluminescent medium 400 comprises a luminous layer 30 containing a phosphorescent Ir complex. The luminous layer 30 contains a host compound and the Ir complex is doped in the host compound. A positive-hole transport layer 20 is between the anode(+) and the luminous layer 30. A hole injection modification layer 10 is between the anode(+) and the positive-hole transport layer 20. A hole-inhibiting layer 40 is between a cathode(-) and the luminous layer 30, and the hole-inhibiting layer 40 contacts with the luminous layer 30. An electron transport layer 50 is between the hole-inhibiting layer 40 and the cathode(-). <P>COPYRIGHT: (C)2005,JPO&NCIPI",CHIEN HON SHEN,CHIEN HONG CHENG;;JIUN PEY DUAN;;DINESH KUMAR RAYABARAPU;;BETTY MARIE JENNIFER S P,,https://lens.org/009-421-663-968-905,Patent Application,no,2,18,8,8,0,C09K11/06;;C09K2211/1029;;C09K2211/185;;H05B33/14;;Y10S428/917;;C09K11/06;;C09K11/06;;C09K2211/1029;;C09K2211/185;;H05B33/14;;Y10S428/917,H01L51/50;;C09K11/06;;H05B33/14;;H05B33/20;;H05B33/22,,0,0,,,,ACTIVE
175,US,A1,US 2005/0227109 A1,190-426-068-833-42X,2005-10-13,2005,US 82264704 A,2004-04-13,TW 92120288 A,2003-07-24,Organic light emitting diode containing a novel Ir complex as a phosphorescent emitter,"A phosphorescent Ir complex having the following structures (I) or (II) is used as an emitter in an organic light emitting diode (OLED): wherein X is an arbitrary monoanionic bidentate ligand; Z is an arbitrary moiety constituting a nitrogen-containing heterocyclic group; R 1 is a substituent on the nitrogen-containing heterocyclic group; m is 0 or a positive integer; R 2 and R 3 independently are H, halogen, C1-C6 alkyl, a halogen-substituted C1-C6 alkyl, C1-C6 alkoxy, phenyl C1-C6 alkyl, amino, aryl, heterocyclic aryl substituent.",CHIEN HONG CHENG,CHENG CHIEN-HONG;;DUAN JIUN-PEY;;RAYABARAPU DINESH K;;JENNIFER S P BETTY M,SAMSUNG DISPLAY CO. LTD (2020-09-23);;CHENG CHIEN-HONG (2004-03-31);;CARLYLE TECHNOLOGY INNOVATION LLC (2014-02-26);;KAITUOZHE INTELLECTUAL PROPERTY MANAGEMENT CONSULTANTS LIMITED (2013-10-02);;NATIONAL TSING HUA UNIVERSITY (2006-11-20),https://lens.org/190-426-068-833-42X,Patent Application,yes,10,16,8,8,0,C09K11/06;;C09K2211/1029;;C09K2211/185;;H05B33/14;;Y10S428/917;;C09K11/06;;C09K11/06;;C09K2211/1029;;C09K2211/185;;H05B33/14;;Y10S428/917,C09K11/06;;H01L51/50;;H05B33/14;;H05B33/20;;H05B33/22,428/690;;428/917;;313/504;;313/506;;257/102,0,0,,,,ACTIVE
176,US,A1,US 2023/0144519 A1,003-129-868-954-148,2023-05-11,2023,US 202217965514 A,2022-10-13,US 202217965514 A;;US 201916576707 A;;US 201715684775 A;;US 201662379199 P,2016-08-24,METHOD TO VISUALIZE AND MANUFACTURE ALIGNER BY MODIFYING TOOTH POSITION,Orthodontic systems and related methods are disclosed for designing and providing improved or more effective tooth moving systems for eliciting a desired tooth movement and/or repositioning teeth into a desired arrangement. Methods and orthodontic systems include the generation of an overcorrection in the tooth-receiving cavities of an appliance worn in the dentition. The overcorrection may provide an improved and more accurately applied force or moment applied to a tooth. The overcorrected force or moment can move a tooth closer to a desired position than if not overcorrected as sufficient force can still applied to the tooth as it gets closer to the desired position. The overcorrected force or moment may also better target the root of the tooth where the biological response to tooth movement occurs. The overcorrection may be calculated in various ways as described herein.,ALIGN TECHNOLOGY INC,MATOV VADIM;;WU FUMING;;CHENG JIHUA;;CHEN JENNIFER;;LI CHUNHUA;;PESENTI BASTIEN;;KVASOV IGOR,ALIGN TECHNOLOGY INC (2017-09-08),https://lens.org/003-129-868-954-148,Patent Application,yes,0,0,13,13,0,A61C7/002;;A61C7/08;;B33Y80/00;;G16H20/40;;G16H50/50;;G06F30/00;;A61C7/002;;A61C7/08,A61C7/08;;A61C7/00,,0,0,,,,PENDING
177,EP,A1,EP 3503837 A1,118-326-194-250-322,2019-07-03,2019,EP 17844369 A,2017-08-23,US 201662379199 P;;US 2017/0048275 W,2016-08-24,METHOD TO VISUALIZE AND MANUFACTURE ALIGNER BY MODIFYING TOOTH POSITION,,ALIGN TECHNOLOGY INC,KVASOV IGOR;;MATOV VADIM;;WU FUMING;;CHENG JIHUA;;CHEN JENNIFER;;LI CHUNHUA;;PESENTI BASTIEN,,https://lens.org/118-326-194-250-322,Patent Application,yes,0,0,13,13,0,A61C7/002;;A61C7/08;;B33Y80/00;;G16H20/40;;G16H50/50;;G06F30/00;;A61C7/002;;A61C7/08,A61C7/00;;A61C7/08,,0,0,,,,ACTIVE
178,EP,B1,EP 3503837 B1,055-796-636-494-176,2023-06-07,2023,EP 17844369 A,2017-08-23,US 201662379199 P;;US 2017/0048275 W,2016-08-24,METHOD TO VISUALIZE AND MANUFACTURE ALIGNER BY MODIFYING TOOTH POSITION,,ALIGN TECHNOLOGY INC,KVASOV IGOR;;MATOV VADIM;;WU FUMING;;CHENG JIHUA;;CHEN JENNIFER;;LI CHUNHUA;;PESENTI BASTIEN,,https://lens.org/055-796-636-494-176,Granted Patent,yes,7,0,13,13,0,A61C7/002;;A61C7/08;;B33Y80/00;;G16H20/40;;G16H50/50;;G06F30/00;;A61C7/002;;A61C7/08,A61C7/00;;A61C7/08;;B33Y80/00;;G16H50/70,,0,0,,,,ACTIVE
179,US,A1,US 2009/0093663 A1,081-140-098-633-685,2009-04-09,2009,US 97310107 A,2007-10-05,US 97310107 A,2007-10-05,Lightly branched higher olefin oligomerization with surface modified zeolite catalyst,"A substantially surface-deactivated catalyst composition that is stable at least to 300° C. The catalyst includes a zeolite catalyst (e.g., ZSM-22, ZSM-23, or ZSM-57) having active internal Brönsted acid sites and a surface-deactivating amount of a rare earth or yttrium oxide (e.g., chosen from lanthanum oxide or lanthanides oxide). This catalyst is preferably used in a process for producing a higher olefin by oligomerizing a light olefin, wherein the process includes contacting a light olefin under oligomerization conditions with the substantially surface-deactivated catalyst composition.",CHENG JANE C;;MISEO SAL;;SOLED STUART L;;BUCHANAN JOHN S;;FEELEY JENNIFER S,CHENG JANE C;;MISEO SAL;;SOLED STUART L;;BUCHANAN JOHN S;;FEELEY JENNIFER S,EXXONMOBIL RESEARCH AND ENGINEERING COMPANY (2007-12-14),https://lens.org/081-140-098-633-685,Patent Application,yes,9,11,3,3,0,B01J29/7076;;B01J29/7092;;B01J29/7096;;B01J2229/123;;B01J2229/18;;B01J2229/20;;B01J2229/42;;C07C2/12;;C07C2/12;;B01J2229/123;;B01J2229/42;;B01J2229/18;;B01J29/7076;;B01J2229/20;;B01J29/7096;;B01J29/7092,C07C2/12,585/533;;502/73,0,0,,,,INACTIVE
180,US,A1,US 2010/0248944 A1,175-578-685-741-626,2010-09-30,2010,US 79626910 A,2010-06-08,US 79626910 A;;US 97310107 A,2007-10-05,Lightly Branched Higher Olefin Oligomerization with Surface Modified Zeolite Catalyst,"A substantially surface-deactivated catalyst composition that is stable at least to 300° C. The catalyst includes a zeolite catalyst (e.g., ZSM-22, ZSM-23, or ZSM-57) having active internal Brönsted acid sites and a surface-deactivating amount of a rare earth or yttrium oxide (e.g., chosen from lanthanum oxide or lanthanides oxide). This to catalyst is preferably used in a process for producing a higher olefin by oligomerizing a light olefin, wherein the process includes contacting a light olefin under oligomerization conditions with the substantially surface-deactivated catalyst composition.",EXXONMOBIL RES & ENG CO,CHENG JANE C;;MISEO SAL;;SOLED STUART L;;BUCHANAN JOHN S;;FEELEY JENNIFER S,,https://lens.org/175-578-685-741-626,Patent Application,yes,8,16,3,3,0,B01J29/7076;;B01J29/7092;;B01J29/7096;;B01J2229/123;;B01J2229/18;;B01J2229/20;;B01J2229/42;;C07C2/12;;C07C2/12;;B01J2229/123;;B01J2229/42;;B01J2229/18;;B01J29/7076;;B01J2229/20;;B01J29/7096;;B01J29/7092,B01J29/40,502/73,0,0,,,,DISCONTINUED
181,EP,C0,EP 3503837 C0,175-503-240-956-484,2023-06-07,2023,EP 17844369 A,2017-08-23,US 201662379199 P;;US 2017/0048275 W,2016-08-24,METHOD TO VISUALIZE AND MANUFACTURE ALIGNER BY MODIFYING TOOTH POSITION,,ALIGN TECHNOLOGY INC,KVASOV IGOR;;MATOV VADIM;;WU FUMING;;CHENG JIHUA;;CHEN JENNIFER;;LI CHUNHUA;;PESENTI BASTIEN,,https://lens.org/175-503-240-956-484,Unknown,no,0,0,13,13,0,A61C7/002;;A61C7/08;;B33Y80/00;;G16H20/40;;G16H50/50;;G06F30/00;;A61C7/002;;A61C7/08,A61C7/00;;A61C7/08;;B33Y80/00;;G16H50/70,,0,0,,,,ACTIVE
182,US,B1,US 6465007 B1,186-085-596-671-236,2002-10-15,2002,US 34050999 A,1999-07-01,US 34050999 A;;US 9160898 P,1998-07-02,Transgene expression in polarized cells,"
    The well-differentiated airway epithelium is the principal target tissue for gene therapy for the treatment of CF. However, recent studies have shown that gene delivery vehicles, such as cationic lipid:DNA complexes, can be inefficient at binding to and internalizing into polarized epithelial cells. The present invention provides a method to improve gene therapy by using a compound capable of disrupting tight junctions. In the practice of the invention, the transfection of a biologically active molecule by a cationic amphiphile:biologically active molecule complex or other lipid or viral or nonviral vectors is improved by treating the cells with a class of compounds known in the art as absorption enhancers or tight junction disrupting compounds. 
",GENZYME CORP,EASTMAN SIMON J;;CHU QUIMING;;TOUSIGNANT JENNIFER D;;CHENG SENG H;;SCHEULE RONALD K,GENZYME CORPORATION (1999-09-07),https://lens.org/186-085-596-671-236,Granted Patent,yes,13,6,6,6,0,A61K48/0008;;A61K48/0008;;A61K48/00;;A61K48/00;;A61P9/00;;A61P35/00;;A61P43/00,A61K48/00;;A61P9/00;;A61P35/00;;A61P43/00,424/450;;514/2;;514/44;;424/93.1;;424/93.2;;424/93.6;;435/455;;435/456;;435/325;;435/320.1,70,69,046-199-397-456-065;;028-963-750-841-908;;068-610-214-464-341;;059-603-579-320-605;;021-222-283-045-52X;;014-444-265-062-57X;;076-172-108-459-47X;;091-988-167-378-675;;031-168-076-827-391;;028-963-750-841-908;;024-573-617-297-414;;029-915-086-396-649;;015-731-869-750-064;;019-047-328-534-646;;060-431-632-176-68X;;057-231-981-587-132;;086-907-956-743-235;;068-277-195-669-15X;;062-766-650-052-346;;004-176-818-625-686;;056-108-021-687-814;;092-288-888-105-334;;051-219-587-836-508;;032-538-323-945-507;;077-278-673-676-866;;127-204-896-079-356;;054-920-963-725-487;;081-963-712-727-698;;026-079-040-478-067;;110-826-201-110-177;;037-526-874-089-886;;025-810-052-685-139;;014-430-992-456-906;;008-628-603-158-38X;;108-592-158-161-313;;081-418-228-627-704;;069-298-858-710-053;;076-863-111-177-871;;067-456-686-516-681;;089-881-502-781-129;;013-879-907-179-646;;015-369-832-041-513;;019-728-549-929-450;;012-990-935-470-093;;038-273-932-298-824;;019-074-113-685-344;;001-387-175-415-351;;074-023-785-110-417;;078-841-236-417-643;;081-054-267-506-492;;018-064-179-452-863;;055-617-411-707-349;;051-156-550-826-634;;030-763-382-009-290;;092-582-680-558-42X;;031-273-647-242-368;;078-556-082-926-732;;039-348-820-469-473;;010-518-795-661-856;;061-635-482-417-88X;;042-472-023-368-561;;048-712-591-299-961;;134-130-791-516-825;;074-449-088-353-200;;040-156-341-807-622;;027-230-932-810-913;;001-001-557-562-58X;;064-744-283-625-493;;007-027-354-249-837,10.3109/10611869808997878;;9769018;;8932437;;10.1023/a:1016078728202;;10.1016/0092-8674(93)90353-r;;7686820;;10.1096/fasebj.4.10.2197151;;2197151;;10.1126/science.8211164;;8211164;;pmc1159463;;10.1111/j.1469-7793.1997.637bm.x;;9218222;;10.1152/ajpcell.1996.270.5.c1326;;8967432;;10.1016/s0092-8674(00)81099-5;;8612275;;1553349;;10.1023/a:1018997625726;;8932437;;10.1023/a:1016078728202;;8773957;;10.1021/js9504604;;7853188;;7920449;;10.1248/bpb.17.753;;10.1089/10430349950019165;;10022528;;1989595;;10.1016/0006-291x(91)90497-u;;10.1165/ajrcmb.16.4.9115758;;9115758;;9374736;;10.1152/ajplung.1997.273.5.l1065;;10.1152/ajplung.1995.268.6.l1021;;7611424;;10.1016/s0021-9258(18)53749-2;;8094083;;10.1016/0010-4825(92)90066-v;;1643850;;10.1023/a:1018909210879;;8321854;;10.1016/0378-1119(88)90219-3;;3417148;;10.1023/a:1018906504944;;8378262;;10.1038/nm0195-39;;7584951;;8548549;;9349430;;10.1038/sj.gt.3300481;;3924406;;10.1111/j.1365-2184.1985.tb00669.x;;10.1046/j.1365-2958.1997.5381914.x;;9383187;;10.1152/ajprenal.1998.274.1.f1;;9458817;;10.1152/ajpcell.1995.269.2.c487;;7653531;;9425440;;10.1038/sj.gt.3300524;;7631813;;10.1152/ajplung.1995.269.1.l45;;pmc299306;;10.1073/pnas.84.21.7413;;2823261;;10.1038/sj.gt.3300391;;9135733;;10.1002/jez.1402320216;;6438270;;8534481;;10.1165/ajrcmb.14.1.8534481;;10.1016/0009-3084(94)90066-3;;8076400;;10.1083/jcb.123.6.1631;;pmc2290864;;8276885;;10.1021/bi00014a042;;7718591;;2661561;;10.1083/jcb.108.6.2183;;pmc2115588;;10.1007/bf02634283;;7633672;;3514924;;10.1016/s0022-2828(86)80468-0;;10.1016/s0021-9258(18)82130-5;;8388390;;8886841;;10.1089/hum.1996.7.14-1701;;2317491;;10.1016/0005-2736(90)90017-i;;8995411;;10.1074/jbc.272.2.1117;;10.1016/0955-0674(94)90075-2;;7986532;;10.1016/0005-2736(93)90159-w;;8499468;;10.1016/0014-5793(93)80257-u;;8365482;;8517795;;10.1007/bf01309672;;10.1038/sj.gt.3300390;;9135734;;8636221;;10.1083/jcb.132.3.451;;pmc2120728;;9034842;;10.1007/bf01007837;;10.1172/jci118020;;7542277;;pmc185188;;1867862;;3931652;;8592005;;10.1002/(sici)1097-4652(199602)166:2<446::aid-jcp23>3.3.co;2-k;;10.1002/(sici)1097-4652(199602)166:2<446::aid-jcp23>3.0.co;2-7;;10.1016/0009-3084(86)90066-6;;3742669;;10.1046/j.1471-4159.1995.64052230.x;;7722508;;7875036;;10.1002/cyto.990170404;;10.1038/scientificamerican1295-52;;8525348;;1403789;;10.1002/jps.2600790706;;2118953;;10.1152/ajplung.1993.265.2.l170;;8396338;;9095409;;10.1089/hum.1997.8.5-575;;9294121;;10.1172/jci119676;;pmc508334;;10.1074/jbc.270.32.18997;;7642560;;pmc309219;;8383843;;10.1093/nar/21.4.871;;pmc20356;;10.1073/pnas.94.7.3256;;9096380,"Marttin et al., J. of Drug Targeting 6: 17-36, Efficacy, safety and mechanism of cyclodextrins as absorption enhancers in nasal delivery of peptide and protein drugs, 1998.*;;Freeman, D.J. and Niven, R.W., 1996, Pharmaceutical Research, 13: 202-209.*;;Welsh et al., ""Molecular Mechanisms of CFTR Chloride Channel Dysfunction in Cystic Fibrosis,"" Cell, 73:1251-1254 (1993).;;Quinton, ""Cystic Fibrosis: A disease in Electrolyte Transport"", Faseb J., 4:2709-2717 (1990).;;Jiang et al., ""Altered Fluid Transport Across Airway Epithelium in Cystic Fibrosis,"" Science, 262: 424-427 (1993).;;Jiang et a., ""Fluid Transport Across Cultures of Human Tracheal Glands is Altered in Cystic Fibrosis,"" J. Physiol. (London), 501.3:637-647 (1997).;;Zhang et al., ""In Vivo Analysis of Fluid Transport in Cystic Fibrosis Airway Epithelial of Bronchial Xenografts,"" Am. J. Physiol., 270:C1326-1335 (1996).;;Smith et al., ""Cystic Fibrosis Airway Epithelial Fail to Kill Bacteria Because of Abnormal Airway Surface Fluid,"" Cell, 85:229-236 (1996).;;Adjei et al., ""Bioavailability of Leuprolide Acetate Following Nasal and Inhalation Delivery to Rats and Healthy Humans,"" Pharm. Res., 9:244-249 (1992).;;Freeman & Niven, ""The Influence of Sodium Glycocholate and Other Additives on the in vivo Transfection of Plasmid DNA in the Lungs,"" Pharm. Res., 13:202-209 (1996).;;Tomita et al.,"" Absorption-Enhancing Mechanism of EDTA, Caprate, and Decanoylcarnitine in Caco-2 Cells,"" J. of Pharm. Sciences, 85:608-611 (1996).;;Tomita et al., ""Absorption-Enhancing Sodium Caprate, and Decanoylcarnitine in Caco-2 Cells,"" J. of Pharm. & Exp. Therap., 272:739-743 (1995).;;Tomita et al., ""Comparison of Absorption-Enhancing Effect between Sodium Caprate and Disodium Ethylenediaminetetraacetate in Caco-2 Cells,"" Biol. Pharm. Bull., 17(5):753-755 (1994).;;Chu, Q., et al., ""Binding and uptake of cationic lipid:pDNA complexes by polarized airway epithelial cells,"" Hum. Gene Ther. 10, 25-36. (1999).;;Arimura et al., ""Isolation and Indentification of C-type Natriuretic Peptide in Chicken Brain,"" Biochem. Biphys. Res. Commun., 174: 142-148 (1991).;;Kelly et al., ""C-type Natriuretic Peptide Increases Chloride Permeability in Normal and Cystic Fibrosis Airway Cells"", Am. J. Respir. Cell Mol. Biol., 16:464-470 (1997).;;Kelly et al., ""In Vivo Activation of CFTR-Dependent Chloride Transport in Murine Airway Epithelium by CNP"", Am J. Physiol., 36:L1065-L1072 (1995).;;Geary et al., ""Role of CNP in Huyman Airways: CGMP-mediated Stimulation of Ciliary Beat Frequency"", Am. J. Physiol., 268:L1021-L1028 (1995).;;Chrisman et al., ""Seminal Plasma Factors that Cause Large Elevations in Cellular Cyclic CMP are C-type Natriuretic Peptides,"" J. Bio. Chem., 268:3698-3703 (1993).;;Abed, S.Y. et al., ""Cell cycle kinetics analysis of HeLa cells exposed to aphidicolin: computer simulation,"" Computers in Biology & Medicine. 22:269-275 (1992).;;Anderberg et al., ""Sodium Caprate Elicits Dilatationsin Human Intestinal Tight Junctions and Enhances Drug Absorption by the Paracellular Route,"" Pharmaceutical Research. 10:857-864 (1993).;;Berger, J. et al., ""Secreted placental alkaline phosphatase: a powerful new quantitative indicator of gene expression in eukaryotic cells,"" Gene. 66:1-11 (1988).;;Bhat, M. et al., ""Regulation of tight junction permeability by calcium mediators and cell cytoskeleton in rabbit tracheal epithelium,"" Pharmaceutical Research. 10:991-997 (1993).;;Caplen, N.J.et al., ""Liposomemediated CFTR gene transfer to the nasal epithelium of patients with cystic fibrosis,"" Nature Medicine. 1:39-46. (1995).;;Caplen, N.J.et al., ""In vitro liposome-mediated DNA transfection of epithelial cell lines using the cationic liposome DC-Chol/DOPE,"" Gene Therapy. 2:603-613 (1995).;;Chadwick, S.L. et al., ""Safety of a single aerosol administration of escalating doses of the cationic lipid GL-67/ DOPE/ DMPE-PEG5000 formulation to the lungs of normal volunteers,"" Gene Therapy. 4:937-942 (1997).;;Chou, R.H. et al., ""Combined effects of aphidicolin and retinoic acid on proliferation and differentiation of human leukaemic (HL-60) cells,"" Cell & Tissue Kinetics. 18:387-97 (1985).;;Cornelissen, C.N. et al., ""Energy-dependent changes in the gonococcal transferrin receptor,"" Molecular Microbiology. 26:25-35 (1997).;;Denker, B.M. et al., ""Molecular structure and assembly of the tight junction,"" American Journal of Physiology. 43:F1-F9 (1998).;;Du, J. et al., ""Abnormal polarization of EGF receptors and autocrine stimulation of cyst epithelial growth in human ADPKD,"" American Journal of Physiology. 269:C487-C495 (1995).;;Fasbender, A. et al., ""A Low Rate of Cell Proliferation and Reduced Dna Uptake Limit Cationic Lipid-mediated Gene Transfer to Primary Cultures of Ciliated Human Airway Epithelia,"" Gene Therapy. 4:1173-1180 (1997).;;Fasbender et al., ""Optimization of Cationic Lipidmediated Gene Transfer to Airway Epithelia,"" American Journal of Physiology. 269:L45-L51 (1995).;;Felgner, et al., ""Lipofection: a Highly Efficient, Lipid-mediated Dna-transfection Procedure,"" Proceedings of the National Academy of Sciences of the United States of America. 84:7413-7417 (1987).;;Gill, et al., ""A Placebo-controlled Study of Liposome-mediated Gene Transfer to the Nasal Epithelium of Patients with Cystic Fibrosis,"" Gene Therapy. 4:199-209 (1997).;;Goldin, et al., ""The Role of Cell Proliferation and Cellular Shape Change in Branching Morphogenesis of the Embryonic Mouse Lung: Analysis Using Aphidicolin and Cytochalasins,"" Journal of Experimental Zoology. 232:287-296 (1984).;;Gray, et al., ""Mucociliary Differentiation of Serially Passaged Normal Human Tracheobronchial Epithelial Cells,"" American Journal of Respiratory Cell & Molecular Biology. 14:104-112 (1996).;;Grebenkamper, et al., ""Translational Diffusion Measurements of a Fluorescent Phospholipid Between Mdck-i Cells Support the Lipid Model of the Tight Junctions,"" Chemistry & Physics of Lipids. 71:133-143 (1994).;;Gumbiner, B.M., ""Breaking Through the Tight Junction Barrier. Journal of Cell Biology,"" 123:1631-1633 (1993).;;Gutierrez-Merino et al., ""Preferential Distribution of the Fluorescent Phospholipid Probes Nbd-phosphatidylcholine and Rhodamine-phosphatidylethanolamine in the Exofacial Leaflet of Acetylcholine Receptor-rich Membranes from Torpedo Marmorata,"" Biochemistry. 34:4846-4855 (1995).;;Haldar, K. et al., ""Transport of Fluorescent Phospholipid Analogues from the Erytyrocyte Membrane to the Parasite in Plasmodium Falciparum-infected Cells,"" Journal of Cell Biology. 108:2183-2192 (1989).;;Holmen et al., ""Efficient Lipid-mediated Transfection of Dna into Primary Rat Hepatocytes,"" In Vitro Cellular & Developmental Biology. Animal. 31:347-51 (1995).;;Im et al., ""Energy Dependent Insulin Binding, Internalization and Degradation in Isolated,"" Journal of Molecular & Cellular Cardiology. 18:157-168 (1986).;;Keefer et al., ""The alpha 2a-adrenergic Receptor Is Targeted Directly to the Basolateral Membrane Domain of Madin-darby Canine Kidney Cells Independent of Coupling to Pertussis Toxin-sensitive Gtp-binding Proteins,"" Journal of Biological Chemistry. 268:11340-11347 (1993).;;Lee et al., ""Detailed Analysis of Structures and Formulations of Cationic Lipids for Efficient Gene Transfer to the Lung,"" Hum. Gene Ther. 7, 1701-1717 (1996).;;Leventis et al., ""Interactions of Mammalian Cells with Lipid Dispersions Containing Novel Metabolizable Cationic Amphiphiles,"" Biochimica et Biophysica Acta. 1023:124-132 (1990).;;Matsui et al., ""Loss of Binding and Entry of Liposome-dna Complexes Decreases Transfection Efficiency in Differentiated Airway Epithelial Cells,"" Journal of Biological Chemistry. 272:1117-1126 (1997).;;Matter et al., ""Mechanisms of Cell Polarity: Sorting and Transport in Epithelial Cells,"" Current Opinion in Cell Biology. 6:545-554 (1994).;;Mcewan et al., ""Polycation-induced Enhancement of Epithelial Paracellular Permeability Is Independent of Tight Junctional Characteristics,"" Biochimica et Biophysica Acta. 1148:51-60 (1993).;;Moro et al., ""Fluoroscence Quenching at Interfaces and the Permeation of Acrylamide and Iodide Across Phospholipid Bilayers,"" Febs Letters. 330:129-132 (1993).;;Nichols et al., ""Use of Fitc-labeled Influenza Virus and Flow Cytometry to Assess Binding and Internalization of Virus by Monocytesmacrophages and Lymphocytes,"" Arch Virol. 130:441-455 (1992).;;Porteous et al., ""Evidence for Safety and Efficacy of Dotap Cationic Liposome Mediated Cftr Gene Transfer to the Nasal Epithelium of Patients with Cystic Fibrosis,"" Gene Therapy. 4:210-218 (1997).;;Rajasekaran et al., Catenins and Zonula Occludens-1 Form a Complex During Early Stages in the Assembly of Tight Junctions. Journal of Cell Biology. 132:451-463 (1996).;;Rezai et al., ""Comparison of Tight Junction Permeability for Albumin in Iris Pigment Epithelium and Retinal Pigment Epithelium in vitro,"" Graefe's Arch Clin Exp Opthalmol 253:48-55 (1997).;;Remacle-bonnet et al., ""Cell Polarity of the Insulin-like Growth Factor System in Human Intestinal Epithelial Cells,"" Journal of Clinical Investigation. 96:192-200 (1995).;;Rose, J.k. et al., ""A New Cationic Liposome Reagent Mediating Nearly Quantitative Transfection. Of Animal Cells,"" Biotechniques. 10:520-525 (1991).;;Spadari et al., ""Control of Cell Division by Aphidicolin Without Adverse Effects upon Resting Cells,"" Arzneimittel-forschung. 35:1108-1116 (1985).;;Thatte et al., ""ATP Depletion Causes Translational Immobilization of Cell Surface Transferrin Receptors in K562 Cells,"" Journal of Cellular Physiology. 166:446-452 (1996).;;Tilcock, ""Lipid Polymorphism,"" Chemistry and Physics of Lipids. 40:109-125 (1986).;;Trivedi et al., ""Liposome-mediated Gene Transfer into Normal and Dystrophin-deficient Mouse Myoblasts,"" Journal of Neurochemistry. 64:2230-2238 (1995).;;Van Amersfoort et al., ""Evaluation of a Flow Cytometric Fluorescence Quenching Assay of Phagocytosis of Sensitized Sheep Erythrocytes by Polymorphonuclear Leukocytes,"" Cytometry. 17:294-301 (1994).;;Welsh, M.J. and Smith, A.E., ""Cystic Fibrosis,"" Scientific American. 273:52-59 (1995).;;Yamamoto et al., ""A Mechanistic Study on Enhancement of Rectal Permeability to Insulin in the albino Rabbit,"" Journal of Pharmacology & Experimental Therapeutics. 263:25-31 (1992).;;Yamashita et al., ""Effect of Adjuvants of Charge-Selective Permeability and Electrical Resistance of Rat Jejunal Membrane,"" Journal of Pharmaceutical Sciences. 79 (7) (1990).;;Yamaya et al., ""Calciumdependent Chloride Secretion Across Cultures of Human Tracheal Surface Epithelium and Glands,"" American Journal of Physiology. 265:L170-L177 (1993).;;Yew et al., ""Optimization of Plasmid Vectors for High-level Expression in Lung Epithelial Cells,"" Hum. Gene Ther. 8:575-584 (1997).;;Zabner et al., ""Comparison of Dna-lipid Complexes and Dna alone for Gene Transfer to Cystic Fibrosis Airway Epithelia in Vivo,"" Journal of Clinical Investigation. 100:1529-1537 (1997).;;Zabner et al., ""Cellular and Molecular Barriers to Gene Transfer by a Cationic Lipid,"" Journal of Biological Chemistry. 270:18997-19007 (1995).;;Croyle, M.A. et al., ""Beta Cyclodextrins Enhance Gene Delivery to the Intestine,"" Proc. of the Int. Symp. Control. Ret. Bioact. Mater., 24:675-676 (1997).;;Midoux et al., ""Specific Gene Transfer Mediated by Lactosylated POLY-L-Lysine into Hepatoma Cells,""Nucleic Acids Research, GB, Oxford University Press, Surrey, 21, 4: 871-878 (1993).;;Buschle et al., ""Transloading of Tumor Antigen-derived Peptides into Antigen-presenting Cells,"" Proceedings of the National Academy of Sciences USA, 94:3256-3261 (1997).",EXPIRED
183,US,B2,US 7759533 B2,062-036-800-766-244,2010-07-20,2010,US 97310107 A,2007-10-05,US 97310107 A,2007-10-05,Lightly branched higher olefin oligomerization with surface modified zeolite catalyst,"A substantially surface-deactivated catalyst composition that is stable at least to 300° C. The catalyst includes a zeolite catalyst (e.g., ZSM-22, ZSM-23, or ZSM-57) having active internal Brönsted acid sites and a surface-deactivating amount of a rare earth or yttrium oxide (e.g., chosen from lanthanum oxide or lanthanides oxide). This catalyst is preferably used in a process for producing a higher olefin by oligomerizing a light olefin, wherein the process includes contacting a light olefin under oligomerization conditions with the substantially surface-deactivated catalyst composition.",EXXONMOBIL RES & ENG CO,CHENG JANE C;;MISEO SAL;;SOLED STUART L;;BUCHANAN JOHN S;;FEELEY JENNIFER S,EXXONMOBIL RESEARCH AND ENGINEERING COMPANY (2007-12-14),https://lens.org/062-036-800-766-244,Granted Patent,yes,19,8,3,3,0,B01J29/7076;;B01J29/7092;;B01J29/7096;;B01J2229/123;;B01J2229/18;;B01J2229/20;;B01J2229/42;;C07C2/12;;C07C2/12;;B01J2229/123;;B01J2229/42;;B01J2229/18;;B01J29/7076;;B01J2229/20;;B01J29/7096;;B01J29/7092,C07C2/12,585/533;;585/510;;585/514;;585/520;;585/527;;585/532,3,0,,,"R. M. Platz et al., ""Catalytic Polymerization of Diesel Fuel"" Abstract Attached.;;G.N. Amezhnova et al., ""Effect of Rare Earth Cations on Activity of Y Zeolites in Ethylene Conversions""-Abstract Attached.;;O. I., Kuznetsov et al., ""Oligomerization of Isobutylene on Zeolite Catalysts""-Abstract Attached.",INACTIVE
184,US,A1,US 2009/0262650 A1,069-718-029-439-25X,2009-10-22,2009,US 34744408 A,2008-12-31,US 34744408 A;;US 4578008 P,2008-04-17,METHOD AND APPARATUS FOR PROVIDING STATISTICAL EVENT CORRELATION IN A NETWORK,"A method and apparatus for providing event correlation in a network are disclosed. For example, the method extracts a plurality of events of interest from a database, and creates one or more event time series from the plurality of events of interest, wherein each of the one or more event time series comprises a set of events of a same type and of a same location that occur within a given time period. The method forms one or more composite events from the one or more event time series, and performs one or more pair-wise correlations for at least one of: the event time-series, or the one or more composite events. The method then identifies one or more pair-wise correlations that are statistically significant.",SHAIKH AMAN;;EE CHENG;;MAHIMKAR AJAY;;WANG JIA;;YATES JENNIFER;;ZHANG YIN;;GE ZIHUI,SHAIKH AMAN;;EE CHENG;;MAHIMKAR AJAY;;WANG JIA;;YATES JENNIFER;;ZHANG YIN;;GE ZIHUI,AT&T INTELLECTUAL PROPERTY I L.P (2009-04-22),https://lens.org/069-718-029-439-25X,Patent Application,yes,3,30,2,2,0,H04L41/0631;;H04L41/0631,H04L12/26,370/242,0,0,,,,ACTIVE
185,US,S,US D0832709 S,088-108-766-788-418,2018-11-06,2018,US 201729596600 F,2017-03-09,US 201729596600 F;;US 201529525469 F,2015-04-29,Bottle,,PEPSICO INC,CHENG HAI SHUO;;CHOU GLORIA;;FINLAY PATRICK J;;ANTCZAK JENNIFER TE-HSIN;;WANG SUSIE,,https://lens.org/088-108-766-788-418,Design Right,no,59,6,6,6,0,,,0901;;D 9516;;D9/538;;D9/539;;D9/556;;D9/558,1,0,,,"Levin, Felicia, “Unique Bottles” Mar. 28, 2011, Felicia and Her Design Journey Blog, site visited Nov. 18, 2016 <http://feliciaides1122.blogspot.com/2011 /03/unique-bottles.html>.",ACTIVE
186,US,S,US D0784144 S,154-855-130-505-073,2017-04-18,2017,US 201529525469 F,2015-04-29,US 201529525469 F,2015-04-29,Bottle,,PEPSICO INC,CHENG HAI SHUO;;CHOU GLORIA;;FINLAY PATRICK J;;ANTCZAK JENNIFER TE-HSIN;;WANG SUSIE,PEPSICO INC (2015-09-21),https://lens.org/154-855-130-505-073,Design Right,no,0,7,6,6,0,,,0901;;D 9538,0,0,,,,ACTIVE
187,EP,A4,EP 3503837 A4,191-920-395-645-119,2020-03-11,2020,EP 17844369 A,2017-08-23,US 201662379199 P;;US 2017/0048275 W,2016-08-24,METHOD TO VISUALIZE AND MANUFACTURE ALIGNER BY MODIFYING TOOTH POSITION,,ALIGN TECHNOLOGY INC,KVASOV IGOR;;MATOV VADIM;;WU FUMING;;CHENG JIHUA;;CHEN JENNIFER;;LI CHUNHUA;;PESENTI BASTIEN,,https://lens.org/191-920-395-645-119,Search Report,no,2,0,13,13,0,A61C7/002;;A61C7/08;;B33Y80/00;;G16H20/40;;G16H50/50;;G06F30/00;;A61C7/002;;A61C7/08,A61C7/00;;A61C7/08;;B33Y80/00;;G16H50/70,,1,0,,,See also references of WO 2018039383A1,ACTIVE
188,EP,A2,EP 4254429 A2,199-729-135-972-231,2023-10-04,2023,EP 23177363 A,2017-08-23,US 201662379199 P;;EP 17844369 A;;US 2017/0048275 W,2016-08-24,METHOD TO VISUALIZE AND MANUFACTURE ALIGNER BY MODIFYING TOOTH POSITION,Orthodontic systems and related methods are disclosed for designing and providing improved or more effective tooth moving systems for eliciting a desired tooth movement and/or repositioning teeth into a desired arrangement. Methods and orthodontic systems include the generation of an overcorrection in the tooth-receiving cavities of an appliance worn in the dentition. The overcorrection may provide an improved and more accurately applied force or moment applied to a tooth. The overcorrected force or moment can move a tooth closer to a desired position than if not overcorrected as sufficient force can still applied to the tooth as it gets closer to the desired position. The overcorrected force or moment may also better target the root of the tooth where the biological response to tooth movement occurs. The overcorrection may be calculated in various ways as described herein.,ALIGN TECHNOLOGY INC,KVASOV IGOR;;MATOV VADIM;;WU FUMING;;CHENG JIHUA;;CHEN JENNIFER;;LI CHUNHUA;;PESENTI BASTIEN,,https://lens.org/199-729-135-972-231,Patent Application,yes,7,0,13,13,0,A61C7/002;;A61C7/08;;B33Y80/00;;G16H20/40;;G16H50/50;;G06F30/00;;A61C7/002;;A61C7/08,G16H50/70,,0,0,,,,PENDING
189,WO,A1,WO 2018/039383 A1,104-938-322-169-342,2018-03-01,2018,US 2017/0048275 W,2017-08-23,US 201662379199 P,2016-08-24,METHOD TO VISUALIZE AND MANUFACTURE ALIGNER BY MODIFYING TOOTH POSITION,Orthodontic systems and related methods are disclosed for designing and providing improved or more effective tooth moving systems for eliciting a desired tooth movement and/or repositioning teeth into a desired arrangement. Methods and orthodontic systems include the generation of an overcorrection in the tooth-receiving cavities of an appliance worn in the dentition. The overcorrection may provide an improved and more accurately applied force or moment applied to a tooth. The overcorrected force or moment can move a tooth closer to a desired position than if not overcorrected as sufficient force can still applied to the tooth as it gets closer to the desired position. The overcorrected force or moment may also better target the root of the tooth where the biological response to tooth movement occurs. The overcorrection may be calculated in various ways as described herein.,ALIGN TECHNOLOGY INC;;KVASOV IGOR,KVASOV IGOR;;MATOV VADIM;;WU FUMING;;CHENG JIHUA;;CHEN JENNIFER;;LI CHUNHUA;;PESENTI BASTIEN,,https://lens.org/104-938-322-169-342,Patent Application,yes,10,2,13,13,0,A61C7/002;;A61C7/08;;B33Y80/00;;G16H20/40;;G16H50/50;;G06F30/00;;A61C7/002;;A61C7/08,A61C7/00;;A61C7/08,,1,0,,,See also references of EP 3503837A4,PENDING
190,US,A1,US 2020/0197131 A1,132-054-276-604-21X,2020-06-25,2020,US 201916576707 A,2019-09-19,US 201916576707 A;;US 201715684775 A;;US 201662379199 P,2016-08-24,METHOD TO VISUALIZE AND MANUFACTURE ALIGNER BY MODIFYING TOOTH POSITION,Orthodontic systems and related methods are disclosed for designing and providing improved or more effective tooth moving systems for eliciting a desired tooth movement and/or repositioning teeth into a desired arrangement. Methods and orthodontic systems include the generation of an overcorrection in the tooth-receiving cavities of an appliance worn in the dentition. The overcorrection may provide an improved and more accurately applied force or moment applied to a tooth. The overcorrected force or moment can move a tooth closer to a desired position than if not overcorrected as sufficient force can still applied to the tooth as it gets closer to the desired position. The overcorrected force or moment may also better target the root of the tooth where the biological response to tooth movement occurs. The overcorrection may be calculated in various ways as described herein.,ALIGN TECHNOLOGY INC,MATOV VADIM;;WU FUMING;;CHENG JIHUA;;CHEN JENNIFER;;LI CHUNHUA;;PESENTI BASTIEN;;KVASOV IGOR,ALIGN TECHNOLOGY INC (2017-09-08),https://lens.org/132-054-276-604-21X,Patent Application,yes,0,2,13,13,0,A61C7/002;;A61C7/08;;B33Y80/00;;G16H20/40;;G16H50/50;;G06F30/00;;A61C7/002;;A61C7/08,A61C7/08;;A61C7/00,,0,0,,,,ACTIVE
191,CN,A,CN 109640869 A,034-307-020-156-345,2019-04-16,2019,CN 201780052092 A,2017-08-23,US 201662379199 P;;US 2017/0048275 W,2016-08-24,METHOD TO VISUALIZE AND MANUFACTURE ALIGNER BY MODIFYING TOOTH POSITION,Orthodontic systems and related methods are disclosed for designing and providing improved or more effective tooth moving systems for eliciting a desired tooth movement and/or repositioning teeth intoa desired arrangement. Methods and orthodontic systems include the generation of an overcorrection in the tooth-receiving cavities of an appliance worn in the dentition. The overcorrection may provide an improved and more accurately applied force or moment applied to a tooth. The overcorrected force or moment can move a tooth closer to a desired position than if not overcorrected as sufficient force can still applied to the tooth as it gets closer to the desired position. The overcorrected force or moment may also better target the root of the tooth where the biological response to tooth movement occurs. The overcorrection may be calculated in various ways as described herein.,ALIGN TECHNOLOGY INC,MATOV VADIM;;WU FUMING;;CHENG JIHUA;;CHEN JENNIFER;;LI CHUNHUA;;PESENTI BASTIEN;;KVASOV IGOR,,https://lens.org/034-307-020-156-345,Patent Application,no,8,2,13,13,0,A61C7/002;;A61C7/08;;B33Y80/00;;G16H20/40;;G16H50/50;;G06F30/00;;A61C7/002;;A61C7/08,A61C7/00;;A61C7/08,,0,0,,,,PENDING
192,US,B2,US 8111626 B2,108-195-031-841-259,2012-02-07,2012,US 34744408 A,2008-12-31,US 34744408 A;;US 4578008 P,2008-04-17,Method and apparatus for providing statistical event correlation in a network,"A method and apparatus for providing event correlation in a network are disclosed. For example, the method extracts a plurality of events of interest from a database, and creates one or more event time series from the plurality of events of interest, wherein each of the one or more event time series comprises a set of events of a same type and of a same location that occur within a given time period. The method forms one or more composite events from the one or more event time series, and performs one or more pair-wise correlations for at least one of: the event time-series, or the one or more composite events. The method then identifies one or more pair-wise correlations that are statistically significant.",SHAIKH AMAN;;EE CHENG;;MAHIMKAR AJAY;;WANG JIA;;YATES JENNIFER;;ZHANG YIN;;GE ZIHUI;;AT & T IP I LP,SHAIKH AMAN;;EE CHENG;;MAHIMKAR AJAY;;WANG JIA;;YATES JENNIFER;;ZHANG YIN;;GE ZIHUI,AT&T INTELLECTUAL PROPERTY I L.P (2009-04-22),https://lens.org/108-195-031-841-259,Granted Patent,yes,3,7,2,2,0,H04L41/0631;;H04L41/0631,H04L12/26;;G01R31/08;;H04J1/16,370/242,0,0,,,,ACTIVE
193,US,B2,US 7320834 B2,114-631-789-566-786,2008-01-22,2008,US 82264704 A,2004-04-13,TW 92120288 A,2003-07-24,Organic light emitting diode containing a novel Ir complex as a phosphorescent emitter,"A phosphorescent Ir complex having the following structures (I) or (II) is used as an emitter in an organic light emitting diode (OLED): wherein X is an arbitrary monoanionic bidentate ligand; Z is an arbitrary moiety constituting a nitrogen-containing heterocyclic group; R 1 is a substituent on the nitrogen-containing heterocyclic group; m is 0 or a positive integer; R 2 and R 3 independently are H, halogen, C1-C6 alkyl, a halogen-substituted C1-C6 alkyl, C1-C6 alkoxy, phenyl C1-C6 alkyl, amino, aryl, heterocyclic aryl substituent.",UNIV TSINGHUA,CHENG CHIEN-HONG;;DUAN JIUN-PEY;;RAYABARAPU DINESH KUMAR;;JENNIFER S P BETTY MARIE,SAMSUNG DISPLAY CO. LTD (2020-09-23);;CHENG CHIEN-HONG (2004-03-31);;CARLYLE TECHNOLOGY INNOVATION LLC (2014-02-26);;KAITUOZHE INTELLECTUAL PROPERTY MANAGEMENT CONSULTANTS LIMITED (2013-10-02);;NATIONAL TSING HUA UNIVERSITY (2006-11-20),https://lens.org/114-631-789-566-786,Granted Patent,yes,10,2,8,8,0,C09K11/06;;C09K2211/1029;;C09K2211/185;;H05B33/14;;Y10S428/917;;C09K11/06;;C09K11/06;;C09K2211/1029;;C09K2211/185;;H05B33/14;;Y10S428/917,H01L51/50;;C09K11/06;;H01L51/54;;H05B33/14;;H05B33/20;;H05B33/22,428/690;;428/917;;313/504;;313/506;;X257E51044,0,0,,,,ACTIVE
194,ES,T3,ES 2603835 T3,111-244-306-796-829,2017-03-01,2017,ES 07810787 T,2007-07-25,US 83328806 P;;US 2007/0016775 W,2006-07-26,Polo(etilenglicol) modificado hidrófobamente para usar en control de brea y sustancias pegajosas en procedimientos de fabricación de papel y pasta de celulosa,"Un procedimiento para inhibir la deposición de contaminantes orgánicos en sistemas de pasta de celulosa o fabricación de papel que comprende añadir al sistema de pasta de celulosa o fabricación de papel una cantidad eficaz para inhibir la deposición de un poli[etilenglicol] modif 5 icado hidrófobamente que comprende la composición de la fórmula: (R1-)x-O-[-CH2-CH2-O-]n-(-R2)y-Z en la que R1 y R2 son un resto hidrófobo, o bloques de restos hidrófobos de unidades repetidas de x e y, enlazados covalentemente a poli[etilenglicol]; n es 2 a 1.200; x es 1 a 10; y es 0 a 10; Z solo está presente cuando y >= 0 y es hidrógeno; y la suma de x e y es mayor que o igual a 2; en la que la composición se prepara haciendo reaccionar al poli[etilenglicol] directamente con reactivo hidrófobo en una proporción molar de poli[etilenglicol] a reactivo hidrófobo de al menos 1:2 y no mayor que 1:5,5.",SOLENIS TECHNOLOGIES CAYMAN LP,GU QU-MING;;CHENG HUAI;;CAREY WILLIAM;;GELMAN ROBERT;;RITTENHOUSE-PRUSS JENNIFER;;DOHERTY ERIN,,https://lens.org/111-244-306-796-829,Granted Patent,no,0,0,21,21,0,C08G65/22;;C08G65/2609;;D21C9/008;;D21H21/02;;C08G2650/34;;C08G65/22;;C08G65/2609;;C08G2650/34;;D21C9/008;;D21H21/02;;D21H21/02;;C08G2650/34;;C08G65/22;;D21C9/008;;C08G65/2609,D21H21/02;;C08L71/02;;C11D1/722;;D21C9/00,,0,0,,,,ACTIVE
195,EP,A3,EP 4254429 A3,192-576-199-935-246,2024-01-03,2024,EP 23177363 A,2017-08-23,US 201662379199 P;;EP 17844369 A;;US 2017/0048275 W,2016-08-24,METHOD TO VISUALIZE AND MANUFACTURE ALIGNER BY MODIFYING TOOTH POSITION,Orthodontic systems and related methods are disclosed for designing and providing improved or more effective tooth moving systems for eliciting a desired tooth movement and/or repositioning teeth into a desired arrangement. Methods and orthodontic systems include the generation of an overcorrection in the tooth-receiving cavities of an appliance worn in the dentition. The overcorrection may provide an improved and more accurately applied force or moment applied to a tooth. The overcorrected force or moment can move a tooth closer to a desired position than if not overcorrected as sufficient force can still applied to the tooth as it gets closer to the desired position. The overcorrected force or moment may also better target the root of the tooth where the biological response to tooth movement occurs. The overcorrection may be calculated in various ways as described herein.,ALIGN TECHNOLOGY INC,KVASOV IGOR;;MATOV VADIM;;WU FUMING;;CHENG JIHUA;;CHEN JENNIFER;;LI CHUNHUA;;PESENTI BASTIEN,,https://lens.org/192-576-199-935-246,Search Report,yes,2,0,13,13,0,A61C7/002;;A61C7/08;;B33Y80/00;;G16H20/40;;G16H50/50;;G06F30/00;;A61C7/002;;A61C7/08,A61C7/00;;A61C7/08;;B33Y80/00;;G16H50/70,,0,0,,,,PENDING
196,US,A1,US 2018/0055600 A1,016-313-322-181-528,2018-03-01,2018,US 201715684775 A,2017-08-23,US 201715684775 A;;US 201662379199 P,2016-08-24,METHOD TO VISUALIZE AND MANUFACTURE ALIGNER BY MODIFYING TOOTH POSITION,Orthodontic systems and related methods are disclosed for designing and providing improved or more effective tooth moving systems for eliciting a desired tooth movement and/or repositioning teeth into a desired arrangement. Methods and orthodontic systems include the generation of an overcorrection in the tooth-receiving cavities of an appliance worn in the dentition. The overcorrection may provide an improved and more accurately applied force or moment applied to a tooth. The overcorrected force or moment can move a tooth closer to a desired position than if not overcorrected as sufficient force can still applied to the tooth as it gets closer to the desired position. The overcorrected force or moment may also better target the root of the tooth where the biological response to tooth movement occurs. The overcorrection may be calculated in various ways as described herein.,ALIGN TECHNOLOGY INC,MATOV VADIM;;WU FUMING;;CHENG JIHUA;;CHEN JENNIFER;;LI CHUNHUA;;PESENTI BASTIEN;;KVASOV IGOR,ALIGN TECHNOLOGY INC (2017-09-08),https://lens.org/016-313-322-181-528,Patent Application,yes,4,29,13,13,0,A61C7/002;;A61C7/08;;B33Y80/00;;G16H20/40;;G16H50/50;;G06F30/00;;A61C7/002;;A61C7/08,A61C7/00;;A61C7/08,,0,0,,,,ACTIVE
197,TW,B,TW I232704 B,000-614-192-861-661,2005-05-11,2005,TW 92120288 A,2003-07-24,TW 92120288 A,2003-07-24,Organic light emitting diode containing a novel Ir complex as a phosphorescent emitter,"The present invention relates to an organic light emitting diode containing Ir complex as phosphorescent emitter. The phosphorescent Ir complex of the present invention has the following formula (I) or (II). In the formula, X is any of monoanionic bidentate ligands; Z is any atom group constructing nitrogen heterocyclic groups; R1 is a substituted group in a nitrogen heterocyclic group; m is 0 or any positive integer; R2 and R3 are independent hydrogen, halogen, alkyl group of C1-C6 or halogen substituted C1-C6 alkyl group, C1-C6 alkoxyl group, phenyl C1-C6 alkyl group, amine group, aromatic group, hetero aromatic ring substituted group.",CHENG CHIEN-HONG,CHENG CHIEN-HONG;;DUAN JIUN-PEY;;RAYABARAPU DINESH KUMAR;;BETTY MARIE JENNIFER S P,,https://lens.org/000-614-192-861-661,Granted Patent,no,0,0,8,8,0,C09K11/06;;C09K2211/1029;;C09K2211/185;;H05B33/14;;Y10S428/917;;C09K11/06;;C09K11/06;;C09K2211/1029;;C09K2211/185;;H05B33/14;;Y10S428/917,C09K11/06;;H01L51/50;;H05B33/14;;H05B33/20;;H05B33/22,,0,0,,,,EXPIRED
198,US,B2,US 11497584 B2,087-796-976-100-859,2022-11-15,2022,US 201916576707 A,2019-09-19,US 201916576707 A;;US 201715684775 A;;US 201662379199 P,2016-08-24,Method to visualize and manufacture aligner by modifying tooth position,Orthodontic systems and related methods are disclosed for designing and providing improved or more effective tooth moving systems for eliciting a desired tooth movement and/or repositioning teeth into a desired arrangement. Methods and orthodontic systems include the generation of an overcorrection in the tooth-receiving cavities of an appliance worn in the dentition. The overcorrection may provide an improved and more accurately applied force or moment applied to a tooth. The overcorrected force or moment can move a tooth closer to a desired position than if not overcorrected as sufficient force can still applied to the tooth as it gets closer to the desired position. The overcorrected force or moment may also better target the root of the tooth where the biological response to tooth movement occurs. The overcorrection may be calculated in various ways as described herein.,ALIGN TECHNOLOGY INC,MATOV VADIM;;WU FUMING;;CHENG JIHUA;;CHEN JENNIFER;;LI CHUNHUA;;PESENTI BASTIEN;;KVASOV IGOR,ALIGN TECHNOLOGY INC (2017-09-08),https://lens.org/087-796-976-100-859,Granted Patent,yes,201,0,13,13,0,A61C7/002;;A61C7/08;;B33Y80/00;;G16H20/40;;G16H50/50;;G06F30/00;;A61C7/002;;A61C7/08,A61C7/00;;A61C7/08;;G06F30/00,,155,79,066-282-335-791-995;;025-616-909-029-765;;012-349-279-389-292;;012-109-303-347-357;;107-771-608-717-858;;062-739-307-619-727;;005-024-996-709-894;;059-588-461-518-39X;;052-731-758-553-641;;081-328-802-841-096;;008-744-219-127-384;;083-235-787-432-859;;009-638-995-800-030;;006-548-225-912-257;;008-400-662-682-578;;008-334-069-985-364;;106-143-739-919-771;;041-946-650-568-904;;026-672-240-066-566;;010-426-032-640-987;;082-594-697-736-865;;007-458-121-098-163;;114-408-402-448-688;;048-527-821-955-377;;052-763-059-483-265;;048-656-201-606-564;;042-727-167-432-165;;109-794-479-707-999;;158-570-183-388-081;;046-112-675-259-076;;046-223-741-691-636;;053-649-857-143-596;;053-005-861-291-15X;;011-087-626-493-243;;007-221-538-620-409;;021-018-768-707-650;;000-494-525-786-513;;034-464-951-348-782;;013-689-140-672-656;;006-370-362-381-143;;150-267-339-118-983;;099-384-176-695-780;;056-064-135-529-61X;;054-749-861-626-632;;136-362-268-202-528;;002-943-783-913-03X;;002-001-653-775-549;;049-270-017-771-054;;114-349-043-008-578;;027-822-397-122-973;;138-684-123-834-414;;056-383-866-369-582;;123-028-396-811-269;;112-073-423-851-594;;021-881-631-200-08X;;007-791-552-338-375;;043-213-859-914-534;;058-953-285-075-855;;004-945-615-972-614;;036-191-696-513-286;;025-329-363-440-138;;006-539-396-314-679;;129-709-346-949-085;;051-296-399-382-894;;069-298-082-055-441;;021-507-277-374-529;;053-048-658-252-470;;049-407-482-660-143;;031-271-546-068-031;;042-526-631-078-104;;027-754-365-457-953;;030-427-969-872-795;;064-378-232-278-762;;046-665-331-726-574;;055-477-823-513-100;;027-316-381-573-41X;;000-788-861-492-825;;055-418-850-870-066;;088-958-363-169-71X,10.1117/12.7972842;;10.1117/12.957387;;2686338;;10.3109/00016358909007713;;4511478;;6943954;;10.1043/0003-3219(1981)051<0252:acsfta>2.0.co;2;;10.1016/0266-4356(84)90080-9;;6235838;;10.1016/0002-9416(72)90076-0;;4501183;;10.1043/0003-3219(1970)040<0028:cdsas>2.0.co;2;;5262685;;10.1109/tip.2004.826093;;15376602;;10.1177/00220345860650031101;;3457048;;298295;;298302;;6937139;;10.1016/0002-9416(81)90310-9;;2089065;;4064420;;6935222;;5248055;;10.1016/s0002-9416(69)90171-7;;2021892;;10356486;;3714886;;10.1097/00006534-198606000-00001;;1022792;;10.1016/0021-9290(76)90187-1;;3058771;;10.14219/jada.archive.1988.0096;;1777659;;298289;;15419274;;10.1016/0002-9416(50)90076-5;;3479893;;10.1016/0889-5406(87)90229-0;;3476699;;10.1016/0278-2391(87)90195-9;;6960008;;2613889;;3333504;;2277050;;10.1016/0021-9290(90)90008-q;;8617829;;6584438;;9563366;;10.1016/s0889-5406(98)80024-3;;10.1179/bjo.16.2.85;;2673344;;271471;;10.1016/0002-9416(78)90100-8;;10.2334/josnusd1959.26.11;;6589367;;6956677;;10.2334/josnusd1959.24.1;;6594373;;10.1177/00220345840630110901;;10.1016/0096-6347(45)90101-3;;21027613;;10.1016/0096-6347(46)90053-1;;10356517;;10.1145/964965.808575;;10.1016/0141-9382(94)90007-8;;10.1016/s0889-5406(96)70036-7;;8876485;;10.1109/42.97596;;18222848;;2738247;;10.14219/jada.archive.1989.0156;;10.14219/jada.archive.1989.0240;;2918147;;3862671;;3911387;;2132100;;10.2334/josnusd1959.19.93;;294475;;10.1109/iecon.1998.724103;;5276727;;10.1016/0002-9416(71)90099-6;;10.1016/s0889-5406(00)70049-7;;10672223;;10.1109/10.133223;;1855790;;1591643;;10.1016/0022-3913(87)90285-x;;3312586;;1783723;;10.14219/jada.archive.1991.0205;;10.1093/ejo/14.2.125;;1582457;;10.1016/0889-5406(87)90412-4;;3477086;;10.1093/ejo/3.4.279;;7028491;;1539546;;10.1016/0889-5406(92)70089-s;;10.1001/archotol.1988.01860160082026;;3348899;;10.1016/0002-9416(71)90006-6;;5280427;;2269115;;1452058;;4504700;;10.1177/00220345720510041901;;4504704;;10.1177/00220345720510042301;;20830889;;10.1016/s0010-4485(96)00054-1;;9874310;;10.1109/42.736056;;2718969;;10.1016/0889-5406(89)90300-4;;2639882;;5272402;;10.1016/0002-9416(70)90106-5;;3553441;;3473186;;10.1109/4233.924800;;11420997;;2486752,"AADR. American Association for Dental Research, Summary of Activities, Mar. 20-23, 1980, Los Angeles, CA, p. 195.;;Alcaniz, et al, “An Advanced System for the Simulation and Planning of Orthodontic Treatments,” Karl Heinz Hohne and Ron Kikinis (eds.), Visualization in Biomedical Computing, 4th Intl. Conf., VBC '96, Hamburg, Germany, Sep. 22-25, 1996, Springer-Verlag, pp. 511-520.;;Alexander et al., “The DigiGraph Work Station Part 2 Clinical Management,” JCO, pp. 402-407 (Jul. 1990).;;Altschuler et al., “Analysis of 3-D Data for Comparative 3-D Serial Growth Pattern Studies of Oral-Facial Structures,” IADR Abstracts, Program and Abstracts of Papers, 57th General Session, IADR Annual Session, Mar. 29, 1979-Apr. 1, 1979, New Orleans Marriot, Journal of Dental Research, vol. 58, Jan. 1979, Special Issue A, p. 221.;;Altschuler et al., “Laser Electro-Optic System for Rapid Three-Dimensional (3D) Topographic Mapping of Surfaces,” Optical Engineering, 20(6):953-961 (1981).;;Altschuler et al., “Measuring Surfaces Space-Coded by a Laser-Projected Dot Matrix,” SPIE Imaging Applications for Automated Industrial Inspection and Assembly, vol. 182, p. 187-191 (1979).;;Altschuler, “3D Mapping of Maxillo-Facial Prosthesis,” AADR Abstract #607, 2 pages total, (1980).;;Andersson et al., “Clinical Results with Titanium Crowns Fabricated with Machine Duplication and Spark Erosion,” Acta. Odontol. Scand., 47:279-286 (1989).;;Andrews, The Six Keys to Optimal Occlusion Straight Wire, Chapter 3, pp. 13-24 (1989).;;Bartels, et al., An Introduction to Splines for Use in Computer Graphics and Geometric Modeling, Morgan Kaufmann Publishers, pp. 422-425 (1987).;;Baumrind et al., “A Stereophotogrammetric System for the Detection of Prosthesis Loosening in Total Hip Arthroplasty,” NATO Symposium on Applications of Human Biostereometrics, Jul. 9-13, 1978, SPIE, vol. 166, pp. 112-123.;;Baumrind et al., “Mapping the Skull in 3-D,” reprinted from J. Calif. Dent. Assoc., 48(2), 11 pages total, (1972 Fall Issue).;;Baumrind, “A System for Craniofacial Mapping Through the Integration of Data from Stereo X-Ray Films and Stereo Photographs,” an invited paper submitted to the 1975 American Society of Photogram Symposium on Close-Range Photogram Systems, University of III., Aug. 26-30, 1975, pp. 142-166.;;Baumrind, “Integrated Three-Dimensional Craniofacial Mapping: Background, Principles, and Perspectives,” Semin. in Orthod., 7(4):223-232 (Dec. 2001).;;Begole et al., “A Computer System for the Analysis of Dental Casts,” The Angle Orthod., 51(3):253-259 (Jul. 1981).;;Bernard et al.,“Computerized Diagnosis in Orthodontics for Epidemiological Studies: A Progress Report,” Abstract, J. Dental Res. Special Issue, vol. 67, p. 169, paper presented at International Association for Dental Research 66th General Session, Mar. 9-13, 1988, Montreal, Canada.;;Bhatia et al., “A Computer-Aided Design for Orthognathic Surgery,” Br. J. Oral Maxillofac. Surg., 22:237-253 (1984).;;Biggerstaff et al., “Computerized Analysis of Occlusion in the Postcanine Dentition,” Am. J. Orthod., 61(3): 245-254 (Mar. 1972).;;Biggerstaff, “Computerized Diagnostic Setups and Simulations,” Angle Orthod., 40(1):28-36 (Jan. 1970).;;Biostar Opeation & Training Manual. Great Lakes Orthodontics, Ltd. 199 Fire Tower Drive, Tonawanda, New York. 14150-5890, 20 pages total (1990).;;Blu, et al., “Linear interpolation revitalized”, IEEE Trans. Image Proc., 13(5):710-719 (May 2004.;;Bourke, “Coordinate System Transformation,” (Jun. 1996), p. 1, retrieved from the Internet Nov. 5, 2004, URL< http://astronomy.swin.edu.au/—pbourke/prolection/coords>.;;Boyd et al., “Three Dimensional Diagnosis and Orthodontic Treatment of Complex Malocclusions With the Invisalign Appliance,” Semin. Orthod., 7(4):274-293 (Dec. 2001).;;Brandestini et al., “Computer Machined Ceramic Inlays: In Vitro Marginal Adaptation,” J. Dent. Res. Special Issue, Abstract 305, vol. 64, p. 208 (1985).;;Brook et al., “An Image Analysis System for the Determination of Tooth Dimensions from Study Casts: Comparison with Manual Measurements of Mesio-distal Diameter,” J. Dent. Res., 65(3):428-431 (Mar. 1986).;;Burstone (interview), “Dr. Charles J. Burstone on The Uses of the Computer in Orthodontic Practice (Part 1),” J. Clin. Orthod., 13(7):442-453 (Jul. 1979).;;Burstone (interview), “Dr. Charles J. Burstone on The Uses of the Computer in Orthodontic Practice (Part 2),” J. Clin. Orthod., 13(8):539-551 (Aug. 1979).;;Burstone et al., Precision Adjustment of the Transpalatal Lingual Arch: Computer Arch Form IN Predetermination, Am, Journal of Orthodontics, vol. 79, No. 2 (Feb. 1981), pp. 115-133.;;Cardinal Industrial Finishes, Powder Coatings information posted at<http://www.cardinalpaint.com> on Aug. 25, 2000, 2 pages.;;Carnaghan, “An Alternative to Holograms for the Portrayal of Human Teeth,” 4th Int'l. Conf. on Holographic Systems, Components and Applications, Sep. 15, 1993, pp. 228-231.;;Chaconas et al., “The DigiGraph Work Station, Part 1, Basic Concepts,” JCO, pp. 360-367 (Jun. 1990).;;Chafetz et al., “Subsidence of the Femoral Prosthesis, A Stereophotogrammetric Evaluation,” Clin. Orthop. Relat. Res., No. 201, pp. 60-67 (Dec. 1985).;;Chiappone, (1980). Constructing the Gnathologic Setup and Positioner, J. Clin. Orthod, vol. 14, pp. 121-133.;;Cottingham, (1969). Gnathologic Clear Plastic Positioner, Am. J. Orthod, vol. 55, pp. 23-31.;;Crawford, “CAD/CAM in the Dental Office: Does It Work?”, Canadian Dental Journal, vol. 57, No. 2, pp. 121-123 (Feb. 1991).;;Crawford, “Computers in Dentistry: Part 1 CAD/CAM: The Computer Moves Chairside,” Part 2 F. Duret—A Man with a Vision,“Part 3 The Computer Gives New Vision—Literally,” Part 4 Bytes 'N Bites—The Computer Moves from the Front Desk to the Operatory, Canadian Dental Journal, vol. 54 (9), pp. 661-666 (1988).;;Crooks, “CAD/CAM Comes to USC,” USC Dentistry, pp. 14-17 (Spring 1990).;;Cureton, Correcting Malaligned Mandibular Incisors with Removable Retainers, J. Clin. Orthod, vol. 30, No. 7 (1996) pp. 390-395.;;Curry et al., “Integrated Three-Dimensional Craniofacial Mapping at the Craniofacial Research Instrumentation Laboratory/University of the Pacific,” Semin. Orthod., 7(4):258-265 (Dec. 2001).;;Cutting et a/., “Three-Dimensional Computer-Assisted Design of Craniofacial Surgical Procedures: Optimization and Interaction with Cephalometric and CT-Based Models,” Plast. 77(6):877-885 (Jun. 1986).;;DCS Dental AG, “The CAD/CAM ‘DCS Titan System’ for Production of Crowns/Bridges,” DSC Production AG, pp. 1-7 (Jan. 1992.;;Definition for gingiva. Dictionary.com p. 1-3. Retrieved from the internet Nov. 5, 2004<http://reference.com/search/search?q=gingiva>.;;Defranco et al., “Three-Dimensional Large Displacement Analysis of Orthodontic Appliances,” J. Biomechanics, 9:793-801 (1976).;;Dental Institute University of Zurich Switzerland, Program for International Symposium JD on Computer Restorations: State of the Art of the CEREC-Method, May 1991, 2 pages total.;;Dentrac Corporation, Dentrac document, pp. 4-13 (1992).;;DENT-X posted on Sep. 24, 1998 at< http://www.dent-x.com/DentSim.htm>, 6 pages.;;Doyle, “Digital Dentistry,” Computer Graphics World, pp. 50-52, 54 (Oct. 2000).;;DuraClearTM product information, Allesee Orthodontic Appliances—Pro Lab, 1 page (1997).;;Duret et al., “CAD-CAM in Dentistry,” J. Am. Dent. Assoc. 117:715-720 (Nov. 1988).;;Duret et al., “CAD/CAM Imaging in Dentistry,” Curr. Opin. Dent., 1:150-154 (1991).;;Duret, “The Dental CAD/CAM, General Description of the Project,” Hennson International Product Brochure, 18 pages total, Jan. 1986.;;Duret,“Vers Une Prosthese Informatisee,” (English translation attached), Tonus, vol. 75, pp. 55-57 (Nov. 15, 1985).;;Economides, “The Microcomputer in the Orthodontic Office,” JCO, pp. 767-772 (Nov. 1979).;;Elsasser, Some Observations on the History and Uses of the Kesling Positioner, Am. J. Orthod. (1950) 36:368-374.;;English translation of Japanese Laid-Open Publication No. 63-11148 to inventor T. Ozukuri (Laid-Open on Jan. 18, 1998) pp. 1-7.;;Felton et al., “A Computerized Analysis of the Shape and Stability of Mandibular Arch Form,” Am. J. Orthod. Dentofacial Orthop., 92(6):478-483 (Dec. 1987).;;Friede et al., “Accuracy of Cephalometric Prediction in Orthognathic Surgery,” Abstract of Papers, J. Dent. Res., 70:754-760 (1987).;;Futterling et al., “Automated Finite Element Modeling of a Human Mandible with Dental Implants,” JS WSCG '98—Conference Program, retrieved from the Internet:<http://wscg.zcu.cz/wscg98/papers98/Strasser 98.pdf, 8 pages.;;Gao et al., “3-D element Generation for Multi-Connected Complex Dental and Mandibular Structure,” Proc. Intl Workshop on Medical Imaging and Augmented Reality, pp. 267-271 (Jun. 12, 2001).;;Gim-Alldent Deutschland, “Das DUX System: Die Technik,” 2 pages total (2002).;;Gottleib et al., “JCO Interviews Dr. James A. McNamura, Jr., on the Frankel Appliance: Part 2: Clinical 1-1 Management,” J. Clin. Orthod., 16(6):390-407 (Jun. 1982).;;Grayson, “New Methods for Three Dimensional Analysis of Craniofacial Deformity, Symposium: JW Computerized Facial Imaging in Oral and Maxiiofacial Surgery,” AAOMS, 3 pages total, (Sep. 13, 1990).;;Guess et al., “Computer Treatment Estimates In Orthodontics and Orthognathic Surgery,” JCO, pp. 262-28 (Apr. 1989).;;Heaven et al., “Computer-Based Image Analysis of Artificial Root Surface Caries,” Abstracts of Papers, J. Dent. Res., 70:528 (Apr. 17-21, 1991).;;Highbeam Research, “Simulating Stress Put on Jaw,” Tooling & Production [online], Nov. 1996, n pp. 1-2, retrieved from the Internet on Nov. 5, 2004, URL http://static.highbeam.com/t/toolingampproduction/november011996/simulatingstressputonfa . . . >.;;Hikage, “Integrated Orthodontic Management System for Virtual Three-Dimensional Computer Graphic Simulation and Optical Video Image Database for Diagnosis and Treatment Planning”, Journal of Japan KA Orthodontic Society, Feb. 1987, English translation, pp. 1-38, Japanese version, 46(2), pp. 248-269 (60 pages total).;;Hoffmann, et al., “Role of Cephalometry for Planning of Jaw Orthopedics and Jaw Surgery Procedures,” (Article Summary in English, article in German), Informatbnen, pp. 375-396 (Mar. 1991).;;Hojjatie et al., “Three-Dimensional Finite Element Analysis of Glass-Ceramic Dental Crowns,” J. Biomech., 23(11):1157-1166 (1990).;;Huckins, “CAD-CAM Generated Mandibular Model Prototype from MRI Data,” AAOMS, p. 96 (1999).;;Important Tip About Wearing the Red White & Blue Active Clear Retainer System. Allesee Orthodontic Appliances-Pro Lab. 1 page (1998).;;International search report with written opinion dated Dec. 5, 2017 for PCT/US2017/048275.;;JCO Interviews, “Craig Andreiko , DDS, MS on the Elan and Orthos Systems,” JCO, pp. 459-468 (Aug. 1994).;;JCO Interviews, “Dr. Homer W. Phillips on Computers in Orthodontic Practice, Part 2,” JCO. 1997; 1983:819-831.;;Jerrold, “The Problem, Electronic Data Transmission and the Law,” AJO-DO, pp. 478-479 (Apr. 1988).;;Jones et al., “An Assessment of the Fit of a Parabolic Curve to Pre- and Post-Treatment Dental Arches,” Br. J. Orthod., 16:85-93 (1989).;;JP Faber et al., “Computerized Interactive Orthodontic Treatment Planning,” Am. J. Orthod., 73(1):36-46 (Jan. 1978).;;KAMADA et.al., Case Reports On Tooth Positioners Using LTV Vinyl Silicone Rubber, J. Nihon University School of Dentistry (1984) 26(1): 11-29.;;KAMADA et.al., Construction of Tooth Positioners with LTV Vinyl Silicone Rubber and Some Case KJ Reports, J. Nihon University School of Dentistry (1982) 24(1):1-27.;;Kanazawa et al., “Three-Dimensional Measurements of the Occlusal Surfaces of Upper Molars in a Dutch Population,” J. Dent Res., 63(11): 1298-1301 (Nov. 1984).;;Kesling et al., The Philosophy of the Tooth Positioning Appliance, American Journal of Orthodontics and Oral surgery. 1945; 31:297-304.;;Kesling, Coordinating the Predetermined Pattern and Tooth Positioner with Conventional Treatment, KN Am. J. Orthod. Oral Surg. (1946) 32:285-293.;;Kleeman et al., The Speed Positioner, J. Clin. Orthod. (1996) 30:673-680.;;Kochanek, “Interpolating Splines with Local Tension, Continuity and Bias Control,” Computer Graphics, ri 18(3):33-41 (Jul. 1984). KM Oral Surgery (1945) 31 :297-30.;;Kunii et al., “Articulation Simulation for an Intelligent Dental Care System,” Displays 15:181-188 (1994).;;Kuroda et al., Three-Dimensional Dental Cast Analyzing System Using Laser Scanning, Am. J. Orthod. Dentofac. Orthop. (1996) 110:365-369.;;Laurendeau, et al., “A Computer-Vision Technique for the Acquisition and Processing of 3-D Profiles of 7 KR Dental Imprints: An Application in Orthodontics,” IEEE Transactions on Medical Imaging, 10(3):453-461 (Sep. 1991.;;Leinfelder, et al., “A New Method for Generating Ceramic Restorations: a CAD-CAM System,” J. Am. 1-1 Dent. Assoc., 118(6):703-707 (Jun. 1989).;;Manetti, et al., “Computer-Aided Cefalometry and New Mechanics in Orthodontics,” (Article Summary in English, article in German), Fortschr Kieferorthop. 44, 370-376 (Nr. 5), 1983.;;McCann, “Inside the ADA,” J. Amer. Dent. Assoc., 118:286-294 (Mar. 1989).;;McNamara et al., “Invisible Retainers,” J. Cfin. Orthod., pp. 570-578 (Aug. 1985).;;McNamara et al., Orthodontic and Orthopedic Treatment in the Mixed Dentition, Needham Press, pp. 347-353 (Jan. 1993).;;Moermann et al., “Computer Machined Adhesive Porcelain Inlays: Margin Adaptation after Fatigue Stress,” IADR Abstract 339, J. Dent. Res., 66(a):763 (1987).;;Moles, “Correcting Mild Malalignments—As Easy As One, Two, Three,” AOA/Pro Corner, vol. 11, No. 1, 2 pages (2002).;;Mormann et al., “Marginale Adaptation von adhasuven Porzellaninlays in vitro,” Separatdruck aus: Schweiz. Mschr. Zahnmed. 95: 1118-1129, 1985.;;Nahoum, “The Vacuum Formed Dental Contour Appliance,” N. Y. State Dent. J., 30(9):385-390 (Nov. 1964).;;Nash, “CEREC CAD/CAM Inlays: Aesthetics and Durability in a Single Appointment,” Dent. Today, 9(8):20, 22-23 (Oct. 1990).;;Nishiyama et al., “A New Construction of Tooth Repositioner by LTV Vinyl Silicone Rubber,” J. Nihon Univ. Sch. Dent., 19(2):93-102 (1977).;;Paul et al., “Digital Documentation of Individual Human Jaw and Tooth Forms for Applications in Orthodontics, Oral Surgery and Forensic Medicine” Proc. of the 24th Annual Conf. of the IEEE Industrial Electronics Society (IECON '98), Sep. 4, 1998, pp. 2415-2418.;;Pinkham, “Foolish Concept Propels Technology,” Dentist, 3 pages total, Jan./Feb. 1989.;;Pinkham, “Inventor's CAD/CAM May Transform Dentistry,” Dentist, 3 pages total, Sep. 1990.;;Ponitz, “Invisible Retainers,” Am. J. Orthod., 59(3):266-272 (Mar. 1971).;;Procera Research Projects, “Procera Research Projects 1993—Abstract Collection,” pp. 3-7; 28 (1993).;;Proffit et al., Contemporary Orthodontics, (Second Ed.), Chapter 15, Mosby Inc., pp. 470-533 (Oct. 1993.;;Raintree Essix & ARS Materials, Inc., Raintree Essix, Technical Magazine Table of contents and Essix Appliances,< http://www.essix.com/magazine/defaulthtml> Aug. 13, 1997.;;Redmond et al., “Clinical Implications of Digital Orthodontics,” Am. J. Orthod. Dentofacial Orthop., 117(2):240-242 (2000).;;Rekow et al., “CAD/CAM for Dental Restorations—Some of the Curious Challenges,” IEEE Trans. Biomed. Eng., 38(4):314-318 (Apr. 1991).;;Rekow et al., “Comparison of Three Data Acquisition Techniques for 3-D Tooth Surface Mapping,” Annual International Conference of the IEEE Engineering in Medicine and Biology Society, 13(1):344-345 1991.;;Rekow, “A Review of the Developments in Dental CAD/CAM Systems,” (contains references to Japanese efforts and content of the papers of particular interest to the clinician are indicated with a one line summary of their content in the bibliography), Curr. Opin. Dent., 2:25-33 (Jun. 1992).;;Rekow, “CAD/CAM in Dentistry: A Historical Perspective and View of the Future,” J. Can. Dent. Assoc., 58(4):283, 287-288 (Apr. 1992).;;Rekow, “Computer-Aided Design and Manufacturing in Dentistry: A Review of the State of the Art,” J. Prosthet. Dent., 58(4):512-516 (Oct. 1987).;;Rekow, “Dental CAD-CAM Systems: What is the State of the Art?”, J. Amer. Dent. Assoc., 122:43-48 1991.;;Rekow, “Feasibility of an Automated System for Production of Dental Restorations, Ph.D. Thesis,” Univ. of Minnesota, 244 pages total, Nov. 1988.;;Richmond et al., “The Development of a 3D Cast Analysis System,” Br. J. Orthod., 13(1):53-54 (Jan. 1986).;;Richmond et al., “The Development of the PAR Index (Peer Assessment Rating): Reliability and Validity,” Eur. J. Orthod., 14:125-139 (1992).;;Richmond, “Recording The Dental Cast In Three Dimensions,” Am. J. Orthod. Dentofacial Orthop., 92(3):199-206 (Sep. 1987).;;Rudge, “Dental Arch Analysis: Arch Form, A Review of the Literature,” Eur. J. Orthod., 3(4):279-284 1981.;;Sakuda et al., “Integrated Information-Processing System In Clinical Orthodontics: An Approach with Use of a Computer Network System,” Am. J. Orthod. Dentofacial Orthop., 101(3): 210-220 (Mar. 1992).;;Schellhas et al., “Three-Dimensional Computed Tomography in Maxillofacial Surgical Planning,” Arch. Otolamp!. Head Neck Sur9., 114:438-442 (Apr. 1988).;;Schroeder et al., Eds. The Visual Toolkit, Prentice Hall PTR, New Jersey (1998) Chapters 6, 8 & 9, (pp. 153-210,309-354, and 355-428, respectively.;;Shilliday, (1971). Minimizing finishing problems with the mini-positioner, Am. J. Orthod. 59:596-599.;;Siemens, “CEREC—Computer-Reconstruction,” High Tech in derZahnmedizin, 14 pages total (2004).;;Sinclair, “The Readers' Corner,” J. Clin. Orthod., 26(6):369-372 (Jun. 1992).;;Sirona Dental Systems GmbH, CEREC 3D, Manuel utiiisateur, Version 2.0X (in French), 2003, 114 pages total.;;Stoll et al., “Computer-aided Technologies in Dentistry,” (article summary in English, article in German), Dtsch Zahna'rztl Z 45, pp. 314-322 (1990).;;Sturman, “Interactive Keyframe Animation of 3-D Articulated Models,” Proceedings Graphics Interface '84, May-Jun. 1984, pp. 35-40.;;The Choice Is Clear: Red, White & Blue . . . The Simple, Affordable, No-Braces Treatment, Allesee Orthodontic Appliances-Pro Lab product information, 6 pages (2003).;;The Choice Is Clear: Red, White & Blue . . . The Simple, Affordable, No-Braces Treatment, Allesee HI Orthodontic Appliances-Pro Lab product information for doctors. http://ormco.com/aoa/appliancesservices/RWB/doctorhtml, 5 pages (May 19, 2003).;;The Choice is Clear: Red, White & Blue . . . The Simple, Affordable, No-Braces Treatment, Allesee HJ Orthodontic Appliances-Pro Lab product information for patients, (http://ormco.com/aoa/appliancesservices/RWB/patients.html), 2 pages (May 19, 2003).;;The Red, White & Blue Way to Improve Your Smile!, Allesee Orthodontic Appliances-Pro Lab product information for patients, 2 pages (1992).;;Truax L., “Truax Clasp-Less(TM) Appliance System,” Funct. Orthod., 9(5):22-4, 26-8 (Sep.-Oct. 1992).;;Tru-Tain Orthodontic & Dental Supplies, Product Brochure, Rochester, Minnesota 55902, 16 pages total (1996).;;U.S. Department of Commerce, National Technical Information Service, “Automated Crown Replication Using Solid Photography SM,” Solid Photography Inc., Melville NY, Oct. 1977, 20 pages total.;;U.S. Department of Commerce, National Technical Information Service, “Holodontography: An Introduction to Dental Laser Holography,” School of Aerospace Medicine Brooks AFB Tex, Mar. 1973, 37 pages total.;;U.S. Appl. No. 60/050,342, filed Jun. 20, 1997, 41 pages total.;;Van Der Linden et al., “Three-Dimensional Analysis of Dental Casts by Means of the Optocom,” J. Dent. Res., p. 1100 (Jul.-Aug. 1972).;;Van Der Linden, “A New Method to Determine Tooth Positions and Dental Arch Dimensions,” J. Dent. Res., 51(4):1104 (Jul.-Aug. 1972).;;Van Der Zel, “Ceramic-Fused-to-Metal Restorations with a New CAD/CAM System,” Quintessence Int., 24(11):769-778 (1993.;;Varady et al., “Reverse Engineering Of Geometric Models—An Introduction,” Computer-Aided Design, 29(4):255-268, 1997.;;Verstreken et al., “An Image-Guided Planning System for Endosseous Oral Implants,” IEEE Trans. Med. Imaging, 17(5):842-852 (Oct. 1998).;;Warunek et al., Physical and Mechanical Properties of Elastomers in Orthodonic Positioners, Am J. Orthod. Dentofac. Orthop, vol. 95, No. 5, (May 1989) pp. 388-400.;;Warunek et.al., Clinical Use of Silicone Elastomer Applicances, JCO (1989) XXIII(10):694-700.;;Wells, Application of the Positioner Appliance in Orthodontic Treatment, Am. J. Orthodont. (1970) 58:351-366.;;Williams, “Dentistry and CAD/CAM: Another French Revolution,” J. Dent. Practice Admin., pp. 2-5 (Jan./Mar. 1987).;;Williams, “The Switzerland and Minnesota Developments in CAD/CAM,” J. Dent. Practice Admin., pp. 50-55 (Apr./Jun. 1987).;;Wishan, “New Advances in Personal Computer Applications for Cephalometric Analysis, Growth Prediction, Surgical Treatment Planning and Imaging Processing,” Symposium: Computerized Facial Imaging in Oral and Maxiiofacial Surgery Presented on Sep. 13, 1990.;;WSCG'98—Conference Program, “The Sixth International Conference in Central Europe on Computer Graphics and Visualization '98,” Feb. 9-13, 1998, pp. 1-7, retrieved from the Internet on Nov. 5, 2004, URL(http://wscg.zcu.cz/wscg98/wscg98.h).;;Xia et al., “Three-Dimensional Virtual-Reality Surgical Planning and Soft-Tissue Prediction for Orthognathic Surgery,” IEEE Trans. Inf. Technol. Biomed., 5(2):97-107 (Jun. 2001).;;Yamamoto et al., “Optical Measurement of Dental Cast Profile and Application to Analysis of Three-Dimensional Tooth Movement in Orthodontics,” Front. Med. Biol. Eng., 1(2):119-130 (1988).;;Yamamoto et al., “Three-Dimensional Measurement of Dental Cast Profiles and Its Applications to Orthodontics,” Conf. Proc. IEEE Eng. Med. Biol. Soc., 12(5):2051-2053 (1990).;;Yamany et al., “A System for Human Jaw Modeling Using Intra-Oral Images,” Proc. of the 20th Annual Conf. of the IEEE Engineering in Medicine and Biology Society, Nov. 1, 1998, vol. 2, pp. 563-566.;;Yoshii, “Research on a New Orthodontic Appliance: The Dynamic Positioner (D.P.); I. The D.P. Concept and Implementation of Transparent Silicone Resin (Orthocon),” Nippon Dental Review, 452:61-74 (Jun. 1980).;;Yoshii, “Research on a New Orthodontic Appliance: The Dynamic Positioner (D.P.); II. The D.P. Manufacturing Procedure and Clinical Applications,” Nippon Dental Review, 454:107-130 (Aug. 1980).;;Yoshii, “Research on a New Orthodontic Appliance: The Dynamic Positioner (D.P.); III. The General Concept of the D.P. Method and Its Therapeutic Effect, Part 1, Dental and Functional Reversed Occlusion Case Reports,” Nippon Dental Review, 457:146-164 (Nov. 1980).;;Yoshii, “Research on a New Orthodontic Appliance: The Dynamic Positioner (D.P.); III.—The General Concept of the D.P. Method and Its Therapeutic Effect, Part 2. Skeletal Reversed Occlusion Case Reports,” Nippon Dental Review, 458:112-129 (Dec. 1980).;;You May Be A Candidate For This Invisible No-Braces Treatment, Allesee Orthodontic Appliances-Pro Lab product information for patients, 2 pages (2002).",ACTIVE
199,CA,C,CA 2255762 C,168-578-769-951-774,2002-06-25,2002,CA 2255762 A,1997-05-30,US 1884496 P;;US 73909996 A;;US 85947897 A;;US 9709151 W,1996-05-31,ELECTRO-OPTICAL AND MAGNETO-OPTICAL SENSING APPARATUS AND METHOD FOR CHARACTERIZING FREE-SPACE ELECTROMAGNETIC RADIATION,"Apparatus and method for characterizing free-space electromagnetic energy, suitable for real-time two-dimensional far-infrared imaging applications. Th e sensing technique is based on a non-linear coupling between a low-frequency electric or magnetic field (12) and a laser beam (16) in an electro-optic or magnetic-optic crystal (14, 32 or 54). A counter-propagating sensing techniq ue (Fig. 1), and a co-linear sensing technique (Figs. 4 and 13) are described f or longer radiated and optical beam interaction length, making imaging applications practical.",RENSSELAER POLYTECH INST,ZHANG XI-CHENG;;LIBELO LOUIS FRANCIS;;WU QI;;SUN FENG-GUO;;RIORDAN JENNIFER ANN,,https://lens.org/168-578-769-951-774,Granted Patent,no,0,1,8,12,0,G01R29/0885;;G01R29/0885;;G01N21/3581;;G01N21/3581;;G02F1/09;;G02F1/09;;G02F1/3515;;G02F1/3515;;G02F1/353;;G02F1/353;;G02F2202/10;;G02F2202/10;;G02F2202/101;;G02F2202/101;;G02F2203/13;;G02F2203/13,G01R33/032;;G01J4/00;;G01N21/21;;G01N21/35;;G01R29/08;;G01R31/302,,0,0,,,,EXPIRED
200,CA,C,CA 2679482 C,099-958-258-029-028,2015-04-21,2015,CA 2679482 A,2008-03-12,US 90633007 P;;US 2008/0003354 W,2007-03-12,OLIGOMER-PROTEASE INHIBITOR CONJUGATES,"The invention provides protease inhibitors that are chemically modified by covalent attachment of a water-soluble oligomer. A conjugate of the invention, when administered by any of a number of administration routes, exhibits characteristics that are different from the protease inhibitors not attached to the water-soluble oligomer.",NEKTAR THERAPEUTICS,RIGGS-SAUTHIER JENNIFER;;CHENG LIN;;VIEGAS TACEY X;;GU XUYUAN;;DUARTE FRANCO J;;ZHANG WEN,,https://lens.org/099-958-258-029-028,Granted Patent,no,0,0,27,58,0,A61K47/60;;A61P31/12;;A61P31/16;;A61P31/18;;A61P43/00;;A61K47/50;;A61K31/164;;A61K47/60,A61K47/48;;A61P31/18,,0,0,,,,ACTIVE
201,CA,A1,CA 2679482 A1,127-383-113-192-907,2008-09-18,2008,CA 2679482 A,2008-03-12,US 90633007 P;;US 2008/0003354 W,2007-03-12,OLIGOMER-PROTEASE INHIBITOR CONJUGATES,"The invention provides protease inhibitors that are chemically modified b y covalent attachment of a water-soluble oligomer. A conjugate of the invent ion, when administered by any of a number of administration routes, exhibits characteristics that are different from the protease inhibitors not attache d to the water-soluble oligomer.",NEKTAR THERAPEUTICS,RIGGS-SAUTHIER JENNIFER;;VIEGAS TACEY X;;DUARTE FRANCO J;;ZHANG WEN;;GU XUYUAN;;CHENG LIN,,https://lens.org/127-383-113-192-907,Patent Application,no,0,0,27,58,0,A61K47/60;;A61P31/12;;A61P31/16;;A61P31/18;;A61P43/00;;A61K47/50;;A61K31/164;;A61K47/60,A61P31/18;;A61K47/48,,0,0,,,,ACTIVE
202,AU,B2,AU 2014/200906 B2,160-011-687-626-283,2016-07-07,2016,AU 2014/200906 A,2014-02-21,AU 2008/226823 A;;AU 2014/200906 A,2008-03-12,OLIGOMER-PROTEASE INHIBITOR CONJUGATES,"Abstract The invention provides protease inhibitors that are chemically modified by covalent attachment of a water-soluble oligomer. A conjugate of the invention, when administered 5 by any of a number of administration routes, exhibits characteristics that are different from the protease inhibitors not attached to the water-soluble oligomer. 5136858 1 (GHMatters) P81855.AU.1",NEKTAR THERAPEUTICS,RIGGS-SAUTHIER JENNIFER;;CHENG LIN;;VIEGAS TRACEY X;;GU XUYUAN;;DUARTE FRANCO J;;ZHANG WEN,,https://lens.org/160-011-687-626-283,Granted Patent,no,2,0,2,2,0,,A61K47/48;;A61P31/18,,1,1,038-334-210-991-906,15546199;;10.1021/bc0498875,"GUNASEELAN, S. et al. '', Bioconjugate Chemistry. 2004, vol. 15, pages 1322-1333",ACTIVE
203,ES,T3,ES 2163032 T3,000-949-848-659-111,2002-01-16,2002,ES 96925277 T,1996-07-08,GB 9602977 A;;US 105595 P,1995-07-11,SAL BISULFATO DE TRIAZOLILMETIL-INDOL ETILAMINA.,"The bisulfate salt of N,N-dimethyl-2-[5-(1,2,4-triazol-1-ylmethyl)-1H-indol-3-yl]ethylamine is a selective agonist of 5-HT1-like receptors and is useful in the treatment of migraine and associated disorders.",MERCK & CO INC,CHENG CHEN Y;;LARSEN ROBERT D;;MCCAULEY JAMES A;;VANDRILLA JENNIFER L;;VERHOEVEN THOMAS R,,https://lens.org/000-949-848-659-111,Granted Patent,no,0,0,11,14,0,A61K31/4196;;C07D231/12;;C07D233/56;;C07D249/08;;A61P25/04;;A61P25/06;;A61P43/00,A61K31/41;;A61K31/4196;;C07D403/06;;A61P25/04;;A61P25/06;;A61P43/00;;C07D521/00,,0,0,,,,EXPIRED
204,US,A1,US 2014/0045770 A1,072-588-256-279-781,2014-02-13,2014,US 201314055581 A,2013-10-16,US 201314055581 A;;US 53036310 A;;US 2008/0003354 W;;US 90633007 P,2007-03-12,OLIGOMER-PROTEASE INHIBITOR CONJUGATES,"The invention provides small molecule drugs that are chemically modified by covalent attachment of a water-soluble oligomer. A conjugate of the invention, when administered by any of a number of administration routes, exhibits characteristics that are different from the small molecule drug not attached to the water-soluble oligomer.",NEKTAR THERAPEUTICS,RIGGS-SAUTHIER JENNIFER;;CHENG LIN;;VIEGAS TACEY X;;GU XUYUAN;;DUARTE FRANCO J;;ZHANG WEN,,https://lens.org/072-588-256-279-781,Patent Application,yes,0,0,27,58,0,A61K47/60;;A61P31/12;;A61P31/16;;A61P31/18;;A61P43/00;;A61K47/50;;A61K31/164;;A61K47/60,A61K47/48,514/20.1;;546/146;;546/332;;549/464;;546/282.1;;514/336,0,0,,,,ACTIVE
205,KR,A,KR 20230137286 A,115-123-865-861-61X,2023-10-04,2023,KR 20237012251 A,2021-09-10,US 202063077553 P;;US 202063093673 P;;US 2021/0049940 W,2020-09-11,KRAS G12C 억제제의 결정 형태,"본 발명은 KRas G12C 억제제의 결정 형태 및 그의 염에 관한 것이다. 특히, 본 발명은 KRas G12C 억제제 2-[(2S)-4-[7-(8-클로로-1-나프틸)-2-[[(2S)-1-메틸피롤리딘-2-일]메톡시]-6,8-디하이드로-5H-피리도[3,4-d]피리미딘-4-일]-1-(2-플루오로프로프-2-에노일)피페라진-2-일]아세토니트릴의 결정 형태, 결정 형태를 포함하는 약제학적 조성물, 결정 형태의 제조 공정 및 그의 사용 방법에 관한 것이다.",MIRATI THERAPEUTICS INC,ANDRES PATRICIA;;ANDREW SAMUEL;;CHEN CHENG YI;;GANCEDO SUSANA DEL RIO;;GHARBAOUI TAWFIK;;NELSON JENNIFER,,https://lens.org/115-123-865-861-61X,Patent Application,no,0,0,11,12,0,A61P35/00;;C07D471/04;;A61P35/00;;C07D471/04;;C07D471/04;;A61K31/519;;A61P35/00;;C07B2200/13;;A61P35/00;;C07B2200/13;;C07D471/04,C07D471/04;;A61K31/519;;A61P35/00,,0,0,,,,PENDING
206,WO,A1,WO 2017/078987 A1,151-215-541-071-199,2017-05-11,2017,US 2016/0058712 W,2016-10-25,US 201562249442 P,2015-11-02,ADDITIVELY MANUFACTURING BIO-BASED CONDUCTIVE SHAPE MEMORY POLYMER MACROSTRUCTURE PARTS WITH HIGHLY ORDERED MICROSTRUCTURES,An additive manufacturing apparatus includes an additive manufacturing print head and a nozzle that receives a bio-based shape memory polymer material and a bio-based material. The nozzle extrudes the bio-based shape memory polymer material and the bio-based material onto a substrate to form a bio-based shape memory polymer part or product.,L LIVERMORE NAT SECURITY LLC,RODRIGUEZ JENNIFER NICOLE;;DUOSS ERIC B;;LEWICKI JAMES;;SPADACCINI CHRISTOPHER;;WILSON THOMAS G;;ZHU CHENG,,https://lens.org/151-215-541-071-199,Patent Application,yes,3,8,2,2,0,B33Y80/00;;B29C64/106;;B29C64/165;;B33Y70/10;;B29C64/106;;B33Y80/00;;B33Y70/10;;B33Y10/00;;B33Y30/00;;B33Y50/02;;C08K3/046;;B29C64/321;;B29C64/209;;B29C64/393;;B29C64/165;;B29K2063/00;;B29K2105/124;;B29K2507/04;;C08K7/04;;C08K2201/011;;C08L63/00;;C08L91/00,B29K105/12;;B29C67/00;;B33Y70/00,,2,2,040-002-502-275-865;;059-869-557-526-467,10.1002/adfm.200600434;;26402320;;10.1002/adma.201503132,"JENNIFER A. LEWIS: ""Direct Ink Writing of 3D Functional Materials"", ADV. FUNCT. MATER, vol. 16, no. 17, 2006, pages 2193 - 2204, XP001500487;;MATT ZAREK ET AL.: ""3D Printing of Shape Memory Polymers for Flexible Electro nic Devices"", ADVANCED MATERIALS, vol. 28, no. 22, 24 September 2015 (2015-09-24), pages 4449 - 4454, XP055381292",PENDING
207,AU,A,AU 1996/065428 A,198-857-720-147-195,1997-02-10,1997,AU 1996/065428 A,1996-07-08,GB 9602977 A;;US 105595 P;;US 9611370 W,1995-07-11,A triazolylmethyl-indole ethylamine bisulfate salt,"The bisulfate salt of N,N-dimethyl-2-[5-(1,2,4-triazol-1-ylmethyl)-1H-indol-3-yl]ethylamine is a selective agonist of 5-HT1-like receptors and is useful in the treatment of migraine and associated disorders.",MERCK & CO INC,CHENG CHEN Y;;LARSEN ROBERT D;;MCCAULEY JAMES A;;VANDRILLA JENNIFER L;;VERHOEVEN THOMAS R,,https://lens.org/198-857-720-147-195,Patent Application,no,0,0,11,14,0,A61K31/4196;;C07D231/12;;C07D233/56;;C07D249/08;;A61P25/04;;A61P25/06;;A61P43/00,C07D403/06;;A61K31/41;;A61K31/4196;;A61P25/04;;A61P25/06;;A61P43/00;;C07D521/00,,0,0,,,,PENDING
208,KR,A,KR 20110056277 A,001-682-533-342-423,2011-05-26,2011,KR 20117002684 A,2009-09-18,US 9859708 P;;US 9907408 P;;US 10446608 P;;US 2009/0057493 W,2008-09-19,FORMATION OF DEVICES BY EPITAXIAL LAYER OVERGROWTH,,TAIWAN SEMICONDUCTOR MFG,FIORENZA JAMES;;LOCHTEFELD ANTHONY;;BAI JIE;;PARK JI SOO;;HYDRICK JENNIFER;;LI JIZHONG;;CHENG ZHIYUAN,,https://lens.org/001-682-533-342-423,Patent Application,no,0,3,19,19,0,H01L21/02381;;H01L21/02538;;H01L21/20;;H01L21/02381;;H01L21/0245;;H01L21/0245;;H01L21/02461;;H01L21/02461;;H01L21/02463;;H01L21/02463;;H01L21/02543;;H01L21/02543;;H01L21/02546;;H01L21/02546;;H01L21/02636;;H01L21/02636;;H01L21/02639;;H01L21/02639;;H01L21/02647;;H01L21/02647;;H01L29/205;;H01L31/04;;H01L31/0687;;H01L31/0687;;H01L31/06875;;H01L31/06875;;H01L31/1808;;H01L31/1808;;H01L31/1852;;H01L31/1852;;H01L31/1892;;H01L31/1892;;Y02E10/544;;Y02E10/544,H01L21/20;;H01L31/042,,0,0,,,,ACTIVE
209,CN,B,CN 102160145 B,004-138-871-985-034,2013-08-21,2013,CN 200980136547 A,2009-09-18,US 2009/0057493 W;;US 9859708 P;;US 9907408 P;;US 10446608 P,2008-09-19,Formation of devices by epitaxial layer overgrowth,,TAIWAN SEMICONDUCTOR MFG,FIORENZA JAMES;;LOCHTEFELD ANTHONY;;BAI JIE;;PARK JI-SOO;;HYDRICK JENNIFER;;LI JIZHONG;;ZHIYUAN CHENG,,https://lens.org/004-138-871-985-034,Granted Patent,no,0,0,19,19,0,H01L21/02381;;H01L21/02538;;H01L21/20;;H01L21/02381;;H01L21/0245;;H01L21/0245;;H01L21/02461;;H01L21/02461;;H01L21/02463;;H01L21/02463;;H01L21/02543;;H01L21/02543;;H01L21/02546;;H01L21/02546;;H01L21/02636;;H01L21/02636;;H01L21/02639;;H01L21/02639;;H01L21/02647;;H01L21/02647;;H01L29/205;;H01L31/04;;H01L31/0687;;H01L31/0687;;H01L31/06875;;H01L31/06875;;H01L31/1808;;H01L31/1808;;H01L31/1852;;H01L31/1852;;H01L31/1892;;H01L31/1892;;Y02E10/544;;Y02E10/544,H01L21/20;;H01L31/042,,0,0,,,,ACTIVE
210,AU,A1,AU 2014/200906 A1,029-241-352-230-61X,2014-03-13,2014,AU 2014/200906 A,2014-02-21,AU 2008/226823 A;;AU 2014/200906 A,2008-03-12,OLIGOMER-PROTEASE INHIBITOR CONJUGATES,"Abstract The invention provides protease inhibitors that are chemically modified by covalent attachment of a water-soluble oligomer. A conjugate of the invention, when administered 5 by any of a number of administration routes, exhibits characteristics that are different from the protease inhibitors not attached to the water-soluble oligomer. 5136858 1 (GHMatters) P81855.AU.1",NEKTAR THERAPEUTICS,RIGGS-SAUTHIER JENNIFER;;CHENG LIN;;VIEGAS TRACEY X;;GU XUYUAN;;DUARTE FRANCO J;;ZHANG WEN,,https://lens.org/029-241-352-230-61X,Patent Application,no,0,0,2,2,0,,A61K47/48;;A61P31/18,,0,0,,,,ACTIVE
211,CN,A,CN 102816111 A,119-827-059-411-973,2012-12-12,2012,CN 201210257651 A,2008-03-12,US 90633007 P,2007-03-12,Oligomer-Protease Inhibitor Conjugates,"The invention provides small molecule drugs that are chemically modified by covalent attachment of a water-soluble oligomer. A conjugate of the invention, when administered by any of a number of administration routes, exhibits characteristics that are different from the small molecule drug not attached to the water-soluble oligomer.",NEKTAR THERAPEUTICS,RIGGS-SAUTHIER JENNIFER;;CHENG LIN;;VIEGAS TACEY X;;GU XUYUAN;;DUARTE FRANCO J;;ZHANG WEN,,https://lens.org/119-827-059-411-973,Patent Application,no,3,2,27,58,0,A61K47/60;;A61P31/12;;A61P31/16;;A61P31/18;;A61P43/00;;A61K47/50;;A61K31/164;;A61K47/60,C07D213/42;;A61K31/4418;;A61K47/48;;A61P31/18;;C08G65/333,,0,0,,,,ACTIVE
212,EP,A1,EP 2522367 A1,135-476-272-909-728,2012-11-14,2012,EP 12178362 A,2008-03-12,EP 08742083 A;;US 90633007 P,2007-03-12,Oligomer-protease inhibitor conjugates,"The invention provides small molecule protease inhibitors that are chemically modified by covalent attachment of water-soluble oligomer. A conjugate of the invention, when administered by any of a number of administration routes, exhibits characteristics that are different from the small molecule protease inhibitor not attached to the water-soluble oligomer.",NEKTAR THERAPEUTICS,RIGGS-SAUTHIER JENNIFER;;CHENG LIN;;VIEGAS TACEY X;;GU XUYUAN;;DUARTE FRANCO J;;ZHANG WEN,,https://lens.org/135-476-272-909-728,Patent Application,yes,27,0,27,58,0,A61K47/60;;A61P31/12;;A61P31/16;;A61P31/18;;A61P43/00;;A61K47/50;;A61K31/164;;A61K47/60,A61K47/48;;A61P31/18,,15,12,011-256-459-180-120;;038-334-210-991-906;;124-769-862-069-925;;051-780-238-835-252;;002-276-833-366-497;;017-989-392-397-902;;003-793-280-475-635;;038-334-210-991-906;;077-295-491-167-117;;058-789-596-477-892;;091-442-146-191-671;;015-301-295-258-870,10.1023/a:1020913631309;;12458677;;15546199;;10.1021/bc0498875;;pmc1481600;;16635263;;10.1186/1742-6405-3-12;;16902393;;2405486;;10.1126/science.2405486;;16905788;;10.1001/jama.296.7.827;;11705466;;10.1016/s0008-6215(01)00260-9;;15546199;;10.1021/bc0498875;;10.1002/0471220574;;11674697;;10.1021/jo990620m;;pmc245361;;10.1128/aac.35.11.2209;;1803993;;10.1016/0166-0934(88)90134-6;;2460479,"ROUQUAYROL M ET AL: ""Transepithelial transport of prodrugs of the HIV protease inhibitors saquinavir, indinavir, and nelfinavir across Cavo-2 cell monolayers"", PHARMACEUTICAL RESEARCH, KLUWER ACADEMIC PUBLISHERS, NEW YORK, NY, US, vol. 19, no. 11, 1 November 2002 (2002-11-01), pages 1704 - 1712, XP002370285, ISSN: 0724-8741, DOI: 10.1023/A:1020913631309;;GUNASEELAN S ET AL: ""Synthesis of poly(ethylene glycol)-based saquinavir prodrug conjugates and assessment of release and anti-HIV-1 bioactivity using a novel protease inhibition assay"", BIOCONJUGATE CHEMISTRY, ACS, WASHINGTON, DC, US, vol. 15, no. 6, 1 November 2004 (2004-11-01), pages 1322 - 1333, XP002347556, ISSN: 1043-1802;;WAN LI ET AL: ""Novel multi-component nanopharmaceuticals derived from poly(ethylene) glycol, retro-inverso-Tat nonapeptide and saquinavir demonstrate combined anti-HIV effects"", AIDS RESEARCH AND THERAPY, BIOMED CENTRAL, LONDON, GB, vol. 3, no. 1, 24 April 2006 (2006-04-24), pages 12, XP021019216, ISSN: 1742-6405, DOI: 10.1186/1742-6405-3-12;;MMWR, vol. 55, no. 31, 11 August 2006 (2006-08-11), pages 841 - 844;;SCIENCE, vol. 247, no. 4941, 1990, pages 454 - 456;;HAMMER ET AL., JAMA, vol. 296, no. 7, 2006, pages 827 - 843;;CARBOHYDR. RES., vol. 336, 2001, pages 161 - 180;;GUNASEELAN ET AL., BIOCONJUGATE CHEM., vol. 15, 2004, pages 1322 - 1333;;T.W. GREENE; G.M. WUTS: ""Protecting Groups in Organic Synthesis, Third Edition,"", 1999, WILEY;;CHEN Y.; BAKER, G.L., J. ORG. CHEM., 1999, pages 6870 - 6873;;KEMPF ET AL., ANTIMICROB. AGENTS CHEMOTHER., vol. 35, no. 11, 1991, pages 2209 - 2214;;PAUWELS ET AL., J. VIROL METHODS, vol. 20, 1988, pages 309 - 321;;""Remington: The Science & Practice of Pharmacy,19th ed.,"", 1995, WILLIAMS & WILLIAMS;;""Physician's Desk Reference, 52'"" ed.,"", 1998, MEDICAL ECONOMICS;;KIBBE, A.H.: ""Handbook of Pharmaceutical Excipients, 3d Edition,"", 2000, AMERICAN PHARMACEUTICAL ASSOCIATION",ACTIVE
213,US,B2,US 8034697 B2,067-128-038-662-928,2011-10-11,2011,US 68087209 A,2009-09-18,US 68087209 A;;US 9859708 P;;US 9907408 P;;US 10446608 P;;US 2009/0057493 W,2008-09-19,Formation of devices by epitaxial layer overgrowth,"Methods and structures are provided for formation of devices, e.g., solar cells, on substrates including, e.g., lattice-mismatched materials, by the use of aspect ratio trapping (ART) and epitaxial layer overgrowth (ELO). In general, in a first aspect, embodiments of the invention may include a method of forming a structure. The method includes forming a first opening in a masking layer disposed over a substrate that includes a first semiconductor material. A first layer, which includes a second semi-conductor material lattice-mismatched to the first semiconductor material, is formed within the first opening. The first layer has a thickness sufficient to extend above a top surface of the masking layer. A second layer, which includes the second semiconductor material, is formed on the first layer and over at least a portion of the masking layer. A vertical growth rate of the first layer is greater than a lateral growth rate of the first layer and a lateral growth rate of the second layer is greater than a vertical growth rate of the second layer.",TAIWAN SEMICONDUCTOR MFG,FIORENZA JAMES;;LOCHTEFELD ANTHONY;;BAI JIE;;PARK JI-SOO;;HYDRICK JENNIFER;;LI JIZHONG;;CHENG ZHIYUAN,AMBERWAVE SYSTEMS (2009-11-23);;TAIWAN SEMICONDUCTOR MANUFACTURING CO. LTD (2010-05-13);;TAIWAN SEMICONDUCTOR MANUFACTURING COMPANY LTD (2009-11-22),https://lens.org/067-128-038-662-928,Granted Patent,yes,16,34,19,19,0,H01L21/02381;;H01L21/02538;;H01L21/20;;H01L21/02381;;H01L21/0245;;H01L21/0245;;H01L21/02461;;H01L21/02461;;H01L21/02463;;H01L21/02463;;H01L21/02543;;H01L21/02543;;H01L21/02546;;H01L21/02546;;H01L21/02636;;H01L21/02636;;H01L21/02639;;H01L21/02639;;H01L21/02647;;H01L21/02647;;H01L29/205;;H01L31/04;;H01L31/0687;;H01L31/0687;;H01L31/06875;;H01L31/06875;;H01L31/1808;;H01L31/1808;;H01L31/1852;;H01L31/1852;;H01L31/1892;;H01L31/1892;;Y02E10/544;;Y02E10/544,H01L21/20;;H01L21/36,438/481;;X257E2109;;438/94,1,0,,,"PCT International Search Report of PCT/US2009/057493, form PCT/ISA/210, mailed Mar. 22, 2010, Applicant: Amberwave System Corporation et al., 3 pages.",ACTIVE
214,CN,B,CN 101631568 B,099-657-328-203-468,2012-08-22,2012,CN 200880007943 A,2008-03-12,US 2008/0003354 W;;US 90633007 P,2007-03-12,Oligomer-protease inhibitor conjugates,"The invention provides small molecule drugs that are chemically modified by covalent attachment of a water-soluble oligomer. A conjugate of the invention, when administered by any of a number of administration routes, exhibits characteristics that are different from the small molecule drug not attached to the water-soluble oligomer.",NEKTAR THERAPEUTICS AL CORP US,JENNIFER RIGGS-SAUTHIER;;LIN CHENG;;VIEGAS TACEY X;;XUYUAN GU;;DUARTE FRANCO J;;WEN ZHANG,,https://lens.org/099-657-328-203-468,Granted Patent,no,0,0,27,58,0,A61K47/60;;A61P31/12;;A61P31/16;;A61P31/18;;A61P43/00;;A61K47/50;;A61K31/164;;A61K47/60,A61P31/18;;A61K47/48,,0,0,,,,ACTIVE
215,EP,A1,EP 0840733 A1,133-264-080-376-069,1998-05-13,1998,EP 96925277 A,1996-07-08,GB 9602977 A;;US 9611370 W;;US 105595 P,1995-07-11,A TRIAZOLYLMETHYL-INDOLE ETHYLAMINE BISULFATE SALT,"The bisulfate salt of N,N-dimethyl-2-[5-(1,2,4-triazol-1-ylmethyl)-1H-indol-3-yl]ethylamine is a selective agonist of 5-HT1-like receptors and is useful in the treatment of migraine and associated disorders.",MERCK & CO INC,CHENG CHEN Y;;LARSEN ROBERT D;;MCCAULEY JAMES A;;VANDRILLA JENNIFER L;;VERHOEVEN THOMAS R,"MERCK SHARP & DOHME CORP., US (2013-05-14);;MERCK SHARP & DOHME CORP., RAHWAY, US (2013-05-14);;SCHERING CORPORATION, US (2013-03-18);;MERCK  SHARP & DOHME CORP. (2012-10-19)",https://lens.org/133-264-080-376-069,Patent Application,yes,0,0,11,14,0,A61K31/4196;;C07D231/12;;C07D233/56;;C07D249/08;;A61P25/04;;A61P25/06;;A61P43/00,A61K31/41;;A61K31/4196;;C07D403/06;;A61P25/04;;A61P25/06;;A61P43/00;;C07D521/00,,0,0,,,,EXPIRED
216,WO,A3,WO 2010/033813 A3,185-186-070-164-578,2010-06-03,2010,US 2009/0057493 W,2009-09-18,US 9907408 P;;US 10446608 P;;US 9859708 P,2008-09-19,FORMATION OF DEVICES BY EPITAXIAL LAYER OVERGROWTH,"Methods and structures are provided for formation of devices, e.g., solar cells, on substrates including, e.g., lattice-mismatched materials, by the use of aspect ratio trapping (ART) and epitaxial layer overgrowth (ELO). In general, in a first aspect, embodiments of the invention may include a method of forming a structure. The method includes forming a first opening in a masking layer disposed over a substrate that includes a first semiconductor material. A first layer, which includes a second semiconductor material lattice-mismatched to the first semiconductor material, is formed within the first opening. The first layer has a thickness sufficient to extend above a top surface of the masking layer. A second layer, which includes the second semiconductor material, is formed on the first layer and over at least a portion of the masking layer. A vertical growth rate of the first layer is greater than a lateral growth rate of the first layer and a lateral growth rate of the second layer is greater than a vertical growth rate of the second layer.",AMBERWAVE SYSTEM CORP;;FIORENZA JAMES;;LOCHTEFELD ANTHONY;;BAI JIE;;PARK JI-SOO;;HYDRICK JENNIFER;;LI JIZHONG;;ZHIYUAN CHENG,FIORENZA JAMES;;LOCHTEFELD ANTHONY;;BAI JIE;;PARK JI-SOO;;HYDRICK JENNIFER;;LI JIZHONG;;ZHIYUAN CHENG,,https://lens.org/185-186-070-164-578,Search Report,yes,4,0,19,19,0,H01L21/02381;;H01L21/02538;;H01L21/20;;H01L21/02381;;H01L21/0245;;H01L21/0245;;H01L21/02461;;H01L21/02461;;H01L21/02463;;H01L21/02463;;H01L21/02543;;H01L21/02543;;H01L21/02546;;H01L21/02546;;H01L21/02636;;H01L21/02636;;H01L21/02639;;H01L21/02639;;H01L21/02647;;H01L21/02647;;H01L29/205;;H01L31/04;;H01L31/0687;;H01L31/0687;;H01L31/06875;;H01L31/06875;;H01L31/1808;;H01L31/1808;;H01L31/1852;;H01L31/1852;;H01L31/1892;;H01L31/1892;;Y02E10/544;;Y02E10/544,H01L21/20;;H01L31/042,,1,0,,,See also references of EP 2335273A4,PENDING
217,WO,A3,WO 2008/112289 A3,189-095-451-401-153,2008-12-24,2008,US 2008/0003354 W,2008-03-12,US 90633007 P,2007-03-12,OLIGOMER-PROTEASE INHIBITOR CONJUGATES,"The invention provides protease inhibitors that are chemically modified by covalent attachment of a water-soluble oligomer. A conjugate of the invention, when administered by any of a number of administration routes, exhibits characteristics that are different from the protease inhibitors not attached to the water-soluble oligomer.",NEKTAR THERAPEUTICS AL CORP;;RIGGS-SAUTHIER JENNIFER;;CHENG LIN;;VIEGAS TACEY X;;GU XUYUAN;;DUARTE FRANCO J;;ZHANG WEN,RIGGS-SAUTHIER JENNIFER;;CHENG LIN;;VIEGAS TACEY X;;GU XUYUAN;;DUARTE FRANCO J;;ZHANG WEN,,https://lens.org/189-095-451-401-153,Search Report,yes,4,0,27,58,0,A61K47/60;;A61P31/12;;A61P31/16;;A61P31/18;;A61P43/00;;A61K47/50;;A61K31/164;;A61K47/60,A61P31/18;;A61K47/48,,1,1,038-334-210-991-906,15546199;;10.1021/bc0498875,"GUNASEELAN S ET AL: ""Synthesis of poly(ethylene glycol)-based saquinavir prodrug conjugates and assessment of release and anti-HIV-1 bioactivity using a novel protease inhibition assay"", BIOCONJUGATE CHEMISTRY, ACS, WASHINGTON, DC, US, vol. 15, no. 6, 1 November 2004 (2004-11-01), pages 1322 - 1333, XP002347556, ISSN: 1043-1802",PENDING
218,BR,A2,BR 112023004569 A2,033-942-072-954-37X,2023-04-04,2023,BR 112023004569 A,2021-09-10,US 2021/0049940 W;;US 202063077553 P;;US 202063093673 P,2020-09-11,FORMAS CRISTALINAS DE UM INIBIDOR DE KRAS G12C,"FORMAS CRISTALINAS DE UM INIBIDOR DE KRAS G12C. A presente invenção se refere a formas cristalinas de um inibidor de KRas G12C e sal do mesmo. Em particular, a presente invenção se refere a formas cristalinas do inibidor de KRas GT2C 2-[(2S)-4-[7-(8-cloro-1-naftil)-2-[[(2S)-1-metilpirrolidin-2-il]metóxi]-6,8-di-hidro-5H-pirido[3,4-d]pirimidin-4-il]-1-(2-fluoroprop-2-enoil)piperazin-2-il]acetonitrila, composições farmacêuticas compreendendo as formas cristalinas, processos para preparação das formas cristalinas e métodos de uso das mesmas.",MIRATI THERAPEUTICS INC,PATRICIA ANDRES;;SAMUEL ANDREW;;CHENG YI CHEN;;TAWFIK GHARBAOUI;;JENNIFER NELSON;;SUSANA DEL RIO GANCEDO,,https://lens.org/033-942-072-954-37X,Patent Application,no,0,0,11,12,0,A61P35/00;;C07D471/04;;A61P35/00;;C07D471/04;;C07D471/04;;A61K31/519;;A61P35/00;;C07B2200/13;;A61P35/00;;C07B2200/13;;C07D471/04,A61P35/00;;C07D471/04;;C07D519/00,,0,0,,,,PENDING
219,CN,B,CN 102816111 B,080-066-876-274-860,2014-08-06,2014,CN 201210257651 A,2008-03-12,US 90633007 P,2007-03-12,Oligomer-protease inhibitor conjugates,,NEKTAR THERAPEUTICS,RIGGS-SAUTHIER JENNIFER;;CHENG LIN;;VIEGAS TACEY X;;GU XUYUAN;;DUARTE FRANCO J;;ZHANG WEN,,https://lens.org/080-066-876-274-860,Granted Patent,no,0,0,27,58,0,A61K47/60;;A61P31/12;;A61P31/16;;A61P31/18;;A61P43/00;;A61K47/50;;A61K31/164;;A61K47/60,C07D213/42;;A61K31/4418;;A61K47/48;;A61P31/18;;C08G65/333,,0,0,,,,ACTIVE
220,US,A1,US 2002/0042383 A1,025-171-825-573-684,2002-04-11,2002,US 39246299 A,1999-09-09,US 39246299 A;;US 9958398 P,1998-09-09,METHYLATION AND/Or CpG REMOVAL OF PLASMID VECTORS,"
   Unmethylated plasmid DNA vectors are a major contributor to the inflammatory response associated with gene delivery. Results of clinical studies where CF subjects were subjected to either aerosolized liposomes alone or cationic lipid:DNA complexes indicated that bacterial derived plasmid DNA may be inflammatory. Additionally, unmethylated CpG dinucleotides have been shown to be immunostimulatory and are present at a much higher frequency in bacterially derived plasmid DNA compared to vertebrate DNA. The invention provides for methods of modulating the immunostimulatory response to gene delivery by modifying the plasmid delivered to the cell. The plasmid is modified to reduce or eliminate the immunostimulatory response in order to preserve the efficacy of gene transfer but reduce the associated toxicity. In a preferred embodiment, the invention provides for a method of reducing inflammatory response to gene delivery by methylating CpG motifs of the plasmid vector and or removing CpG motifs of the plasmid vector. 
",YEW NELSON S.;;PRZBYLSKA MALGORZATA;;MARSHALL JOHN;;SCHEULE RONALD K.;;TOUSIGNANT JENNIFER;;CHENG SENG H.,YEW NELSON S;;PRZBYLSKA MALGORZATA;;MARSHALL JOHN;;SCHEULE RONALD K;;TOUSIGNANT JENNIFER;;CHENG SENG H,GENZYME CORPORATION (1999-10-01),https://lens.org/025-171-825-573-684,Patent Application,yes,0,37,15,15,0,A61K48/00;;A61K48/00;;A61P1/18;;A61P29/00;;A61P37/02;;A61P37/06;;C12N15/88;;C12N15/88;;C12N2799/021;;C12N2799/021;;C12P19/34;;C12P19/34,C12N15/09;;A61K31/35;;A61K31/365;;A61K31/4706;;A61K31/473;;A61K31/711;;A61K48/00;;A61P1/18;;A61P29/00;;A61P37/02;;A61P37/06;;C12N15/88;;C12P19/34,514/44;;435/91.1;;435/91.4;;435/458;;536/23.1,0,0,,,,DISCONTINUED
221,US,A1,US 2023/0357231 A1,048-299-104-035-488,2023-11-09,2023,US 202118025817 A,2021-09-10,US 202118025817 A;;US 202063077553 P;;US 202063093673 P;;US 2021/0049940 W,2020-09-11,CRYSTALLINE FORMS OF A KRAS G12C INHIBITOR,"The present invention relates to crystalline forms of a KRas G12C inhibitor and salt thereof. In particular, the present invention relates to crystalline forms of the KRas GT2C inhibitor 2-[(2S)-4-[7-(8-chloro-1-naphthyI)-2-[[(2S)-1-methylpyrrolidin-2-yl]methoxy]-6,8-dihydro-5H-pyrido[3,4-d]pyrimidin-4-yI]-1-(2-fluoroprop-2-enoyi)piperazin-2-yl]acetonitrile, pharmaceutical compositions comprising the crystalline forms, processes for preparing the crystalline forms and methods of use thereof.",MIRATI THERAPEUTICS INC,ANDRES PATRICIA;;ANDREW SAMUEL;;CHEN CHENG YI;;GANCEDO SUSANA DEL RIO;;GHARBAOUI TAWFIK;;NELSON JENNIFER,,https://lens.org/048-299-104-035-488,Patent Application,yes,0,0,11,12,0,A61P35/00;;C07D471/04;;A61P35/00;;C07D471/04;;C07D471/04;;A61K31/519;;A61P35/00;;C07B2200/13;;A61P35/00;;C07B2200/13;;C07D471/04,C07D471/04;;A61P35/00,,0,0,,,,PENDING
222,EP,A2,EP 2131865 A2,030-418-333-517-064,2009-12-16,2009,EP 08742083 A,2008-03-12,US 2008/0003354 W;;US 90633007 P,2007-03-12,OLIGOMER-PROTEASE INHIBITOR CONJUGATES,,NEKTAR THERAPEUTICS,RIGGS-SAUTHIER JENNIFER;;CHENG LIN;;VIEGAS TACEY X;;GU XUYUAN;;DUARTE FRANCO J;;ZHANG WEN,NEKTAR THERAPEUTICS (2011-03-16),https://lens.org/030-418-333-517-064,Patent Application,yes,0,0,27,58,0,A61K47/60;;A61P31/12;;A61P31/16;;A61P31/18;;A61P43/00;;A61K47/50;;A61K31/164;;A61K47/60,A61P31/18;;A61K47/48,,0,0,,,,ACTIVE
223,EP,B1,EP 2522367 B1,037-290-621-647-394,2016-01-20,2016,EP 12178362 A,2008-03-12,EP 08742083 A;;US 90633007 P,2007-03-12,Oligomer-protease inhibitor conjugates,,NEKTAR THERAPEUTICS,RIGGS-SAUTHIER JENNIFER;;CHENG LIN;;VIEGAS TACEY X;;GU XUYUAN;;DUARTE FRANCO J;;ZHANG WEN,,https://lens.org/037-290-621-647-394,Granted Patent,yes,3,0,27,58,0,A61K47/60;;A61P31/12;;A61P31/16;;A61P31/18;;A61P43/00;;A61K47/50;;A61K31/164;;A61K47/60,A61K47/48;;A61P31/18,,3,0,,,"ROUQUAYROL M ET AL: ""Transepithelial transport of prodrugs of the HIV protease inhibitors saquinavir, indinavir, and nelfinavir across Cavo-2 cell monolayers"", PHARMACEUTICAL RESEARCH, KLUWER ACADEMIC PUBLISHERS, NEW YORK, NY, US, vol. 19, no. 11, 1 November 2002 (2002-11-01), pages 1704-1712, XP002370285, ISSN: 0724-8741, DOI: 10.1023/A:1020913631309;;GUNASEELAN S ET AL: ""Synthesis of poly(ethylene glycol)-based saquinavir prodrug conjugates and assessment of release and anti-HIV-1 bioactivity using a novel protease inhibition assay"", BIOCONJUGATE CHEMISTRY, ACS, WASHINGTON, DC, US, vol. 15, no. 6, 1 November 2004 (2004-11-01), pages 1322-1333, XP002347556, ISSN: 1043-1802;;WAN LI ET AL: ""Novel multi-component nanopharmaceuticals derived from poly(ethylene) glycol, retro-inverso-Tat nonapeptide and saquinavir demonstrate combined anti-HIV effects"", AIDS RESEARCH AND THERAPY, BIOMED CENTRAL, LONDON, GB, vol. 3, no. 1, 24 April 2006 (2006-04-24), page 12, XP021019216, ISSN: 1742-6405, DOI: 10.1186/1742-6405-3-12",ACTIVE
224,CN,A,CN 102160145 A,032-167-024-171-644,2011-08-17,2011,CN 200980136547 A,2009-09-18,US 2009/0057493 W;;US 9859708 P;;US 9907408 P;;US 10446608 P,2008-09-19,Formation of devices by epitaxial layer overgrowth,"Methods and structures are provided for formation of devices, e.g., solar cells, on substrates including, e.g., lattice-mismatched materials, by the use of aspect ratio trapping (ART) and epitaxial layer overgrowth (ELO). In general, in a first aspect, embodiments of the invention may include a method of forming a structure. The method includes forming a first opening in a masking layer disposed over a substrate that includes a first semiconductor material. A first layer, which includes a second semiconductor material lattice-mismatched to the first semiconductor material, is formed within the first opening. The first layer has a thickness sufficient to extend above a top surface of the masking layer. A second layer, which includes the second semiconductor material, is formed on the firstlayer and over at least a portion of the masking layer. A vertical growth rate of the first layer is greater than a lateral growth rate of the first layer and a lateral growth rate of the second layer is greater than a vertical growth rate of the second layer.",AMBERWAVE SYSTEM CORP,JAMES FIORENZA;;ANTHONY LOCHTEFELD;;JIE BAI;;JI-SOO PARK;;JENNIFER HYDRICK;;JIZHONG LI;;CHENG ZHIYUAN,,https://lens.org/032-167-024-171-644,Patent Application,no,6,1,19,19,0,H01L21/02381;;H01L21/02538;;H01L21/20;;H01L21/02381;;H01L21/0245;;H01L21/0245;;H01L21/02461;;H01L21/02461;;H01L21/02463;;H01L21/02463;;H01L21/02543;;H01L21/02543;;H01L21/02546;;H01L21/02546;;H01L21/02636;;H01L21/02636;;H01L21/02639;;H01L21/02639;;H01L21/02647;;H01L21/02647;;H01L29/205;;H01L31/04;;H01L31/0687;;H01L31/0687;;H01L31/06875;;H01L31/06875;;H01L31/1808;;H01L31/1808;;H01L31/1852;;H01L31/1852;;H01L31/1892;;H01L31/1892;;Y02E10/544;;Y02E10/544,H01L21/20;;H01L31/042,,0,0,,,,ACTIVE
225,AU,B2,AU 2008/226823 B2,090-188-399-600-501,2014-03-13,2014,AU 2008/226823 A,2008-03-12,US 90633007 P;;US 2008/0003354 W,2007-03-12,Oligomer-protease inhibitor conjugates,"The invention provides protease inhibitors that are chemically modified by covalent attachment of a water-soluble oligomer. A conjugate of the invention, when administered by any of a number of administration routes, exhibits characteristics that are different from the protease inhibitors not attached to the water-soluble oligomer.",NEKTAR THERAPEUTICS,DUARTE FRANCO J;;CHENG LIN;;GU XUYUAN;;ZHANG WEN;;VIEGAS TACEY X;;RIGGS-SAUTHIER JENNIFER,,https://lens.org/090-188-399-600-501,Granted Patent,no,3,0,27,58,0,A61K47/60;;A61P31/12;;A61P31/16;;A61P31/18;;A61P43/00;;A61K47/50;;A61K31/164;;A61K47/60,A61K47/48;;A61P31/18,,1,1,038-334-210-991-906,15546199;;10.1021/bc0498875,"GUNASEELAN, S. et al., Bioconjugate Chemistry, 2004, vol. 15, pages 1322-1333",ACTIVE
226,EP,A1,EP 4224254 A1,020-301-404-985-93X,2023-08-09,2023,EP 22155168 A,2022-02-04,EP 22155168 A,2022-02-04,METROLOGY METHOD AND ASSOCIATED METROLOGY DEVICE,"Disclosed is a method of determining a value for a parameter of interest from a target on a substrate. The method comprises obtaining metrology data comprising single-wavelength parameter of interest values which were obtained using a respective different measurement wavelength; and determining said value for the parameter of interest from a stack sensitivity derived weighted combination of said single-wavelength parameter of interest values. Also disclosed is a method of selecting wavelengths for a measurement based on at least the derivative of the stack sensitivity with respect to wavelength.
",ASML NETHERLANDS BV,KOOLEN ARMAND EUGENE ALBERT;;CHENG SU-TING;;CRAMER HUGO AUGUSTINUS JOSEPH;;WANG KIRSTEN JENNIFER LYHN,,https://lens.org/020-301-404-985-93X,Patent Application,yes,12,0,2,2,0,G03F9/7046;;G03F7/705;;G03F7/70616;;G03F7/70633,G03F7/20;;G03F9/00,,0,0,,,,PENDING
227,EP,A2,EP 2335273 A2,031-165-175-021-453,2011-06-22,2011,EP 09815273 A,2009-09-18,US 2009/0057493 W;;US 9907408 P;;US 10446608 P;;US 9859708 P,2008-09-19,FORMATION OF DEVICES BY EPITAXIAL LAYER OVERGROWTH,,TAIWAN SEMICONDUCTOR MFG,FIORENZA JAMES;;LOCHTEFELD ANTHONY;;BAI JIE;;PARK JI-SOO;;HYDRICK JENNIFER;;LI JIZHONG;;CHENG ZHIYUAN,,https://lens.org/031-165-175-021-453,Patent Application,yes,0,0,19,19,0,H01L21/02381;;H01L21/02538;;H01L21/20;;H01L21/02381;;H01L21/0245;;H01L21/0245;;H01L21/02461;;H01L21/02461;;H01L21/02463;;H01L21/02463;;H01L21/02543;;H01L21/02543;;H01L21/02546;;H01L21/02546;;H01L21/02636;;H01L21/02636;;H01L21/02639;;H01L21/02639;;H01L21/02647;;H01L21/02647;;H01L29/205;;H01L31/04;;H01L31/0687;;H01L31/0687;;H01L31/06875;;H01L31/06875;;H01L31/1808;;H01L31/1808;;H01L31/1852;;H01L31/1852;;H01L31/1892;;H01L31/1892;;Y02E10/544;;Y02E10/544,H01L21/20;;H01L21/02;;H01L31/042,,0,0,,,,DISCONTINUED
228,WO,A1,WO 1997/003068 A1,104-913-382-113-841,1997-01-30,1997,US 9611370 W,1996-07-08,GB 9602977 A;;US 105595 P,1995-07-11,A TRIAZOLYLMETHYL-INDOLE ETHYLAMINE BISULFATE SALT,"The bisulfate salt of N,N-dimethyl-2-[5-(1,2,4-triazol-1-ylmethyl)-1H-indol-3-yl]ethylamine is a selective agonist of 5-HT1-like receptors and is useful in the treatment of migraine and associated disorders.",MERCK & CO INC;;CHENG CHEN Y;;LARSEN ROBERT D;;MCCAULEY JAMES A;;VANDRILLA JENNIFER L;;VERHOEVEN THOMAS R,CHENG CHEN Y;;LARSEN ROBERT D;;MCCAULEY JAMES A;;VANDRILLA JENNIFER L;;VERHOEVEN THOMAS R,,https://lens.org/104-913-382-113-841,Patent Application,yes,3,2,11,14,0,A61K31/4196;;C07D231/12;;C07D233/56;;C07D249/08;;A61P25/04;;A61P25/06;;A61P43/00,A61K31/41;;A61K31/4196;;C07D403/06;;A61P25/04;;A61P25/06;;A61P43/00;;C07D521/00,,0,0,,,,PATENTED
229,MX,A,MX 2009009850 A,134-080-819-408-947,2009-09-24,2009,MX 2009009850 A,2008-03-12,US 90633007 P;;US 2008/0003354 W,2007-03-12,OLIGOMER-PROTEASE INHIBITOR CONJUGATES.,"The invention provides protease inhibitors that are chemically modified by covalent attachment of a water-soluble oligomer. A conjugate of the invention, when administered by any of a number of administration routes, exhibits characteristics that are different from the protease inhibitors not attached to the water-soluble oligomer.",NEKTAR THERAPEUTICS,RIGGS-SAUTHIER JENNIFER;;CHENG LIN;;VIEGAS TACEY X;;GU XUYUAN;;DUARTE FRANCO J;;ZHANG WEN,,https://lens.org/134-080-819-408-947,Patent Application,no,0,0,27,58,0,A61K47/60;;A61P31/12;;A61P31/16;;A61P31/18;;A61P43/00;;A61K47/50;;A61K31/164;;A61K47/60,A61P31/18;;A61K47/48,,0,0,,,,ACTIVE
230,EP,B1,EP 2131865 B1,180-800-763-333-43X,2014-12-17,2014,EP 08742083 A,2008-03-12,US 2008/0003354 W;;US 90633007 P,2007-03-12,OLIGOMER-PROTEASE INHIBITOR CONJUGATES,,NEKTAR THERAPEUTICS,RIGGS-SAUTHIER JENNIFER;;CHENG LIN;;VIEGAS TACEY X;;GU XUYUAN;;DUARTE FRANCO J;;ZHANG WEN,NEKTAR THERAPEUTICS (2011-03-16),https://lens.org/180-800-763-333-43X,Granted Patent,yes,4,0,27,58,0,A61K47/60;;A61P31/12;;A61P31/16;;A61P31/18;;A61P43/00;;A61K47/50;;A61K31/164;;A61K47/60,A61P31/18;;A61K47/48,,1,0,,,"GUNASEELAN S ET AL: ""Synthesis of poly(ethylene glycol)-based saquinavir prodrug conjugates and assessment of release and anti-HIV-1 bioactivity using a novel protease inhibition assay"" BIOCONJUGATE CHEMISTRY, ACS, WASHINGTON, DC, US, vol. 15, no. 6, 1 November 2004 (2004-11-01), pages 1322-1333, XP002347556 ISSN: 1043-1802 cited in the application",ACTIVE
231,KR,A,KR 20090118965 A,188-279-597-305-56X,2009-11-18,2009,KR 20097018914 A,2008-03-12,US 90633007 P;;US 2008/0003354 W,2007-03-12,OLIGOMER-PROTEASE INHIBITOR CONJUGATES,"The invention provides small molecule drugs that are chemically modified by covalent attachment of a water-soluble oligomer. A conjugate of the invention, when administered by any of a number of administration routes, exhibits characteristics that are different from the small molecule drug not attached to the water-soluble oligomer.",NEKTAR THERAPEUTICS,RIGGS SAUTHIER JENNIFER;;CHENG LIN;;VIEGAS TACEY X;;GU XUYUAN;;DUARTE FRANCO J;;ZHANG WEN,,https://lens.org/188-279-597-305-56X,Patent Application,no,0,0,27,58,0,A61K47/60;;A61P31/12;;A61P31/16;;A61P31/18;;A61P43/00;;A61K47/50;;A61K31/164;;A61K47/60,A61K47/48;;A61K31/164;;A61P31/18,,0,0,,,,ACTIVE
232,US,A1,US 2018/0272599 A1,070-450-079-980-782,2018-09-27,2018,US 201615762494 A,2016-10-25,US 201615762494 A;;US 201562249442 P;;US 2016/0058712 W,2015-11-02,ADDITIVELY MANUFACTURING BIO-BASED CONDUCTIVE SHAPE MEMORY POLYMER MACOSTRUCTURE PARTS WITH HIGHLY ORDERED MICROSTRUCTURES,An additive manufacturing apparatus includes an additive manufacturing print head and a nozzle that receives a bio-based shape memory polymer material and a bio-based material. The nozzle extrudes the bio-based shape memory polymer material and the bio-based material onto a substrate to form a bio-based shape memory polymer part or product.,L LIVERMORE NAT SECURITY LLC,RODRIGUEZ JENNIFER NICOLE;;DUOSS ERIC B;;LEWICKI JAMES;;SPADACCINI CHRISTOPHER;;WILSON THOMAS S;;ZHU CHENG,LAWRENCE LIVERMORE NATIONAL SECURITY LLC (2018-02-21),https://lens.org/070-450-079-980-782,Patent Application,yes,5,12,2,2,0,B33Y80/00;;B29C64/106;;B29C64/165;;B33Y70/10;;B29C64/106;;B33Y80/00;;B33Y70/10;;B33Y10/00;;B33Y30/00;;B33Y50/02;;C08K3/046;;B29C64/321;;B29C64/209;;B29C64/393;;B29C64/165;;B29K2063/00;;B29K2105/124;;B29K2507/04;;C08K7/04;;C08K2201/011;;C08L63/00;;C08L91/00,B29C64/165;;B29C64/209;;B29C64/321;;B29C64/393;;C08K3/04;;C08K7/04;;C08L63/00;;C08L91/00,,0,0,,,,DISCONTINUED
233,EP,B1,EP 2528087 B1,147-027-162-457-849,2016-06-29,2016,EP 12177269 A,2009-09-18,EP 09815273 A;;US 9907408 P;;US 10446608 P;;US 9859708 P,2008-09-19,Formation of devices by epitaxial layer overgrowth,,TAIWAN SEMICONDUCTOR MFG,FIORENZA JAMES;;LOCHTEFELD ANTHONY;;BAI JIE;;PARK JI-SOO;;HYDRICK JENNIFER;;LI JIZHONG;;ZHIYUAN CHENG,"TAIWAN SEMICONDUCTOR MANUFACTURING COMPANY, LTD. (2016-02-24)",https://lens.org/147-027-162-457-849,Granted Patent,yes,1,0,19,19,0,H01L21/02381;;H01L21/02538;;H01L21/20;;H01L21/02381;;H01L21/0245;;H01L21/0245;;H01L21/02461;;H01L21/02461;;H01L21/02463;;H01L21/02463;;H01L21/02543;;H01L21/02543;;H01L21/02546;;H01L21/02546;;H01L21/02636;;H01L21/02636;;H01L21/02639;;H01L21/02639;;H01L21/02647;;H01L21/02647;;H01L29/205;;H01L31/04;;H01L31/0687;;H01L31/0687;;H01L31/06875;;H01L31/06875;;H01L31/1808;;H01L31/1808;;H01L31/1852;;H01L31/1852;;H01L31/1892;;H01L31/1892;;Y02E10/544;;Y02E10/544,H01L21/20;;H01L31/042;;H01L31/0687;;H01L31/18,,2,2,141-764-543-442-220;;008-380-677-238-60X,10.1063/1.1935038;;10.1063/1.2035332,"NOBORISAKA JINICHIRO ET AL: ""Catalyst-free growth of GaAs nanowires by selective-area metalorganic vapor-phase epitaxy"", APPLIED PHYSICS LETTERS, AMERICAN INSTITUTE OF PHYSICS, US, vol. 86, no. 21, 213102, 16 May 2005 (2005-05-16), pages 1 - 3, XP012065664, ISSN: 0003-6951, DOI: 10.1063/1.1935038;;NOBORISAKA J ET AL: ""Fabrication and characterization of freestanding GaAs/AlGaAs core-shell nanowires and AlGaAs nanotubes by using selective-area metalorganic vapor phase epitaxy"", APPLIED PHYSICS LETTERS, AMERICAN INSTITUTE OF PHYSICS, US, vol. 87, no. 9, 093109, 24 August 2005 (2005-08-24), pages 1 - 3, XP012077641, ISSN: 0003-6951, DOI: 10.1063/1.2035332",ACTIVE
234,EP,A4,EP 2335273 A4,028-601-516-667-149,2012-01-25,2012,EP 09815273 A,2009-09-18,US 2009/0057493 W;;US 9907408 P;;US 10446608 P;;US 9859708 P,2008-09-19,FORMATION OF DEVICES BY EPITAXIAL LAYER OVERGROWTH,,TAIWAN SEMICONDUCTOR MFG,FIORENZA JAMES;;LOCHTEFELD ANTHONY;;BAI JIE;;PARK JI-SOO;;HYDRICK JENNIFER;;LI JIZHONG;;CHENG ZHIYUAN,,https://lens.org/028-601-516-667-149,Search Report,no,3,0,19,19,0,H01L21/02381;;H01L21/02538;;H01L21/20;;H01L21/02381;;H01L21/0245;;H01L21/0245;;H01L21/02461;;H01L21/02461;;H01L21/02463;;H01L21/02463;;H01L21/02543;;H01L21/02543;;H01L21/02546;;H01L21/02546;;H01L21/02636;;H01L21/02636;;H01L21/02639;;H01L21/02639;;H01L21/02647;;H01L21/02647;;H01L29/205;;H01L31/04;;H01L31/0687;;H01L31/0687;;H01L31/06875;;H01L31/06875;;H01L31/1808;;H01L31/1808;;H01L31/1852;;H01L31/1852;;H01L31/1892;;H01L31/1892;;Y02E10/544;;Y02E10/544,H01L21/20;;H01L21/02;;H01L31/042,,2,2,081-328-463-248-609;;015-476-364-945-119,10.1063/1.2924410;;10.1063/1.126754,"LI J ET AL: ""Defect reduction of GaAs/Si epitaxy by aspect ratio trapping"", JOURNAL OF APPLIED PHYSICS, AMERICAN INSTITUTE OF PHYSICS. NEW YORK, US, vol. 103, no. 10, 19 May 2008 (2008-05-19), pages 106102 - 106102, XP012108829, ISSN: 0021-8979, DOI: 10.1063/1.2924410;;LANGDO T A ET AL: ""High quality Ge on Si by epitaxial necking"", APPLIED PHYSICS LETTERS, AIP, AMERICAN INSTITUTE OF PHYSICS, MELVILLE, NY, US, vol. 76, no. 25, 19 June 2000 (2000-06-19), pages 3700 - 3702, XP012025569, ISSN: 0003-6951, DOI: 10.1063/1.126754",DISCONTINUED
235,WO,A2,WO 2008/112289 A2,140-101-755-775-787,2008-09-18,2008,US 2008/0003354 W,2008-03-12,US 90633007 P,2007-03-12,OLIGOMER-PROTEASE INHIBITOR CONJUGATES,"The invention provides small molecule drugs that are chemically modified by covalent attachment of a water-soluble oligomer. A conjugate of the invention, when administered by any of a number of administration routes, exhibits characteristics that are different from the small molecule drug not attached to the water-soluble oligomer.",NEKTAR THERAPEUTICS AL CORP;;RIGGS-SAUTHIER JENNIFER;;CHENG LIN;;VIEGAS TACEY X;;GU XUYUAN;;DUARTE FRANCO J;;ZHANG WEN,RIGGS-SAUTHIER JENNIFER;;CHENG LIN;;VIEGAS TACEY X;;GU XUYUAN;;DUARTE FRANCO J;;ZHANG WEN,,https://lens.org/140-101-755-775-787,Patent Application,yes,3,22,27,58,0,A61K47/60;;A61P31/12;;A61P31/16;;A61P31/18;;A61P43/00;;A61K47/50;;A61K31/164;;A61K47/60,A61P31/18;;A61K47/48,,5,1,058-789-596-477-892,11674697;;10.1021/jo990620m,"T.W. CREENE; G.M. WUTS: ""Protecting Groups in Organic Synthesis, Third Edition,"", 1999, WILEY;;CHEN Y.; BAKER, G.L., J. ORG. CHEM., 1999, pages 6870 - 6873;;""Remington: The Science & Practice of Pharmacy, 19th ed.,"", 1995, WILLIAMS & WILLIAMS;;""Physician's Desk Reference, 52nd ed.,"", 1998, MEDICAL ECONOMICS;;KIBBE, A.H.: ""Handbook ofPharmaceutical Excipients, 3rd Edition,"", 2000, AMERICAN PHARMACEUTICAL ASSOCIATION",PENDING
236,US,A1,US 2011/0269677 A1,140-920-612-807-293,2011-11-03,2011,US 53036308 A,2008-03-12,US 53036308 A;;US 90633007 P;;US 2008/0003354 W,2007-03-12,Oligomer-Protease Inhibitor Conjugates,"The invention provides protease inhibitors that are chemically modified by covalent attachment of a water-soluble oligomer. A conjugate of the invention, when administered by any of a number of administration routes, exhibits characteristics that are different from the protease inhibitors not attached to the water-soluble oligomer.",NEKTAR THERAPEUTICS,RIGGS-SAUTHIER JENNIFER;;CHENG LIN;;VIEGAS TACEY X;;GU XUYUAN;;DUARTE FRANCO J;;ZHANG WEN,NEKTAR THERAPEUTICS (2010-05-11);;NEKTAR THERAPEUTICS AL CORPORATION (2008-05-30),https://lens.org/140-920-612-807-293,Patent Application,yes,2,3,27,58,0,A61K47/60;;A61P31/12;;A61P31/16;;A61P31/18;;A61P43/00;;A61K47/50;;A61K31/164;;A61K47/60,A61K38/05;;A61K31/427;;A61K31/4418;;A61K31/4433;;A61K31/472;;A61K31/496;;A61K31/513;;A61K31/635;;A61K31/665;;A61P31/18;;C07D213/56;;C07D217/26;;C07D239/10;;C07D307/20;;C07D401/06;;C07D401/12;;C07D405/12;;C07D417/12;;C07D493/04;;C07F9/655,514/4.1;;549/475;;546/332;;549/222;;544/360;;544/316;;546/146;;548/204;;546/282.1;;549/464;;514/158;;514/357;;514/99;;514/253.13;;514/274;;514/307;;514/365;;514/336,1,1,038-334-210-991-906,15546199;;10.1021/bc0498875,"Simi Gunaseelan, et al, Synthesis of Poly(ethylene glycol)-Based Saquinavir Prodrug Conjugates and Assessment of Release and Anti-HIV-1 Bioactivity Using a Novel Protease Inhibition Assay, 15 BIOCONJ. CHEM. 1322, 1328-29 (2004)",ACTIVE
237,CN,A,CN 101631568 A,069-933-825-260-746,2010-01-20,2010,CN 200880007943 A,2008-03-12,US 2008/0003354 W;;US 90633007 P,2007-03-12,Oligomer-protease inhibitor conjugates,"The invention provides small molecule drugs that are chemically modified by covalent attachment of a water-soluble oligomer. A conjugate of the invention, when administered by any of a number of administration routes, exhibits characteristics that are different from the small molecule drug not attached to the water-soluble oligomer.",NEKTAR THERAPEUTICS AL CORP,JENNIFER RIGGS-SAUTHIER;;LIN CHENG;;VIEGAS TACEY X;;XUYUAN GU;;DUARTE FRANCO J;;WEN ZHANG,,https://lens.org/069-933-825-260-746,Patent Application,no,0,3,27,58,0,A61K47/60;;A61P31/12;;A61P31/16;;A61P31/18;;A61P43/00;;A61K47/50;;A61K31/164;;A61K47/60,A61K47/48,,0,0,,,,ACTIVE
238,US,B2,US 9107956 B2,093-409-473-471-732,2015-08-18,2015,US 201314055581 A,2013-10-16,US 201314055581 A;;US 53036310 A;;US 2008/0003354 W;;US 90633007 P,2007-03-12,Oligomer-protease inhibitor conjugates,"The invention provides small molecule drugs that are chemically modified by covalent attachment of a water-soluble oligomer. A conjugate of the invention, when administered by any of a number of administration routes, exhibits characteristics that are different from the small molecule drug not attached to the water-soluble oligomer.",NEKTAR THERAPEUTICS,RIGGS-SAUTHIER JENNIFER;;CHENG LIN;;VIEGAS TACEY X;;GU XUYUAN;;DUARTE FRANCO J;;ZHANG WEN,,https://lens.org/093-409-473-471-732,Granted Patent,yes,38,5,27,58,0,A61K47/60;;A61P31/12;;A61P31/16;;A61P31/18;;A61P43/00;;A61K47/50;;A61K31/164;;A61K47/60,A61K47/48,,58,14,091-197-353-551-151;;058-789-596-477-892;;011-565-742-695-524;;038-334-210-991-906;;017-989-392-397-902;;091-442-146-191-671;;002-276-833-366-497;;015-301-295-258-870;;003-793-280-475-635;;011-256-459-180-120;;124-769-862-069-925;;051-780-238-835-252;;024-021-975-726-957;;016-016-918-440-489,16078135;;10.1007/s11095-005-5271-y;;11674697;;10.1021/jo990620m;;10.1177/095632020001100202;;10819434;;15546199;;10.1021/bc0498875;;16905788;;10.1001/jama.296.7.827;;pmc245361;;10.1128/aac.35.11.2209;;1803993;;2405486;;10.1126/science.2405486;;10.1016/0166-0934(88)90134-6;;2460479;;11705466;;10.1016/s0008-6215(01)00260-9;;10.1023/a:1020913631309;;12458677;;pmc1481600;;16635263;;10.1186/1742-6405-3-12;;16902393;;10.1021/jm0499110;;15537350;;10.1021/jm049454n;;15771440,"Bachmeier, et al., ""Quantitative Assessment of HIV-1 Protease Inhibitor Interactions with Drug Efflux Transporters in the Blood-Brain Barrier"", Pharm. Res., vol. 22, No. 8, pp. 1259-1268, (Aug. 2005).;;Chen, et al., ""Synthesis and Properties of ABA Amphiphiles"", J. Org. Chem., vol. 64, pp. 6870-6873, (1999).;;Giorgio, et al, ""Synthesis and anti-HIV activity of prodrugs derived from saquinavir and indinavir"", Antiviral Chemistry and Chemo Therapy, vol. 11, No. 2, pp. 97-110, (2000).;;Gunaseelan, et al., ""Synthesis of Poly(ethylene glycol)-Based Saquinavir Prodrug Conjugates and Assessment of Release and Anti-HIV-1 Bioactivity Using a Novel Protease Inhibition Assay"", Bioconjugate, Chem., vol. 15, pp. 1322-1333, (2004).;;Hammer, et al., ""Treatment for Adult HIV Infection: 2006 Recommendations of the International Aids Society-USA Panel"", JAMA, vol. 296, No. 7, pp. 827-843, (2006).;;Kempf, et al., ""Antiviral and Pharmacokinetic Properties of C2 Symmetric Inhibitors of the Human Immunodeficiency Virus Type 1 Protease"", Antimicrob. Agents and Chemotherp., vol. 35, No. 11, pp. 2209-2214, (Nov. 1991).;;McQuade, et al., ""A Synthetic HIV-1 Protease Inhibitor with Antiviral Activity Arrests HIV-Like Particle Maturation"", Science, vol. 247, pp. 454-456, (Jan. 26, 1990).;;Pauwels, et al., ""Rapid and automated tetrazolium-based colorimetric assay for the detection of anti-HIV compounds"", J. of Virological Methods, vol. 20, pp. 309-321, (1988).;;Rouquayrol, et al., ""Synthesis and anti-HIV activity of glucose-containing prodrugs derived from saquinavir, indinavir and nelfinavir"", Carbohy. Res., vol. 336, pp. 161-180, (2001).;;Rouquayrol, et al., ""Transepithelial Transport of Prodrugs of the HIV Protease Inhibitors Saquinavir, Indinavir, and Nelfinavir across Caco-2 Cell Monolayers"", Pharm. Res., vol. 19, No. 11, pp. 1704-1712, (Nov. 2002).;;Wan, et al., ""Novel multi-component nanopharmaceuticals derived from poly(ethylene) glycol, retro-inverso-Tat nonapeptide and saquinavir demonstrate combined anti-HIV effects"", AIDS Res. And Therp., 3:12, pp. 1-15, (2006).;;Center for Disease Control and Prevention, MMWR, vol. 55, No. 31, pp. 841-844, (Aug. 11, 2006).;;PCT International Search Report in PCT Patent Application No. PCT/US2008/003354 date of mailing Nov. 6, 2008.;;PCT International Preliminary Report on Patentability in PCT Patent Application No. PCT/US2008/003354 date of issuance of report Sep. 15, 2009.;;Enzon Pharmaceuticals, Macromolecular Engineering Technologies, 16 pages, (2004).;;NEKTAR(TM)-Transforming Therapeutics, Nektar Molecule Engineering: Polyethylene Glycol and Derivatives for Advanced PEGylation, 24 pages, Catalog-2003, (Jul. 2003).;;NEKTAR(TM)-Transforming Therapeutics, Nektar Advanced PEGylation: Polyethylene Glycol and Derivatives for Advanced PEGylation, 27 pages, Catalog-2004, (Jul. 2004).;;NEKTAR(TM)-Transforming Therapeutics, Nektar Advanced PEGylation: Polyethylene Glycol and Derivatives for Advanced PEGylation, 33 pages, (Catalog 2005-2006).;;NOF Corporation, PEG Derivatives, Phospholipid and Drug Delivery Materials for Pharmaceuticals, 46 pages, Catalogue 2003-1st, (Jan. 2003).;;NOF Corporation, PEG Derivatives, Phospholipid and Drug Delivery Materials for Pharmaceuticals, 27 pages, Catalogue 2003-2nd, (Mar. 2004).;;NOF Corporation, PEG Derivatives, Phospholipids and Drug Delivery Materials for Pharmaceutical Products and Formulations, 60 pages, Catalogue Ver. 8, (Apr. 2006).;;Polypure Products, PEG amines; PEG acids and amino acids; PEG thiols and disulfides; Biotins, 5 pages, (Apr. 2004).;;Polypure Products, PEG amines; PEG acids and amino acids; PEG thiols and disulfides; Biotins, 5 pages, (Apr. 2005).;;Quanta Biodesign, Labeling, Derivatization and Crosslinking Reagents for Biological and Related Materials with dPEG(TM), 38 pages, (Mar. 12, 2004).;;Quanta Biodesign, Labeling, Modification and Crosslinking Reagents incorporating our unique monodispersed dPEG(TM) Technology, 31 pages, (Nov. 5, 2004).;;Quanta Biodesign, Ltd., Leading innovator, producer and provider of monodisperse discrete PEG(TM) (dPEG(TM)) derivatives, (Product Catalog), 26 pages, (Updated: Jul. 18, 2005).;;Quanta Biodesign, Ltd., Leading innovator, producer and provider of monodisperse discrete PEG(TM) (dPEG(TM)) derivatives, (Product Catalog), 26 pages, (Updated: Nov. 17, 2005).;;Shearwater Polymers, Inc., Polyethylene Glycol Derivatives, 50 pages, Catalog-(Mar. 1995).;;Shearwater Polymers, Inc., Polyethylene Glycol Derivatives, 55 pages, Catalog 1997-1998, (Jul. 1997).;;Shearwater Polymers, Inc., Polyethylene Glycol and Derivatives: Functionalized Biocompatible Polymers for Research and Pharmaceuticals, 50 pages, Catalog-(Jan. 2000).;;Shearwater Corporation, Polyethylene Glycol and Derivatives for Biomedical Applications, 20 pages, Catalog-(Jul. 2001).;;Examiner's First Report corresponding to Australian Patent Application No. 2008226823 dated May 23, 2012.;;Notification of the First Office Action corresponding to Chinese Patent Application No. 200880007943.X dated Apr. 21, 2011.;;Notification of the Second Office Action corresponding to Chinese Patent Application No. 200880007943.X dated Dec. 6, 2011.;;Examination Report corresponding to European Patent Application No. 08 742 083.2-1216 dated Jul. 26, 2010.;;Office Communication corresponding to European Patent Application No. 08 742 083.2-1216 dated Jul. 5, 2012.;;Office Communication with extended European Search Report corresponding to European Patent Application No. 12178362.5-1216 dated Oct. 11, 2012.;;First Substantive Examination Report corresponding to Israeli Patent Application No. 200846 dated Feb. 23, 2012.;;Office Action corresponding to Mexican Patent Application No. MX/a/2009/009850 dated Mar. 23, 2012.;;Shuman, et al., ""Improved Structure-Activity Relationship Analysis of HIV-1 Protease Inhibitors Using Interaction Kinetic Data"", J. Med. Chem., vol. 47, pp. 5953-5961, (2004).;;Surleraux, et al., ""Design of HIV-1 Protease Inhibitors Active on Multidrug-Resistant Virus"", J. Med. Chem., vol. 48, pp. 1965-1973, (2005).;;Cynkowski, et al., ""Synthesis and properties of novel prodrugs of saquinavir with short chain polyethylene glycols, polyoxa acids and amino acids"", Database CAPLUS on STN, AN 1998:529831, Book of Abstracts, 216th ACS National Meeting, (Aug. 1998).;;Canadian Office Action corresponding to Canadian Patent Application No. 2,679,482 dated Jun. 26, 2013.;;European Communication corresponding to European Patent Application No. 08 742 083.2 dated Jul. 1, 2013.;;European Communication corresponding to European Patent Application No. 12 178 362.5 dated Jul. 11, 2013.;;Japanese Notice of Reasons for Rejection corresponding to Japanese Patent Application No. 2009-553629 mailing date Mar. 6, 2013.;;Japanese Notice of Reasons for Rejection corresponding to Japanese Patent Application No. 2009-553629 mailing date Aug. 15, 2013.;;Mexican Official Letter corresponding to Mexican Patent Application No. MX/a/2009/009850 dated Mar. 27, 2013.;;Canadian Office Communication corresponding to Canadian Patent Application No. 2,679,482 dated Apr. 14, 2014.;;Chinese Notification of the First Office Action corresponding to Chinese Patent Application No. 201210257651.X date of notification Dec. 25, 2013.;;European Communication corresponding to European Patent Application No. 12 178 362.5 dated Jun. 10, 2014.;;Israel Communication corresponding to Israel Patent Application No. 200846 dated Sep. 30, 2013.;;Indian First Examination Report corresponding to Indian Patent Application No. 5631/DELNP/2009 dated Nov. 26, 2014.;;Korean Notice of Grounds for Rejection corresponding to Korean Patent Application No. 2009-7018914 issuance date Apr. 1, 2014.;;Korean Notice of Final Rejection corresponding to Korean Patent Application No. 2009-7018914 issuance date Oct. 24, 2014.;;Australian Patent Examination Report No. 2 corresponding to Australian Patent Application No. 2008226823 date of issue Feb. 10, 2014.;;Japanese Notice of Reasons for Rejection corresponding to Japanese Patent Application No. 2013-233740 mailing date Oct. 14, 2014.;;Mexican Official Letter corresponding to Mexican Patent Application No. MX/a/2009/009850 dated Dec. 12, 2013.",ACTIVE
239,US,A,US 5834502 A,122-295-712-641-418,1998-11-10,1998,US 68281596 A,1996-07-11,US 68281596 A;;US 105595 P,1995-07-11,Triazolylmethyl-indole ethylamine bisulfate salt,"The bisulfate salt of N,N-dimethyl-2-�5-(1,2,4-triazol-1-ylmethyl)-1H-indol-3-yl!ethylamine is a selective agonist of 5-HT.sub.1 -like receptors and is useful in the treatment of migraine and associated disorders.",MERCK & CO INC,CHENG CHEN Y;;MCCAULEY JAMES A;;VANDRILLA JENNIFER L;;VERHOEVEN THOMAS R;;LARSEN ROBERT D,MERCK SHARP & DOHME CORP (2012-04-26),https://lens.org/122-295-712-641-418,Granted Patent,yes,6,18,2,14,0,C07D231/12;;C07D231/12;;C07D233/56;;C07D233/56;;C07D249/08;;C07D249/08,C07D/;;C07D521/00,514/383;;548/266.4,1,1,071-670-502-591-188,10.1007/bf00166952;;2234095,"Martin et al. Analysis of the 5 HT receptor, etc. Arch. Pharmacol (1990) pp. 111 119, 342.",EXPIRED
240,EP,B1,EP 0840733 B1,180-498-092-382-841,2001-10-24,2001,EP 96925277 A,1996-07-08,GB 9602977 A;;US 9611370 W;;US 105595 P,1995-07-11,A TRIAZOLYLMETHYL-INDOLE ETHYLAMINE BISULFATE SALT,"The bisulfate salt of N,N-dimethyl-2-[5-(1,2,4-triazol-1-ylmethyl)-1H-indol-3-yl]ethylamine is a selective agonist of 5-HT1-like receptors and is useful in the treatment of migraine and associated disorders.",MERCK & CO INC,CHENG CHEN Y;;LARSEN ROBERT D;;MCCAULEY JAMES A;;VANDRILLA JENNIFER L;;VERHOEVEN THOMAS R,"MERCK SHARP & DOHME CORP., US (2013-05-14);;MERCK SHARP & DOHME CORP., RAHWAY, US (2013-05-14);;SCHERING CORPORATION, US (2013-03-18);;MERCK  SHARP & DOHME CORP. (2012-10-19)",https://lens.org/180-498-092-382-841,Granted Patent,yes,3,0,11,14,0,A61K31/4196;;C07D231/12;;C07D233/56;;C07D249/08;;A61P25/04;;A61P25/06;;A61P43/00,A61K31/41;;A61K31/4196;;C07D403/06;;A61P25/04;;A61P25/06;;A61P43/00;;C07D521/00,,0,0,,,,EXPIRED
241,EP,A3,EP 2528087 A3,192-453-252-566-196,2013-03-20,2013,EP 12177269 A,2009-09-18,EP 09815273 A;;US 9907408 P;;US 10446608 P;;US 9859708 P,2008-09-19,Formation of devices by epitaxial layer overgrowth,"Methods and structures are provided for formation of devices, e.g., solar cells, on substrates including, e.g., lattice-mismatched materials, by the use of aspect ratio trapping (ART) and epitaxial layer overgrowth (ELO). In general, in a first aspect, embodiments of the invention may include a method of forming a structure. The method includes forming a first opening in a masking layer disposed over a substrate that includes a first semiconductor material. A first layer, which includes a second semiconductor material lattice-mismatched to the first semiconductor material, is formed within the first opening. The first layer has a thickness sufficient to extend above a top surface of the masking layer. A second layer, which includes the second semiconductor material, is formed on the first layer and over at least a portion of the masking layer. A vertical growth rate of the first layer is greater than a lateral growth rate of the first layer and a lateral growth rate of the second layer is greater than a vertical growth rate of the second layer.
",TAIWAN SEMICONDUCTOR MFG,FIORENZA JAMES;;LOCHTEFELD ANTHONY;;BAI JIE;;PARK JI-SOO;;HYDRICK JENNIFER;;LI JIZHONG;;ZHIYUAN CHENG,"TAIWAN SEMICONDUCTOR MANUFACTURING COMPANY, LTD. (2016-02-24)",https://lens.org/192-453-252-566-196,Search Report,yes,6,0,19,19,0,H01L21/02381;;H01L21/02538;;H01L21/20;;H01L21/02381;;H01L21/0245;;H01L21/0245;;H01L21/02461;;H01L21/02461;;H01L21/02463;;H01L21/02463;;H01L21/02543;;H01L21/02543;;H01L21/02546;;H01L21/02546;;H01L21/02636;;H01L21/02636;;H01L21/02639;;H01L21/02639;;H01L21/02647;;H01L21/02647;;H01L29/205;;H01L31/04;;H01L31/0687;;H01L31/0687;;H01L31/06875;;H01L31/06875;;H01L31/1808;;H01L31/1808;;H01L31/1852;;H01L31/1852;;H01L31/1892;;H01L31/1892;;Y02E10/544;;Y02E10/544,H01L21/20;;H01L21/02;;H01L31/042;;H01L31/0687;;H01L31/18,,1,1,015-476-364-945-119,10.1063/1.126754,"LANGDO T A ET AL: ""High quality Ge on Si by epitaxial necking"", APPLIED PHYSICS LETTERS, AIP, AMERICAN INSTITUTE OF PHYSICS, MELVILLE, NY, US, vol. 76, no. 25, 19 June 2000 (2000-06-19), pages 3700 - 3702, XP012025569, ISSN: 0003-6951, DOI: 10.1063/1.126754",ACTIVE
242,CO,A2,CO 2023004141 A2,036-621-692-342-675,2023-08-28,2023,CO 2023004141 A,2023-03-30,US 2021/0049940 W;;US 202063077553 P;;US 202063093673 P,2020-09-11,Formas cristalinas de un inhibidor de kras g12c,"La presente invención se relaciona con formas cristalinas de un inhibidor de KRas G12C y sal de este. En particular, la presente invención se relaciona con formas cristalinas del inhibidor KRas GT2C 2-[(2S)-4-[7-(8-cloro-1-naftil)-2-[[(2S)-1-metilpirrolidin-2-il]metoxi]-6,8-dihidro-5H-pirido[3,4-d]pirimidin-4-il]-1-(2-fluoroprop-2-enoil)piperazin-2-il]acetonitrilo,composiciones farmacéuticas que comprenden las formas cristalinas, procesos para preparar las formas cristalinas y métodos de uso de estos.",MIRATI THERAPEUTICS INC,ANDRES PATRICIA;;ANDREW SAMUEL;;CHEN CHENG YI;;GANCEDO SUSANA DEL RIO;;GHARBAOUI TAWFIK;;NELSON JENNIFER,,https://lens.org/036-621-692-342-675,Patent Application,no,0,0,11,12,0,A61P35/00;;C07D471/04;;A61P35/00;;C07D471/04;;C07D471/04;;A61K31/519;;A61P35/00;;C07B2200/13;;A61P35/00;;C07B2200/13;;C07D471/04,A61P35/00;;C07D471/04;;C07D519/00,,0,0,,,,PENDING
243,CA,A1,CA 2225416 A1,069-578-152-277-792,1997-01-30,1997,CA 2225416 A,1996-07-08,US 105595 P;;GB 9602977 A;;US 9611370 W,1995-07-11,A TRIAZOLYLMETHYL-INDOLE ETHYLAMINE BISULFATE SALT,"The bisulfate salt of N,N-dimethyl-2-¢5-(1,2,4-triazol-1-ylmethyl)-1H-indol-3-yl!ethylamine is a selective agonist of 5-HT1-like receptors and is useful in the treatment of migraine and associated disorders.",MERCK & CO INC,CHENG CHEN Y;;VANDRILLA JENNIFER L;;VERHOEVEN THOMAS R;;MCCAULEY JAMES A;;LARSEN ROBERT D,,https://lens.org/069-578-152-277-792,Patent Application,no,0,0,11,14,0,A61K31/4196;;C07D231/12;;C07D233/56;;C07D249/08;;A61P25/04;;A61P25/06;;A61P43/00,C07D403/06;;A61K31/41;;A61K31/4196;;A61P25/04;;A61P25/06;;A61P43/00;;C07D521/00,,0,0,,,,EXPIRED
244,IL,A,IL 301236 A,093-146-030-306-154,2023-05-01,2023,IL 30123623 A,2023-03-09,US 202063077553 P;;US 202063093673 P;;US 2021/0049940 W,2020-09-11,Crystalline forms of a kras g12c inhibitor,,MIRATI THERAPEUTICS INC;;ANDRES PATRICIA;;ANDREW SAMUEL;;CHEN CHENG YI;;GANCEDO SUSANA DEL RIO;;GHARBAOUI TAWFIK;;NELSON JENNIFER,ANDRES PATRICIA;;ANDREW SAMUEL;;CHEN CHENG YI;;GANCEDO SUSANA DEL RIO;;GHARBAOUI TAWFIK;;NELSON JENNIFER,,https://lens.org/093-146-030-306-154,Patent Application,no,0,0,11,12,0,A61P35/00;;C07D471/04;;A61P35/00;;C07D471/04;;C07D471/04;;A61K31/519;;A61P35/00;;C07B2200/13;;A61P35/00;;C07B2200/13;;C07D471/04,A61P35/00,,0,0,,,,PENDING
245,AU,A1,AU 2008/226823 A1,198-019-594-309-321,2008-09-18,2008,AU 2008/226823 A,2008-03-12,US 90633007 P;;US 2008/0003354 W,2007-03-12,Oligomer-protease inhibitor conjugates,,NEKTAR THERAPEUTICS,RIGGS-SAUTHIER JENNIFER;;ZHANG WEN;;VIEGAS TACEY X;;DUARTE FRANCO J;;GU XUYUAN;;CHENG LIN,,https://lens.org/198-019-594-309-321,Patent Application,no,0,0,27,58,0,A61K47/60;;A61P31/12;;A61P31/16;;A61P31/18;;A61P43/00;;A61K47/50;;A61K31/164;;A61K47/60,A61K47/48;;A61P31/18,,0,0,,,,ACTIVE
246,ZA,B,ZA 965837 B,196-075-721-444-213,1997-01-31,1997,ZA 965837 A,1996-07-10,US 105595 P,1995-07-11,A triazolylmethyl-indole ethylamine bisulfate salt,,MERCK & CO INC,CHENG CHEN Y;;LARSEN ROBERT D;;MCCAULEY JAMES A;;VANDRILLA JENNIFER L;;VERHOEVEN THOMAS R,,https://lens.org/196-075-721-444-213,Granted Patent,no,0,0,2,14,0,C07D231/12;;C07D231/12;;C07D233/56;;C07D233/56;;C07D249/08;;C07D249/08,C07D/;;C07D521/00,,0,0,,,,EXPIRED
247,EP,A2,EP 2528087 A2,045-185-659-513-215,2012-11-28,2012,EP 12177269 A,2009-09-18,EP 09815273 A;;US 9907408 P;;US 10446608 P;;US 9859708 P,2008-09-19,Formation of devices by epitaxial layer overgrowth,"Methods and structures are provided for formation of devices, e.g., solar cells, on substrates including, e.g., lattice-mismatched materials, by the use of aspect ratio trapping (ART) and epitaxial layer overgrowth (ELO). In general, in a first aspect, embodiments of the invention may include a method of forming a structure. The method includes forming a first opening in a masking layer disposed over a substrate that includes a first semiconductor material. A first layer, which includes a second semiconductor material lattice-mismatched to the first semiconductor material, is formed within the first opening. The first layer has a thickness sufficient to extend above a top surface of the masking layer. A second layer, which includes the second semiconductor material, is formed on the first layer and over at least a portion of the masking layer. A vertical growth rate of the first layer is greater than a lateral growth rate of the first layer and a lateral growth rate of the second layer is greater than a vertical growth rate of the second layer.
",TAIWAN SEMICONDUCTOR MFG,FIORENZA JAMES;;LOCHTEFELD ANTHONY;;BAI JIE;;PARK JI-SOO;;HYDRICK JENNIFER;;LI JIZHONG;;ZHIYUAN CHENG,"TAIWAN SEMICONDUCTOR MANUFACTURING COMPANY, LTD. (2016-02-24)",https://lens.org/045-185-659-513-215,Patent Application,yes,0,2,19,19,0,H01L21/02381;;H01L21/02538;;H01L21/20;;H01L21/02381;;H01L21/0245;;H01L21/0245;;H01L21/02461;;H01L21/02461;;H01L21/02463;;H01L21/02463;;H01L21/02543;;H01L21/02543;;H01L21/02546;;H01L21/02546;;H01L21/02636;;H01L21/02636;;H01L21/02639;;H01L21/02639;;H01L21/02647;;H01L21/02647;;H01L29/205;;H01L31/04;;H01L31/0687;;H01L31/0687;;H01L31/06875;;H01L31/06875;;H01L31/1808;;H01L31/1808;;H01L31/1852;;H01L31/1852;;H01L31/1892;;H01L31/1892;;Y02E10/544;;Y02E10/544,H01L21/20;;H01L31/042;;H01L31/0687;;H01L31/18,,0,0,,,,ACTIVE
248,AT,T1,AT E207485 T1,159-170-426-826-968,2001-11-15,2001,AT 96925277 T,1996-07-08,GB 9602977 A;;US 105595 P;;US 9611370 W,1995-07-11,EIN TRIAZOLYLMETHYL-INDOL-ETHYLAMIN-BISULFAT-SALZ,"The bisulfate salt of N,N-dimethyl-2-[5-(1,2,4-triazol-1-ylmethyl)-1H-indol-3-yl]ethylamine is a selective agonist of 5-HT1-like receptors and is useful in the treatment of migraine and associated disorders.",MERCK & CO INC,CHENG CHEN Y;;LARSEN ROBERT D;;MCCAULEY JAMES A;;VANDRILLA JENNIFER L;;VERHOEVEN THOMAS R,,https://lens.org/159-170-426-826-968,Granted Patent,no,0,0,11,14,0,A61K31/4196;;C07D231/12;;C07D233/56;;C07D249/08;;A61P25/04;;A61P25/06;;A61P43/00,C07D403/06;;A61K31/41;;A61K31/4196;;A61P25/04;;A61P25/06;;A61P43/00;;C07D521/00,,0,0,,,,DISCONTINUED
249,US,A1,US 2022/0402194 A1,052-708-269-783-520,2022-12-22,2022,US 202217820144 A,2022-08-16,US 202217820144 A;;US 201815762494 A,2018-03-22,ADDITIVELY MANUFACTURING BIO-BASED CONDUCTIVE SHAPE MEMORY POLYMER MACOSTRUCTURE PARTS WITH HIGHLY ORDERED MICROSTRUCTURES,An additive manufacturing apparatus includes an additive manufacturing print head and a nozzle that receives a bio-based shape memory polymer material and a bio-based material. The nozzle extrudes the bio-based shape memory polymer material and the bio-based material onto a substrate to form a bio-based shape memory polymer part or product.,L LIVERMORE NAT SECURITY LLC,RODRIGUEZ JENNIFER NICOLE;;DUOSS ERIC B;;LEWICKI JAMES;;SPADACCINI CHRISTOPHER;;WILSON THOMAS S;;ZHU CHENG,LAWRENCE LIVERMORE NATIONAL SECURITY LLC (2018-02-21),https://lens.org/052-708-269-783-520,Patent Application,yes,1,0,1,1,0,C08G59/027;;C08G59/38;;C09D191/06;;B29C64/106;;B33Y10/00;;B33Y70/10;;C08K3/046;;B29C64/106;;B33Y80/00;;B33Y70/10;;B33Y10/00;;B33Y30/00;;B33Y50/02;;C08K3/046;;B29C64/321;;B29C64/209;;B29C64/393;;B29C64/165;;B29K2063/00;;B29K2105/124;;B29K2507/04;;C08K7/04;;C08K2201/011;;C08L63/00;;C08L91/00,B29C64/106;;B29C64/165;;B29C64/209;;B29C64/321;;B29C64/393;;B33Y70/10;;C08K3/04;;C08K7/04;;C08L63/00;;C08L91/00,,0,0,,,,PENDING
250,CA,C,CA 2225416 C,107-641-253-573-457,2009-02-24,2009,CA 2225416 A,1996-07-08,US 105595 P;;GB 9602977 A;;US 9611370 W,1995-07-11,A TRIAZOLYLMETHYL-INDOLE ETHYLAMINE BISULFATE SALT,"The bisulfate salt of N,N-dimethyl-2-[5-(1,2,4-triazol-1-ylmethyl)-1H-indol- 3- yl]ethylamine is a selective agonist of 5-HT1-like receptors and is useful in the treatment of migraine and associated disorder s.",MERCK & CO INC,MCCAULEY JAMES A;;VANDRILLA JENNIFER L;;VERHOEVEN THOMAS R;;LARSEN ROBERT D;;CHENG CHEN Y,,https://lens.org/107-641-253-573-457,Granted Patent,no,0,0,11,14,0,A61K31/4196;;C07D231/12;;C07D233/56;;C07D249/08;;A61P25/04;;A61P25/06;;A61P43/00,C07D403/06;;A61K31/41;;A61K31/4196;;A61P25/04;;A61P25/06;;A61P43/00;;C07D521/00,,0,0,,,,EXPIRED
251,WO,A2,WO 2010/033813 A2,175-816-735-402-261,2010-03-25,2010,US 2009/0057493 W,2009-09-18,US 9907408 P;;US 10446608 P;;US 9859708 P,2008-09-19,FORMATION OF DEVICES BY EPITAXIAL LAYER OVERGROWTH,"Methods and structures are provided for formation of devices, e.g., solar cells, on substrates including, e.g., lattice-mismatched materials, by the use of aspect ratio trapping (ART) and epitaxial layer overgrowth (ELO). In general, in a first aspect, embodiments of the invention may include a method of forming a structure. The method includes forming a first opening in a masking layer disposed over a substrate that includes a first semiconductor material. A first layer, which includes a second semiconductor material lattice-mismatched to the first semiconductor material, is formed within the first opening. The first layer has a thickness sufficient to extend above a top surface of the masking layer. A second layer, which includes the second semiconductor material, is formed on the first layer and over at least a portion of the masking layer. A vertical growth rate of the first layer is greater than a lateral growth rate of the first layer and a lateral growth rate of the second layer is greater than a vertical growth rate of the second layer.",AMBERWAVE SYSTEM CORP;;FIORENZA JAMES;;LOCHTEFELD ANTHONY;;BAI JIE;;PARK JI-SOO;;HYDRICK JENNIFER;;LI JIZHONG;;ZHIYUAN CHENG,FIORENZA JAMES;;LOCHTEFELD ANTHONY;;BAI JIE;;PARK JI-SOO;;HYDRICK JENNIFER;;LI JIZHONG;;ZHIYUAN CHENG,,https://lens.org/175-816-735-402-261,Patent Application,yes,0,10,19,19,0,H01L21/02381;;H01L21/02538;;H01L21/20;;H01L21/02381;;H01L21/0245;;H01L21/0245;;H01L21/02461;;H01L21/02461;;H01L21/02463;;H01L21/02463;;H01L21/02543;;H01L21/02543;;H01L21/02546;;H01L21/02546;;H01L21/02636;;H01L21/02636;;H01L21/02639;;H01L21/02639;;H01L21/02647;;H01L21/02647;;H01L29/205;;H01L31/04;;H01L31/0687;;H01L31/0687;;H01L31/06875;;H01L31/06875;;H01L31/1808;;H01L31/1808;;H01L31/1852;;H01L31/1852;;H01L31/1892;;H01L31/1892;;Y02E10/544;;Y02E10/544,H01L21/20;;H01L31/042,,1,0,,,See references of EP 2335273A4,PENDING
252,CA,A1,CA 3190944 A1,162-735-476-158-914,2022-03-17,2022,CA 3190944 A,2021-09-10,US 202063077553 P;;US 202063093673 P;;US 2021/0049940 W,2020-09-11,CRYSTALLINE FORMS OF A KRAS G12C INHIBITOR,"The present invention relates to crystalline forms of a KRas G12C inhibitor and salt thereof. In particular, the present invention relates to crystalline forms of the KRas GT2C inhibitor 2-[(2S)- 4-[7-(8-chloro-l-naphthyI)-2-[[(2S)-l-methylpyrrolidin-2-yl]methoxy]-6,8-dihydro-5H- pyrido[3,4-d]pyrimidin-4-yI]-l-(2-fluoroprop-2-enoyi)piperazin-2-yl]acetonitrile, pharmaceutical compositions comprising the crystalline forms, processes for preparing the crystalline forms and methods of use thereof.",MIRATI THERAPEUTICS INC,ANDRES PATRICIA;;ANDREW SAMUEL;;CHEN CHENG YI;;GANCEDO SUSANA DEL RIO;;GHARBAOUI TAWFIK;;NELSON JENNIFER,,https://lens.org/162-735-476-158-914,Patent Application,no,0,0,11,12,0,A61P35/00;;C07D471/04;;A61P35/00;;C07D471/04;;C07D471/04;;A61K31/519;;A61P35/00;;C07B2200/13;;A61P35/00;;C07B2200/13;;C07D471/04,C07D471/04;;A61K31/519;;A61P35/00,,0,0,,,,PENDING
253,CL,A1,CL 2023000693 A1,040-234-881-589-014,2023-10-20,2023,CL 2023000693 A,2023-03-10,US 202063077553 P;;US 202063093673 P,2020-09-11,Crystalline forms of a kras g12c inhibitor,"The present invention relates to crystalline forms of a KRas G12C inhibitor and salt thereof. In particular, the present invention relates to crystalline forms of the KRas GT2C inhibitor 2-[(2S)- 4-[7-(8-chloro-l-naphthyI)-2-[[(2S)-l-methylpyrrolidin-2-yl]methoxy]-6,8-dihydro-5H- pyrido[3,4-d]pyrimidin-4-yI]-l-(2-fluoroprop-2-enoyi)piperazin-2-yl]acetonitrile, pharmaceutical compositions comprising the crystalline forms, processes for preparing the crystalline forms and methods of use thereof.",MIRATI THERAPEUTICS INC,ANDRES PATRICIA;;ANDREW SAMUEL;;CHEN CHENG YI;;GANCEDO SUSANA DEL RIO;;GHARBAOUI TAWFIK;;NELSON JENNIFER,,https://lens.org/040-234-881-589-014,Patent Application,no,0,0,11,12,0,A61P35/00;;C07D471/04;;A61P35/00;;C07D471/04;;C07D471/04;;A61K31/519;;A61P35/00;;C07B2200/13;;A61P35/00;;C07B2200/13;;C07D471/04,A61P35/00;;C07D471/04;;C07D519/00,,0,0,,,,PENDING
254,EP,A1,EP 4210833 A1,128-990-756-075-967,2023-07-19,2023,EP 21867707 A,2021-09-10,US 202063077553 P;;US 202063093673 P;;US 2021/0049940 W,2020-09-11,CRYSTALLINE FORMS OF A KRAS G12C INHIBITOR,,MIRATI THERAPEUTICS INC,ANDRES PATRICIA;;ANDREW SAMUEL;;CHEN CHENG YI;;GANCEDO SUSANA DEL RIO;;GHARBAOUI TAWFIK;;NELSON JENNIFER,,https://lens.org/128-990-756-075-967,Patent Application,yes,0,0,11,12,0,A61P35/00;;C07D471/04;;A61P35/00;;C07D471/04;;C07D471/04;;A61K31/519;;A61P35/00;;C07B2200/13;;A61P35/00;;C07B2200/13;;C07D471/04,A61P35/00;;C07D471/04;;C07D519/00,,0,0,,,,PENDING
255,US,B2,US 8598364 B2,182-070-339-420-893,2013-12-03,2013,US 53036308 A,2008-03-12,US 53036308 A;;US 90633007 P;;US 2008/0003354 W,2007-03-12,Oligomer-protease inhibitor conjugates,"The invention provides protease inhibitors that are chemically modified by covalent attachment of a water-soluble oligomer. A conjugate of the invention, when administered by any of a number of administration routes, exhibits characteristics that are different from the protease inhibitors not attached to the water-soluble oligomer.",RIGGS-SAUTHIER JENNIFER;;CHENG LIN;;VIEGAS TACEY X;;GU XUYUAN;;DUARTE FRANCO J;;ZHANG WEN;;NEKTAR THERAPEUTICS,RIGGS-SAUTHIER JENNIFER;;CHENG LIN;;VIEGAS TACEY X;;GU XUYUAN;;DUARTE FRANCO J;;ZHANG WEN,NEKTAR THERAPEUTICS (2010-05-11);;NEKTAR THERAPEUTICS AL CORPORATION (2008-05-30),https://lens.org/182-070-339-420-893,Granted Patent,yes,36,6,27,58,0,A61K47/60;;A61P31/12;;A61P31/16;;A61P31/18;;A61P43/00;;A61K47/50;;A61K31/164;;A61K47/60,C07D213/00;;C07D239/02;;C07D217/00;;C07D277/30;;C07D307/02;;C07D401/00;;C07D405/00;;C07D493/00;;C07F9/06;;C07F9/28,548/204;;544/316;;544/360;;546/146;;546/282.1;;546/332;;549/222;;549/464;;549/475,40,14,038-334-210-991-906;;038-334-210-991-906;;091-197-353-551-151;;017-989-392-397-902;;091-442-146-191-671;;002-276-833-366-497;;015-301-295-258-870;;003-793-280-475-635;;011-256-459-180-120;;124-769-862-069-925;;051-780-238-835-252;;058-789-596-477-892;;011-565-742-695-524;;038-334-210-991-906,15546199;;10.1021/bc0498875;;15546199;;10.1021/bc0498875;;16078135;;10.1007/s11095-005-5271-y;;16905788;;10.1001/jama.296.7.827;;pmc245361;;10.1128/aac.35.11.2209;;1803993;;2405486;;10.1126/science.2405486;;10.1016/0166-0934(88)90134-6;;2460479;;11705466;;10.1016/s0008-6215(01)00260-9;;10.1023/a:1020913631309;;12458677;;pmc1481600;;16635263;;10.1186/1742-6405-3-12;;16902393;;11674697;;10.1021/jo990620m;;10.1177/095632020001100202;;10819434;;15546199;;10.1021/bc0498875,"Simi Gunaseelan, et al, Synthesis of Poly(ethylene glycol)-Based Saquinavir Prodrug Conjugates and Assessment of Release and Anti-HIV-1 Bioactivity Using a Novel Protease Inhibition Assay, 15 Bioconjug. Chem. 1322 (2004).;;Simi Gunaseelan, et al, Synthesis of Poly(ethylene glycol)-Based Saquinavir Prodrug Conjugates and Assessment of Release and Anti-HIV-1 Bioactivity Using a Novel Protease Inhibition Assay, 15 Bioconj. Chem. 1322, 1328-29 (2004).;;Notification of the First Office Action corresponding to Chinese Patent Application No. 200880007943.X dated Apr. 21, 2011.;;Notification of the Second Office Action corresponding to Chinese Patent Application No. 200880007943.X dated Dec. 6, 2011.;;Examination Report corresponding to European Patent Application No. 08 742 083.2-1216 dated Jul. 26, 2010.;;First Substantive Examination Report corresponding to Israeli Patent Application No. 200846 dated Feb. 23, 2012.;;Office Action corresponding to Mexican Patent Application No. MX/a/2009/009850 dated Mar. 23, 2012.;;Bachmeier, et al., ""Quantitative Assessment of HIV-1 Protease Inhibitor Interactions with Drug Efflux Transporters in the Blood-Brain Barrier"", Pharm. Res., vol. 22, No. 8, pp. 1259-1268, (Aug. 2005).;;Hammer, et al., ""Treatment for Adult HIV Infection: 2006 Recommendations of the International AIDS Society-USA Panel"", JAMA, vol. 296, No. 7, pp. 827-843, (2006).;;Kempf, et al., ""Antiviral and Pharmacokinetic Properties of C2 Symmetric Inhibitors of the Human Immunodeficiency Virus Type 1 Protease"", Antimicrob. Agents and Chemotherp., vol. 35, No. 11, pp. 2209-2214, (Nov. 1991).;;McQuade, et al., ""A Synthetic HIV-1 Protease Inhibitor with Antiviral Activity Arrests HIV-Like Particle Maturation"", Science, vol. 247, pp. 454-456, (Jan. 26, 1990).;;Pauwels, et al., ""Rapid and automated tetrazolium-based colorimetric assay for the detection of anti-HIV compounds"", J. of Virological Methods, vol. 20, pp. 309-321, (1988).;;Rouquayrol, et al., ""Synthesis and anti-HIV activity of glucose-containing prodrugs derived from saquinavir, indinavir and nelfinavir"", Carbohy. Res., vol. 336, pp. 161-180, (2001).;;Rouquayrol, et al., ""Transepithelial Transport of Prodrugs of the HIV Protease Inhibitors Saquinavir, Indinavir, and Nelfinavir across Caco-2 Cell Monolayers"", Pharm. Res., vol. 19, No. 11, pp. 1704-1712, (Nov. 2002).;;Wan, et al., ""Novel multi-component nanopharmaceuticals derived from poly(ethylene) glycol, retro-inverso-Tat nonapeptide and saquinavir demonstrate combined anti-HIV effects"", AIDS Res. and Therp., 3:t2, pp. t-t5, (2006).;;Center for Disease Control and Prevention, MMWR, vol. 55, No. 31, pp. 841-844, (Aug. 11, 2006).;;PCT International Search Report in PCT Patent Application No. PCT/US2008/003354 date of mailing Nov. 6, 2008.;;PCT International Preliminary Report on Patentability in PCT Patent Application No. PCT/US2008/003354 date of issuance of report Sep. 15, 2009.;;Enzon Pharmaceuticals, Macromolecular Engineering Technologies, pp. 1-14, (2004).;;Nektar(TM)-Transforming Therapeutics, Nektar Molecule Engineering: Polyethylene Glycol and Derivatives for Advanced PEGylation, pp. 1-20, (Catalog-2003).;;Nektar(TM)-Transforming Therapeutics, Nektar Advanced PEGylation: Polyethylene Glycol and Derivatives for Advanced PEGylation, pp. 1-24, (Catalog-2004).;;NOF Corporation, ""PEG Derivatives, Phospholipid and Drug Delivery Materials for Pharmaceuticals"", pp. 1-46, (Catalogue 2003-1st).;;NOF Corporation, ""PEG Derivatives, Phospholipid and Drug Delivery Materials for Pharmaceuticals"", pp. 1-50, (Catalogue 2003-2nd).;;NOF Corporation, ""PEG Derivatives, Phospholipids and Drug Delivery Materials for Pharmaceutical Products and Formulations"", pp. 1-59, (Catalogue Ver. 8-Apr. 2006).;;Polypure, Products; PEG amines; PEG acids and amino acids; PEG thiols and disulfides; BIOTINS, (Apr. 2004).;;Polypure, Products; PEG amines; PEG acids and amino acids; PEG thiols and disulfides; BIOTINS, (Apr. 2005).;;Quanta Biodesign, Labeling, Derivatization and Crosslinking Reagents for Biological and Related Materials with dPEG(TM), pp. 1-38, (Mar. 12, 2004).;;Quanta Biodesign, Labeling, Modification and Crosslinking Reagents incorporating our unique monodispersed dPEG(TM) Technology, pp. 1-31, (Nov. 5, 2004).;;Quanta Biodesign, Ltd., Leading innovator, producer and provider of monodisperse discrete PEG(TM) (dPEG(TM)) derivatives, (Product Catalog), pp. 1-51, (Updated: Jul. 18, 2005).;;Quanta Biodesign, Ltd., Leading innovator, producer and provider of monodisperse discrete PEG(TM) (dPEG(TM)) derivatives, (Product Catalog), pp. 1-51, (Updated: Nov. 17, 2005).;;Shearwater Polymers, Inc., p. 2-49, (Catalog-Mar. 1995).;;Shearwater Polymers, Inc., Polyethylene Glycol and Derivatives, pp. 1-53, (Catalog-Jul. 1997).;;Shearwater Polymers, Inc., Polyethylene Glycol and Derivatives: Functionalized Biocompatible Polymers for Research and Pharmaceuticals, pp. 1-50, (Catalog-2000).;;Shearwater Corporation, Polyethylene Glycol and Derivatives for Biomedical Applications, pp. 1-17, (Catalog-2001).;;Chen, et al., ""Synthesis and Properties of ABA Amphiphiles"", J. Org. Chem., vol. 64, No. 18, pp. 6870-6873, (1999).;;Giorgio, et al., ""Synthesis and anti-HIV activity of prodrugs derived from saquinavir and indinavir"", Antiviral Chemistry and Chemotherapy, vol. 11, No. 2, pp. 97-110, (2000).;;Gunaseelan, et al., ""Synthesis of Poly(ethylene glycol)-Based Saquinavir Prodrug Conjugates and Assessment of Release and Anti-HIV-1 Bioactivity Using a Novel Protease Inhibition Assay"", Bioconjugate Chem., vol. 15, No. 6, pp. 1322-1333, (2004).;;Examiner's First Report corresponding to Australian Patent Application No. 2008226823 dated May 23, 2012.;;Office Communication corresponding to European Patent Application No. 08 742 083.2-1216 dated Jul. 5, 2012.;;Office Communication with extended European Search Report corresponding to European Patent Application No. 12178362.5-1216 dated Oct. 11, 2012.",ACTIVE
256,US,A1,US 2010/0216277 A1,061-441-750-946-812,2010-08-26,2010,US 68087209 A,2009-09-18,US 68087209 A;;US 9859708 P;;US 9907408 P;;US 10446608 P;;US 2009/0057493 W,2008-09-19,Formation of Devices by Epitaxial Layer Overgrowth,"Methods and structures are provided for formation of devices, e.g., solar cells, on substrates including, e.g., lattice-mismatched materials, by the use of aspect ratio trapping (ART) and epitaxial layer overgrowth (ELO). In general, in a first aspect, embodiments of the invention may include a method of forming a structure. The method includes forming a first opening in a masking layer disposed over a substrate that includes a first semiconductor material. A first layer, which includes a second semi-conductor material lattice-mismatched to the first semiconductor material, is formed within the first opening. The first layer has a thickness sufficient to extend above a top surface of the masking layer. A second layer, which includes the second semiconductor material, is formed on the first layer and over at least a portion of the masking layer. A vertical growth rate of the first layer is greater than a lateral growth rate of the first layer and a lateral growth rate of the second layer is greater than a vertical growth rate of the second layer.",TAIWAN SEMICONDUCTOR MFG,FIORENZA JAMES;;LOCHTEFELD ANTHONY;;BAI JIE;;PARK JI-SOO;;HYDRICK JENNIFER;;LI JIZHONG;;CHENG ZHIYUAN,AMBERWAVE SYSTEMS (2009-11-23);;TAIWAN SEMICONDUCTOR MANUFACTURING CO. LTD (2010-05-13);;TAIWAN SEMICONDUCTOR MANUFACTURING COMPANY LTD (2009-11-22),https://lens.org/061-441-750-946-812,Patent Application,yes,16,36,19,19,0,H01L21/02381;;H01L21/02538;;H01L21/20;;H01L21/02381;;H01L21/0245;;H01L21/0245;;H01L21/02461;;H01L21/02461;;H01L21/02463;;H01L21/02463;;H01L21/02543;;H01L21/02543;;H01L21/02546;;H01L21/02546;;H01L21/02636;;H01L21/02636;;H01L21/02639;;H01L21/02639;;H01L21/02647;;H01L21/02647;;H01L29/205;;H01L31/04;;H01L31/0687;;H01L31/0687;;H01L31/06875;;H01L31/06875;;H01L31/1808;;H01L31/1808;;H01L31/1852;;H01L31/1852;;H01L31/1892;;H01L31/1892;;Y02E10/544;;Y02E10/544,H01L31/18;;B32B38/10;;C30B25/04;;H01L21/20,438/94;;117/97;;156/247;;438/481;;X257E2109;;X257E31002,0,0,,,,ACTIVE
257,AU,A,AU 1999/059118 A,010-109-638-615-963,2000-03-27,2000,AU 1999/059118 A,1999-09-09,US 9958398 P;;US 9920506 W,1998-09-09,Methylation of plasmid vectors,,GENZYME CORP,CHENG SENG H;;MARSHALL JOHN;;SCHEULE RONALD K;;YEW NELSON S;;TOUSIGNANT JENNIFER D;;PRZYBYLSKA MALGORZATA,,https://lens.org/010-109-638-615-963,Patent Application,no,0,0,15,15,0,A61K48/00;;A61K48/00;;A61P1/18;;A61P29/00;;A61P37/02;;A61P37/06;;C12N15/88;;C12N15/88;;C12N2799/021;;C12N2799/021;;C12P19/34;;C12P19/34,C12N15/09;;A61K31/35;;A61K31/365;;A61K31/4706;;A61K31/473;;A61K31/711;;A61K48/00;;A61P1/18;;A61P29/00;;A61P37/02;;A61P37/06;;C12N15/88;;C12P19/34,,0,0,,,,DISCONTINUED
258,ES,T3,ES 2394458 T3,047-955-982-403-252,2013-01-31,2013,ES 06021432 T,1999-09-09,US 9958398 P,1998-09-09,Metilación de vectores plasmídicos,"Uso de un plásmido que comprende un gen de interés para la fabricación de un medicamento para eltratamiento de un mamífero mediante terapia génica, en el que el uso comprende la modificación del plásmidomediante la eliminación de un dinucleótido CpG o su mutación a un dinucleótido no-CpG de al menos undinucleótido CpG dentro de dicho plásmido, y en el que el tratamiento comprende la administración del plásmido encombinación con un anfífilo catiónico.",GENZYME CORP,CHENG SENG H;;MARSHALL JOHN;;SCHEULE RONALD K;;YEW NELSON S;;TOUSIGNANT JENNIFER D;;PRZYBYLSKA MALGORZATA,,https://lens.org/047-955-982-403-252,Granted Patent,no,0,0,15,15,0,A61K48/00;;A61K48/00;;A61P1/18;;A61P29/00;;A61P37/02;;A61P37/06;;C12N15/88;;C12N15/88;;C12N2799/021;;C12N2799/021;;C12P19/34;;C12P19/34,C12N15/09;;C12N15/85;;A61K31/35;;A61K31/365;;A61K31/4706;;A61K31/473;;A61K31/711;;A61K48/00;;A61P1/18;;A61P29/00;;A61P37/02;;A61P37/06;;C12N15/88;;C12P19/34,,0,0,,,,EXPIRED
259,CA,A1,CA 2337794 A1,053-092-211-181-969,2000-01-13,2000,CA 2337794 A,1999-07-01,US 9160898 P;;US 9915009 W,1998-07-02,TRANSGENE EXPRESSION IN POLARIZED CELLS,"The well-differentiated airway epithelium is the principal target tissue for gene therapy for the treatment of CF. However, recent studies have shown tha t gene delivery vehicles, such as cationic lipid:DNA complexes, can be inefficient at binding to and internalizing into polarized epithelial cells. The present invention provides a method to improve gene therapy by using a compound capable of disrupting tight junctions. In the practice of the invention, the transfection of a biologically active molecule by a cationic amphiphile:biologically active molecule complex or other lipid or viral or nonviral vectors is improved by treating the cells with a class of compounds known in the art as absorption enhancers or tight junction disrupting compounds.",GENZYME CORP,CHENG SENG H;;TOUSIGNANT JENNIFER D;;FANG SHAONA L;;EASTMAN SIMON;;SCHEULE RONALD K;;CHU QUIMING,,https://lens.org/053-092-211-181-969,Patent Application,no,0,0,6,6,0,A61K48/0008;;A61K48/0008;;A61K48/00;;A61K48/00;;A61P9/00;;A61P35/00;;A61P43/00,A61K48/00;;A61P9/00;;A61P35/00;;A61P43/00,,0,0,,,,DISCONTINUED
260,SG,A,SG 10201800682S A,127-754-860-020-308,2018-03-28,2018,SG 10201800682S A,2010-10-26,US 25498209 P;;US 38128710 P,2009-10-26,HUMAN IL-23 ANTIGEN BINDING PROTEINS,,AMGEN INC,TOWNE JENNIFER;;CHENG JANET;;O'NEILL JASON;;ZHANG YU;;SUN YU;;CERNE HEATHER;;PIPER DEREK;;KETCHEM RANDAL,,https://lens.org/127-754-860-020-308,Unknown,no,0,0,86,87,0,A61K2039/505;;C07K2317/21;;C07K2317/55;;C07K2317/92;;A61K47/6845;;C07K16/244;;A61P37/00;;C07K16/244;;A61K2039/505;;C07K2317/626;;C07K2317/21;;C07K2317/76;;A61K47/6845;;C07K2317/54;;A61K39/395;;C07K2317/31;;C07K16/24;;A61P37/00;;C07K2317/92;;C07K2317/24;;C07K2317/622;;C07K2317/55;;C07K2317/565;;A61K39/00;;A61K39/395;;A61K39/39533;;A61K39/3955;;C07K16/18;;C07K16/24;;C07K16/244;;A61K2039/505;;C07K2317/21;;C07K2317/55;;C07K2317/92;;A61K47/6845;;C07K16/244;;A61K39/395;;C07K16/24;;C07K2317/24;;C07K2317/31;;C07K2317/54;;C07K2317/565;;C07K2317/622;;C07K2317/626;;C07K2317/76,,,0,0,,,,PENDING
261,EP,B1,EP 1832657 B1,013-832-843-898-044,2012-10-24,2012,EP 06021432 A,1999-09-09,EP 99946789 A;;US 9958398 P,1998-09-09,Methylation of plasmid vectors,,GENZYME CORP,CHENG SENG H;;MARSHALL JOHN;;SCHEULE RONALD K;;YEW NELSON S;;TOUSIGNANT JENNIFER D;;PRZYBYLSKA MALGORZATA,,https://lens.org/013-832-843-898-044,Granted Patent,yes,4,0,15,15,0,A61K48/00;;A61K48/00;;A61P1/18;;A61P29/00;;A61P37/02;;A61P37/06;;C12N15/88;;C12N15/88;;C12N2799/021;;C12N2799/021;;C12P19/34;;C12P19/34,C12N15/09;;C12N15/85;;A61K31/35;;A61K31/365;;A61K31/4706;;A61K31/473;;A61K31/711;;A61K48/00;;A61P1/18;;A61P29/00;;A61P37/02;;A61P37/06;;C12N15/88;;C12P19/34,,8,0,,,"GILBERT W: ""pUC13c cloning vector (beta-galactosidase mRNA on complementary strand)"" EMBL SEQUENCE DATABASE, 25 March 1993 (1993-03-25), XP002131903 HEIDELBERG DE;;OKA ET AL.: ""Nucleotide sequence of the kanamycin resistance transposon Tn903"" EMBL SEQUENCE DATABASE, 9 June 1982 (1982-06-09), XP002131904 HEIDELBERG DE;;KRIEG A M ET AL: ""CPG MOTIFS IN BACTERIAL DNA TRIGGER DIRECT B-CELL ACTIVATION"" NATURE,GB,MACMILLAN JOURNALS LTD. LONDON, vol. 374, 6 April 1995 (1995-04-06), page 546-549, XP002910391 ISSN: 0028-0836;;DATABASE WPI Section Ch, Week 199439 Derwent Publications Ltd., London, GB; Class B04, AN 1994-312814 XP002131905 & JP 06 237773 A (SHIDA H) 30 August 1994 (1994-08-30);;PATENT ABSTRACTS OF JAPAN vol. 1997, no. 12, 25 December 1997 (1997-12-25) & JP 09 206077 A (CALPIS FOOD IND CO LTD:THE), 12 August 1997 (1997-08-12);;DATABASE WPI Section Ch, Week 199534 Derwent Publications Ltd., London, GB; Class D15, AN 1995-260052 XP002131906 & JP 07 163377 A (KOKUZEI CHO CHOKAN) 27 June 1995 (1995-06-27);;PATENT ABSTRACTS OF JAPAN vol. 015, no. 259 (C-0846), 2 July 1991 (1991-07-02) & JP 03 087173 A (TEIJIN LTD;OTHERS: 01), 11 April 1991 (1991-04-11);;PATENT ABSTRACTS OF JAPAN vol. 1998, no. 10, 31 August 1998 (1998-08-31) & JP 10 127287 A (CENTEON PHARMA GMBH), 19 May 1998 (1998-05-19)",EXPIRED
262,CA,A1,CA 2342284 A1,114-054-833-896-890,2000-03-16,2000,CA 2342284 A,1999-09-09,US 9958398 P;;US 9920506 W,1998-09-09,METHYLATION OF PLASMID VECTORS,"Unmethylated plasmid DNA vectors are a major contributor to the inflammatory response associated with gene delivery. Results of clinical studies where CF subjects were subjected to either aerosolized liposomes alone or cationic lipid:DNA complexes indicated that bacterial derived plasmid DNA may be inflammatory. Additionally, unmethylated CpG dinucleotides have been shown t o be immunostimulatory and are present at a much higher frequency in bacterial ly- derived plasmid DNA compared to vertebrate DNA. The invention provides for methods of modulating the immunostimulatory response to gene delivery by modifying the plasmid delivered to the cell. The plasmid is modified to redu ce or eliminate the immunostimulatory response in order to preserve the efficac y of gene transfer but reduce the associated toxicity. In a preferred embodiment, the invention provides for a method of reducing inflammatory response to gene delivery by methylating CpG motifs of the plasmid vector and/or removing CpG motifs of the plasmid vector.",GENZYME CORP,YEW NELSON S;;SCHEULE RONALD K;;CHENG SENG H;;MARSHALL JOHN;;TOUSIGNANT JENNIFER D;;PRZYBYLSKA MALGORZATA,,https://lens.org/114-054-833-896-890,Patent Application,no,0,0,15,15,1,A61K48/00;;A61K48/00;;A61P1/18;;A61P29/00;;A61P37/02;;A61P37/06;;C12N15/88;;C12N15/88;;C12N2799/021;;C12N2799/021;;C12P19/34;;C12P19/34,C12N15/09;;A61K31/35;;A61K31/365;;A61K31/4706;;A61K31/473;;A61K31/711;;A61K48/00;;A61P1/18;;A61P29/00;;A61P37/02;;A61P37/06;;C12N15/88;;C12P19/34,,0,0,,,,DISCONTINUED
263,CY,T1,CY 1113553 T1,007-900-184-044-452,2016-06-22,2016,CY 131100063 T,2013-01-23,EP 06021432 A;;US 9958398 P,1998-09-09,ΜΕΘΥΛΙΩΣΗ ΠΛΑΣΜΙΔΙΑΚΩΝ ΚΟΜΙΣΤΩΝ,"Η παρούσα εφεύρεση παρέχει μέθοδο περιορισμού της ανοσοδιεγερτικής απόκρισης ενός θηλαστικού έναντι σύνθεσης περιλαμβάνουσα το στάδιο χορήγησης της εν λόγω σύνθεσης όπου η εν λόγω σύνθεση περιλαμβάνει τουλάχιστον ένα πλασμίδιο, και τουλάχιστον μία κατιονική αμφίφιλη ένωση, όπου το εν λόγω τουλάχιστον ένα πλασμίδιο είναι CpG τροποποιημένο πλασμίδιο και η μέθοδος τροποποίησης του εν λόγω πλασμιδίου επιλέγεται από απομάκρυνση τουλάχιστον ενός CpG μοτίβου από το εν λόγω πλασμίδιο, μεθυλίωση τουλάχιστον ενός CpG μοτίβου του εν λόγω πλασμιδίου, ή απομάκρυνση τουλάχιστον ενός CpG μοτίβου και μεθυλίωση τουλάχιστον ενός CpG μοτίβου.",GENZYME CORP,CHENG SENG H;;MARSHALL JOHN;;SCHEULE RONALD K;;YEW NELSON S;;TOUSIGNANT JENNIFER D;;PRZYBYLSKA MALGORZATA,,https://lens.org/007-900-184-044-452,Granted Patent,no,0,0,15,15,0,A61K48/00;;A61K48/00;;A61P1/18;;A61P29/00;;A61P37/02;;A61P37/06;;C12N15/88;;C12N15/88;;C12N2799/021;;C12N2799/021;;C12P19/34;;C12P19/34,C12N15/09;;C12N15/85;;A61K31/35;;A61K31/365;;A61K31/4706;;A61K31/473;;A61K31/711;;A61K48/00;;A61P1/18;;A61P29/00;;A61P37/02;;A61P37/06;;C12N15/88;;C12P19/34,,0,0,,,,ACTIVE
264,US,A1,US 2018/0035697 A1,012-876-471-334-923,2018-02-08,2018,US 201715788621 A,2017-10-19,US 201715788621 A;;US 201615097922 A;;US 201562149365 P,2015-04-17,COMPOSITION AND METHODS TO CONTROL THE OUTGROWTH OF PATHOGENS AND SPOILAGE MICROORGANISMS IN HIGH MOISTURE AND LOW SODIUM SYSTEMS,"A method of inhibiting the outgrowth of pathogens and spoilage microorganisms in food and beverage products having a moisture content of about 38-80% by weight, a salt content of less than about 5.0% by weight, and a pH range of about 4.6 to about 8.5. The application of an organic acid or its salt with a fermentation derived antimicrobial peptide offers a robust solution to curtail growth of spores and vegetative cells without the need for chemicals, such as sodium nitrite, sodium nitrate or sorbate.",KERRY LUXEMBOURG S A R L,SHEEHAN VIVIEN;;CHENG YIQING;;COOPER RENETTA;;OSHEA EILEEN;;KLATT JENNIFER;;JONES BETH;;PERUMALLA AMARA VENKATA SUNIL,KERRY LUXEMBOURG S.A.R.L (2019-03-29);;KERRY GROUP SERVICES INTERNATIONAL LIMITED (2022-01-11),https://lens.org/012-876-471-334-923,Patent Application,yes,2,1,2,24,0,A23L3/34635;;A23B4/20;;A23K20/105;;A23K20/147;;A23K20/195;;A23L3/3571;;A01N37/46;;A23B4/12;;A23B4/24;;A23B7/155;;A23L2/44;;A23L3/3508;;A23L3/358;;A23B4/22;;A01N63/50;;A23L3/3571;;A01N37/46;;A01N43/90;;A23B4/12;;A23K30/00;;A23B4/24;;A23B7/155;;A23L2/44;;A23L3/3508;;A23L3/358;;A23B4/22;;A23L3/34635;;A23B4/20;;A23K20/105;;A23K20/147;;A23K20/195;;A01N63/50,A23L3/3571;;A01N37/46;;A01N43/90;;A01N63/50;;A23B4/12;;A23B4/22;;A23B4/24;;A23B7/155;;A23L2/44;;A23L3/3508;;A23L3/358,,1,0,,,the European Patent Application 384319,ACTIVE
265,EP,A2,EP 1109924 A2,167-674-143-645-103,2001-06-27,2001,EP 99946789 A,1999-09-09,US 9920506 W;;US 9958398 P,1998-09-09,METHYLATION OF PLASMID VECTORS,,GENZYME CORP,CHENG SENG H;;MARSHALL JOHN;;SCHEULE RONALD K;;YEW NELSON S;;TOUSIGNANT JENNIFER D;;PRZYBYLSKA MALGORZATA,GENZYME CORPORATION (2006-01-25),https://lens.org/167-674-143-645-103,Patent Application,yes,0,0,15,15,0,A61K48/00;;A61K48/00;;A61P1/18;;A61P29/00;;A61P37/02;;A61P37/06;;C12N15/88;;C12N15/88;;C12N2799/021;;C12N2799/021;;C12P19/34;;C12P19/34,C12N15/09;;A61K31/35;;A61K31/365;;A61K31/4706;;A61K31/473;;A61K31/711;;A61K48/00;;A61P1/18;;A61P29/00;;A61P37/02;;A61P37/06;;C12N15/88;;C12P19/34,,1,0,,,See references of WO 0014262A3,DISCONTINUED
266,WO,A2,WO 2000/014262 A2,034-763-574-958-680,2000-03-16,2000,US 9920506 W,1999-09-09,US 9958398 P,1998-09-09,METHYLATION OF PLASMID VECTORS,"Unmethylated plasmid DNA vectors are a major contributor to the inflammatory response associated with gene delivery. Results of clinical studies where CF subjects were subjected to either aerosolized liposomes alone or cationic lipid:DNA complexes indicated that bacterial derived plasmid DNA may be inflammatory. Additionally, unmethylated CpG dinucleotides have been shown to be immunostimulatory and are present at a much higher frequency in bacterially-derived plasmid DNA compared to vertebrate DNA. The invention provides for methods of modulating the immunostimulatory response to gene delivery by modifying the plasmid delivered to the cell. The plasmid is modified to reduce or eliminate the immunostimulatory response in order to preserve the efficacy of gene transfer but reduce the associated toxicity. In a preferred embodiment, the invention provides for a method of reducing inflammatory response to gene delivery by methylating CpG motifs of the plasmid vector and/or removing CpG motifs of the plasmid vector.",GENZYME CORP,CHENG SENG H;;MARSHALL JOHN;;SCHEULE RONALD K;;YEW NELSON S;;TOUSIGNANT JENNIFER D;;PRZYBYLSKA MALGORZATA,,https://lens.org/034-763-574-958-680,Patent Application,yes,0,21,15,15,1,A61K48/00;;A61K48/00;;A61P1/18;;A61P29/00;;A61P37/02;;A61P37/06;;C12N15/88;;C12N15/88;;C12N2799/021;;C12N2799/021;;C12P19/34;;C12P19/34,C12N15/09;;A61K31/35;;A61K31/365;;A61K31/4706;;A61K31/473;;A61K31/711;;A61K48/00;;A61P1/18;;A61P29/00;;A61P37/02;;A61P37/06;;C12N15/88;;C12P19/34,,0,0,,,,PENDING
267,NZ,A,NZ 574310 A,170-386-214-973-860,2012-05-25,2012,NZ 57431007 A,2007-07-25,US 83328806 P;;US 2007/0016775 W,2006-07-26,HYDROPHOBICALLY MODIFIED POLY(ETHYLENE GLYCOL) FOR USE IN PITCH AND STICKIES CONTROL IN PULP AND PAPERMAKING PROCESSES,"Disclosed herein is a method of inhibiting the deposition of organic contaminants in pulp or papermaking systems comprising adding to the pulp or papermaking system an effective deposition inhibiting amount of a hydrophobically modified poly[ethylene glycol] composition comprising the formula: (R1-)x-O-[-CH2-CH2-O-]n-(R2)y-Z Wherein the substituents are as defined in the specification, said hydrophobically modified poly[ethylene glycol] composition is derived from the reaction of a polyethylene glycol and a hydrophobic reagent, the reagent selected from the group consisting of an epoxide, a ketene dimmer, a glycidyl ether and alkenyl succinic anhydride; and wherein the viscosity of a 5 wt% concentration of the hydrophobically modified poly[ethylene glycol] composition is from about 1cP to about 10,000 cP.",HERCULES INC,GU QU-MING;;CHENG HUAI N;;CAREY WILLIAM;;GELMAN ROBERT;;RITTENHOUSE-PRUSS JENNIFER;;DOHERTY ERIN A,"SOLENIS TECHNOLOGIES CAYMAN L.P., CH (2014-11-06);;HERCULES INCORPORATED, US (2012-04-27)",https://lens.org/170-386-214-973-860,Patent Application,no,0,0,21,21,0,C08G65/22;;C08G65/2609;;D21C9/008;;D21H21/02;;C08G2650/34;;C08G65/22;;C08G65/2609;;C08G2650/34;;D21C9/008;;D21H21/02;;D21H21/02;;C08G2650/34;;C08G65/22;;D21C9/008;;C08G65/2609,D21H21/02;;C08L71/02;;C11D1/722;;D21C9/00,,0,0,,,,DISCONTINUED
268,US,A1,US 2023/0394211 A1,086-627-715-298-787,2023-12-07,2023,US 202217805198 A,2022-06-02,US 202217805198 A,2022-06-02,TIMING-AWARE AND SIMULTANEOUS OPTIMIZATION OF LATCH CLUSTERING AND PLACEMENT IN AN INTEGRATED CIRCUIT,"Embodiments are provided for providing enhanced fabrication and design of an integrated circuit in a computing system by a processor. One or more latches may be clustered by augmenting an integer linear program (“ILP”) operation with a facility-location allocation (FLA) operation, wherein the clustering of the one or more latches is timing-aware. The one or more latches may be placed and assigned in the integrated chip based on clustering one or more latches.",IBM,JUNG JINWOOK;;NAM GI-JOON;;KAZDA JENNIFER;;TELLEZ GUSTAVO ENRIQUE;;HUANG CHAU-CHIN;;CHENG YAO-WEN,INTERNATIONAL BUSINESS MACHINES CORPORATION (2022-05-19),https://lens.org/086-627-715-298-787,Patent Application,yes,0,0,1,1,0,G06F30/3315;;G06F30/327;;G06F30/392;;G06F30/3315;;G06F30/327;;G06F2119/06;;G06F2119/12;;G06F2119/18,G06F30/3315;;G06F30/327,,0,0,,,,PENDING
269,EP,A1,EP 1832657 A1,054-744-013-370-969,2007-09-12,2007,EP 06021432 A,1999-09-09,EP 99946789 A;;US 9958398 P,1998-09-09,Methylation of plasmid vectors,"The present invention provides a method of reducing a mammal's immunostimulatory response to a composition comprising the step of administering said composition wherein said composition comprises at least one plasmid, and at least one cationic amphiphile, wherein said at least one plasmid is a CpG altered plasmid and the method of altering said plasmid is chosen from removing at least one CpG motif from said plasmid, mehtylating at least one CpG motif of said plasmid, or removing at least one CpG motif and methylating at least one CpG motif.",GENZYME CORP,CHENG SENG H;;MARSHALL JOHN;;SCHEULE RONALD K;;YEW NELSON S;;TOUSIGNANT JENNIFER D;;PRZYBYLSKA MALGORZATA,,https://lens.org/054-744-013-370-969,Patent Application,yes,12,2,15,15,1,A61K48/00;;C12N15/88;;C12N2799/021;;C12P19/34;;A61P1/18;;A61P29/00;;A61P37/02;;A61P37/06;;C12N15/88;;A61K48/00;;C12N2799/021;;C12P19/34,C12N15/09;;A61K31/35;;C12N15/85;;A61K31/365;;A61K31/4706;;A61K31/473;;A61K31/711;;A61K48/00;;A61P1/18;;A61P29/00;;A61P37/02;;A61P37/06;;C12N15/88;;C12P19/34,,47,34,026-190-484-845-337;;068-610-214-464-341;;059-603-579-320-605;;021-222-283-045-52X;;014-444-265-062-57X;;076-172-108-459-47X;;091-988-167-378-675;;014-430-992-456-906;;006-633-671-296-980;;060-690-836-753-166;;006-633-671-296-980;;068-341-057-570-26X;;088-363-175-189-876;;026-667-306-674-809;;060-239-731-117-722;;022-139-438-803-540;;089-511-593-403-351;;012-990-935-470-093;;026-190-484-845-337;;039-946-393-613-441;;081-458-248-874-063;;088-399-851-323-095;;040-927-232-074-186;;062-333-814-343-796;;054-093-810-160-677;;072-155-754-778-766;;082-219-282-268-575;;013-257-986-831-420;;020-796-309-835-13X;;080-919-556-956-266;;040-156-341-807-622;;012-990-935-470-093;;020-220-664-012-830;;012-990-935-470-093,10.1038/374546a0;;7700380;;10.1016/0092-8674(93)90353-r;;7686820;;10.1096/fasebj.4.10.2197151;;2197151;;10.1126/science.8211164;;8211164;;pmc1159463;;10.1111/j.1469-7793.1997.637bm.x;;9218222;;10.1152/ajpcell.1996.270.5.c1326;;8967432;;10.1016/s0092-8674(00)81099-5;;8612275;;pmc299306;;10.1073/pnas.84.21.7413;;2823261;;8300583;;10.1016/s0021-9258(17)41980-6;;10.1073/pnas.86.18.6982;;2780554;;pmc297976;;8300583;;10.1016/s0021-9258(17)41980-6;;10.1006/meth.1993.1009;;2801762;;10.1097/00000441-198910000-00013;;10.1016/0006-291x(91)91366-k;;1883357;;pmc312463;;10.1093/nar/20.12.3233;;1377820;;7687073;;10.1126/science.7687073;;10.1021/bi00041a033;;7577942;;8886841;;10.1089/hum.1996.7.14-1701;;10.1038/374546a0;;7700380;;pmc39727;;10.1073/pnas.93.7.2879;;8610135;;8662521;;10.1126/science.273.5273.352;;9202058;;10.1172/jci119523;;pmc508166;;10.1002/(sici)1521-4141(199806)28:06<2045::aid-immu2045>3.0.co;2-8;;9645386;;9341778;;10.1002/eji.1830270931;;10.4049/jimmunol.156.12.4570;;8648098;;9574565;;8757300;;10.4049/jimmunol.157.5.1840;;10.1002/eji.1830270712;;9247576;;9113516;;10.1089/hum.1997.8.6-765;;9048198;;10.1089/hum.1997.8.3-313;;9095409;;10.1089/hum.1997.8.5-575;;8886841;;10.1089/hum.1996.7.14-1701;;9113509;;10.1089/hum.1997.8.6-689;;8886841;;10.1089/hum.1996.7.14-1701,"GILBERT W: ""pUC13c cloning vector (beta-galactosidase mRNA on complementary strand)"", EMBL SEQUENCE DATABASE, 25 March 1993 (1993-03-25), HEIDELBERG DE, XP002131903;;OKA ET AL.: ""Nucleotide sequence of the kanamycin resistance transposon Tn903"", EMBL SEQUENCE DATABASE, 9 June 1982 (1982-06-09), HEIDELBERG DE, XP002131904;;KRIEG A M ET AL: ""CPG MOTIFS IN BACTERIAL DNA TRIGGER DIRECT B-CELL ACTIVATION"", NATURE,GB,MACMILLAN JOURNALS LTD. LONDON, vol. 374, 6 April 1995 (1995-04-06), pages 546-549, XP002910391, ISSN: 0028-0836;;DATABASE WPI Section Ch Week 199439, Derwent World Patents Index; Class B04, AN 1994-312814, XP002131905;;PATENT ABSTRACTS OF JAPAN vol. 1997, no. 12 25 December 1997 (1997-12-25);;DATABASE WPI Section Ch Week 199534, Derwent World Patents Index; Class D15, AN 1995-260052, XP002131906;;PATENT ABSTRACTS OF JAPAN vol. 015, no. 259 (C - 0846) 2 July 1991 (1991-07-02);;PATENT ABSTRACTS OF JAPAN vol. 1998, no. 10 31 August 1998 (1998-08-31);;WELSH, M.J., CELL, vol. 73, 1993, pages 1251 - 1254;;QUINTON, P.M., FASEB LETT., vol. 4, 1990, pages 2709 - 2717;;JIANG, C, SCIENCE, vol. 262, 1993, pages 424 - 427;;JIANG, C., J. PHYSIOL., vol. 501, no. 3, 1997, pages 637 - 647;;SMITH, J.J., J. CLIN. INVEST., vol. 91, 1993, pages 1148 - 1153;;ZHANG, Y, AM.J.PHYSIOL, vol. 270, 1996, pages C1326 - 1335;;SMITH, J.J., CELL, vol. 85, 1996, pages 229 - 236;;FEIGNER, PROC. NATL. ACAD. SCI. USA, vol. 84, 1987, pages 7413 - 7417;;FEIGNER, JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 269, no. 4, 1994, pages 2550 - 2561;;BEHR, PROC. NATL. ACAD. SCI., vol. 86, 1989, pages 6982 - 6986;;FELGNER, THE JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 269, no. 4, 1994, pages 2550 - 2561;;FELGNER, METHODS IN ENZYMOLOGY, vol. 5, 1993, pages 67 - 75;;BRIGHAM, K.L. ET AL.: ""In vivo transfection of murine lungs with functioning prokaryotic gene using a liposome vehicle"", AM.J.MED.SCI., vol. 298, 1989, pages 278 - 281;;GAO, X.A.; L. HUANG: ""A novel cationic liposome reagent for efficient transfection of mammalian cells"", BIOCHEM BIOPHYS RES COMMUN, vol. 179, 1991, pages 280 - 285;;YOSHIMURA, K. ET AL.: ""Expression of the human cystic fibrosis transmembrane conductance regulator gene in the mouse lung after in vivo intratracheal plasmid-mediated gene transfer"", NUCL.ACIDS RES., vol. 20, 1992, pages 3233 - 3240;;ZHU, N. ET AL.: ""Systemic gene expression after intravenous DNA delivery into adult mice"", SCIENCE, vol. 261, 1993, pages 209 - 211;;SOLODIN, I. ET AL.: ""A novel series of amphiphilic imidazolinium compounds for in vitro and in vivo gene delivery"", BIOCHEM., vol. 34, 1995, pages 13537 - 13544;;LEE, E.R. ET AL.: ""Detailed analysis of structure and formulations of cationic lipids for efficient gene transfer to the lung"", HUM. GENE THER., vol. 7, 1996, pages 1701 - 1717;;KRIEG, NATURE, vol. 374, 1995, pages 546 - 9;;KLINMAN, PROC. NATL. ACAD. SCI. USA, vol. 83, 1996, pages 2879 - 2883;;SATO, SCIENCE, vol. 273, 1996, pages 352 - 4;;SCHWARTZ, J. CLIN. INVEST., vol. 100, 1997, pages 68 - 73;;SPARWASSER, EUR. J. IMMUNOL., vol. 28, 1998, pages 2045 - 2054;;LIPFORD, EUR. J. IMMUNOL., vol. 27, 1997, pages 2340 - 2344;;SATO, SCIENCE, vol. 273, 1995, pages 352 - 4;;COWDERY, J. IMMUNOL., vol. 156, 1996, pages 4370 - 4575;;FRIEMARK, J. IMMUNOL., vol. 160, 1998, pages 4580 - 6;;KRIEG, TRENDS MICROBIOL., vol. 4, 1995, pages 73 - 76;;BALLAS, J. IMMUNOL., vol. 157, 1996, pages 1840 - 5;;SPARWASSER, EUR. J. IMMUNOL., vol. 27, 1997, pages 1671 - 9;;SIMON J. EASTMAN, HUMAN GENE THERAPY, vol. 8, 1997, pages 765 - 773;;SIMON J. EASTMAN, HUMAN GENE THERAPY, vol. 8, 1997, pages 313 - 322;;YEW, HUM. GENE THER., vol. 8, 1997, pages 575 - 84;;LEE, HUM. GENE THER., vol. 7, 1996, pages 1701 - 1717;;SCHEULE, HUM. GENE THER., vol. 8, 1997, pages 689 - 707;;LEE, HUM. GENE THER., vol. 7, 1996, pages 1701 - 1717;;""FUNDAMENTALS OF CLINICAL CHEMISTRY"", 1976, SAUNDERS;;""CLINICAL DIAGNOSIS BY LABORATORY METHODS"", 1974, SAUNDERS;;""IMMUNOLOGY"", 1998, MOSBY INTERNATIONAL LTD",EXPIRED
270,DK,T3,DK 1832657 T3,009-514-822-817-905,2012-12-17,2012,DK 06021432 T,1999-09-09,US 9958398 P;;EP 99946789 A,1998-09-09,Methylering af plasmid-vektorer,,GENZYME CORP,CHENG SENG H;;MARSHALL JOHN;;SCHEULE RONALD K;;YEW NELSON S;;TOUSIGNANT JENNIFER D;;PRZYBYLSKA MALGORZATA,,https://lens.org/009-514-822-817-905,Granted Patent,no,0,0,15,15,0,A61K48/00;;A61K48/00;;A61P1/18;;A61P29/00;;A61P37/02;;A61P37/06;;C12N15/88;;C12N15/88;;C12N2799/021;;C12N2799/021;;C12P19/34;;C12P19/34,C12N15/09;;C12N15/85;;A61K31/35;;A61K31/365;;A61K31/4706;;A61K31/473;;A61K31/711;;A61K48/00;;A61P1/18;;A61P29/00;;A61P37/02;;A61P37/06;;C12N15/88;;C12P19/34,,0,0,,,,EXPIRED
271,US,B2,US 10327463 B2,050-127-246-618-372,2019-06-25,2019,US 201715788621 A,2017-10-19,US 201715788621 A;;US 201615097922 A;;US 201562149365 P,2015-04-17,Composition and methods to control the outgrowth of pathogens and spoilage microorganisms in high moisture and low sodium systems,"A method of inhibiting the outgrowth of pathogens and spoilage microorganisms in food and beverage products having a moisture content of about 38-80% by weight, a salt content of less than about 5.0% by weight, and a pH range of about 4.6 to about 8.5. The application of an organic acid or its salt with a fermentation derived antimicrobial peptide offers a robust solution to curtail growth of spores and vegetative cells without the need for chemicals, such as sodium nitrite, sodium nitrate or sorbate.",KERRY LUXEMBOURG S A R L,SHEEHAN VIVIEN;;CHENG YIQING;;COOPER RENETTA;;O'SHEA EILEEN;;KLATT JENNIFER;;JONES BETH;;PERUMALLA AMARA VENKATA SUNIL,KERRY LUXEMBOURG S.A.R.L (2019-03-29);;KERRY GROUP SERVICES INTERNATIONAL LIMITED (2022-01-11),https://lens.org/050-127-246-618-372,Granted Patent,yes,15,2,2,24,0,A23L3/34635;;A23B4/20;;A23K20/105;;A23K20/147;;A23K20/195;;A23L3/3571;;A01N37/46;;A23B4/12;;A23B4/24;;A23B7/155;;A23L2/44;;A23L3/3508;;A23L3/358;;A23B4/22;;A01N63/50;;A23L3/3571;;A01N37/46;;A01N43/90;;A23B4/12;;A23K30/00;;A23B4/24;;A23B7/155;;A23L2/44;;A23L3/3508;;A23L3/358;;A23B4/22;;A23L3/34635;;A23B4/20;;A23K20/105;;A23K20/147;;A23K20/195;;A01N63/50,A23B4/12;;A01N37/46;;A01N43/90;;A01N63/50;;A23B4/20;;A23B4/22;;A23B4/24;;A23B7/155;;A23K20/105;;A23K20/147;;A23K20/195;;A23K30/00;;A23L2/44;;A23L3/3463;;A23L3/3508;;A23L3/3571;;A23L3/358,,11,7,044-842-187-452-59X;;011-900-796-991-711;;003-181-598-091-706;;064-797-472-608-106;;149-190-507-799-944;;081-804-125-115-314;;066-392-307-260-019,22062728;;10.1016/j.meatsci.2006.04.014;;pmc379710;;4580194;;10.1128/am.26.1.22-26.1973;;10.1016/0168-1605(93)90019-d;;8257656;;10.5897/ajb11.979;;10.1016/s0740-0020(95)80129-4;;10.1080/01635580701684872;;pmc2661797;;18444144;;10.1016/j.ijfoodmicro.2003.10.012;;15135954,"International Search Report dated Jul. 19, 2016 from the International Searching Authority in counterpart International Application No. PCT/US2016/027520.;;Written Opinion of the International Seraching Authority dated Jul. 19, 2016 in counterpart International Application No. PCT/US2016/027520.;;Desmond, E.; Reducing salt: A challenge for the meat industry, Meat Science, 74 (2006), pp. 188-196.;;Bouvard, et al.; On behalf of the International Agency for Research on Cancer Monograph Working Group, The Carcinogenicity of consumption of red and processed meat. The Lancet Oncology. Published Online: Oct. 26, 2015; 3 pages.;;Hustad, G. O et al.; Effect of sodium nitrite and sodium nitrate on botulinal toxin production and nitrosamine formation in wieners. Appl. Microbiology, Jul. 1973, p. 22-26, vol. 26, No. 1.;;Schlyter, J.H.; The effects of diacetate with nitrite, lactate, or pediocin on the viability of Listeria monocytogenes in turkey slurries. International Journal of Food Microbiology, 19 (1993) 271-281.;;Jozala, A.F. et al.; Processing of byproducts to improve nisin production by Lactococcus lactis; African Journal of Biotechnology, vol. 10(66), pp. 4920-14925, Oct. 24, 2011.;;Farber, J. et al.; Modelling the effects of various parameters on the growth of Listeria monocytogenes on liver pate. Food Microbiology, 1995, 12, 447-453.;;Santarelli, R. L. et al.; Processed meat and colorectal cancer: a review of epidemiologic and experimental evidence. Nutrition and Cancer, 60(2), 131-144., 2008.;;Juneja, V. K. et al.: Inhibitory effects of organic acid salts on growth of Clostridium perfringens from spore inocula during chilling of marinated ground turkey breast. International Journal of Food Microbiology, 93 (2004) :155-163.;;USDA; Scientific Report of the 2015 Dietary Guidelines Advisory Committee, Advisory Report of the Secretary of Health and Human Services and the Secretary of the Agriculture; Feb. 2015; 571 pages.",ACTIVE
272,US,A1,US 2003/0220277 A1,043-594-186-695-411,2003-11-27,2003,US 29104102 A,2002-11-08,US 29104102 A;;US 39246299 A;;US 9958398 P,1998-09-09,Methylation of plasmid vectors,"
   Unmethylated plasmid DNA vectors are a major contributor to the inflammatory response associated with gene delivery. Results of clinical studies where CF subjects were subjected to either aerosolized liposomes alone or cationic lipid:DNA complexes indicated that bacterial derived plasmid DNA may be inflammatory. Additionally, unmethylated CpG dinucleotides have been shown to be immunostimulatory and are present at a much higher frequency in bacterially-derived plasmid DNA compared to vertebrate DNA. The invention provides for methods of modulating the immunostimulatory response to gene delivery by modifying the plasmid delivered to the cell. The plasmid is modified to reduce or eliminate the immunostimulatory response in order to preserve the efficacy of gene transfer but reduce the associated toxicity. In a preferred embodiment, the invention provides for a method of reducing inflammatory response to gene delivery by methylating CpG motifs of the plasmid vector and/or removing CpG motifs of the plasmid vector. 
",GENZYME CORP,YEW NELSON S;;PRZYBYLSKA MALGORZATA;;MARSHALL JOHN;;SCHEULE RONALD K;;TOUSIGNANT JENNIFER D;;CHENG SENG H,,https://lens.org/043-594-186-695-411,Patent Application,yes,9,13,15,15,1,A61K48/00;;A61K48/00;;A61P1/18;;A61P29/00;;A61P37/02;;A61P37/06;;C12N15/88;;C12N15/88;;C12N2799/021;;C12N2799/021;;C12P19/34;;C12P19/34,C12N15/09;;A61K31/35;;A61K31/365;;A61K31/4706;;A61K31/473;;A61K31/711;;A61K48/00;;A61P1/18;;A61P29/00;;A61P37/02;;A61P37/06;;C12N15/88;;C12P19/34,514/44;;536/23.2,0,0,,,,DISCONTINUED
273,EP,A1,EP 1091762 A1,073-258-159-644-673,2001-04-18,2001,EP 99937198 A,1999-07-01,US 9915009 W;;US 9160898 P,1998-07-02,TRANSGENE EXPRESSION IN POLARIZED CELLS,,GENZYME CORP,EASTMAN SIMON;;CHU QUIMING;;TOUSIGNANT JENNIFER D;;FANG SHAONA L;;CHENG SENG H;;SCHEULE RONALD K,GENZYME CORPORATION (2003-12-03),https://lens.org/073-258-159-644-673,Patent Application,yes,0,0,6,6,0,A61K48/0008;;A61K48/0008;;A61K48/00;;A61K48/00;;A61P9/00;;A61P35/00;;A61P43/00,A61K48/00;;A61P9/00;;A61P35/00;;A61P43/00,,1,0,,,See references of WO 0001418A1,DISCONTINUED
274,WO,A2,WO 2019/050546 A2,190-489-293-131-916,2019-03-14,2019,US 2017/0050993 W,2017-09-11,US 2017/0050993 W,2017-09-11,METHODS FOR TREATMENT AND PREVENTION OF ACUTE LIVER FAILURE,,STEMINENT BIOTHERAPEUTICS INC;;HO JENNIFER HUI CHUN,HO JENNIFER HUI-CHUN;;CHANG RYAN;;LEE OSCAR KUANG-SHENG;;LIN NIANG-CHENG;;LUI CHIN-SU,,https://lens.org/190-489-293-131-916,Patent Application,yes,0,1,2,2,0,A61K35/28;;A61K38/1833;;A61K38/1866,A61K35/28,,0,0,,,,PENDING
275,WO,A9,WO 2000/014262 A9,059-401-386-062-86X,2000-08-17,2000,US 9920506 W,1999-09-09,US 9958398 P,1998-09-09,METHYLATION OF PLASMID VECTORS,"Unmethylated plasmid DNA vectors are a major contributor to the inflammatory response associated with gene delivery. Results of clinical studies where CF subjects were subjected to either aerosolized liposomes alone or cationic lipid:DNA complexes indicated that bacterial derived plasmid DNA may be inflammatory. Additionally, unmethylated CpG dinucleotides have been shown to be immunostimulatory and are present at a much higher frequency in bacterially-derived plasmid DNA compared to vertebrate DNA. The invention provides for methods of modulating the immunostimulatory response to gene delivery by modifying the plasmid delivered to the cell. The plasmid is modified to reduce or eliminate the immunostimulatory response in order to preserve the efficacy of gene transfer but reduce the associated toxicity. In a preferred embodiment, the invention provides for a method of reducing inflammatory response to gene delivery by methylating CpG motifs of the plasmid vector and/or removing CpG motifs of the plasmid vector.",GENZYME CORP,CHENG SENG H;;MARSHALL JOHN;;SCHEULE RONALD K;;YEW NELSON S;;TOUSIGNANT JENNIFER D;;PRZYBYLSKA MALGORZATA,,https://lens.org/059-401-386-062-86X,Patent Application,no,0,0,15,15,0,A61K48/00;;A61K48/00;;A61P1/18;;A61P29/00;;A61P37/02;;A61P37/06;;C12N15/88;;C12N15/88;;C12N2799/021;;C12N2799/021;;C12P19/34;;C12P19/34,C12N15/09;;A61K31/35;;A61K31/365;;A61K31/4706;;A61K31/473;;A61K31/711;;A61K48/00;;A61P1/18;;A61P29/00;;A61P37/02;;A61P37/06;;C12N15/88;;C12P19/34,,0,0,,,,PENDING
276,WO,A3,WO 2000/014262 A3,051-022-120-669-583,2000-06-29,2000,US 9920506 W,1999-09-09,US 9958398 P,1998-09-09,METHYLATION OF PLASMID VECTORS,"Unmethylated plasmid DNA vectors are a major contributor to the inflammatory response associated with gene delivery. Results of clinical studies where CF subjects were subjected to either aerosolized liposomes alone or cationic lipid:DNA complexes indicated that bacterial derived plasmid DNA may be inflammatory. Additionally, unmethylated CpG dinucleotides have been shown to be immunostimulatory and are present at a much higher frequency in bacterially-derived plasmid DNA compared to vertebrate DNA. The invention provides for methods of modulating the immunostimulatory response to gene delivery by modifying the plasmid delivered to the cell. The plasmid is modified to reduce or eliminate the immunostimulatory response in order to preserve the efficacy of gene transfer but reduce the associated toxicity. In a preferred embodiment, the invention provides for a method of reducing inflammatory response to gene delivery by methylating CpG motifs of the plasmid vector and/or removing CpG motifs of the plasmid vector.",GENZYME CORP,CHENG SENG H;;MARSHALL JOHN;;SCHEULE RONALD K;;YEW NELSON S;;TOUSIGNANT JENNIFER D;;PRZYBYLSKA MALGORZATA,,https://lens.org/051-022-120-669-583,Search Report,yes,4,0,15,15,0,A61K48/00;;A61K48/00;;A61P1/18;;A61P29/00;;A61P37/02;;A61P37/06;;C12N15/88;;C12N15/88;;C12N2799/021;;C12N2799/021;;C12P19/34;;C12P19/34,C12N15/09;;A61K31/35;;A61K31/365;;A61K31/4706;;A61K31/473;;A61K31/711;;A61K48/00;;A61P1/18;;A61P29/00;;A61P37/02;;A61P37/06;;C12N15/88;;C12P19/34,,8,1,026-190-484-845-337,10.1038/374546a0;;7700380,"GILBERT W: ""pUC13c cloning vector (beta-galactosidase mRNA on complementary strand)"", EMBL SEQUENCE DATABASE, 25 March 1993 (1993-03-25), HEIDELBERG DE, XP002131903;;OKA ET AL.: ""Nucleotide sequence of the kanamycin resistance transposon Tn903"", EMBL SEQUENCE DATABASE, 9 June 1982 (1982-06-09), HEIDELBERG DE, XP002131904;;KRIEG A M ET AL: ""CPG MOTIFS IN BACTERIAL DNA TRIGGER DIRECT B-CELL ACTIVATION"", NATURE,GB,MACMILLAN JOURNALS LTD. LONDON, vol. 374, 6 April 1995 (1995-04-06), pages 546-549, XP002910391, ISSN: 0028-0836;;DATABASE WPI Section Ch Week 199439, Derwent World Patents Index; Class B04, AN 1994-312814, XP002131905;;PATENT ABSTRACTS OF JAPAN vol. 1997, no. 12 25 December 1997 (1997-12-25);;DATABASE WPI Section Ch Week 199534, Derwent World Patents Index; Class D15, AN 1995-260052, XP002131906;;PATENT ABSTRACTS OF JAPAN vol. 015, no. 259 (C - 0846) 2 July 1991 (1991-07-02);;PATENT ABSTRACTS OF JAPAN vol. 1998, no. 10 31 August 1998 (1998-08-31)",PENDING
277,ES,T3,ES 2613236 T3,027-647-218-206-480,2017-05-23,2017,ES 10774095 T,2010-10-26,US 25498209 P;;US 38128710 P;;US 2010/0054148 W,2009-10-26,Proteínas de unión a un antígeno de IL-23 humana,"Una proteína de unión al antígeno que se une a la IL-23 humana, en donde dicha proteína de unión al antígeno comprende: (i) (a) una región variable de cadena pesada que comprende una CDRH1 que tiene SEQ ID NO: 91, una CDRH2 que tiene SEQ ID NO: 92 y una CDRH3 que tiene SEQ ID NO: 93, y una región variable de cadena ligera que comprende una CDRL1 que tiene SEQ ID NO: 62, una CDRL2 que tiene SEQ ID NO: 63 y una CDRL3 que tiene SEQ ID NO: 64; o (b) una región variable de cadena pesada que comprende una CDRH1 que tiene SEQ ID NO: 109, una CDRH2 que tiene SEQ ID NO: 116 y una CDRH3 que tiene SEQ ID NO: 111, y una región variable de cadena ligera que comprende una CDRL1 que tiene SEQ ID NO: 80, una CDRL2 que tiene SEQ ID NO: 81 y una CDRL3 que tiene la SEQ ID NO: 76; y en donde dicha proteína de unión al antígeno de acuerdo con (a) o (b) se une a la IL-23 humana con un KD de <= 5x10-12 M; o (ii) una región variable de cadena pesada de SEQ ID NO: 31 y una región variable de cadena ligera de SEQ ID NO: 1; o una región variable de cadena pesada de SEQ ID NO: 46 o 153 y una región variable de cadena ligera de SEQ ID NO: 15; en donde dicha proteína de unión al antígeno es un anticuerpo monoclonal, un anticuerpo recombinante, un anticuerpo humano, un anticuerpo quimérico, un anticuerpo multiespecífico o un fragmento del anticuerpo del mismo.",AMGEN INC,TOWNE JENNIFER;;CHENG JANET;;O'NEILL JASON;;ZHANG YU;;SUN YU;;CERNE HEATHER;;PIPER DEREK;;KETCHEM RANDAL,,https://lens.org/027-647-218-206-480,Granted Patent,no,0,0,86,87,0,A61K2039/505;;C07K2317/21;;C07K2317/55;;C07K2317/92;;A61K47/6845;;C07K16/244;;A61P37/00;;C07K16/244;;A61K2039/505;;C07K2317/626;;C07K2317/21;;C07K2317/76;;A61K47/6845;;C07K2317/54;;A61K39/395;;C07K2317/31;;C07K16/24;;A61P37/00;;C07K2317/92;;C07K2317/24;;C07K2317/622;;C07K2317/55;;C07K2317/565;;A61K39/00;;A61K39/395;;A61K39/39533;;A61K39/3955;;C07K16/18;;C07K16/24;;C07K16/244;;A61K2039/505;;C07K2317/21;;C07K2317/55;;C07K2317/92;;A61K47/6845;;C07K16/244;;A61K39/395;;C07K16/24;;C07K2317/24;;C07K2317/31;;C07K2317/54;;C07K2317/565;;C07K2317/622;;C07K2317/626;;C07K2317/76,C07K16/24;;A61K39/395,,0,0,,,,ACTIVE
278,PT,E,PT 1832657 E,038-565-590-072-060,2013-01-08,2013,PT 06021432 T,1999-09-09,US 9958398 P,1998-09-09,METHYLATION OF PLASMID VECTORS,,GENZYME CORP,YEW NELSON S;;CHENG SENG H;;MARSHALL JOHN;;SCHEULE RONALD K;;TOUSIGNANT JENNIFER D;;PRZYBYLSKA MALGORZATA,,https://lens.org/038-565-590-072-060,Granted Patent,no,0,0,15,15,0,A61K48/00;;A61K48/00;;A61P1/18;;A61P29/00;;A61P37/02;;A61P37/06;;C12N15/88;;C12N15/88;;C12N2799/021;;C12N2799/021;;C12P19/34;;C12P19/34,C12N15/09;;C12N15/85;;A61K31/35;;A61K31/365;;A61K31/4706;;A61K31/473;;A61K31/711;;A61K48/00;;A61P1/18;;A61P29/00;;A61P37/02;;A61P37/06;;C12N15/88;;C12P19/34,,0,0,,,,EXPIRED
279,TW,A,TW 201919665 A,067-417-080-622-111,2019-06-01,2019,TW 107131238 A,2018-09-06,US 2017/0050993 W,2017-09-11,Methods for treatment and prevention of acute liver failure,"The invention provides a method for prevention or treatment of acute liver dysfunction with an elevation of serum ammonia, serum creatinine, or INR in a subject, comprising infusion administering a single unit dose of a mesenchymal stem cell population in an effective amount of about 0.5 x 10<SP>4</SP> to about 5 x 10<SP>6</SP> cells/kg body weight to the subject, wherein the serum ammonia, serum creatinine and INR is greater than about 70 [mu]g/dL, about 1.3 mg/dL and 1.2, respectively.",STEMINENT BIOTHERAPEUTICS INC;;UNIV NAT YANG MING,CHANG RYAN;;HO JENNIFER HUI-CHUN;;LEE OSCAR KUANG-SHENG;;LIN NIANG-CHENG;;LUI CHIN-SU,,https://lens.org/067-417-080-622-111,Patent of Addition,no,0,0,2,2,0,A61K35/28;;A61K38/1833;;A61K38/1866,A61K35/28;;A61P1/16,,0,0,,,,PENDING
280,WO,A1,WO 2000/001418 A1,136-889-816-461-717,2000-01-13,2000,US 9915009 W,1999-07-01,US 9160898 P,1998-07-02,TRANSGENE EXPRESSION IN POLARIZED CELLS,"The well-differentiated airway epithelium is the principal target tissue for gene therapy for the treatment of CF. However, recent studies have shown that gene delivery vehicles, such as cationic lipid:DNA complexes, can be inefficient at binding to and internalizing into polarized epithelial cells. The present invention provides a method to improve gene therapy by using a compound capable of disrupting tight junctions. In the practice of the invention, the transfection of a biologically active molecule by a cationic amphiphile:biologically active molecule complex or other lipid or viral or nonviral vectors is improved by treating the cells with a class of compounds known in the art as absorption enhancers or tight junction disrupting compounds.",GENZYME CORP,EASTMAN SIMON;;CHU QUIMING;;TOUSIGNANT JENNIFER D;;FANG SHAONA L;;CHENG SENG H;;SCHEULE RONALD K,,https://lens.org/136-889-816-461-717,Patent Application,yes,2,4,6,6,0,A61K48/0008;;A61K48/0008;;A61K48/00;;A61K48/00;;A61P9/00;;A61P35/00;;A61P43/00,A61K48/00;;A61P9/00;;A61P35/00;;A61P43/00,,5,4,028-963-750-841-908;;064-744-283-625-493;;007-027-354-249-837;;019-047-328-534-646,8932437;;10.1023/a:1016078728202;;pmc309219;;8383843;;10.1093/nar/21.4.871;;pmc20356;;10.1073/pnas.94.7.3256;;9096380;;10.1089/10430349950019165;;10022528,"FREEMAN D J ET AL: ""THE INFLUENCE OF SODIUM GLYCOCHOLATE AND OTHER ADDITIVES ON THE IN VIVO TRANSFECTION OF PLASMID DNA IN THE LUNGS"", PHARMACOLOGICAL RESEARCH,GB,ACADEMIC PRESS, LONDON, vol. 13, no. 2, 1996, pages 202-209, XP000646438, ISSN: 1043-6618;;CROYLE MA ET AL.,: ""Beta cyclodextrins enhance gene delivery to the intestine"", PROCEEDINGS OF THE INT. SYMP.CONTROL.REL.BIOACT.MATER., vol. 24, 1997, XP002122911;;MIDOUX P ET AL: ""SPECIFIC GENE TRANSFER MEDIATED BY LACTOSYLATED POLY-L-LYSINE INTO HEPATOMA CELLS"", NUCLEIC ACIDS RESEARCH,GB,OXFORD UNIVERSITY PRESS, SURREY, vol. 21, no. 4, 25 February 1993 (1993-02-25), pages 871-878, XP000371764, ISSN: 0305-1048;;BUSCHLE M ET AL: ""Transloading of tumor antigen-derived peptides into antigen-presenting cells"", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF USA,US,NATIONAL ACADEMY OF SCIENCE. WASHINGTON, vol. 94, pages 3256-3261, XP002086009, ISSN: 0027-8424;;CHU Q ET AL.: ""Binding and uptake of cationic lipid:pDNA complexes by polarized airway epithelial cells"", HUMAN GENE THERAPY, vol. 10, no. 1, 1 January 1999 (1999-01-01), pages 25 - 36, XP002122912",PENDING
281,SG,A,SG 10202103260T A,048-168-867-161-597,2021-05-28,2021,SG 10202103260T A,2010-10-26,US 25498209 P;;US 38128710 P,2009-10-26,HUMAN IL-23 ANTIGEN BINDING PROTEINS,,AMGEN INC,TOWNE JENNIFER;;CHENG JANET;;O'NEILL JASON;;ZHANG YU;;SUN YU;;CERNE HEATHER;;PIPER DEREK;;KETCHEM RANDAL,,https://lens.org/048-168-867-161-597,Unknown,no,0,0,86,87,0,A61K2039/505;;C07K2317/21;;C07K2317/55;;C07K2317/92;;A61K47/6845;;C07K16/244;;A61P37/00;;C07K16/244;;A61K2039/505;;C07K2317/626;;C07K2317/21;;C07K2317/76;;A61K47/6845;;C07K2317/54;;A61K39/395;;C07K2317/31;;C07K16/24;;A61P37/00;;C07K2317/92;;C07K2317/24;;C07K2317/622;;C07K2317/55;;C07K2317/565;;A61K39/00;;A61K39/395;;A61K39/39533;;A61K39/3955;;C07K16/18;;C07K16/24;;C07K16/244;;A61K2039/505;;C07K2317/21;;C07K2317/55;;C07K2317/92;;A61K47/6845;;C07K16/244;;A61K39/395;;C07K16/24;;C07K2317/24;;C07K2317/31;;C07K2317/54;;C07K2317/565;;C07K2317/622;;C07K2317/626;;C07K2317/76,,,0,0,,,,PENDING
282,AU,A,AU 1999/052077 A,135-953-424-814-832,2000-01-24,2000,AU 1999/052077 A,1999-07-01,US 9160898 P;;US 9915009 W,1998-07-02,Transgene expression in polarized cells,,GENZYME CORP,EASTMAN SIMON;;CHU QUIMING;;TOUSIGNANT JENNIFER D;;FANG SHAONA L;;CHENG SENG H;;SCHEULE RONALD K,,https://lens.org/135-953-424-814-832,Patent Application,no,0,0,6,6,0,A61K48/0008;;A61K48/0008;;A61K48/00;;A61K48/00;;A61P9/00;;A61P35/00;;A61P43/00,A61K48/00;;A61P9/00;;A61P35/00;;A61P43/00,,0,0,,,,DISCONTINUED
283,US,A1,US 2012/0068226 A1,072-229-928-239-623,2012-03-22,2012,US 201113243521 A,2011-09-23,US 201113243521 A;;US 68087210 A;;US 2009/0057493 W;;US 9859708 P;;US 9907408 P;;US 10446608 P,2008-09-19,Formation of Devices by Epitaxial Layer Overgrowth,"Methods and structures are provided for formation of devices on substrates including, e.g., lattice-mismatched materials, by the use of aspect ratio trapping and epitaxial layer overgrowth. A method includes forming an opening in a masking layer disposed over a substrate that includes a first semiconductor material. A first layer, which includes a second semiconductor material lattice-mismatched to the first semiconductor material, is formed within the opening. The first layer has a thickness sufficient to extend above a top surface of the masking layer. A second layer, which includes the second semiconductor material, is formed on the first layer and over at least a portion of the masking layer. A vertical growth rate of the first layer is greater than a lateral growth rate of the first layer and a lateral growth rate of the second layer is greater than a vertical growth rate of the second layer.",HYDRICK JENNIFER;;LI JIZHONG;;CHENG ZHIYUAN;;FIORENZA JAMES G;;BAI JIE;;PARK JI-SOO;;LOCHTEFELD ANTHONY;;TAIWAN SEMICONDUCTOR MFG,HYDRICK JENNIFER;;LI JIZHONG;;CHENG ZHIYUAN;;FIORENZA JAMES G;;BAI JIE;;PARK JI-SOO;;LOCHTEFELD ANTHONY,,https://lens.org/072-229-928-239-623,Patent Application,yes,1,6,19,19,0,H01L21/02381;;H01L21/02538;;H01L21/20;;H01L21/02381;;H01L21/0245;;H01L21/0245;;H01L21/02461;;H01L21/02461;;H01L21/02463;;H01L21/02463;;H01L21/02543;;H01L21/02543;;H01L21/02546;;H01L21/02546;;H01L21/02636;;H01L21/02636;;H01L21/02639;;H01L21/02639;;H01L21/02647;;H01L21/02647;;H01L29/205;;H01L31/04;;H01L31/0687;;H01L31/0687;;H01L31/06875;;H01L31/06875;;H01L31/1808;;H01L31/1808;;H01L31/1852;;H01L31/1852;;H01L31/1892;;H01L31/1892;;Y02E10/544;;Y02E10/544,H01L29/20;;H01L21/20,257/190;;438/481;;X257E2109;;X257E29089,0,0,,,,ACTIVE
284,PT,T,PT 2044263 T,151-704-878-363-880,2016-10-20,2016,PT 07810787 T,2007-07-25,US 83328806 P,2006-07-26,"METHOD FOR PITCH AND STICKIES CONTROL IN PULP AND PAPERMAKING PROCESSES, USING HYDROPHOBICALLY MODIFIED POLY(ETHYLENE GLYCOL)",,SOLENIS TECHNOLOGIES CAYMAN LP,ERIN A S DOHERTY;;QU-MING GU;;HUAI N CHENG;;WILLIAM CAREY;;ROBERT GELMAN;;JENNIFER RITTENHOUSE-PRUSS,,https://lens.org/151-704-878-363-880,Patent Application,no,0,0,21,21,0,C08G65/22;;C08G65/2609;;D21C9/008;;D21H21/02;;C08G2650/34;;C08G65/22;;C08G65/2609;;C08G2650/34;;D21C9/008;;D21H21/02;;D21H21/02;;C08G2650/34;;C08G65/22;;D21C9/008;;C08G65/2609,D21H21/02;;C08L71/02;;C11D1/722;;D21C9/00,,0,0,,,,PENDING
285,US,B2,US 9537925 B2,139-381-939-567-169,2017-01-03,2017,US 201313937646 A,2013-07-09,US 201313937646 A,2013-07-09,Browser notifications,"A non-transitory computer-readable storage medium may comprise instructions stored thereon that, when executed by at least one processor, are configured to cause an intermediary server to at least receive, from a first client device, a first login request via a first browser installed on the first client device, the first login request identifying a user account, receive, from a third-party server, a message request, the message request including an identifier and indicating a browser application or a browser extension, map the identifier to the user account, determine whether the user account has installed the browser application or browser extension, and if the user account has installed the browser application or browser extension, send a first message to the first browser based on the message request.",GOOGLE INC,WILLIAMSON PETER H;;CHENG DANIEL;;THYAGARAJA SOMAS;;DEWITT JUSTIN;;DOSHI MUNJAL;;TITOV DMITRY;;BRAITHWAITE JENNIFER;;LIU XIAOYONG,GOOGLE LLC (2013-08-05),https://lens.org/139-381-939-567-169,Granted Patent,yes,4,3,2,2,0,H04L67/34;;H04L67/02;;H04L67/53;;H04L67/34;;H04L67/53;;H04L67/02,G06F11/14;;H04L29/08,,3,0,,,"""Android Cloud to Device Messaging Framework"", Google Developers, retrieved from https://developers.google.com/android/c2dm/, Sep. 26, 2012, 9 pages.;;""Web Browser"", from Wikipedia, the free encyclopedia, retrieved on Jul. 6, 2013 from http://en.wikipedia.org/wiki/web-browser, 1 page.;;Javaid, ""Tango Video & Audio Chat Client Now Available for Windows"", Oct. 1, 2011, 4 pages.",INACTIVE
286,WO,A2,WO 2008/013875 A2,071-947-289-244-337,2008-01-31,2008,US 2007/0016775 W,2007-07-25,US 83328806 P,2006-07-26,HYDROPHOBICALLY MODIFIED POLY(ETHYLENE GLYCOL) FOR USE IN PITCH AND STICKIES CONTROL IN PULP AND PAPERMAKING PROCESSES,Methods for inhibiting the depositions of organic contaminants from pulp in pulp and papermaking systems are disclosed. Hydrophobically modified poly[ethylene glycol] are added to the pulp or applied to deposition-prone surfaces of a papermaking system.,HERCULES INC,GU QU-MING;;CHENG HUAI N;;CAREY WILLIAM;;GELMAN ROBERT;;RITTENHOUSE-PRUSS JENNIFER;;DOHERTY ERIN A S,,https://lens.org/071-947-289-244-337,Patent Application,yes,0,8,21,21,0,C08G65/22;;C08G65/2609;;D21C9/008;;D21H21/02;;C08G2650/34;;C08G65/22;;C08G65/2609;;C08G2650/34;;D21C9/008;;D21H21/02;;D21H21/02;;C08G2650/34;;C08G65/22;;D21C9/008;;C08G65/2609,C08L71/02;;D21H21/02;;C11D1/722;;D21C9/00,,0,0,,,,PENDING
287,WO,A3,WO 2008/013875 A3,070-224-242-781-906,2008-04-03,2008,US 2007/0016775 W,2007-07-25,US 83328806 P,2006-07-26,HYDROPHOBICALLY MODIFIED POLY(ETHYLENE GLYCOL) FOR USE IN PITCH AND STICKIES CONTROL IN PULP AND PAPERMAKING PROCESSES,Methods for inhibiting the depositions of organic contaminants from pulp in pulp and papermaking systems are disclosed. Hydrophobically modified poly[ethylene glycol] are added to the pulp or applied to deposition-prone surfaces of a papermaking system.,HERCULES INC,GU QU-MING;;CHENG HUAI N;;CAREY WILLIAM;;GELMAN ROBERT;;RITTENHOUSE-PRUSS JENNIFER;;DOHERTY ERIN A S,,https://lens.org/070-224-242-781-906,Search Report,yes,5,0,21,21,0,C08G65/22;;C08G65/2609;;D21C9/008;;D21H21/02;;C08G2650/34;;C08G65/22;;C08G65/2609;;C08G2650/34;;D21C9/008;;D21H21/02;;D21H21/02;;C08G2650/34;;C08G65/22;;D21C9/008;;C08G65/2609,D21H21/02;;C08L71/02;;C11D1/722;;D21C9/00,,0,0,,,,PENDING
288,EP,A2,EP 2044263 A2,116-048-683-737-123,2009-04-08,2009,EP 07810787 A,2007-07-25,US 2007/0016775 W;;US 83328806 P,2006-07-26,"METHOD FOR PITCH AND STICKIES CONTROL IN PULP AND PAPERMAKING PROCESSES, USING HYDROPHOBICALLY MODIFIED POLY(ETHYLENE GLYCOL)",,HERCULES INC,GU QU-MING;;CHENG HUAI N;;CAREY WILLIAM;;GELMAN ROBERT;;RITTENHOUSE-PRUSS JENNIFER;;DOHERTY ERIN A S,"SOLENIS TECHNOLOGIES CAYMAN, L.P. (2014-12-31)",https://lens.org/116-048-683-737-123,Patent Application,yes,0,0,21,21,0,C08G65/22;;C08G65/2609;;D21C9/008;;D21H21/02;;C08G2650/34;;C08G65/22;;C08G65/2609;;C08G2650/34;;D21C9/008;;D21H21/02;;D21H21/02;;C08G2650/34;;C08G65/22;;D21C9/008;;C08G65/2609,D21H21/02;;C08L71/02;;C11D1/722;;D21C9/00,,0,0,,,,ACTIVE
289,MX,A,MX 2009000831 A,199-242-383-043-760,2009-02-04,2009,MX 2009000831 A,2007-07-25,US 83328806 P;;US 2007/0016775 W,2006-07-26,HYDROPHOBICALLY MODIFIED POLY(ETHYLENE GLYCOL) FOR USE IN PITCH AND STICKIES CONTROL IN PULP AND PAPERMAKING PROCESSES.,Methods for inhibiting the depositions of organic contaminants from pulp in pulp and papermaking systems are disclosed. Hydrophobically modified poly[ethylene glycol] are added to the pulp or applied to deposition-prone surfaces of a papermaking system.,HERCULES INC,CHENG HUAI N;;GU QU-MING;;DOHERTY ERIN A S;;CAREY WILLIAM;;GELMAN ROBERT;;RITTENHOUSE-PRUSS JENNIFER,,https://lens.org/199-242-383-043-760,Patent Application,no,0,0,21,21,0,C08G65/22;;C08G65/2609;;D21C9/008;;D21H21/02;;C08G2650/34;;C08G65/22;;C08G65/2609;;C08G2650/34;;D21C9/008;;D21H21/02;;D21H21/02;;C08G2650/34;;C08G65/22;;D21C9/008;;C08G65/2609,D21H21/02;;C08L71/02;;C11D1/722;;D21C9/00,,0,0,,,,ACTIVE
290,US,A1,US 2017/0367574 A1,128-866-518-232-818,2017-12-28,2017,US 201715497015 A,2017-04-25,US 201715497015 A;;US 201662354150 P,2016-06-24,EYE CYTOMETER FOR CONTINUOUS HEALTH MONITORING,"Systems and methods are provided for cytometric measurement of blood cells traversing microvasculature single-file in the eye of a subject. A miniature imaging device, having cellular resolution, records image data that can be rendered into a microcirculation time sequence and analyzed to provide useful biological information.",VERILY LIFE SCIENCES LLC,BELTHANGADY CHINMAY;;LEE SEUNG AH;;PERREAULT JOHN D;;HAN JENNIFER SY-EN;;WU CHENG-HSUN;;LEE MARK,VERILY LIFE SCIENCES LLC (2017-04-19),https://lens.org/128-866-518-232-818,Patent Application,yes,6,3,2,2,0,A61B3/1241;;A61B3/1241;;A61B3/113;;A61B3/145;;A61B5/14535;;A61B5/1455;;G01N15/1434;;G01N2015/144,A61B3/14;;A61B3/113;;A61B5/145;;A61B5/1455;;G01N15/14,,0,0,,,,DISCONTINUED
291,US,B1,US 9497331 B1,009-907-956-310-226,2016-11-15,2016,US 201514727647 A,2015-06-01,US 201514727647 A;;US 32525408 A,2008-11-30,Apparatus and methods for remote control of access to facilities,"Apparatus and methods are disclosed for simplifying and improving the reliability of communication between end users and access control systems such as those that include door and/or gate controllers, tenant access to buildings, and the like. In certain embodiments using an analog modem at the controller end of the system, the corresponding remote analog modem (which communicates with that analog modem at the controller end) is not within the direct control of the end user, and the end user's communicates instead via the user's standard hardware/software for communicating generally, such as via the Internet. Depending on the application, the control data can be maintained and/or synched at any selected combination or sub-combination of several locations: (1) the user's local system; (2) an intermediate server system; and/or (3) the controller end system. Preferred communication connections between the components provide improved ease of installation and use and reliability, as compared to prior art systems in which an end user's analog modem must be configured to directly communicate with a corresponding analog modem on a selected control device (such as a gate or door controller). Corresponding telephone/voice control preferably is also provided within the system, via POTS, a cellular telephone connection, VOIP, etc.",RICHMOND THOMAS R;;RICHMOND SUZANNE;;KOCHIE PATRICK S;;CHENG YU JENNIFER;;BEAR EITAN T;;GUEORGUIEVA NADEJDA V,RICHMOND THOMAS R;;RICHMOND SUZANNE;;KOCHIE PATRICK S;;CHENG YU JENNIFER;;BEAR EITAN T;;GUEORGUIEVA NADEJDA V,DOORKING INC (2015-08-06),https://lens.org/009-907-956-310-226,Granted Patent,yes,2,0,2,2,0,H04M11/025;;H04M11/025;;H04M11/007,H04M11/02;;H04M11/00,,0,0,,,,ACTIVE
292,US,B2,US 8384196 B2,042-651-092-472-50X,2013-02-26,2013,US 201113243521 A,2011-09-23,US 201113243521 A;;US 68087210 A;;US 2009/0057493 W;;US 9859708 P;;US 9907408 P;;US 10446608 P,2008-09-19,Formation of devices by epitaxial layer overgrowth,"Methods and structures are provided for formation of devices on substrates including, e.g., lattice-mismatched materials, by the use of aspect ratio trapping and epitaxial layer overgrowth. A method includes forming an opening in a masking layer disposed over a substrate that includes a first semiconductor material. A first layer, which includes a second semiconductor material lattice-mismatched to the first semiconductor material, is formed within the opening. The first layer has a thickness sufficient to extend above a top surface of the masking layer. A second layer, which includes the second semiconductor material, is formed on the first layer and over at least a portion of the masking layer. A vertical growth rate of the first layer is greater than a lateral growth rate of the first layer and a lateral growth rate of the second layer is greater than a vertical growth rate of the second layer.",TAIWAN SEMICONDUCTOR MFG;;CHENG ZHIYUAN;;FIORENZA JAMES;;HYDRICK JENNIFER M;;LOCHTEFELD ANTHONY J;;PARK JI-SOO;;BAI JIE;;LI JIZHONG,CHENG ZHIYUAN;;FIORENZA JAMES;;HYDRICK JENNIFER M;;LOCHTEFELD ANTHONY J;;PARK JI-SOO;;BAI JIE;;LI JIZHONG,,https://lens.org/042-651-092-472-50X,Granted Patent,yes,100,42,19,19,0,H01L21/02381;;H01L21/02538;;H01L21/20;;H01L21/02381;;H01L21/0245;;H01L21/0245;;H01L21/02461;;H01L21/02461;;H01L21/02463;;H01L21/02463;;H01L21/02543;;H01L21/02543;;H01L21/02546;;H01L21/02546;;H01L21/02636;;H01L21/02636;;H01L21/02639;;H01L21/02639;;H01L21/02647;;H01L21/02647;;H01L29/205;;H01L31/04;;H01L31/0687;;H01L31/0687;;H01L31/06875;;H01L31/06875;;H01L31/1808;;H01L31/1808;;H01L31/1852;;H01L31/1852;;H01L31/1892;;H01L31/1892;;Y02E10/544;;Y02E10/544,H01L29/06,257/618;;X257E27112;;X257E29003;;X257E29004;;X257E29022;;X257E31002;;257/622;;257/623;;257/628,99,55,008-530-678-141-763;;175-398-365-229-895;;040-909-734-564-485;;178-150-542-150-222;;133-113-438-285-359;;062-368-725-861-006;;028-556-979-299-207;;102-213-460-908-819;;115-850-058-906-042;;022-242-047-529-391;;079-818-934-736-386;;083-229-810-843-728;;049-502-180-552-353;;071-876-125-633-373;;073-668-985-013-701;;087-636-094-702-257;;002-857-097-343-259;;027-781-550-152-995;;065-331-410-107-447;;006-318-974-945-511;;000-441-718-514-435;;014-386-777-298-719;;008-545-140-631-519;;030-140-015-125-299;;008-367-177-625-236;;001-494-245-431-378;;080-093-225-381-383;;043-524-225-858-807;;059-447-576-972-737;;114-296-946-806-021;;023-605-252-286-583;;044-513-601-319-202;;061-872-973-577-035;;017-936-222-722-021;;149-454-555-555-473;;080-477-859-035-661;;050-136-077-567-627;;057-536-317-235-734;;044-210-719-844-725;;120-854-140-514-514;;015-735-653-484-658;;005-474-890-552-508;;117-381-598-229-082;;097-703-768-592-999;;010-770-729-336-080;;084-373-405-786-603;;143-070-723-191-12X;;075-457-992-830-93X;;000-599-789-885-356;;001-758-892-754-823;;043-975-508-372-850;;028-563-376-667-619;;072-825-255-412-460;;046-082-546-231-603;;054-024-260-747-430,10.1002/9781118014769.ch8;;10.1109/islc.2000.882312;;10.1063/1.2036800;;10.1063/1.1325394;;15475961;;10.1038/nmat1235;;10.1063/1.1604471;;10.1016/j.physe.2003.11.119;;10.1109/55.748907;;10.1088/0268-1242/20/2/004;;10.1109/iedm.1987.191335;;10.1063/1.113248;;10.1016/j.jcrysgro.2004.07.061;;10.1116/1.588357;;10.1109/isdrs.2003.1272049;;10.1016/s0022-0248(97)00067-5;;10.1109/csics.2005.1531740;;10.1063/1.124916;;10.1109/55.17828;;10.1109/mwsym.2006.249759;;10.1038/nmat1530;;16299508;;10.1116/1.1421554;;10.1016/s0022-0248(02)01894-8;;10.1109/led.2007.902078;;10.1109/leos.1998.737879;;10.1016/0921-5107(91)90162-o;;10.1109/iedm.2006.346813;;10.1109/iciprm.2003.1205397;;10.1364/oe.14.009203;;19529301;;10.1063/1.1516838;;10.1109/led.2006.883286;;10.1088/0268-1242/19/1/l02;;10.1063/1.355810;;10.1002/(sici)1521-396x(199902)171:2<475::aid-pssa475>3.3.co;2-3;;10.1007/bf02652921;;10.1007/bf02665973;;10.1063/1.342834;;10.1063/1.340059;;10.1063/1.105351;;10.1116/1.584600;;10.1147/rd.501.0005;;10.1016/s0039-6028(99)00663-9;;10.1109/6.866283;;10.1088/0268-1242/8/6/006;;10.1016/j.jcrysgro.2003.11.054;;10.1063/1.2199445;;10.1002/pssb.200304252;;10.1063/1.1525865;;10.1016/0022-0248(94)90239-9;;10.1117/12.479611;;10.1021/nl060553t;;16895377;;10.1016/s0022-0248(00)00707-7;;10.1016/s0040-6090(96)09086-4;;10.1063/1.1415406;;10.1109/ted.2002.802675;;10.1088/0256-307x/23/3/048,"Kwok K. Ng, ""Resonant-Tunneling Diode,"" Complete Guide to Semiconductor Devices, Chapter 10. Nov. 3, 2010, pp. 75-83.;;""Communication pursuant to Article 94(3) EPC,"" Application No. 06 770 525.1-2203, Applicant: Taiwan Semiconductor Company, Ltd., Feb. 17, 2011, 4 pages.;;68 Applied Physics Letters 7, 1999, pp. 774-779 (trans. of relevant portions attached).;;Ames, ""Intel Says More Efficient Chips are Coming,"" PC World, available at: http://www.pcworld.com/printable/article/id,126044/printable.html (Jun. 12, 2006); 4 pages.;;Asano et al., ""AlGaInN laser diodes grown on an ELO-GaN substrate vs. on a sapphire substrate,"" Semiconductor Laser Conference (2000) Conference Digest, IEEE 17th International, 2000, pp. 109-110.;;Asaoka, et al., ""Observation of 1 f x/noise of GaInP/GaAs triple barrier resonant tunneling diodes,"" AIP Conf. Proc., vol. 780, Issue 1, 2005, pp. 492-495.;;Ashby, et al., ""Low-dislocation-density GaN from a single growth on a textured substrate,"" Applied Physics Letters, vol. 77, No. 20, Nov. 13, 2000, pp. 3233-3235.;;Ashley, et al., ""Heternogeneous InSb Quantum Well Transistors on Silicon for Ultra-High Speed, Low Power Logic Applications,"" 43 Electronics Letters 14, Jul. 2007, 2 pages.;;Bai et al., ""Study of the Defect Elimination Mechanisms in Aspect Ratio Trapping Ge Growth,"" Applied Physics Letters, vol. 90, 2007, 3 pages.;;Bakkers et al., ""Epitaxial Growth on InP Nanowires on Germanium,"" Nature Materials, vol. 3, Nov. 2004, pp. 769-773.;;Baron et al., ""Chemical Vapor Deposition of Ge Nanocrystals on SiO2,"" Applied Physics Letters, vol. 83, No. 7, Aug. 18, 2003, pp. 1444-1446.;;Bean et al., ""GexSi1-x/Si strained-later Superlattice grown by molecular beam Epitaxy,"" Journal of Vacuum Science Technology A2 (2), Jun. 1984, pp. 436-440.;;Beckett et al., ""Towards a reconfigurable nanocomputer platform,"" ACM International Conference Proceeding Series, vol. 19, 2002, pp. 141-150.;;Beltz et al., ""A Theoretical Model for Threading Dislocation Reduction During Selective Area Growth,"" Materials Science and Engineering, A234-236, 1997, pp. 794-797.;;Belyaev, et al., ""Resonance and current instabilities in AlN/GaN resonant tunneling diodes,"" 21 Physica E 2-4, 2004, pp. 752-755.;;Berg, J., ""Electrical Characterization of Silicon Nanogaps,"" Doktorsavhandlingar vid Chalmers Tekniska Hagskola, 2005, No. 2355, 2 pages.;;Bergman et al., ""RTD/CMOS Nanoelectronic Circuits: Thin-Film InP-based Resonant Tunneling Diodes Integrated with CMOS circuits,"" 20 Electron Device Letters 3, 1999, pp. 119-122.;;Blakeslee, ""The Use of Superlattices to Block the Propagation of Dislocations in Semiconductors,"" Mat. Res. Soc. Symposium Proceedings 148, 1989, pp. 217-227.;;Bogumilowicz et al., ""Chemical Vapour Etching of Si, SiGe and Ge with HCL: Applications to the Formation of Thin Relaxed SiGe Buffers and to the Revelation of Threading Dislocations,"" 20 Semicond. Sci. Tech. 2005, pp. 127-134.;;Borland, ""Novel Device structures by selective epitaxial growth (SEG),"" Electron Devices Meeting, vol. 33, 1987, pp. 12-15.;;Bryskiewicz, ""Dislocation filtering in SiGe and InGaAs buffer layers grown by selective lateral overgrowth method,"" Applied Physics Letters, vol. 66, No. 10, Mar. 6, 1995, pp. 1237-1239.;;Burenkov et al., ""Corner Effect in Double and Triple Gate FinFETs""European solid-state device research, 33rd Conference on Essderc '03 Sep. 16-18, 2003, Piscataway, NJ, USA, IEEE, vol. 16, pp. 135-138, XPo10676716.;;Bushroa et al., ""Lateral epitaxial overgrowth and reduction in defect density of 3C-SiC on patterned Si substrates,"" Journal of Crystal Growth, vol. 271, No. 1-2, Oct. 15, 2004, pp. 200-206.;;Calado, et al., ""Modeling of a resonant tunneling diode optical modulator,"" University of Algarve, Department of Electronics and Electrical Engineering, 2005, pp. 96-99.;;Campo et al., ""Comparison of Etching Processes of Silicon and Germanium in SF6-O2 Radio-Frequency Plasma,"" 13 Journal of Vac. Sci. Tech., B-2, 1995, pp. 235-241.;;Cannon et al., ""Monolithic Si-based Technology for Optical Receiver Circuits,"" Proceedings of SPIE, vol. 4999, 2003, pp. 145-155.;;Chan et al., ""Influence of Metalorganic Sources on the Composition Uniformity of Selectively Grown GaxIn1-xP,"" Japan. Journal of Applied Physics, vol. 33, 1994, pp. 4812-4819.;;Chang et al. ""3-D simulation of strained Si/SiGe heterojunction FinFET5"" Semiconductor Device Research Symposium, Dec. 10-12, 2003, pp. 176-177.;;Chang et al., ""Effect of growth temperature on epitaxial lateral overgrowth of GaAs on Si substrate,"" Journal of Crystal Growth, vol. 174, No. 1-4, Apr. 1997, pp. 630-634.;;Chang et al., ""Epitaxial Lateral Overgrowth of Wide Dislocation-Free GaAs on Si Substrates,"" Electrochemical Society Proceedings, vol. 97-21, May 13, 1998, pp. 196-200.;;Chau et al., Opportunities and Challenges of III-V Nanoelectronics for Future High-Speed, Low Power Logic Applications, IEEE CSIC Digest, 2005, pp. 17-20.;;Chen et al., ""Dislocation reduction in GaN thin films via lateral overgrowth from trenches,"" Applied Physics Letters, vol. 75, No. 14, Oct. 4, 1999, pp. 2062-2063.;;Chengrong, et al., ""DBRTD with a high PVCR and a peak current density at room temperature,"" Chinese Journal of Semiconductors vol. 26, No. 10, Oct. 2005, pp. 1871-1874.;;Choi et al., ""Monolithic Integration GaAs/AlGaAs LED and Si Driver Circuit,"" 9 Electron Device Letters 10, Oct. 1988, 3 pages.;;Choi et al., ""Monolithic Integration of GaAs/AlGaAs Double-Heterostructure LEDs and Si MOSFETs,"" Electron Device Letters, vol. EDL-7, No. 9, Sep. 1986, 3 pages.;;Choi et al., ""Monolithic Integration of Si MOSFETs and GaAs MESFETs,"" Electron Device Letters, vol. EDL-7, No. 4, Apr. 1986, 3 pages.;;Choi, et al., ""Low-voltage low-power K-band balanced RTD-based MMIC VCO,"" 2006 IEEE, Department of EECS, Korea Advanced Institute of Science and Technology, 2006, pp. 743-746.;;Cloutier et al., ""Optical gain and stimulated emission in periodic nanopatterned crystalline silicon,"" Nature Materials, Nov. 2005, 5 pages.;;Currie et al., ""Carrier Mobilities and Process Stability of Strained Si n- and p-MOSFETs on SiGe Virtual Substrates,"" J. Vacuum Science Technology, B, vol. 19, No. 6, 2001, pp. 2268-2279.;;Dadgar et al., ""MOVPE growth of GaN on Si (111) substrates,"" Journal of Crystal Growth, vol. 248, Feb. 1, 2003, pp. 556-562.;;Datta et al., ""Silicon and III-V Nanoelectronics,"" IEEE International Conference on Indium Phosphide & Related Materials, 2005, pp. 7-8.;;Datta et al., ""Ultrahigh-Speed 0.5 V Supply Voltage In0.7Ga0.3As Quantum-Well Transistors on Silicon Substrate,"" 28 Electron Device Letters 8, 2007, pp. 685-687.;;Davis et al., ""Lateral epitaxial overgrowth of and defect reduction in GaN thin films,"" Lasers and Electro-Optics Society Annual Meeting (1998) LEOS '98. IEEE, vol. 1, Dec. 1-4, 1998, pp. 360-361.;;De Boeck et al., ""The fabrication on a novel composite GaAs/SiO2 nucleation layer on silicon for heteroepitaxial overgrowth by molecular beam Epitaxy,"" Material Science and Engineering, B9, 1991, pp. 137-141.;;Donaton et al., ""Design and Fabrication of MOSFETs with a Reverse Embedded SiGe (Rev. e-SiGe) Structure,"" 2006 IEDM, pp. 465-468.;;Dong, Y., et al, ""Selective area growth of InP through narrow openings by MOVCD and its application to InP HBT,"" 2003 International Conference on Indium Phosphide and Related Materials, May 12-16, 2003, pp. 389-392.;;European Patent Office, Extended European Search Report and Search Opinion dated Jan. 26, 2011 in EP Patent Application No. 10003084.0-2203 (9 pages).;;European Search Report issued by the European Patent Office on Dec. 15, 2010 in European Patent Application No. 10002884.4 (10 pages).;;Examination Report in European Patent Application No. 06800414.2, mailed Mar. 5, 2009, 3 pages.;;Fang et al., ""Electrically pumped hybrid AlGaInAs-silicon evanescent laser,"" 14 Optics Express 20, 2006, pp. 9203-9210.;;Feltin et al., ""Epitaxial lateral overgrowth of GaN on Si (111),"" Journal of Applied Physics, vol. 93, No. 1, Jan. 1, 2003, pp. 182-185.;;Feng et al., ""Integration of Germanium-on Insulator and Silicon Substrate,"" 27 Electron Device Letters 11, 2006, pp. 911-913.;;Fiorenza et al., ""Film Thickness Constraints for Manufacturable Strained Silicon CMOS,"" 19 Semiconductor Science Technology, 2004, p. L4.;;Fischer et al., ""Elastic stress relaxation in SiGe epilayers on patterned Si substrates,"" 75 Journal of Applied Physics 1, 1994, pp. 657-659.;;Fischer et al., ""State of stress and critical thickness of Strained small-area SiGe layers,""Phys. Stat. Sol. (a) vol. 171, 1999, pp. 475-485.;;Fitzgerald et al., ""Elimination of Dislocations in Heteroepitaxial MBE and RTCVD GexSi1-x Grown on Patterned Si Substrates,"" Journal of Electronic Materials, vol. 19, No. 9, 1990, pp. 949-955.;;Fitzgerald et al., ""Epitaxial Necking in GaAs Growth on Pre-patterned Si Substrates,"" Journal of Electronic Materials, vol. 20, No. 10, 1991, pp. 839-853.;;Fitzgerald et al., ""Nucleation Mechanisms and the Elimination of Misfit Dislocations at Mismatched Interfaces by Reduction in Growth Areas,"" Journal of Applied Physics, vol. 65, No. 6, Mar. 15, 1989, pp. 2220-2237.;;Fitzgerald et al., ""Structure and recombination in InGaAs/GaAs heterostructures,"" 63 Journal of Applied Physics, vol. 3, 1988, pp. 693-703.;;Fitzgerald et al., ""Totally relaxed GexSi1-x layers with low threading dislocation densities grown on Si Substrates,"" vol. 59, Applied Physics Letters 7, 1991, pp. 811-813.;;Fitzgerald, ""The Effect of Substrate Growth Area on Misfit and Threading Dislocation Densities in Mismatched Heterostructures,"" Journal of Vacuum Science Technology, vol. 7, No. 4, Jul./Aug. 1989, pp. 782-788.;;Gallagher et al., ""Development of the magnetic tunnel junction MRAM at IBM: From first junctions to a 16-Mb MRAM demonstrator chip,"" 50 IBM J. Research & Dev. 1, Jan. 2006, pp. 5-23A.;;Gallas et al., ""Influence of Doping on Facet Formation at the SiO2/Si Interface,"" Surface Sci. 440, 1999, pp. 41-48.;;Geppert, ""Quantum transistors: toward nanoelectronics,"" IEEE Spectrum, Sep. 2000, pp. 46-51.;;Gibbon et al., ""Selective-area low-pressure MOCVD of GaInAsP and related materials on planar InP substrates,"" Semicond. Sci. Tech. vol. 8, 1993, pp. 998-1010.;;Glew et al., ""New DFB grating structure using dopant-induced refractive index step,"" J. Crystal Growth 261, 2004, pp. 349-354.;;Golka, et al., ""Negative differential resistance in dislocation-free GaN/AlGan double-barrier diodes grown on bulk GaN,"" 88 Applied Physics Letters 17, Apr. 2006, pp. 172106-1-172106-3.;;Goodnick, S.M., ""Radiation Physics and Reliability Issues in III-V Compound Semiconductor Nanoscale Heterostructure Devices,"" Final Technical Report, Arizona State Univ. Dept. Electrical & Computer Eng, 80 pages, 1996-1999.;;Gould et al., ""Magnetic resonant tunneling diodes as voltage-controlled spin selectors,"" 241 Phys. Stat. Sol. (B), vol. 3, 2004, pp. 700-703.;;Groenert et al., ""Monolithic integration of room-temperature cw GaAs/AlGaAs lasers on Si substrates via relaxed graded GeSi buffer layers,"" 93 Journal of Applied Physics, No. 362, Jan. 2003, pp. 362-367.;;Gruber, et al., ""Semimagnetic Resonant Tunneling Diodes for Electron Spin Manipulation,"" Nanostructures: Physics & Technology, 8th International Symposium, 2000, pp. 483-486.;;Gustafsson et al., ""Cathodoluminescence from relaxed GexSi1-x grown by heteroepitaxial lateral overgrowth,"" Journal of Crystal Growth 141, 1994, pp. 363-370.;;Gustafsson et al., ""Investigations of high quality GexSi1-x grown by heteroepitaxial lateral overgrowth using cathodoluminescence,"" Inst. Phys. Conf. Ser., No. 134, Section 11, Apr. 1993, pp. 675-678.;;Hammerschmidt, ""Intel to Use Trigate Transistors from 2009 on,"" EETIMES Online, available at: http://www.eetimes.com/showArticle.jhtml?articleID=189400035 (Jun. 12, 2006). 1 page.;;Hasegawa, et al., ""Sensing Terahertz Signals with III-V Quantum Nanostructures,"" Quantum Sensing: Evolution and Revolution from Past to Future, SPIE 2003, pp. 96-105.;;Hayafuji et al., Japan, Journal of Applied Physics, vol. 29, 1990, pp. 2371.;;Hersee et al., ""The Controlled Growth of GaN Nanowires,"" Nano Letters, vol. 6, No. 8, 2006, pp. 1808-1811.;;Hiramatsu et al., ""Fabrication and characterization of low defect density GaN using facet-controlled epitaxial lateral overgrowth (FACELO),"" Journal of Crystal Growth, vol. 221, Dec. 2000, pp. 316-326.;;Hollander et al., ""Strain and Misfit Dislocation Density in Finite Lateral Size Si1-xGex/Si Films Grown by Selective Epitaxy,"" Thin Solid Films, vol. 292, 1997, pp. 213-217.;;Hu et al., ""Growth of Well-Aligned Carbon Nanotube arrays on Silicon Substrates Using Porous Alumina Film as a Nanotemplate,"" 79 Applied Physics Letters 19, 2001, 3 pages.;;Yanlong, et al., ""Monolithically fabricated OEICs using RTD and MSM,"" Chinese Journal Semiconductors vol. 27, No. 4, Apr. 2006, pp. 641-645.;;Huang et al., ""Electron and Hole Mobility Enhancement in Strained SOI by Wafer Bonding,"" 49 IEEE Transactions on Electron Devices 9, 2002, pp. 1566-1570.;;Ying-Long, et al., ""Resonant tunneling diodes and high electron mobility transistors integrated on GaAs substrates,"" Chinese Physics Letters 23, vol. 3, Mar. 2006, pp. 697-700.;;Hydrick et al., ""Chemical Mechanical Polishing of Epitaxial Germanium on Si02-patterned Si(001) Substrates,"" ECS Transactions, 16 (10), 2008, (pp. 237-248).;;Intel Press Release, ""Intel's Tri-Gate Transistor to Enable Next Era in Energy-Efficient Performance,"" Intel Corporation (Jun. 12, 2006). 2 pages.;;Intel to Develop Tri-Gate Transistors Based Processors, available at: http://news.techwhack.com/3822/tri-gate-transistors/ (Jun. 13, 2006) 6 pages.;;International Preliminary Report on Patentability for International Application No. PCT/US2006/019152 mailed.Nov. 29, 2007, 2 pages.;;International Preliminary Report on Patentability for International Application No. PCT/US2006/029247 mailed Feb. 7, 2008, 12 pages.;;International Preliminary Report on Patentability for International Application No. PCT/US2006/033859 mailed Mar. 20, 2008, 14 pages.;;International Preliminary Report on Patentability for International Application No. PCT/US2007/019568 mailed Mar. 19, 2009, 10 pages.;;International Preliminary Report on Patentability for International Application No. PCT/US2007/020181 mailed Apr. 2, 2009, 9 pages.;;International Preliminary Report on Patentability for International Application No. PCT/US2007/020777 mailed Apr. 9, 2009, 12 pages.;;International Preliminary Report on Patentability for International Application No. PCT/US2007/021023 mailed Apr. 9, 2009, 8 pages.;;International Preliminary Report on Patentability for International Application No. PCT/US2007/022392 mailed Apr. 30, 2009, 14 pages.;;International Search Report and Written Opinion for International Application No. PCT/US2006/019152 mailed Oct. 19, 2006, 11 pages.;;International Search Report and Written Opinion for International Application No. PCT/US2006/029247 mailed May 7, 2007, 19 pages.;;International Search Report and Written Opinion for International Application No. PCT/US2008/068377, mailed Jul. 6, 2009, 19 pages.;;International Search Report and Written Opinion for International Application No. PCT/US2006/033859 mailed Sep. 12, 2007, 22 pages.;;International Search Report and Written Opinion for International Application No. PCT/US2007/007373, dated Oct. 5, 2007, 13 pages.",ACTIVE
293,US,B1,US 9049306 B1,024-673-466-730-273,2015-06-02,2015,US 32525408 A,2008-11-30,US 32525408 A,2008-11-30,Apparatus and methods for remote control of access to facilities,"Apparatus and methods are disclosed for simplifying and improving the reliability of communication between end users and access control systems such as those that include door and/or gate controllers, tenant access to buildings, and the like. In certain embodiments using an analog modem at the controller end of the system, the corresponding remote analog modem (which communicates with that analog modem at the controller end) is not within the direct control of the end user, and the end user's communicates instead via the user's standard hardware/software for communicating generally, such as via the Internet. Depending on the application, the control data can be maintained and/or synched at any selected combination or sub-combination of several locations: (1) the user's local system; (2) an intermediate server system; and/or (3) the controller end system. Preferred communication connections between the components provide improved ease of installation and use and reliability, as compared to prior art systems in which an end user's analog modem must be configured to directly communicate with a corresponding analog modem on a selected control device (such as a gate or door controller). Corresponding telephone/voice control preferably is also provided within the system, via POTS, a cellular telephone connection, VoIP, etc.",GUEORGUIEVA NADEJDA V;;RICHMOND THOMAS R;;RICHMOND SUZANNE;;KOCHIE PATRICK S;;CHENG YU JENNIFER;;BEAR EITAN T,GUEORGUIEVA NADEJDA V;;RICHMOND THOMAS R;;RICHMOND SUZANNE;;KOCHIE PATRICK S;;CHENG YU JENNIFER;;BEAR EITAN T,DOORKING INC (2015-08-06),https://lens.org/024-673-466-730-273,Granted Patent,yes,4,9,2,2,0,H04M11/025;;H04M11/025;;H04M11/007,H04M11/00;;H04M11/02,,0,0,,,,ACTIVE
294,US,B2,US 9934967 B2,186-551-009-920-29X,2018-04-03,2018,US 201313737731 A,2013-01-09,US 201313737731 A;;US 201113243521 A;;US 68087210 A;;US 2009/0057493 W;;US 9859708 P;;US 9907408 P;;US 10446608 P,2008-09-19,Formation of devices by epitaxial layer overgrowth,"Methods and structures are provided for formation of devices, e.g., solar cells, on substrates including, e.g., lattice-mismatched materials, by the use of aspect ratio trapping and epitaxial layer overgrowth. A method includes forming an opening in a masking layer disposed over a substrate that includes a first semiconductor material. A first layer, which includes a second semiconductor material lattice-mismatched to the first semiconductor material, is formed within the opening. The first layer has a thickness sufficient to extend above a top surface of the masking layer. A second layer, which includes the second semiconductor material, is formed on the first layer and over at least a portion of the masking layer. A vertical growth rate of the first layer is greater than a lateral growth rate of the first layer and a lateral growth rate of the second layer is greater than a vertical growth rate of the second layer.",TAIWAN SEMICONDUCTOR MFG CO LTD;;TAIWAN SEMICONDUCTOR MFG CO LTD,HYDRICK JENNIFER M;;LI JIZHONG;;CHENG ZHINYUAN;;FIORENZA JAMES;;BAI JIE;;PARK JI-SOO;;LOCHTEFELD ANTHONY J,,https://lens.org/186-551-009-920-29X,Granted Patent,yes,499,4,19,19,0,H01L21/02381;;H01L21/02538;;H01L21/20;;H01L21/02381;;H01L21/0245;;H01L21/0245;;H01L21/02461;;H01L21/02461;;H01L21/02463;;H01L21/02463;;H01L21/02543;;H01L21/02543;;H01L21/02546;;H01L21/02546;;H01L21/02636;;H01L21/02636;;H01L21/02639;;H01L21/02639;;H01L21/02647;;H01L21/02647;;H01L29/205;;H01L31/04;;H01L31/0687;;H01L31/0687;;H01L31/06875;;H01L31/06875;;H01L31/1808;;H01L31/1808;;H01L31/1852;;H01L31/1852;;H01L31/1892;;H01L31/1892;;Y02E10/544;;Y02E10/544,H01L31/18;;H01L21/02;;H01L29/205;;H01L31/0687,,280,190,141-341-712-271-641;;008-530-678-141-763;;175-398-365-229-895;;040-909-734-564-485;;178-150-542-150-222;;133-113-438-285-359;;062-368-725-861-006;;028-556-979-299-207;;102-213-460-908-819;;115-850-058-906-042;;022-242-047-529-391;;079-818-934-736-386;;083-229-810-843-728;;049-502-180-552-353;;071-876-125-633-373;;073-668-985-013-701;;087-636-094-702-257;;002-857-097-343-259;;027-781-550-152-995;;065-331-410-107-447;;006-318-974-945-511;;000-441-718-514-435;;014-386-777-298-719;;008-545-140-631-519;;030-140-015-125-299;;008-367-177-625-236;;001-494-245-431-378;;080-093-225-381-383;;043-524-225-858-807;;059-447-576-972-737;;114-296-946-806-021;;023-605-252-286-583;;044-513-601-319-202;;061-872-973-577-035;;017-936-222-722-021;;149-454-555-555-473;;080-477-859-035-661;;050-136-077-567-627;;057-536-317-235-734;;044-210-719-844-725;;120-854-140-514-514;;015-735-653-484-658;;005-474-890-552-508;;117-381-598-229-082;;097-703-768-592-999;;010-770-729-336-080;;084-373-405-786-603;;143-070-723-191-12X;;075-457-992-830-93X;;000-599-789-885-356;;001-758-892-754-823;;043-975-508-372-850;;028-563-376-667-619;;072-825-255-412-460;;046-082-546-231-603;;054-024-260-747-430;;083-883-146-200-738;;083-613-987-498-508;;045-482-960-475-87X;;013-373-333-803-922;;155-874-557-394-552;;053-537-110-444-415;;117-445-423-901-930;;093-716-030-359-119;;145-902-185-230-698;;093-519-095-944-009;;078-263-144-014-976;;015-501-829-710-304;;009-900-083-296-784;;007-870-167-309-784;;029-845-464-045-547;;172-495-148-011-860;;180-151-741-618-293;;087-263-507-460-841;;084-844-659-269-030;;096-407-236-744-581;;015-476-364-945-119;;122-020-606-727-469;;050-819-384-145-574;;107-520-673-114-512;;105-703-402-854-788;;057-361-451-786-463;;011-977-632-281-25X;;040-040-531-878-531;;037-857-067-104-951;;028-807-791-346-693;;014-984-812-319-66X;;081-328-463-248-609;;059-328-896-673-523;;061-236-193-544-833;;047-689-673-310-811;;031-646-782-196-068;;091-589-027-838-395;;093-233-668-175-312;;014-434-218-325-585;;138-584-423-771-250;;044-005-802-996-604;;074-895-625-161-248;;137-484-933-655-183;;031-286-924-076-031;;053-280-765-979-241;;037-612-376-997-479;;045-699-868-215-917;;058-942-911-154-62X;;059-543-021-530-37X;;035-365-252-997-508;;141-764-543-442-220;;008-380-677-238-60X;;007-375-838-728-552;;015-950-051-865-893;;071-263-088-410-629;;025-932-657-068-286;;050-261-804-835-708;;152-494-984-849-845;;042-693-276-478-880;;040-371-196-893-940;;041-082-063-508-071;;139-879-846-066-937;;088-330-130-140-170;;025-757-982-901-74X;;024-666-772-808-74X;;101-958-100-978-987;;085-132-229-905-35X;;150-492-905-301-370;;163-546-763-202-627;;029-168-177-038-971;;014-600-325-860-912;;108-071-243-899-343;;016-234-111-730-261;;127-799-209-018-726;;174-081-906-986-142;;030-697-192-205-933;;154-918-586-078-108;;067-412-217-829-656;;046-539-752-343-072;;002-781-954-965-389;;034-869-991-959-428;;044-051-886-813-197;;028-851-999-310-903;;065-819-798-071-637;;009-765-822-104-215;;066-888-145-550-361;;032-431-625-487-812;;177-446-091-111-65X;;097-854-042-311-914;;100-583-088-542-544;;046-234-034-765-097;;096-976-267-025-029;;051-670-569-047-667;;064-718-265-131-327;;070-910-010-060-165;;085-341-019-016-897;;030-541-982-951-307;;170-561-385-825-366;;178-611-686-312-234;;029-816-503-628-727;;132-670-348-683-244;;086-611-254-353-117;;022-820-099-034-86X;;125-183-325-589-907;;004-280-996-232-586;;036-503-139-921-201;;089-616-285-993-741;;030-181-521-107-924;;043-581-291-141-004;;102-778-182-297-453;;070-160-372-141-229;;009-651-511-693-651;;019-417-739-840-344;;170-481-376-050-175;;002-011-809-029-067;;097-348-123-485-156;;108-238-928-520-940;;076-705-461-446-02X;;066-944-879-202-378;;106-264-405-651-315;;092-790-427-299-002;;116-949-738-635-844;;146-774-146-207-99X;;080-093-225-381-383;;000-409-096-991-391;;015-265-566-221-338;;136-572-282-286-364;;024-165-556-971-440;;089-579-032-463-224;;035-332-229-282-730;;121-451-737-890-387;;079-347-559-311-889;;081-446-892-907-93X;;030-955-348-079-603,10.1016/s0040-6090(02)00315-2;;10.1002/9781118014769.ch8;;10.1109/islc.2000.882312;;10.1063/1.2036800;;10.1063/1.1325394;;15475961;;10.1038/nmat1235;;10.1063/1.1604471;;10.1016/j.physe.2003.11.119;;10.1109/55.748907;;10.1088/0268-1242/20/2/004;;10.1109/iedm.1987.191335;;10.1063/1.113248;;10.1016/j.jcrysgro.2004.07.061;;10.1116/1.588357;;10.1109/isdrs.2003.1272049;;10.1016/s0022-0248(97)00067-5;;10.1109/csics.2005.1531740;;10.1063/1.124916;;10.1109/55.17828;;10.1109/mwsym.2006.249759;;10.1038/nmat1530;;16299508;;10.1116/1.1421554;;10.1016/s0022-0248(02)01894-8;;10.1109/led.2007.902078;;10.1109/leos.1998.737879;;10.1016/0921-5107(91)90162-o;;10.1109/iedm.2006.346813;;10.1109/iciprm.2003.1205397;;10.1364/oe.14.009203;;19529301;;10.1063/1.1516838;;10.1109/led.2006.883286;;10.1088/0268-1242/19/1/l02;;10.1063/1.355810;;10.1002/(sici)1521-396x(199902)171:2<475::aid-pssa475>3.3.co;2-3;;10.1007/bf02652921;;10.1007/bf02665973;;10.1063/1.342834;;10.1063/1.340059;;10.1063/1.105351;;10.1116/1.584600;;10.1147/rd.501.0005;;10.1016/s0039-6028(99)00663-9;;10.1109/6.866283;;10.1088/0268-1242/8/6/006;;10.1016/j.jcrysgro.2003.11.054;;10.1063/1.2199445;;10.1002/pssb.200304252;;10.1063/1.1525865;;10.1016/0022-0248(94)90239-9;;10.1117/12.479611;;10.1021/nl060553t;;16895377;;10.1016/s0022-0248(00)00707-7;;10.1016/s0040-6090(96)09086-4;;10.1063/1.1415406;;10.1109/ted.2002.802675;;10.1088/0256-307x/23/3/048;;10.1109/16.2563;;10.1143/jjap.24.1267;;10.1063/1.106034;;10.1016/s0040-6090(96)09104-3;;10.1109/iciprm.2006.1634107;;10.1016/j.jcrysgro.2003.11.107;;10.1063/1.107817;;10.1109/jstqe.2005.853743;;10.1002/1521-396x(200208)192:2<296::aid-pssa296>3.0.co;2-z;;10.1143/jjap.40.4903;;10.1063/1.126775;;10.1109/led.2004.829668;;10.1143/jjap.38.609;;10.1016/s0254-0584(00)00342-4;;10.1116/1.587562;;10.1016/j.jcrysgro.2005.10.027;;10.1016/s0921-5107(02)00043-0;;10.1143/jjap.40.l192;;10.1109/58.108866;;18267631;;10.1002/9781118014769.ch18;;10.1063/1.126754;;10.1063/1.1811799;;10.1063/1.2756165;;10.1063/1.1790027;;10.1149/1.3129463;;10.1063/1.2067708;;10.1063/1.1632037;;10.1063/1.1854204;;10.1116/1.1676595;;10.1063/1.1691175;;10.1149/1.1946368;;10.1063/1.2924410;;10.1149/1.1604789;;10.1109/sim.2000.939221;;10.1063/1.125187;;10.1109/lpt.2002.802078;;10.1063/1.97204;;10.1016/j.mssp.2004.09.053;;10.1143/jjap.44.4790;;10.1109/iciprm.2006.1634162;;10.1016/s0022-0248(99)00678-8;;10.1016/s0022-0248(01)02290-4;;10.1016/0022-0248(74)90424-2;;10.1049/el:19991005;;10.1002/pssa.200565389;;10.1063/1.120164;;10.1016/s0022-0248(02)01864-x;;10.1143/jjap.34.l1432;;10.1109/iedm.2000.904285;;10.1016/s0022-0248(02)01852-3;;10.1063/1.1935038;;10.1063/1.2035332;;10.1016/j.physe.2005.12.170;;10.1109/iscs.2003.1239898;;10.1143/jjap.44.7809;;10.1063/1.116271;;10.1557/proc-0994-f10-05;;10.1063/1.2435603;;10.1149/1.3076192;;10.1143/jjap.45.8581;;10.1109/vlsit.2004.1345389;;10.1109/iciprm.1994.328185;;10.1063/1.107064;;10.1063/1.1994676;;10.1063/1.101357;;10.1063/1.1866502;;10.1109/iedm.1995.499251;;10.1002/pip.448;;10.1063/1.125776;;10.1063/1.120044;;10.1063/1.121907;;10.1143/jjap.31.l359;;10.1109/55.761012;;10.1016/s0022-0248(02)02045-6;;10.1109/68.806875;;10.1109/iedm.1990.237130;;10.1109/55.6940;;10.1109/16.7366;;10.1063/1.1843281;;10.1109/soi.2000.892794;;10.1109/imnc.2005.203773;;10.1149/1.2202091;;10.1149/1.2180529;;10.1109/iciprm.2003.1205369;;10.1109/iciprm.2002.1014410;;10.1109/iciprm.2004.1442723;;10.1109/iciprm.2000.850273;;10.1063/1.1593213;;10.1063/1.1609231;;10.1109/icimw.2005.1572452;;10.1143/jjap.43.2019;;10.1143/jjap.44.2546;;10.1016/0022-0248(94)00827-2;;10.1063/1.1394716;;10.1109/led.2004.825195;;10.1109/jstqe.2004.837735;;10.1063/1.127069;;10.1016/0022-0248(92)90146-a;;10.1109/jqe.1985.1072693;;10.1063/1.93508;;10.1063/1.120033;;10.1116/1.1736634;;10.1143/jjap.28.l337;;10.1016/j.apsusc.2003.11.058;;10.1143/jjap.36.l899;;10.1063/1.2205728;;10.1016/j.jcrysgro.2005.03.065;;10.1063/1.365212;;10.1016/j.physe.2005.12.014;;10.1149/1.2163813;;10.1016/j.jcrysgro.2005.03.064;;10.1109/jmems.2003.820936;;10.1063/1.2756106;;10.1063/1.2363148;;10.1116/1.584815;;10.1063/1.1655688;;10.1063/1.102636;;10.1063/1.100257;;10.1002/pip.366;;10.1002/pip.606;;10.1016/0022-0248(89)90535-6;;10.1063/1.125745;;10.1109/ted.2005.856185;;10.1109/iciprm.2003.1205397;;10.1063/1.2335976;;10.1143/jjap.36.l459;;10.1063/1.1338968;;10.1063/1.2189114;;10.1063/1.2126138;;10.1016/j.jcrysgro.2003.11.067;;10.1007/s11664-998-0078-3;;10.1063/1.1290152;;10.1016/s0022-0248(00)00832-0;;10.1007/s11664-001-0062-7,"Zytkiewicz et al., Laterally Overgrown Structures as Substrates for lattice Mismatched Epitaxy, Thin Solid Films, vol. 412, p. 64-75 (2002).;;Kwok K. Ng, “Resonant-Tunneling Diode,” Complete Guide to Semiconductor Devices, Chapter 10. Nov. 3, 2010, pp. 75-83.;;“Communication pursuant to Article 94(3) EPC,” Application No. 06 770 525.1-2203, Applicant: Taiwan Semiconductor Company, Ltd., Feb. 17, 2011, 4 pages.;;68 Applied Physics Letters 7, 1999, pp. 774-779 (trans. of relevant portions attached).;;Ames, “Intel Says More Efficient Chips are Coming,” PC World, available at: http://www.pcworld.com/printable/article/id,126044/printable.html (Jun. 12, 2006); 4 pages.;;Asano et al., “AlGaInN laser diodes grown on an ELO-GaN substrate vs. on a sapphire substrate,” Semiconductor Laser Conference (2000) Conference Digest, IEEE 17th International, 2000, pp. 109-110.;;Asaoka, et al., “Observation of 1 f x/noise of GaInP/GaAs triple barrier resonant tunneling diodes,” AIP Conf. Proc., vol. 780, Issue 1 , 2005, pp. 492-495.;;Ashby, et al., “Low-dislocation-density GaN from a single growth on a textured substrate,” Applied Physics Letters, vol. 77, No. 20, Nov. 13, 2000, pp. 3233-3235.;;Ashley, et al., “Heternogeneous InSb Quantum Well Transistors on Silicon for Ultra-High Speed, Low Power Logic Applications,” 43 Electronics Letters 14, Jul. 2007, 2 pages.;;Bai et al., “Study of the Defect Elimination Mechanisms in Aspect Ratio Trapping Ge Growth,” Applied Physics Letters, vol. 90, 2007, 3 pages.;;Bakkers et al., “Epitaxial Growth on InP Nanowires on Germanium,” Nature Materials, vol. 3, Nov. 2004, pp. 769-773.;;Baron et al., “Chemical Vapor Deposition of Ge Nanocrystals on SiO2,” Applied Physics Letters, vol. 83, No. 7, Aug. 18, 2003, pp. 1444-1446.;;Bean et al., “GexSi1-x/Si strained-later Superlattice grown by molecular beam Epitaxy,” Journal of Vacuum Science Technology A2 (2), Jun. 1984, pp. 436-440.;;Beckett et al., “Towards a reconfigurable nanocomputer platform,” ACM International Conference Proceeding Series, vol. 19, 2002 , pp. 141-150.;;Beltz et al., “A Theoretical Model for Threading Dislocation Reduction During Selective Area Growth,” Materials Science and Engineering, A234-236, 1997, pp. 794-797.;;Belyaev, et al., “Resonance and current instabilities in AlN/GaN resonant tunneling diodes,” 21 Physica E 2-4, 2004, pp. 752-755.;;Berg, J., “Electrical Characterization of Silicon Nanogaps,” Doktorsavhandlingar vid Chalmers Tekniska Hagskola, 2005, No. 2355, 2 pages.;;Bergman et al., “RTD/CMOS Nanoelectronic Circuits: Thin-Film InP-based Resonant Tunneling Diodes Integrated with CMOS circuits,” 20 Electron Device Letters 3, 1999, pp. 119-122.;;Blakeslee, “The Use of Superlattices to Block the Propagation of Dislocations in Semiconductors,” Mat. Res. Soc. Symposium Proceedings 148, 1989, pp. 217-227.;;Bogumilowicz et al., “Chemical Vapour Etching of Si, SiGe and Ge with HCL: Applications to the Formation of Thin Relaxed SiGe Buffers and to the Revelation of Threading Dislocations,” 20 Semicond. Sci. Tech. 2005, pp. 127-134.;;Borland, “Novel Device structures by selective epitaxial growth (SEG),” Electron Devices Meeting, vol. 33, 1987, pp. 12-15.;;Bryskiewicz, “Dislocation filtering in SiGe and InGaAs buffer layers grown by selective lateral overgrowth method,” Applied Physics Letters, vol. 66, No. 10, Mar. 6, 1995, pp. 1237-1239.;;Burenkov et al., “Corner Effect in Double and Triple Gate FinFETs”European solid-state device research, 33rd Conference on Essderc '03 Sep. 16-18, 2003, Piscataway, NJ, USA, IEEE, vol. 16, pp. 135-138, XPo10676716.;;Bushroa et al., “Lateral epitaxial overgrowth and reduction in defect density of 3C—SiC on patterned Si substrates,” Journal of Crystal Growth, vol. 271, No. 1-2, Oct. 15, 2004, pp. 200-206.;;Calado, et al., “Modeling of a resonant tunneling diode optical modulator,” University of Algarve, Department of Electronics and Electrical Engineering, 2005, pp. 96-99.;;Campo et al., “Comparison of Etching Processes of Silicon and Germanium in SF6—O2 Radio-Frequency Plasma,” 13 Journal of Vac. Sci. Tech., B-2, 1995, pp. 235-241.;;Cannon et al., “Monolithic Si-based Technology for Optical Receiver Circuits,” Proceedings of SPIE, vol. 4999, 2003, pp. 145-155.;;Chan et al., “Influence of Metalorganic Sources on the Composition Uniformity of Selectively Grown GaxIn1-xP,” Japan. Journal of Applied Physics, vol. 33, 1994, pp. 4812-4819.;;Chang et al. “3-D simulation of strained Si/SiGe heterojunction FinFETs” Semiconductor Device Research Symposium, Dec. 10-12, 2003, pp. 176-177.;;Chang et al., “Effect of growth temperature on epitaxial lateral overgrowth of GaAs on Si substrate,” Journal of Crystal Growth, vol. 174, No. 1-4, Apr. 1997, pp. 630-634.;;Chang et al., “Epitaxial Lateral Overgrowth of Wide Dislocation-Free GaAs on Si Substrates,” Electrochemical Society Proceedings, vol. 97-21, May 13, 1998, pp. 196-200.;;Chau et al., Opportunities and Challenges of III-V Nanoelectronics for Future High-Speed, Low Power Logic Applications, IEEE CSIC Digest, 2005, pp. 17-20.;;Chen et al., “Dislocation reduction in GaN thin films via lateral overgrowth from trenches,” Applied Physics Letters, vol. 75, No. 14, Oct. 4, 1999, pp. 2062-2063.;;Chengrong, et al., “DBRTD with a high PVCR and a peak current density at room temperature,” Chinese Journal of Semiconductors vol. 26, No. 10, Oct. 2005, pp. 1871-1874.;;Choi et al., “Monolithic Integration GaAs/AlGaAs LED and Si Driver Circuit,” 9 Electron Device Letters 10, Oct. 1988, 3 pages.;;Choi et al., “Monolithic Integration of GaAs/AlGaAs Double-Heterostructure LEDs and Si MOSFETs,” Electron Device Letters, vol. EDL-7, No. 9, Sep. 1986, 3 pages.;;Choi et al., “Monolithic Integration of Si MOSFETs and GaAs MESFETs,” Electron Device Letters, vol. EDL-7, No. 4, Apr. 1986, 3 pages.;;Choi, et al., “Low-voltage low-power K-band balanced RTD-based MMIC VCO,” 2006 IEEE, Department of EECS, Korea Advanced Institute of Science and Technology, 2006, pp. 743-746.;;Cloutier et al., “Optical gain and stimulated emission in periodic nanopatterned crystalline silicon,” Nature Materials, Nov. 2005, 5 pages.;;Currie et al., “Carrier Mobilities and Process Stability of Strained Si n- and p-MOSFETs on SiGe Virtual Substrates,” J. Vacuum Science Technology, B, vol. 19, No. 6, 2001, pp. 2268-2279.;;Dadgar et al., “MOVPE growth of GaN on Si (111) substrates,” Journal of Crystal Growth, vol. 248, Feb. 1, 2003, pp. 556-562.;;Datta et al., “Silicon and III-V Nanoelectronics,” IEEE International Conference on Indium Phosphide & Related Materials, 2005, pp. 7-8.;;Datta et al., “Ultrahigh-Speed 0.5 V Supply Voltage In0.7Ga0.3As Quantum-Well Transistors on Silicon Substrate,” 28 Electron Device Letters 8, 2007, pp. 685-687.;;Davis et al., “Lateral epitaxial overgrowth of and defect reduction in GaN thin films,” Lasers and Electro-Optics Society Annual Meeting (1998) LEOS '98. IEEE, vol. 1, Dec. 1-4, 1998, pp. 360-361.;;De Boeck et al., “The fabrication on a novel composite GaAs/SiO2 nucleation layer on silicon for heteroepitaxial overgrowth by molecular beam Epitaxy,” Material Science and Engineering, B9, 1991, pp. 137-141.;;Donaton et al., “Design and Fabrication of MOSFETs with a Reverse Embedded SiGe (Rev. e-SiGe) Structure,” 2006 IEDM, pp. 465-468.;;Dong, Y., et al, “Selective area growth of InP through narrow openings by MOCVD and its application to InP HBT,” 2003 International Conference on Indium Phosphide and Related Materials, May 12-16, 2003, pp. 389-392.;;European Patent Office, Extended European Search Report and Search Opinion dated Jan. 26, 2011 in EP Patent Application No. 10003084.0-2203 (9 pages).;;European Search Report issued by the European Patent Office dated Dec. 15, 2010 in European Patent Application No. 10002884.4 (10 pages).;;Examination Report in European Patent Application No. 06800414.2, dated Mar. 5, 2009, 3 pages.;;Extended European Search Report, Applicant: Taiwan Semiconductor Manufacturing Company, Ltd., Application No. 09815273.9-2203/2335273 PCT/US2009057493, dated Dec. 22, 2011, 15 pages.;;Fang et al., “Electrically pumped hybrid AlGaInAs-silicon evanescent laser,” 14 Optics Express 20, 2006, pp. 9203-9210.;;Feltin et al., “Epitaxial lateral overgrowth of GaN on Si (111),” Journal of Applied Physics, vol. 93, No. 1, Jan. 1, 2003, pp. 182-185.;;Feng et al., “Integration of Germanium-on Insulator and Silicon Substrate,” 27 Electron Device Letters 11, 2006, pp. 911-913.;;Fiorenza et al., “Film Thickness Constraints for Manufacturable Strained Silicon CMOS,” 19 Semiconductor Science Technology, 2004, p. L4.;;Fischer et al., “Elastic stress relaxation in SiGe epilayers on patterned Si substrates,” 75 Journal of Applied Physics 1, 1994, pp. 657-659.;;Fischer et al., “State of stress and critical thickness of Strained small-area SiGe layers,”Phys. Stat. Sol. (a) vol. 171, 1999, pp. 475-485.;;Fitzgerald et al., “Elimination of Dislocations in Heteroepitaxial MBE and RTCVD GexSi1-x Grown on Patterned Si Substrates,” Journal of Electronic Materials, vol. 19, No. 9, 1990, pp. 949-955.;;Fitzgerald et al., “Epitaxial Necking in GaAs Growth on Pre-patterned Si Substrates,” Journal of Electronic Materials, vol. 20, No. 10, 1991, pp. 839-853.;;Fitzgerald et al., “Nucleation Mechanisms and the Elimination of Misfit Dislocations at Mismatched Interfaces by Reduction in Growth Areas,” Journal of Applied Physics, vol. 65, No. 6, Mar. 15, 1989, pp. 2220-2237.;;Fitzgerald et al., “Structure and recombination in InGaAs/GaAs heterostructures,” 63 Journal of Applied Physics, vol. 3, 1988, pp. 693-703.;;Fitzgerald et al., “Totally relaxed GexSi1-x layers with low threading dislocation densities grown on Si Substrates,” vol. 59, Applied Physics Letters 7, 1991, pp. 811-813.;;Fitzgerald, “The Effect of Substrate Growth Area on Misfit and Threading Dislocation Densities in Mismatched Heterostructures,” Journal of Vacuum Science Technology, vol. 7, No. 4, Jul./Aug. 1989, pp. 782-788.;;Gallagher et al., “Development of the magnetic tunnel junction MRAM at IBM: From first junctions to a 16-Mb MRAM demonstrator chip,” 50 IBM J. Research & Dev. 1, Jan. 2006, pp. 5-23A.;;Gallas et al., “Influence of Doping on Facet Formation at the SiO2/Si Interface,” Surface Sci. 440, 1999, pp. 41-48.;;Geppert, “Quantum transistors: toward nanoelectronics,” IEEE Spectrum, Sep. 2000, pp. 46-51.;;Gibbon et al., “Selective-area low-pressure MOCVD of GaInAsP and related materials on planar InP substrates,” Semicond. Sci. Tech. vol. 8, 1993, pp. 998-1010.;;Glew et al., “New DFB grating structure using dopant-induced refractive index step,” J. Crystal Growth 261, 2004, pp. 349-354.;;Golka, et al., “Negative differential resistance in dislocation-free GaN/AlGan double-barrier diodes grown on bulk GaN,” 88 Applied Physics Letters 17, Apr. 2006, pp. 172106-1-172106-3.;;Goodnick, S.M., “Radiation Physics and Reliability Issues in III-V Compound Semiconductor Nanoscale Heterostructure Devices,” Final Technical Report, Arizona State Univ. Dept. Electrical & Computer Eng, 80 pages, 1996-1999.;;Gould et al., “Magnetic resonant tunneling diodes as voltage-controlled spin selectors,” 241 Phys. Stat. Sol. (B), vol. 3, 2004, pp. 700-703.;;Groenert et al., “Monolithic integration of room-temperature cw GaAs/AlGaAs lasers on Si substrates via relaxed graded GeSi buffer layers,” 93 Journal of Applied Physics, No. 362, Jan. 2003, pp. 362-367.;;Gruber, et al., “Semimagnetic Resonant Tunneling Diodes for Electron Spin Manipulation,” Nanostructures: Physics & Technology, 8th International Symposium, 2000, pp. 483-486.;;Gustafsson et al., “Cathodoluminescence from relaxed GexSi1-x grown by heteroepitaxial lateral overgrowth,” Journal of Crystal Growth 141, 1994, pp. 363-370.;;Gustafsson et al., “Investigations of high quality GexSi1-x grown by heteroepitaxial lateral overgrowth using cathodoluminescence,” Inst. Phys. Conf. Ser., No. 134, Section 11, Apr. 1993, pp. 675-678.;;Hammerschmidt, “Intel to Use Trigate Transistors from 2009 on,” EETIMES Online, available at: http://www.eetimes.com/showArticle.jhtml?articleID=189400035 (Jun. 12, 2006). 1 page.;;Hasegawa, et al., “Sensing Terahertz Signals with III-V Quantum Nanostructures,” Quantum Sensing: Evolution and Revolution from Past to Future, SPIE 2003, pp. 96-105.;;Hayafuji et al., Japan, Journal of Applied Physics, vol. 29, 1990, pp. 2371.;;Hersee et al., “The Controlled Growth of GaN Nanowires,” Nano Letters, vol. 6, No. 8, 2006, pp. 1808-1811.;;Hiramatsu et al., “Fabrication and characterization of low defect density GaN using facet-controlled epitaxial lateral overgrowth (FACELO),” Journal of Crystal Growth, vol. 221, Dec. 2000, pp. 316-326.;;Hollander et al., “Strain and Misfit Dislocation Density in Finite Lateral Size Si1-xGex/Si Films Grown by Selective Epitaxy,” Thin Solid Films, vol. 292, 1997, pp. 213-217.;;Hu et al., “Growth of Well-Aligned Carbon Nanotube arrays on Silicon Substrates Using Porous Alumina Film as a Nanotemplate,” 79 Applied Physics Letters 19, 2001, 3 pages.;;Yanlong, et al., “Monolithically fabricated OEICs using RTD and MSM,” Chinese Journal Semiconductors vol. 27, No. 4, Apr. 2006, pp. 641-645.;;Huang et al., “Electron and Hole Mobility Enhancement in Strained SOI by Wafer Bonding,” 49 IEEE Transactions on Electron Devices 9, 2002, pp. 1566-1570.;;Ying-Long, et al., “Resonant tunneling diodes and high electron mobility transistors integrated on GaAs substrates,” Chinese Physics Letters 23, vol. 3, Mar. 2006, pp. 697-700.;;Hydrick et al., “Chemical Mechanical Polishing of Epitaxial Germanium on Si02-patterned Si(001) Substrates,” ECS Transactions, 16 (10), 2008, (pp. 237-248).;;Intel Press Release, “Intel's Tri-Gate Transistor to Enable Next Era in Energy-Efficient Performance,” Intel Corporation (Jun. 12, 2006). 2 pages.;;Intel to Develop Tri-Gate Transistors Based Processors, available at: http://news.techwhack.com/3822/tri-gate-transistors/ (Jun. 13, 2006) 6 pages.;;International Preliminary Report on Patentability for International Application No. PCT/US2006/019152 dated Nov. 29, 2007, 2 pages.;;International Preliminary Report on Patentability for International Application No. PCT/US2006/029247 dated Feb. 7, 2008, 12 pages.;;International Preliminary Report on Patentability for International Application No. PCT/US2006/033859 dated Mar. 20, 2008, 14 pages.;;International Preliminary Report on Patentability for International Application No. PCT/US2007/019568 dated Mar. 19, 2009, 10 pages.;;International Preliminary Report on Patentability for International Application No. PCT/US2007/020181 dated Apr. 2, 2009, 9 pages.;;International Preliminary Report on Patentability for International Application No. PCT/US2007/020777 dated Apr. 9, 2009, 12 pages.;;International Preliminary Report on Patentability for International Application No. PCT/US2007/021023 dated Apr. 9, 2009, 8 pages.;;International Preliminary Report on Patentability for International Application No. PCT/US2007/022392 dated Apr. 30, 2009, 14 pages.;;International Search Report and Written Opinion for International Application No. PCT/US2006/019152 dated Oct. 19, 2006, 11 pages.;;International Search Report and Written Opinion for International Application No. PCT/US2006/029247 dated May 7, 2007, 19 pages.;;International Search Report and Written Opinion for International Application No. PCT/US2008/068377, dated Jul. 6, 2009, 19 pages.;;International Search Report and Written Opinion for International Application No. PCT/US2006/033859 dated Sep. 12, 2007, 22 pages.;;International Search Report and Written Opinion for International Application No. PCT/US2007/007373, dated Oct. 5, 2007, 13 pages.;;International Search Report and Written Opinion for International Application No. PCT/US2007/019568 dated Feb. 6, 2008, 13 pages.;;International Search Report and Written Opinion for International Application No. PCT/US2007/020181 dated Jan. 25, 2008, 15 pages.;;International Search Report and Written Opinion for International Application No. PCT/US2007/020777 dated Feb. 8, 2008, 18 pages.;;International Search Report and Written Opinion for International Application No. PCT/US2007/021023 dated Jun. 6, 2008, 10 pages.;;International Search Report and Written Opinion for International Application No. PCT/US2007/022392 dated Apr. 11, 2008, 20 pages.;;International Search Report for International Application No. PCT/US2006/019152, dated May 17, 2005. 11 pages.;;International Technology Roadmap for Semiconductors—Front End Processes, pp. 1-62 (2005).;;Ipri et al., “MONO/POLY technology for fabricating low-capacitance CMOS integrated circuits,” Electron Devices, IEEE Transactions, vol. 35, No. 8, Aug. 1988 pp. 1382-1383.;;Ishibashi, et al., “3rd Topical Workshop on Heterostructure Microelectronics for Information Systems Applications,” Aug.-Sep. 1998, 115 pages.;;Ishitani et al., “Facet Formation in Selective Silicon Epitaxial Growth,” 24 Japan, Journal of Applied Physics, vol. 10, 1985, pp. 1267-1269.;;Ismail et al., “High-quality GaAs on Sawtooth-patterned Si Substrates,” 59 Applied Physics Letters 19, 1991, pp. 2418-2420.;;Jain et al., “Stresses in strained GeSi stripes and quantum structures: calculation using the finite element method and determination using micro-Raman and other measurements,” Thin Solid Films 292, 1997, pp. 218-226.;;Jeong, et al., “Performance improvement of InP-based differential HBT VCO using the resonant tunneling diode,” 2006 International Conf. on Indium Phosphide and Related Mat. Conf. Proc., pp. 42-45.;;Ju et al., “Epitaxial lateral overgrowth of gallium nitride on silicon substrate,” Journal of Crystal Growth, vol. 263, No. 1-4, Mar. 1, 2004, pp. 30-34.;;Kamins et al., “Kinetics of Selective Epitaxial Depostion of Si1—xGex,” Hewlett-Packard Company, Palo Alto, CA, Appl. Phys. Lett. 61 (6), Aug. 10, 1992 (pp. 669-671).;;Kamiyama, et al., “UV laser diode with 350.9-nm-lasing wavelength grown by hetero-epitaxial-lateral overgrowth technology,” Selected Topics in Quantum Electronics, IEEE Journal of Selected Topics in Quantum Electronics, vol. 11, No. 5, Sep.-Oct. 2005, pp. 1069-1073.;;Kamiyama, et al., “UV light-emitting diode fabricated on hetero-ELO-grown Al0.22Ga0.78N with low dislocation density,” Physica Status Solidi A, vol. 192, No. 2, Aug. 2002, pp. 296-300.;;Kawai, et al., “Epitaxial Growth of InN Films and InN Nano-Columns by RF-MBE,” The Institute of Electronics, Information and Communication Engineers, Gijutsu Kenkyu, vol. 13, No. 343 (CPM2003 102-116), 2003, pp. 33-37.;;Kazi et al., “Realization of GaAs/AlGaAs Lasers on Si Substrates Using Epitaxial Lateral Overgrowth by Metalorganic Chemical Vapor Deposition,” Japan, Journal of Applied Physics, vol. 40, 2001, pp. 4903-4906.;;Kidoguchi et al., “Air-bridged lateral epitaxial overgrowth of GaN thin Films,” Applied Physics Letters, vol. 76, No. 25, Jun. 19, 2000, pp. 3768-3770.;;Kim et al., “Silicon-Based Field-Induced Band-to-Band Tunneling Effect Transistor,” IEEE Electron Device Letters, No. 25, No. 6, 2004, pp. 439-441.;;Kim et al., “GaN nano epitaxial lateral overgrowth on holographically patterned substrates,” School of Physics and Inter-University Semiconductor Research Center, Seoul National University, Aug. 25-27, 2003, pp. 27-28.;;Kimura et al., “Vibronic Fine Structure Found in the Blue Luminescence from Silicon Nanocolloids,” Japan, Journal of Applied Physics, vol. 38, 1999, pp. 609-612.;;Klapper, “Generation and Propagation of Dislocations During Crystal Growth,” Mat. Chem. and Phys. vol. 66, 2000, pp. 101-109.;;Knall et al., “Threading Dislocations in GaAs Grown with Free Sidewalls on Si mesas,” Journal of Vac. Sci. Technol. B, vol. 12, No. 6, Nov./Dec. 1994, pp. 3069-3074.;;Kollonitsch, et al., “Improved Structure and Performance of the GaAsSb/InP Interface in a Resonant Tunneling Diode,” Journal of Crystal Growth, vol. 287, 2006, pp. 536-540.;;Krishnamurthy, et al., “I—V characteristics in resonant tunneling devices: Difference Equation Method,” Journal of Applied Physics, vol. 84, Issue 9, Condensed Matter: Electrical and Magnetic Properties (PACS 71-76), 1998, 9 pages.;;Krost et al., “GaN-based Optoelectronics on Silicon Substrates,” Materials Science & Engineering, B93, 2002, pp. 77-84.;;Sudirgo et al., “Si-Based Resonant Interband Tunnel Diode/CMOS Integrated Memory Circuits,” Rochester Institute of Technology, IEEE, 2006, pp. 109-112.;;Kusakabe, K. et al., Characterization of Overgrown GaN layers on Nano-Columns Grown by RF-Molecular Beam Epitaxy, Japan, Journal of Applied Physics, Part 2, vol. 40, No. 3A, 2001, pp. L192-L194.;;Kushida et al., “Epitaxial growth of PbTiO3 films on SrTiO3 by RF magnetron sputtering,” Ultrasonics, Ferroelectrics and Frequency Control, IEEE Transactions on Ultrasonics Ferroelectrics and Frequency Control, vol. 38, No. 6, Nov. 1991, pp. 656-662.;;Kwok, “Barrier-Injection Transit Time Diode,” Complete Guide to Semiconductor Devices, 2nd ed., Chapter 18, 2002, pp. 137-144.;;Lammers, “Trigate and High-k stack up vs. planar,” EETIMES Online, available at: http://www.eetimes.com/showArticle.jhtml?articleID=188703323&pgno=2&printable=true (Jun. 12, 2006). 2 pages.;;Langdo et al., “High Quality Ge on Si by Epitaxial Necking,” Applied Physics Letters, vol. 76, No. 25, Jun. 19, 2000, pp. 3700-3702.;;Langdo, “Selective SiGe Nanostructures,” PhD Thesis, Massachusetts Institute of Technology, Jun. 2001, 215 pages.;;Lee et al., “Growth of GaN on a nanoscale periodic faceted Si substrate by metal organic vapor phase epitaxy,” Compound Semiconductors: Post-Conference Proceedings, Aug. 25-27, 2003, pp. 15-21.;;Lee et al., “Strain-relieved, Dislocation-free InxGa1-xAs/GaAs(001) Heterostructure by Nanoscale-patterned Growth,” Applied Physics Letters, vol. 85, No. 18, Nov. 1, 2004, pp. 4181-4183.;;Li et al., “Defect Reduction of GasAs Epitaxy on Si (001) Using Selective Aspect Ratio Trapping,” 91 Applied Physics Letters, 2007, pp. 021114-1-021114-3.;;Li et al., “Heteroepitaxy of High-quality Ge on Si by Nanoscale Ge seeds Grown through a Thin Layer of SiO2,” Applied Physics Letters, vol. 85, No. 11, Sep. 13, 2004, pp. 1928-1930.;;Li et al., “Monolithic Integration of GaAs/InGaAs Lasers on Virtual Ge Substrates via Aspect-Ratio Trapping,” Journal of The Electrochemical Society, vol. 156, No. 7, 2009, pp. H574-H578.;;Li et al., “Morphological Evolution and Strain Relaxation of Ge Islands Grown on Chemically Oxidized Si (100) by Molecular-Beam Epitaxy,” Journal of Applied Physics, vol. 98, 2005, pp. 073504-1-073504-8.;;Li et al., “Selective Growth of Ge on Si (100) through Vias of Si02 Nanotemplate Using Solid Source Molecular Beam Epitaxy,” Applied Physics Letters, vol. 83, No. 24, Dec. 15, 2003, pp. 5032-5034.;;Liang et al., “Critical Thickness enhancement of Epitaxial SiGe films Grown on Small Structures,” Journal of Applied Physics, vol. 97, 2005, pp. 043519-1-043519-7.;;Lim et al., “Facet Evolution in Selective Epitaxial Growth of Si by cold-wall ultrahigh vacuum chemical vapor deposition,” Journal of Vac. Sci. Tech., vol. B 22, No. 2, 2004, pp. 682.;;Liu et al., “High Quality Single-crystal Ge on Insulator by Liquid-phase Epitaxy on Si Substrates,” Applied Physics Letters, vol. 84, No. 14, Apr. 4, 2004, pp. 2563-2565.;;Liu et al., “Rapid Melt Growth of Germanium Crystals with Self Aligned Microcrucibles on Si Substrates,” Journal of the Electrochemical Society, vol. 152, No. 8, 2005, pp. G688-G693.;;Li, J. Z.,et al., “Defect reduction of GaAs/Si epitaxy by aspect ratio trapping”, Journal of Applied Physics 103, 2008 American Institute of Physics, 3 pages.;;Loo et al., “Successful Selective Epitaxial Si1-xGex Deposition Process for HBT-BiCMOS and High Mobility Heterojunction pMOS Applications,” 150 Journal of Electrochemical Society 10, 2003, pp. G638-G647.;;Lourdudoss et al., “Semi-insulating epitaxial layers for optoelectronic devices,” Semiconducting and Insulating Materials Conference, SIMC-XI, 2000, pp. 171-178.;;Luan et al., “High-quality Ge Epilayers on Si with Low Threading-dislocation Densities,” Applied Physics Letters, vol. 75, No. 19, Nov. 8, 1999, pp. 2909-2911.;;Luan, “Ge Photodetectors for Si Microphotonics,” PhD Thesis, Massachusetts Institute of Technology, Department of Materials Science & Engineering, Jan. 12, 2001, 155 pages.;;Lubnow et al., “Effect of III/V-Compound Epitaxy on Si Metal-Oxide-Semiconductor Circuits,” Japan, Journal of Applied Physics, vol. 33, 1994, pp. 3628-3634.;;Luo et al., Enhancement of (IN,Ga)N Light-Emitting Diode Performance by Laser Liftoff and Transfer From Sapphire to Silicon, IEEE Photonics Technology Letters, vol. 14, No. 10, 2002, pp. 1400-1402.;;Luryi et al., “New Approach to the High Quality Epitaxial Growth of Latticed-Mismatched Materials,” Applied Physics Letters, vol. 49, No. 3, Jul. 21, 1986, pp. 140-142.;;Ma, et al., “A small signal equivalent circuit model for resonant tunneling diode,” Chinese Physics Letters, vol. 23, No. 8, Aug. 2006, pp. 2292-2295.;;Ma, et al., “Fabrication of an AlAs/In0.53/Ga0.47/As/InAs resonant tunneling diode on InP substrate for high-speed circuit applications,” 27 Chinese J. Semiconductors 6, Jun. 2006, pp. 959-962.;;Maekawa, et al., “High PVCR Si/Si1-x/Gex DW RTD formed with a new triple-layer buffer,” Materials Science in Semiconductor Processing, vol. 8, 2005, pp. 417-421.;;Maezawa, et al., “Metamorphic resonant tunneling diodes and its application to chaos generator ICs,”44 Jap. J. Applied Physics, Part 1, No. 7A, Jul. 2005, pp. 4790-4794.;;Maezawa, et al., “InP-based resonant tunneling diode/HEMT integrated circuits for ultrahigh-speed operation,” IEEE Nagoya University, Institute for Advanced Research, 2006, pp. 252-257.;;Martinez et al., “Characterization of GaAs Conformal Layers Grown by Hydride Vapour Phase Epitaxy on Si Substrates by Microphotoluminescence Cathodoluminescence and MicroRaman,” Journal of Crystal Growth, vol. 210, 2000, pp. 198-202.;;Matsunaga et al., “A New Way to Achieve Dislocation-Free Heteroepitaxial Growth by Molecular Beam Epitaxy: Vertical Microchannel Epitaxy,” Journal of Crystal Growth, vol. 237-239, 2002, pp. 1460-1465.;;Matthews et al., “Defects in Epitaxial Multilayers—Misfit Dislocations,” Journal of Crystal Growth, vol. 27, 1974, pp. 118-125.;;Monroy, et al., “High UV/visible Contrast Photodiodes Based on Epitaxial Lateral Overgrown GaN layers,” Electronics Letters, vol. 35, No. 17, Aug. 19, 1999, pp. 1488-1489.;;Nakano et al., “Epitaxial Lateral Overgrowth of AIN Layers on Patterned Sapphire Substrates,” Source: Physica Status Solidi A, vol. 203, No. 7, May 2006, pp. 1632-1635.;;Nam et al., “Lateral Epitaxy of Low Defect Density GaN Layers via Organometallic Vapor Phase Epitaxy,” Applied Physics Letters, vol. 71, No. 18, Nov. 3, 1997, pp. 2638-2640.;;Naoi et al., “Epitaxial Lateral Overgrowth of GaN on Selected-area Si (111) Substrate with Nitrided Si Mask,” Journal of Crystal Growth, vol. 248, 2003, pp. 573-577.;;Naritsuka et al., “InP Layer Grown on (001) Silicon Substrate by Epitaxial Lateral Overgrowth,” Japan, Journal of Applied Physics, vol. 34, 1995, pp. L1432-L1435.;;Naritsuka et al., “Vertical Cavity Surface Emitting Laser Fabricated on GaAs Laterally Grown on Si Substrate,” Electrochemical Society Proceedings, vol. 97, No. 21, pp. 86-90.;;Neudeck, et al., “Novel silicon Epitaxy for advanced MOSFET devices,” Electron Devices Meeting, IEDM Technical Digest International, 2000, pp. 169-172.;;Neumann et al., “Growth of III-V Resonant Tunneling Diode on Si Substrate with LP-MOVPE,” Journal of Crystal Growth, vol. 248, 2003, pp. 380-383.;;Noborisaka, J., et al., “Catalyst-free growth of GaAs nanowires by selective-area metalorganic vapor-phase epitaxy,” Applied Physics Letters, vol. 86, May 16, 2005, pp. 213102-1-213102-3.;;Noborisaka, J., et al., “Fabrication and characterization of freestanding GaAs/AlGaAs core-shell nanowires and AlGaAs nanotubes by suing selective-area metalorganic vapor phase epitaxy,” Applied Physics Letters, vol. 87, Aug. 24, 2005, pp. 093109-1-093109-3.;;Noda, et al., “Current-voltage characteristics in double-barrier resonant tunneling diodes with embedded GaAs quantum rings,” Physica E 32, 2006, pp. 550-553.;;Norman, et al., “Characterization of MOCVD Lateral Epitaxial Overgrown III-V Semiconductor Layers on GaAs Substrates,” Compound Semiconductors, Aug. 25-27, 2003, pp. 45-46.;;Notification of Transmittal of the International Search Report and the Written Opinion of the International Searching Authority for PCT/US2010/029552, Applicant: Taiwan Semiconductor Manufacturing Company, Ltd., dated May 26, 2010, 14 pages.;;Oehrlein et al., “Studies of the Reactive Ion Etching of SiGe Alloys,” J. Vac. Sci. Tech, A9, No. 3, May/Jun. 1991, pp. 768-774.;;Orihashi, et al., “Experimental and theoretical characteristics of sub-terahertz and terahertz oscillations of resonant tunneling diodes integrated with slot antennas,” 44 Jap. J. Applied Physics, Part 1, No. 11, Nov. 2005, pp. 7809-7815.;;Parillaud et al., “High Quality InP on Si by Conformal Growth,” Applied Physics Letters, vol. 68, No. 19, May 6, 1996, pp. 2654-2656.;;Park et al., “Defect Reduction and its Mechanism of Selective Ge Epitaxy in Trenches on Si(001) Substrates Using Aspect Ratio Trapping,” Mat. Res. Society Symp. Proc., vol. 994, 2007, 6 pages.;;Park et al., “Defect Reduction of Selective Ge Epitaxy in Trenches on Si (001) Substrates Using Aspect Ratio Trapping,” Applied Physics Letters 90, 052113, Feb. 2, 2007, 3 pages.;;Park et al., “Fabrication of Low-Defectivity, Compressively Strained Geon Si0.2Ge0.8 Structures Using Aspect Ratio Trapping,” Journal of The Electrochemical Society, vol. 156, No. 4, 2009, pp. H249-H254.;;Park et al., “Growth of Ge Thick Layers on Si (001) Substrates Using Reduced Pressure Chemical Vapor Deposition,” 45 Japan, Journal of Applied Physics, vol. 11, 2006, pp. 8581-8585.;;Partial International Search for International Application No. PCT/US2006/033859 dated Jun. 22, 2007, 7 pages.;;Partial International Search Report for International Application No. PCT/US2008/004564 completed Jul. 22, 2009, dated Oct. 16, 2009, 5 pages.;;Partial International Search Report for International Application No. PCT/US2008/068377, completed Mar. 19, 2008, dated Apr. 22, 2008, 3 pages.;;PCT International Search Report of PCT/US2009/057493, from PCT/ISA/210, dated Mar. 22, 2010, Applicant: Amberwave System Corporation et al., 2 pages.;;Pidin et al., “MOSFET Current Drive Optimization Using Silicon Nitride Capping Layer for 65-nm Technology Node,” Symposium on VLSI Technology, Dig. Tech. Papers, 2004, pp. 54-55.;;Piffault et al., “Assessment of the Strain of InP Films on Si Obtained by HVPE Conformal Growth,” Indium Phosphide and Related Materials, Conference Proceedings, Sixth International Conference on Mar. 27-31, 1994, pp. 155-158.;;Pribat et al., “High Quality GaAs on Si by Conformal Growth,” Applied Physics Letters, vol. 60, No. 17, Apr. 27, 1992, pp. 2144-2146.;;Prost, ed. “QUDOS Technical Report,” 2002-2004, 77 pages.;;Prost, et al., “High-speed InP-based resonant tunneling diode on silicon substrate,” Proceedings of the 31st European Solid-State Device Research Conf., 2005, pp. 257-260.;;Radulovic, et al., “Transient Quantum Drift-Diffusion Modelling of Resonant Tunneling Heterostructure Nanodevices,” Physics of Semiconductors: 27th International Conference on the Physics of Semiconductors—ICPS-27, Jun. 2005 AIP Conf. Proc., pp. 1485-1486.;;Reed et al., “Realization of a Three-Terminal Resonant Tunneling Device: The Bipolar Quantum Resonant Tunneling Transistor,” 54 Applied Physics Letters 11, 1989, p. 1034.;;Ren et al., “Low-dislocation-density, Nonplanar GaN Templates for Buried Heterostructure Lasers Grown by Lateral Epitaxial Overgrowth,” Applied Physics Letters, vol. 86, No. 11, Mar. 14, 2005, pp. 111901-1-111901-3.;;Rim et al., “Enhanced Hole Mobilities in Surface-Channel Strained-Si p-MOSFETs,” 1995 IEDM, pp. 517-520. et al.",ACTIVE
295,CA,C,CA 2658112 C,050-736-733-249-002,2013-12-31,2013,CA 2658112 A,2007-07-25,US 83328806 P;;US 2007/0016775 W,2006-07-26,HYDROPHOBICALLY MODIFIED POLY[ETHYLENE GLYCOL] FOR USE IN PITCH AND STICKIES CONTROL IN PULP AND PAPERMAKING PROCESSES,Methods for inhibiting the depositions of organic contaminants from pulp in pulp and papermaking systems are disclosed. Hydrophobically modified poly[ethylene glycol] are added to the pulp or applied to deposition-prone surfaces of a papermaking system.,HERCULES INC,GU QU-MING;;CHENG HUAI N;;CAREY WILLIAM;;GELMAN ROBERT;;RITTENHOUSE-PRUSS JENNIFER;;DOHERTY ERIN A S,,https://lens.org/050-736-733-249-002,Granted Patent,no,0,0,21,21,0,C08G65/22;;C08G65/2609;;D21C9/008;;D21H21/02;;C08G2650/34;;C08G65/22;;C08G65/2609;;C08G2650/34;;D21C9/008;;D21H21/02;;D21H21/02;;C08G2650/34;;C08G65/22;;D21C9/008;;C08G65/2609,D21H21/02;;C08L71/02;;C11D1/722;;D21C9/00,,0,0,,,,ACTIVE
296,AU,B2,AU 2007/277202 B2,074-039-300-319-690,2013-04-11,2013,AU 2007/277202 A,2007-07-25,US 83328806 P;;US 2007/0016775 W,2006-07-26,Hydrophobically modified poly(ethylene glycol) for use in pitch and stickies control in pulp and papermaking processes,Methods for inhibiting the depositions of organic contaminants from pulp in pulp and papermaking systems are disclosed. Hydrophobically modified poly[ethylene glycol] are added to the pulp or applied to deposition-prone surfaces of a papermaking system.,SOLENIS TECHNOLOGIES CAYMAN LP,GELMAN ROBERT;;DOHERTY ERIN A S;;RITTENHOUSE-PRUSS JENNIFER;;CAREY WILLIAM;;CHENG HUAI N;;GU QU-MING,"SOLENIS TECHNOLOGIES CAYMAN, L.P. (2014-11-20)",https://lens.org/074-039-300-319-690,Granted Patent,no,1,0,21,21,0,C08G65/22;;C08G65/2609;;D21C9/008;;D21H21/02;;C08G2650/34;;C08G65/22;;C08G65/2609;;C08G2650/34;;D21C9/008;;D21H21/02;;D21H21/02;;C08G2650/34;;C08G65/22;;D21C9/008;;C08G65/2609,C08L71/02;;C11D1/722;;D21C9/00;;D21H21/02,,0,0,,,,ACTIVE
297,WO,A1,WO 2017/222659 A1,133-593-866-934-269,2017-12-28,2017,US 2017/0031686 W,2017-05-09,US 201662354150 P;;US 201715497015 A,2016-06-24,EYE CYTOMETER FOR CONTINUOUS HEALTH MONITORING,"Systems and methods are provided for cytometric measurement of blood cells traversing microvasculature single-file in the eye of a subject. A miniature imaging device, having cellular resolution, records image data that can be rendered into a microcirculation time sequence and analyzed to provide useful biological information.",VERILY LIFE SCIENCES LLC,BELTHANGADY CHINMAY;;LEE SEUNG AH;;PERREAULT JOHN D;;HAN JENNIFER SY-EN;;WU CHENG-HSUN;;LEE MARK,,https://lens.org/133-593-866-934-269,Patent Application,yes,8,1,2,2,0,A61B3/1241;;A61B3/1241;;A61B3/113;;A61B3/145;;A61B5/14535;;A61B5/1455;;G01N15/1434;;G01N2015/144,A61B3/12,,0,0,,,,PENDING
298,CN,A,CN 104947491 A,150-370-251-206-116,2015-09-30,2015,CN 201510305024 A,2007-07-25,US 83328806 P;;CN 200780031812 A,2006-07-26,Hydrophobically modified poly(ethylene glycol) for use in pitch and stickies control in pulp and papermaking processes,Methods for inhibiting the depositions of organic contaminants from pulp in pulp and papermaking systems are disclosed. Hydrophobically modified poly[ethylene glycol] are added to the pulp or applied to deposition-prone surfaces of a papermaking system.,HERCULES INC,GU QU-MING;;CHENG HUAI-NAN;;WILLIAM CAREY;;ROBERT GELMAN;;JENNIFER RITTENHOUSE PRUSS;;DOHERTY ERIN A S,,https://lens.org/150-370-251-206-116,Patent Application,no,0,2,21,21,0,C08G65/22;;C08G65/2609;;D21C9/008;;D21H21/02;;C08G2650/34;;C08G65/22;;C08G65/2609;;C08G2650/34;;D21C9/008;;D21H21/02;;D21H21/02;;C08G2650/34;;C08G65/22;;D21C9/008;;C08G65/2609,D21C9/00;;C08G65/00;;C08G65/48;;D21H21/02,,0,0,,,,DISCONTINUED
299,EP,B1,EP 2044263 B1,001-766-053-727-664,2016-09-07,2016,EP 07810787 A,2007-07-25,US 2007/0016775 W;;US 83328806 P,2006-07-26,"METHOD FOR PITCH AND STICKIES CONTROL IN PULP AND PAPERMAKING PROCESSES, USING HYDROPHOBICALLY MODIFIED POLY(ETHYLENE GLYCOL)",,SOLENIS TECHNOLOGIES CAYMAN LP,GU QU-MING;;CHENG HUAI N;;CAREY WILLIAM;;GELMAN ROBERT;;RITTENHOUSE-PRUSS JENNIFER;;DOHERTY ERIN A S,"SOLENIS TECHNOLOGIES CAYMAN, L.P. (2014-12-31)",https://lens.org/001-766-053-727-664,Granted Patent,yes,5,0,21,21,0,C08G65/22;;C08G65/2609;;D21C9/008;;D21H21/02;;C08G2650/34;;C08G65/22;;C08G65/2609;;C08G2650/34;;D21C9/008;;D21H21/02;;D21H21/02;;C08G2650/34;;C08G65/22;;D21C9/008;;C08G65/2609,D21H21/02;;C08L71/02;;C11D1/722;;D21C9/00,,0,0,,,,ACTIVE
300,CA,A1,CA 2658112 A1,002-452-327-699-889,2008-01-31,2008,CA 2658112 A,2007-07-25,US 83328806 P;;US 2007/0016775 W,2006-07-26,HYDROPHOBICALLY MODIFIED POLY(ETHYLENE GLYCOL) FOR USE IN PITCH AND STICKIES CONTROL IN PULP AND PAPERMAKING PROCESSES,Methods for inhibiting the depositions of organic contaminants from pulp in pulp and papermaking systems are disclosed. Hydrophobically modified poly [ethylene glycol] are added to the pulp or applied to deposition-prone surfa ces of a papermaking system.,HERCULES INC,DOHERTY ERIN A S;;RITTENHOUSE-PRUSS JENNIFER;;CAREY WILLIAM;;GELMAN ROBERT;;CHENG HUAI N;;GU QU-MING,,https://lens.org/002-452-327-699-889,Patent Application,no,0,0,21,21,0,C08G65/22;;C08G65/2609;;D21C9/008;;D21H21/02;;C08G2650/34;;C08G65/22;;C08G65/2609;;C08G2650/34;;D21C9/008;;D21H21/02;;D21H21/02;;C08G2650/34;;C08G65/22;;D21C9/008;;C08G65/2609,D21H21/02;;C08L71/02;;C11D1/722;;D21C9/00,,0,0,,,,ACTIVE
301,US,A1,US 2013/0134480 A1,077-765-023-452-789,2013-05-30,2013,US 201313737731 A,2013-01-09,US 201313737731 A;;US 201113243521 A;;US 68087210 A;;US 2009/0057493 W;;US 9859708 P;;US 9907408 P;;US 10446608 P,2008-09-19,Formation of Devices by Epitaxial Layer Overgrowth,"Methods and structures are provided for formation of devices, e.g., solar cells, on substrates including, e.g., lattice-mismatched materials, by the use of aspect ratio trapping and epitaxial layer overgrowth. A method includes forming an opening in a masking layer disposed over a substrate that includes a first semiconductor material. A first layer, which includes a second semiconductor material lattice-mismatched to the first semiconductor material, is formed within the opening. The first layer has a thickness sufficient to extend above a top surface of the masking layer. A second layer, which includes the second semiconductor material, is formed on the first layer and over at least a portion of the masking layer. A vertical growth rate of the first layer is greater than a lateral growth rate of the first layer and a lateral growth rate of the second layer is greater than a vertical growth rate of the second layer.",TAIWAN SEMICONDUCTOR MFG;;TAIWAN SEMICONDUCTOR MFG,HYDRICK JENNIFER M;;LI JIZHONG;;CHENG ZHINYUAN;;FIORENZA JAMES;;BAI JIE;;PARK JI-SOO;;LOCHTEFELD ANTHONY J,,https://lens.org/077-765-023-452-789,Patent Application,yes,0,8,19,19,0,H01L21/02381;;H01L21/02538;;H01L21/20;;H01L21/02381;;H01L21/0245;;H01L21/0245;;H01L21/02461;;H01L21/02461;;H01L21/02463;;H01L21/02463;;H01L21/02543;;H01L21/02543;;H01L21/02546;;H01L21/02546;;H01L21/02636;;H01L21/02636;;H01L21/02639;;H01L21/02639;;H01L21/02647;;H01L21/02647;;H01L29/205;;H01L31/04;;H01L31/0687;;H01L31/0687;;H01L31/06875;;H01L31/06875;;H01L31/1808;;H01L31/1808;;H01L31/1852;;H01L31/1852;;H01L31/1892;;H01L31/1892;;Y02E10/544;;Y02E10/544,H01L21/02;;H01L29/205,257/183;;438/479;;438/458,0,0,,,,ACTIVE
302,PL,T3,PL 2044263 T3,133-640-317-033-686,2017-08-31,2017,PL 07810787 T,2007-07-25,US 83328806 P,2006-07-26,"METHOD FOR PITCH AND STICKIES CONTROL IN PULP AND PAPERMAKING PROCESSES, USING HYDROPHOBICALLY MODIFIED POLY(ETHYLENE GLYCOL)",,SOLENIS TECHNOLOGIES CAYMAN LP,GU QU-MING;;CHENG HUAI N;;CAREY WILLIAM;;GELMAN ROBERT;;RITTENHOUSE-PRUSS JENNIFER;;DOHERTY ERIN A S,,https://lens.org/133-640-317-033-686,Patent Application,no,0,0,21,21,0,C08G65/22;;C08G65/2609;;D21C9/008;;D21H21/02;;C08G2650/34;;C08G65/22;;C08G65/2609;;C08G2650/34;;D21C9/008;;D21H21/02;;D21H21/02;;C08G2650/34;;C08G65/22;;D21C9/008;;C08G65/2609,D21H21/02;;C08L71/02;;C11D1/722;;D21C9/00,,0,0,,,,PENDING
303,AU,A1,AU 2007/277202 A1,164-547-793-027-613,2008-01-31,2008,AU 2007/277202 A,2007-07-25,US 83328806 P;;US 2007/0016775 W,2006-07-26,Hydrophobically modified poly(ethylene glycol) for use in pitch and stickies control in pulp and papermaking processes,,HERCULES INC,DOHERTY ERIN A S;;RITTENHOUSE-PRUSS JENNIFER;;CHENG HUAI N;;GELMAN ROBERT;;CAREY WILLIAM;;GU QU-MING,"SOLENIS TECHNOLOGIES CAYMAN, L.P. (2014-11-20)",https://lens.org/164-547-793-027-613,Patent Application,no,0,0,21,21,0,C08G65/22;;C08G65/2609;;D21C9/008;;D21H21/02;;C08G2650/34;;C08G65/22;;C08G65/2609;;C08G2650/34;;D21C9/008;;D21H21/02;;D21H21/02;;C08G2650/34;;C08G65/22;;D21C9/008;;C08G65/2609,C08L71/02;;C11D1/722;;D21C9/00;;D21H21/02,,0,0,,,,ACTIVE
304,NO,L,NO 20090720 L,107-713-072-944-298,2009-02-25,2009,NO 20090720 A,2009-02-13,US 83328806 P;;US 2007/0016775 W,2006-07-26,Hydrofobisk modifisert poly(etylenglykol) ved kontroll av harpiks- og klebeharpiks i masse- og papirmassefremstilling,Det beskrives metoder for inhibering av avsetninger av organiske kontaminanter fra masse i masse og papirfremstillingssystemer. Hydrofobmodifiserte polyetylen glykol settes til massen eller legges på avsetningsutsatte overflater av et papirfremstillingssystem.,HERCULES INC,CHENG HUAI N;;GU QU-MING;;CAREY WILLIAM;;GELMAN ROBERT;;RITTENHOUSE-PRUSS JENNIFER;;DOHERTY ERIN A S,"SOLENIS TECHNOLOGIES CAYMAN, CH (2015-10-26)",https://lens.org/107-713-072-944-298,Abstract,no,0,0,21,21,0,C08G65/22;;C08G65/2609;;D21C9/008;;D21H21/02;;C08G2650/34;;C08G65/22;;C08G65/2609;;C08G2650/34;;D21C9/008;;D21H21/02;;D21H21/02;;C08G2650/34;;C08G65/22;;D21C9/008;;C08G65/2609,D21H21/02;;D21C9/08,,0,0,,,,DISCONTINUED
305,US,A1,US 2013/0268837 A1,117-496-514-289-660,2013-10-10,2013,US 201213443103 A,2012-04-10,US 201213443103 A,2012-04-10,METHOD AND SYSTEM TO MANAGE INTERACTIVE CONTENT DISPLAY PANELS,"A method for managing information displayed on a computing device includes automatically creating, using an application executed by a processor of the computing device, an interactive content display panel, wherein the interactive content display panel includes a graphical user interface element associated with HTML content. The interactive content display panel is displayed in front of all other windows displayed in a work area of a display of the computing device. The displaying includes automatically adjusting the size the interactive content display panel, based on updates to the HTML content, and automatically positioning the interactive content display panel in the display, based on the automatic adjustment of the size of the interactive content display panel and based on available space in the work area of the display.",BRAITHWAITE JENNIFER WAI-FUNG;;TITOV DMITRY;;LEVIN DAVID EDWIN;;LI JIAN;;CHENG DANIEL;;MOORE KENNETH BRIAN;;TAMMANA PRASAD;;GOOGLE INC,BRAITHWAITE JENNIFER WAI-FUNG;;TITOV DMITRY;;LEVIN DAVID EDWIN;;LI JIAN;;CHENG DANIEL;;MOORE KENNETH BRIAN;;TAMMANA PRASAD,GOOGLE INC (2012-03-17);;ETHICON ENDO-SURGERY LLC (2015-11-06),https://lens.org/117-496-514-289-660,Patent Application,yes,8,65,2,2,0,G06Q10/10;;G06F9/451;;G06F16/958;;G06Q10/10;;G06F9/451;;G06F16/958,G06F17/00,715/234,0,0,,,,DISCONTINUED
306,WO,A1,WO 2003/088304 A1,113-694-693-956-044,2003-10-23,2003,US 0311019 W,2003-04-11,US 12227102 A,2002-04-12,PLASMA PROCESSING CHAMBER HAVING MAGNETIC ASSEMBLY AND METHOD,"A magnetic assembly for a plasma processing chamber includes an annular housing having a radially inwardly facing opening, a cover plate to seal the radially inwardly facing opening, and a plurality of magnets in the annular housing. The magnets may be in preassembled modulates that abut one another in a ring configuration within the annular housing. A plasma processing chamber using the magnetic assembly includes a substrate support that can fit in an inner radius of the magnetic assembly, a gas supply to maintain process gas at a pressure in the chamber, a gas energizer to energize the process gas, and an exhaust the process gas.",APPLIED MATERIALS INC,WU ROBERT W;;CHENG WING L;;WANG YOU;;THACH SENH;;NOORBAKHSH HAMID;;WONG KWOK MANUS;;SUN JENNIFER Y,,https://lens.org/113-694-693-956-044,Patent Application,yes,2,0,3,3,0,H01J37/32623;;H01J37/32623,H01J37/32,,0,0,,,,PENDING
307,US,B2,US 6713114 B2,080-148-123-229-650,2004-03-30,2004,US 78371001 A,2001-02-14,US 78371001 A,2001-02-14,Frozen beverage topping,"
    The invention relates to a frozen beverage topping composition which provides a frothy or foam layer to a beverage. The beverage topping composition provides creaming and can flavor, sweeten, and slightly cool coffee and other beverages. The frozen beverage topping composition of the invention may be made in non-dairy, dairy (containing non-fat dry milk and non-dairy fat), and real dairy (containing non-fat dry mile and butterfat) forms, as well as caloric and non-caloric sweetened versions. Methods of producing the frozen beverage topping composition are provided as well as methods of using the frozen beverage topping compositions. 
",UNIV ILLINOIS,KLEIN BARBARA;;FALLER JAMES;;PAESCHKE TERESA;;MOROS ELEFTHERIOS;;GRADY JENNIFER;;CHENG MAUREEN;;LOFTON GLINDA;;MAGDEN LYNN;;ROMERO NICOLE,BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (2001-06-15),https://lens.org/080-148-123-229-650,Granted Patent,yes,28,10,2,2,0,A23F5/243;;A23G9/045;;A23G9/322;;A23G2200/12;;A23G2220/02;;A23G9/322;;A23G2220/02;;A23G2200/12;;A23G9/045;;A23F5/243,A23F5/24;;A23G9/00;;A23G9/04;;A23G9/32,426/565;;426/101;;426/590;;426/584,1,0,,,"Decker, K.J. ""Making a Better Coffee Creamer"" (Nov. 1999) Food Product Design pp. 71-92.",EXPIRED
308,WO,A2,WO 2007/057768 A2,043-648-902-494-399,2007-05-24,2007,IB 2006003287 W,2006-11-06,US 73815405 P;;US 75375905 P;;US 79920706 P;;US 86354206 P,2005-11-18,SULFONYL DERIVATIVES,"The present invention relates to compounds, pharmaceutical compositions comprising these compounds and methods for treating a condition that is mediated by the modulation of the 11-β-hsd-1 enzyme.",PFIZER PROD INC;;CHENG HENGMIAO;;CRIPPS STEPHAN JAMES;;LAFONTAINE JENNIFER ANNE;;LE PHUONG THI QUY;;MATTHEWS JEAN JOO;;NAIR SAJIV KRISHNAN,CHENG HENGMIAO;;CRIPPS STEPHAN JAMES;;LAFONTAINE JENNIFER ANNE;;LE PHUONG THI QUY;;MATTHEWS JEAN JOO;;NAIR SAJIV KRISHNAN,,https://lens.org/043-648-902-494-399,Patent Application,yes,0,40,2,2,0,A61P3/10;;C07D207/48;;C07D211/96;;C07D265/30,,,0,0,,,,PENDING
309,US,B1,US 7642082 B1,143-858-408-492-049,2010-01-05,2010,US 63122403 A,2003-07-28,US 63122403 A,2003-07-28,Methods for determining the presence of staphylococcal enterotoxin A gene in a sample,The present invention relates to methods and assays for determining the presence of staphylococcal enterotoxin A in a sample through detection of a nucleic acid encoding staphylococcal enterotoxin A.,US ARMY,CAO CHENG J;;KHAN AKBAR S;;O'CONNELL KEVIN P;;BUCHER JENNIFER R;;GOSTOMSKI MARK V;;VALDES JAMES J,UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF THE ARMY (2003-07-23),https://lens.org/143-858-408-492-049,Granted Patent,yes,4,2,1,1,8,C12Q1/689;;C12Q1/689,C07H21/02;;C12N1/20;;G01N33/569,435/252.3;;435/7.33;;536/23.1,5,2,039-588-319-424-610;;066-016-064-021-478,12944115;;10.1016/s0890-8508(03)00045-8;;10.1128/iai.61.12.5421-5425.1993;;pmc281336;;8225618,"O'Connell et al., 23rd Army Science Conference, Dec. 2002.;;Letertre et al., Molecular and Cellular Probes, vol. 17, pp. 139-147, 2003.;;Borst et al., Infection and Immunity vol. 61, No. 12, pp. 5421-5425, 1993.;;Sequence alignment # STAENAB for SEQ ID No. 3 and SEQ ID No. 5.;;Sequence alignment # AED45640 for SEQ ID No. 1 and SEQ ID No. 2.",INACTIVE
310,WO,A3,WO 2007/057768 A3,154-742-653-644-151,2007-11-01,2007,IB 2006003287 W,2006-11-06,US 73815405 P;;US 75375905 P;;US 79920706 P;;US 86354206 P,2005-11-18,SULFONYL DERIVATIVES,"The present invention relates to compounds, pharmaceutical compositions comprising these compounds and methods for treating a condition that is mediated by the modulation of the 11-β-hsd-1 enzyme.",PFIZER PROD INC;;CHENG HENGMIAO;;CRIPPS STEPHAN JAMES;;LAFONTAINE JENNIFER ANNE;;LE PHUONG THI QUY;;MATTHEWS JEAN JOO;;NAIR SAJIV KRISHNAN,CHENG HENGMIAO;;CRIPPS STEPHAN JAMES;;LAFONTAINE JENNIFER ANNE;;LE PHUONG THI QUY;;MATTHEWS JEAN JOO;;NAIR SAJIV KRISHNAN,,https://lens.org/154-742-653-644-151,Search Report,yes,2,0,2,2,0,A61P3/10;;C07D207/48;;C07D211/96;;C07D265/30,C07D207/48;;A61K31/403;;A61K31/435;;A61P3/10;;C07D211/96;;C07D265/30,,0,0,,,,PENDING
311,US,A1,US 2003/0192646 A1,114-550-017-968-692,2003-10-16,2003,US 12227102 A,2002-04-12,US 12227102 A,2002-04-12,Plasma processing chamber having magnetic assembly and method,"
   A magnetic assembly for a plasma processing chamber includes an annular housing having a radially outward face and a radially inwardly facing opening, a cover plate to seal the radially inwardly facing opening, and a plurality of magnets in the annular housing. The magnets may be in preassembled modules that abut one another in a ring configuration within the annular housing. A plasma processing chamber using the magnetic assembly includes a substrate support that can fit in an inner radius of the magnetic assembly, a gas supply to maintain process gas at a pressure in the chamber, a gas energizer to energize the process gas, and an exhaust to exhaust the process gas. 
",APPLIED MATERIALS INC,WU ROBERT W;;CHENG WING L;;WANG YOU;;THACH SENH;;NOORBAKHSH HAMID;;WONG KWOK MANUS;;SUN JENNIFER Y,APPLIED MATERIALS INC (2002-04-08),https://lens.org/114-550-017-968-692,Patent Application,yes,15,30,3,3,0,H01J37/32623;;H01J37/32623,H01J37/32,156/345.49;;156/345.42;;156/345.46;;156/345.51;;118/723;;118/728,0,0,,,,DISCONTINUED
312,TW,A,TW 200307999 A,038-174-476-088-992,2003-12-16,2003,TW 92108473 A,2003-04-11,US 12227102 A,2002-04-12,Plasma processing chamber having magnetic assembly and method,"A magnetic assembly for a plasma processing chamber includes an annular housing having a radially outward face and a radially inwardly facing opening, a cover plate to seal the radially inwardly facing opening, and a plurality of magnets in the annular housing. The magnets may be in pre-assembled modules that abut one another in a ring configuration within the annular housing. A plasma processing chamber using the magnetic assembly includes a substrate support that can fit in an inner radius of the magnetic assembly, a gas supply to maintain process gas at a pressure in the chamber, a gas energizer to energize the process gas, and an exhaust to exhaust the process gas.",APPLIED MATERIALS INC,WU ROBERT W;;CHENG WING L;;WANG YOU;;THACH SENH;;NOORBAKHSH HAMID;;KWOK MANUS WONG;;JENNIFER Y SUN,,https://lens.org/038-174-476-088-992,Patent of Addition,no,0,1,3,3,0,H01J37/32623;;H01J37/32623,H01J37/32,,0,0,,,,PENDING
313,WO,A1,WO 2013/154904 A1,126-066-380-199-550,2013-10-17,2013,US 2013/0035252 W,2013-04-04,US 201213443103 A,2012-04-10,METHOD AND SYSTEM TO MANAGE INTERACTIVE CONTENT DISPLAY PANELS,"A method for managing information displayed on a computing device includes automatically creating, using an application executed by a processor of the computing device, an interactive content display panel, wherein the interactive content display panel includes a graphical user interface element associated with HTML content. The interactive content display panel is displayed in front of all other windows displayed in a work area of a display of the computing device. The displaying includes automatically adjusting the size the interactive content display panel, based on updates to the HTML content, and automatically positioning the interactive content display panel in the display, based on the automatic adjustment of the size of the interactive content display panel and based on available space in the work area of the display.",GOOGLE INC;;BRAITHWAITE JENNIFER WAI-FUNG;;TITOV DMITRY;;LEVIN DAVID EDWIN;;LI JIAN;;CHENG DANIEL;;MOORE KENNETH BRIAN;;TAMMANA PRASAD,BRAITHWAITE JENNIFER WAI-FUNG;;TITOV DMITRY;;LEVIN DAVID EDWIN;;LI JIAN;;CHENG DANIEL;;MOORE KENNETH BRIAN;;TAMMANA PRASAD,,https://lens.org/126-066-380-199-550,Patent Application,yes,5,3,2,2,0,G06Q10/10;;G06F9/451;;G06F16/958;;G06Q10/10;;G06F9/451;;G06F16/958,G06F9/44;;G06F17/30;;G06Q10/10,,0,0,,,,PENDING
314,BR,A2,BR PI0714708 A2,109-429-465-435-78X,2013-05-14,2013,BR PI0714708 A,2007-07-25,US 83328806 P;;US 2007/0016775 W,2006-07-26,poli[etileno glicol] hidrofobicamente modificado para uso no controle de breu e cola em polpa e nos processos de fabricaÇço de papel,POLI(ETILENO GLICOL] HIDROFOBICAMENTE MODIFICADO PARA USO NO CONTROLE DE BREU E COLA EM POLPA E NOS PROCESSOS DE FABRICAÇçO DE PAPEL. Métodos para inibir as sedimentações de contaminadores orgânicos da polpa em sistemas de polpa e fabricação de papel são descritos. O poli[etileno glicol] hidrofobicamente modificado é adicionado à polpa ou aplicado para as superfícies propensas à sedimentação de um sistema de fabricação de papel.,HERCULES INC,GU QU-MING;;CHENG HUAI N;;CAREY WILLIAM;;GELMAN ROBERT A;;RITTEN-HOUSE-PRUSS JENNIFER;;DOHERTY ERIN A S,"SOLENIS TECHNOLOGIES CAYMAN, L.P. (CH) (2016-04-12)",https://lens.org/109-429-465-435-78X,Patent Application,no,0,0,21,21,0,C08G65/22;;C08G65/2609;;D21C9/008;;D21H21/02;;C08G2650/34;;C08G65/22;;C08G65/2609;;C08G2650/34;;D21C9/008;;D21H21/02;;D21H21/02;;C08G2650/34;;C08G65/22;;D21C9/008;;C08G65/2609,D21H21/02;;C08L71/02;;C11D1/722;;D21C9/00,,0,0,,,,ACTIVE
315,US,A1,US 2015/0256415 A1,007-585-103-912-32X,2015-09-10,2015,US 201313937646 A,2013-07-09,US 201313937646 A,2013-07-09,BROWSER NOTIFICATIONS,"A non-transitory computer-readable storage medium may comprise instructions stored thereon that, when executed by at least one processor, are configured to cause an intermediary server to at least receive, from a first client device, a first login request via a first browser installed on the first client device, the first login request identifying a user account, receive, from a third-party server, a message request, the message request including an identifier and indicating a browser application or a browser extension, map the identifier to the user account, determine whether the user account has installed the browser application or browser extension, and if the user account has installed the browser application or browser extension, send a first message to the first browser based on the message request.",GOOGLE INC,WILLIAMSON PETER HUNT;;CHENG DANIEL;;THYAGARAJA SOMAS;;DEWITT JUSTIN;;DOSHI MUNJAL;;TITOV DMITRY;;BRAITHWAITE JENNIFER WAI-FUNG;;LIU KEVIN,GOOGLE LLC (2013-08-05),https://lens.org/007-585-103-912-32X,Patent Application,yes,0,21,2,2,0,H04L67/34;;H04L67/02;;H04L67/53;;H04L67/34;;H04L67/53;;H04L67/02,H04L12/24,,0,0,,,,INACTIVE
316,EA,B1,EA 025366 B1,018-630-397-387-151,2016-12-30,2016,EA 201270571 A,2010-10-26,US 25498209 P;;US 38128710 P;;US 2010/0054148 W,2009-10-26,"HUMAN ISOLATED IL-23 ANTIGEN BINDING PROTEINS, METHODS OF PRODUCTION AND USE THEREOF","The invention relates to isolated antigen binding proteins that bind to human IL-23 protein, and to a method of production thereof. Nucleic acids encoding the antigen binding protein, vectors, and cells encoding the same, and pharmaceutical compositions comprising said protein are also provided. The antigen binding proteins are used for purposes of diagnosing and therapy of diseases or conditions related to human IL-23 or reducing IL-23 activity.",AMGEN INC,TOWNE JENNIFER E;;CHENG JANET D;;O'NEILL JASON C;;ZHANG YU;;CERNE HEATHER;;PIPER DEREK E;;KETCHEM RANDAL R,,https://lens.org/018-630-397-387-151,Granted Patent,no,6,0,86,87,0,A61K2039/505;;C07K2317/21;;C07K2317/55;;C07K2317/92;;A61K47/6845;;C07K16/244;;A61P37/00;;C07K16/244;;A61K2039/505;;C07K2317/626;;C07K2317/21;;C07K2317/76;;A61K47/6845;;C07K2317/54;;A61K39/395;;C07K2317/31;;C07K16/24;;A61P37/00;;C07K2317/92;;C07K2317/24;;C07K2317/622;;C07K2317/55;;C07K2317/565;;A61K39/00;;A61K39/395;;A61K39/39533;;A61K39/3955;;C07K16/18;;C07K16/24;;C07K16/244;;A61K2039/505;;C07K2317/21;;C07K2317/55;;C07K2317/92;;A61K47/6845;;C07K16/244;;A61K39/395;;C07K16/24;;C07K2317/24;;C07K2317/31;;C07K2317/54;;C07K2317/565;;C07K2317/622;;C07K2317/626;;C07K2317/76,C07K16/24;;A61K39/395,,3,3,019-397-556-890-001;;000-861-223-602-303;;003-570-249-164-056,18708069;;10.1016/j.jmb.2008.08.001;;10.1093/protein/gzp073;;20022918;;18606226;;10.1016/j.coi.2008.06.004,"BEYER, B.M. ; INGRAM, R. ; RAMANATHAN, L. ; REICHERT, P. ; LE, H.V. ; MADISON, V. ; ORTH, P.: ""Crystal Structures of the Pro-Inflammatory Cytokine Interleukin-23 and Its Complex with a High-Affinity Neutralizing Antibody"", JOURNAL OF MOLECULAR BIOLOGY, ACADEMIC PRESS, UNITED KINGDOM, vol. 382, no. 4, 17 October 2008 (2008-10-17), United Kingdom, pages 942 - 955, XP025409951, ISSN: 0022-2836, DOI: 10.1016/j.jmb.2008.08.001;;MABRY R., ET AL: ""Engineering of stable bispecific antibodies targeting IL-17A and IL-23"", PROTEIN ENGINEERING, DESIGN AND SELECTION, OXFORD JOURNAL, LONDON, GB, vol. 23, no. 3, 1 March 2010 (2010-03-01), GB, pages 115 - 127, XP002616663, ISSN: 1741-0126, DOI: 10.1093/protein/gzp073;;LONBERG, N.: ""Fully human antibodies from transgenic mouse and phage display platforms"", CURRENT OPINION IN IMMUNOLOGY., ELSEVIER, OXFORD., GB, vol. 20, no. 4, 1 August 2008 (2008-08-01), GB, pages 450 - 459, XP023612045, ISSN: 0952-7915, DOI: 10.1016/j.coi.2008.06.004",ACTIVE
317,US,A1,US 2019/0376202 A1,124-469-923-401-940,2019-12-12,2019,US 201916433990 A,2019-06-06,US 201916433990 A;;US 201862683379 P,2018-06-11,ENHANCED ANODIZATION FOR PROCESSING EQUIPMENT,"An enhanced anodization method includes forming a porous anodization layer comprising columns of anodization layer material with pores between adjacent columns. The method further includes sealing the porous layer by forming a sealing layer at a top of the porous layer. The sealing layer may be formed by using a hybrid sealing process that combines, in any order, two or more of de-ionized (DI) water seal, Ni sealing, and, PTFE sealing. Alternatively, the sealing layer is formed by conformally coating the columns in the porous layer with one or more layers of a coating material. Further, the coating material may be surface-fluorinated to improve plasma resistance.",APPLIED MATERIALS INC,HE XIAO-MING;;SUN JENNIFER Y;;FENWICK DAVID;;CHOU CHENG-HSUAN;;WU XIAOWEI;;RAMALINGAM CHIDAMBARA A;;RICE MICHAEL R,,https://lens.org/124-469-923-401-940,Patent Application,yes,0,2,1,1,0,C25D11/246;;C25D11/246;;C25D11/06;;C25D11/18;;C25D11/20,C25D11/24;;C25D11/20,,0,0,,,,DISCONTINUED
318,EP,A2,EP 1085857 A2,118-820-889-320-917,2001-03-28,2001,EP 99930442 A,1999-06-18,US 9913875 W;;US 8987998 P,1998-06-19,CATIONIC AMPHIPHILE MICELLAR COMPLEXES,,GENZYME CORP,TOUSIGNANT JENNIFER D;;EASTMAN SIMON J;;CHU QUIMING;;LEE EDWARD R;;NIETUPSKI JANNIFER;;SCHEULE RONALD;;CHENG SENG;;MARSHALL JOHN,,https://lens.org/118-820-889-320-917,Patent Application,yes,0,0,7,7,0,A61K9/1272;;A61K47/6907;;A61K47/6911,C12N15/00;;A61K9/00;;A61K9/127;;A61K31/711;;A61K39/395;;A61K47/24;;A61K47/34;;A61K47/42;;A61K47/44;;A61K47/48;;A61K48/00,,1,0,,,See references of WO 9965461A3,DISCONTINUED
319,US,B2,US 10002480 B2,011-527-088-777-869,2018-06-19,2018,US 201615017357 A,2016-02-05,US 201615017357 A,2016-02-05,Apparatus and methods for entry control over a cellular network,"Apparatus and methods for controlling physical access to a location include an entry system including at least one barrier at the physical location, with the barrier configured to selectively permit access into and/or from and/or within the physical location upon proper credentials and/or authorization. A cellular device is connected to or integrated with the entry system and is configured to transmit and receive voice and/or data information to the entry system that includes the credentials and/or authorization. The cellular device can be a retrofit to prior art/installed systems, can be external to an otherwise operational system, and/or can be integrated natively into the entry system. Methods and apparatus are disclosed to determine the power status and network link state of the cellular device and/or to establish communication through/to same, as well as for the cellular device to be connected to and control a plurality of entry systems and/or barriers. A plurality of entry systems and/or barriers can be controlled by one or more cellular devices, and the usage (and associated billing charges from cellular service providers) on any/all of those cellular devices monitored and selected to optimize (reduce) the expense of any data or other charges imposed by a cellular carrier associated with the cellular device. Optimization can include allocation to the aforementioned voice and/or data cellular plans related to specific of the plurality of entry systems and/or barriers.",DOORKING INC,RICHMOND THOMAS R;;RICHMOND SUZANNE;;KOCHIE PATRICK S;;CHENG YU JENNIFER;;BEAR EITAN T;;GUEORGUIEVA NADEJDA V;;CEBALLOS EMMANUEL G,DOORKING INC (2016-05-18),https://lens.org/011-527-088-777-869,Granted Patent,yes,6,1,2,2,0,G07C9/00817;;G07C2009/00761;;G07C2009/00793;;H04M15/00;;H04M15/68;;H04W4/24;;G07C9/00309;;H04W4/021;;H04W4/14;;H04M15/8033;;H04M1/72412;;G07C9/00309;;H04W4/021;;H04W4/14;;H04M15/8033;;G07C2009/0038;;G07C9/00817;;G07C2009/00761;;G07C2009/00793;;H04M15/68;;H04W4/24;;H04M15/00;;G07C9/257;;H04M1/72412,H04M11/00;;G07C9/00;;H04M1/72412;;H04M15/00;;H04W4/02;;H04W4/14,,0,0,,,,ACTIVE
320,CN,A,CN 108075061 A,036-168-224-198-876,2018-05-25,2018,CN 201610987137 A,2016-11-09,CN 201610987137 A,2016-11-09,Battery pack,"The invention provides a battery pack used for hybrid power vehicles. The battery pack comprises a plurality of battery units, a shell, a first end plate, a second end plate, a carrier plate and an upper cover, wherein the shell is provided with a bottom and a side wall extending from the bottom to the periphery, and an upper opening is formed in the shell; the shell is used for accommodating thebattery units and the two end plates; when the battery units are sequentially installed in the shell, the first end plate and the second end plate are positioned at two ends of the sequentially arranged battery units, and are used for transversely fixing the battery units; the carrier plate is installed at the upper parts of the tops of the battery units; the upper cover is installed at the upperpart of the shell so that the upper opening of the shell covers.",JOHNSON CONTROLS TECH CO,FAN BINBIN;;CHENG LIANG;;QU WEI;;SONG PENG;;FU YINGYAO;;LIU CHANG;;MARTIN WIEGMANN;;JENNIFER CZARNECKI;;JASON FUHR;;XUGANG ZHANG,,https://lens.org/036-168-224-198-876,Patent Application,no,9,10,9,9,0,H01M50/284;;H01M50/244;;H01M50/51;;H01M50/249;;H01M50/204;;H01M50/258;;H01M50/289;;H01M10/613;;H01M10/625;;H01M10/6563;;H01M10/6566;;H01M10/482;;H01M2010/4271;;H01M2200/103;;H01M2220/20;;H01M10/625;;H01M10/6563;;H01M10/613;;F04D25/0613;;F04D29/601;;H01M50/24;;H01M50/3425;;H01M50/553;;H01M50/507;;H01M50/367;;H01M50/284;;H01M50/55;;H01M50/51;;H01M50/583;;H01M50/244;;H01M50/271;;H01M50/298;;H01M50/209;;H01M50/517;;H01M50/296;;H01M50/242;;H01M50/227;;Y02E60/10;;B60L50/64;;B60L58/26;;F04D25/0673;;F04D29/601;;H01M10/425;;H01M2010/4271;;H01M2220/20;;H01M50/342;;H01M10/482;;H01M50/55;;H01M50/367;;H01M50/583;;H01M50/517;;H01M50/507;;H01M50/553;;H01M50/242;;H01M50/227;;H01M50/296;;H01M50/284;;H01M50/298;;H01M50/271;;H01M50/244;;H01M50/209;;H01M50/51,B60L11/18;;H01M50/209;;H01M50/227;;H01M50/242;;H01M50/244;;H01M50/249;;H01M50/271;;H01M50/284;;H01M50/296;;H01M50/298;;H01M50/367;;H01M50/507;;H01M50/51;;H01M50/517;;H01M50/55;;H01M50/553;;H01M50/583,,0,0,,,,ACTIVE
321,US,B2,US 10755900 B2,109-060-928-925-850,2020-08-25,2020,US 201815965794 A,2018-04-27,US 201815965794 A;;US 201762504471 P,2017-05-10,Multi-layer plasma erosion protection for chamber components,"A method of applying a multi-layer plasma resistant coating on an article comprises performing plating or ALD to form a conformal first plasma resistant layer on an article, wherein the conformal first plasma resistant layer is formed on a surface of the article and on walls of high aspect ratio features in the article. The conformal first plasma resistant coating has a porosity of approximately 0% and a thickness of approximately 200 nm to approximately 1 micron. One of electron beam ion assisted deposition (EB-IAD), plasma enhanced chemical vapor deposition (PECVD), aerosol deposition or plasma spraying is then performed to form a second plasma resistant layer that covers the conformal first plasma resistant layer at a region of the surface but not at the walls of the high aspect ratio features.",APPLIED MATERIALS INC,TRAN TOAN;;KALITA LAKSHESWAR;;KIM TAE WON;;LUBOMIRSKY DMITRY;;WU XIAOWEI;;HE XIAO-MING;;CHOU CHENG-HSUAN;;SUN JENNIFER Y,APPLIED MATERIALS INC (2018-08-23),https://lens.org/109-060-928-925-850,Granted Patent,yes,110,6,12,12,0,H01J37/32477;;H01J37/32495;;C23C16/04;;C23C16/40;;C23C16/4404;;C23C16/45544;;C23C16/45565;;C23C28/042;;C23C24/04;;C25D7/123;;C23C18/36;;H01J37/32495;;C23C16/403;;C23C16/0254;;H01J37/32477;;H01J37/32495;;C23C16/403;;H01J2237/0203;;C23C16/0254;;C23C16/45525;;C23C28/042;;C23C16/45544;;C23C18/36;;C23C16/04;;C23C16/4404;;C23C16/45565;;C25D7/123;;C23C16/40;;C23C24/04;;H01J37/32477,C23C16/40;;C23C16/02;;C23C16/04;;C23C16/44;;C23C16/455;;C23C18/36;;C23C24/04;;C23C28/04;;C25D7/12;;H01J37/32,,0,0,,,,ACTIVE
322,CN,A,CN 105412075 A,010-338-005-620-323,2016-03-23,2016,CN 201510759398 A,2015-11-10,CN 201510759398 A,2015-11-10,Application of dihydroartemisinin to preparing medicine for treating osteoporosis,"The invention discloses application of dihydroartemisinin to preparing medicine for treating osteoporosis. An inventor deeply researches dihydroartemisinin on the basis of limitation of existing application of dihydroartemisinin, finds that dihydroartemisinin can inhibit osteoclast differentiation and formation and bone resorption activity and finds that dihydroartemisinin has an obvious bone loss prevention function in animal bodies so that dihydroartemisinin can be used for treating osteoporosis. The direct effect of dihydroartemisinin on osteoporosis is reported for the first time in the application, medicinal value of dihydroartemisinin is analyzed, the blank in the field at home and abroad is made up for, and new application of dihydroartemisinin is exploited. Dihydroartemisinin belongs to natural plant active products, so that sources of dihydroartemisinin is wide, and dihydroartemisinin has wide market prospects and high economic value in the aspect of application to preparation of medicine for treating osteoporosis..",JIAKE XU;;ZHOU LIN;;LIU QIAN;;WANG TAO,JIAKE XU;;ZHOU LIN;;LIU QIAN;;YANG MINGLI;;WANG TAO;;YAO JUN;;CHENG JIANWEN;;YUAN JINBO;;ZHAO JINMIN;;JENNIFER TICKNER,,https://lens.org/010-338-005-620-323,Patent Application,no,1,0,1,1,0,,A61K31/357;;A61P19/10,,2,0,,,"冯明宣等: ""双氢青蒿素通过AKT/ Src通路抑制钛颗粒介导的骨吸收"", 《2015年浙江省骨质疏松与骨矿盐疾病学术年会暨骨质疏松症和骨质疏松性骨折诊治进展专题研讨会论文汇编》;;YE JI等: ""Anti-tumor effects of dihydroartemisinin on human osteosarcoma"", 《MOLECULAR AND CELLULAR BIOCHEMISTRY》",DISCONTINUED
323,CR,A,CR 20120210 A,048-407-738-149-124,2012-07-20,2012,CR 20120210 A,2012-04-26,US 25498209 P;;US 38128710 P,2009-10-26,PROTEÍNAS DE ENLACE AL ANTIGENO IL-23 HUMANAS,Se proporcionan proteinas de enlace al antigeno que enlazan a la proteina IL-23 humano.,AMGEN INC,TOWNE E JENNIFER;;CHENG D JANET;;O'NEILL JASON;;ZHANG YU;;SUN YU;;CERNE HEATHER;;PIPER E DEREK;;KETCHEM R RANDAL,,https://lens.org/048-407-738-149-124,Patent Application,no,0,0,86,87,0,A61K2039/505;;C07K2317/21;;C07K2317/55;;C07K2317/92;;A61K47/6845;;C07K16/244;;A61P37/00;;C07K16/244;;A61K2039/505;;C07K2317/626;;C07K2317/21;;C07K2317/76;;A61K47/6845;;C07K2317/54;;A61K39/395;;C07K2317/31;;C07K16/24;;A61P37/00;;C07K2317/92;;C07K2317/24;;C07K2317/622;;C07K2317/55;;C07K2317/565;;A61K39/00;;A61K39/395;;A61K39/39533;;A61K39/3955;;C07K16/18;;C07K16/24;;C07K16/244;;A61K2039/505;;C07K2317/21;;C07K2317/55;;C07K2317/92;;A61K47/6845;;C07K16/244;;A61K39/395;;C07K16/24;;C07K2317/24;;C07K2317/31;;C07K2317/54;;C07K2317/565;;C07K2317/622;;C07K2317/626;;C07K2317/76,C07K16/24;;A61K39/395,,0,0,,,,PENDING
324,US,B2,US 8388806 B2,152-821-471-236-328,2013-03-05,2013,US 88112807 A,2007-07-25,US 88112807 A;;US 83328806 P,2006-07-26,Hydrophobically modifed poly[ethylene glycol] for use in pitch and stickies control in pulp and papermaking processes,Methods for inhibiting the depositions of organic contaminants from pulp in pulp and papermaking systems are disclosed. Hydrophobically modified poly[ethylene glycol] are added to the pulp or applied to deposition-prone surfaces of a papermaking system.,GU QU-MING;;CHENG HUAI N;;CAREY WILLIAM S;;GELMAN ROBERT A;;RITTENHOUSE-PRUSS JENNIFER L;;DOHERTY ERIN A S;;HERCULES INC,GU QU-MING;;CHENG HUAI N;;CAREY WILLIAM S;;GELMAN ROBERT A;;RITTENHOUSE-PRUSS JENNIFER L;;DOHERTY ERIN A S,HERCULES INCORPORATED (2007-07-20),https://lens.org/152-821-471-236-328,Granted Patent,yes,12,6,21,21,0,C08G65/22;;C08G65/2609;;D21C9/008;;D21H21/02;;C08G2650/34;;C08G65/22;;C08G65/2609;;C08G2650/34;;D21C9/008;;D21H21/02;;D21H21/02;;C08G2650/34;;C08G65/22;;D21C9/008;;C08G65/2609,D21H21/02,162/158;;162/72;;162/199,2,0,,,"Polyethylene Glycols data sheet, JECFA, published FNP 38 1988, downloaded online Apr. 6, 2012.;;Chemical Abstracts 82:18896.",ACTIVE
325,CN,B,CN 102741285 B,178-745-366-824-98X,2015-03-25,2015,CN 201080059062 A,2010-10-26,US 2010/0054148 W;;US 25498209 P;;US 38128710 P,2009-10-26,Human IL-23 antigen binding proteins,,AMGEN INC,TOWNE JENNIFER E;;CHENG JANET D;;O'NEILL JASON C;;ZHANG YU;;SUN YU;;CERNE HEATHER;;PIPER DEREK E;;KETCHEM RANDAL,,https://lens.org/178-745-366-824-98X,Granted Patent,no,0,0,86,87,0,A61K2039/505;;C07K2317/21;;C07K2317/55;;C07K2317/92;;A61K47/6845;;C07K16/244;;A61P37/00;;C07K16/244;;A61K2039/505;;C07K2317/626;;C07K2317/21;;C07K2317/76;;A61K47/6845;;C07K2317/54;;A61K39/395;;C07K2317/31;;C07K16/24;;A61P37/00;;C07K2317/92;;C07K2317/24;;C07K2317/622;;C07K2317/55;;C07K2317/565;;A61K39/00;;A61K39/395;;A61K39/39533;;A61K39/3955;;C07K16/18;;C07K16/24;;C07K16/244;;A61K2039/505;;C07K2317/21;;C07K2317/55;;C07K2317/92;;A61K47/6845;;C07K16/244;;A61K39/395;;C07K16/24;;C07K2317/24;;C07K2317/31;;C07K2317/54;;C07K2317/565;;C07K2317/622;;C07K2317/626;;C07K2317/76,C07K16/24;;A61K39/395,,0,0,,,,ACTIVE
326,CN,A,CN 114583369 A,053-238-122-905-485,2022-06-03,2022,CN 202210145475 A,2016-11-09,CN 202210145475 A;;CN 201610987137 A,2016-11-09,Battery pack,"The invention provides a battery pack used for a hybrid vehicle, the battery pack comprises a plurality of battery units, a shell, a first end plate, a second end plate, a carrier plate and an upper cover, the shell is provided with a bottom and side walls extending from the periphery of the bottom and forms an upper opening, the shell is used for accommodating the plurality of battery units and the two end plates, and the first end plate and the second end plate are arranged in the shell. When the plurality of battery units are sequentially arranged and installed in the shell, the first end plate and the second end plate are located on the two end sides of the plurality of battery units which are sequentially arranged and used for transversely fixing the plurality of battery units, the carrier plate is installed on the upper portions of the tops of the plurality of battery units, and the upper cover is installed on the upper portion of the shell so as to cover an upper opening of the shell.",CPS SCIENCE AND TECH CONTROLLED LIMITED COMPANY,FAN BINBIN;;CHENG LIANG;;QU WEI;;SONG PENG;;FU YINGYAO;;LIU CHANG;;FUHR JASON;;WIEGMANN MARTIN;;ZHANG XUGANG;;CZARNECKI JENNIFER,,https://lens.org/053-238-122-905-485,Patent Application,no,0,0,9,9,0,H01M50/284;;H01M50/244;;H01M50/51;;H01M50/249;;H01M50/204;;H01M50/258;;H01M50/289;;H01M10/613;;H01M10/625;;H01M10/6563;;H01M10/6566;;H01M10/482;;H01M2010/4271;;H01M2200/103;;H01M2220/20;;H01M10/625;;H01M10/6563;;H01M10/613;;F04D25/0613;;F04D29/601;;H01M50/24;;H01M50/3425;;H01M50/553;;H01M50/507;;H01M50/367;;H01M50/284;;H01M50/55;;H01M50/51;;H01M50/583;;H01M50/244;;H01M50/271;;H01M50/298;;H01M50/209;;H01M50/517;;H01M50/296;;H01M50/242;;H01M50/227;;Y02E60/10;;B60L50/64;;B60L58/26;;F04D25/0673;;F04D29/601;;H01M10/425;;H01M2010/4271;;H01M2220/20;;H01M50/342;;H01M10/482;;H01M50/55;;H01M50/367;;H01M50/583;;H01M50/517;;H01M50/507;;H01M50/553;;H01M50/242;;H01M50/227;;H01M50/296;;H01M50/284;;H01M50/298;;H01M50/271;;H01M50/244;;H01M50/209;;H01M50/51,H01M50/249;;H01M10/613;;H01M10/625;;H01M10/6563;;H01M10/6566;;H01M50/204;;H01M50/209;;H01M50/227;;H01M50/242;;H01M50/244;;H01M50/258;;H01M50/271;;H01M50/284;;H01M50/289;;H01M50/296;;H01M50/298;;H01M50/367;;H01M50/507;;H01M50/51;;H01M50/517;;H01M50/55;;H01M50/553;;H01M50/583,,0,0,,,,PENDING
327,TW,U,TW M574331 U,180-363-471-813-535,2019-02-11,2019,TW 107206105 U,2018-05-10,US 201762504471 P;;US 201815965794 A,2017-05-10,Article having multi-layer plasma erosion protection,"A method of applying a multi-layer plasma resistant coating on an article comprises performing plating or ALD to form a conformal first plasma resistant layer on an article, wherein the conformal first plasma resistant layer is formed on a surface of the article and on walls of high aspect ratio features in the article. The conformal first plasma resistant coating has a porosity of approximately 0% and a thickness of approximately 200 nm to approximately 1 micron. One of electron beam ion assisted deposition (EB-IAD), plasma enhanced chemical vapor deposition (PECVD), aerosol deposition or plasma spraying is then performed to form a second plasma resistant layer that covers the conformal first plasma resistant layer at a region of the surface but not at the walls of the high aspect ratio features.",APPLIED MATERIALS INC,TRAN TOAN;;LAKSHESWAR KALITA;;KIM TAE-WON;;LUBOMIRSKY DMITRY;;WU XIAO-WEI;;HE XIAOMING;;CHOU CHENG-HSUAN;;SUN JENNIFER Y,,https://lens.org/180-363-471-813-535,Limited Patent,no,0,1,12,12,0,H01J37/32477;;H01J37/32495;;C23C16/04;;C23C16/40;;C23C16/4404;;C23C16/45544;;C23C16/45565;;C23C28/042;;C23C24/04;;C25D7/123;;C23C18/36;;H01J37/32495;;C23C16/403;;C23C16/0254;;H01J37/32477;;H01J37/32495;;C23C16/403;;H01J2237/0203;;C23C16/0254;;C23C16/45525;;C23C28/042;;C23C16/45544;;C23C18/36;;C23C16/04;;C23C16/4404;;C23C16/45565;;C25D7/123;;C23C16/40;;C23C24/04;;H01J37/32477,H01L21/3065,,0,0,,,,ACTIVE
328,EP,A1,EP 3181586 A1,139-588-623-436-865,2017-06-21,2017,EP 16199576 A,2010-10-26,US 25498209 P;;US 38128710 P;;EP 10774095 A,2009-10-26,HUMAN IL-23 ANTIGEN BINDING PROTEINS,"Antigen binding proteins that bind to human IL-23 protein are provided. Nucleic acids encoding the antigen binding protein, vectors, and cells encoding the same as well as use of IL-23 antigen binding proteins for diagnostic and therapeutic purposes are also provided.",AMGEN INC,TOWNE JENNIFER;;O'NEILL JASON C;;ZHANG YU;;SUN YU;;CERNE HEATHER;;PIPER DEREK E;;KETCHEM RANDAL R;;CHENG JANET D,,https://lens.org/139-588-623-436-865,Patent Application,yes,71,2,86,87,155,A61K2039/505;;C07K2317/21;;C07K2317/55;;C07K2317/92;;A61K47/6845;;C07K16/244;;A61P37/00;;C07K16/244;;A61K2039/505;;C07K2317/626;;C07K2317/21;;C07K2317/76;;A61K47/6845;;C07K2317/54;;A61K39/395;;C07K2317/31;;C07K16/24;;A61P37/00;;C07K2317/92;;C07K2317/24;;C07K2317/622;;C07K2317/55;;C07K2317/565;;A61K39/00;;A61K39/395;;A61K39/39533;;A61K39/3955;;C07K16/18;;C07K16/24;;C07K16/244;;A61K2039/505;;C07K2317/21;;C07K2317/55;;C07K2317/92;;A61K47/6845;;C07K16/244;;A61K39/395;;C07K16/24;;C07K2317/24;;C07K2317/31;;C07K2317/54;;C07K2317/565;;C07K2317/622;;C07K2317/626;;C07K2317/76,C07K16/24;;A61K39/395,,159,117,019-397-556-890-001;;000-861-223-602-303;;003-570-249-164-056;;027-477-313-726-928;;002-771-789-858-985;;039-460-067-637-00X;;068-238-957-669-243;;084-232-242-673-081;;059-694-149-712-381;;114-738-893-000-504;;000-879-344-254-347;;066-119-584-271-19X;;113-982-061-284-768;;016-815-797-562-455;;015-979-728-056-035;;039-724-297-100-685;;098-276-747-378-726;;050-176-401-076-536;;041-241-834-308-816;;019-397-556-890-001;;106-248-968-254-022;;024-413-081-573-499;;014-277-808-472-992;;029-745-513-975-612;;061-754-151-573-898;;113-327-994-370-771;;064-787-766-418-165;;012-273-285-250-15X;;043-293-799-149-190;;073-260-982-304-977;;193-574-402-839-215;;163-587-638-794-871;;023-907-179-348-058;;032-728-154-591-070;;049-134-753-209-354;;024-995-475-936-443;;027-903-185-617-733;;019-982-436-313-59X;;030-607-398-087-475;;006-574-964-805-278;;042-204-626-457-327;;045-094-249-115-990;;040-428-679-610-399;;089-899-040-309-502;;032-820-729-763-323;;043-108-278-056-872;;050-836-464-727-069;;071-707-020-428-907;;023-468-000-960-289;;060-375-551-951-388;;083-549-078-331-651;;020-753-772-581-741;;038-613-711-274-229;;016-219-576-017-946;;032-071-991-081-664;;020-855-322-534-259;;040-577-067-037-463;;104-212-297-137-759;;017-150-654-990-340;;002-264-966-090-625;;162-131-697-723-828;;036-431-051-779-618;;052-714-495-277-870;;066-749-017-721-197;;001-467-559-709-949;;040-397-285-492-490;;103-477-074-900-777;;063-263-492-125-344;;129-978-431-330-653;;015-109-431-185-638;;067-226-137-053-81X;;032-055-913-011-134;;003-246-587-515-619;;130-802-862-883-854;;076-270-369-964-609;;129-447-558-597-627;;079-975-841-354-505;;034-705-920-623-82X;;106-794-363-564-085;;150-526-239-777-942;;069-863-076-076-464;;052-835-629-769-725;;105-521-401-667-801;;056-196-705-544-876;;013-281-398-303-904;;085-329-927-828-899;;154-374-780-007-386;;068-962-117-616-007;;017-449-753-661-071;;039-141-300-950-038;;003-278-824-816-658;;115-435-737-255-802;;010-670-795-970-321;;010-916-105-450-247;;011-724-225-446-939;;061-444-349-075-997;;052-327-980-622-279;;102-808-907-197-009;;065-114-602-989-551;;101-171-874-734-776;;026-974-217-132-522;;020-236-161-344-688;;086-016-360-704-586;;067-057-135-512-133;;021-074-280-354-982;;071-662-142-202-504;;001-910-820-229-599;;055-578-442-289-160;;000-999-407-005-345;;021-991-205-274-008;;005-984-586-162-249;;021-512-087-228-498;;003-598-409-932-232;;017-927-510-116-179;;048-819-440-392-261;;054-418-959-978-111;;023-476-471-521-012,18708069;;10.1016/j.jmb.2008.08.001;;10.1093/protein/gzp073;;20022918;;18606226;;10.1016/j.coi.2008.06.004;;10.1073/pnas.79.6.1979;;pmc346105;;6804947;;10.4049/jimmunol.165.8.4505;;11035090;;20956338;;pmc3776381;;10.4049/jimmunol.1001538;;10556249;;10.1093/protein/12.10.879;;10082364;;10.1002/pro.5560070802;;pmc2144089;;pmc2142342;;8443598;;10.1002/pro.5560020209;;012023369;;10.4049/jimmunol.168.11.5699;;12023369;;19161422;;10.1111/j.1600-065x.2008.00705.x;;12610626;;10.1038/nature01355;;17888176;;pmc2212562;;10.1186/ar2297;;17291186;;10.1146/annurev.immunol.22.012703.104758;;10.1093/rheumatology/kem055;;17569750;;16645485;;10.1097/01.qco.0000224818.42729.67;;10.1002/eji.200324038;;12778462;;10.1158/1535-7163.mct-06-0003;;16648552;;16688182;;10.1038/nature04808;;18708069;;10.1016/j.jmb.2008.08.001;;10.1016/j.jmb.2008.07.051;;18680750;;pmc2666310;;10.1016/0076-6879(83)92023-2;;6855613;;10.4049/jimmunol.137.11.3614;;2431039;;10.1016/0161-5890(88)90085-5;;3343974;;10.1016/0042-6822(90)90025-m;;1693247;;1697100;;10.1111/j.1365-3083.1990.tb02896.x;;10.1002/prot.10497;;12945055;;10.1021/bp030070k;;15176864;;9041643;;pmc2143633;;10.1002/pro.5560060217;;11968500;;10.1385/1-59259-240-6:303;;10.1385/0896032469;;8205184;;10.1385/0896032760;;8004156;;10.1385/0-89603-276-0:1;;10.1385/0-89603-246-9:1;;10.1007/978-1-349-21355-9;;pmc50453;;1438297;;10.1073/pnas.89.22.10915;;10.1016/0022-2836(70)90057-4;;5420325;;10.1016/0022-2836(87)90412-8;;3681981;;10.1038/342877a0;;2687698;;15572068;;10.1016/j.dci.2004.07.003;;11397087;;10.1006/jmbi.2001.4662;;pmc392030;;10.1073/pnas.81.21.6851;;6436822;;10.1038/321522a0;;3713831;;3127726;;10.1038/332323a0;;10.1126/science.2451287;;2451287;;10.1073/pnas.90.6.2551;;8460171;;pmc46126;;8459850;;10.1038/362255a0;;8159246;;10.1038/368856a0;;7494109;;10.3109/08830189509061738;;10.1111/j.1749-6632.1995.tb55879.x;;7486582;;1475190;;10.1093/nar/20.23.6287;;pmc334518;;10.1093/intimm/5.6.647;;8347558;;8144892;;10.1007/978-3-642-78432-3_3;;10.1093/intimm/6.4.579;;8018598;;10.1038/nbt0796-845;;9631008;;pmc4119940;;25033887;;10.1038/ng0297-146;;9020839;;10.1016/0022-2836(92)90894-p;;1404359;;1748994;;10.1016/0022-2836(91)90498-u;;2180597;;pmc1534963;;10.1111/j.1365-2249.1990.tb08089.x;;10.4049/jimmunol.148.5.1547;;1531669;;3140379;;10.1126/science.3140379;;10.1073/pnas.85.16.5879;;3045807;;pmc281868;;11968507;;10.1385/1-59259-240-6:379;;11566601;;10.1016/s1389-0344(01)00090-9;;10.1016/s1389-0344(01)00083-1;;11535414;;8341653;;10.1073/pnas.90.14.6444;;pmc46948;;10.1016/s0969-2126(94)00113-8;;7704521;;14985542;;10.1093/protein/gzh012;;10.1016/s0022-1759(00)00290-8;;11292488;;pmc47274;;8367454;;10.1073/pnas.90.17.7995;;7584477;;8768901;;10.1016/s0958-1669(96)80118-2;;4358940;;10.1021/bi00699a002;;10.1021/bi00699a001;;4358939;;364941;;10.1002/9780470122921.ch2;;354496;;10.1146/annurev.bi.47.070178.001343;;pmc148146;;9847191;;10.1093/nar/27.1.244;;10.1016/s0959-440x(97)80054-1;;9204279;;9204280;;10.1016/s0959-440x(97)80055-3;;8805507;;10.1016/s0969-2126(96)00005-6;;10.1126/science.1853201;;1853201;;10.1016/0076-6879(90)83011-w;;2314273;;pmc305087;;10.1073/pnas.84.13.4355;;3474607;;10.1038/354105a0;;1944583;;10.1021/jm00390a019;;2885419;;10.1146/annurev.bi.61.070192.002131;;1497316;;10.1146/annurev.biochem.61.1.387;;8187882;;10.1016/0014-5793(94)00383-1;;7532457;;10.1006/smim.1994.1035;;pmc52963;;1660140;;10.1073/pnas.88.23.10535;;10.1002/0471142735.im1019as48;;10.1002/j.1460-2075.1994.tb06715.x;;8076595;;pmc395319;;0007018830;;7018830;;2825601;;10.1016/0003-9861(87)90469-3;;10.1016/0003-2697(81)90168-8;;6175244;;2439875;;10.1016/0076-6879(87)38030-9;;10.1038/nbt0792-779;;1368267;;10.1002/bit.10790;;14574701;;10.1038/290304a0;;6259538;;6322160;;10.1073/pnas.81.3.659;;pmc344894;;6257399;;10.1016/0092-8674(80)90555-3;;358198;;pmc392859;;10.1073/pnas.75.8.3727;;6337371;;10.1073/pnas.80.1.21;;pmc393301;;10.1016/0092-8674(84)90258-7;;6567483;;3006998;;10.1101/sqb.1985.050.01.050;;10.1038/315115a0;;2986015;;6091894;;10.1016/0092-8674(84)90259-9;;pmc365231;;10.1128/mcb.7.4.1436;;10.1128/mcb.7.4.1436-1444.1987;;3037318;;10.1016/0092-8674(86)90280-1;;3011271;;10.1101/gad.1.3.268;;3678824;;10.1128/mcb.5.7.1639;;pmc367282;;2410773;;10.1128/mcb.5.7.1639-1648.1985;;10.1101/gad.1.2.161;;3500093;;10.1038/315338a0;;3858676;;3719696;;10.1016/0092-8674(86)90862-7;;10.1016/0092-8674(87)90248-0;;2434242;;2984571;;10.1038/314283a0;;10.1126/science.3097822;;3097822;;10.1038/312768a0;;6096720;;10.1107/s0907444994003112;;15299374;;10.1107/s0907444998003254;;9757107,"BEYER B M ET AL: ""Crystal Structures of the Pro-Inflammatory Cytokine Interleukin-23 and Its Complex with a High-Affinity Neutralizing Antibody"", JOURNAL OF MOLECULAR BIOLOGY, LONDON, GB, vol. 382, no. 4, 17 October 2008 (2008-10-17), pages 942 - 955, XP025409951, ISSN: 0022-2836, [retrieved on 20080807], DOI: 10.1016/J.JMB.2008.08.001;;MABRY ROBERT ET AL: ""Engineering of stable bispecific antibodies targeting IL-17A and IL-23"", PROTEIN ENGINEERING DESIGN & SELECTION, vol. 23, no. 3, March 2010 (2010-03-01), pages 115 - 127, XP002616663, ISSN: 1741-0126;;LONBERG ET AL: ""Fully human antibodies from transgenic mouse and phage display platforms"", CURRENT OPINION IN IMMUNOLOGY, ELSEVIER, OXFORD, GB, vol. 20, no. 4, 1 August 2008 (2008-08-01), pages 450 - 459, XP023612045, ISSN: 0952-7915, [retrieved on 20080721], DOI: 10.1016/J.COI.2008.06.004;;RUDIKOFF S ET AL: ""Single amino acid substitution altering antigen-binding specificity"", PROCEEDINGS NATIONAL ACADEMY OF SCIENCES PNAS, NATIONAL ACADEMY OF SCIENCES, US, vol. 79, 1 March 1982 (1982-03-01), pages 1979 - 1983, XP007901436, ISSN: 0027-8424, DOI: 10.1073/PNAS.79.6.1979;;WINKLER K ET AL: ""Changing the antigen binding specificity by single point mutations of an anti-p24 (HIV-1) antibody"", THE JOURNAL OF IMMUNOLOGY, THE AMERICAN ASSOCIATION OF IMMUNOLOGISTS, US, vol. 165, no. 8, 15 October 2000 (2000-10-15), pages 4505 - 4514, XP002579393, ISSN: 0022-1767;;G. TONEL ET AL: ""Cutting Edge: A Critical Functional Role for IL-23 in Psoriasis"", THE JOURNAL OF IMMUNOLOGY, vol. 185, no. 10, 18 October 2010 (2010-10-18), pages 5688 - 5691, XP055203326, ISSN: 0022-1767, DOI: 10.4049/jimmunol.1001538;;HIROYUKI KOBAYASHI ET AL: ""Tryptophan H33 plays an important role in pyrimidine (6-4) pyrimidone photoproduct binding by a high-affinity antibody"", PROTEIN ENGINEERING, 1 January 1999 (1999-01-01), pages 879 - 884, XP055364172, Retrieved from the Internet <URL:https://academic.oup.com/peds/article-pdf/12/10/879/9908089/120879.pdf> [retrieved on 20170412];;CASIPIT C L ET AL: ""IMPROVING THE BINDING AFFINITY OF AN ANTIBODY USING MOLECULAR MODELING AND SITE-DIRECTED MUTAGENESIS"", PROTEIN SCIENCE, WILEY, US, vol. 7, 1 August 1998 (1998-08-01), pages 1671 - 1680, XP001007633, ISSN: 0961-8368;;JOEL F. SCHILDBACH ET AL: ""Modulation of antibody affinity by a non-contact residue"", PROTEIN SCIENCE, vol. 2, no. 2, 1 February 1993 (1993-02-01), pages 206 - 214, XP055103868, ISSN: 0961-8368, DOI: 10.1002/pro.5560020209;;OPPMANN ET AL., IMMUNITY, vol. 13, 2000, pages 713 - 715;;PARHAM ET AL., J. IMMUNOL., vol. 168, 2002, pages 5699 - 708;;AHERN ET AL., IMMUN. REV., vol. 226, 2008, pages 147 - 159;;CUA ET AL., NATURE, vol. 421, 2003, pages 744 - 748;;YAGO ET AL., ARTHRITIS RES AND THER., vol. 9, no. 5, 2007, pages R96;;KASTELEIN ET AL., ANNUAL REVIEW OF IMMUNOLOGY, vol. 25, 2007, pages 221 - 42;;LIU ET AL., RHEUMATOLOGY, vol. 46, no. 8, 2007, pages 1266 - 73;;BOWMAN ET AL., CURRENT OPINION IN INFECTIOUS DISEASES, vol. 19, 2006, pages 245 - 52;;FIESCHI; CASANOVA, EUR. J. IMMUNOL., vol. 33, 2003, pages 1461 - 4;;MEERAN ET AL., MOL. CANCER THER., vol. 5, 2006, pages 825 - 32;;LANGOWSKI ET AL., NATURE, vol. 442, 2006, pages 461 - 5;;SAMBROOK ET AL.: ""Molecular Cloning: A Laboratory Manual, 3rd ed."", 2001, COLD SPRING HARBOR LABORATORY PRESS;;AUSUBEL ET AL.: ""Current Protocols in Molecular Biology"", 1992, GREENE PUBLISHING ASSOCIATES;;HARLOW; LANE: ""Antibodies: A Laboratory Manual"", 1990, COLD SPRING HARBOR LABORATORY PRESS;;BEYER ET AL., J MOL BIOL, vol. 382, no. 4, 2008, pages 942 - 55;;LUPARDUS; GARCIA, J. MOL. BIOL., vol. 382, 2008, pages 931 - 941;;E. S. GOLUB AND D. R. GREN: ""Immunology-A Synthesis, 2nd ed."", 1991, SINAUER ASSOCIATES;;STAHLI ET AL., METHODS IN ENZYMOLOGY, vol. 92, 1983, pages 242 - 253;;KIRKLAND ET AL., J. IMMUNOL., vol. 137, 1986, pages 3614 - 3619;;HARLOW; LANE: ""Antibodies, A Laboratory Manual"", 1988, COLD SPRING HARBOR PRESS;;MOREL ET AL., MOLEC. IMMUNOL., vol. 25, 1988, pages 7 - 15;;CHEUNG ET AL., VIROLOGY, vol. 176, 1990, pages 546 - 552;;MOLDENHAUER ET AL., SCAND. J. IMMUNOL., vol. 32, 1990, pages 77 - 82;;KORNDORFER ET AL., PROTEINS: STRUCTURE, FUNCTION, AND BIOINFORMATICS, vol. 53, no. 1, 2003, pages 121 - 129;;ROQUE ET AL., BIOTECHNOL. PROG., vol. 20, 2004, pages 639 - 654;;BLOOM ET AL., PROTEIN SCIENCE, vol. 6, 1997, pages 407;;LANTTO ET AL., METHODS MOL. BIOL., vol. 178, 2002, pages 303 - 316;;PAUL, W.: ""Fundamental Immunology, 2nd ed."", 1989, RAVEN PRESS, article ""Ch. 7"";;LESK, A. M.: ""Computational Molecular Biology"", 1988, OXFORD UNIVERSITY PRESS;;SMITH, D. W.: ""Biocomputing Informatics and Genome Projects"", 1993, ACADEMIC PRESS;;GRIFFIN, A. M., AND GRIFFIN, H. G.: ""Computer Analysis of Sequence Data"", 1994, HUMANA PRESS;;VON HEINJE, G.: ""Sequence Analysis in Molecular Biology"", 1987, ACADEMIC PRESS;;GRIBSKOV, M. AND DEVEREUX, J.: ""Sequence Analysis Primer"", 1991, M. STOCKTON PRESS;;CARILLO ET AL., SIAM J. APPLIED MATH., vol. 48, 1988, pages 1073;;DAYHOFF ET AL.: ""Atlas of Protein Sequence and Structure"", vol. 5, 1978, pages: 345 - 352;;HENIKOFF ET AL., PROC. NATL. ACAD. SCI. U.S.A., vol. 89, 1992, pages 10915 - 10919;;NEEDLEMAN ET AL., J. MOL. BIOL., vol. 48, 1970, pages 443 - 453;;KABAT ET AL.: ""Sequences of Proteins of Immunological Interest, 5th ed."", 1991, PHS, NIH, NIH PUBLICATION NO. 91-3242;;CHOTHIA; LESK, J. MOL. BIOL., vol. 196, 1987, pages 901 - 917;;CHOTHIA ET AL., NATURE, vol. 342, 1989, pages 878 - 883;;LEFRANC ET AL., DEV. COMP. IMMUNOL., vol. 29, 2005, pages 185 - 203;;HONEGGER; PLUCKTHUN, J. MOL. BIOL., vol. 309, no. 3, 2001, pages 657 - 670;;MORRISON, PROC. NATL. ACAD. SCI. USA, vol. 81, 1985, pages 6851 - 6855;;JONES ET AL., NATURE, vol. 321, 1986, pages 522 - 525;;RIECHMANN ET AL., NATURE, vol. 332, 1988, pages 323 - 27;;VERHOEYEN ET AL., SCIENCE, vol. 239, 1988, pages 1534 - 1536;;JAKOBOVITS ET AL., PROC. NATL. ACAD. SCI. USA, vol. 90, 1993, pages 2551 - 2555;;JAKOBOVITS ET AL., NATURE, vol. 362, 1993, pages 255 - 258;;BRUGGERMANN ET AL., YEAR IN IMMUNOL., vol. 7, 1993, pages 33;;LONBERG ET AL., NATURE, vol. 368, 1994, pages 856 - 859;;LONBERG; HUSZAR, INTERN. REV. IMMUNOL., vol. 13, 1995, pages 65 - 93;;HARDING; LONBERG, ANN. N.YACAD. SCI., vol. 764, 1995, pages 536 - 546;;TAYLOR ET AL., NUCLEIC ACIDS RESEARCH, vol. 20, 1992, pages 6287 - 6295;;CHEN ET AL., INTERNATIONAL IMMUNOLOGY, vol. 5, 1993, pages 647 - 656;;TUAILLON ET AL., J. IMMUNOL., vol. 152, 1994, pages 2912 - 2920;;LONBERG: ""Handbook of Exp. Pharmacology"", vol. 113, 1994, pages: 49 - 101;;TAYLOR ET AL., INTERNATIONAL IMMUNOLOGY, vol. 6, 1994, pages 579 - 591;;HARDING; LONBERG, ANN. N.Y ACAD. SCI., vol. 764, 1995, pages 536 - 546;;FISHWILD ET AL., NATURE BIOTECHNOLOGY, vol. 14, 1996, pages 845 - 85;;MENDEZ ET AL., NATURE GENETICS, vol. 15, 1997, pages 146 - 156;;HOOGENBOOM, J. MOL. BIOL., vol. 227, 1991, pages 381;;MARKS, J. MOL. BIOL., vol. 222, 1991, pages 581;;SONGSIVILAI; LACHMANN, CLIN. EXP. IMMUNOL., vol. 79, 1990, pages 315 - 321;;KOSTELNY ET AL., J. IMMUNOL., vol. 148, 1992, pages 1547 - 1553;;BIRD, SCIENCE, vol. 242, 1988, pages 423;;HUSTON ET AL., PROC. NATL. ACAD. SCI. U.S.A., vol. 85, 1988, pages 5879;;WARD ET AL., NATURE, vol. 334, 1989, pages 544;;DE GRAAF ET AL., METHODS MOL BIOL., vol. 178, 2002, pages 379 - 387;;KORTT ET AL., PROT. ENG., vol. 10, 1997, pages 423;;KORTT ET AL., BIOMOL. ENG., vol. 18, 2001, pages 95 - 108;;KRIANGKUM ET AL., BIOMOL. ENG., vol. 18, 2001, pages 31 - 40;;HOLLIGER ET AL., PROC. NATL. ACAD. SCI. USA, vol. 90, 1993, pages 6444 - 48;;POLJAK ET AL., STRUCTURE, vol. 2, 1994, pages 1121 - 23;;FREDERICKS ET AL., PROTEIN ENGINEERING, DESIGN & SELECTION, vol. 17, 2004, pages 95 - 106;;POWERS ET AL., JOURNAL OF IMMUNOLOGICAL METHODS, vol. 251, 2001, pages 123 - 135;;SHU ET AL., PROC. NATL. ACAD. SCI. USA, vol. 90, 1993, pages 7995 - 7999;;HAYDEN ET AL., THERAPEUTIC IMMUNOLOGY, vol. 1, 1994, pages 3 - 15;;KYTE ET AL., J. MOL. BIOL., vol. 157, 1982, pages 105 - 131;;MOULT, CURR. OP. IN BIOTECH., vol. 7, 1996, pages 422 - 427;;CHOU ET AL., BIOCHEM., vol. 13, 1974, pages 222 - 245;;CHOU ET AL., BIOCHEMISTRY, vol. 113, 1974, pages 211 - 222;;CHOU ET AL., ADV. ENZYMOL. RELAT. AREAS MOL. BIOL., vol. 47, 1978, pages 45 - 148;;CHOU ET AL., ANN. REV. BIOCHEM., vol. 47, 1979, pages 251 - 276;;CHOU ET AL., BIOPHYS. J., vol. 26, 1979, pages 367 - 384;;HOLM ET AL., NUCL. ACID. RES., vol. 27, 1999, pages 244 - 247;;BRENNER ET AL., CURR. OP. STRUCT. BIOL., vol. 7, 1997, pages 369 - 376;;JONES, CURR. OPIN. STRUCT. BIOL., vol. 7, 1997, pages 377 - 387;;SIPPL ET AL., STRUCTURE, vol. 4, 1996, pages 15 - 19;;BOWIE ET AL., SCIENCE, vol. 253, 1991, pages 164 - 170;;GRIBSKOV ET AL., METH. ENZYM., vol. 183, 1990, pages 146 - 159;;GRIBSKOV ET AL., PROC. NAT. ACAD. SCI., vol. 84, 1987, pages 4355 - 4358;;CREIGHTON: ""Proteins, Structures and Molecular Principles"", 1984, W. H. NEW YORK: FREEMAN AND COMPANY;;BRANDEN AND TOOZE: ""Introduction to Protein Structure"", 1991, GARLAND PUBLISHING;;THORNTON ET AL., NATURE, vol. 354, 1991, pages 105;;FAUCHERE, ADV. DRUG RES., vol. 15, 1986, pages 29;;VEBER; FREIDINGER, TINS, 1985, pages 392;;EVANS ET AL., J. MED. CHEM., vol. 30, 1987, pages 1229;;RIZO; GIERASCH, ANN. REV. BIOCHEM., vol. 61, 1992, pages 387;;HOPP ET AL., BIOLTECHNOLOGY, vol. 6, 1988, pages 1204;;HOPPE ET AL., FEBS LETTERS, vol. 344, 1994, pages 191;;FANSLOW, SEMIN. IMMUNOL., vol. 6, 1994, pages 267 - 278;;ASHKENAZI ET AL., PROC. NATL. ACAD. SCI. USA, vol. 88, 1991, pages 10535;;BYRN ET AL., NATURE, vol. 344, 1990, pages 677;;HOLLENBAUGH ET AL.: ""Construction of Immunoglobulin Fusion Proteins"", CURRENT PROTOCOLS IN IMMUNOLOGY, 1992, pages 10.19.1 - 10.19.11;;BAUM ET AL., EMBO J., vol. 13, 1994, pages 3992 - 4001;;APLIN; WRISTON, CRC CRIT. REV, BIOCHEM., 1981, pages 259 - 306;;HAKIMUDDIN, ARCH. BIOCHEM. BIOPHYS., vol. 259, 1987, pages 52;;EDGE ET AL., ANAL. BIOCHEM., vol. 118, 1981, pages 131;;THOTAKURA ET AL., METH. ENZYMOL., vol. 138, 1987, pages 350;;DUSKIN ET AL., J. BIOL. CHEM., vol. 257, 1982, pages 3105;;MARKS ET AL., BIOTECHNOLOGY, vol. 10, 1992, pages 779;;SAMBROOK; FRITSCH; MANIATIS: ""Molecular Cloning: A Laboratory Manual"", 2001, COLD SPRING HARBOR LABORATORY PRESS;;AUSUBEL ET AL.: ""Current Protocols in Molecular Biology"", 1995, JOHN WILEY & SONS, INC.;;KENNET ET AL.: ""Monoclonal Antibodies, Hybridomas: A New Dimension in Biological Analyses"", 1980, PLENUM PRESS;;HARLOW AND LANE: ""Antibodies: A Laboratory Manual"", 1988, COLD SPRING HARBOR LABORATORY PRESS;;BIANCHI; MCGREW, BIOTECH. BIOTECHNOL. BIOENG., vol. 84, 2003, pages 439 - 44;;D. V. GOEDDEL: ""Methods Enzymol."", vol. 185, 1990, ACADEMIC PRESS;;BENOIST; CHAMBON, NATURE, vol. 290, 1981, pages 304 - 310;;THORNSEN ET AL., PROC. NATL. ACAD. U.S.A., vol. 81, 1984, pages 659 - 663;;YAMAMOTO ET AL., CELL, vol. 22, 1980, pages 787 - 797;;WAGNER ET AL., PROC. NATL. ACAD. SCI. U.S.A., vol. 78, 1981, pages 1444 - 1445;;PRINSTER ET AL., NATURE, vol. 296, 1982, pages 39 - 42;;VILLA-KAMAROFF ET AL., PROC. NATL. ACAD. SCI. U.S.A., vol. 75, 1978, pages 3727 - 3731;;DEBOER ET AL., PROC. NATL. ACAD. SCI. U.S.A., vol. 80, 1983, pages 21 - 25;;SWIFT ET AL., CELL, vol. 38, 1984, pages 639 - 646;;ORNITZ ET AL., COLD SPRING HARBOR SYMP. QUANT. BIOL., vol. 50, 1986, pages 399 - 409;;MACDONALD, HEPATOLOGY, vol. 7, 1987, pages 425 - 515;;HANAHAN, NATURE, vol. 315, 1985, pages 115 - 122;;GROSSCHEDL ET AL., CELL, vol. 38, 1984, pages 647 - 658;;ADAMES ET AL., NATURE, vol. 318, 1985, pages 533 - 538;;ALEXANDER ET AL., MOL. CELL. BIOL., vol. 7, 1987, pages 1436 - 1444;;LEDER ET AL., CELL, vol. 45, 1986, pages 485 - 495;;PINKERT ET AL., GENES AND DEVEL., vol. 1, 1987, pages 268 - 276;;KRUMLAUF ET AL., MOL. CELL. BIOL., vol. 5, 1985, pages 1639 - 1648;;HAMMER ET AL., SCIENCE, vol. 253, 1987, pages 53 - 58;;KELSEY ET AL., GENES AND DEVEL., vol. 1, 1987, pages 161 - 171;;MOGRAM ET AL., NATURE, vol. 315, 1985, pages 338 - 340;;KOLLIAS ET AL., CELL, vol. 46, 1986, pages 89 - 94;;READHEAD ET AL., CELL, vol. 48, 1987, pages 703 - 712;;SANI, NATURE, vol. 314, 1985, pages 283 - 286;;MASON ET AL., SCIENCE, vol. 234, 1986, pages 1372 - 1378;;COSMAN ET AL., NATURE, vol. 312, 1984, pages 768;;HARLOW; LANE: ""Antibodies: A Laboratory Manual"", 1988, COLD SPRING HARBOR;;JOHN E. COLIGAN: ""Current Protocols In Immunology"", 1993, JOHN WILEY & SONS;;""Remington's Pharmaceutical Sciences including, 21st ed."", 2005, MACK PUBLISHING COMPANY;;HARLOW; LANE: ""Antibodies: A Laboratory Manual"", 1990, COLD SPRING HARBOR LABORATORY PRESS, pages: 23;;LUPARDUS; GARCIA, J MOL BIOL, vol. 382, 2008, pages 931 - 941;;""The CCP4 suite: programs for protein crystallography"", ACTA CRYSTALLOGR D BIOL CRYSTALLOGR, vol. 50, 1994, pages 760 - 3;;BRUNGER ET AL., ACTA CRYSTALLOGR D BIOL CRYSTALLOGR, vol. 54, 1998, pages 905 - 21;;DELANO, W.L., THE PYMOL GRAPHICS SYSTEM, 2002",DISCONTINUED
329,CN,A,CN 102741285 A,079-066-936-995-411,2012-10-17,2012,CN 201080059062 A,2010-10-26,US 2010/0054148 W;;US 25498209 P;;US 38128710 P,2009-10-26,Human IL-23 antigen binding proteins,"Antigen binding proteins that bind to human IL-23 protein are provided. Nucleic acids encoding the antigen binding protein, vectors, and cells encoding the same as well as use of IL-23 antigen binding proteins for diagnostic and therapeutic purposes are also provided.",AMGEN INC,TOWNE JENNIFER E;;CHENG JANET D;;O'NEILL JASON C;;YU ZHANG;;YU SUN;;HEATHER CERNE;;PIPER DEREK E;;RANDAL KETCHEM,,https://lens.org/079-066-936-995-411,Patent Application,no,3,2,86,87,0,A61K2039/505;;C07K2317/21;;C07K2317/55;;C07K2317/92;;A61K47/6845;;C07K16/244;;A61P37/00;;C07K16/244;;A61K2039/505;;C07K2317/626;;C07K2317/21;;C07K2317/76;;A61K47/6845;;C07K2317/54;;A61K39/395;;C07K2317/31;;C07K16/24;;A61P37/00;;C07K2317/92;;C07K2317/24;;C07K2317/622;;C07K2317/55;;C07K2317/565;;A61K39/00;;A61K39/395;;A61K39/39533;;A61K39/3955;;C07K16/18;;C07K16/24;;C07K16/244;;A61K2039/505;;C07K2317/21;;C07K2317/55;;C07K2317/92;;A61K47/6845;;C07K16/244;;A61K39/395;;C07K16/24;;C07K2317/24;;C07K2317/31;;C07K2317/54;;C07K2317/565;;C07K2317/622;;C07K2317/626;;C07K2317/76,C07K16/24;;A61K39/395,,0,0,,,,ACTIVE
330,CN,U,CN 209104115 U,144-396-954-996-562,2019-07-12,2019,CN 201820696272 U,2018-05-10,US 201762504471 P;;US 201815965794 A,2017-05-10,Articles having multi-layer plasma erosion protection,"An article having multi-layer plasma erosion protection. The article includes a body including a surface and a plurality of high aspect ratio features in the body, the plurality of high aspect ratio features having an aspect ratio of about 1: 1 to about 300: 1. The article also includes a conformal first anti-plasma layer on the surface and walls of the plurality of high aspect ratio features, thefirst anti-plasma layer having a porosity of about 0% and a thickness of about 100 nanometers to about 1 micron. The article further includes a second plasma resistant layer, the second anti-plasma layer covers the conformal first anti-plasma layer at an area of the surface but does not cover the conformal first anti-plasma layer at the wall of the plurality of high aspect ratio features, the second anti-plasma layer having a porosity of less than 1% and a thickness of about 1-10 microns.",APPLIED MATERIALS INC,TRAN TOAN;;CHOU CHENG-HSUAN;;LAKSHESWAR KALITA;;SUN JENNIFER Y;;KIM TAE WON;;LUBOMIRSKY DMITRY;;WU XIAOWEI;;HE XIAO-MING,,https://lens.org/144-396-954-996-562,Limited Patent,no,0,1,12,12,0,H01J37/32477;;H01J37/32495;;C23C16/04;;C23C16/40;;C23C16/4404;;C23C16/45544;;C23C16/45565;;C23C28/042;;C23C24/04;;C25D7/123;;C23C18/36;;H01J37/32495;;C23C16/403;;C23C16/0254;;H01J37/32477;;H01J37/32495;;C23C16/403;;H01J2237/0203;;C23C16/0254;;C23C16/45525;;C23C28/042;;C23C16/45544;;C23C18/36;;C23C16/04;;C23C16/4404;;C23C16/45565;;C25D7/123;;C23C16/40;;C23C24/04;;H01J37/32477,H01J37/32,,0,0,,,,INACTIVE
331,US,B1,US 6189013 B1,180-229-199-888-935,2001-02-13,2001,US 33992599 A,1999-06-24,US 33992599 A;;US 81175897 A;;US 3256396 P,1996-12-12,Project-based full length biomolecular sequence database,Disclosed is a relational database system for storing biomolecular sequence information in a manner that allows sequences to be catalogued and searched according to association with one or more projects for obtaining full-length biomolecular sequences from shorter sequences. The relational database has sequence records containing information identifying one or more projects to which each of the sequence records belong. Each project groups together one or more biomolecular sequences generated during work to obtain a full-length gene sequence from a shorter sequence. The computer system has a user interface allowing a user to selectively view information regarding one or more projects. The relational database also provides interfaces and methods for accessing and manipulating and analyzing project-based information.,INCYTE GENOMICS INC,MASLYN TIMOTHY J;;AU-YOUNG JANICE;;HILLMAN JENNIFER L;;HIBBERT HAROLD;;AKERBLOM INGRID E;;CHENG RACHEL J;;TANG YUANHUA T,INCYTE GENOMICS INC (1997-06-02),https://lens.org/180-229-199-888-935,Granted Patent,yes,4,66,2,4,0,G16B30/00;;G16B45/00;;G16B50/00;;G16B30/10;;G16B50/10;;G16B30/20;;G16B50/00;;Y10S707/99945;;Y10S707/99948;;Y10S707/99936;;G16B30/00;;G16B45/00;;G16B50/10;;G16B30/10;;G16B30/20,G16B50/10;;G06F17/30;;G16B30/10;;G16B30/20;;G16B45/00,707/104;;702/20;;707/6,26,6,008-273-238-627-941;;019-443-367-783-025;;061-678-499-019-650;;079-271-886-785-450;;009-746-075-150-280;;052-781-443-908-837,10.1126/science.8456298;;8456298;;7660118;;10.1126/science.7660118;;10.1016/0958-1669(93)90048-2;;7764463;;2047873;;10.1126/science.2047873;;8790454;;10.1089/cmb.1994.1.65;;8783942;;10.1016/0168-9525(96)10038-x,"The Institute for Genomic Research, TIGR Database. Internet-http://www.tigr.org (Downloaded Dec. 23, 1997).;;National Center for Biotechnology Information (Index). Internet-http://www3.ncbi.nlm.nih.gov/(Downloaded Dec. 23, 1997).;;National Center for Biotechnology Information; ENTREZ. Internet-http://www3.ncbi.nlm.nih.gov/entrez (Downloaded Dec. 23, 1997).;;National Center for Biotechnology Information; UniGene. Internet-http://www3.ncbi.nlm.nih.gov/unigene (Downloaded Dec. 23, 1997).;;National Center for Biotechnology Information; GenBank. Internet-http://www3.ncbi.nlm.nih.gov/web/genbank (Downloaded Dec. 23, 1997).;;Magpie: Automated Genome Project Investigation Environment. Internet-http://www.mcs.anl.gov/home/gaasterl/magpie.html (Downloaded Dec. 23, 1997).;;Stanford University, Stanford Genomic Resources. Internet-http://genome-www.stanford.edu, Sep. 1996 and Dec. 20, 1997.;;Incyte Pharmaceuticals, LIFESEQ Version 4.2 Release Notes and Physical Data Model, Oct. 1996.;;Incyte Pharmaceuticals, LIFESEQ Version 4.1 Release Notes and Physical Data Model, Jul. 1996.;;Incyte Pharmaceuticals, LIFESEQ Version 3.4 Release Notes, Jan. 1996.;;Incyte Pharmaceuticals, LIFESEQ Version 2.5 Release Notes, Jun. 1995.;;Incyte Pharmaceuticals, LIFESEQ Version 3.0 Release Notes, Sep. 1995.;;Incyte Pharmaceuticals, LIFESEQ Version 4.0 Release Notes, Apr. 1996.;;Incyte Pharmaceuticals, Introduction to the LIFESEQ Database, Version 3.4, Jan. 1996.;;Incyte Pharmaceuticals, LIFESEQ Training Manual, Version 4.1, Jul. 1996.;;Green, et al., ""Ancient Conserved Regions in New Gene Sequences and the Protein Databases"", Science, v.259, n. 5102, pp. 1711-1716 (1993).;;Waldrop, et al. ""Online Archives Let Biologist Interrogate the Genome"", Science, v. 269 n. 5229, pp. 1356-1358 (1995).;;No Author, ""Incyte Serves Up Information, part I"", In Vivo the Business & Medicine Report, p. 32, ISSN: 0258-851X (1996).;;Martin, et al., ""Accessing Genetics Databases"", Database, v. 17, n. 1p. 51(8) (1994).;;Matsubara, K. and Okubo, K. ""Identification of New Genes by Systematic Analysis of cDNAs and Database Construction"", Current Opinion in Biotechnology, 1993, No. 4, pp. 672-677.;;Kanehisa, M. ""Toward Pathway Engineering: A New Database Old Genetic and Molecular Pathways."" Science and Technology Japan, 1995, No. 59, pp. 34-38.;;Gaasterland, T. and Sensen, C. ""Using Multiple Tools for Automated Genome Interpretation in an Integrated Environment"", Trends In Genetics, Jan. 1996.;;Adams, M.D. et al. ""Complementary DNA Sequencing: Expressed Sequence Tags and Human Genome Project"", Science, Jun. 21, 1991, vol. 252, p. 1651-1656.;;Keele, J.W., ""A Conceptual Database Model for Genomic Research"", Journal of Computational Biology, vol. 1, No. 1, pp. 65-76. (1994).;;Fickett, J.W. ""Finding genes by computer: the state of the art"" TIG vol. 12, No. 8, pp. 316-320 (Sep. 1996).;;""GDB 6.0 Goals"", http://gbd.gdbnet.ad.jp/gdb/docs/gdb6-goals.htm pp. 1-5 (Mar. 1995).",EXPIRED
332,US,A,US 5953727 A,045-775-036-392-808,1999-09-14,1999,US 81175897 A,1997-03-06,US 81175897 A;;US 2828496 P;;US 3256396 P,1996-10-10,Project-based full-length biomolecular sequence database,Disclosed is a relational database system for storing biomolecular sequence information in a manner that allows sequences to be catalogued and searched according to association with one or more projects for obtaining full-length biomolecular sequences from shorter sequences. The relational database has sequence records containing information identifying one or more projects to which each of the sequence records belong. Each project groups together one or more biomolecular sequences generated during work to obtain a full-length gene sequence from a shorter sequence. The computer system has a user interface allowing a user to selectively view information regarding one or more projects. The relational database also provides interfaces and methods for accessing and manipulating and analyzing project-based information.,INCYTE PHARMA INC,MASLYN TIMOTHY J;;AU-YOUNG JANICE;;HILLMAN JENNIFER L;;HIBBERT HAROLD;;AKERBLOM INGRID E;;CHENG RACHEL J;;TANG YUANHUA T,INCYTE GENOMICS INC (1997-06-02),https://lens.org/045-775-036-392-808,Granted Patent,yes,2,147,1,4,0,G16B30/00;;G16B45/00;;G16B50/00;;G16B30/10;;G16B50/10;;G16B50/00;;Y10S707/99948;;Y10S707/99945;;G16B45/00;;G16B30/00;;G16B30/10;;G16B50/10,G16B50/10;;G06F17/30;;G16B30/00;;G16B30/10;;G16B45/00,707/104;;707/10;;435/6,27,6,009-746-075-150-280;;061-678-499-019-650;;052-781-443-908-837;;008-273-238-627-941;;019-443-367-783-025;;079-271-886-785-450,8790454;;10.1089/cmb.1994.1.65;;10.1016/0958-1669(93)90048-2;;7764463;;8783942;;10.1016/0168-9525(96)10038-x;;10.1126/science.8456298;;8456298;;7660118;;10.1126/science.7660118;;2047873;;10.1126/science.2047873,"Keele, J.W., A Conceptual Database Model for Genomic Research , Journal of Computational Biology, vol. 1, No. 1, pp. 65 76, 1994.;;Matsubara K,. Identification of new genes by systematic analysis of cDNAs and database construction, Current Opinion in Biology, vol. 4, pp. 672 677, 1993.;;Fickett, J. W. Finding genes by computer: the state of the art TIG vol. 12, No. 8, pp. 316 320, Sep. 1996.;;GDB 6.0 Goals , http://gbd.gdbnet.ad.jp/gdb/docs/gdb6 goals.htm pp. 1 5 Mar. 1995.;;The Institute for Genomic Research, TIGR Database. Internet http://www.tigr.org (Downloaded Dec. 23, 1997).;;National Center for Biotechnology Information (Index). Internet http://www3.ncbi.nlm.nih.gov/ (Downloaded Dec. 23, 1997).;;National Center for Biotechnology Information; ENTREZ. Internet http://www3.ncbi.nlm.nih.gov/entrez (Downloaded Dec. 23, 1997).;;National Center for Biotechnology Information; UniGene. Internet http://www3.ncbi.nlm.nih.gov/unigene (Downloaded Dec. 23, 1997).;;National Center for Biotechnology Information; GenBank. Internet http://www3.ncbi.nlm.nih.gov/web/genbank (Downloaded Dec. 23, 1997).;;MAGPIE; Automated Genome Project Investigation Environment. Internet http://www.mcs.anl.gov/home/gaasterl/magpie.html. (Downloaded Dec. 23, 1997).;;Stanford University, Stanford Genomic Resources. Internet http://genome www.stanford.edu Sep. 22, 1996 and Dec. 20, 1997.;;Incyte Pharmaceuticals, LIFESEQ Version 4.2 Release Notes and Physical Data Model, Oct. 1996.;;Incyte Pharmaceuticals, LIFESEQ Version 4.1 Release Notes and Physical Data Model, Jul. 1996.;;Incyte Pharmaceuticals, LIFESEQ Version 3.4 Release Notes, Jan. 1996.;;Incyte Pharmaceuticals, LIFESEQ Verison 2.5 Release Notes, Jun. 1995.;;Incyte Pharmaceuticals, LIFESEQ Version 3.0 Release Notes, Sep. 1995.;;Incyte Pharmaceuticals, LIFESEQ Verison 4.0 Release Notes, Apr. 1996.;;Incyte Pharmaceuticals, Introduction to the LIFESEQ Database, Version 3.4, Jan. 1996.;;Incyte Pharmaceuticals, LIFESEQ Training Manual, Version 4.1, Jul. 1996.;;Green, et al., Ancient Conserved Regions in New Gene Sequences and the Protein Databases , Science, v. 259, n. 5102, pp. 1711 1716 (1993).;;http://wehih.edu.au/ (1995).;;Waldrop, et al., On line Archives Let Biologists Interrogate the Genome , Science, v. 269, n. 5229, pp. 1356 1358 (1995).;;No Author, Incyte Serves Up Information, part I , In Vivo the Business & Medicine Report, p. 32, ISSN: 0258 851X (1996).;;Martin, et al., Accessing Genetics Databases , Database, v. 17, n. 1, p. 51(8).;;Kanehisa, M. Toward Pathway Engineering: A New Database Old Genetic and Molecular Pathways. Science and Technology Japan, 1995, No. 59, pp. 34 38.;;Gaasterland, T. and Sensen, C. Using Multiple Tools for Automated Genome Interpretation in an Integrated Environment , Trends In Genetics, Jan. 1996.;;Adams, M.D. et al. Complementary DNA Sequencing: Expressed Sequence Tags and Human Genome Project , Science, Jun. 21, 1991, vol. 252, pp. 1651 1656.",EXPIRED
333,CA,A1,CA 2920171 A1,135-046-646-503-272,2017-08-05,2017,CA 2920171 A,2016-02-05,CA 2920171 A,2016-02-05,APPARATUS AND METHODS FOR ENTRY CONTROL OVER A CELLULAR NETWORK,"Apparatus and methods for controlling physical access to a location include an entry system including at least one barrier at the physical location, with the barrier configured to selectively permit access into and/or from and/or within the physical location upon proper credentials and/or authorization. A cellular device is connected to or integrated with the entry system and is configured to transmit and receive voice and/or data information to the entry system that includes the credentials and/or authorization. The cellular device can be a retrofit to prior art/installed systems, can be external to an otherwise operational system, and/or can be integrated natively into the entry system. Methods and apparatus are disclosed to determine the power status and network link state of the cellular device and/or to establish communication through/to same, as well as for the cellular device to be connected to and control a plurality of entry systems and/or barriers. A plurality of entry systems and/or barriers can be controlled by one or more cellular devices, and the usage (and associated billing charges from cellular service providers) on any/all of those cellular devices monitored and selected to optimize (reduce) the expense of any data or other charges imposed by a cellular carrier associated with the cellular device. Optimization can include allocation to the aforementioned voice and/or data cellular plans related to specific of the plurality of entry systems and/or barriers.",DOORKING INC,RICHMOND THOMAS R;;RICHMOND SUZANNE;;KOCHIE PATRICK S;;CHENG YU JENNIFER;;BEAR EITAN T;;GUEORGUIEVA NADEJDA V;;CEBALLOS EMMANUEL G,,https://lens.org/135-046-646-503-272,Patent Application,no,0,0,1,1,0,G08C17/02;;H04L12/28;;H04W4/00;;H04W28/12;;H04L12/40052;;H04W4/02;;G07C9/27;;G07C9/27,G07C9/00;;E05F15/77;;G08C17/02;;H04L12/28;;H04W4/00;;H04W4/02;;H04W28/12;;H04W52/00,,0,0,,,,DISCONTINUED
334,US,A1,US 2018/0330923 A1,168-379-572-090-294,2018-11-15,2018,US 201815965794 A,2018-04-27,US 201815965794 A;;US 201762504471 P,2017-05-10,MULTI-LAYER PLASMA EROSION PROTECTION FOR CHAMBER COMPONENTS,"A method of applying a multi-layer plasma resistant coating on an article comprises performing plating or ALD to form a conformal first plasma resistant layer on an article, wherein the conformal first plasma resistant layer is formed on a surface of the article and on walls of high aspect ratio features in the article. The conformal first plasma resistant coating has a porosity of approximately 0% and a thickness of approximately 200 nm to approximately 1 micron. One of electron beam ion assisted deposition (EB-IAD), plasma enhanced chemical vapor deposition (PECVD), aerosol deposition or plasma spraying is then performed to form a second plasma resistant layer that covers the conformal first plasma resistant layer at a region of the surface but not at the walls of the high aspect ratio features.",APPLIED MATERIALS INC,TRAN TOAN;;KALITA LAKSHESWAR;;KIM TAE WON;;LUBOMIRSKY DMITRY;;WU XIAOWEI;;HE XIAO-MING;;CHOU CHENG-HSUAN;;SUN JENNIFER Y,APPLIED MATERIALS INC (2018-08-23),https://lens.org/168-379-572-090-294,Patent Application,yes,0,17,12,12,0,H01J37/32477;;H01J37/32495;;C23C16/04;;C23C16/40;;C23C16/4404;;C23C16/45544;;C23C16/45565;;C23C28/042;;C23C24/04;;C25D7/123;;C23C18/36;;H01J37/32495;;C23C16/403;;C23C16/0254;;H01J37/32477;;H01J37/32495;;C23C16/403;;H01J2237/0203;;C23C16/0254;;C23C16/45525;;C23C28/042;;C23C16/45544;;C23C18/36;;C23C16/04;;C23C16/4404;;C23C16/45565;;C25D7/123;;C23C16/40;;C23C24/04;;H01J37/32477,H01J37/32;;C23C16/40,,0,0,,,,ACTIVE
335,BR,B1,BR PI0714708 B1,154-605-059-513-406,2017-10-17,2017,BR PI0714708 A,2007-07-25,US 83328806 P;;US 2007/0016775 W,2006-07-26,métodos para inibir a sedimentaçao de contaminadores orgânicos nos sistemas de fabricação de polpa ou papel,poli(etileno glicol] hidrofobicamente modificado para uso no controle de breu e cola em polpa e nos processos de fabricação de papel. métodos para inibir as sedimentações de contaminadores orgânicos da polpa em sistemas de polpa e fabricação de papel são descritos. o poli[etileno glicol] hidrofobicamente modificado é adicionado à polpa ou aplicado para as superfícies propensas à sedimentação de um sistema de fabricação de papel.,HERCULES INC;;SOLENIS TECHNOLOGIES CAYMAN LP,ERIN A S DOHERTY;;HUAI N CHENG;;JENNIFER L RITTENHOUSE-PRUSS;;QU-MING GU;;ROBERT A GELMAN;;WILLIAM S CAREY,"SOLENIS TECHNOLOGIES CAYMAN, L.P. (CH) (2016-04-12)",https://lens.org/154-605-059-513-406,Granted Patent,no,0,0,21,21,0,C08G65/22;;C08G65/2609;;D21C9/008;;D21H21/02;;C08G2650/34;;C08G65/22;;C08G65/2609;;C08G2650/34;;D21C9/008;;D21H21/02;;D21H21/02;;C08G2650/34;;C08G65/22;;D21C9/008;;C08G65/2609,C11D1/722;;C08L71/02;;D21C9/00;;D21H21/02,,0,0,,,,ACTIVE
336,EP,A1,EP 3656790 A1,171-707-536-101-919,2020-05-27,2020,EP 19202723 A,2010-10-26,US 25498209 P;;US 38128710 P;;EP 16199576 A;;EP 10774095 A;;US 2010/0054148 W,2009-10-26,HUMAN IL-23 ANTIGEN BINDING PROTEINS,"Antigen binding proteins that bind to human IL-23 protein are provided. Nucleic acids encoding the antigen binding protein, vectors, and cells encoding the same as well as use of IL-23 antigen binding proteins for diagnostic and therapeutic purposes are also provided.
 
",AMGEN INC,TOWNE JENNIFER;;O'NEILL JASON C;;ZHANG YU;;SUN YU;;CERNE HEATHER;;PIPER DEREK E;;KETCHEM RANDAL R;;CHENG JANET D,,https://lens.org/171-707-536-101-919,Patent Application,yes,71,0,86,87,155,A61K2039/505;;C07K2317/21;;C07K2317/55;;C07K2317/92;;A61K47/6845;;C07K16/244;;A61P37/00;;C07K16/244;;A61K2039/505;;C07K2317/626;;C07K2317/21;;C07K2317/76;;A61K47/6845;;C07K2317/54;;A61K39/395;;C07K2317/31;;C07K16/24;;A61P37/00;;C07K2317/92;;C07K2317/24;;C07K2317/622;;C07K2317/55;;C07K2317/565;;A61K39/00;;A61K39/395;;A61K39/39533;;A61K39/3955;;C07K16/18;;C07K16/24;;C07K16/244;;A61K2039/505;;C07K2317/21;;C07K2317/55;;C07K2317/92;;A61K47/6845;;C07K16/244;;A61K39/395;;C07K16/24;;C07K2317/24;;C07K2317/31;;C07K2317/54;;C07K2317/565;;C07K2317/622;;C07K2317/626;;C07K2317/76,C07K16/24;;A61K39/395;;A61P37/00,,133,104,019-397-556-890-001;;000-861-223-602-303;;003-570-249-164-056;;027-477-313-726-928;;002-771-789-858-985;;039-460-067-637-00X;;068-238-957-669-243;;084-232-242-673-081;;059-694-149-712-381;;157-531-857-346-593;;043-992-140-825-19X;;114-738-893-000-504;;000-879-344-254-347;;066-119-584-271-19X;;113-982-061-284-768;;016-815-797-562-455;;015-979-728-056-035;;039-724-297-100-685;;098-276-747-378-726;;050-176-401-076-536;;041-241-834-308-816;;019-982-436-313-59X;;023-907-179-348-058;;061-754-151-573-898;;106-248-968-254-022;;106-248-968-254-022;;020-855-322-534-259;;024-413-081-573-499;;014-277-808-472-992;;029-745-513-975-612;;113-327-994-370-771;;064-787-766-418-165;;012-273-285-250-15X;;043-293-799-149-190;;073-260-982-304-977;;032-820-729-763-323;;049-134-753-209-354;;066-141-497-990-023;;032-728-154-591-070;;027-903-185-617-733;;030-607-398-087-475;;006-574-964-805-278;;042-204-626-457-327;;045-094-249-115-990;;089-899-040-309-502;;043-108-278-056-872;;050-836-464-727-069;;071-707-020-428-907;;023-468-000-960-289;;060-375-551-951-388;;083-549-078-331-651;;020-753-772-581-741;;038-613-711-274-229;;016-219-576-017-946;;040-577-067-037-463;;104-212-297-137-759;;002-264-966-090-625;;162-131-697-723-828;;052-714-495-277-870;;001-467-559-709-949;;040-397-285-492-490;;103-477-074-900-777;;129-978-431-330-653;;003-762-234-479-609;;015-109-431-185-638;;067-226-137-053-81X;;032-055-913-011-134;;003-246-587-515-619;;130-802-862-883-854;;076-270-369-964-609;;129-447-558-597-627;;079-975-841-354-505;;034-705-920-623-82X;;106-794-363-564-085;;150-526-239-777-942;;069-863-076-076-464;;052-327-980-622-279;;052-835-629-769-725;;105-521-401-667-801;;056-196-705-544-876;;013-281-398-303-904;;085-329-927-828-899;;154-374-780-007-386;;068-962-117-616-007;;017-449-753-661-071;;039-141-300-950-038;;115-435-737-255-802;;010-670-795-970-321;;010-916-105-450-247;;102-808-907-197-009;;011-724-225-446-939;;061-444-349-075-997;;065-114-602-989-551;;101-171-874-734-776;;067-057-135-512-133;;020-236-161-344-688;;003-598-409-932-232;;021-074-280-354-982;;055-578-442-289-160;;021-512-087-228-498;;017-927-510-116-179;;048-819-440-392-261;;054-418-959-978-111;;023-476-471-521-012,18708069;;10.1016/j.jmb.2008.08.001;;10.1093/protein/gzp073;;20022918;;18606226;;10.1016/j.coi.2008.06.004;;10.1073/pnas.79.6.1979;;pmc346105;;6804947;;10.4049/jimmunol.165.8.4505;;11035090;;20956338;;pmc3776381;;10.4049/jimmunol.1001538;;10556249;;10.1093/protein/12.10.879;;10082364;;10.1002/pro.5560070802;;pmc2144089;;pmc2142342;;8443598;;10.1002/pro.5560020209;;10.1002/9780470059180.ch13;;1901023;;10.1021/bi00226a010;;012023369;;10.4049/jimmunol.168.11.5699;;12023369;;19161422;;10.1111/j.1600-065x.2008.00705.x;;12610626;;10.1038/nature01355;;17888176;;pmc2212562;;10.1186/ar2297;;17291186;;10.1146/annurev.immunol.22.012703.104758;;10.1093/rheumatology/kem055;;17569750;;16645485;;10.1097/01.qco.0000224818.42729.67;;10.1002/eji.200324038;;12778462;;10.1158/1535-7163.mct-06-0003;;16648552;;16688182;;10.1038/nature04808;;11397087;;10.1006/jmbi.2001.4662;;pmc50453;;1438297;;10.1073/pnas.89.22.10915;;10.1016/0042-6822(90)90025-m;;1693247;;10.1016/j.jmb.2008.07.051;;18680750;;pmc2666310;;10.1016/j.jmb.2008.07.051;;18680750;;pmc2666310;;1748994;;10.1016/0022-2836(91)90498-u;;10.1016/0076-6879(83)92023-2;;6855613;;10.4049/jimmunol.137.11.3614;;2431039;;10.1016/0161-5890(88)90085-5;;3343974;;1697100;;10.1111/j.1365-3083.1990.tb02896.x;;10.1002/prot.10497;;12945055;;10.1021/bp030070k;;15176864;;9041643;;pmc2143633;;10.1002/pro.5560060217;;11968500;;10.1385/1-59259-240-6:303;;8159246;;10.1038/368856a0;;10.1016/0022-2836(87)90412-8;;3681981;;10.1093/nar/12.1part1.387;;6546423;;pmc321012;;10.1016/0022-2836(70)90057-4;;5420325;;15572068;;10.1016/j.dci.2004.07.003;;pmc392030;;10.1073/pnas.81.21.6851;;6436822;;10.1038/321522a0;;3713831;;3127726;;10.1038/332323a0;;10.1126/science.2451287;;2451287;;8459850;;10.1038/362255a0;;7494109;;10.3109/08830189509061738;;10.1111/j.1749-6632.1995.tb55879.x;;7486582;;1475190;;10.1093/nar/20.23.6287;;pmc334518;;10.1093/intimm/5.6.647;;8347558;;8144892;;10.1007/978-3-642-78432-3_3;;10.1093/intimm/6.4.579;;8018598;;10.1038/nbt0796-845;;9631008;;pmc4119940;;25033887;;10.1038/ng0297-146;;9020839;;2180597;;pmc1534963;;10.1111/j.1365-2249.1990.tb08089.x;;10.4049/jimmunol.148.5.1547;;1531669;;10.1073/pnas.85.16.5879;;3045807;;pmc281868;;11968507;;10.1385/1-59259-240-6:379;;10.1016/s1389-0344(01)00083-1;;11535414;;10.1016/s0969-2126(94)00113-8;;7704521;;14985542;;10.1093/protein/gzh012;;10.1016/s0022-1759(00)00290-8;;11292488;;7584477;;7108955;;10.1016/0022-2836(82)90515-0;;8768901;;10.1016/s0958-1669(96)80118-2;;4358940;;10.1021/bi00699a002;;10.1021/bi00699a001;;4358939;;364941;;10.1002/9780470122921.ch2;;354496;;10.1146/annurev.bi.47.070178.001343;;pmc148146;;9847191;;10.1093/nar/27.1.244;;10.1016/s0959-440x(97)80054-1;;9204279;;9204280;;10.1016/s0959-440x(97)80055-3;;8805507;;10.1016/s0969-2126(96)00005-6;;10.1126/science.1853201;;1853201;;10.1016/0076-6879(90)83011-w;;2314273;;pmc305087;;10.1073/pnas.84.13.4355;;3474607;;6322160;;10.1073/pnas.81.3.659;;pmc344894;;10.1038/354105a0;;1944583;;10.1021/jm00390a019;;2885419;;10.1146/annurev.bi.61.070192.002131;;1497316;;10.1146/annurev.biochem.61.1.387;;8187882;;10.1016/0014-5793(94)00383-1;;7532457;;10.1006/smim.1994.1035;;pmc52963;;1660140;;10.1073/pnas.88.23.10535;;10.1002/0471142735.im1019as48;;10.1002/j.1460-2075.1994.tb06715.x;;8076595;;pmc395319;;0007018830;;7018830;;10.1016/0003-2697(81)90168-8;;6175244;;2439875;;10.1016/0076-6879(87)38030-9;;10.1038/nbt0792-779;;1368267;;6257399;;10.1016/0092-8674(80)90555-3;;10.1002/bit.10790;;14574701;;10.1038/290304a0;;6259538;;358198;;pmc392859;;10.1073/pnas.75.8.3727;;6337371;;10.1073/pnas.80.1.21;;pmc393301;;6091894;;10.1016/0092-8674(84)90259-9;;3006998;;10.1101/sqb.1985.050.01.050;;2984571;;10.1038/314283a0;;pmc365231;;10.1128/mcb.7.4.1436;;10.1128/mcb.7.4.1436-1444.1987;;3037318;;10.1128/mcb.5.7.1639;;pmc367282;;2410773;;10.1128/mcb.5.7.1639-1648.1985;;10.1016/0092-8674(87)90248-0;;2434242;;10.1126/science.3097822;;3097822;;10.1038/312768a0;;6096720;;10.1107/s0907444994003112;;15299374;;10.1107/s0907444998003254;;9757107,"BEYER B M ET AL: ""Crystal Structures of the Pro-Inflammatory Cytokine Interleukin-23 and Its Complex with a High-Affinity Neutralizing Antibody"", JOURNAL OF MOLECULAR BIOLOGY, LONDON, GB, vol. 382, no. 4, 17 October 2008 (2008-10-17), pages 942 - 955, XP025409951, ISSN: 0022-2836, [retrieved on 20080807], DOI: 10.1016/J.JMB.2008.08.001;;MABRY ROBERT ET AL: ""Engineering of stable bispecific antibodies targeting IL-17A and IL-23"", PROTEIN ENGINEERING DESIGN & SELECTION, vol. 23, no. 3, March 2010 (2010-03-01), pages 115 - 127, XP002616663, ISSN: 1741-0126;;LONBERG ET AL: ""Fully human antibodies from transgenic mouse and phage display platforms"", CURRENT OPINION IN IMMUNOLOGY, ELSEVIER, OXFORD, GB, vol. 20, no. 4, 1 August 2008 (2008-08-01), pages 450 - 459, XP023612045, ISSN: 0952-7915, [retrieved on 20080721], DOI: 10.1016/J.COI.2008.06.004;;RUDIKOFF S ET AL: ""Single amino acid substitution altering antigen-binding specificity"", PROCEEDINGS NATIONAL ACADEMY OF SCIENCES PNAS, NATIONAL ACADEMY OF SCIENCES, US, vol. 79, 1 March 1982 (1982-03-01), pages 1979 - 1983, XP007901436, ISSN: 0027-8424, DOI: 10.1073/PNAS.79.6.1979;;WINKLER K ET AL: ""Changing the antigen binding specificity by single point mutations of an anti-p24 (HIV-1) antibody"", THE JOURNAL OF IMMUNOLOGY, THE AMERICAN ASSOCIATION OF IMMUNOLOGISTS, US, vol. 165, no. 8, 15 October 2000 (2000-10-15), pages 4505 - 4514, XP002579393, ISSN: 0022-1767;;G. TONEL ET AL: ""Cutting Edge: A Critical Functional Role for IL-23 in Psoriasis"", THE JOURNAL OF IMMUNOLOGY, vol. 185, no. 10, 18 October 2010 (2010-10-18), pages 5688 - 5691, XP055203326, ISSN: 0022-1767, DOI: 10.4049/jimmunol.1001538;;HIROYUKI KOBAYASHI ET AL: ""Tryptophan H33 plays an important role in pyrimidine (6-4) pyrimidone photoproduct binding by a high-affinity antibody"", PROTEIN ENGINEERING, 1 January 1999 (1999-01-01), pages 879 - 884, XP055364172, Retrieved from the Internet <URL:https://academic.oup.com/peds/article-pdf/12/10/879/9908089/120879.pdf> [retrieved on 20170412];;CASIPIT C L ET AL: ""IMPROVING THE BINDING AFFINITY OF AN ANTIBODY USING MOLECULAR MODELING AND SITE-DIRECTED MUTAGENESIS"", PROTEIN SCIENCE, WILEY, US, vol. 7, 1 August 1998 (1998-08-01), pages 1671 - 1680, XP001007633, ISSN: 0961-8368;;JOEL F. SCHILDBACH ET AL: ""Modulation of antibody affinity by a non-contact residue"", PROTEIN SCIENCE, vol. 2, no. 2, 1 February 1993 (1993-02-01), pages 206 - 214, XP055103868, ISSN: 0961-8368, DOI: 10.1002/pro.5560020209;;""Bioinformatics for Geneticists"", 1 January 2003, JOHN WILEY & SONS, LTD, Chichester, UK, ISBN: 978-0-470-02619-9, article MATTHEW J BETTS ET AL: ""Amino Acid Properties and Consequences of Substitutions"", pages: 289 - 316, XP055515752, DOI: 10.1002/9780470059180.ch13;;GLOCKSHUBER R ET AL: ""MAPPING AND MODIFICATION OF AN ANTIBODY HAPTEN BINDING SITE A SITE-DIRECTED MUTAGENESIS STUDY OF MCPC603"", BIOCHEMISTRY, ACS PUBLICATIONS, vol. 30, no. 12, 1 January 1991 (1991-01-01), pages 3049 - 3054, XP009511569, ISSN: 0006-2960, DOI: 10.1021/BI00226A010;;PARHAM ET AL., J. IMMUNOL., vol. 168, 2002, pages 5699 - 708;;AHERN ET AL., IMMUN. REV., vol. 226, 2008, pages 147 - 159;;CUA ET AL., NATURE, vol. 421, 2003, pages 744 - 748;;YAGO ET AL., ARTHRITIS RES AND THER., vol. 9, no. 5, 2007, pages R96;;KASTELEIN ET AL., ANNUAL REVIEW OF IMMUNOLOGY, vol. 25, 2007, pages 221 - 42;;LIU ET AL., RHEUMATOLOGY, vol. 46, no. 8, 2007, pages 1266 - 73;;BOWMAN ET AL., CURRENT OPINION IN INFECTIOUS DISEASES, vol. 19, 2006, pages 245 - 52;;FIESCHICASANOVA, EUR. J. IMMUNOL., vol. 33, 2003, pages 1461 - 4;;MEERAN ET AL., MOL. CANCER THER., vol. 5, 2006, pages 825 - 32;;LANGOWSKI ET AL., NATURE, vol. 442, 2006, pages 461 - 5;;HONEGGERPLUCKTHUN, J. MOL. BIOL., vol. 309, no. 3, 2001, pages 657 - 670;;HENIKOFF ET AL., PROC. NATL. ACAD. SCI. U.S.A., vol. 89, 1992, pages 10915 - 10919;;CHEUNG ET AL., VIROLOGY, vol. 176, 1990, pages 546 - 552;;""GenBank"", Database accession no. NM _ 005535;;OPPMANN ET AL., IMMUNITY, vol. 13, 2000, pages 713 - 715;;LUPARDUSGARCIA, J MOL BIOL, vol. 382, no. 4, 2008, pages 931 - 941;;LUPARDUSGARCIA, J. MOL. BIOL., vol. 382, 2008, pages 931 - 941;;HOOGENBOOM, J. MOL. BIOL., vol. 222, 1991, pages 581;;STAHLI ET AL., METHODS IN ENZYMOLOGY, vol. 92, 1983, pages 242 - 253;;KIRKLAND ET AL., J. IMMUNOL., vol. 137, 1986, pages 3614 - 3619;;MOREL ET AL., MOLEC. IMMUNOL., vol. 25, 1988, pages 7 - 15;;MOLDENHAUER ET AL., SCAND. J. IMMUNOL., vol. 32, 1990, pages 77 - 82;;KORNDORFER ET AL., PROTEINS: STRUCTURE, FUNCTION, AND BIOINFORMATICS, vol. 53, no. 1, 2003, pages 121 - 129;;ROQUE ET AL., BIOTECHNOL. PROG., vol. 20, 2004, pages 639 - 654;;BLOOM ET AL., PROTEIN SCIENCE, vol. 6, 1997, pages 407;;LANTTO ET AL., METHODS MOL. BIOL., vol. 178, 2002, pages 303 - 316;;CHOTHIA ET AL., NATURE, vol. 334, 1989, pages 544 - 883;;CARILLO ET AL., SIAM J. APPLIED MATH., vol. 48, 1988, pages 1073;;JAKOBOVITS ET AL., PROC. NATL. ACAD. SCI. USA, vol. 90, 1993, pages 7995 - 7999;;LONBERG ET AL., NATURE, vol. 368, 1994, pages 856 - 859;;CHOTHIALESK, J. MOL. BIOL., vol. 196, 1987, pages 901 - 917;;DEVEREUX ET AL., NUCL. ACID RES., vol. 12, 1984, pages 387;;DAYHOFF ET AL., ATLAS OF PROTEIN SEQUENCE AND STRUCTURE, vol. 5, 1978, pages 345 - 352;;NEEDLEMAN ET AL., J. MOL. BIOL., vol. 48, 1970, pages 443 - 453;;LEFRANC ET AL., DEV. COMP. IMMUNOL., vol. 29, 2005, pages 185 - 203;;MORRISON, PROC. NATL. ACAD. SCI. USA, vol. 81, 1985, pages 6851 - 6855;;JONES ET AL., NATURE, vol. 321, 1986, pages 522 - 525;;RIECHMANN ET AL., NATURE, vol. 332, 1988, pages 323 - 27;;VERHOEYEN ET AL., SCIENCE, vol. 242, 1988, pages 1534 - 1536;;JAKOBOVITS ET AL., NATURE, vol. 362, 1993, pages 255 - 258;;BRUGGERMANN ET AL., YEAR IN IMMUNOL., vol. 7, 1993, pages 33;;LONBERGHUSZAR, INTERN. REV. IMMUNOL., vol. 13, 1995, pages 65 - 93;;HARDINGLONBERG, ANN. N.YACAD. SCI., vol. 764, 1995, pages 536 - 546;;TAYLOR ET AL., NUCLEIC ACIDS RESEARCH, vol. 20, 1992, pages 6287 - 6295;;CHEN ET AL., INTERNATIONAL IMMUNOLOGY, vol. 5, 1993, pages 647 - 656;;TUAILLON ET AL., J. IMMUNOL., vol. 152, 1994, pages 2912 - 2920;;LONBERG, HANDBOOK OF EXP. PHARMACOLOGY, vol. 113, 1994, pages 49 - 101;;TAYLOR ET AL., INTERNATIONAL IMMUNOLOGY, vol. 6, 1994, pages 579 - 591;;HARDINGLONBERG, ANN. N.Y ACAD. SCI., vol. 764, 1995, pages 536 - 546;;FISHWILD ET AL., NATURE BIOTECHNOLOGY, vol. 14, 1996, pages 845 - 85;;MENDEZ ET AL., NATURE GENETICS, vol. 15, 1997, pages 146 - 156;;SONGSIVILAILACHMANN, CLIN. EXP. IMMUNOL., vol. 79, 1990, pages 315 - 321;;KOSTELNY ET AL., J. IMMUNOL., vol. 148, 1992, pages 1547 - 1553;;HUSTON ET AL., PROC. NATL. ACAD. SCI. U.S.A., vol. 85, 1988, pages 5879;;DE GRAAF ET AL., METHODS MOL BIOL., vol. 178, 2002, pages 379 - 387;;KORTT ET AL., PROT. ENG., vol. 10, 1997, pages 423;;KRIANGKUM ET AL., BIOMOL. ENG., vol. 18, 2001, pages 31 - 108;;POLJAK ET AL., STRUCTURE, vol. 2, 1994, pages 1121 - 23;;FREDERICKS ET AL., PROTEIN ENGINEERING, DESIGN & SELECTION, vol. 17, 2004, pages 95 - 106;;POWERS ET AL., JOURNAL OF IMMUNOLOGICAL METHODS, vol. 251, 2001, pages 123 - 135;;HAYDEN ET AL., THERAPEUTIC IMMUNOLOGY, vol. 1, 1994, pages 3 - 15;;KYTE, J. MOL. BIOL., vol. 157, 1982, pages 105 - 131;;MOULT, CURR. OP. IN BIOTECH., vol. 7, 1996, pages 422 - 427;;CHOU ET AL., BIOCHEM., vol. 13, 1974, pages 222 - 245;;CHOU ET AL., BIOCHEMISTRY, vol. 113, 1974, pages 211 - 222;;CHOU ET AL., ADV. ENZYMOL. RELAT. AREAS MOL. BIOL., vol. 47, 1978, pages 45 - 148;;CHOU ET AL., ANN. REV. BIOCHEM., vol. 47, 1979, pages 251 - 276;;CHOU ET AL., BIOPHYS. J., vol. 26, 1979, pages 367 - 384;;HOLM ET AL., NUCL. ACID. RES., vol. 27, 1999, pages 244 - 247;;BRENNER ET AL., CURR. OP. STRUCT. BIOL., vol. 7, 1997, pages 369 - 376;;JONES, CURR. OPIN. STRUCT. BIOL., vol. 7, 1997, pages 377 - 387;;SIPPL ET AL., STRUCTURE, vol. 4, 1996, pages 15 - 19;;BOWIE ET AL., SCIENCE, vol. 253, 1991, pages 164 - 170;;GRIBSKOV ET AL., METH. ENZYM., vol. 183, 1990, pages 146 - 159;;GRIBSKOV ET AL., PROC. NAT. ACAD. SCI., vol. 84, 1987, pages 4355 - 4358;;THORNSEN ET AL., PROC. NATL. ACAD. U.S.A., vol. 81, 1984, pages 659 - 663;;THORNTON ET AL., NATURE, vol. 354, 1991, pages 105;;FAUCHERE, ADV. DRUG RES., vol. 15, 1986, pages 29;;VEBERFREIDINGER, TINS, 1985, pages 392;;EVANS ET AL., J. MED. CHEM., vol. 30, 1987, pages 1229;;RIZOGIERASCH, ANN. REV. BIOCHEM., vol. 61, 1992, pages 387;;HOPP ET AL., BIOLTECHNOLOGY, vol. 6, 1988, pages 1204;;HOPPE ET AL., FEBS LETTERS, vol. 344, 1994, pages 191;;FANSLOW, SEMIN. IMMUNOL., vol. 6, 1994, pages 267 - 278;;ASHKENAZI ET AL., PROC. NATL. ACAD. SCI. USA, vol. 88, 1991, pages 10535;;BYRN ET AL., NATURE, vol. 344, 1990, pages 677;;HOLLENBAUGH ET AL.: ""Construction of Immunoglobulin Fusion Proteins"", CURRENT PROTOCOLS IN IMMUNOLOGY, vol. 4, 1992, pages 10.19.1 - 10.19.11;;BAUM ET AL., EMBO J., vol. 13, 1994, pages 3992 - 4001;;APLINWRISTON, CRC CRIT. REV, BIOCHEM., 1981, pages 259 - 306;;HAKIMUDDIN ET AL., ARCH. BIOCHEM. BIOPHYS., vol. 259, 1987, pages 52;;EDGE ET AL., ANAL. BIOCHEM., vol. 118, 1981, pages 131;;THOTAKURA ET AL., METH. ENZYMOL., vol. 138, 1987, pages 350;;DUSKIN ET AL., J. BIOL. CHEM., vol. 257, 1982, pages 3105;;MARKS ET AL., BIOTECHNOLOGY, vol. 10, 1992, pages 779;;SAMBROOKFRITSCHMANIATIS: ""Molecular Cloning: A Laboratory Manual"", 2001, COLD SPRING HARBOR LABORATORY PRESS;;""Current Protocols in Molecular Biology"", 1995, JOHN WILEY & SONS, INC.;;YAMAMOTO ET AL., CELL, vol. 22, 1980, pages 787 - 797;;HARLOWLANE: ""Antibodies: A Laboratory Manual, Harlow and Lane"", 1988, COLD SPRING HARBOR LABORATORY PRESS;;BIANCHIMCGREW, BIOTECH. BIOTECHNOL. BIOENG., vol. 84, 2003, pages 439 - 44;;HARLOWLANE: ""Antibodies: A Laboratory Manual"", vol. 185, 1990, COLD SPRING HARBOR LABORATORY PRESS, pages: 23;;BENOISTCHAMBON, NATURE, vol. 290, 1981, pages 304 - 310;;WAGNER ET AL., PROC. NATL. ACAD. SCI. U.S.A., vol. 78, 1981, pages 1444 - 1445;;PRINSTER ET AL., NATURE, vol. 296, 1982, pages 39 - 42;;VILLA-KAMAROFF ET AL., PROC. NATL. ACAD. SCI. U.S.A., vol. 75, 1978, pages 3727 - 3731;;DEBOER ET AL., PROC. NATL. ACAD. SCI. U.S.A., vol. 80, 1983, pages 21 - 25;;GROSSCHEDL ET AL., CELL, vol. 38, 1984, pages 647 - 658;;ORNITZ ET AL., COLD SPRING HARBOR SYMP. QUANT. BIOL., vol. 50, 1986, pages 399 - 409;;MACDONALD, HEPATOLOGY, vol. 7, 1987, pages 425 - 515;;MOGRAM ET AL., NATURE, vol. 314, 1985, pages 283 - 286;;ALEXANDER ET AL., MOL. CELL. BIOL., vol. 7, 1987, pages 1436 - 1444;;KOLLIAS ET AL., CELL, vol. 46, 1986, pages 485 - 495;;PINKERT ET AL., GENES AND DEVEL., vol. 1, 1987, pages 161 - 171;;KRUMLAUF ET AL., MOL. CELL. BIOL., vol. 5, 1985, pages 1639 - 1648;;HAMMER ET AL., SCIENCE, vol. 253, 1987, pages 53 - 58;;READHEAD ET AL., CELL, vol. 48, 1987, pages 703 - 712;;MASON ET AL., SCIENCE, vol. 234, 1986, pages 1372 - 1378;;COSMAN ET AL., NATURE, vol. 312, 1984, pages 768;;""Current Protocols In Immunology"", 1993, JOHN WILEY & SONS;;""Remington's Pharmaceutical Sciences"", 2005, MACK PUBLISHING COMPANY;;""The CCP4 suite: programs for protein crystallography"", ACTA CRYSTALLOGR D BIOL CRYSTALLOGR, vol. 50, 1994, pages 760 - 3;;BRUNGER ET AL., ACTA CRYSTALLOGR D BIOL CRYSTALLOGR, vol. 54, 1998, pages 905 - 21;;DELANO, W.L.PALO ALTO: ""The PyMOL Graphics System"", 2002, SCHRODINGER, LLC",PENDING
337,CN,A,CN 108878246 A,188-103-519-060-06X,2018-11-23,2018,CN 201810444173 A,2018-05-10,US 201762504471 P;;US 201815965794 A,2017-05-10,MULTI-LAYER PLASMA EROSION PROTECTION FOR CHAMBER COMPONENTS,"A method of applying a multi-layer plasma resistant coating on an article comprises performing plating or ALD to form a conformal first plasma resistant layer on an article, wherein the conformal first plasma resistant layer is formed on a surface of the article and on walls of high aspect ratio features in the article. The conformal first plasma resistant coating has a porosity of approximately 0% and a thickness of approximately 200 nm to approximately 1 micron. One of electron beam ion assisted deposition (EB-IAD), plasma enhanced chemical vapor deposition (PECVD), aerosol deposition or plasma spraying is then performed to form a second plasma resistant layer that covers the conformal first plasma resistant layer at a region of the surface but not at the walls of the high aspect ratio features.",APPLIED MATERIALS INC,TRAN TOAN;;LAKSHESWAR KALITA;;KIM TAE WON;;LUBOMIRSKY DMITRY;;WU XIAOWEI;;HE XIAO-MING;;CHOU CHENG-HSUAN;;SUN JENNIFER Y,,https://lens.org/188-103-519-060-06X,Patent Application,no,5,7,12,12,0,H01J37/32477;;H01J37/32495;;C23C16/04;;C23C16/40;;C23C16/4404;;C23C16/45544;;C23C16/45565;;C23C28/042;;C23C24/04;;C25D7/123;;C23C18/36;;H01J37/32495;;C23C16/403;;C23C16/0254;;H01J37/32477;;H01J37/32495;;C23C16/403;;H01J2237/0203;;C23C16/0254;;C23C16/45525;;C23C28/042;;C23C16/45544;;C23C18/36;;C23C16/04;;C23C16/4404;;C23C16/45565;;C25D7/123;;C23C16/40;;C23C24/04;;H01J37/32477,H01J37/32,,0,0,,,,ACTIVE
338,US,A1,US 2017/0228950 A1,074-093-940-058-131,2017-08-10,2017,US 201615017357 A,2016-02-05,US 201615017357 A,2016-02-05,APPARATUS AND METHODS FOR ENTRY CONTROL OVER A CELLULAR NETWORK,"Apparatus and methods for controlling physical access to a location include an entry system including at least one barrier at the physical location, with the barrier configured to selectively permit access into and/or from and/or within the physical location upon proper credentials and/or authorization. A cellular device is connected to or integrated with the entry system and is configured to transmit and receive voice and/or data information to the entry system that includes the credentials and/or authorization. The cellular device can be a retrofit to prior art/installed systems, can be external to an otherwise operational system, and/or can be integrated natively into the entry system. Methods and apparatus are disclosed to determine the power status and network link state of the cellular device and/or to establish communication through/to same, as well as for the cellular device to be connected to and control a plurality of entry systems and/or barriers. A plurality of entry systems and/or barriers can be controlled by one or more cellular devices, and the usage (and associated billing charges from cellular service providers) on any/all of those cellular devices monitored and selected to optimize (reduce) the expense of any data or other charges imposed by a cellular carrier associated with the cellular device. Optimization can include allocation to the aforementioned voice and/or data cellular plans related to specific of the plurality of entry systems and/or barriers.",DOORKING INC,RICHMOND THOMAS R;;RICHMOND SUZANNE;;KOCHIE PATRICK S;;CHENG YU JENNIFER;;BEAR EITAN T;;GUEORGUIEVA NADEJDA V;;CEBALLOS EMMANUEL G,DOORKING INC (2016-05-18),https://lens.org/074-093-940-058-131,Patent Application,yes,0,5,2,2,0,G07C9/00817;;G07C2009/00761;;G07C2009/00793;;H04M15/00;;H04M15/68;;H04W4/24;;G07C9/00309;;H04W4/021;;H04W4/14;;H04M15/8033;;H04M1/72412;;G07C9/00309;;H04W4/021;;H04W4/14;;H04M15/8033;;G07C2009/0038;;G07C9/00817;;G07C2009/00761;;G07C2009/00793;;H04M15/68;;H04W4/24;;H04M15/00;;G07C9/257;;H04M1/72412,G07C9/00;;H04M1/72412;;H04M15/00;;H04W4/02;;H04W4/14,,0,0,,,,ACTIVE
339,JP,A,JP 2018190983 A,080-535-962-314-370,2018-11-29,2018,JP 2018090417 A,2018-05-09,US 201762504471 P;;US 201815965794 A,2017-05-10,MULTI-LAYER PLASMA EROSION PROTECTION FOR CHAMBER COMPONENT,"PROBLEM TO BE SOLVED: To provide a chamber component having plasma resistance.SOLUTION: A multi-layer plasma resistant coating is formed on an article. A forming method comprises the step of forming a conformal first plasma resistant layer 150 on an article by executing plating or ALD. The conformal first plasma resistant layer 150 is formed on a surface of the article and on walls of high aspect ratio features in the article. A conformal first plasma resistant coating has a porosity rate of approximately 0% and a thickness of approximately 200 nm to approximately 1 micron. One of electron beam ion assisted deposition (EB-IAD), plasma enhanced chemical vapor deposition (PECVD), aerosol deposition or plasma spraying is then performed to form a second plasma resistant layer 152 that covers the conformal first plasma resistant layer 150 in one region of the surface but does not cover it on the walls of the high aspect ratio features.SELECTED DRAWING: Figure 1B",APPLIED MATERIALS INC,TRAN TOAN;;LAKSHESWAR KALITA;;KIM TAE WON;;DMITRY LUBOMIRSKY;;WU XIAOWEI;;HE XIAO-MING;;CHOU CHENG-HSUAN;;SUN JENNIFER Y,,https://lens.org/080-535-962-314-370,Patent Application,no,12,4,12,12,0,H01J37/32477;;H01J37/32495;;C23C16/04;;C23C16/40;;C23C16/4404;;C23C16/45544;;C23C16/45565;;C23C28/042;;C23C24/04;;C25D7/123;;C23C18/36;;H01J37/32495;;C23C16/403;;C23C16/0254;;H01J37/32477;;H01J37/32495;;C23C16/403;;H01J2237/0203;;C23C16/0254;;C23C16/45525;;C23C28/042;;C23C16/45544;;C23C18/36;;C23C16/04;;C23C16/4404;;C23C16/45565;;C25D7/123;;C23C16/40;;C23C24/04;;H01J37/32477,H01L21/3065;;C23C14/00;;C23C14/08;;C23C16/40;;H01L21/205;;H01L21/31;;H05H1/46,,0,0,,,,ACTIVE
340,BR,A8,BR PI0714708 A8,115-133-569-656-872,2016-11-29,2016,BR PI0714708 A,2007-07-25,US 83328806 P;;US 2007/0016775 W,2006-07-26,poli[etileno glicol] hidrofobicamente modificado para uso no controle de breu e cola em polpa e nos processos de fabricação de papel,poli(etileno glicol] hidrofobicamente modificado para uso no controle de breu e cola em polpa e nos processos de fabricação de papel. métodos para inibir as sedimentações de contaminadores orgânicos da polpa em sistemas de polpa e fabricação de papel são descritos. o poli[etileno glicol] hidrofobicamente modificado é adicionado à polpa ou aplicado para as superfícies propensas à sedimentação de um sistema de fabricação de papel.,HERCULES INC;;SOLENIS TECHNOLOGIES CAYMAN LP,DOHERTY ERIN A S;;CHENG HUAI N;;RITTENHOUSE-PRUSS JENNIFER L;;GU QU-MING;;GELMAN ROBERT A;;CAREY WILLIAM S,"SOLENIS TECHNOLOGIES CAYMAN, L.P. (CH) (2016-04-12)",https://lens.org/115-133-569-656-872,Patent Application,no,0,0,21,21,0,C08G65/22;;C08G65/2609;;D21C9/008;;D21H21/02;;C08G2650/34;;C08G65/22;;C08G65/2609;;C08G2650/34;;D21C9/008;;D21H21/02;;D21H21/02;;C08G2650/34;;C08G65/22;;D21C9/008;;C08G65/2609,C11D1/722;;C08L71/02;;D21C9/00;;D21H21/02,,0,0,,,,ACTIVE
341,US,A1,US 2008/0029231 A1,176-299-631-184-734,2008-02-07,2008,US 88112807 A,2007-07-25,US 88112807 A;;US 83328806 P,2006-07-26,Hydrophobically modifed poly[ethylene glycol] for use in pitch and stickies control in pulp and papermaking processes,Methods for inhibiting the depositions of organic contaminants from pulp in pulp and papermaking systems are disclosed. Hydrophobically modified poly[ethylene glycol] are added to the pulp or applied to deposition-prone surfaces of a papermaking system.,GU QU-MING;;CHENG HUAI N;;CAREY WILLIAM S;;GELMAN ROBERT A;;RITTENHOUSE PRUSS JENNIFER L;;DOHERTY ERIN A S,GU QU-MING;;CHENG HUAI N;;CAREY WILLIAM S;;GELMAN ROBERT A;;RITTENHOUSE PRUSS JENNIFER L;;DOHERTY ERIN A S,HERCULES INCORPORATED (2007-07-20),https://lens.org/176-299-631-184-734,Patent Application,yes,8,11,21,21,0,C08G65/22;;C08G65/2609;;D21C9/008;;D21H21/02;;C08G2650/34;;C08G65/22;;C08G65/2609;;C08G2650/34;;D21C9/008;;D21H21/02;;D21H21/02;;C08G2650/34;;C08G65/22;;D21C9/008;;C08G65/2609,D21H17/00;;D21C5/02,162/5;;162/164.1,1,0,,,"Polyethylene Glycols data sheet, JECFA, published FNP 38 1988, downloaded online 4/6/2012.",ACTIVE
342,US,B1,US 6363399 B1,024-001-426-551-068,2002-03-26,2002,US 75524901 A,2001-01-03,US 75524901 A;;US 33992599 A;;US 81175897 A;;US 3256396 P;;US 2828496 P,1996-10-10,Project-based full-length biomolecular sequence database with expression categories,"
    Disclosed is a relational database system for storing biomolecular sequence information in a manner that allows sequences to be catalogued and searched according to association with one or more projects for obtaining full-length biomolecular sequences from shorter sequences. The relational database has sequence records containing information identifying one or more projects to which each of the sequence records belong. Each project groups together one or more biomolecular sequences generated during work to obtain a full-length gene sequence from a shorter sequence. The computer system has a user interface allowing a user to selectively view information regarding one or more projects. The relational database also provides interfaces and methods for accessing and manipulating and analyzing project-based information. 
",INCYTE GENOMICS INC,MASLYN TIMOTHY J;;AU-YOUNG JANICE;;HILLMAN JENNIFER L;;HIBBERT HAROLD;;AKERBLOM INGRID E;;CHENG RACHEL J;;TANG YUANHUA T,,https://lens.org/024-001-426-551-068,Granted Patent,yes,7,54,2,4,0,G16B30/00;;G16B45/00;;G16B50/00;;G16B30/10;;G16B50/10;;G16B30/20;;G16B50/00;;Y10S707/99945;;Y10S707/99948;;Y10S707/99936;;G16B30/00;;G16B45/00;;G16B50/10;;G16B30/10;;G16B30/20,G16B50/10;;G06F17/30;;G16B30/10;;G16B30/20;;G16B45/00,707/104;;702/20;;707/6,33,12,008-273-238-627-941;;019-443-367-783-025;;061-678-499-019-650;;079-271-886-785-450;;009-746-075-150-280;;052-781-443-908-837;;040-207-641-735-680;;018-836-216-412-973;;006-381-752-720-802;;066-465-714-515-95X;;014-065-259-226-128;;022-442-902-707-432,10.1126/science.8456298;;8456298;;7660118;;10.1126/science.7660118;;10.1016/0958-1669(93)90048-2;;7764463;;2047873;;10.1126/science.2047873;;8790454;;10.1089/cmb.1994.1.65;;8783942;;10.1016/0168-9525(96)10038-x;;10.1093/nar/22.12.2360;;pmc523695;;8036164;;10.1093/nar/21.13.3021;;pmc309730;;8332524;;1422879;;10.1093/bioinformatics/8.5.461;;10.1016/b978-0-08-092596-7.50007-1;;8855227;;pmc38202;;10.1073/pnas.93.20.10614;;1422880;;10.1093/bioinformatics/8.5.467,"The Institute for Genomic Research, TIGR Database. Internet-http://www.tigr.org (Downloaded Dec. 23, 1997).;;National Center for Biotechnology Information (Index). Internet-http://www3.ncbi.nlm.nih.gov/ (Downloaded Dec. 23, 1997).;;National Center for Biotechnology Information; ENTREZ. Internet-http://www3.ncbi.nlm.nih.gov/entrez (Downloaded Dec. 23, 1997).;;National Center for Biotechnology Information; UniGene. Internet-http://www3.ncbi.nlm.nih.gov/unigene (Downloaded Dec. 23, 1997).;;National Center for Biotechnology Information; GenBank. Internet-http://www3.ncbi.nlm.nih.gov/web/genbank (Downloaded Dec. 23, 1997).;;MAGPIE; Automated Genome Project Investigation Environment. Internet-http://www.mcs.anl.gov/home/gaasterl/magpie.html (Downloaded Dec. 23, 1997).;;Stanford University, Stanford Genomic Resources. Internet-http://genome-www.stanford.edu, Sep. 1996 and Dec. 20, 1997.;;Incyte Pharmaceuticals, LIFESEQ Version 4.2 Release Notes and Physical Data Model, Oct. 1996.;;Incyte Pharmaceuticals, LIFESEQ Version 4.1 Release Notes and Physical Data Model, Jul. 1996.;;Incyte Pharmaceuticals, LIFESEQ Version 3.4 Release Notes, Jan. 1996.;;Incyte Pharmaceuticals, LIFESEQ Version 2.5 Release Notes, Jun. 1995.;;Incyte Pharmaceuticals, LIFESEQ Version 3.0 Release Notes, Sep. 1995.;;Incyte Pharmaceuticals, LIFESEQ Version 4.0 Release Notes, Apr. 1996.;;Incyte Pharmaceuticals, Introduction to the LIFESEQ Database, Version 3.4, Jan. 1996.;;Incyte Pharmaceuticals, LIFESEQ Training Manual, Version 4.1, Jul. 1996.;;Green, et al., ""Ancient Conserved Regions in New Gene Sequences and the Protein Databases"", Science, v.259, n. 5102, pp. 1711-1716 (1993).;;Waldrop, et al. ""Online Archives Let Biologist Interrogate the Genome"", Science, v. 269 n. 5229, pp. 1356-1358 (1995).;;No Author, ""Incyte Serves Up Information, part I"", In Vivo the Business & Medicine Report, p.32, ISSN: 0258-851X (1996).;;Martin, et al., ""Accessing Genetics Databases"", Database, v. 17, n. 1p. 51(8) (1994).;;Matsubara, K. and Okubo, K. ""Identification of New Genes by Systematic Analysis of cDNAs and Database Construction"", Current Opinion in Biotechnology, 1993, No. 4, pp. 672-677.;;Kanehisa, M. ""Toward Pathway Engineering: A New Database Old Genetic and Molecular Pathways."" Science and Technology Japan, 1995, No. 59, pp. 34-38.;;Gaasterland, T. and Sensen, C. ""Using Multiple Tools for Automated Genome Interpretation in an Integrated Environment"", Trends In Genetics, Jan. 1996.;;Adams, M.D. et al. ""Complementary DNA Sequencing: Expressed Sequence Tags and Human Genome Project"", Science, Jun. 21, 1991, vol. 252, p. 1651-1656.;;Keele, J.W., ""A Conceptual Database Model for Genomic Research"", Journal of Computational Biology, vol. 1, No. 1, pp. 65-76. (1994).;;Fickett, J.W. ""Finding genes by computer: the state of the art"" TIG vol. 12, No. 8, pp. 316-320. (Sep. 1996).;;""GDB 6.0 Goals"", http://gbd.gdbnet.ad.jp/gdb/docs/gdb6-goals.htm pp 1-5 (Mar. 1995).;;Duret, et al., ""HOVERGEN: a database of homologous vertebrate genes"", Nucleic Acids Research, Received Feb. 17, 1994, Revised and Accepted May 10, 1994, vol. 22, No. 12, pp. 2360-2365.;;Larsen, et al., ""The ribosomal database project"", Nucleic Acids Research, 1993, vol. 21, No. 13, pp. 3021-3023.;;D.W. Smith, et al., ""Biocomputing: Informatics Genome Projects"", Academic Press, Inc., Department of Biology and Center for Molecular Genetics, University of California, 1994, pp. 51-85.;;Parsons, et al., ""Clustering CDNA Sequences"", CABIOS, 8(5) 461-466.;;Henikoff, Steven, ""Comparative Sequence Analysis: Finding Genes"", Academic Press, Inc., 1994, pp. 867-111.;;Schena, et al., ""Parallel human genome analysis: Microarray-based expression monitoring of 1000 genes"", Proc. Natl. Acad. Sci. USA, vol. 93, Oct. 1994, pp. 10614-10619.;;Cuticchia, et al., ""CMAP: contig mapping and analysis package, a relational database for chromosome reconstruction"", Department of Genetics, The University of Georgia, vol. 8, No. 5, 1992, pp. 467-474.",EXPIRED
343,TW,B,TW I753163 B,076-851-141-876-51X,2022-01-21,2022,TW 107115900 A,2018-05-10,US 201762504471 P;;US 201815965794 A,2017-05-10,Multi-layer plasma erosion protection for chamber components,,APPLIED MATERIALS INC,TRAN TOAN;;LAKSHESWAR KALITA;;KIM TAE WON;;LUBOMIRSKY DMITRY;;WU XIAOWEI;;HE XIAO-MING;;CHOU CHENG HSUAN;;SUN JENNIFER Y,,https://lens.org/076-851-141-876-51X,Granted Patent,no,4,0,12,12,0,H01J37/32477;;H01J37/32495;;C23C16/04;;C23C16/40;;C23C16/4404;;C23C16/45544;;C23C16/45565;;C23C28/042;;C23C24/04;;C25D7/123;;C23C18/36;;H01J37/32495;;C23C16/403;;C23C16/0254;;H01J37/32477;;H01J37/32495;;C23C16/403;;H01J2237/0203;;C23C16/0254;;C23C16/45525;;C23C28/042;;C23C16/45544;;C23C18/36;;C23C16/04;;C23C16/4404;;C23C16/45565;;C25D7/123;;C23C16/40;;C23C24/04;;H01J37/32477,,,0,0,,,,ACTIVE
344,KR,A,KR 20180123983 A,163-558-947-883-074,2018-11-20,2018,KR 20180053225 A,2018-05-09,US 201762504471 P;;US 201815965794 A,2017-05-10,- MULTI-LAYER PLASMA EROSION PROTECTION FOR CHAMBER COMPONENTS,"A method for applying a multi-layer plasma resistant coating on an article includes the step of performing plating or ALD to form a conformal first plasma resistant layer on the article, wherein the conformal first plasma resistant layer is formed on the surface of the article and walls of high aspect ratio features in the article. The conformal first plasma resistant coating has porosity of approximately 0% and a thickness of approximately 200nm to approximately 1 micron. And then, one of electron beam ion assisted deposition (EB-IAD), plasma enhanced chemical vapor deposition (PECVD), and aerosol deposition or plasma spraying is performed to form a second plasma resistant layer that covers the conformal first plasma resistant layer at a region of the surface but not at the walls of the high aspect ratio features. Accordingly, the present invention can reduce tool down time, tool costs, particles and contamination of a processed substrate, and improve uniformity between processes.",APPLIED MATERIALS INC,TRAN TOAN;;LAKSHESWAR KALITA;;KIM TAE WON;;LUBOMIRSKY DMITRY;;WU XIAOWEI;;HE XIAO MING;;CHOU CHENG HSUAN;;SUN JENNIFER Y,,https://lens.org/163-558-947-883-074,Patent Application,no,2,1,12,12,0,H01J37/32477;;H01J37/32495;;C23C16/04;;C23C16/40;;C23C16/4404;;C23C16/45544;;C23C16/45565;;C23C28/042;;C23C24/04;;C25D7/123;;C23C18/36;;H01J37/32495;;C23C16/403;;C23C16/0254;;H01J37/32477;;H01J37/32495;;C23C16/403;;H01J2237/0203;;C23C16/0254;;C23C16/45525;;C23C28/042;;C23C16/45544;;C23C18/36;;C23C16/04;;C23C16/4404;;C23C16/45565;;C25D7/123;;C23C16/40;;C23C24/04;;H01J37/32477,H01L21/02;;H01L21/67;;H05H1/46,,0,0,,,,ACTIVE
345,PE,A1,PE 20161327 A1,043-675-398-150-151,2016-12-03,2016,PE 2016002001 A,2010-10-26,US 25498209 P;;US 38128710 P,2009-10-26,PROTEINAS DE ENLACE AL ANTIGENO IL-23 HUMANA,"Se refiere a una proteina de enlace al antigeno tal como un anticuerpo que se enlaza a IL-23. Tambien se refiere a una composicion farmaceutica de dicho anticuerpo que es util en el tratamiento de esclerosis multiple, artritis reumatoide, cancer y psoriasis, entre otros",AMGEN INC,CERNE HEATHER;;CHENG JANET D;;KETCHEM RANDAL R;;ZHANG YU;;PIPER DEREK EVAN;;SUN YU;;TOWNE JENNIFER E;;O'NEILL JASON CHARLES,,https://lens.org/043-675-398-150-151,Patent Application,no,0,0,86,87,0,A61K2039/505;;C07K2317/21;;C07K2317/55;;C07K2317/92;;A61K47/6845;;C07K16/244;;A61P37/00;;C07K16/244;;A61K2039/505;;C07K2317/626;;C07K2317/21;;C07K2317/76;;A61K47/6845;;C07K2317/54;;A61K39/395;;C07K2317/31;;C07K16/24;;A61P37/00;;C07K2317/92;;C07K2317/24;;C07K2317/622;;C07K2317/55;;C07K2317/565;;A61K39/00;;A61K39/395;;A61K39/39533;;A61K39/3955;;C07K16/18;;C07K16/24;;C07K16/244;;A61K2039/505;;C07K2317/21;;C07K2317/55;;C07K2317/92;;A61K47/6845;;C07K16/244;;A61K39/395;;C07K16/24;;C07K2317/24;;C07K2317/31;;C07K2317/54;;C07K2317/565;;C07K2317/622;;C07K2317/626;;C07K2317/76,A61K39/395;;C07K16/24,,0,0,,,,DISCONTINUED
346,SI,T1,SI 2493925 T1,072-788-357-111-490,2017-05-31,2017,SI 201031391 A,2010-10-26,US 25498209 P;;US 38128710 P;;US 2010/0054148 W;;EP 10774095 A,2009-10-26,HUMAN IL-23 ANTIGEN BINDING PROTEINS,,AMGEN INC,TOWNE JENNIFER E;;CHENG JANET D;;O'NEILL JASON C;;ZHANG YU;;SUN YU;;CERNE HEATHER;;PIPER DEREK E;;KETCHEM RANDAL R,,https://lens.org/072-788-357-111-490,Granted Patent,no,0,0,86,87,0,A61K2039/505;;C07K2317/21;;C07K2317/55;;C07K2317/92;;A61K47/6845;;C07K16/244;;A61P37/00;;C07K16/244;;A61K2039/505;;C07K2317/626;;C07K2317/21;;C07K2317/76;;A61K47/6845;;C07K2317/54;;A61K39/395;;C07K2317/31;;C07K16/24;;A61P37/00;;C07K2317/92;;C07K2317/24;;C07K2317/622;;C07K2317/55;;C07K2317/565;;A61K39/00;;A61K39/395;;A61K39/39533;;A61K39/3955;;C07K16/18;;C07K16/24;;C07K16/244;;A61K2039/505;;C07K2317/21;;C07K2317/55;;C07K2317/92;;A61K47/6845;;C07K16/244;;A61K39/395;;C07K16/24;;C07K2317/24;;C07K2317/31;;C07K2317/54;;C07K2317/565;;C07K2317/622;;C07K2317/626;;C07K2317/76,C07K16/00;;A61K39/00,,0,0,,,,ACTIVE
347,US,A1,US 2022/0059893 A1,086-326-880-871-648,2022-02-24,2022,US 202117518179 A,2021-11-03,US 202117518179 A;;CN 201610987137 A;;US 201916348447 A;;IB 2017056996 W,2016-11-09,BATTERY PACK,"The present disclosure provides a battery pack for a hybrid vehicle. The battery pack includes: multiple battery cells, a housing, a first end plate, a second end plate, a bearing plate and an upper cover, wherein the housing is provided with a bottom portion and side walls extending from the periphery of the bottom portion and forming an upper portion opening; the housing is configured for accommodating the multiple battery cells and the two end plates, when the multiple battery cells are sequentially arranged and mounted into the housing, the first end plate and the second end plate are located at two end sides of the sequentially arranged multiple battery cells to laterally fix the multiple battery cells; the bearing plate is mounted above the top portions of the multiple battery cells; and the upper cover is mounted above the housing to cover the upper portion opening of the housing.",CPS TECH HOLDINGS LLC;;CLARIOS ADVANCED SOLUTIONS GMBH,FAN BINBIN;;CHENG LIANG;;QU WEI;;SONG PENG;;FU YINGYAO;;LIU CHANG;;FUHR JASON;;WIEGMANN MARTIN;;ZHANG XUGANG;;CZARNECKI JENNIFER L,CPS TECHNOLOGY HOLDINGS LLC (2019-04-30);;CLARIOS ADVANCED SOLUTIONS GMBH (2019-10-01);;JOHNSON CONTROLS TECHNOLOGY COMPANY (2019-09-09),https://lens.org/086-326-880-871-648,Patent Application,yes,2,0,9,9,0,H01M50/284;;H01M50/244;;H01M50/51;;H01M50/249;;H01M50/204;;H01M50/258;;H01M50/289;;H01M10/613;;H01M10/625;;H01M10/6563;;H01M10/6566;;H01M10/482;;H01M2010/4271;;H01M2200/103;;H01M2220/20;;H01M10/625;;H01M10/6563;;H01M10/613;;F04D25/0613;;F04D29/601;;H01M50/24;;H01M50/3425;;H01M50/553;;H01M50/507;;H01M50/367;;H01M50/284;;H01M50/55;;H01M50/51;;H01M50/583;;H01M50/244;;H01M50/271;;H01M50/298;;H01M50/209;;H01M50/517;;H01M50/296;;H01M50/242;;H01M50/227;;Y02E60/10;;B60L50/64;;B60L58/26;;F04D25/0673;;F04D29/601;;H01M10/425;;H01M2010/4271;;H01M2220/20;;H01M50/342;;H01M10/482;;H01M50/55;;H01M50/367;;H01M50/583;;H01M50/517;;H01M50/507;;H01M50/553;;H01M50/242;;H01M50/227;;H01M50/296;;H01M50/284;;H01M50/298;;H01M50/271;;H01M50/244;;H01M50/209;;H01M50/51,H01M50/20;;B60L50/64;;B60L58/26;;F04D25/06;;F04D29/60;;H01M10/42;;H01M50/209;;H01M50/227;;H01M50/242;;H01M50/244;;H01M50/249;;H01M50/271;;H01M50/284;;H01M50/296;;H01M50/298;;H01M50/342;;H01M50/35;;H01M50/367;;H01M50/502;;H01M50/507;;H01M50/51;;H01M50/517;;H01M50/543;;H01M50/55;;H01M50/553;;H01M50/583,,2,1,163-635-514-936-333,10.4324/9781003217718-7,Machine Translation of DE-102020213987-B3 (2/24/2023) (Year: 2023);;Machine Translation of CN-113574726-A (2/24/2023) (Year: 2023),ACTIVE
348,NZ,A,NZ 599875 A,104-840-864-211-423,2014-10-31,2014,NZ 59987510 A,2010-10-26,US 2010/0054148 W;;US 38128710 P;;US 25498209 P,2009-10-26,Human il-23 antigen binding proteins,"Disclosed is an antigen binding protein that binds IL-23, comprising the CDRs selected from the group consisting of the CDRs as defined in table 3 of the specification. Also disclosed are methods of making the said binding protein and its use in treating IL-23 associated disorders.",AMGEN INC,KETCHEM RANDAL R;;CHENG JANET D;;ZHANG YU;;NEILL JASON C;;CERNE HEATHER;;SUN YU;;PIPER DEREK E;;TOWNE JENNIFER E,,https://lens.org/104-840-864-211-423,Patent Application,no,0,0,86,87,0,A61K2039/505;;C07K2317/21;;C07K2317/55;;C07K2317/92;;A61K47/6845;;C07K16/244;;A61P37/00;;C07K16/244;;A61K2039/505;;C07K2317/626;;C07K2317/21;;C07K2317/76;;A61K47/6845;;C07K2317/54;;A61K39/395;;C07K2317/31;;C07K16/24;;A61P37/00;;C07K2317/92;;C07K2317/24;;C07K2317/622;;C07K2317/55;;C07K2317/565;;A61K39/00;;A61K39/395;;A61K39/39533;;A61K39/3955;;C07K16/18;;C07K16/24;;C07K16/244;;A61K2039/505;;C07K2317/21;;C07K2317/55;;C07K2317/92;;A61K47/6845;;C07K16/244;;A61K39/395;;C07K16/24;;C07K2317/24;;C07K2317/31;;C07K2317/54;;C07K2317/565;;C07K2317/622;;C07K2317/626;;C07K2317/76,C07K16/24;;A61K39/395,,0,0,,,,PENDING
349,US,A1,US 2021/0024626 A1,155-591-348-004-837,2021-01-28,2021,US 202017060905 A,2020-10-01,US 202017060905 A;;US 202016793610 A;;US 201916453482 A;;US 201816194896 A;;US 201815922675 A;;US 201615271315 A;;US 201414228556 A;;US 201213504449 A;;US 2010/0054148 W;;US 38128710 P;;US 25498209 P,2009-10-26,HUMAN IL-23 ANTIGEN BINDING PROTEINS,"Antigen binding proteins that bind to human IL-23 protein are provided. Nucleic acids encoding the antigen binding protein, vectors, and cells encoding the same as well as use of IL-23 antigen binding proteins for diagnostic and therapeutic purposes are also provided.",AMGEN INC,TOWNE JENNIFER E;;CHENG JANET D;;O'NEILL JASON C;;ZHANG YU;;SUN YU;;CERNE HEATHER;;PIPER DEREK E;;KETCHEM RANDAL R,AMGEN INC (2012-06-11),https://lens.org/155-591-348-004-837,Patent Application,yes,0,0,86,87,155,A61K2039/505;;C07K2317/21;;C07K2317/55;;C07K2317/92;;A61K47/6845;;C07K16/244;;A61P37/00;;C07K16/244;;A61K2039/505;;C07K2317/626;;C07K2317/21;;C07K2317/76;;A61K47/6845;;C07K2317/54;;A61K39/395;;C07K2317/31;;C07K16/24;;A61P37/00;;C07K2317/92;;C07K2317/24;;C07K2317/622;;C07K2317/55;;C07K2317/565;;A61K39/00;;A61K39/395;;A61K39/39533;;A61K39/3955;;C07K16/18;;C07K16/24;;C07K16/244;;A61K2039/505;;C07K2317/21;;C07K2317/55;;C07K2317/92;;A61K47/6845;;C07K16/244;;A61K39/395;;C07K16/24;;C07K2317/24;;C07K2317/31;;C07K2317/54;;C07K2317/565;;C07K2317/622;;C07K2317/626;;C07K2317/76,C07K16/24;;A61K39/395;;A61K47/68,,0,0,,,,DISCONTINUED
350,TW,A,TW 201417830 A,143-730-933-317-73X,2014-05-16,2014,TW 103103013 A,2010-10-26,US 25498209 P;;US 38128710 P,2009-10-26,Human IL-23 antigen binding proteins,"Antigen binding proteins that bind to human IL-23 protein are provided. Nucleic acids encoding the antigen binding protein, vectors, and cells encoding the same as well as use of IL-23 antigen binding proteins for diagnostic and therapeutic purposes are also provided.",AMGEN INC,TOWNE JENNIFER E;;CHENG JANET D;;O'NEILL JASON C;;ZHANG YU;;SUN YU;;CERNE HEATHER;;PIPER DEREK E;;KETCHEM RANDAL R,,https://lens.org/143-730-933-317-73X,Patent of Addition,no,0,0,86,87,0,A61K2039/505;;C07K2317/21;;C07K2317/55;;C07K2317/92;;A61K47/6845;;C07K16/244;;A61P37/00;;C07K16/244;;A61K2039/505;;C07K2317/626;;C07K2317/21;;C07K2317/76;;A61K47/6845;;C07K2317/54;;A61K39/395;;C07K2317/31;;C07K16/24;;A61P37/00;;C07K2317/92;;C07K2317/24;;C07K2317/622;;C07K2317/55;;C07K2317/565;;A61K39/00;;A61K39/395;;A61K39/39533;;A61K39/3955;;C07K16/18;;C07K16/24;;C07K16/244;;A61K2039/505;;C07K2317/21;;C07K2317/55;;C07K2317/92;;A61K47/6845;;C07K16/244;;A61K39/395;;C07K16/24;;C07K2317/24;;C07K2317/31;;C07K2317/54;;C07K2317/565;;C07K2317/622;;C07K2317/626;;C07K2317/76,A61K39/395;;A61P37/00;;C07K16/24,,0,0,,,,PENDING
351,AU,B2,AU 2010/315557 B2,061-026-783-770-982,2014-02-27,2014,AU 2010/315557 A,2010-10-26,US 38128710 P;;US 25498209 P;;US 2010/0054148 W,2009-10-26,Human IL-23 antigen binding proteins,"Antigen binding proteins that bind to human IL-23 protein are provided. Nucleic acids encoding the antigen binding protein, vectors, and cells encoding the same as well as use of IL-23 antigen binding proteins for diagnostic and therapeutic purposes are also provided.",AMGEN INC,TOWNE JENNIFER E;;CHENG JANET D;;O'NEILL JASON C;;ZHANG YU;;SUN YU;;CERNE HEATHER;;PIPER DEREK E;;KETCHEM RANDAL R,,https://lens.org/061-026-783-770-982,Granted Patent,no,3,0,86,87,0,A61K2039/505;;C07K2317/21;;C07K2317/55;;C07K2317/92;;A61K47/6845;;C07K16/244;;A61P37/00;;C07K16/244;;A61K2039/505;;C07K2317/626;;C07K2317/21;;C07K2317/76;;A61K47/6845;;C07K2317/54;;A61K39/395;;C07K2317/31;;C07K16/24;;A61P37/00;;C07K2317/92;;C07K2317/24;;C07K2317/622;;C07K2317/55;;C07K2317/565;;A61K39/00;;A61K39/395;;A61K39/39533;;A61K39/3955;;C07K16/18;;C07K16/24;;C07K16/244;;A61K2039/505;;C07K2317/21;;C07K2317/55;;C07K2317/92;;A61K47/6845;;C07K16/244;;A61K39/395;;C07K16/24;;C07K2317/24;;C07K2317/31;;C07K2317/54;;C07K2317/565;;C07K2317/622;;C07K2317/626;;C07K2317/76,C07K16/24;;A61K39/395,,0,0,,,,ACTIVE
352,MA,B1,MA 33757 B1,171-387-015-833-567,2012-11-01,2012,MA 34877 A,2012-05-18,US 25498209 P;;US 38128710 P;;US 2010/0054148 W,2009-10-26,بروتين رابط مستضد il-23 بشري,"La présente invention concerne des protéines de liaison à un antigène se liant à la protéine il-23 humaine. L'invention concerne également des acides nucléiques codant pour la protéine de liaison à un antigène, des vecteurs, et des cellules codant pour celle-ci ainsi que l'utilisation des protéines de liaison à l'antigène de l'il-23 humaine à des fins de diagnostic et thérapeutiques.",AMGEN INC,O'NEILL JASON C;;ZHANG YU;;SUN YU;;CERNE HEATHER;;PIPPER DEREK E;;KETCHEM RANDAL R;;TOWNE JENNIFER E;;CHENG JANET D,,https://lens.org/171-387-015-833-567,Granted Patent,no,0,0,86,87,0,A61K2039/505;;C07K2317/21;;C07K2317/55;;C07K2317/92;;A61K47/6845;;C07K16/244;;A61P37/00;;C07K16/244;;A61K2039/505;;C07K2317/626;;C07K2317/21;;C07K2317/76;;A61K47/6845;;C07K2317/54;;A61K39/395;;C07K2317/31;;C07K16/24;;A61P37/00;;C07K2317/92;;C07K2317/24;;C07K2317/622;;C07K2317/55;;C07K2317/565;;A61K39/00;;A61K39/395;;A61K39/39533;;A61K39/3955;;C07K16/18;;C07K16/24;;C07K16/244;;A61K2039/505;;C07K2317/21;;C07K2317/55;;C07K2317/92;;A61K47/6845;;C07K16/244;;A61K39/395;;C07K16/24;;C07K2317/24;;C07K2317/31;;C07K2317/54;;C07K2317/565;;C07K2317/622;;C07K2317/626;;C07K2317/76,C07K16/24;;A61K39/395,,0,0,,,,ACTIVE
353,CO,A2,CO 6531481 A2,168-122-764-513-665,2012-09-28,2012,CO 12068924 A,2012-04-26,US 25498209 P;;US 38128710 P,2009-10-26,PROTEINAS DE ENLACE AL ANTIGENO IL-23 HUMANAS,"Se proporcionan proteínas de enlace al antígeno que enlazan a la proteína IL-23 humano. También se proporcionan ácidos nucleicos que codifican la proteína de enlace al antígeno, vectores, y células que codifican los mismos así como uso de proteínas de enlace al antígeno IL-23 para propósitos de diagnóstico y terapéuticos.",AMGEN INC,TOWNE JENNIFER E;;CHENG JANET D;;O'NEILL JASON C;;ZHANG YU;;SUN YU;;CERNE HEATHER;;PIPER DEREK EVAN;;KETCHEM RANDAL ROBERT,,https://lens.org/168-122-764-513-665,Patent Application,no,0,0,86,87,0,A61K2039/505;;C07K2317/21;;C07K2317/55;;C07K2317/92;;A61K47/6845;;C07K16/244;;A61P37/00;;C07K16/244;;A61K2039/505;;C07K2317/626;;C07K2317/21;;C07K2317/76;;A61K47/6845;;C07K2317/54;;A61K39/395;;C07K2317/31;;C07K16/24;;A61P37/00;;C07K2317/92;;C07K2317/24;;C07K2317/622;;C07K2317/55;;C07K2317/565;;A61K39/00;;A61K39/395;;A61K39/39533;;A61K39/3955;;C07K16/18;;C07K16/24;;C07K16/244;;A61K2039/505;;C07K2317/21;;C07K2317/55;;C07K2317/92;;A61K47/6845;;C07K16/244;;A61K39/395;;C07K16/24;;C07K2317/24;;C07K2317/31;;C07K2317/54;;C07K2317/565;;C07K2317/622;;C07K2317/626;;C07K2317/76,C07K16/24,,0,0,,,,PENDING
354,BR,A2,BR 112012009854 A2,066-216-792-489-278,2016-11-22,2016,BR 112012009854 A,2010-10-26,US 2010/0054148 W;;US 25498209 P;;US 38128710 P,2009-10-26,proteína de ligação de antígeno il-23 humana,"proteína de ligação de antígeno il-23 humana. proteínas de ligação ao antígeno que se ligam a il-23 humano proteínas são fornecidos. os ácidos nucleicos que codificam a proteína de ligação ao antígeno, vectores e células que codifica o mesmo bem como a utilização de proteínas il-23 de ligação ao antígeno para fins de diagnóstico e terapêuticos são também fornecidos.",AMGEN INC,PIPER DEREK E;;CERNE HEATHER;;CHENG JANET D;;O'NEIL JASON C;;TOWNE JENNIFER E;;KETCHEM RANDAL R;;SUN YU;;ZHANG YU,,https://lens.org/066-216-792-489-278,Patent Application,no,0,0,86,87,0,A61K2039/505;;C07K2317/21;;C07K2317/55;;C07K2317/92;;A61K47/6845;;C07K16/244;;A61P37/00;;C07K16/244;;A61K2039/505;;C07K2317/626;;C07K2317/21;;C07K2317/76;;A61K47/6845;;C07K2317/54;;A61K39/395;;C07K2317/31;;C07K16/24;;A61P37/00;;C07K2317/92;;C07K2317/24;;C07K2317/622;;C07K2317/55;;C07K2317/565;;A61K39/00;;A61K39/395;;A61K39/39533;;A61K39/3955;;C07K16/18;;C07K16/24;;C07K16/244;;A61K2039/505;;C07K2317/21;;C07K2317/55;;C07K2317/92;;A61K47/6845;;C07K16/244;;A61K39/395;;C07K16/24;;C07K2317/24;;C07K2317/31;;C07K2317/54;;C07K2317/565;;C07K2317/622;;C07K2317/626;;C07K2317/76,A61K39/395;;C07K16/24,,0,0,,,,ACTIVE
355,BR,A8,BR 112012009854 A8,101-023-652-112-598,2019-10-08,2019,BR 112012009854 A,2010-10-26,US 2010/0054148 W;;US 25498209 P;;US 38128710 P,2009-10-26,proteínas de ligação de antígeno il-23 humana,"proteína de ligação de antígeno il-23 humana. proteínas de ligação ao antígeno que se ligam a il-23 humano proteínas são fornecidos. os ácidos nucleicos que codificam a proteína de ligação ao antígeno, vectores e células que codifica o mesmo bem como a utilização de proteínas il-23 de ligação ao antígeno para fins de diagnóstico e terapêuticos são também fornecidos.",AMGEN INC,DEREK E PIPER;;HEATHER CERNE;;JASON C O'NEILL;;JANET D CHENG;;JENNIFER E TOWNE;;RANDAL R KETCHEM;;YU SUN;;YU ZHANG,,https://lens.org/101-023-652-112-598,Patent Application,no,0,0,86,87,0,A61K2039/505;;C07K2317/21;;C07K2317/55;;C07K2317/92;;A61K47/6845;;C07K16/244;;A61P37/00;;C07K16/244;;A61K2039/505;;C07K2317/626;;C07K2317/21;;C07K2317/76;;A61K47/6845;;C07K2317/54;;A61K39/395;;C07K2317/31;;C07K16/24;;A61P37/00;;C07K2317/92;;C07K2317/24;;C07K2317/622;;C07K2317/55;;C07K2317/565;;A61K39/00;;A61K39/395;;A61K39/39533;;A61K39/3955;;C07K16/18;;C07K16/24;;C07K16/244;;A61K2039/505;;C07K2317/21;;C07K2317/55;;C07K2317/92;;A61K47/6845;;C07K16/244;;A61K39/395;;C07K16/24;;C07K2317/24;;C07K2317/31;;C07K2317/54;;C07K2317/565;;C07K2317/622;;C07K2317/626;;C07K2317/76,A61K39/395;;C07K16/24,,0,0,,,,ACTIVE
356,CN,A,CN 104761642 A,126-979-616-328-547,2015-07-08,2015,CN 201510065612 A,2010-10-26,US 25498209 P;;US 38128710 P;;CN 201080059062 A,2009-10-26,Human IL-23 antigen binding proteins,"Antigen binding proteins that bind to human IL-23 protein are provided. Nucleic acids encoding the antigen binding protein, vectors, and cells encoding the same as well as use of IL-23 antigen binding proteins for diagnostic and therapeutic purposes are also provided.",AMGEN INC,TOWNE JENNIFER E;;CHENG JANET D;;O'NEILL JASON C;;ZHANG YU;;SUN YU;;CERNE HEATHER;;PIPER DEREK E;;KETCHEM RANDAL R,,https://lens.org/126-979-616-328-547,Patent Application,no,6,3,86,87,0,A61K2039/505;;C07K2317/21;;C07K2317/55;;C07K2317/92;;A61K47/6845;;C07K16/244;;A61P37/00;;C07K16/244;;A61K2039/505;;C07K2317/626;;C07K2317/21;;C07K2317/76;;A61K47/6845;;C07K2317/54;;A61K39/395;;C07K2317/31;;C07K16/24;;A61P37/00;;C07K2317/92;;C07K2317/24;;C07K2317/622;;C07K2317/55;;C07K2317/565;;A61K39/00;;A61K39/395;;A61K39/39533;;A61K39/3955;;C07K16/18;;C07K16/24;;C07K16/244;;A61K2039/505;;C07K2317/21;;C07K2317/55;;C07K2317/92;;A61K47/6845;;C07K16/244;;A61K39/395;;C07K16/24;;C07K2317/24;;C07K2317/31;;C07K2317/54;;C07K2317/565;;C07K2317/622;;C07K2317/626;;C07K2317/76,C07K16/24;;A61K39/395;;A61P1/00;;A61P3/10;;A61P17/06;;A61P19/02;;A61P25/00;;A61P29/00;;A61P35/00;;A61P37/02;;C12N15/11;;C12N15/13;;C12Q1/68,,1,0,,,"BRIAN M. BEYER 等: ""“Crystal Structures of the Pro-Inflammatory Cytokine Interleukin-23 and Its Complex with a High-Affinity Neutralizing Antibody”"", 《JOURNAL OF MOLECULAR BIOLOGY》",DISCONTINUED
357,ZA,B,ZA 201203058 B,145-889-589-450-60X,2013-01-30,2013,ZA 201203058 A,2012-04-25,US 25498209 P;;US 38128710 P;;US 2010/0054148 W,2009-10-26,HUMAN IL-23 ANTIGEN BINDING PROTEINS,,AMGEN INC,TOWNE JENNIFER E;;O'NEILL JASON C;;SUN YU;;PIPER DEREK EVAN;;CHENG JANET D;;ZHANG YU;;CERNE HEATHER;;KETCHEM RANDAL ROBERT,,https://lens.org/145-889-589-450-60X,Granted Patent,no,0,0,86,87,0,A61K2039/505;;C07K2317/21;;C07K2317/55;;C07K2317/92;;A61K47/6845;;C07K16/244;;A61P37/00;;C07K16/244;;A61K2039/505;;C07K2317/626;;C07K2317/21;;C07K2317/76;;A61K47/6845;;C07K2317/54;;A61K39/395;;C07K2317/31;;C07K16/24;;A61P37/00;;C07K2317/92;;C07K2317/24;;C07K2317/622;;C07K2317/55;;C07K2317/565;;A61K39/00;;A61K39/395;;A61K39/39533;;A61K39/3955;;C07K16/18;;C07K16/24;;C07K16/244;;A61K2039/505;;C07K2317/21;;C07K2317/55;;C07K2317/92;;A61K47/6845;;C07K16/244;;A61K39/395;;C07K16/24;;C07K2317/24;;C07K2317/31;;C07K2317/54;;C07K2317/565;;C07K2317/622;;C07K2317/626;;C07K2317/76,A61K/;;C07K/,,0,0,,,,ACTIVE
358,US,B2,US 9951129 B2,156-824-737-528-993,2018-04-24,2018,US 201615271315 A,2016-09-21,US 201615271315 A;;US 201414228556 A;;US 201213504449 A;;US 2010/0054148 W;;US 38128710 P;;US 25498209 P,2009-10-26,Human IL-23 antigen binding proteins,"Antigen binding proteins that bind to human IL-23 protein are provided. Nucleic acids encoding the antigen binding protein, vectors, and cells encoding the same as well as use of IL-23 antigen binding proteins for diagnostic and therapeutic purposes are also provided.",AMGEN INC,TOWNE JENNIFER E;;CHENG JANET D;;O'NEILL JASON C;;ZHANG YU;;SUN YU;;CERNE HEATHER;;PIPER DEREK E;;KETCHEM RANDAL R,AMGEN INC (2012-06-11),https://lens.org/156-824-737-528-993,Granted Patent,yes,152,1,86,87,155,A61K2039/505;;C07K2317/21;;C07K2317/55;;C07K2317/92;;A61K47/6845;;C07K16/244;;A61P37/00;;C07K16/244;;A61K2039/505;;C07K2317/626;;C07K2317/21;;C07K2317/76;;A61K47/6845;;C07K2317/54;;A61K39/395;;C07K2317/31;;C07K16/24;;A61P37/00;;C07K2317/92;;C07K2317/24;;C07K2317/622;;C07K2317/55;;C07K2317/565;;A61K39/00;;A61K39/395;;A61K39/39533;;A61K39/3955;;C07K16/18;;C07K16/24;;C07K16/244;;A61K2039/505;;C07K2317/21;;C07K2317/55;;C07K2317/92;;A61K47/6845;;C07K16/244;;A61K39/395;;C07K16/24;;C07K2317/24;;C07K2317/31;;C07K2317/54;;C07K2317/565;;C07K2317/622;;C07K2317/626;;C07K2317/76,C12N15/24;;A61K39/00;;A61K39/395;;A61K47/68;;C07K16/24,,181,159,054-418-959-978-111;;006-294-819-324-316;;057-983-868-048-104;;000-879-344-254-347;;075-555-351-927-589;;039-141-300-950-038;;154-374-780-007-386;;017-449-753-661-071;;057-188-880-087-429;;061-444-349-075-997;;019-397-556-890-001;;011-724-225-446-939;;066-841-655-291-162;;112-514-905-529-435;;043-293-799-149-190;;106-794-363-564-085;;039-724-297-100-685;;129-447-558-597-627;;020-120-613-015-267;;062-170-867-080-500;;065-509-287-960-156;;023-476-471-521-012;;002-837-409-782-018;;137-607-161-868-61X;;047-573-440-316-329;;023-468-000-960-289;;061-754-151-573-898;;049-134-753-209-354;;024-995-475-936-443;;130-802-862-883-854;;067-226-137-053-81X;;003-246-587-515-619;;048-819-440-392-261;;066-119-584-271-19X;;020-296-196-517-635;;162-131-697-723-828;;101-171-874-734-776;;066-141-497-990-023;;083-000-601-623-651;;115-435-737-255-802;;105-521-401-667-801;;085-329-927-828-899;;098-276-747-378-726;;038-613-711-274-229;;040-397-285-492-490;;036-375-883-050-99X;;150-526-239-777-942;;069-863-076-076-464;;054-793-868-125-193;;014-201-444-265-19X;;016-951-862-040-407;;050-836-464-727-069;;129-978-431-330-653;;018-213-281-272-849;;023-907-179-348-058;;006-316-080-689-484;;007-224-607-447-181;;066-749-017-721-197;;076-270-369-964-609;;013-323-148-570-367;;002-649-962-296-826;;019-982-436-313-59X;;032-071-991-081-664;;076-436-009-754-971;;002-264-966-090-625;;040-428-679-610-399;;089-899-040-309-502;;006-574-964-805-278;;079-975-841-354-505;;016-815-797-562-455;;146-024-412-957-37X;;014-277-808-472-992;;064-787-766-418-165;;036-431-051-779-618;;043-624-776-168-982;;104-212-297-137-759;;052-714-495-277-870;;036-247-824-576-178;;082-596-938-068-845;;003-762-234-479-609;;041-241-834-308-816;;073-260-982-304-977;;071-662-142-202-504;;020-367-308-901-689;;027-903-185-617-733;;046-845-561-202-870;;116-478-741-055-56X;;043-108-278-056-872;;032-820-729-763-323;;003-570-249-164-056;;083-549-078-331-651;;106-248-968-254-022;;000-861-223-602-303;;020-950-767-861-522;;010-916-105-450-247;;020-855-322-534-259;;017-927-510-116-179;;114-858-675-505-463;;050-176-401-076-536;;016-219-576-017-946;;113-327-994-370-771;;029-745-513-975-612;;030-607-398-087-475;;015-109-431-185-638;;032-728-154-591-070;;046-042-144-895-793;;020-236-161-344-688;;062-761-744-997-508;;050-836-217-550-470;;001-910-820-229-599;;001-467-559-709-949;;103-477-074-900-777;;021-512-087-228-498;;042-204-626-457-327;;056-196-705-544-876;;012-273-285-250-15X;;027-477-313-726-928;;003-598-409-932-232;;012-378-195-919-957;;004-667-776-679-593;;063-263-492-125-344;;034-705-920-623-82X;;003-278-824-816-658;;040-577-067-037-463;;024-413-081-573-499;;026-974-217-132-522;;071-707-020-428-907;;020-753-772-581-741;;052-327-980-622-279;;052-835-629-769-725;;010-670-795-970-321;;039-460-067-637-00X;;060-375-551-951-388;;051-707-000-800-833;;093-461-724-410-757;;045-094-249-115-990;;065-114-602-989-551;;110-859-707-485-225;;074-817-300-512-106;;053-566-592-276-030;;113-982-061-284-768;;102-808-907-197-009;;101-336-210-882-496;;058-224-328-956-207;;039-206-790-543-279;;111-688-158-429-847;;003-011-267-840-74X;;061-282-572-464-283;;033-614-188-386-084;;032-615-818-756-560;;023-791-970-140-820;;155-171-030-721-421;;056-909-245-647-264;;053-627-861-267-834;;059-176-157-859-658;;025-096-410-637-730;;034-028-027-123-835;;034-849-028-103-586;;078-542-425-593-03X,10.1107/s0907444994003112;;15299374;;3906410;;10.1038/318533a0;;pmc1868863;;17328715;;10.1111/j.1365-2249.2007.03356.x;;19161422;;10.1111/j.1600-065x.2008.00705.x;;10.1126/science.2426778;;2426778;;0007018830;;7018830;;pmc52963;;1660140;;10.1073/pnas.88.23.10535;;10.1002/j.1460-2075.1994.tb06715.x;;8076595;;pmc395319;;12023338;;10.4049/jimmunol.168.11.5448;;10.1038/290304a0;;6259538;;18708069;;10.1016/j.jmb.2008.08.001;;10.1002/bit.10790;;14574701;;10.1126/science.1494-b;;10.1126/science.242.4885.1494-b;;10.1111/j.0022-202x.2004.23552.x;;9041643;;pmc2143633;;10.1002/pro.5560060217;;10.1126/science.1853201;;1853201;;16645485;;10.1097/01.qco.0000224818.42729.67;;10.1016/s0959-440x(97)80054-1;;9204279;;10.1038/296039a0;;6278311;;10.4049/jimmunol.156.9.3285;;8617951;;8372511;;10.1107/s0907444998003254;;9757107;;10.1038/344667a0;;1970124;;10.1137/0148063;;16670771;;10.1172/jci25308;;pmc1450386;;10.1093/intimm/5.6.647;;8347558;;10.1016/0042-6822(90)90025-m;;1693247;;10.1016/0022-2836(87)90412-8;;3681981;;10.1038/342877a0;;2687698;;354496;;10.1146/annurev.bi.47.070178.001343;;4358940;;10.1021/bi00699a002;;364941;;10.1002/9780470122921.ch2;;10.1038/312768a0;;6096720;;12610626;;10.1038/nature01355;;9373310;;10.1016/s1380-2933(96)00045-0;;11968507;;10.1385/1-59259-240-6:379;;6337371;;10.1073/pnas.80.1.21;;pmc393301;;10.1093/nar/12.1part1.387;;6546423;;pmc321012;;10.1016/s0021-9258(19)81080-3;;7061468;;10.1016/0003-2697(81)90168-8;;6175244;;10.1021/jm00390a019;;2885419;;7532457;;10.1006/smim.1994.1035;;10.1002/eji.200324038;;12778462;;10.1038/nbt0796-845;;9631008;;pmc4119940;;25033887;;14985542;;10.1093/protein/gzh012;;14978083;;10.4049/jimmunol.172.5.2827;;10.1016/0076-6879(90)83011-w;;2314273;;pmc305087;;10.1073/pnas.84.13.4355;;3474607;;pmc304773;;10.1073/pnas.84.9.2926;;3106981;;2432657;;10.1126/science.2432657;;16157683;;pmc2212952;;10.1084/jem.20050193;;10.1111/j.1749-6632.1995.tb55879.x;;7486582;;7584477;;10.1089/vim.2008.0014;;18570589;;pmc2570712;;pmc50453;;1438297;;10.1073/pnas.89.22.10915;;pmc2777488;;10.1093/rheumatology/kep293;;19815670;;10.1002/eji.200535239;;16482511;;8341653;;10.1073/pnas.90.14.6444;;pmc46948;;pmc148146;;9847191;;10.1093/nar/27.1.244;;14573361;;10.1016/j.tibtech.2003.08.007;;18512248;;10.1002/ibd.20475;;11397087;;10.1006/jmbi.2001.4662;;10.1016/0022-2836(92)90894-p;;1404359;;10.1038/nbt1088-1204;;10.1073/pnas.85.16.5879;;3045807;;pmc281868;;10.1073/pnas.90.6.2551;;8460171;;pmc46126;;8459850;;10.1038/362255a0;;10.1038/321522a0;;3713831;;9204280;;10.1016/s0959-440x(97)80055-3;;17291186;;10.1146/annurev.immunol.22.012703.104758;;10.4049/jimmunol.175.2.788;;16002675;;10.3410/f.1026900.326466;;10.4049/jimmunol.137.11.3614;;2431039;;10.1002/prot.10497;;12945055;;11566601;;10.1016/s1389-0344(01)00090-9;;10.1093/protein/10.4.423;;9194168;;10.4049/jimmunol.148.5.1547;;1531669;;10.1016/s1389-0344(01)00083-1;;11535414;;10.2165/11538950-000000000-00000;;21348542;;10.4049/jimmunol.152.1.146;;8254187;;7108955;;10.1016/0022-2836(82)90515-0;;16688182;;10.1038/nature04808;;11968500;;10.1385/1-59259-240-6:303;;10.1016/0092-8674(86)90280-1;;3011271;;1961196;;10.1016/0161-5890(91)90003-3;;15572068;;10.1016/j.dci.2004.07.003;;10.1016/j.intimp.2004.01.010;;15120653;;10.1002/(sici)1099-1352(199903/04)12:2<103::aid-jmr447>3.0.co;2-b;;10398401;;7494109;;10.3109/08830189509061738;;8159246;;10.1038/368856a0;;18606226;;10.1016/j.coi.2008.06.004;;10.1007/978-3-642-78432-3_3;;10.1016/j.jmb.2008.07.051;;18680750;;pmc2666310;;10.1093/protein/gzp073;;20022918;;3542783;;10.1002/hep.1840070708;;10.1038/nbt0792-779;;1368267;;1748994;;10.1016/0022-2836(91)90498-u;;10.1126/science.3097822;;3097822;;11701516;;10.1146/annurev.bioeng.2.1.339;;10.1158/1535-7163.mct-06-0003;;16648552;;10.1038/ng0297-146;;9020839;;1697100;;10.1111/j.1365-3083.1990.tb02896.x;;10.1016/0161-5890(88)90085-5;;3343974;;pmc392030;;10.1073/pnas.81.21.6851;;6436822;;8768901;;10.1016/s0958-1669(96)80118-2;;10.1016/0022-2836(70)90057-4;;5420325;;11114383;;10.1016/s1074-7613(00)00070-4;;3006998;;10.1101/sqb.1985.050.01.050;;pmc280147;;10.1073/pnas.85.9.3080;;3129726;;9705314;;10.1074/jbc.273.34.21769;;10.1101/gad.1.3.268;;3678824;;10.1016/s0969-2126(94)00113-8;;7704521;;10.1016/s0022-1759(00)00290-8;;11292488;;10.1016/0092-8674(87)90248-0;;2434242;;3127726;;10.1038/332323a0;;10.1146/annurev.bi.61.070192.002131;;1497316;;10.1146/annurev.biochem.61.1.387;;10.1021/bp030070k;;15176864;;10.1073/pnas.79.6.1979;;pmc346105;;6804947;;2984571;;10.1038/314283a0;;10.1002/pro.5560030503;;8061604;;pmc2142714;;7691815;;10.1016/s0021-9258(20)80605-x;;pmc47274;;8367454;;10.1073/pnas.90.17.7995;;8805507;;10.1016/s0969-2126(96)00005-6;;2825601;;10.1016/0003-9861(87)90469-3;;2180597;;pmc1534963;;10.1111/j.1365-2249.1990.tb08089.x;;10.1016/0076-6879(83)92023-2;;6855613;;10.1016/0092-8674(84)90258-7;;6567483;;1475190;;10.1093/nar/20.23.6287;;pmc334518;;10.1093/intimm/6.4.579;;8018598;;6322160;;10.1073/pnas.81.3.659;;pmc344894;;10.1038/354105a0;;1944583;;2439875;;10.1016/0076-6879(87)38030-9;;20956338;;pmc3776381;;10.4049/jimmunol.1001538;;8144892;;12079396;;10.1016/s0022-2836(02)00264-4;;10.1016/0166-2236(85)90140-7;;10.1126/science.2451287;;2451287;;358198;;pmc392859;;10.1073/pnas.75.8.3727;;10.1073/pnas.78.3.1441;;pmc319146;;6262799;;10.1038/341544a0;;2677748;;10.1093/protein/13.5.339;;10835107;;17888176;;pmc2212562;;10.1186/ar2297;;6257399;;10.1016/0092-8674(80)90555-3;;10.1016/s0093-3619(08)70740-8;;24321565;;10.1016/j.cellimm.2013.11.003;;21585245;;10.3109/07853890.2011.577093;;10.1007/s11926-007-0075-1;;pmc2893221;;18177599;;17658397;;10.1016/s0140-6736(07)61128-3;;10.1084/jem.20061099;;17030949;;pmc2118132;;10.1084/jem.20061082;;17030948;;pmc2118119;;14707118;;pmc1887731;;10.1084/jem.20030451;;18486739;;10.1016/s0140-6736(08)60725-4;;10.1038/nature05663;;17314973;;19641206;;10.1056/nejmra0804595;;10.1038/nm0107-26;;17206128;;15199399;;10.1172/jci22147;;10.1172/jci200422147;;pmc420513;;18486740;;10.1016/s0140-6736(08)60726-6;;10.2217/imt.11.122;;22053885;;10.4049/jimmunol.176.3.1908;;16424222;;10.1016/j.jaad.2007.07.016;;17706835,"The CCP4 Suite: Programs for Protein Crystallography, Acta Crystallogr D Biol Crystallogr, 50(Pt 5): p. 760-3 (1994).;;Adams et al., The c-myc oncogene driven by immunoglobulin enhancers induces lymphoid malignancy in transgenic mice, Nature, 318:533-538 (1985).;;Afzali et al., The role of T helper 17 (Th17) and regulatory T cells (Treg) in human organ transplantation and autoimmune disease, Clinical and Experimental Immunology, 148:32-46 (2007).;;Ahern et al., The interleukin-23 axis in intestinal inflammation, Immun. Rev., 226:147-159 (2008).;;Alexander et al., Expression of the c-myc Oncogene under control of an immunologulin enhancer in Eμ-myc Transgenic Mice, Mol. Cell. Biol., 7:1436-1444 (1987).;;Amit et al., Three-dimensional structure of an antigen-antibody complex at 2.8 A resolution, Science, 233(4765):747-53 (1986).;;Aplin and Wriston, Preparation, Properties, and Applications of Carbohydrate Conjugates of Proteins and Lipids, CRC Crit. Rev, Biochem., pp. 259-306 (1981).;;Ashkenazi et al., Protection against endotoxic shock by a tumor necrosis factor receptor immunoadhesin, Proc. Natl. Acad. Sci. USA, 88:10535 (1991).;;Baum et al., Identification of ligands for OX40 receptor, EMBO J., 13:3992-4001 (1994).;;Belladonna et al., IL-23 and IL-12 have overlapping, but distinct, effects on murine dendritic cells, The Journal of Immunology, 168:5448-5454 (2002).;;Benoist and Chambon, in vivo sequence requirements of the SV40 early promoter region, Nature, 290:304-310 (1981).;;Beyer et al., Crystal structures of the pro-inflammatory cytokine interleukin-23 and its complex with a high-affinity neutralizing antibody, J. Mol. Biol., 382(4):942-55 (2008).;;Beyer, et al., Crystal Structures of the Pro-Inflammatory Cytokine Interleukin-23 and Its Complex with a High-Affinity Neutralizing Antibody, J Mol Biol, 382(4):942-55 (2008).;;Bianchi and McGrew, High-Level Expression of Full-Length Antibodies Using Trans-Complementing Expression Vectors, Biotech. Biotechnol. Bioeng. 84:439-44 (2003).;;Bird et al., Single-Chain Antigen-Binding Proteins, Science, 242:423 (1988).;;Blauvelt, in this Issue—Full Court Press on Psoriasis, The Journal of Investigative Dermatology, pp. vii-viii (2004).;;Bloom et al., Intrachain disulfide bond in the core hinge region of human IgG4, Protein Science, 6:407 (1997).;;Bowie et al., A method to identify protein sequences that fold into a known three-dimensional structure, Science, 253:164-170 (1991).;;Bowman et al., Rationale and safety of anti-interleukin-23 and anti-interleukin-17A therapy, Current Opinion in Infectious Diseases, 19:245-52 (2006).;;Brenner et al., Population statistics of protein structures: lessons from structural classifications, Curr. Op. Struct. Biol., 7:369-376 (1997).;;Brinster et al., Regulation of metallothionein—thymidine kinase fusion plasmids injected into mouse eggs, Nature, 296:39-42 (1982).;;Brown et al., Tolerance of single, but not multiple, amino acid replacements in antibody VH CDR 2: a means of minimizing B cell wastage from somatic hypermutation?, J. Immunol., 156(9):3285-91 (1996).;;Bruggermann et al., Designer mice: the production of human antibody repertoires in transgenic animals, Year in Immunol., 7:33-40 (1993).;;Brunger, et al., Crystallography & NMR System: A new software suite for macromolecular structure determination, Acta Crystallogr D Biol Crystallogr, 54(Pt 5): p. 905-21 (1998).;;Byrn et al., Biological properties of a CD4 immunoadhesin, Nature, 344:677 (1990).;;Carillo et al., The Multiple Sequence Alignment Problem in Biology, SIAM J. Applied Math., 48:1073 (1988).;;Chen et al., Anti-IL-23 therapy inhibits multiple inflammatory pathways and ameliorates autoimune encephalomyelitis, The Journal of Clinical Investigation, 116:1317-1326 (2006).;;Chen et al., Immunoglobulin gene rearrangement in B cell deficient mice generated by targeted deletion of the JH locus, International Immunology, 5:647-656 (1993).;;Cheung, et al., Epitope-Specific Antibody Response to the Surface Antigen of Duck Hepatitus B Virus in Infected Ducks, Virology, 176:546-552 (1990).;;Chothia & Lesk, Canonical Structures for the Hypervariable Regions of Immunoglobulins, J. Mol. Biol., 196:901-917 (1987).;;Chothia et al., Conformations of immunoglobulin hypervariable regions, Nature, 342:878-883 (1989).;;Chou et al., Conformational Parameters for Amino Acids in Helical, β-Sheet, and Random Coil Regions Calculated from Proteins, Biochemistry, 113:211-222 (1974).;;Chou et al., Empirical Predictions of Proteins Conformation, Ann. Rev. Biochem., 47:251-276 (1979).;;Chou et al., Prediction of Protein Conformation, Biochem., 13:222-245 (1974).;;Chou et al., Prediction of the secondary structure of proteins from their amino acid sequence, Adv. Enzymol. Relat. Areas Mol. Biol., 47:45-148 (1978).;;Chou et al., Prediction of β-Turns, Biophys. J., 26:367-384 (1979).;;ClinicalTrials.gov, Identifier: NCT01094093, Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AMG 139 in Healthy Subjects and Subjects With Moderate to Severe Psoriasis, dated Mar. 25, 2010.;;Cosman et al., Cloning, sequence and expression of human interleukin-2 receptor, Nature, 312:768 (1984).;;Cua et al., Interleukin-23 rather than Interleukin-12 is the critical cytokine for autoimmune inflammation of the brain, Nature, 421:744-748 (2003).;;Davies et al., Affinity improvement of single antibody VH domains: residues in all three hypervariable regions affect antigen binding, Immunotechnology, 2(3):169-79 (1996).;;Dayhoff ef al., A model of evolutionary change in proteins, Atlas of Protein Sequence and Structure, 5:345-352 (1978).;;de Graaf et al., Expression of scFvs and scFv Fusion Proteins in Eukaryotic Cells, Methods Mol Biol., 178:379-387 (2002).;;DeBoer et al., The tac promoter: A functional hybrid derived from the trp and lac promoters, Proc. Natl. Acad. Sci. U.S.A., 80:21-25 (1983).;;Devereux et al., A comprehensive set of sequence analysis programs for the VAX, Nucl. Acid Res., 12:387 (1984).;;Duskin et al., Relationship of the structure and biological activity of the natural homologues of tunicamycin, J. Biol. Chem., 257:3105 (1982).;;Edge et al., Deglycosylation of Glycoproteins by Trifluoromethanesulfonic Acid, Anal. Biochem., 118:131 (1981).;;Evans et al., Design of Nonpeptidal Ligands for a Peptide Receptor: Cholecystokinin Antagonists, J. Med. Chem., 30:1229 (1987).;;Fanslow et al., Structural characteristics of CD40 ligand that determine biological function, Semin. Immunol., 6:267-278 (1994).;;Fauchere, Elements for the Rational Design of Peptide Drugs, Adv. Drug Res., 15:29 (1986).;;Fieschi and Casanova, Mini Review: The role of interleukin-12 in human infectious diseases: only a faint signature, Eur. J. Immunol., 33:1461-4 (2003).;;Fishwild et al., High-avidity human IgGk monoclonal antibodies from a novel strain of minilocus transgenic mice, Nature Biotechnology, 14:845-85 (1996).;;Fredericks et al, Identification of potent human anti-IL-IRI antagonist antibodies, Protein Engineering, Design & Selection, 17:95-106 (2004).;;GenBank Accession No. AB030000.;;GenBank Accession No. M65272.;;GenBank Accession No. NM 005535.;;GenBank Accession No. NM 144701.;;Ghilardi et al., Compromised Humoral and Delayed-Type Hypersensitivity Responses in IL-23-Deficient Mice, The Journal of Immunology, 172:2827-2833 (2004).;;Gribskov et al., Profile Analysis, Meth. Enzym., 183:146-159 (1990).;;Gribskov et al., Profile analysis: Detection of distantly related proteins, Proc. Nat. Acad. Sci., 84:4355-4358 (1987).;;Grosschedl et al., Introduction of a μ Immunoglobulin Gene into the Mouse Germ Line: Specific Expression in Lymphoid Cells and Synthesis of Functional Antibody, Cell, 38:647-658 (1984).;;Guisti et al., Somatic diversification of S107 from an antiphosphocholine to an anti-DNA autoantibody is due to a single base change in its heavy chain variable region, Proc. Natl. Acad. Sci. USA, 84(9):2926-30 (1987).;;Hammer et al., Diversity of alpha-fetoprotein gene expression in mice is generated by a combination of separate enhancer elements, Science, 253:53-58 (1987).;;Hanahan, Heritable formation of pancreatic β-cell tumours in transgenic mice expressing recombinant insulin/simian virus 40 oncogenes, Nature, 315:115-122 (1985).;;Happel et al., Divergent roles of IL-23 and IL-12 in host defense against Klebsiella pneumoniae, The Journal of Experimental Medicine, 202:761-769 (2005).;;Harding and Lonberg, Class Switching in Human Immunoglobulin Transgenic Mice, Ann. N. Y Acad. Sci., 764:536-546 (1995).;;Hayden et al., Single-chain mono- and bispecific antibody derivatives with novel biological properties and antitumour activity from a COS cell transient expression system, Therapeutic Immunology, 1 :3-15 (1994).;;Held et al., Generation of a Protective T-Cell Response Following Coronavirus Infection of the Central Nervous System Is Not Dependent on IL-12/23 Signaling, Viral Immunology, 21:173-187 (2008).;;Henikoff et al., Amino acid substitution matrices from protein blocks, Proc. Natl. Acad. Sci. U.S.A., 89:10915-10919 (1992).;;Hillyer et al., Investigating the role of the interleukin-23/-17A axis in rheumatoid arthritis, Rheumatology, 48:1581-1589 (2009).;;Hoeve et al., Divergent effects of IL-12 and IL-23 on the production of IL-17 by human T cells, Eur. J. Immunol., 36:1-10 (2006).;;Holliger et al., Diabodies: Small bivalent and bispecific antibody fragments, Proc. Natl. Acad. Sci. USA, 90:6444-48 (1993).;;Holm et al., Protein folds and families: sequence and structure alignments, Nucl. Acid. Res., 27:244-247 (1999).;;Holt et al., Domain antibodies: proteins for therapy, Trends Biotechnol., 21(11):484-90 (2003).;;Holtta et al., IL-23/IL-17 Immunity as a Hallmark of Crohn's Disease, Inflamm Bowel Dis., 14:1175-1184 (2008).;;Honegger and Pluckthun, Yet another numbering scheme for immunoglobulin variable domains: an automatic modeling and analysis tool, J. Mol. Biol., 309(3):657-670 (2001).;;Hoogenboom et al., By-passing Immunisation Human Antibodies from Synthetic Repertoires of Germline VH Gene Segments Rerranged in Vitro, J. Mol. Biol., 227:381 (1991).;;Hopp et al., A Short Polypeptide Marker Sequence Useful for Recombinant Protein Identification and Purification, Bio/Technology, 6:1204 (1988).;;Hoppe et al., A parallel three stranded α-helical bundle at the nucleation site of collagen triple-helix formation, FEBS Letters, 344:191 (1994).;;Huston et al., Protein engineering of antibody binding sites: recovery of specific activity in an anti-digoxin single-chain Fv analogue produced in Escherichia coli, Proc. Natl. Acad. Sci. U.S.A., 85:5879 (1988).;;Jakobovits et al., Analysis of homozygous mutant chimeric mice: Deletion of the immunoglobulin heavy-chain joining region blocks B-cell development and antibody production, Proc. Natl. Acad. Sci. USA, 90:2551-2555 (1993).;;Jakobovits et al., Germ-line transmission and expression of a human-derived yeast artificial chromosome, Nature, 362:255-258 (1993).;;Jones et al., Replacing the complementarity-determining regions in a human antibody with those from a mouse, Nature, 321 :522-525 (1986).;;Jones, Progress in protein structure prediction, Curr. Opin. Struct. Biol., 7:377-387 (1997).;;Kabat et al., Sequences of Proteins of Immunological Interest, 5th Ed., US Dept. of Health and Human Services, PHS, NIH, NIH Publication No. 91-3242 (1991).;;Kastelein, et al., Discovery and Biology of IL-23 and IL-27: Related but Functionally Distinct Regulators of Inflammation, Annual Review of Immunology, 25:221-42 (2007).;;Kelsey et al., Species- and tissue-specific expression of human α1-antitrypsin in transgenic mice, Genes and Devel., 1 :161-171 (1987).;;Khader et al., IL-23 Compensates for the Absence of IL-12p70 and Is Essential for the IL-17 Response during Tuberculosis but Is Dispensable for Protection and Antigen-Specific IFN-y Responses if IL-12p70 Is Available, The Journal of Immunology, 175:788-795 (2005).;;Kirkland et al., Analysis of the fine specificity and cross-reactivity of monoclonal anti-lipid A antibodies, J. Immunol., 137:3614-3619 (1986).;;Kollias et al., Regulated Expression of Human Aγ-, β-, and Hybrid γβ-Globin Genes in Transgenic Mice: Manipulation of the Developmental Expression Patterns, Cell, 46:89-94 (1986).;;Korndorfer et al., Crystallographic Analysis of an Anticalin With Tailored Specificity for fluorescein Reveals High Structural Plasticity of the Lipocalin Loop Region, Proteins: Structure, Function, and Bioinformatics, 53(1):121-9 (2003).;;Kortt et ai, Dimeric and trimeric antibodies: high avidity scFvs for cancer targeting, Biomol. Eng., 18:95-108 (2001).;;Kortt et al., Single-chain Fv fragments of anti-neuraminidase antibody NC10 containing five- and ten-residue linkers form dimers and with zero-residue linker a trimer, Prot. Eng., 10:423 (1997).;;Kostelny et al., Formation of a bispecific antibody by the use of leucine zippers, J. Immunol., 148:1547-1553 (1992).;;Kriangkum et al., Bispecific and bifunctional single chain recombinant antibodies, Biomol. Eng., 18:31-40 (2001).;;Krumlauf et al., Developmental regulation of α-fetoprotein genes in transgenic mice, Mol. Cell. Biol., 5:1639-1648 (1985).;;Kurzeja et al., New Interleukin-23 pathway inhibitors in dermatology, Am. J. Clin. Dermatol., 12:113-125 (2011).;;Kussie et al., A single engineered amino acid substitution changes antibody fine specificity, J. Immunol., 152(1):146-52 (1994).;;Kyte et al., A simple method for displaying the hydropathic character of a protein, J. Mol. Biol., 157:105-131 (1982).;;Langowski et al., IL-23 promotes tumour incidence and growth, Nature, 442: 461-5 (2006).;;Lantto et al., Chain Shuffling to modify properties of recombinant immunoglobulins, Methods Mol. Biol., 178:303-316 (2002).;;Leder et al., Consequences of widespread deregulation of the c-myc gene in transgenic mice: multiple neoplasms and normal development, Cell, 45:485-495 (1986).;;Lederman et al., A single amino acid substitution in a common African allele of the CD4 molecule ablates binding of the monoclonal antibody, OKT4, Mol. Immunol., 28(11):1171-81 (1991).;;Lefranc et al, IMGT unique numbering for immunoglobulin and T cell receptor constant domain and Ig superfamily C-like domains, Dev. Comp. Immunol., 29:185-203 (2005).;;Li et al., Temporal associations between interleukin 22 and the extracellular domains of IL-22R and IL-10R2, Int. Immunopharmacol., 4(5):693-708 (2004).;;Liu et al., Fine mapping of the antigen-antibody interaction of scFv215, a recombinant antibody inhibiting RNA polymerase II from Drosophila melanogaster, J. Mol. Recognit., 12(2):103-11 (1999).;;Liu, et al., Interleukin (IL)-23 p19 expression induced by IL-1β in human fibroblast-like synoviocytes with rheumatoid arthritis via active nuclear factor-kB and AP-1 dependent pathway, Rheumatology, 46(8):1266-73 (2007).;;Lonberg and Huszar, Human Antibodies from Transgenic Mice, Intern. Rev. Immunol., 13: 65-93 (1995).;;Lonberg et al., Antigen-specific human antibodies from mice comprising four distinct genetic modifications, Nature, 368:856-859 (1994).;;Lonberg et al., Fully human antibodies from transgenic mouse and phage display platforms, Current Opinion in Immunology, 20(4):450-459 (2008).;;Lonberg, Chapter 3, Transgenic Approaches to Human Monoclonal Antibodies, Handbook of Exp. Pharmacology, 113:49-101 (1994).;;Lupardus and Garcia, The Structure of Interleukin-23 Reveals the Molecular Basis of p40 subunit sharing with Interleukin-12, J. Mol. Biol., 382:931-941 (2008).;;Mabry et al., Engineering of stable bispecific antibodies targeting IL-17A and IL23, Protein Engineering Design & Selection, 23(3):115-127 (2010).;;MacDonald, Expression of the pancreatic elastase I gene in transgenic mice, Hepatology, 7:425-515 (1987).;;Magram et al., Developmental regulation of a cloned adult β-globin gene in transgenic mice, Nature, 315:338-340 (1985).;;Marks et al., By-Passing Immunization: building high affinity human antibodies by chain shuffling, BioTechnology, 10:779 (1992).;;Marks et al., Human Antibodies from V-gene Libraries Displayed on Phage, J. Mol. Biol., 222:581 (1991).;;Mason et al., The hypogonadal mouse: reproductive functions restored by gene therapy, Science, 234:1372-1378 (1986).;;Maynard et al., Antibody engineering, Annu. Rev. Biomed. Eng., 2:339-76 (2000).;;Meeran et al., Interleukin-12-deficient mice are at greater risk of UV radiation-induced skin tumors and malignant transformation of papillomas to carcinomas, Mol. Cancer Ther., 5: 825-32 (2006).;;Mendez et al., Functional transplant of megabase human immunoglobulin loci recapitulates human antibody response in mice, Nature Genetics, 15:146-156 (1997).;;Moldenhauer et al., Identity of HML-1 antigen on intestinal intraepithelial T cells and of B-ly7 antigen on hairy cell leukaemia, Scand. J. Immunol., 32:77-82 (1990).;;Morel et al., Monoclonal antibodies to bovine serum albumin: affinity and specificity determinations, Molec. Immunol., 25:7-15 (1988).;;Morrison et al., Chimeric human antibody molecules: mouse antigen-binding domains with human constant region domains, Proc. Natl. Acad. Sci. USA, 81:6851-6855 (1985).;;Moult, The current state of the art in protein structure predicton, Curr. Op. in Biotech., 7:422-427 (1996).;;Needleman et al., A general method applicable to the search for similarities in the amino acid sequence of two proteins, J. Mol. Biol., 48:443-453 (1970).;;Oppmann et al., Novel p19 protein engages IL-12p40 to Form a cytokine, IL-23, with biological activities similar as well as distinct from IL-12, Immunity, 13:715-725 (2000).;;Ornitz et al., Elastase I Promoter Directs Expression of Human Growth Hormone and SV40 T Antigen Genes to Pancreatic Acinar Cells in Transgenic Mice, Cold Spring Harbor Symp. Quant. Biol., 50:399-409 (1986).;;Panka et al., Variable region framework differences result in decreased or increased affinity of variant anti-digoxin antibodies, Proc. Natl. Acad. Sci. USA, 85(9):3080-4 (1988).;;Parham et al., A receptor for the heterodimeric cytokine IL-23 is composed of IL-12Rβ1 and a novel cytokine receptor subunit, IL-23R1, J. Immunol., 168:5699-708 (2002).;;Pini et al., Design and use of a phage display library. Human antibodies with subnanomolar affinity against a marker of angiogenesis eluted from a two-dimensional gel, J. Biol. Chem., 273(34):21769-76 (1998).;;Pinkert et al., An albumin enhancer located 10 kb upstream functions along with its promoter to direct efficient, liver-specific expression in transgenic mice, Genes and Devel., 1:268-276 (1987).;;Poljak et al., Production and structure of diabodies, Structure, 2:1121-23 (1994).;;Powers et al., Expression of single-chain Fv-Fc fusions in Pichia pastoris, Journal of Immunological Methods, 251 :123-135 (2001).;;Readhead et al., Expression of a myelin basic protein gene in transgenic shiverer mice: correction of the dysmyelinating phenotype, Cell, 48:703-712 (1987).;;Riechmann et al., Reshaping human antibodies for therapy, Nature, 332:323-27 (1988).;;Rizo and Gierasch, Constrained peptides: models of bioactive peptides and protein substructures, Ann. Rev. Biochem., 61:387 (1992).;;Roque et al., Antibodies and genetically engineered related molecules: production and purification, Biotechnol. Prog., 20:639-654 (2004).;;Rudikoff et al., Single amino acid substitution altering antigen-binding specificity, Proc. Natl. Acad. Sci. USA, 79(6):1979-83 (1982).;;Sani, Tissue-specific expression of rat myosin light-chain 2 gene in transgenic mice, Nature, 314:283-286 (1985).;;Schildbach et al., Contribution of a single heavy chain residue to specificity of an anti-digoxin monoclonal antibody, Protein Sci., 3(5):737-49 (1994).;;Schildbach et al., Heavy chain position 50 is a determinant of affinity and specificity for the anti-digoxin antibody 26-10, J. Biol. Chem., 268(29):21739-47 (1993).;;Shu et al., Secretion of a single-gene-encoded immunoglobulin from myeloma cells, Proc. Natl. Acad. Sci. USA, 90:7995-7999 (1993).;;Sippl et al., Threading thrills and threats, Structure, 4:15-19 (1996).;;Sojar et al., A chemical method for the deglycosylation of proteins, Arch. Biochem. Biophys., 259:52 (1987).;;Songsivilai and Lachmann, Bispecific antibody: a tool for diagnosis and treatment of disease, Clin. Exp. Immunol., 79:315-321 (1990).;;Stahli et al., Distinction of Epitopes by Monoclonal Antibodies, Methods in Enzymology, 92:242-253 (1983).;;Swift et al., Tissue-Specific Expression of the Rat Pancreatic Elastase / Gene in Transgenic Mice, Cell, 38:639-646 (1984).;;Taylor et al., A transgenic mouse that expresses a diversity of human sequence heavy and light chain immunoglobulins, Nucleic Acids Research, 20:6287-6295 (1992).;;Taylor et al., Human immunoglobulin transgenes undergo rearrangement, somatic mutation and class switching in mice that lack endogenous IgM, International Immunology, 6:579-591 (1994).;;Thomsen et al., Promoter-regulatory region of the major immediate early gene of human cytomegalovirus, Proc. Natl. Acad. U.S.A., 81:659-663 (1984).;;Thornton et al., Prediction of progress at last, Nature, 354:105 (1991).;;Thotakura et al., Enzymatic deglycosylation of glycoproteins, Meth. Enzymol., 138:350 (1987).;;Tonel et al., Cutting edge: A critical functional role for IL-23 in psoriasis, J. Immunol., 185(10):5688-91 (2010).;;Tuaillon et al., Biased utilization of DHQ52 and JH4 Gene Segments in a Human Ig Transgenic Minilocus is Independent of Antigenic Selection, J. Immunol., 152:2912-2920 (1994).;;Vajdos et al., Comprehensive functional maps of the antigen-binding site of an anti-ErbB2 antibody obtained with shotgun scanning mutagenesis, J. Mol. Biol., 230(2):415-28 (2002).;;Veber and Freidinger, The design of metabolically-stable peptide analogs, TINS, p. 392-396 (1985).;;Verhoeyen et al., Reshaping human antibodies: grafting an antilysozyme activity, Science, 239:1534-1536 (1988).;;Villa-Kamaroff et al., A bacterial clone synthesizing proinsulin, Proc. Natl. Acad. Sci. U.S.A., 75:3727-3731 (1978).;;Wagner et al., Nucleotide sequence of the thymidine kinase gene of herpes simplex virus type 1, Proc. Natl. Acad. Sci. U.S.A., 78:1444-1445 (1981).;;Ward et al., Binding activities of a repertoire of single immunoglobulin variable domains secreted from Escherichia coli, Nature, 334:544 (1989).;;Xiang et al., Study of B72.3 combining sites by molecular modeling and site-directed mutagenesis, Protein Eng., 13(5):339-44 (2000).;;Yago et al., IL-23 induces human osteoclastogenesis via IL-17 in vitro, and anti-IL-23 antibody attenuates collagen-induced arthritis in rats, Arthritis Res and Ther., 9(5):R96 (2007).;;Yamamoto et al., Identification of a functional promoter in the long terminal repeat of rous sarcoma virus, Cell, 22:787-797 (1980).;;Cargill et al., A large-scale genetic association study confirms IL12B and leads to the identification of IL23R as psoriasis-risk genes, Am. J. Hum. Genet., 80(2):273-90 (2007).;;Bandzar et al., Crohn's disease: a review of treatment options and current research, Cell Immunol., 286(1-2):45-52 (2013).;;Duvallet et al., Interleukin-23: A key cytokine in inflammatory diseases, Ann. Med., 43(7):503-11 (2011).;;Fitch et al., Pathophysiology of psoriasis: recent advances on IL-23 and Th17 cytokines, Curr Rheumatol Rep., 9(6):461-4 (2007).;;Griffiths et al., Pathogenesis and clinical features of psoriasis, Lancet.;370(9583):263-71 (2007).;;Harlow et al., Antibodies: A Laboratory Manual Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y. (1990).;;Hue et al., Interleukin-23 drives innate and T cell-mediated intestinal inflammation, J. Exp. Med., 203(11):2473-83 (2006).;;Kullberg et al., IL-23 plays a key role in Helicobacter hepaticus-induced T cell-dependent colitis, J. Exp. Med., 203(11):2485-94 (2006).;;Lee et al., Increased expression of interleukin 23 p19 and p40 in lesional skin of patients with psoriasis vulgaris, J. Exp. Med., 199(1):125-30 (2004).;;Leonardi et al., Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1), Lancet, 371(9625):1665-74 (2008).;;Lowes et al., Pathogenesis and therapy of psoriasis, Nature, 445(7130):866-73 (2007).;;Nestle et al., Psoriasis, N. Engl. J. Med., 361(5):496-509 (2009).;;Neurath, IL-23: a master regulator in Crohn disease, Nat. Med., 13(1):26-8 (2007).;;Nickoloff et al., Recent insights into the immunopathogenesis of psoriasis provide new therapeutic opportunities, J. Clin. Invest.,113(12):1664-75 (2004).;;Papp et al., Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2), Lancet,371(9625):1675-84 2(2008).;;Perrier et al., Cytokine blockade in inflammatory bowel diseases, Immunotherapy, 3(11):1341-52 (2011).;;Piskin et al., In vitro and in situ expression of IL-23 by keratinocytes in healthy skin and psoriasis lesions: enhanced expression in psoriatic skin, J. Immunol., 176(3):1908-15 (2006).;;Torti et al., Interleukin-12, interleukin-23, and psoriasis: Current prospects, J. Amer. Acad. Derm., 57(6):1059-68 (2007).",ACTIVE
359,AU,A1,AU 2010/315557 A1,180-354-069-834-931,2012-09-20,2012,AU 2010/315557 A,2010-10-26,US 38128710 P;;US 25498209 P;;US 2010/0054148 W,2009-10-26,Human IL-23 antigen binding proteins,"Antigen binding proteins that bind to human IL-23 protein are provided. Nucleic acids encoding the antigen binding protein, vectors, and cells encoding the same as well as use of IL-23 antigen binding proteins for diagnostic and therapeutic purposes are also provided.",AMGEN INC,TOWNE JENNIFER E;;CHENG JANET D;;O'NEILL JASON C;;ZHANG YU;;SUN YU;;CERNE HEATHER;;PIPER DEREK E;;KETCHEM RANDAL R,,https://lens.org/180-354-069-834-931,Patent Application,no,0,0,86,87,0,A61K2039/505;;C07K2317/21;;C07K2317/55;;C07K2317/92;;A61K47/6845;;C07K16/244;;A61P37/00;;C07K16/244;;A61K2039/505;;C07K2317/626;;C07K2317/21;;C07K2317/76;;A61K47/6845;;C07K2317/54;;A61K39/395;;C07K2317/31;;C07K16/24;;A61P37/00;;C07K2317/92;;C07K2317/24;;C07K2317/622;;C07K2317/55;;C07K2317/565;;A61K39/00;;A61K39/395;;A61K39/39533;;A61K39/3955;;C07K16/18;;C07K16/24;;C07K16/244;;A61K2039/505;;C07K2317/21;;C07K2317/55;;C07K2317/92;;A61K47/6845;;C07K16/244;;A61K39/395;;C07K16/24;;C07K2317/24;;C07K2317/31;;C07K2317/54;;C07K2317/565;;C07K2317/622;;C07K2317/626;;C07K2317/76,C07K16/24;;A61K39/395,,0,0,,,,ACTIVE
360,KR,A,KR 20120090091 A,015-004-413-233-180,2012-08-16,2012,KR 20127013696 A,2010-10-26,US 25498209 P;;US 38128710 P,2009-10-26,HUMAN IL-23 ANTIGEN BINDING PROTEINS,,AMGEN INC,TOWNE JENNIFER E;;CHENG JANET D;;O'NEILL JASON C;;ZHANG YU;;SUN YU;;CERNE HEATHER;;PIPER DEREK E;;KETCHEM RANDAL R,,https://lens.org/015-004-413-233-180,Patent Application,no,0,0,86,87,64,A61K2039/505;;C07K2317/21;;C07K2317/55;;C07K2317/92;;A61K47/6845;;C07K16/244;;A61P37/00;;C07K16/244;;A61K2039/505;;C07K2317/626;;C07K2317/21;;C07K2317/76;;A61K47/6845;;C07K2317/54;;A61K39/395;;C07K2317/31;;C07K16/24;;A61P37/00;;C07K2317/92;;C07K2317/24;;C07K2317/622;;C07K2317/55;;C07K2317/565;;A61K39/00;;A61K39/395;;A61K39/39533;;A61K39/3955;;C07K16/18;;C07K16/24;;C07K16/244;;A61K2039/505;;C07K2317/21;;C07K2317/55;;C07K2317/92;;A61K47/6845;;C07K16/244;;A61K39/395;;C07K16/24;;C07K2317/24;;C07K2317/31;;C07K2317/54;;C07K2317/565;;C07K2317/622;;C07K2317/626;;C07K2317/76,C07K16/24;;A61K39/395;;A61P29/00;;C12N15/13,,0,0,,,,ACTIVE
361,HK,A1,HK 1212357 A1,030-667-697-958-124,2016-06-10,2016,HK 16100056 A,2016-01-06,US 25498209 P;;US 38128710 P,2009-10-26,HUMAN IL-23 ANTIGEN BINDING PROTEINS IL-23,,AMGEN INC,TOWNE JENNIFER E;;CHENG JANET D;;ONEILL JASON C;;ZHANG YU;;SUN YU;;CERNE HEATHER;;PIPER DEREK E;;KETCHEM RANDAL R,,https://lens.org/030-667-697-958-124,Patent Application,no,0,0,86,87,0,A61K2039/505;;C07K2317/21;;C07K2317/55;;C07K2317/92;;A61K47/6845;;C07K16/244;;A61P37/00;;C07K16/244;;A61K2039/505;;C07K2317/626;;C07K2317/21;;C07K2317/76;;A61K47/6845;;C07K2317/54;;A61K39/395;;C07K2317/31;;C07K16/24;;A61P37/00;;C07K2317/92;;C07K2317/24;;C07K2317/622;;C07K2317/55;;C07K2317/565;;A61K39/00;;A61K39/395;;A61K39/39533;;A61K39/3955;;C07K16/18;;C07K16/24;;C07K16/244;;A61K2039/505;;C07K2317/21;;C07K2317/55;;C07K2317/92;;A61K47/6845;;C07K16/244;;A61K39/395;;C07K16/24;;C07K2317/24;;C07K2317/31;;C07K2317/54;;C07K2317/565;;C07K2317/622;;C07K2317/626;;C07K2317/76,C07K/;;A61K/;;A61P/;;C12N/;;C12Q/,,0,0,,,,PENDING
362,US,A1,US 2014/0212428 A1,039-569-102-824-61X,2014-07-31,2014,US 201414228556 A,2014-03-28,US 201414228556 A;;US 201213504449 A;;US 2010/0054148 W;;US 38128710 P;;US 25498209 P,2009-10-26,HUMAN IL-23 ANTIGEN BINDING PROTEINS,"Antigen binding proteins that bind to human IL-23 protein are provided. Nucleic acids encoding the antigen binding protein, vectors, and cells encoding the same as well as use of IL-23 antigen binding proteins for diagnostic and therapeutic purposes are also provided.",TOWNE JENNIFER E;;CHENG JANET D;;O'NEILL JASON C;;ZHANG YU;;SUN YU;;CERNE HEATHER;;PIPER DEREK E;;KETCHEM RANDAL R;;AMGEN INC,TOWNE JENNIFER E;;CHENG JANET D;;O'NEILL JASON C;;ZHANG YU;;SUN YU;;CERNE HEATHER;;PIPER DEREK E;;KETCHEM RANDAL R,AMGEN INC (2012-06-11),https://lens.org/039-569-102-824-61X,Patent Application,yes,0,1,86,87,155,A61K2039/505;;C07K2317/21;;C07K2317/55;;C07K2317/92;;A61K47/6845;;C07K16/244;;A61P37/00;;C07K16/244;;A61K2039/505;;C07K2317/626;;C07K2317/21;;C07K2317/76;;A61K47/6845;;C07K2317/54;;A61K39/395;;C07K2317/31;;C07K16/24;;A61P37/00;;C07K2317/92;;C07K2317/24;;C07K2317/622;;C07K2317/55;;C07K2317/565;;A61K39/00;;A61K39/395;;A61K39/39533;;A61K39/3955;;C07K16/18;;C07K16/24;;C07K16/244;;A61K2039/505;;C07K2317/21;;C07K2317/55;;C07K2317/92;;A61K47/6845;;C07K16/244;;A61K39/395;;C07K16/24;;C07K2317/24;;C07K2317/31;;C07K2317/54;;C07K2317/565;;C07K2317/622;;C07K2317/626;;C07K2317/76,C07K16/24,424/139.1;;530/387.9,0,0,,,,ACTIVE
363,EP,B1,EP 2493925 B1,053-979-801-825-83X,2016-11-23,2016,EP 10774095 A,2010-10-26,US 25498209 P;;US 38128710 P;;US 2010/0054148 W,2009-10-26,HUMAN IL-23 ANTIGEN BINDING PROTEINS,,AMGEN INC,TOWNE JENNIFER E;;CHENG JANET D;;O'NEILL JASON C;;ZHANG YU;;SUN YU;;CERNE HEATHER;;PIPER DEREK E;;KETCHEM RANDAL R,,https://lens.org/053-979-801-825-83X,Granted Patent,yes,0,0,86,87,0,A61K2039/505;;C07K2317/21;;C07K2317/55;;C07K2317/92;;A61K47/6845;;C07K16/244;;A61P37/00;;C07K16/244;;A61K2039/505;;C07K2317/626;;C07K2317/21;;C07K2317/76;;A61K47/6845;;C07K2317/54;;A61K39/395;;C07K2317/31;;C07K16/24;;A61P37/00;;C07K2317/92;;C07K2317/24;;C07K2317/622;;C07K2317/55;;C07K2317/565;;A61K39/00;;A61K39/395;;A61K39/39533;;A61K39/3955;;C07K16/18;;C07K16/24;;C07K16/244;;A61K2039/505;;C07K2317/21;;C07K2317/55;;C07K2317/92;;A61K47/6845;;C07K16/244;;A61K39/395;;C07K16/24;;C07K2317/24;;C07K2317/31;;C07K2317/54;;C07K2317/565;;C07K2317/622;;C07K2317/626;;C07K2317/76,C07K16/24;;A61K39/395,,3,3,027-477-313-726-928;;002-771-789-858-985;;039-460-067-637-00X,10.1073/pnas.79.6.1979;;pmc346105;;6804947;;10.4049/jimmunol.165.8.4505;;11035090;;20956338;;pmc3776381;;10.4049/jimmunol.1001538,"RUDIKOFF S ET AL: ""Single amino acid substitution altering antigen-binding specificity"", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES, NATIONAL ACADEMY OF SCIENCES, US, vol. 79, 1 March 1982 (1982-03-01), pages 1979 - 1983, XP007901436, ISSN: 0027-8424, DOI: 10.1073/PNAS.79.6.1979;;WINKLER K ET AL: ""Changing the antigen binding specificity by single point mutations of an anti-p24 (HIV-1) antibody"", THE JOURNAL OF IMMUNOLOGY, THE AMERICAN ASSOCIATION OF IMMUNOLOGISTS, US, vol. 165, no. 8, 15 October 2000 (2000-10-15), pages 4505 - 4514, XP002579393, ISSN: 0022-1767;;G. TONEL ET AL: ""Cutting Edge: A Critical Functional Role for IL-23 in Psoriasis"", THE JOURNAL OF IMMUNOLOGY, vol. 185, no. 10, 18 October 2010 (2010-10-18), pages 5688 - 5691, XP055203326, ISSN: 0022-1767, DOI: 10.4049/jimmunol.1001538",ACTIVE
364,US,B1,US 7267943 B1,063-876-376-832-334,2007-09-11,2007,US 985204 A,2004-12-02,US 985204 A;;US 32822602 A;;US 38399902 P,2002-05-29,Methods for detecting bacteriophage MS2,The present invention relates to methods and assays for detecting bacteriophage MS2 in a sample.,US ARMY,O'CONNELL KEVIN P;;KHAN AKBAR S;;CAO CHENG J;;BUCHER JENNIFER R;;GOSTOMSKI MARK V;;VALDES JAMES J;;ANDERSON PATRICIA E,,https://lens.org/063-876-376-832-334,Granted Patent,yes,0,2,5,5,17,C12Q1/701;;C12Q1/701;;C12Q1/686;;C12Q1/686,C12Q1/70;;C12Q1/68,435/5,0,0,,,,INACTIVE
365,TN,A1,TN 2012000167 A1,082-551-237-470-779,2013-12-12,2013,TN 2012000167 A,2012-04-10,US 2010/0054148 W;;US 25498209 P;;US 38128710 P,2009-10-26,HUMAN IL-23 ANTIGEN BINDING PROTEINS,"Antigen binding proteins that bind to human IL-23 protein are provided. Nucleic acids encoding the antigen binding protein, vectors, and cells encoding the same as well as use of IL-23 antigen binding proteins for diagnostic and therapeutic purposes are also provided.",AMGEN INC,TOWNE JENNIFER E;;CHENG JANET D;;ONEILL JASON C;;ZHANG YU;;SUN YU;;CERNE HEATHER;;PIPER DEREK E;;KETCHEM RANDAL R,,https://lens.org/082-551-237-470-779,Patent Application,no,0,0,86,87,0,A61K2039/505;;C07K2317/21;;C07K2317/55;;C07K2317/92;;A61K47/6845;;C07K16/244;;A61P37/00;;C07K16/244;;A61K2039/505;;C07K2317/626;;C07K2317/21;;C07K2317/76;;A61K47/6845;;C07K2317/54;;A61K39/395;;C07K2317/31;;C07K16/24;;A61P37/00;;C07K2317/92;;C07K2317/24;;C07K2317/622;;C07K2317/55;;C07K2317/565;;A61K39/00;;A61K39/395;;A61K39/39533;;A61K39/3955;;C07K16/18;;C07K16/24;;C07K16/244;;A61K2039/505;;C07K2317/21;;C07K2317/55;;C07K2317/92;;A61K47/6845;;C07K16/244;;A61K39/395;;C07K16/24;;C07K2317/24;;C07K2317/31;;C07K2317/54;;C07K2317/565;;C07K2317/622;;C07K2317/626;;C07K2317/76,A61K39/395;;C07K16/24,,0,0,,,,PENDING
366,US,A1,US 2020/0109299 A1,128-824-170-513-444,2020-04-09,2020,US 201816153501 A,2018-10-05,US 201816153501 A,2018-10-05,BIO-INK STRUCTURES AND METHODS OF PRODUCING THE SAME,"In various embodiments, the present disclosure provides methods of making a living structure from a bio-ink material of freeze-dried cells and methods of using the living structure for biosensing, tissue regeneration, environment sensing, drug discovery, catalysis, and/or clinical implementation.",L LIVERMORE NAT SECURITY LLC,QIAN FANG;;BAKER SARAH;;DEOTTE JOSHUA R;;DUOSS ERIC;;KNIPE JENNIFER MARIE;;RUELAS SAMANTHA;;SPADACCINI CHRISTOPHER;;STOLAROFF JOSHUAH K;;ZHU CHENG,LAWRENCE LIVERMORE NATIONAL SECURITY LLC (2019-02-08),https://lens.org/128-824-170-513-444,Patent Application,yes,0,2,1,1,0,C09D11/14;;C09D11/101;;C09D11/03;;C09D11/30;;B29C64/106;;B33Y70/00;;C12P7/00;;Y02E50/10;;B33Y70/10;;B33Y80/00;;B33Y10/00;;C09D11/03;;C09D11/101;;C12P7/06;;B29K2105/16;;B33Y10/00;;B29C64/106;;B33Y70/00,C09D11/03;;B29C64/106;;B33Y10/00;;B33Y70/00;;C09D11/101;;C12P7/06,,20,17,014-883-060-232-154;;010-175-244-087-497;;026-909-682-663-846;;109-486-037-861-935;;100-493-194-634-160;;032-588-725-673-458;;078-064-766-039-121;;083-042-620-432-063;;017-770-220-175-960;;046-787-340-155-588;;047-940-241-449-614;;040-385-542-442-411;;059-591-969-772-521;;114-113-818-292-850;;136-445-249-474-396;;021-808-830-748-354;;043-103-683-351-522,10.1186/s40824-018-0122-1;;pmc5889544;;29636985;;10.3390/gels4030061;;30674837;;pmc6209244;;10.1126/sciadv.aao6804;;29214219;;pmc5711516;;16095589;;10.1016/j.cryobiol.2005.06.002;;20580082;;10.1016/j.biomaterials.2010.05.055;;10.1021/acs.biomac.5b00188;;25806996;;10.1007/s002030000192;;11081789;;pmc148055;;10.1128/jb.185.5.1485-1491.2003;;12591863;;10.1016/j.idairyj.2004.02.001;;10.1021/bp034136n;;14763847;;24750766;;10.1016/j.carbpol.2012.03.059;;25871651;;10.1002/jemt.22508;;10.1089/bio.2015.0013;;26418068;;10.1016/j.sdentj.2018.06.002;;30202174;;pmc6128323;;pmc6787111;;10.1007/s10856-019-6318-7;;31599365;;pmc8383174;;34253695;;10.7555/jbr.35.20210036;;32106515;;10.3390/nano10030406;;pmc7152840,"Gopinathan, ""Recent trends in bioinks for 3D printing"". Biomaterials Research volume 22, Article number: 11 (April 6, 2018) <URL: https://biomaterialsres.biomedcentral.com/articles/10.1186/s40824-018-0122-1> (Year: 2018);;Perez-Luna, ""Encapsulation of Biological Agents in Hydrogels for Therapeutic Applications"". Gels, 4(3), 61 (July 11, 2018) <URL: https://www.mdpi.com/2310-2861/4/3/61/htm> (Year: 2018);;Schaffner, ""3D printing of bacteria into functional complex materials"". Science Advances, 3(12) (December 1, 2017) <URL: https://www.science.org/doi/10.1126/sciadv.aao6804> (Year: 2017);;OPS Diagnostics, ""Bacteria Lyophilization Overview"". Retrieved from The Wayback Machine (August 11, 2017) <URL: https://web.archive.org/web/20170811020121/https://opsdiagnostics.com/notes/ranpri/bacteria_lyophilization_overview.htm> (Year: 2017);;Han, Ying, et al. ""Improved preservation of human red blood cells by lyophilization."" Cryobiology 51.2 (2005): 152-164. (Year: 2005);;Guillotin, Bertrand, et al. ""Laser assisted bioprinting of engineered tissue with high cell density and microscale organization."" Biomaterials 31.28 (2010): 7250-7256. (Year: 2010);;BioNumbers; https://bionumbers.hms.harvard.edu/bionumber.aspx?id=105906&ver=2&trm=volume+of+a+mammalian+cell&org=; accessed 3/21/2023 (Year: 2023);;Markstedt, Kajsa, et al. ""3D bioprinting human chondrocytes with nanocellulose–alginate bioink for cartilage tissue engineering applications."" Biomacromolecules 16.5 (2015): 1489-1496. (Year: 2015);;Argüelles, Juan Carlos. ""Physiological roles of trehalose in bacteria and yeasts: a comparative analysis."" Archives of microbiology 174 (2000): 217-224. (Year: 2000);;Stewart, Philip S. ""Diffusion in biofilms."" Journal of bacteriology 185.5 (2003): 1485-1491. (Year: 2003);;Carvalho, Ana S., et al. ""Relevant factors for the preparation of freeze-dried lactic acid bacteria."" International Dairy Journal 14.10 (2004): 835-847. (Year: 2004);;Fonseca, Fernanda, et al. ""Collapse Temperature of Freeze‐Dried Lactobacillus bulgaricusSuspensions and Protective Media."" Biotechnology progress 20.1 (2004): 229-238. (Year: 2004);;Ruka, Dianne R., George P. Simon, and Katherine M. Dean. ""Altering the growth conditions of Gluconacetobacter xylinus to maximize the yield of bacterial cellulose."" Carbohydrate polymers 89.2 (2012): 613-622. (Year: 2012);;Santana, Bianca Palma, et al. ""Comparing different methods to fix and to dehydrate cells on alginate hydrogel scaffolds using scanning electron microscopy."" Microscopy research and technique 78.7 (2015): 553-561. (Year: 2015);;Runyon, Daniel E., and Adam Z. Higgins. ""The Effect of Human Serum Albumin and Hematocrit on the Cake Collapse Temperature of Lyophilized Red Blood Cells."" Biopreservation and Biobanking 13.5 (2015): 376-378. (Year: 2015);;Ammar, Mohamed M., et al. ""Growth factor release and enhanced encapsulated periodontal stem cells viability by freeze-dried platelet concentrate loaded thermo-sensitive hydrogel for periodontal regeneration."" The Saudi Dental Journal 30.4 (2018): 355-364. (Year: 2018);;Catoira, Marta Calvo, et al. ""Overview of natural hydrogels for regenerative medicine applications."" Journal of Materials Science: Materials in Medicine 30 (2019): 1-10. (Year: 2019);;Cleveland museum of art; https://www.clevelandart.org/art/1942.215.3; accessed 10/4/2023 (Year: 2023);;Barja F. Bacterial nanocellulose production and biomedical applications. J Biomed Res. 2021 May 14;35(4):310-317. doi: 10.7555/JBR.35.20210036. PMID: 34253695; PMCID: PMC8383174. (Year: 2021);;Choi, Soon Mo, and Eun Joo Shin. ""The nanofication and functionalization of bacterial cellulose and its applications."" Nanomaterials 10.3 (2020): 406. (Year: 2020)",PENDING
367,WO,A1,WO 2011/056600 A1,159-951-998-802-680,2011-05-12,2011,US 2010/0054148 W,2010-10-26,US 25498209 P;;US 38128710 P,2009-10-26,HUMAN IL-23 ANTIGEN BINDING PROTEINS,"Antigen binding proteins that bind to human IL-23 protein are provided. Nucleic acids encoding the antigen binding protein, vectors, and cells encoding the same as well as use of IL-23 antigen binding proteins for diagnostic and therapeutic purposes are also provided.",AMGEN INC;;TOWNE JENNIFER E;;CHENG JANET D;;O'NEILL JASON C;;ZHANG YU;;SUN YU;;CERNE HEATHER;;PIPER DEREK E;;KETCHEM RANDAL R,TOWNE JENNIFER E;;CHENG JANET D;;O'NEILL JASON C;;ZHANG YU;;SUN YU;;CERNE HEATHER;;PIPER DEREK E;;KETCHEM RANDAL R,,https://lens.org/159-951-998-802-680,Patent Application,yes,71,35,86,87,155,A61K2039/505;;C07K2317/21;;C07K2317/55;;C07K2317/92;;A61K47/6845;;C07K16/244;;A61P37/00;;C07K16/244;;A61K2039/505;;C07K2317/626;;C07K2317/21;;C07K2317/76;;A61K47/6845;;C07K2317/54;;A61K39/395;;C07K2317/31;;C07K16/24;;A61P37/00;;C07K2317/92;;C07K2317/24;;C07K2317/622;;C07K2317/55;;C07K2317/565;;A61K39/00;;A61K39/395;;A61K39/39533;;A61K39/3955;;C07K16/18;;C07K16/24;;C07K16/244;;A61K2039/505;;C07K2317/21;;C07K2317/55;;C07K2317/92;;A61K47/6845;;C07K16/244;;A61K39/395;;C07K16/24;;C07K2317/24;;C07K2317/31;;C07K2317/54;;C07K2317/565;;C07K2317/622;;C07K2317/626;;C07K2317/76,C07K16/24;;A61K39/395,,148,109,019-397-556-890-001;;000-861-223-602-303;;003-570-249-164-056;;114-738-893-000-504;;000-879-344-254-347;;066-119-584-271-19X;;113-982-061-284-768;;016-815-797-562-455;;015-979-728-056-035;;039-724-297-100-685;;098-276-747-378-726;;050-176-401-076-536;;041-241-834-308-816;;019-397-556-890-001;;106-248-968-254-022;;024-413-081-573-499;;014-277-808-472-992;;029-745-513-975-612;;061-754-151-573-898;;113-327-994-370-771;;012-273-285-250-15X;;073-260-982-304-977;;193-574-402-839-215;;163-587-638-794-871;;066-141-497-990-023;;023-907-179-348-058;;032-728-154-591-070;;049-134-753-209-354;;024-995-475-936-443;;027-903-185-617-733;;019-982-436-313-59X;;030-607-398-087-475;;006-574-964-805-278;;042-204-626-457-327;;045-094-249-115-990;;040-428-679-610-399;;089-899-040-309-502;;032-820-729-763-323;;043-108-278-056-872;;050-836-464-727-069;;071-707-020-428-907;;023-468-000-960-289;;060-375-551-951-388;;083-549-078-331-651;;020-753-772-581-741;;043-108-278-056-872;;038-613-711-274-229;;016-219-576-017-946;;032-071-991-081-664;;020-855-322-534-259;;040-577-067-037-463;;104-212-297-137-759;;017-150-654-990-340;;002-264-966-090-625;;162-131-697-723-828;;036-431-051-779-618;;052-714-495-277-870;;066-749-017-721-197;;001-467-559-709-949;;040-397-285-492-490;;103-477-074-900-777;;063-263-492-125-344;;129-978-431-330-653;;015-109-431-185-638;;067-226-137-053-81X;;032-055-913-011-134;;003-246-587-515-619;;130-802-862-883-854;;076-270-369-964-609;;129-447-558-597-627;;079-975-841-354-505;;034-705-920-623-82X;;106-794-363-564-085;;150-526-239-777-942;;069-863-076-076-464;;052-835-629-769-725;;105-521-401-667-801;;056-196-705-544-876;;076-436-009-754-971;;013-281-398-303-904;;085-329-927-828-899;;017-449-753-661-071;;039-141-300-950-038;;115-435-737-255-802;;010-670-795-970-321;;010-916-105-450-247;;011-724-225-446-939;;061-444-349-075-997;;052-327-980-622-279;;102-808-907-197-009;;065-114-602-989-551;;101-171-874-734-776;;026-974-217-132-522;;020-236-161-344-688;;086-016-360-704-586;;067-057-135-512-133;;021-074-280-354-982;;071-662-142-202-504;;001-910-820-229-599;;055-578-442-289-160;;000-999-407-005-345;;021-991-205-274-008;;005-984-586-162-249;;021-512-087-228-498;;003-598-409-932-232;;017-927-510-116-179;;048-819-440-392-261;;054-418-959-978-111;;023-476-471-521-012,18708069;;10.1016/j.jmb.2008.08.001;;10.1093/protein/gzp073;;20022918;;18606226;;10.1016/j.coi.2008.06.004;;012023369;;10.4049/jimmunol.168.11.5699;;12023369;;19161422;;10.1111/j.1600-065x.2008.00705.x;;12610626;;10.1038/nature01355;;17888176;;pmc2212562;;10.1186/ar2297;;17291186;;10.1146/annurev.immunol.22.012703.104758;;10.1093/rheumatology/kem055;;17569750;;16645485;;10.1097/01.qco.0000224818.42729.67;;10.1002/eji.200324038;;12778462;;10.1158/1535-7163.mct-06-0003;;16648552;;16688182;;10.1038/nature04808;;18708069;;10.1016/j.jmb.2008.08.001;;10.1016/j.jmb.2008.07.051;;18680750;;pmc2666310;;10.1016/0076-6879(83)92023-2;;6855613;;10.4049/jimmunol.137.11.3614;;2431039;;10.1016/0161-5890(88)90085-5;;3343974;;10.1016/0042-6822(90)90025-m;;1693247;;1697100;;10.1111/j.1365-3083.1990.tb02896.x;;10.1021/bp030070k;;15176864;;11968500;;10.1385/1-59259-240-6:303;;10.1385/0896032469;;8205184;;10.1385/0896032760;;8004156;;10.1385/0-89603-276-0:1;;10.1385/0-89603-246-9:1;;10.1007/978-1-349-21355-9;;10.1093/nar/12.1part1.387;;6546423;;pmc321012;;pmc50453;;1438297;;10.1073/pnas.89.22.10915;;10.1016/0022-2836(70)90057-4;;5420325;;10.1016/0022-2836(87)90412-8;;3681981;;10.1038/342877a0;;2687698;;15572068;;10.1016/j.dci.2004.07.003;;11397087;;10.1006/jmbi.2001.4662;;pmc392030;;10.1073/pnas.81.21.6851;;6436822;;10.1038/321522a0;;3713831;;3127726;;10.1038/332323a0;;10.1126/science.2451287;;2451287;;10.1073/pnas.90.6.2551;;8460171;;pmc46126;;8459850;;10.1038/362255a0;;8159246;;10.1038/368856a0;;7494109;;10.3109/08830189509061738;;10.1111/j.1749-6632.1995.tb55879.x;;7486582;;1475190;;10.1093/nar/20.23.6287;;pmc334518;;10.1093/intimm/5.6.647;;8347558;;8144892;;10.1007/978-3-642-78432-3_3;;10.1093/intimm/6.4.579;;8018598;;7494109;;10.3109/08830189509061738;;10.1038/nbt0796-845;;9631008;;pmc4119940;;25033887;;10.1038/ng0297-146;;9020839;;10.1016/0022-2836(92)90894-p;;1404359;;1748994;;10.1016/0022-2836(91)90498-u;;2180597;;pmc1534963;;10.1111/j.1365-2249.1990.tb08089.x;;10.4049/jimmunol.148.5.1547;;1531669;;3140379;;10.1126/science.3140379;;10.1073/pnas.85.16.5879;;3045807;;pmc281868;;11968507;;10.1385/1-59259-240-6:379;;11566601;;10.1016/s1389-0344(01)00090-9;;10.1016/s1389-0344(01)00083-1;;11535414;;8341653;;10.1073/pnas.90.14.6444;;pmc46948;;10.1016/s0969-2126(94)00113-8;;7704521;;14985542;;10.1093/protein/gzh012;;10.1016/s0022-1759(00)00290-8;;11292488;;pmc47274;;8367454;;10.1073/pnas.90.17.7995;;7584477;;8768901;;10.1016/s0958-1669(96)80118-2;;4358940;;10.1021/bi00699a002;;10.1021/bi00699a001;;4358939;;364941;;10.1002/9780470122921.ch2;;354496;;10.1146/annurev.bi.47.070178.001343;;pmc148146;;9847191;;10.1093/nar/27.1.244;;10.1016/s0959-440x(97)80054-1;;9204279;;9204280;;10.1016/s0959-440x(97)80055-3;;8805507;;10.1016/s0969-2126(96)00005-6;;10.1126/science.1853201;;1853201;;10.1016/0076-6879(90)83011-w;;2314273;;pmc305087;;10.1073/pnas.84.13.4355;;3474607;;10.1038/354105a0;;1944583;;10.1021/jm00390a019;;2885419;;10.1146/annurev.bi.61.070192.002131;;1497316;;10.1146/annurev.biochem.61.1.387;;10.1038/nbt1088-1204;;8187882;;10.1016/0014-5793(94)00383-1;;7532457;;10.1006/smim.1994.1035;;10.1002/j.1460-2075.1994.tb06715.x;;8076595;;pmc395319;;0007018830;;7018830;;10.1016/0003-2697(81)90168-8;;6175244;;2439875;;10.1016/0076-6879(87)38030-9;;10.1038/nbt0792-779;;1368267;;10.1002/bit.10790;;14574701;;10.1038/290304a0;;6259538;;6322160;;10.1073/pnas.81.3.659;;pmc344894;;6257399;;10.1016/0092-8674(80)90555-3;;358198;;pmc392859;;10.1073/pnas.75.8.3727;;6337371;;10.1073/pnas.80.1.21;;pmc393301;;10.1016/0092-8674(84)90258-7;;6567483;;3006998;;10.1101/sqb.1985.050.01.050;;10.1038/315115a0;;2986015;;6091894;;10.1016/0092-8674(84)90259-9;;pmc365231;;10.1128/mcb.7.4.1436;;10.1128/mcb.7.4.1436-1444.1987;;3037318;;10.1016/0092-8674(86)90280-1;;3011271;;10.1101/gad.1.3.268;;3678824;;10.1128/mcb.5.7.1639;;pmc367282;;2410773;;10.1128/mcb.5.7.1639-1648.1985;;10.1101/gad.1.2.161;;3500093;;10.1038/315338a0;;3858676;;3719696;;10.1016/0092-8674(86)90862-7;;10.1016/0092-8674(87)90248-0;;2434242;;2984571;;10.1038/314283a0;;10.1126/science.3097822;;3097822;;10.1038/312768a0;;6096720;;10.1107/s0907444994003112;;15299374;;10.1107/s0907444998003254;;9757107,"BEYER B M ET AL: ""Crystal Structures of the Pro-Inflammatory Cytokine Interleukin-23 and Its Complex with a High-Affinity Neutralizing Antibody"", JOURNAL OF MOLECULAR BIOLOGY, LONDON, GB, vol. 382, no. 4, 17 October 2008 (2008-10-17), pages 942 - 955, XP025409951, ISSN: 0022-2836, [retrieved on 20080807], DOI: DOI:10.1016/J.JMB.2008.08.001;;MABRY ROBERT ET AL: ""Engineering of stable bispecific antibodies targeting IL-17A and IL-23"", PROTEIN ENGINEERING DESIGN & SELECTION, vol. 23, no. 3, March 2010 (2010-03-01), pages 115 - 127, XP002616663, ISSN: 1741-0126;;LONBERG ET AL: ""Fully human antibodies from transgenic mouse and phage display platforms"", CURRENT OPINION IN IMMUNOLOGY, ELSEVIER, OXFORD, GB, vol. 20, no. 4, 1 August 2008 (2008-08-01), pages 450 - 459, XP023612045, ISSN: 0952-7915, [retrieved on 20080721], DOI: DOI:10.1016/J.COI.2008.06.004;;OPPMANN ET AL., IMMUNITY, vol. 13, 2000, pages 713 - 715;;PARHAM ET AL., J. IMMUNOL., vol. 168, 2002, pages 5699 - 708;;AHERN ET AL., IMMUN. REV., vol. 226, 2008, pages 147 - 159;;CUA ET AL., NATURE, vol. 421, 2003, pages 744 - 748;;YAGO ET AL., ARTHRITIS RES AND THER., vol. 9, no. 5, 2007, pages R96;;KASTELEIN ET AL., ANNUAL REVIEW OF IMMUNOLOGY, vol. 25, 2007, pages 221 - 42;;LIU ET AL., RHEUMATOLOGY, vol. 46, no. 8, 2007, pages 1266 - 73;;BOWMAN ET AL., CURRENT OPINION IN INFECTIOUS DISEASES, vol. 19, 2006, pages 245 - 52;;FIESCHI; CASANOVA, EUR. J. IMMUNOL., vol. 33, 2003, pages 1461 - 4;;MEERAN ET AL., MOL. CANCER THER., vol. 5, 2006, pages 825 - 32;;LANGOWSKI ET AL., NATURE, vol. 442, 2006, pages 461 - 5;;SAMBROOK ET AL.: ""Molecular Cloning: A Laboratory Manual, 3rd ed.,"", 2001, COLD SPRING HARBOR LABORATORY PRESS;;AUSUBEL ET AL.: ""Current Protocols in Molecular Biology"", 1992, GREENE PUBLISHING ASSOCIATES;;HARLOW; LANE: ""Antibodies: A Laboratory Manual"", 1990, COLD SPRING HARBOR LABORATORY PRESS;;BEYER ET AL., J MOL BIOL, vol. 382, no. 4, 2008, pages 942 - 55;;LUPARDUS; GARCIA, J. MOL. BIOL., vol. 382, 2008, pages 931 - 941;;E. S. GOLUB AND D. R. GREN: ""Immunology-A Synthesis, 2nd Edition,"", 1991, SINAUER ASSOCIATES: SUNDERLAND;;STAHLI ET AL., METHODS IN ENZYMOLOGY, vol. 92, 1983, pages 242 - 253;;KIRKLAND ET AL., J. IMMUNOL., vol. 137, 1986, pages 3614 - 3619;;HARLOW; LANE: ""Antibodies, A Laboratory Manual"", 1988, COLD SPRING HARBOR PRESS;;MOREL ET AL., MOLEC. IMMUNOL., vol. 25, 1988, pages 7 - 15;;CHEUNG ET AL., VIROLOGY, vol. 176, 1990, pages 546 - 552;;MOLDENHAUER ET AL., SCAND. J. IMMUNOL., vol. 32, 1990, pages 77 - 82;;KOMDORFER ET AL., PROTEINS: STRUCTURE, FUNCTION, AND BIOINFORMATICS, vol. 53, no. 1, 2003, pages 121 - 129;;ROQUE ET AL., BIOTECHNOL. PROG., vol. 20, 2004, pages 639 - 654;;LANTTO ET AL., METHODS MOL. BIOL., vol. 178, 2002, pages 303 - 316;;PAUL W.: ""Fundamental Immunology, 2nd ed.,"", 1989, RAVEN PRESS, article ""Ch. 7"";;LESK, A. M.,: ""Computational Molecular Biology"", 1988, OXFORD UNIVERSITY PRESS;;SMITH, D. W.,: ""Biocomputing Informatics and Genome Projects"", 1993, ACADEMIC PRESS;;GRIFFIN, A. M., AND GRIFFIN, H. G., E: ""Computer Analysis of Sequence Data"", 1994, HUMANA PRESS;;HEINJE, G.: ""Sequence Analysis in Molecular Biology"", 1987, ACADEMIC PRESS;;GRIBSKOV, M. AND DEVEREUX, J.,: ""Sequence Analysis Primer"", 1991, M. STOCKTON PRESS;;CARILLO ET AL., SIAM J. APPLIED MATH., vol. 48, 1988, pages 1073;;DEVEREUX ET AL., NUCL. ACID RES., vol. 12, 1984, pages 387;;DAYHOFF ET AL., ATLAS OF PROTEIN SEQUENCE AND STRUCTURE, vol. 5, 1978, pages 345 - 352;;HENIKOFF ET AL., PROC. NATL. ACAD. SCI. U.S.A., vol. 89, 1992, pages 10915 - 10919;;NEEDLEMAN ET AL., J. MOL. BIOL., vol. 48, 1970, pages 443 - 453;;CHOTHIA; LESK, J. MOL. BIOL., vol. 196, 1987, pages 901 - 917;;CHOTHIA ET AL., NATURE, vol. 342, 1989, pages 878 - 883;;LEFRANC ET AL., DEV. COMP. IMMUNOL., vol. 29, 2005, pages 185 - 203;;HONEGGER; PLUCKTHUN, J. MOL. BIOL., vol. 309, no. 3, 2001, pages 657 - 670;;MORRISON ET AL., PROC. NATL. ACAD. SCI. USA, vol. 81, pages 6851 - 6855;;JONES ET AL., NATURE, vol. 321, 1986, pages 522 - 525;;RIECHMANN ET AL., NATURE, vol. 332, 1988, pages 323 - 27;;VERHOEYEN, SCIENCE, vol. 239, 1988, pages 1534 - 1536;;JAKOBOVITS ET AL., PROC. NATL. ACAD. SCI. USA, vol. 90, 1993, pages 2551 - 2555;;JAKOBOVITS ET AL., NATURE, vol. 362, 1993, pages 255 - 258;;BRUGGERMANN ET AL., YEAR IN IMMUNOL., vol. 7, 1993, pages 33;;LONBERG ET AL., NATURE, vol. 368, 1994, pages 856 - 859;;LONBERG; HUSZAR, INTERN. REV. IMMUNOL., vol. 13, 1995, pages 65 - 93;;HARDING; LONBERG, ANN. N. Y ACAD. SCI., vol. 764, 1995, pages 536 - 546;;TAYLOR ET AL., NUCLEIC ACIDS RESEARCH, vol. 20, 1992, pages 6287 - 6295;;CHEN ET AL., INTERNATIONAL IMMUNOLOGY, vol. 5, 1993, pages 647 - 656;;TUAILLON ET AL., J. IMMUNOL., vol. 152, 1994, pages 2912 - 2920;;LONBERG, HANDBOOK OF EXP. PHARMACOLOGY, vol. 113, 1994, pages 49 - 101;;TAYLOR ET AL., INTEMATIONAL IMMUNOLOGY, vol. 6, 1994, pages 579 - 591;;LONBERG; HUSZAR, INTEM. REV. IMMUNOL., vol. 13, 1995, pages 65 - 93;;FISHWILD ET AL., NATURE BIOTECHNOLOGY, vol. 14, 1996, pages 845 - 85;;MENDEZ ET AL., NATURE GENETICS, vol. 15, 1997, pages 146 - 156;;HOOGENBOOM, J. MOL. BIOL., vol. 227, 1991, pages 381;;MARKS ET AL., J. MOL. BIOL., vol. 222, 1991, pages 581;;SONGSIVILAI; LACHMANN, CLIN. EXP. IMMUNOL, vol. 79, 1990, pages 315 - 321;;KOSTELNY ET AL., J. IMMUNOL., vol. 148, 1992, pages 1547 - 1553;;BIRD, SCIENCE, vol. 242, 1988, pages 423;;HUSTON ET AL., PROC. NATL. ACAD. SCI. U.S.A., vol. 85, 1988, pages 5879;;WARD ET AL., NATURE, vol. 334, 1989, pages 544;;DE GRAAF ET AL., METHODS MOL BIOL., vol. 178, 2002, pages 379 - 387;;KORTT ET AL., PROTO ENG., vol. 10, 1997, pages 423;;KORTT ET AL., BIOMOL. ENG., vol. 18, 2001, pages 95 - 108;;KRIANGKUM ET AL., BIOMOL. ENG., vol. 18, 2001, pages 31 - 40;;HOLLIGER ET AL., PROC. NATL. ACAD. SCI. USA, vol. 90, 1993, pages 6444 - 48;;POLJAK ET AL., STRUCTURE, vol. 2, 1994, pages 1121 - 23;;FREDERICKS ET AL., PROTEIN ENGINEERING, DESIGN & SELECTION, vol. 17, 2004, pages 95 - 106;;POWERS ET AL., JOURNAL OF IMMUNOLOGICAL METHODS, vol. 251, 2001, pages 123 - 135;;SHU ET AL., PROC. NATL. ACAD. SCI. USA, vol. 90, 1993, pages 7995 - 7999;;HAYDEN ET AL., THERAPEUTIC IMMUNOLOGY, vol. 1, 1994, pages 3 - 15;;KYTE ET AL., J. MOL. BIOL., vol. 157, 1982, pages 105 - 131;;MOULT, CURT. OP. IN BIOTECH., vol. 7, 1996, pages 422 - 427;;CHOU ET AL., BIOCHEM., vol. 13, 1974, pages 222 - 245;;CHOU ET AL., BIOCHEMISTRY, vol. 113, 1974, pages 211 - 222;;CHOU ET AL., ADV. ENZYMOL. RELAT. AREAS MOL. BIOL., vol. 47, 1978, pages 45 - 148;;CHOU ET AL., ANN. REV. BIOCHEM., vol. 47, 1979, pages 251 - 276;;CHOU ET AL., BIOPHYS. J., vol. 26, 1979, pages 367 - 384;;HOLM ET AL., NUCL. ACID. RES., vol. 27, 1999, pages 244 - 247;;BRENNER ET AL., CUFF. OP. STRUCT. BIOL., vol. 7, 1997, pages 369 - 376;;JONES, CURR. OPIN. STRUCT. BIOL., vol. 7, 1997, pages 377 - 387;;SIPPL ET AL., STRUCTURE, vol. 4, 1996, pages 15 - 19;;BOWIE ET AL., SCIENCE, vol. 253, 1991, pages 164 - 170;;GRIBSKOV ET AL., METH. ENZYM., vol. 183, 1990, pages 146 - 159;;GRIBSKOV ET AL., PROC. NAT. ACAD. SCI., vol. 84, 1987, pages 4355 - 4358;;CREIGHTON,: ""Proteins, Structures and Molecular Principles"", 1984, FREEMAN AND COMPANY;;BRANDEN AND TOOZE,: ""Introduction to Protein Structure"", 1991, GARLAND PUBLISHING;;THORNTON ET AL., NATURE, vol. 354, 1991, pages 105;;FAUCHERE, ADV. DRUG RES., vol. 15, 1986, pages 29;;VEBER; FREIDINGER, TINS, 1985, pages 392;;EVANS ET AL., J. MED. CHEM., vol. 30, 1987, pages 1229;;RIZO; GIERASCH, ANN. REV. BIOCHEM., vol. 61, 1992, pages 387;;HOPP ET AL., BIO/TECHNOLOGY, vol. 6, 1988, pages 1204;;HOPPE ET AL., FEBS LETTERS, vol. 344, 1994, pages 191;;FANSLOW ET AL., SEMIN. IMMUNOL., vol. 6, 1994, pages 267 - 278;;BAUM, EMBO J., vol. 13, 1994, pages 3992 - 4001;;APLIN; WRISTON, CRC CRIT. REV, BIOCHEM., 1981, pages 259 - 306;;HAKIMUDDIN ET AL., ARCH. BIOCHEM. BIOPHYS., vol. 259, 1987, pages 52;;EDGE ET AL., ANAL. BIOCHEM., vol. 118, 1981, pages 131;;THOTAKURA ET AL., METH. ENZYMOL., vol. 138, 1987, pages 350;;DUSKIN ET AL., J. BIOL. CHEM., vol. 257, 1982, pages 3105;;MARKS ET AL., BIOTECHNOLOGY, vol. 10, 1992, pages 779;;SAMBROOK; FRITSCH; MANIATIS: ""Molecular Cloning: A Laboratory Manual"", 2001, COLD SPRING HARBOR LABORATORY PRESS;;AUSUBEL ET AL.,: ""Current Protocols in Molecular Biology"", 1995, JOHN WILEY & SONS, INC.;;KENNET ET AL.: ""Monoclonal Antibodies, Hybridomas: A New Dimension in Biological Analyses"", 1980, PLENUM PRESS;;HARLOW AND LANE: ""Antibodies: A Laboratory Manual"", 1988, COLD SPRING HARBOR LABORATORY PRESS;;BIANCHI; MCGREW, BIOTECH. BIOTECHNOL. BIOENG., vol. 84, 2003, pages 439 - 44;;D. V. GOEDDEL,: ""Methods Enzymol."", vol. 185, 1990, ACADEMIC PRESS;;BENOIST; CHAMBON, NATURE, vol. 290, 1981, pages 304 - 310;;THOMSEN ET AL., PROC. NATL. ACAD. U.S.A., vol. 81, 1984, pages 659 - 663;;YAMAMOTO ET AL., CELL, vol. 22, 1980, pages 787 - 797;;WAGNER ET AL., PROC. NATL. ACAD. SCI. U.S.A., vol. 78, 1981, pages 1444 - 1445;;PRINSTER ET AL., NATURE, vol. 296, 1982, pages 39 - 42;;VILLA-KAMAROFF ET AL., PROC. NATL. ACAD. SCI. U.S.A., vol. 75, 1978, pages 3727 - 3731;;DEBOER ET AL., PROC. NATL. ACAD. SCI. U.S.A., vol. 80, 1983, pages 21 - 25;;SWIFT ET AL., CELL, vol. 38, 1984, pages 639 - 646;;ORNITZ ET AL., COLD SPRING HARBOR SYMP. QUANT. BIOL., vol. 50, 1986, pages 399 - 409;;MACDONALD, HEPATOLOGY, vol. 7, 1987, pages 425 - 515;;HANAHAN, NATURE, vol. 315, 1985, pages 115 - 122;;GROSSCHEDL ET AL., CELL, vol. 38, 1984, pages 647 - 658;;ADAMES ET AL., NATURE, vol. 318, 1985, pages 533 - 538;;ALEXANDER ET AL., MOL. CELL. BIOL., vol. 7, 1987, pages 1436 - 1444;;LEDER ET AL., CELL, vol. 45, 1986, pages 485 - 495;;PINKERT ET AL., GENES AND DEVEL., vol. 1, 1987, pages 268 - 276;;KRUMLAUF ET AL., MOL. CELL. BIOL., vol. 5, 1985, pages 1639 - 1648;;HAMMER ET AL., SCIENCE, vol. 253, 1987, pages 53 - 58;;KELSEY ET AL., GENES AND DEVEL., vol. 1, 1987, pages 161 - 171;;MOGRAM ET AL., NATURE, vol. 315, 1985, pages 338 - 340;;KOLLIAS ET AL., CELL, vol. 46, 1986, pages 89 - 94;;READHEAD ET AL., CELL, vol. 48, 1987, pages 703 - 712;;SANI, NATURE, vol. 314, 1985, pages 283 - 286;;MASON ET AL., SCIENCE, vol. 234, 1986, pages 1372 - 1378;;COSMAN, NATURE, vol. 312, 1984, pages 768;;HARLOW; LANE: ""Antibodies: A Laboratory Manual"", 1988, COLD SPRING HARBOR;;JOHN E. COLIGAN,: ""Current Protocols In Immunology"", 1993, JOHN WILEY & SONS;;""Remington's Pharmaceutical Sciences 21st Ed."", 2005, MACK PUBLISHING COMPANY;;HARLOW; LANE: ""Antibodies: A Laboratory Manual"", 1990, COLD SPRING HARBOR LABORATORY PRESS, pages: 23;;LUPARDUS; GARCIA, J MOL BIOL, vol. 382, 2008, pages 931 - 941;;ACTA CRYSTALLOGR D BIOL CRYSTALLOGR, vol. 50, 1994, pages 760 - 3;;BRUNGER ET AL., ACTA CRYSTALLOGR D BIOL CRYSTALLOGR, vol. 54, 1998, pages 905 - 21",PENDING
368,JP,A,JP 2018117626 A,164-181-563-461-47X,2018-08-02,2018,JP 2018045121 A,2018-03-13,US 25498209 P;;US 38128710 P,2009-10-26,HUMAN IL-23 ANTIGEN BINDING PROTEINS,"PROBLEM TO BE SOLVED: To provide antigen binding proteins that bind to human IL-23 proteins.SOLUTION: Antigen binding proteins that bind to human IL-23 proteins having specific sequences are provided. Nucleic acids encoding the antigen binding proteins, vectors, and cells encoding the proteins as well as use of the IL-23 antigen binding proteins for diagnostic and therapeutic purposes are also provided.SELECTED DRAWING: None",AMGEN INC,JENNIFER E TOWNE;;JANET D CHENG;;JASON C O'NEILL;;ZHANG YU;;SUN YU;;HEATHER CERNE;;DEREK E PIPER;;KETCHEM RANDAL R,,https://lens.org/164-181-563-461-47X,Patent Application,no,1,1,86,87,155,A61K2039/505;;C07K2317/21;;C07K2317/55;;C07K2317/92;;A61K47/6845;;C07K16/244;;A61P37/00;;C07K16/244;;A61K2039/505;;C07K2317/626;;C07K2317/21;;C07K2317/76;;A61K47/6845;;C07K2317/54;;A61K39/395;;C07K2317/31;;C07K16/24;;A61P37/00;;C07K2317/92;;C07K2317/24;;C07K2317/622;;C07K2317/55;;C07K2317/565;;A61K39/00;;A61K39/395;;A61K39/39533;;A61K39/3955;;C07K16/18;;C07K16/24;;C07K16/244;;A61K2039/505;;C07K2317/21;;C07K2317/55;;C07K2317/92;;A61K47/6845;;C07K16/244;;A61K39/395;;C07K16/24;;C07K2317/24;;C07K2317/31;;C07K2317/54;;C07K2317/565;;C07K2317/622;;C07K2317/626;;C07K2317/76,C12N15/13;;A61K39/395;;A61P1/04;;A61P3/10;;A61P17/06;;A61P19/02;;A61P25/00;;A61P29/00;;A61P35/00;;A61P37/02;;C07K16/24;;C12N1/15;;C12N1/19;;C12N1/21;;C12N5/10;;C12N15/85;;C12P21/08;;C12Q1/6876,,0,0,,,,PENDING
369,MY,A,MY 156286 A,059-450-774-186-056,2016-01-29,2016,MY PI2012001807 A,2010-10-26,US 25498209 P;;US 38128710 P,2009-10-26,HUMAN IL-23 ANTIGEN BINDING PROTEINS,"ANTIGEN BINDING PROTEINS THAT BIND TO HUMAN IL-23 PROTEIN ARE PROVIDED. NUCLEIC ACIDS ENCODING THE ANTIGEN BINDING PROTEIN, VECTORS, AND CELLS ENCODING THE SAME AS WELL AS USE OF IL-23 ANTIGEN BINDING PROTEINS FOR DIAGNOSTIC AND THERAPEUTIC PURPOSES ARE ALSO PROVIDED. NO SUITABLE",AMGEN INC,TOWNE JENNIFER E;;CHENG JANET D;;O'NEILL JASON C;;YU ZHANG;;YU SUN;;HEATHER CERNE;;PIPER DEREK E;;KETCHEM RANDAL R,,https://lens.org/059-450-774-186-056,Granted Patent,no,0,0,86,87,0,A61K2039/505;;C07K2317/21;;C07K2317/55;;C07K2317/92;;A61K47/6845;;C07K16/244;;A61P37/00;;C07K16/244;;A61K2039/505;;C07K2317/626;;C07K2317/21;;C07K2317/76;;A61K47/6845;;C07K2317/54;;A61K39/395;;C07K2317/31;;C07K16/24;;A61P37/00;;C07K2317/92;;C07K2317/24;;C07K2317/622;;C07K2317/55;;C07K2317/565;;A61K39/00;;A61K39/395;;A61K39/39533;;A61K39/3955;;C07K16/18;;C07K16/24;;C07K16/244;;A61K2039/505;;C07K2317/21;;C07K2317/55;;C07K2317/92;;A61K47/6845;;C07K16/244;;A61K39/395;;C07K16/24;;C07K2317/24;;C07K2317/31;;C07K2317/54;;C07K2317/565;;C07K2317/622;;C07K2317/626;;C07K2317/76,C07K16/24,,0,0,,,,ACTIVE
370,HK,A1,HK 1177469 A1,109-828-467-429-875,2013-08-23,2013,HK 13104578 A,2013-04-16,US 2010/0054148 W;;US 25498209 P;;US 38128710 P,2009-10-26,HUMAN IL-23 ANTIGEN BINDING PROTEINS IL-23,,AMGEN INC,TOWNE JENNIFER E;;CHENG JANET D;;ONEILL JASON C;;ZHANG YU;;SUN YU;;CERNE HEATHER;;PIPER DEREK E;;KETCHEM RANDAL R,,https://lens.org/109-828-467-429-875,Patent Application,no,0,0,86,87,0,A61K2039/505;;C07K2317/21;;C07K2317/55;;C07K2317/92;;A61K47/6845;;C07K16/244;;A61P37/00;;C07K16/244;;A61K2039/505;;C07K2317/626;;C07K2317/21;;C07K2317/76;;A61K47/6845;;C07K2317/54;;A61K39/395;;C07K2317/31;;C07K16/24;;A61P37/00;;C07K2317/92;;C07K2317/24;;C07K2317/622;;C07K2317/55;;C07K2317/565;;A61K39/00;;A61K39/395;;A61K39/39533;;A61K39/3955;;C07K16/18;;C07K16/24;;C07K16/244;;A61K2039/505;;C07K2317/21;;C07K2317/55;;C07K2317/92;;A61K47/6845;;C07K16/244;;A61K39/395;;C07K16/24;;C07K2317/24;;C07K2317/31;;C07K2317/54;;C07K2317/565;;C07K2317/622;;C07K2317/626;;C07K2317/76,C07K/;;A61K/,,0,0,,,,PENDING
371,CA,C,CA 2778112 C,132-882-001-124-851,2019-02-26,2019,CA 2778112 A,2010-10-26,US 25498209 P;;US 38128710 P;;US 2010/0054148 W,2009-10-26,HUMAN IL-23 ANTIGEN BINDING PROTEINS,"Antigen binding proteins that bind to human IL-23 protein are provided. Nucleic acids encoding the antigen binding protein, vectors, and cells encoding the same as well as use of IL-23 antigen binding proteins for diagnostic and therapeutic purposes are also provided.",AMGEN INC,TOWNE JENNIFER E;;CHENG JANET D;;O'NEILL JASON C;;ZHANG YU;;SUN YU;;CERNE HEATHER;;PIPER DEREK E;;KETCHEM RANDAL R,,https://lens.org/132-882-001-124-851,Granted Patent,no,0,0,86,87,155,A61K2039/505;;C07K2317/21;;C07K2317/55;;C07K2317/92;;A61K47/6845;;C07K16/244;;A61P37/00;;C07K16/244;;A61K2039/505;;C07K2317/626;;C07K2317/21;;C07K2317/76;;A61K47/6845;;C07K2317/54;;A61K39/395;;C07K2317/31;;C07K16/24;;A61P37/00;;C07K2317/92;;C07K2317/24;;C07K2317/622;;C07K2317/55;;C07K2317/565;;A61K39/00;;A61K39/395;;A61K39/39533;;A61K39/3955;;C07K16/18;;C07K16/24;;C07K16/244;;A61K2039/505;;C07K2317/21;;C07K2317/55;;C07K2317/92;;A61K47/6845;;C07K16/244;;A61K39/395;;C07K16/24;;C07K2317/24;;C07K2317/31;;C07K2317/54;;C07K2317/565;;C07K2317/622;;C07K2317/626;;C07K2317/76,C07K16/24;;A61K39/395,,0,0,,,,ACTIVE
372,CN,A,CN 110407936 A,181-905-609-470-548,2019-11-05,2019,CN 201910176289 A,2010-10-26,US 25498209 P;;US 38128710 P;;CN 201080059062 A,2009-10-26,HUMAN IL-23 ANTIGEN BINDING PROTEINS,"Antigen binding proteins that bind to human IL-23 protein are provided. Nucleic acids encoding the antigen binding protein, vectors, and cells encoding the same as well as use of IL-23 antigen bindingproteins for diagnostic and therapeutic purposes are also provided.",AMGEN INC,TOWNE JENNIFER E;;CHENG JANET D;;O'NEILL JASON C;;ZHANG YU;;SUN YU;;CERNE HEATHER;;PIPER DEREK E;;KETCHEM RANDAL R,,https://lens.org/181-905-609-470-548,Patent Application,no,3,6,86,87,0,A61K2039/505;;C07K2317/21;;C07K2317/55;;C07K2317/92;;A61K47/6845;;C07K16/244;;A61P37/00;;C07K16/244;;A61K2039/505;;C07K2317/626;;C07K2317/21;;C07K2317/76;;A61K47/6845;;C07K2317/54;;A61K39/395;;C07K2317/31;;C07K16/24;;A61P37/00;;C07K2317/92;;C07K2317/24;;C07K2317/622;;C07K2317/55;;C07K2317/565;;A61K39/00;;A61K39/395;;A61K39/39533;;A61K39/3955;;C07K16/18;;C07K16/24;;C07K16/244;;A61K2039/505;;C07K2317/21;;C07K2317/55;;C07K2317/92;;A61K47/6845;;C07K16/244;;A61K39/395;;C07K16/24;;C07K2317/24;;C07K2317/31;;C07K2317/54;;C07K2317/565;;C07K2317/622;;C07K2317/626;;C07K2317/76,C07K16/24;;A61K39/395;;A61P1/00;;A61P1/04;;A61P3/10;;A61P9/00;;A61P17/06;;A61P19/02;;A61P19/08;;A61P25/00;;A61P29/00;;A61P35/00;;A61P37/02;;C12N15/13;;C12N15/63,,0,0,,,,PENDING
373,EP,A1,EP 2493925 A1,179-574-185-361-157,2012-09-05,2012,EP 10774095 A,2010-10-26,US 25498209 P;;US 38128710 P;;US 2010/0054148 W,2009-10-26,HUMAN IL-23 ANTIGEN BINDING PROTEINS,,AMGEN INC,TOWNE JENNIFER E;;CHENG JANET D;;O'NEILL JASON C;;ZHANG YU;;SUN YU;;CERNE HEATHER;;PIPER DEREK E;;KETCHEM RANDAL R,,https://lens.org/179-574-185-361-157,Patent Application,yes,0,2,86,87,0,A61K2039/505;;C07K2317/21;;C07K2317/55;;C07K2317/92;;A61K47/6845;;C07K16/244;;A61P37/00;;C07K16/244;;A61K2039/505;;C07K2317/626;;C07K2317/21;;C07K2317/76;;A61K47/6845;;C07K2317/54;;A61K39/395;;C07K2317/31;;C07K16/24;;A61P37/00;;C07K2317/92;;C07K2317/24;;C07K2317/622;;C07K2317/55;;C07K2317/565;;A61K39/00;;A61K39/395;;A61K39/39533;;A61K39/3955;;C07K16/18;;C07K16/24;;C07K16/244;;A61K2039/505;;C07K2317/21;;C07K2317/55;;C07K2317/92;;A61K47/6845;;C07K16/244;;A61K39/395;;C07K16/24;;C07K2317/24;;C07K2317/31;;C07K2317/54;;C07K2317/565;;C07K2317/622;;C07K2317/626;;C07K2317/76,C07K16/24;;A61K39/395,,0,0,,,,ACTIVE
374,WO,A1,WO 2018/087682 A1,184-857-446-885-444,2018-05-17,2018,IB 2017056996 W,2017-11-09,CN 201610987137 A,2016-11-09,BATTERY PACK,"The present disclosure provides a battery pack for a hybrid vehicle. The battery pack includes: multiple battery cells, a housing, a first end plate, a second end plate, a bearing plate and an upper cover, wherein the housing is provided with a bottom portion and side walls extending from the periphery of the bottom portion and forming an upper portion opening; the housing is configured for accommodating the multiple battery cells and the two end plates, when the multiple battery cells are sequentially arranged and mounted into the housing, the first end plate and the second end plate are located at two end sides of the sequentially arranged multiple battery cells to laterally fix the multiple battery cells; the bearing plate is mounted above the top portions of the multiple battery cells; and the upper cover is mounted above the housing to cover the upper portion opening of the housing.",JOHNSON CONTROLS TECH CO,FAN BINBIN;;CHENG LIANG;;QU WEI;;SONG PENG;;FU YINGYAO;;LIU CHANG;;FUHR JASON;;WIEGMANN MARTIN;;ZHANG XUGANG;;CZARNECKI JENNIFER LYNN,,https://lens.org/184-857-446-885-444,Patent Application,yes,3,3,9,9,0,H01M50/284;;H01M50/244;;H01M50/51;;H01M50/249;;H01M50/204;;H01M50/258;;H01M50/289;;H01M10/613;;H01M10/625;;H01M10/6563;;H01M10/6566;;H01M10/482;;H01M2010/4271;;H01M2200/103;;H01M2220/20;;H01M10/625;;H01M10/6563;;H01M10/613;;F04D25/0613;;F04D29/601;;H01M50/24;;H01M50/3425;;H01M50/553;;H01M50/507;;H01M50/367;;H01M50/284;;H01M50/55;;H01M50/51;;H01M50/583;;H01M50/244;;H01M50/271;;H01M50/298;;H01M50/209;;H01M50/517;;H01M50/296;;H01M50/242;;H01M50/227;;Y02E60/10;;B60L50/64;;B60L58/26;;F04D25/0673;;F04D29/601;;H01M10/425;;H01M2010/4271;;H01M2220/20;;H01M50/342;;H01M10/482;;H01M50/55;;H01M50/367;;H01M50/583;;H01M50/517;;H01M50/507;;H01M50/553;;H01M50/242;;H01M50/227;;H01M50/296;;H01M50/284;;H01M50/298;;H01M50/271;;H01M50/244;;H01M50/209;;H01M50/51,F04D29/60;;F04D29/64;;H01M10/42;;H01M10/48;;H01M10/613;;H01M10/625;;H01M10/6563;;H01M50/209;;H01M50/227;;H01M50/242;;H01M50/244;;H01M50/249;;H01M50/271;;H01M50/284;;H01M50/296;;H01M50/298;;H01M50/367;;H01M50/507;;H01M50/51;;H01M50/517;;H01M50/55;;H01M50/553;;H01M50/583;;H05K7/20,,0,0,,,,PENDING
375,HU,T2,HU E030871 T2,008-196-142-527-974,2017-06-28,2017,HU E10774095 A,2010-10-26,US 25498209 P;;US 38128710 P,2009-10-26,HUMAN IL-23 ANTIGEN BINDING PROTEINS,,AMGEN INC,TOWNE JENNIFER E;;CHENG JANET D;;O'NEILL JASON C;;ZHANG YU;;SUN YU;;CERNE HEATHER;;PIPER DEREK E;;KETCHEM RANDAL R,,https://lens.org/008-196-142-527-974,Amended Patent,no,0,0,86,87,0,A61K2039/505;;C07K2317/21;;C07K2317/55;;C07K2317/92;;A61K47/6845;;C07K16/244;;A61P37/00;;C07K16/244;;A61K2039/505;;C07K2317/626;;C07K2317/21;;C07K2317/76;;A61K47/6845;;C07K2317/54;;A61K39/395;;C07K2317/31;;C07K16/24;;A61P37/00;;C07K2317/92;;C07K2317/24;;C07K2317/622;;C07K2317/55;;C07K2317/565;;A61K39/00;;A61K39/395;;A61K39/39533;;A61K39/3955;;C07K16/18;;C07K16/24;;C07K16/244;;A61K2039/505;;C07K2317/21;;C07K2317/55;;C07K2317/92;;A61K47/6845;;C07K16/244;;A61K39/395;;C07K16/24;;C07K2317/24;;C07K2317/31;;C07K2317/54;;C07K2317/565;;C07K2317/622;;C07K2317/626;;C07K2317/76,C07K16/24,,0,0,,,,PENDING
376,US,A1,US 2019/0322737 A1,035-738-040-098-825,2019-10-24,2019,US 201916453482 A,2019-06-26,US 201916453482 A;;US 201816194896 A;;US 201815922675 A;;US 201615271315 A;;US 201414228556 A;;US 201213504449 A;;US 2010/0054148 W;;US 38128710 P;;US 25498209 P,2009-10-26,HUMAN IL-23 ANTIGEN BINDING PROTEINS,"Antigen binding proteins that bind to human IL-23 protein are provided. Nucleic acids encoding the antigen binding protein, vectors, and cells encoding the same as well as use of IL-23 antigen binding proteins for diagnostic and therapeutic purposes are also provided.",AMGEN INC,TOWNE JENNIFER E;;CHENG JANET D;;O'NEILL JASON C;;ZHANG YU;;SUN YU;;CERNE HEATHER;;PIPER DEREK E;;KETCHEM RANDAL R,AMGEN INC (2012-06-11),https://lens.org/035-738-040-098-825,Patent Application,yes,0,0,86,87,155,A61K2039/505;;C07K2317/21;;C07K2317/55;;C07K2317/92;;A61K47/6845;;C07K16/244;;A61P37/00;;C07K16/244;;A61K2039/505;;C07K2317/626;;C07K2317/21;;C07K2317/76;;A61K47/6845;;C07K2317/54;;A61K39/395;;C07K2317/31;;C07K16/24;;A61P37/00;;C07K2317/92;;C07K2317/24;;C07K2317/622;;C07K2317/55;;C07K2317/565;;A61K39/00;;A61K39/395;;A61K39/39533;;A61K39/3955;;C07K16/18;;C07K16/24;;C07K16/244;;A61K2039/505;;C07K2317/21;;C07K2317/55;;C07K2317/92;;A61K47/6845;;C07K16/244;;A61K39/395;;C07K16/24;;C07K2317/24;;C07K2317/31;;C07K2317/54;;C07K2317/565;;C07K2317/622;;C07K2317/626;;C07K2317/76,C07K16/24;;A61K39/395;;A61K47/68,,0,0,,,,DISCONTINUED
377,TW,B,TW I432210 B,046-561-970-452-649,2014-04-01,2014,TW 99136594 A,2010-10-26,US 25498209 P;;US 38128710 P,2009-10-26,Human il-23 antigen binding proteins,,AMGEN INC,TOWNE JENNIFER E;;CHENG JANET D;;O'NEILL JASON C;;ZHANG YU;;SUN YU;;CERNE HEATHER;;PIPER DEREK E;;KETCHEM RANDAL R,,https://lens.org/046-561-970-452-649,Granted Patent,no,0,0,86,87,0,A61K2039/505;;C07K2317/21;;C07K2317/55;;C07K2317/92;;A61K47/6845;;C07K16/244;;A61P37/00;;C07K16/244;;A61K2039/505;;C07K2317/626;;C07K2317/21;;C07K2317/76;;A61K47/6845;;C07K2317/54;;A61K39/395;;C07K2317/31;;C07K16/24;;A61P37/00;;C07K2317/92;;C07K2317/24;;C07K2317/622;;C07K2317/55;;C07K2317/565;;A61K39/00;;A61K39/395;;A61K39/39533;;A61K39/3955;;C07K16/18;;C07K16/24;;C07K16/244;;A61K2039/505;;C07K2317/21;;C07K2317/55;;C07K2317/92;;A61K47/6845;;C07K16/244;;A61K39/395;;C07K16/24;;C07K2317/24;;C07K2317/31;;C07K2317/54;;C07K2317/565;;C07K2317/622;;C07K2317/626;;C07K2317/76,,,0,0,,,,INACTIVE
378,CL,A1,CL 2012001096 A1,103-608-884-776-496,2012-09-28,2012,CL 2012001096 A,2012-04-26,US 25498209 P;;US 38128710 P,2009-10-26,"Proteina de enlace a antigeno aislada que enlaza il-23, que comprende al menos tanto una region variable de cadena pesada como de cadena liviana que comprenden cdrs mutadas; acido nucleico, vector y celula hospedera que la codifican; composicion farmaceutica; y su uso para tratar enfermedades asociadas a il-23 en un paciente.","Proteína de enlace a antígeno aislada que enlaza IL-23, que comprende al menos tanto una región variable de cadena pesada como de cadena liviana que comprenden CDRS mutadas; ácido nucleico, vector y célula hospedera que la codifican; composición farmacéutica; y su uso para tratar enfermedades asociadas a IL-23 en un paciente.",AMGEN INC,TOWNE JENNIFER E;;CHENG JANET D;;O'NEILL JASON C;;ZHANG YU;;SUN YU;;CERNE HEATHER;;PIPER DEREK E;;KETCHEM RANDAL R,,https://lens.org/103-608-884-776-496,Patent Application,no,0,0,86,87,0,A61K2039/505;;C07K2317/21;;C07K2317/55;;C07K2317/92;;A61K47/6845;;C07K16/244;;A61P37/00;;C07K16/244;;A61K2039/505;;C07K2317/626;;C07K2317/21;;C07K2317/76;;A61K47/6845;;C07K2317/54;;A61K39/395;;C07K2317/31;;C07K16/24;;A61P37/00;;C07K2317/92;;C07K2317/24;;C07K2317/622;;C07K2317/55;;C07K2317/565;;A61K39/00;;A61K39/395;;A61K39/39533;;A61K39/3955;;C07K16/18;;C07K16/24;;C07K16/244;;A61K2039/505;;C07K2317/21;;C07K2317/55;;C07K2317/92;;A61K47/6845;;C07K16/244;;A61K39/395;;C07K16/24;;C07K2317/24;;C07K2317/31;;C07K2317/54;;C07K2317/565;;C07K2317/622;;C07K2317/626;;C07K2317/76,A61K39/395;;A61P1/00;;A61P29/00;;A61P35/00;;A61P37/00;;C07K16/24;;C12N5/10;;C12N15/13;;C12N15/63,,0,0,,,,PENDING
379,CA,A1,CA 3030092 A1,117-385-169-804-366,2011-05-12,2011,CA 3030092 A,2010-10-26,US 25498209 P;;US 38128710 P;;CA 2778112 A,2009-10-26,HUMAN IL-23 ANTIGEN BINDING PROTEINS,"Antigen binding proteins that bind to human IL-23 protein are provided. Nucleic acids encoding the antigen binding protein, vectors, and cells encoding the same as well as use of IL-23 antigen binding proteins for diagnostic and therapeutic purposes are also provided.",AMGEN INC,TOWNE JENNIFER E;;CHENG JANET D;;O'NEILL JASON C;;ZHANG YU;;SUN YU;;CERNE HEATHER;;PIPER DEREK E;;KETCHEM RANDAL R,,https://lens.org/117-385-169-804-366,Patent Application,no,0,0,86,87,155,A61K2039/505;;C07K2317/21;;C07K2317/55;;C07K2317/92;;A61K47/6845;;C07K16/244;;A61P37/00;;C07K16/244;;A61K2039/505;;C07K2317/626;;C07K2317/21;;C07K2317/76;;A61K47/6845;;C07K2317/54;;A61K39/395;;C07K2317/31;;C07K16/24;;A61P37/00;;C07K2317/92;;C07K2317/24;;C07K2317/622;;C07K2317/55;;C07K2317/565;;A61K39/00;;A61K39/395;;A61K39/39533;;A61K39/3955;;C07K16/18;;C07K16/24;;C07K16/244;;A61K2039/505;;C07K2317/21;;C07K2317/55;;C07K2317/92;;A61K47/6845;;C07K16/244;;A61K39/395;;C07K16/24;;C07K2317/24;;C07K2317/31;;C07K2317/54;;C07K2317/565;;C07K2317/622;;C07K2317/626;;C07K2317/76,C07K16/24;;A61K39/395;;A61K49/00;;A61K51/10;;C12N5/10;;C12N15/13;;C12P21/08;;C12Q1/6876;;G01N33/53,,0,0,,,,PENDING
380,US,B1,US 7220540 B1,129-431-902-585-136,2007-05-22,2007,US 161404 A,2004-11-29,US 161404 A;;US 32822602 A;;US 38399902 P,2002-05-29,Methods for detecting bacteriophage MS2,The present invention relates to methods and assays for detecting bacteriophage MS2 in a sample.,US ARMY,O'CONNELL KEVIN P;;KHAN AKBAR S;;CAO CHENG J;;BUCHER JENNIFER R;;GOSTOMSKI MARK V;;VALDES JAMES J;;ANDERSON PATRICIA E,,https://lens.org/129-431-902-585-136,Granted Patent,yes,0,1,5,5,17,C12Q1/701;;C12Q1/701;;C12Q1/686;;C12Q1/686,C12Q1/70;;C12Q1/68,435/5;;435/4;;435/7.1,3,3,000-738-663-236-606;;065-516-799-483-731;;013-046-609-139-586,pmc1352182;;10.1128/aem.72.1.478-483.2006;;16391081;;16145106;;pmc1234060;;10.1128/jcm.43.9.4551-4557.2005;;10489530;;10.1021/ac981425v,"O'Connell Kevin P; Bucher Jennifer R; Anderson Patricia E; Cao Cheng J; Khan Akbar S; Gostomski Mark V; Valdes James J Real-time fluorogenic reverse transcription-PCR assays for detection of bacteriophage MS2. Applied and environmental microbiology. Jan. 2006, 72 (1) p. 478-83.;;Dreier, J., M. Störmer, and K. Kleesiek. 2005. Use of bacteriophage MS2 as an internal control in viral reverse transcription-PCR assays. J. Clin. Microbiol. 43:4551-4557.;;Rowe C A; Tender L M; Feldstein M J; Golden J P; Scruggs S B; MacCraith B D ; Cras J J; Ligler F S. Array biosensor for simultaneous identification of bacterial, viral, and protein analytes. Analytical chemistry. Sep. 1, 1999, 71 (17) p. 3846-52.",EXPIRED
381,US,A1,US 2003/0143266 A1,161-542-947-437-382,2003-07-31,2003,US 30186702 A,2002-11-22,US 30186702 A;;US 33568999 A,1999-06-18,Cationic amphiphile micellar complexes,"
   The effective introduction of foreign genes and other biologically active molecules into targeted mammalian cells is a challenge still facing those skilled in the art. Gene therapy, for example, requires successful transfection of target cells in a patient. The present invention relates to novel micellar complexes of cationic amphiphilic compounds that facilitate delivery of biologically active molecules to the targeted cells of a mammal. The novel micellar complexes are comprised of a cationic amphiphile, a biologically active molecule, a derivative of polyethylene glycol (PEG), and optionally, a co-lipid. A further aspect of the invention is the use of targeting agents in any of the methods that effectuate the delivery of biologically active molecules into the cells of mammals. A targeting agent is usually any molecule, peptide sequence, or large protein that preferentially targets or binds to specific mammalian celis. 
",GENZYME CORP,TOUSIGNANT JENNIFER D;;EASTMAN SIMON J;;LEE EDWARD R;;SCHEULE RONALD K;;CHENG SENG H;;NIETUPSKI J;;CHU QUIMING;;MARSHALL JOHN,,https://lens.org/161-542-947-437-382,Patent Application,yes,12,6,2,2,0,A61K9/1075;;A61K9/1272;;A61K48/00;;C12N15/88;;A61K9/1272;;C12N15/88;;A61K9/1075;;A61K48/00,A61K9/107;;A61K9/127;;A61K48/00;;C12N15/88,42445;;435/458,0,0,,,,DISCONTINUED
382,JP,A,JP 2020018308 A,198-489-492-845-576,2020-02-06,2020,JP 2019166277 A,2019-09-12,US 25498209 P;;US 38128710 P,2009-10-26,HUMAN IL-23 ANTIGEN BINDING PROTEINS,"To provide antigen binding proteins that bind to human IL-23 protein.SOLUTION: The present invention provides an expression system containing a cell strain, for producing IL-23 antigen binding proteins, and diagnostic and therapeutic methods for human IL-23 related diseases.SELECTED DRAWING: None",AMGEN INC,JENNIFER E TOWNE;;JANET D CHENG;;JASON C O'NEILL;;ZHANG YU;;SUN YU;;HEATHER CERNE;;DEREK E PIPER;;KETCHEM RANDAL R,,https://lens.org/198-489-492-845-576,Patent Application,no,2,0,86,87,0,A61K2039/505;;C07K2317/21;;C07K2317/55;;C07K2317/92;;A61K47/6845;;C07K16/244;;A61P37/00;;C07K16/244;;A61K2039/505;;C07K2317/626;;C07K2317/21;;C07K2317/76;;A61K47/6845;;C07K2317/54;;A61K39/395;;C07K2317/31;;C07K16/24;;A61P37/00;;C07K2317/92;;C07K2317/24;;C07K2317/622;;C07K2317/55;;C07K2317/565;;A61K39/00;;A61K39/395;;A61K39/39533;;A61K39/3955;;C07K16/18;;C07K16/24;;C07K16/244;;A61K2039/505;;C07K2317/21;;C07K2317/55;;C07K2317/92;;A61K47/6845;;C07K16/244;;A61K39/395;;C07K16/24;;C07K2317/24;;C07K2317/31;;C07K2317/54;;C07K2317/565;;C07K2317/622;;C07K2317/626;;C07K2317/76,C12N15/13;;A61K39/395;;A61P1/04;;A61P3/10;;A61P7/06;;A61P9/02;;A61P25/00;;A61P29/00;;A61P35/00;;A61P37/02;;C07K16/18;;C07K16/24;;C12N1/15;;C12N1/19;;C12N1/21;;C12N5/10;;C12N15/63;;C12P21/08,,2,0,,,"INFLAMM BOWEL DIS, vol. 12,1, JPN6022005068, 2006, pages 9 - 15, ISSN: 0004699731;;N ENGL J MED., vol. 361(21), JPN6022005070, 2009, pages 2066 - 2078, ISSN: 0004699732",ACTIVE
383,NZ,A,NZ 625630 A,067-218-990-502-74X,2016-09-30,2016,NZ 62563010 A,2010-10-26,US 38128710 P;;US 25498209 P;;NZ 59987510 A,2009-10-26,Human il-23 antigen binding proteins,"Discloses an isolated antigen binding protein that binds human IL-23, wherein a covered patch formed when said antigen binding protein is bound to human IL-23 comprises residue contacts corresponding to residues 30, 31, 32, 49, 50, 52, 53, 56, 92 and 94 of SEQ ID NO:15, wherein said residue contacts have a solvent exposed surface area difference value of greater than or equal to 10Å2, and wherein the antigen binding protein binds to human IL-23 with a KD of ≤ 5x10-12 M, wherein the sequences are as defined in the complete specification.",AMGEN INC,KETCHEM RANDAL R;;CHENG JANET D;;ZHANG YU;;O’NEILL JASON C;;CERNE HEATHER;;SUN YU;;PIPER DEREK E;;TOWNE JENNIFER E,,https://lens.org/067-218-990-502-74X,Patent Application,no,0,0,86,87,0,A61K2039/505;;C07K2317/21;;C07K2317/55;;C07K2317/92;;A61K47/6845;;C07K16/244;;A61P37/00;;C07K16/244;;A61K2039/505;;C07K2317/626;;C07K2317/21;;C07K2317/76;;A61K47/6845;;C07K2317/54;;A61K39/395;;C07K2317/31;;C07K16/24;;A61P37/00;;C07K2317/92;;C07K2317/24;;C07K2317/622;;C07K2317/55;;C07K2317/565;;A61K39/00;;A61K39/395;;A61K39/39533;;A61K39/3955;;C07K16/18;;C07K16/24;;C07K16/244;;A61K2039/505;;C07K2317/21;;C07K2317/55;;C07K2317/92;;A61K47/6845;;C07K16/244;;A61K39/395;;C07K16/24;;C07K2317/24;;C07K2317/31;;C07K2317/54;;C07K2317/565;;C07K2317/622;;C07K2317/626;;C07K2317/76,C07K16/24;;A61K39/395,,0,0,,,,PENDING
384,US,B2,US 8722033 B2,097-986-248-991-294,2014-05-13,2014,US 201013504449 A,2010-10-26,US 201013504449 A;;US 38128710 P;;US 25498209 P;;US 2010/0054148 W,2009-10-26,Human IL-23 antigen binding proteins,"Antigen binding proteins that bind to human IL-23 protein are provided. Nucleic acids encoding the antigen binding protein, vectors, and cells encoding the same as well as use of IL-23 antigen binding proteins for diagnostic and therapeutic purposes are also provided.",TOWNE JENNIFER E;;CHENG JANET D;;O'NEILL JASON C;;ZHANG YU;;SUN YU;;CERNE HEATHER;;PIPER DEREK E;;KETCHEM RANDAL R;;AMGEN INC,TOWNE JENNIFER E;;CHENG JANET D;;O'NEILL JASON C;;ZHANG YU;;SUN YU;;CERNE HEATHER;;PIPER DEREK E;;KETCHEM RANDAL R,AMGEN INC (2012-06-11),https://lens.org/097-986-248-991-294,Granted Patent,yes,105,8,86,87,155,A61K2039/505;;C07K2317/21;;C07K2317/55;;C07K2317/92;;A61K47/6845;;C07K16/244;;A61P37/00;;C07K16/244;;A61K2039/505;;C07K2317/626;;C07K2317/21;;C07K2317/76;;A61K47/6845;;C07K2317/54;;A61K39/395;;C07K2317/31;;C07K16/24;;A61P37/00;;C07K2317/92;;C07K2317/24;;C07K2317/622;;C07K2317/55;;C07K2317/565;;A61K39/00;;A61K39/395;;A61K39/39533;;A61K39/3955;;C07K16/18;;C07K16/24;;C07K16/244;;A61K2039/505;;C07K2317/21;;C07K2317/55;;C07K2317/92;;A61K47/6845;;C07K16/244;;A61K39/395;;C07K16/24;;C07K2317/24;;C07K2317/31;;C07K2317/54;;C07K2317/565;;C07K2317/622;;C07K2317/626;;C07K2317/76,C07K16/24;;A61K39/395,424/85.2;;530/387.1;;530/388.1;;530/388.23,105,102,020-367-308-901-689;;046-845-561-202-870;;062-761-744-997-508;;027-477-313-726-928;;075-555-351-927-589;;019-397-556-890-001;;006-294-819-324-316;;057-983-868-048-104;;000-879-344-254-347;;021-074-280-354-982;;039-141-300-950-038;;154-374-780-007-386;;017-449-753-661-071;;057-188-880-087-429;;061-444-349-075-997;;019-397-556-890-001;;011-724-225-446-939;;066-841-655-291-162;;112-514-905-529-435;;043-293-799-149-190;;106-794-363-564-085;;039-724-297-100-685;;129-447-558-597-627;;020-120-613-015-267;;065-509-287-960-156;;023-476-471-521-012;;002-837-409-782-018;;137-607-161-868-61X;;047-573-440-316-329;;023-468-000-960-289;;061-754-151-573-898;;049-134-753-209-354;;024-995-475-936-443;;032-055-913-011-134;;130-802-862-883-854;;012-264-326-804-266;;067-226-137-053-81X;;003-246-587-515-619;;048-819-440-392-261;;066-119-584-271-19X;;162-131-697-723-828;;101-171-874-734-776;;066-141-497-990-023;;083-000-601-623-651;;115-435-737-255-802;;105-521-401-667-801;;085-329-927-828-899;;098-276-747-378-726;;038-613-711-274-229;;040-397-285-492-490;;036-375-883-050-99X;;150-526-239-777-942;;069-863-076-076-464;;067-057-135-512-133;;014-201-444-265-19X;;086-016-360-704-586;;016-951-862-040-407;;050-836-464-727-069;;129-978-431-330-653;;018-213-281-272-849;;023-907-179-348-058;;006-316-080-689-484;;007-224-607-447-181;;066-749-017-721-197;;076-270-369-964-609;;002-649-962-296-826;;019-982-436-313-59X;;032-071-991-081-664;;076-436-009-754-971;;013-281-398-303-904;;002-264-966-090-625;;040-428-679-610-399;;089-899-040-309-502;;006-574-964-805-278;;079-975-841-354-505;;016-815-797-562-455;;000-999-407-005-345;;146-024-412-957-37X;;014-277-808-472-992;;005-984-586-162-249;;064-787-766-418-165;;036-431-051-779-618;;043-624-776-168-982;;104-212-297-137-759;;052-714-495-277-870;;055-578-442-289-160;;036-247-824-576-178;;003-762-234-479-609;;041-241-834-308-816;;073-260-982-304-977;;071-662-142-202-504;;027-903-185-617-733;;015-979-728-056-035;;043-108-278-056-872;;032-820-729-763-323;;003-570-249-164-056;;083-549-078-331-651;;106-248-968-254-022;;000-861-223-602-303;;020-950-767-861-522;;021-991-205-274-008;;010-916-105-450-247,1961196;;10.1016/0161-5890(91)90003-3;;10.1016/j.intimp.2004.01.010;;15120653;;pmc280147;;10.1073/pnas.85.9.3080;;3129726;;10.1073/pnas.79.6.1979;;pmc346105;;6804947;;10.1126/science.2426778;;2426778;;18708069;;10.1016/j.jmb.2008.08.001;;3906410;;10.1038/318533a0;;pmc1868863;;17328715;;10.1111/j.1365-2249.2007.03356.x;;19161422;;10.1111/j.1600-065x.2008.00705.x;;pmc365231;;10.1128/mcb.7.4.1436;;10.1128/mcb.7.4.1436-1444.1987;;3037318;;0007018830;;7018830;;pmc52963;;1660140;;10.1073/pnas.88.23.10535;;10.1002/j.1460-2075.1994.tb06715.x;;8076595;;pmc395319;;12023338;;10.4049/jimmunol.168.11.5448;;10.1038/290304a0;;6259538;;18708069;;10.1016/j.jmb.2008.08.001;;10.1002/bit.10790;;14574701;;10.1126/science.1494-b;;10.1126/science.242.4885.1494-b;;10.1111/j.0022-202x.2004.23552.x;;9041643;;pmc2143633;;10.1002/pro.5560060217;;10.1126/science.1853201;;1853201;;16645485;;10.1097/01.qco.0000224818.42729.67;;10.1016/s0959-440x(97)80054-1;;9204279;;10.1038/296039a0;;6278311;;8372511;;10.1107/s0907444998003254;;9757107;;10.1038/344667a0;;1970124;;10.1137/0148063;;16670771;;10.1172/jci25308;;pmc1450386;;10.1093/intimm/5.6.647;;8347558;;10.1016/0042-6822(90)90025-m;;1693247;;10.1016/0022-2836(87)90412-8;;3681981;;10.1038/342877a0;;2687698;;10.1021/bi00699a001;;4358939;;354496;;10.1146/annurev.bi.47.070178.001343;;10.1016/s0006-3495(79)85259-5;;pmc1328558;;262423;;4358940;;10.1021/bi00699a002;;364941;;10.1002/9780470122921.ch2;;10.1038/312768a0;;6096720;;12610626;;10.1038/nature01355;;11968507;;10.1385/1-59259-240-6:379;;6337371;;10.1073/pnas.80.1.21;;pmc393301;;10.1093/nar/12.1part1.387;;6546423;;pmc321012;;10.1016/s0021-9258(19)81080-3;;7061468;;10.1016/0003-2697(81)90168-8;;6175244;;10.1021/jm00390a019;;2885419;;7532457;;10.1006/smim.1994.1035;;10.1002/eji.200324038;;12778462;;10.1038/nbt0796-845;;9631008;;pmc4119940;;25033887;;14985542;;10.1093/protein/gzh012;;14978083;;10.4049/jimmunol.172.5.2827;;10.1016/0076-6879(90)83011-w;;2314273;;pmc305087;;10.1073/pnas.84.13.4355;;3474607;;6091894;;10.1016/0092-8674(84)90259-9;;2432657;;10.1126/science.2432657;;10.1038/315115a0;;2986015;;16157683;;pmc2212952;;10.1084/jem.20050193;;10.1111/j.1749-6632.1995.tb55879.x;;7486582;;7584477;;10.1089/vim.2008.0014;;18570589;;pmc2570712;;pmc50453;;1438297;;10.1073/pnas.89.22.10915;;pmc2777488;;10.1093/rheumatology/kep293;;19815670;;10.1002/eji.200535239;;16482511;;8341653;;10.1073/pnas.90.14.6444;;pmc46948;;pmc148146;;9847191;;10.1093/nar/27.1.244;;18512248;;10.1002/ibd.20475;;11397087;;10.1006/jmbi.2001.4662;;10.1016/0022-2836(92)90894-p;;1404359;;10.1038/nbt1088-1204;;8187882;;10.1016/0014-5793(94)00383-1;;10.1073/pnas.85.16.5879;;3045807;;pmc281868;;10.1073/pnas.90.6.2551;;8460171;;pmc46126;;8459850;;10.1038/362255a0;;10.1038/321522a0;;3713831;;9204280;;10.1016/s0959-440x(97)80055-3;;17291186;;10.1146/annurev.immunol.22.012703.104758;;10.1101/gad.1.2.161;;3500093;;10.4049/jimmunol.175.2.788;;16002675;;10.3410/f.1026900.326466;;10.4049/jimmunol.137.11.3614;;2431039;;3719696;;10.1016/0092-8674(86)90862-7;;10.1002/prot.10497;;12945055;;11566601;;10.1016/s1389-0344(01)00090-9;;10.1093/protein/10.4.423;;9194168;;10.4049/jimmunol.148.5.1547;;1531669;;10.1016/s1389-0344(01)00083-1;;11535414;;10.1128/mcb.5.7.1639;;pmc367282;;2410773;;10.1128/mcb.5.7.1639-1648.1985;;10.2165/11538950-000000000-00000;;21348542;;7108955;;10.1016/0022-2836(82)90515-0;;16688182;;10.1038/nature04808;;11968500;;10.1385/1-59259-240-6:303;;10.1016/0092-8674(86)90280-1;;3011271;;15572068;;10.1016/j.dci.2004.07.003;;10.1093/rheumatology/kem055;;17569750;;7494109;;10.3109/08830189509061738;;8159246;;10.1038/368856a0;;18606226;;10.1016/j.coi.2008.06.004;;10.1007/978-3-642-78432-3_3;;10.1016/j.jmb.2008.07.051;;18680750;;pmc2666310;;10.1093/protein/gzp073;;20022918;;3542783;;10.1002/hep.1840070708;;10.1038/315338a0;;3858676;;10.1038/nbt0792-779;;1368267,"Lederman et al (1991), Molecular Immunology, vol. 28, No. 11, pp. 1171-1181.;;Li et al. (2004), International Immunology, vol. 4, pp. 693-708.;;Panka et al. Proc. Natl. Acad. Sci. USA vol. 85, pp. 3080-3084 (May 1988).;;Rudikoff et al. Proc. Natl. Acad. Sci. USA vol. 79, pp. 1979-1983 (Mar. 1982).;;Amit et al. Science, Vot. 233, pp. 747-753, (Aug. 1986).;;Beyer et al (2008), Journal of Molecular Biology, vol. 382, No. 4, pp. 942-955.;;Adams et al., ""The c-myc oncogene driven by immunoglobulin enhancers induces lymphoid malignancy in transgenic mice"", Nature, 318:533-538 (1985).;;Afzali et al., ""The role of T helper 17 (Th17) and regulatory T cells (Treg) in human organ transplantation and autoimmune disease"", Clinical and Experimental Immunology, 148:32-46 (2007).;;Ahern et al., ""The interleukin-23 axis in intestinal inflammation"", Immun. Rev., 226:147-159 (2008).;;Alexander et al., ""Expression of the c-myc Oncogene under control of an immunologulin enhancer in Emu-myc Transgenic Mice"", Mol. Cell. Biol., 7:1436-1444 (1987).;;Aplin and Wriston, ""Preparation, Properties, and Applications of Carbohydrate Conjugates of Proteins and Lipids"", CRC Crit. Rev, Biochem., pp. 259-306 (1981).;;Ashkenazi et al., ""Protection against endotoxic shock by a tumor necrosis factor receptor immunoadhesin"", Proc. Natl. Acad. Sci. USA, 88:10535 (1991).;;Baum et al., ""Identification of ligands for OX40 receptor"", EMBO J., 13:3992-4001 (1994).;;Belladonna et al., ""IL-23 and IL-12 have overlapping, but distinct, effects on murine dendritic cells"", The Journal of Immunology, 168:5448-5454 (2002).;;Benoist and Chambon, ""In vivo sequence requirements of the SV40 early promoter region"", Nature, 290:304-310 (1981).;;Beyer, et al., ""Crystal Structures of the Pro-Inflammatory Cytokine Interleukin-23 and Its Complex with a High-Affinity Neutralizing Antibody"", J Mol Biol, 382(4):942-55 (2008).;;Bianchi and McGrew, ""High-Level Expression of Full-Length Antibodies Using Trans-Complementing Expression Vectors"", Biotech. Biotechnol. Bioeng. 84:439-44 (2003).;;Bird et al., ""Single-Chain Antigen-Binding Proteins"", Science, 242:423 (1988).;;Blauvelt, ""In this Issue-Full Court Press on Psoriasis"", The Journal of Investigative Dermatology, pp. vii-viii (2004).;;Bloom et al., ""Intrachain disulfide bond in the core hinge region of human IgG4"", Protein Science, 6:407 (1997).;;Bowie et al., ""A method to identify protein sequences that fold into a known three-dimensional structure"", Science, 253:164-170 (1991).;;Bowman et al., ""Rationale and safety of anti-interleukin-23 and anti-interleukin-17A therapy"", Current Opinion in Infectious Diseases, 19:245-52 (2006).;;Brenner et al., ""Population statistics of protein structures: lessons from structural classifications"", Curr. Op. Struct. Biol., 7:369-376 (1997).;;Brinster et al., ""Regulation of metallothionein-thymidine kinase fusion plasmids injected into mouse eggs"", Nature, 296:39-42 (1982).;;Bruggermann et al., ""Designer mice: the production of human antibody repertoires in transgenic animals"", Year in Immunol., 7:33-40 (1993).;;Brunger, et al., ""Crystallography & NMR System: A new software suite for macromolecular structure determination"", Acta Crystallogr D Biol Crystallogr, 54(Pt 5): p. 905-21 (1998).;;Byrn et al., ""Biological properties of a CD4 immunoadhesin"", Nature, 344:677 (1990).;;Carillo et al., ""The Multiple Sequence Alignment Problem in Biology"", SIAM J. Applied Math., 48:1073 (1988).;;Chen et al., ""Anti-IL-23 therapy inhibits multiple inflammatory pathways and ameliorates autoimune encephalomyelitis"", The Journal of Clinical Investigation, 116:1317-1326 (2006).;;Chen et al., ""Immunoglobulin gene rearrangement in B cell deficient mice generated by targeted deletion of the JH locus"", International Immunology, 5:647-656 (1993).;;Cheung, et al., ""Epitope-Specific Antibody Response to the Surface Antigen of Duck Hepatitus B Virus in Infected Ducks"", Virology, 176:546-552 (1990).;;Chothia & Lesk, ""Canonical Structures for the Hypervariable Regions of Immunoglobulins"", J. Mol. Biol., 196:901-917 (1987).;;Chothia et al., ""Conformations of immunoglobulin hypervariable regions"", Nature, 342:878-883 (1989).;;Chou et al., ""Conformational Parameters for Amino Acids in Helical, beta-Sheet, and Random Coil Regions Calculated from Proteins"", Biochemistry, 113:211-222 (1974).;;Chou et al., ""Empirical Predictions of Proteins Conformation"", Ann. Rev. Biochem., 47:251-276 (1979).;;Chou et al., ""Prediction of beta-Turns"", Biophys. J., 26:367-384 (1979).;;Chou et al., ""Prediction of Protein Conformation"", Biochem., 13:222-245 (1974).;;Chou et al., ""Prediction of the secondary structure of proteins from their amino acid sequence"", Adv. Enzymol. Relat. Areas Mol. Biol., 47:45-148 (1978).;;Cosman et al., ""Cloning, sequence and expression of human interleukin-2 receptor"", Nature, 312:768 (1984).;;Cua et al., ""Interleukin-23 rather than Interleukin-12 is the critical cytokine for autoimmune inflammation of the brain"", Nature, 421:744-748 (2003).;;Dayhoff ef al., ""A model of evolutionary change in proteins"", Atlas of Protein Sequence and Structure, 5:345-352 (1978).;;de Graaf et al., ""Expression of scFvs and scFv Fusion Proteins in Eukaryotic Cells"", Methods Mol Biol., 178:379-387 (2002).;;DeBoer et al., ""The tac promoter: A functional hybrid derived from the trp and lac promoters"", Proc. Natl. Acad. Sci. U.S.A., 80:21-25 (1983).;;Devereux et al., ""A comprehensive set of sequence analysis programs for the VAX"", Nucl. Acid Res., 12:387 (1984).;;Duskin et al., ""Relationship of the structure and biological activity of the natural homologues of tunicamycin"", J. Biol. Chem., 257:3105 (1982).;;Edge et al., ""Deglycosylation of Glycoproteins by Trifluoromethanesulfonic Acid"", Anal. Biochem., 118:131 (1981).;;Evans et al., ""Design of Nonpeptidal Ligands for a Peptide Receptor: Cholecystokinin Antagonists"", J. Med. Chem., 30:1229 (1987).;;Fanslow et al., ""Structural characteristics of CD40 ligand that determine biological function"", Semin. Immunol., 6:267-278 (1994).;;Fauchere, ""Elements for the Rational Design of Peptide Drugs"", Adv. Drug Res., 15:29 (1986).;;Fieschi and Casanova, ""Mini Review: The role of interleukin-12 in human infectious diseases: only a faint signature"", Eur. J. Immunol., 33:1461-4 (2003).;;Fishwild et al., ""High-avidity human IgGk monoclonal antibodies from a novel strain of minilocus transgenic mice"", Nature Biotechnology, 14:845-85 (1996).;;Fredericks et al, ""Identification of potent human anti-IL-IRI antagonist antibodies"", Protein Engineering, Design & Selection, 17:95-106 (2004).;;Ghilardi et al., ""Compromised Humoral and Delayed-Type Hypersensitivity Responses in IL-23-Deficient Mice"", The Journal of Immunology, 172:2827-2833 (2004).;;Gribskov et al., ""Profile Analysis"", Meth. Enzym., 183:146-159 (1990).;;Gribskov et al., ""Profile analysis: Detection of distantly related proteins"", Proc. Nat. Acad. Sci., 84:4355-4358 (1987).;;Grosschedl et al., ""Introduction of a mu Immunoglobulin Gene into the Mouse Germ Line: Specific Expression in Lymphoid Cells and Synthesis of Functional Antibody"", Cell, 38:647-658 (1984).;;Hammer et al., ""Diversity of alpha-fetoprotein gene expression in mice is generated by a combination of separate enhancer elements"", Science, 253:53-58 (1987).;;Hanahan, ""Heritable formation of pancreatic beta-cell tumours in transgenic mice expressing recombinant insulin/simian virus 40 oncogenes"", Nature, 315:115-122 (1985).;;Happel et al., ""Divergent roles of IL-23 and IL-12 in host defense against Klebsiella pneumoniae"", The Journal of Experimental Medicine, 202:761-769 (2005).;;Harding and Lonberg, ""Class Switching in Human Immunoglobulin Transgenic Mice"", Ann. N. Y Acad. Sci., 764:536-546 (1995).;;Hayden et al., ""Single-chain mono- and bispecific antibody derivatives with novel biological properties and antitumour activity from a COS cell transient expression system"", Therapeutic Immunology, 1 :3-15 (1994).;;Held et al., ""Generation of a Protective T-Cell Response Following Coronavirus Infection of the Central Nervous System Is Not Dependent on IL-12/23 Signaling"", Viral Immunology, 21:173-187 (2008).;;Henikoff et al., ""Amino acid substitution matrices from protein blocks"", Proc. Natl. Acad. Sci. U.S.A., 89:10915-10919 (1992).;;Hillyer et al., ""Investigating the role of the interleukin-23/-17A axis in rheumatoid arthritis"", Rheumatology, 48:1581-1589 (2009).;;Hoeve et al., ""Divergent effects of IL-12 and IL-23 on the production of IL-17 by human T cells"", Eur. J. Immunol., 36:1-10 (2006).;;Holliger et al., ""Diabodies"": Small bivalent and bispecific antibody fragments, Proc. Natl. Acad. Sci. USA, 90:6444-48 (1993).;;Holm et al., ""Protein folds and families: sequence and structure alignments"", Nucl. Acid. Res., 27:244-247 (1999).;;Holtta et al., ""IL-23/IL-17 Immunity as a Hallmark of Crohn's Disease"", Inflamm Bowel Dis., 14:1175-1184 (2008).;;Honegger and Pluckthun, ""Yet another numbering scheme for immunoglobulin variable domains: an automatic modeling and analysis tool"", J. Mol. Biol., 309(3):657-670 (2001).;;Hoogenboom et al., ""By-passing Immunisation Human Antibodies from Synthetic Repertoires of Germline VH Gene Segments Rerranged in Vitro"", J. Mol. Biol., 227:381 (1991).;;Hopp et al., ""A Short Polypeptide Marker Sequence Useful for Recombinant Protein Identification and Purification"", Bio/Technology, 6:1204 (1988).;;Hoppe et al., ""A parallel three stranded alpha-helical bundle at the nucleation site of collagen triple-helix formation"", FEBS Letters, 344:191 (1994).;;Huston et al., ""Protein engineering of antibody binding sites: recovery of specific activity in an anti-digoxin single-chain Fv analogue produced in Escherichia coli"", Proc. Natl. Acad. Sci. U.S.A., 85:5879 (1988).;;Jakobovits et al., ""Analysis of homozygous mutant chimeric mice: Deletion of the immunoglobulin heavy-chain joining region blocks B-cell development and antibody production"", Proc. Natl. Acad. Sci. USA, 90:2551-2555 (1993).;;Jakobovits et al., ""Germ-line transmission and expression of a human-derived yeast artificial chromosome"", Nature, 362:255-258 (1993).;;Jones et al., ""Replacing the complementarity-determining regions in a human antibody with those from a mouse"", Nature, 321 :522-525 (1986).;;Jones, ""Progress in protein structure prediction"", Curr. Opin. Struct. Biol., 7:377-387 (1997).;;Kabat et al., Sequences of Proteins of Immunological Interest, 5th Ed., US Dept. of Health and Human Services, PHS, NIH, NIH Publication No. 91-3242 (1991).;;Kastelein, et al., ""Discovery and Biology of IL-23 and IL-27: Related but Functionally Distinct Regulators of Inflammation"", Annual Review of Immunology, 25:221-42 (2007).;;Kelsey et al., ""Species- and tissue-specific expression of human alpha1-antitrypsin in transgenic mice"", Genes and Devel., 1 :161-171 (1987).;;Khader et al., ""IL-23 Compensates for the Absence of IL-12p70 and Is Essential for the IL-17 Response during Tuberculosis but Is Dispensable for Protection and Antigen-Specific IFN-y Responses if IL-12p70 Is Available"", The Journal of Immunology, 175:788-795 (2005).;;Kirkland et al., ""Analysis of the fine specificity and cross-reactivity of monoclonal anti-lipid A antibodies"", J. Immunol., 137:3614-3619 (1986).;;Kollias et al., ""Regulated Expression of Human Agamma-, beta-, and Hybrid gammabeta-Globin Genes in Transgenic Mice: Manipulation of the Developmental Expression Patterns"", Cell, 46:89-94 (1986).;;Korndorfer et al., ""Crystallographic Analysis of an ""Anticalin"" With Tailored Specificity for fluorescein Reveals High Structural Plasticity of the Lipocalin Loop Region"", Proteins: Structure, Function, and Bioinformatics, vol. 53, Issue 1:121-129 (2003).;;Kortt et ai, ""Dimeric and trimeric antibodies: high avidity scFvs for cancer targeting"", Biomol. Eng., 18:95-108 (2001).;;Kortt et al., ""Single-chain Fv fragments of anti-neuraminidase antibody NC10 containing five- and ten-residue linkers form dimers and with zero-residue linker a trimer"", Prot. Eng., 10:423 (1997).;;Kostelny et al., ""Formation of a bispecific antibody by the use of leucine zippers"", J. Immunol., 148:1547-1553 (1992).;;Kriangkum et al., ""Bispecific and bifunctional single chain recombinant antibodies"", Biomol. Eng., 18:31-40 (2001).;;Krumlauf et al., ""Developmental regulation of alpha-fetoprotein genes in transgenic mice"", Mol. Cell. Biol., 5:1639-1648 (1985).;;Kurzeja et al., ""New Interleukin-23 pathway inhibitors in dermatology"", Am. J. Clin. Dermatol., 12:113-125 (2011).;;Kyte et al., ""A simple method for displaying the hydropathic character of a protein"", J. Mol. Biol., 157:105-131 (1982).;;Langowski et al., ""IL-23 promotes tumour incidence and growth"", Nature, 442: 461-5 (2006).;;Lantto et al., ""Chain Shuffling to modify properties of recombinant immunoglobulins"", Methods Mol. Biol., 178:303-316 (2002).;;Leder et al., ""Consequences of widespread deregulation of the c-myc gene in transgenic mice: multiple neoplasms and normal development"", Cell, 45:485-495 (1986).;;Lefranc et al, ""IMGT unique numbering for immunoglobulin and T cell receptor constant domain and Ig superfamily C-like domains"", Dev. Comp. Immunol., 29:185-203 (2005).;;Liu, et al., ""Interleukin (IL)-23 p19 expression induced by IL-1beta in human fibroblast-like synoviocytes with rheumatoid arthritis via active nuclear factor-kB and AP-1 dependent pathway"", Rheumatology, 46(8):1266-73 (2007).;;Lonberg and Huszar, ""Human Antibodies from Transgenic Mice"", Intern. Rev. Immunol., 13:65-93 (1995).;;Lonberg et al., ""Antigen-specific human antibodies from mice comprising four distinct genetic modifications"", Nature, 368:856-859 (1994).;;Lonberg et al., ""Fully human antibodies from transgenic mouse and phage display platforms"", Current Opinion in Immunology, 20(4):450-459 (2008).;;Lonberg, Chapter 3, ""Transgenic Approaches to Human Monoclonal Antibodies"", Handbook of Exp. Pharmacology, 113:49-101 (1994).;;Lupardus and Garcia, ""The Structure of Interleukin-23 Reveals the Molecular Basis of p40 subunit sharing with Interleukin-12"", J. Mol. Biol., 382:931-941 (2008).;;Mabry et al., ""Engineering of stable bispecific antibodies targeting IL-17A and IL23"", Protein Engineering Design & Selection, 23(3):115-127 (2010).;;MacDonald, ""Expression of the pancreatic elastase I gene in transgenic mice"", Hepatology, 7:425-515 (1987).;;Magram et al., ""Developmental regulation of a cloned adult beta-globin gene in transgenic mice"", Nature, 315:338-340 (1985).;;Marks et al., ""By-Passing Immunization: building high affinity human antibodies by chain shuffling"", BioTechnology, 10:779 (1992).",ACTIVE
385,US,A1,US 2001/0048940 A1,158-275-633-803-595,2001-12-06,2001,US 33568999 A,1999-06-18,US 33568999 A,1999-06-18,CATIONIC AMPHIPHILE MICELLAR COMPLEXES,"
   The effective introduction of foreign genes and other biologically active molecules into targeted mammalian cells is a challenge still facing those skilled in the art. Gene therapy, for example, requires successful transfection of target cells in a patient. The present invention relates to novel micellar complexes of cationic amphiphilic compounds that facilitate delivery of biologically active molecules to the targeted cells of a mammal. The novel micellar complexes are comprised of a cationic amphiphile, a biologically active molecule, a derivative of polyethylene glycol (PEG), and optionally, a co-lipid. A further aspect of the invention is the use of targeting agents in any of the methods that effectuate the delivery of biologically active molecules into the cells of mammals. A targeting agent is usually any molecule, peptide sequence, or large protein that preferentially targets or binds to specific mammalian cells. 
",TOUSIGNANT JENNIFER D.;;EASTMAN SIMON J.;;LEE EDWARD R.;;SCHEULE RONALD K.;;CHENG SENG H.;;NIETUPSKI J.;;CHU QIUMING;;MARSHALL JOHN,TOUSIGNANT JENNIFER D;;EASTMAN SIMON J;;LEE EDWARD R;;SCHEULE RONALD K;;CHENG SENG H;;NIETUPSKI J;;CHU QIUMING;;MARSHALL JOHN,GENZYME CORPORATION (1999-09-07),https://lens.org/158-275-633-803-595,Patent Application,yes,0,34,2,2,0,A61K9/1075;;A61K9/1272;;A61K48/00;;C12N15/88;;A61K9/1272;;C12N15/88;;A61K9/1075;;A61K48/00,A61K9/107;;A61K9/127;;A61K48/00;;C12N15/88,42445;;424/468;;514/44;;435/458,0,0,,,,DISCONTINUED
386,MX,A,MX 2012004868 A,014-463-809-659-598,2012-08-03,2012,MX 2012004868 A,2010-10-26,US 25498209 P;;US 38128710 P;;US 2010/0054148 W,2009-10-26,HUMAN IL-23 ANTIGEN BINDING PROTEINS.,"Antigen binding proteins that bind to human IL-23 protein are provided. Nucleic acids encoding the antigen binding protein, vectors, and cells encoding the same as well as use of IL-23 antigen binding proteins for diagnostic and therapeutic purposes are also provided.",AMGEN INC,KETCHEM RANDAL R;;TOWNE JENNIFER E;;CHENG JANET D;;O'NEILL JASON C;;ZHANG YU;;SUN YU;;CERNE HEATHER;;PIPER DEREK E,,https://lens.org/014-463-809-659-598,Patent Application,no,0,0,86,87,0,A61K2039/505;;C07K2317/21;;C07K2317/55;;C07K2317/92;;A61K47/6845;;C07K16/244;;A61P37/00;;C07K16/244;;A61K2039/505;;C07K2317/626;;C07K2317/21;;C07K2317/76;;A61K47/6845;;C07K2317/54;;A61K39/395;;C07K2317/31;;C07K16/24;;A61P37/00;;C07K2317/92;;C07K2317/24;;C07K2317/622;;C07K2317/55;;C07K2317/565;;A61K39/00;;A61K39/395;;A61K39/39533;;A61K39/3955;;C07K16/18;;C07K16/24;;C07K16/244;;A61K2039/505;;C07K2317/21;;C07K2317/55;;C07K2317/92;;A61K47/6845;;C07K16/244;;A61K39/395;;C07K16/24;;C07K2317/24;;C07K2317/31;;C07K2317/54;;C07K2317/565;;C07K2317/622;;C07K2317/626;;C07K2317/76,C07K16/24;;A61K39/395,,0,0,,,,ACTIVE
387,PE,A1,PE 20121579 A1,008-264-840-531-577,2012-12-13,2012,PE 2012000564 A,2010-10-26,US 25498209 P;;US 38128710 P,2009-10-26,PROTEINAS DE ENLACE AL ANTIGENO IL-23 HUMANAS,"SE REFIERE A UNA PROTEINA DE ENLACE AL ANTIGENO TAL COMO UN ANTICUERPO MONOCLONAL HUMANO QUE SE ENLAZA A IL-23 QUE COMPRENDE: A) UNA REGION VARIABLE DE CADENA PESADA QUE TIENE UNA SECUENCIA DE AMINOACIDOS DE SEQ ID Nº 31, 34, 36, 38, 40, 42, 44, 46, 48, 50, ENTRE OTROS, Y COMPRENDE UNA CDRH1 DE SEQ ID Nº 91, 94, 97, 100 Y 103, UNA CDRH2 DE SEQ ID Nº 92, 95, 98, 101, 104, 107 Y 110, Y UNA CDRH3 DE SEQ ID Nº 93, 96, 99, 102 Y 105; Y B) UNA REGION VARIABLE DE CADENA LIGERA QUE TIENE UNA SECUENCIA DE AMINOACIDOS DE SEQ ID Nº 1, 4, 7, 9, 11, 13, 15, 17, 19, 21, ENTRE OTROS, Y COMPRENDE UNA CDRL1 DE SEQ ID Nº 62, 65, 68, 71 Y 74, UNA CDRL2 DE SEQ ID Nº 63, 66, 69, 72, 75 Y 78, Y UNA CDRL3 DE SEQ ID Nº 64, 67, 70 Y 73. TAMBIEN SE REFIERE A UNA COMPOSICION FARMACEUTICA DE DICHO ANTICUERPO QUE ES UTIL EN EL TRATAMIENTO DE ESCLEROSIS MULTIPLE, ARTRITIS REUMATOIDE, CANCER, PSORIASIS",AMGEN INC,TOWNE JENNIFER E;;CHENG JANET D;;O'NEILL JASONC C;;ZHANG YU;;SUN YU;;CERNE HEATHER;;PIPER DEREK E;;KETCHEM RANDAL R,,https://lens.org/008-264-840-531-577,Patent Application,no,0,0,86,87,0,A61K2039/505;;C07K2317/21;;C07K2317/55;;C07K2317/92;;A61K47/6845;;C07K16/244;;A61P37/00;;C07K16/244;;A61K2039/505;;C07K2317/626;;C07K2317/21;;C07K2317/76;;A61K47/6845;;C07K2317/54;;A61K39/395;;C07K2317/31;;C07K16/24;;A61P37/00;;C07K2317/92;;C07K2317/24;;C07K2317/622;;C07K2317/55;;C07K2317/565;;A61K39/00;;A61K39/395;;A61K39/39533;;A61K39/3955;;C07K16/18;;C07K16/24;;C07K16/244;;A61K2039/505;;C07K2317/21;;C07K2317/55;;C07K2317/92;;A61K47/6845;;C07K16/244;;A61K39/395;;C07K16/24;;C07K2317/24;;C07K2317/31;;C07K2317/54;;C07K2317/565;;C07K2317/622;;C07K2317/626;;C07K2317/76,A61K39/395;;C07K16/24,,0,0,,,,ACTIVE
388,US,A1,US 2013/0004501 A1,032-465-412-787-139,2013-01-03,2013,US 201013504449 A,2010-10-26,US 201013504449 A;;US 38128710 P;;US 25498209 P;;US 2010/0054148 W,2009-10-26,HUMAN IL-23 ANTIGEN BINDING PROTEINS,"Antigen binding proteins that bind to human IL-23 protein are provided. Nucleic acids encoding the antigen binding protein, vectors, and cells encoding the same as well as use of IL-23 antigen binding proteins for diagnostic and therapeutic purposes are also provided.",AMGEN INC;;TOWNE JENNIFER E;;CHENG JANET D;;O'NEILL JASON C;;ZHANG YU;;SUN YU;;CERNE HEATHER;;PIPER DEREK E;;KETCHEM RANDAL R,TOWNE JENNIFER E;;CHENG JANET D;;O'NEILL JASON C;;ZHANG YU;;SUN YU;;CERNE HEATHER;;PIPER DEREK E;;KETCHEM RANDAL R,AMGEN INC (2012-06-11),https://lens.org/032-465-412-787-139,Patent Application,yes,6,20,86,87,155,A61K2039/505;;C07K2317/21;;C07K2317/55;;C07K2317/92;;A61K47/6845;;C07K16/244;;A61P37/00;;C07K16/244;;A61K2039/505;;C07K2317/626;;C07K2317/21;;C07K2317/76;;A61K47/6845;;C07K2317/54;;A61K39/395;;C07K2317/31;;C07K16/24;;A61P37/00;;C07K2317/92;;C07K2317/24;;C07K2317/622;;C07K2317/55;;C07K2317/565;;A61K39/00;;A61K39/395;;A61K39/39533;;A61K39/3955;;C07K16/18;;C07K16/24;;C07K16/244;;A61K2039/505;;C07K2317/21;;C07K2317/55;;C07K2317/92;;A61K47/6845;;C07K16/244;;A61K39/395;;C07K16/24;;C07K2317/24;;C07K2317/31;;C07K2317/54;;C07K2317/565;;C07K2317/622;;C07K2317/626;;C07K2317/76,A61K39/395;;C07K16/24;;C12N1/19;;C12N1/21;;C12N5/10;;C12N15/13;;C12N15/63;;C12P21/02,424/139.1;;536/23.53;;435/320.1;;435/252.33;;435/254.2;;435/331;;435/69.6;;530/387.9,6,6,020-367-308-901-689;;046-845-561-202-870;;062-761-744-997-508;;027-477-313-726-928;;075-555-351-927-589;;019-397-556-890-001,1961196;;10.1016/0161-5890(91)90003-3;;10.1016/j.intimp.2004.01.010;;15120653;;pmc280147;;10.1073/pnas.85.9.3080;;3129726;;10.1073/pnas.79.6.1979;;pmc346105;;6804947;;10.1126/science.2426778;;2426778;;18708069;;10.1016/j.jmb.2008.08.001,"Lederman et al (1991), Molecular Immunology, Vol. 28, No. 11, pages 1171-1181.;;Li et al. (2004), International Immunology, Vol. 4, pages 693-708.;;Panka et al. Proc. Natl. Acad. Sci. USA Vol. 85, pages 3080-3084 (May 1988).;;Rudikoff et al. Proc. Natl. Acad. Sci. USA Vol. 79, pages 1979-1983 (March 1982).;;Amit et al. Science, Vot. 233, pages 747-753, (August 1986).;;Beyer et al (2008), Journal of Molecular Biology, vol. 382, no. 4, pages 942-955.",ACTIVE
389,PL,T3,PL 2493925 T3,060-125-333-303-508,2017-09-29,2017,PL 10774095 T,2010-10-26,US 25498209 P;;US 38128710 P,2009-10-26,HUMAN IL-23 ANTIGEN BINDING PROTEINS,,AMGEN INC,TOWNE JENNIFER E;;CHENG JANET D;;O'NEILL JASON C;;ZHANG YU;;SUN YU;;CERNE HEATHER;;PIPER DEREK E;;KETCHEM RANDAL R,,https://lens.org/060-125-333-303-508,Patent Application,no,0,0,86,87,0,A61K2039/505;;C07K2317/21;;C07K2317/55;;C07K2317/92;;A61K47/6845;;C07K16/244;;A61P37/00;;C07K16/244;;A61K2039/505;;C07K2317/626;;C07K2317/21;;C07K2317/76;;A61K47/6845;;C07K2317/54;;A61K39/395;;C07K2317/31;;C07K16/24;;A61P37/00;;C07K2317/92;;C07K2317/24;;C07K2317/622;;C07K2317/55;;C07K2317/565;;A61K39/00;;A61K39/395;;A61K39/39533;;A61K39/3955;;C07K16/18;;C07K16/24;;C07K16/244;;A61K2039/505;;C07K2317/21;;C07K2317/55;;C07K2317/92;;A61K47/6845;;C07K16/244;;A61K39/395;;C07K16/24;;C07K2317/24;;C07K2317/31;;C07K2317/54;;C07K2317/565;;C07K2317/622;;C07K2317/626;;C07K2317/76,C07K16/24;;A61K39/395,,0,0,,,,PENDING
390,CY,T1,CY 1118576 T1,185-376-278-582-549,2017-07-12,2017,CY 171100096 T,2017-01-24,US 25498209 P;;US 38128710 P;;US 2010/0054148 W,2009-10-26,ΠΡΩΤΕΪΝΕΣ ΔΕΣΜΕΥΟΜΕΝΕΣ ΜΕ ΑΝΤΙΓΟΝΟ ΑΝΘΡΩΠΙΝΗΣ IL-23,"Παρέχονται πρωτεΐνες δεσμευόμενες με αντιγόνο οι οποίες δεσμεύονται με ανθρώπινη πρωτεΐνη IL-23. Παρέχονται επίσης νουκλεϊκά οξέα που κωδικοποιούν την δεσμευόμενη με αντιγόνο πρωτεΐνη, φορείς, και κύτταρα που την κωδικοποιούν όπως επίσης και χρήση των πρωτεϊνών που δεσμεύονται με αντιγόνο IL-23 για διαγνωστικούς και θεραπευτικούς σκοπούς.",AMGEN INC,TOWNE JENNIFER E;;CHENG JANET D;;O’NEILL JASON C;;ZHANG YU;;SUN YU;;CERNE HEATHER;;PIPER DEREK E;;KETCHEM RANDAL R,,https://lens.org/185-376-278-582-549,Granted Patent,no,0,0,86,87,0,A61K2039/505;;C07K2317/21;;C07K2317/55;;C07K2317/92;;A61K47/6845;;C07K16/244;;A61P37/00;;C07K16/244;;A61K2039/505;;C07K2317/626;;C07K2317/21;;C07K2317/76;;A61K47/6845;;C07K2317/54;;A61K39/395;;C07K2317/31;;C07K16/24;;A61P37/00;;C07K2317/92;;C07K2317/24;;C07K2317/622;;C07K2317/55;;C07K2317/565;;A61K39/00;;A61K39/395;;A61K39/39533;;A61K39/3955;;C07K16/18;;C07K16/24;;C07K16/244;;A61K2039/505;;C07K2317/21;;C07K2317/55;;C07K2317/92;;A61K47/6845;;C07K16/244;;A61K39/395;;C07K16/24;;C07K2317/24;;C07K2317/31;;C07K2317/54;;C07K2317/565;;C07K2317/622;;C07K2317/626;;C07K2317/76,C07K16/24;;A61K39/395,,0,0,,,,ACTIVE
391,JO,B1,JO 3244 B1,195-118-138-077-541,2018-03-08,2018,JO P20100356 A,2010-10-18,US 25498209 P;;US 38128710 P,2009-10-26,HUMAN IL-23 ANTIGEN BINDING PROTEINS,"Antigen binding proteins that bind to human IL-23 protein are provided. Nucleic acids encoding the antigen binding protein, vectors, and cells encoding the same as well as use of IL-23 antigen binding proteins for diagnostic and therapeutic purposes are also provided.",AMGEN INC,JANET D CHENG;;JASON C O'NEILL;;JENNIFER E TOWNE;;DEREK E PIPER;;RANDAL R KETCHEM;;HEATHER CERNE;;YU ZHANG;;YU SUN,,https://lens.org/195-118-138-077-541,Granted Patent,no,0,0,86,87,0,A61K2039/505;;C07K2317/21;;C07K2317/55;;C07K2317/92;;A61K47/6845;;C07K16/244;;A61P37/00;;C07K16/244;;A61K2039/505;;C07K2317/626;;C07K2317/21;;C07K2317/76;;A61K47/6845;;C07K2317/54;;A61K39/395;;C07K2317/31;;C07K16/24;;A61P37/00;;C07K2317/92;;C07K2317/24;;C07K2317/622;;C07K2317/55;;C07K2317/565;;A61K39/00;;A61K39/395;;A61K39/39533;;A61K39/3955;;C07K16/18;;C07K16/24;;C07K16/244;;A61K2039/505;;C07K2317/21;;C07K2317/55;;C07K2317/92;;A61K47/6845;;C07K16/244;;A61K39/395;;C07K16/24;;C07K2317/24;;C07K2317/31;;C07K2317/54;;C07K2317/565;;C07K2317/622;;C07K2317/626;;C07K2317/76,,,0,0,,,,ACTIVE
392,US,A1,US 2022/0056122 A1,003-138-687-829-940,2022-02-24,2022,US 202117525421 A,2021-11-12,US 202117525421 A;;US 202117229607 A;;US 202017060905 A;;US 202016793610 A;;US 201916453482 A;;US 201816194896 A;;US 201815922675 A;;US 201615271315 A;;US 201414228556 A;;US 201213504449 A;;US 2010/0054148 W;;US 38128710 P;;US 25498209 P,2009-10-26,HUMAN IL-23 ANTIGEN BINDING PROTEINS,"Antigen binding proteins that bind to human IL-23 protein arc provided. Nucleic acids encoding the antigen binding protein, vectors, and cells encoding the same as well as use of IL-23 antigen binding proteins for diagnostic and therapeutic purposes arc also provided.",AMGEN INC,TOWNE JENNIFER E;;CHENG JANET D;;O'NEILL JASON C;;ZHANG YU;;SUN YU;;CERNE HEATHER;;PIPER DEREK E;;KETCHEM RANDEL R,AMGEN INC (2012-06-11),https://lens.org/003-138-687-829-940,Patent Application,yes,0,0,86,87,155,A61K2039/505;;C07K2317/21;;C07K2317/55;;C07K2317/92;;A61K47/6845;;C07K16/244;;A61P37/00;;C07K16/244;;A61K2039/505;;C07K2317/626;;C07K2317/21;;C07K2317/76;;A61K47/6845;;C07K2317/54;;A61K39/395;;C07K2317/31;;C07K16/24;;A61P37/00;;C07K2317/92;;C07K2317/24;;C07K2317/622;;C07K2317/55;;C07K2317/565;;A61K39/00;;A61K39/395;;A61K39/39533;;A61K39/3955;;C07K16/18;;C07K16/24;;C07K16/244;;A61K2039/505;;C07K2317/21;;C07K2317/55;;C07K2317/92;;A61K47/6845;;C07K16/244;;A61K39/395;;C07K16/24;;C07K2317/24;;C07K2317/31;;C07K2317/54;;C07K2317/565;;C07K2317/622;;C07K2317/626;;C07K2317/76,C07K16/24;;A61K39/395;;A61K47/68,,0,0,,,,PENDING
393,BR,B8,BR 122020002402 B8,036-616-707-293-233,2022-03-29,2022,BR 122020002402 A,2010-10-26,US 2010/0054148 W;;US 25498209 P;;US 38128710 P;;BR 112012009854 A,2009-10-26,"Proteína de ligação de antígeno isolada recombinante que liga il-23, composição farmacêutica, molécula de ácido nucleico isolada recombinante, vetor recombinante, célula hospedeira recombinante, métodos de confecção da referida proteína de ligação e uso da mesma","são fornecidas proteínas de ligação de antígeno que se ligam a proteína de il-23 humana. ácidos nucleicos que codificam a proteína de ligação de antígeno, vetores, e células que codificam os mesmos bem como o uso de proteínas de ligação de antígeno de il-23 para objetivos diagnósticos e terapêuticos são também fornecidos.",AMGEN INC,DEREK E PIPER;;CERNE HEATHER;;JANET D CHENG;;JASON C O'NEILL;;JENNIFER E TOWNE;;RANDAL R KETCHEM;;SUN YU;;ZHANG YU,,https://lens.org/036-616-707-293-233,Amended Patent,no,0,0,86,87,0,A61K2039/505;;C07K2317/21;;C07K2317/55;;C07K2317/92;;A61K47/6845;;C07K16/244;;A61P37/00;;C07K16/244;;A61K2039/505;;C07K2317/626;;C07K2317/21;;C07K2317/76;;A61K47/6845;;C07K2317/54;;A61K39/395;;C07K2317/31;;C07K16/24;;A61P37/00;;C07K2317/92;;C07K2317/24;;C07K2317/622;;C07K2317/55;;C07K2317/565;;A61K39/00;;A61K39/395;;A61K39/39533;;A61K39/3955;;C07K16/18;;C07K16/24;;C07K16/244;;A61K2039/505;;C07K2317/21;;C07K2317/55;;C07K2317/92;;A61K47/6845;;C07K16/244;;A61K39/395;;C07K16/24;;C07K2317/24;;C07K2317/31;;C07K2317/54;;C07K2317/565;;C07K2317/622;;C07K2317/626;;C07K2317/76,A61K39/395;;C07K16/24,,0,0,,,,ACTIVE
394,CA,C,CA 3030092 C,034-943-670-497-392,2023-12-19,2023,CA 3030092 A,2010-10-26,US 25498209 P;;US 38128710 P;;CA 2778112 A,2009-10-26,HUMAN IL-23 ANTIGEN BINDING PROTEINS,"Antigen binding proteins that bind to human IL-23 protein are provided. Nucleic acids encoding the antigen binding protein, vectors, and cells encoding the same as well as use of IL-23 antigen binding proteins for diagnostic and therapeutic purposes are also provided.",AMGEN INC,TOWNE JENNIFER E;;CHENG JANET D;;O'NEILL JASON C;;ZHANG YU;;SUN YU;;CERNE HEATHER;;PIPER DEREK E;;KETCHEM RANDAL R,,https://lens.org/034-943-670-497-392,Granted Patent,no,0,0,86,87,155,A61K2039/505;;C07K2317/21;;C07K2317/55;;C07K2317/92;;A61K47/6845;;C07K16/244;;A61P37/00;;C07K16/244;;A61K2039/505;;C07K2317/626;;C07K2317/21;;C07K2317/76;;A61K47/6845;;C07K2317/54;;A61K39/395;;C07K2317/31;;C07K16/24;;A61P37/00;;C07K2317/92;;C07K2317/24;;C07K2317/622;;C07K2317/55;;C07K2317/565;;A61K39/00;;A61K39/395;;A61K39/39533;;A61K39/3955;;C07K16/18;;C07K16/24;;C07K16/244;;A61K2039/505;;C07K2317/21;;C07K2317/55;;C07K2317/92;;A61K47/6845;;C07K16/244;;A61K39/395;;C07K16/24;;C07K2317/24;;C07K2317/31;;C07K2317/54;;C07K2317/565;;C07K2317/622;;C07K2317/626;;C07K2317/76,C07K16/24;;A61K39/395;;A61K49/00;;A61K51/10;;C12N5/10;;C12N15/13;;C12P21/08;;C12Q1/6876;;G01N33/53,,0,0,,,,PENDING
395,US,B1,US 6841346 B1,109-157-807-268-461,2005-01-11,2005,US 32822602 A,2002-12-23,US 32822602 A;;US 38399902 P,2002-05-29,Methods for detecting bacteriophage MS2,The present invention relates to methods and assays for detecting bacteriophage MS2 in a sample.,US ARMY,O'CONNELL KEVIN P;;KHAN AKBAR S;;CAO CHENG J;;BUCHER JENNIFER R;;GOSTOMSKI MARK V;;VALDES JAMES J;;ANDERSON PATRICIA E,ARMY UNITED STATES OF AMERICA AS REPRESENTED BY THE (2002-12-23);;UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF THE ARMY (2002-12-18),https://lens.org/109-157-807-268-461,Granted Patent,yes,0,4,5,5,17,C12Q1/701;;C12Q1/701;;C12Q1/686;;C12Q1/686,C12Q1/68;;C12Q1/70,435/5;;435/5;;435/4;;435/7.1,6,4,026-686-345-701-412;;048-868-490-805-758;;056-684-628-689-109;;052-721-416-844-191,pmc84917;;10.1128/jcm.37.6.1661-1669.1999;;10325304;;pmc52277;;1871133;;10.1073/pnas.88.16.7276;;10.1101/gr.4.6.357;;7580930;;10747142;;10.1128/jcm.38.4.1552-1558.2000;;pmc86487,"Olive, D. M., and Bean, P. Principles and applications of methods for DNA-based typing of microbial organisms. J. Clin. Microbiol. 1999; 37: 1661-1669.*;;Holland, P. M., Abramson, R. D., Watson, R. and Gelfand, D. H. Detection of specific polymerase chain reaction product by utilizing the 5'-3' exonuclease activity of Thermus aquaticus. Proc. Natl. Acad. Sci. 1991; 88:7276-7280.*;;Livak KJ, Flood SJ, Marmaro J, Gius. Oligonucleotides with fluorescent dyes at opposite ends provide a quenched probe system useful for detecting PCR product and nucleic acid hybridization. PCR Methods Appl. Jun. 1995;4(6):357-62.*;;O'Connell et al. Application of Real-Time Fluorogenic Polymerase chain reaction (PCR) to nucleic acid-based detection of simulants and biothreat agents. 23<rd >Army Science Conference, Dec. 2002.*;;Printout of Genome disclosure by NCBI, Complete genome of Enterio bacteriophage MS2, Accession: NC 001417.*;;Schweiger et al. Application of a Fluorogenic PCR Assay for Typing and Subtyping of Influenza Viruses in Respiratory Samples. Journal of Clinical Microbiology, Apr. 2000, p. 1552-1558, vol. 38, No. 4.",EXPIRED
396,KR,A,KR 20140062186 A,080-079-117-613-641,2014-05-22,2014,KR 20147012130 A,2010-10-26,US 25498209 P;;US 38128710 P;;US 2010/0054148 W,2009-10-26,HUMAN IL-23 ANTIGEN BINDING PROTEINS,,AMGEN INC,TOWNE JENNIFER E;;CHENG JANET D;;O'NEILL JASON C;;ZHANG YU;;SUN YU;;CERNE HEATHER;;PIPER DEREK E;;KETCHEM RANDAL R,,https://lens.org/080-079-117-613-641,Patent Application,no,4,0,86,87,306,A61K2039/505;;C07K2317/21;;C07K2317/55;;C07K2317/92;;A61K47/6845;;C07K16/244;;A61P37/00;;C07K16/244;;A61K2039/505;;C07K2317/626;;C07K2317/21;;C07K2317/76;;A61K47/6845;;C07K2317/54;;A61K39/395;;C07K2317/31;;C07K16/24;;A61P37/00;;C07K2317/92;;C07K2317/24;;C07K2317/622;;C07K2317/55;;C07K2317/565;;A61K39/00;;A61K39/395;;A61K39/39533;;A61K39/3955;;C07K16/18;;C07K16/24;;C07K16/244;;A61K2039/505;;C07K2317/21;;C07K2317/55;;C07K2317/92;;A61K47/6845;;C07K16/244;;A61K39/395;;C07K16/24;;C07K2317/24;;C07K2317/31;;C07K2317/54;;C07K2317/565;;C07K2317/622;;C07K2317/626;;C07K2317/76,C07K16/24;;A61K39/395,,0,0,,,,ACTIVE
397,AR,A2,AR 121799 A2,122-031-350-559-169,2022-07-13,2022,AR P210100934 A,2021-04-08,US 25498209 P,2009-10-26,PROTEÍNAS DE UNIÓN A ANTÍGENOS DE IL-23 HUMANA,"Se proporcionan proteínas de unión a antígenos que se unen a la proteína de IL-23 humana. Asimismo, se proporcionan ácidos nucleicos que codifican la proteína de unión al antígeno, vectores, y células que la codifican así como el uso de proteínas de unión a antígenos de IL-23 con fines de diagnóstico y terapéuticos.",AMGEN INC,TOWNE JENNIFER E;;CHENG JANET D;;ONEILL JASON C;;ZHANG YU;;SUN YU;;CERNE HEATHER;;PIPER DEREK E;;KETCHEM RANDAL R,,https://lens.org/122-031-350-559-169,Amended Application,no,0,0,1,87,0,,C07K14/54;;A61K39/395;;A61P37/00;;C07K16/24;;C12N5/22;;C12N15/13;;C12N15/63;;C12N15/79;;G01N33/53,,0,0,,,,PENDING
398,CA,A1,CA 2778112 A1,125-196-995-862-354,2011-05-12,2011,CA 2778112 A,2010-10-26,US 25498209 P;;US 38128710 P;;US 2010/0054148 W,2009-10-26,HUMAN IL-23 ANTIGEN BINDING PROTEINS,"Antigen binding proteins that bind to human IL-23 protein are provided. Nucleic acids encoding the antigen binding protein, vectors, and cells encoding the same as well as use of IL-23 antigen binding proteins for diagnostic and therapeutic purposes are also provided.",AMGEN INC,TOWNE JENNIFER E;;CHENG JANET D;;O'NEILL JASON C;;ZHANG YU;;SUN YU;;CERNE HEATHER;;PIPER DEREK E;;KETCHEM RANDAL R,,https://lens.org/125-196-995-862-354,Patent Application,no,0,0,86,87,155,A61K2039/505;;C07K2317/21;;C07K2317/55;;C07K2317/92;;A61K47/6845;;C07K16/244;;A61P37/00;;C07K16/244;;A61K2039/505;;C07K2317/626;;C07K2317/21;;C07K2317/76;;A61K47/6845;;C07K2317/54;;A61K39/395;;C07K2317/31;;C07K16/24;;A61P37/00;;C07K2317/92;;C07K2317/24;;C07K2317/622;;C07K2317/55;;C07K2317/565;;A61K39/00;;A61K39/395;;A61K39/39533;;A61K39/3955;;C07K16/18;;C07K16/24;;C07K16/244;;A61K2039/505;;C07K2317/21;;C07K2317/55;;C07K2317/92;;A61K47/6845;;C07K16/244;;A61K39/395;;C07K16/24;;C07K2317/24;;C07K2317/31;;C07K2317/54;;C07K2317/565;;C07K2317/622;;C07K2317/626;;C07K2317/76,C07K16/24;;A61K39/395,,0,0,,,,ACTIVE
399,US,A1,US 2020/0181255 A1,175-300-515-258-23X,2020-06-11,2020,US 202016793610 A,2020-02-18,US 202016793610 A;;US 201916453482 A;;US 201816194896 A;;US 201815922675 A;;US 201615271315 A;;US 201414228556 A;;US 201213504449 A;;US 2010/0054148 W;;US 38128710 P;;US 25498209 P,2009-10-26,Human IL-23 Antigen Binding Proteins,"Antigen binding proteins that bind to human IL-23 protein are provided. Nucleic acids encoding the antigen binding protein, vectors, and cells encoding the same as well as use of IL-23 antigen binding proteins for diagnostic and therapeutic purposes are also provided.",AMGEN INC,TOWNE JENNIFER E;;CHENG JANET D;;O'NEILL JASON C;;ZHANG YU;;SUN YU;;CERNE HEATHER;;PIPER DEREK E;;KETCHEM RANDAL R,AMGEN INC (2012-06-11),https://lens.org/175-300-515-258-23X,Patent Application,yes,0,1,86,87,155,A61K2039/505;;C07K2317/21;;C07K2317/55;;C07K2317/92;;A61K47/6845;;C07K16/244;;A61P37/00;;C07K16/244;;A61K2039/505;;C07K2317/626;;C07K2317/21;;C07K2317/76;;A61K47/6845;;C07K2317/54;;A61K39/395;;C07K2317/31;;C07K16/24;;A61P37/00;;C07K2317/92;;C07K2317/24;;C07K2317/622;;C07K2317/55;;C07K2317/565;;A61K39/00;;A61K39/395;;A61K39/39533;;A61K39/3955;;C07K16/18;;C07K16/24;;C07K16/244;;A61K2039/505;;C07K2317/21;;C07K2317/55;;C07K2317/92;;A61K47/6845;;C07K16/244;;A61K39/395;;C07K16/24;;C07K2317/24;;C07K2317/31;;C07K2317/54;;C07K2317/565;;C07K2317/622;;C07K2317/626;;C07K2317/76,C07K16/24;;A61K39/395;;A61K47/68,,0,0,,,,DISCONTINUED
400,US,B2,US 9487580 B2,161-225-689-849-341,2016-11-08,2016,US 201414228556 A,2014-03-28,US 201414228556 A;;US 201213504449 A;;US 2010/0054148 W;;US 38128710 P;;US 25498209 P,2009-10-26,Human IL-23 antigen binding proteins,"Antigen binding proteins that bind to human IL-23 protein are provided. Nucleic acids encoding the antigen binding protein, vectors, and cells encoding the same as well as use of IL-23 antigen binding proteins for diagnostic and therapeutic purposes are also provided.",TOWNE JENNIFER E;;CHENG JANET D;;O'NEILL JASON C;;ZHANG YU;;SUN YU;;CERNE HEATHER;;PIPER DEREK E;;KETCHEM RANDAL R;;AMGEN INC,TOWNE JENNIFER E;;CHENG JANET D;;O'NEILL JASON C;;ZHANG YU;;SUN YU;;CERNE HEATHER;;PIPER DEREK E;;KETCHEM RANDAL R,AMGEN INC (2012-06-11),https://lens.org/161-225-689-849-341,Granted Patent,yes,99,1,86,87,155,A61K2039/505;;C07K2317/21;;C07K2317/55;;C07K2317/92;;A61K47/6845;;C07K16/244;;A61P37/00;;C07K16/244;;A61K2039/505;;C07K2317/626;;C07K2317/21;;C07K2317/76;;A61K47/6845;;C07K2317/54;;A61K39/395;;C07K2317/31;;C07K16/24;;A61P37/00;;C07K2317/92;;C07K2317/24;;C07K2317/622;;C07K2317/55;;C07K2317/565;;A61K39/00;;A61K39/395;;A61K39/39533;;A61K39/3955;;C07K16/18;;C07K16/24;;C07K16/244;;A61K2039/505;;C07K2317/21;;C07K2317/55;;C07K2317/92;;A61K47/6845;;C07K16/244;;A61K39/395;;C07K16/24;;C07K2317/24;;C07K2317/31;;C07K2317/54;;C07K2317/565;;C07K2317/622;;C07K2317/626;;C07K2317/76,A61K39/395;;A61K39/00;;C07K16/24,,99,91,054-418-959-978-111;;006-294-819-324-316;;057-983-868-048-104;;000-879-344-254-347;;021-074-280-354-982;;075-555-351-927-589;;039-141-300-950-038;;154-374-780-007-386;;017-449-753-661-071;;057-188-880-087-429;;061-444-349-075-997;;019-397-556-890-001;;011-724-225-446-939;;066-841-655-291-162;;112-514-905-529-435;;043-293-799-149-190;;106-794-363-564-085;;039-724-297-100-685;;129-447-558-597-627;;020-120-613-015-267;;065-509-287-960-156;;023-476-471-521-012;;002-837-409-782-018;;137-607-161-868-61X;;047-573-440-316-329;;023-468-000-960-289;;061-754-151-573-898;;049-134-753-209-354;;024-995-475-936-443;;032-055-913-011-134;;130-802-862-883-854;;012-264-326-804-266;;067-226-137-053-81X;;003-246-587-515-619;;048-819-440-392-261;;066-119-584-271-19X;;162-131-697-723-828;;101-171-874-734-776;;066-141-497-990-023;;083-000-601-623-651;;115-435-737-255-802;;105-521-401-667-801;;085-329-927-828-899;;098-276-747-378-726;;038-613-711-274-229;;040-397-285-492-490;;036-375-883-050-99X;;150-526-239-777-942;;069-863-076-076-464;;067-057-135-512-133;;014-201-444-265-19X;;086-016-360-704-586;;016-951-862-040-407;;050-836-464-727-069;;129-978-431-330-653;;018-213-281-272-849;;023-907-179-348-058;;006-316-080-689-484;;007-224-607-447-181;;066-749-017-721-197;;076-270-369-964-609;;002-649-962-296-826;;019-982-436-313-59X;;032-071-991-081-664;;076-436-009-754-971;;013-281-398-303-904;;002-264-966-090-625;;040-428-679-610-399;;089-899-040-309-502;;006-574-964-805-278;;079-975-841-354-505;;016-815-797-562-455;;000-999-407-005-345;;146-024-412-957-37X;;014-277-808-472-992;;005-984-586-162-249;;064-787-766-418-165;;036-431-051-779-618;;043-624-776-168-982;;104-212-297-137-759;;052-714-495-277-870;;055-578-442-289-160;;036-247-824-576-178;;003-762-234-479-609;;041-241-834-308-816;;073-260-982-304-977;;071-662-142-202-504;;020-367-308-901-689;;027-903-185-617-733;;046-845-561-202-870;;015-979-728-056-035,10.1107/s0907444994003112;;15299374;;3906410;;10.1038/318533a0;;pmc1868863;;17328715;;10.1111/j.1365-2249.2007.03356.x;;19161422;;10.1111/j.1600-065x.2008.00705.x;;pmc365231;;10.1128/mcb.7.4.1436;;10.1128/mcb.7.4.1436-1444.1987;;3037318;;10.1126/science.2426778;;2426778;;0007018830;;7018830;;pmc52963;;1660140;;10.1073/pnas.88.23.10535;;10.1002/j.1460-2075.1994.tb06715.x;;8076595;;pmc395319;;12023338;;10.4049/jimmunol.168.11.5448;;10.1038/290304a0;;6259538;;18708069;;10.1016/j.jmb.2008.08.001;;10.1002/bit.10790;;14574701;;10.1126/science.1494-b;;10.1126/science.242.4885.1494-b;;10.1111/j.0022-202x.2004.23552.x;;9041643;;pmc2143633;;10.1002/pro.5560060217;;10.1126/science.1853201;;1853201;;16645485;;10.1097/01.qco.0000224818.42729.67;;10.1016/s0959-440x(97)80054-1;;9204279;;10.1038/296039a0;;6278311;;8372511;;10.1107/s0907444998003254;;9757107;;10.1038/344667a0;;1970124;;10.1137/0148063;;16670771;;10.1172/jci25308;;pmc1450386;;10.1093/intimm/5.6.647;;8347558;;10.1016/0042-6822(90)90025-m;;1693247;;10.1016/0022-2836(87)90412-8;;3681981;;10.1038/342877a0;;2687698;;10.1021/bi00699a001;;4358939;;354496;;10.1146/annurev.bi.47.070178.001343;;10.1016/s0006-3495(79)85259-5;;pmc1328558;;262423;;4358940;;10.1021/bi00699a002;;364941;;10.1002/9780470122921.ch2;;10.1038/312768a0;;6096720;;12610626;;10.1038/nature01355;;11968507;;10.1385/1-59259-240-6:379;;6337371;;10.1073/pnas.80.1.21;;pmc393301;;10.1093/nar/12.1part1.387;;6546423;;pmc321012;;10.1016/s0021-9258(19)81080-3;;7061468;;10.1016/0003-2697(81)90168-8;;6175244;;10.1021/jm00390a019;;2885419;;7532457;;10.1006/smim.1994.1035;;10.1002/eji.200324038;;12778462;;10.1038/nbt0796-845;;9631008;;pmc4119940;;25033887;;14985542;;10.1093/protein/gzh012;;14978083;;10.4049/jimmunol.172.5.2827;;10.1016/0076-6879(90)83011-w;;2314273;;pmc305087;;10.1073/pnas.84.13.4355;;3474607;;6091894;;10.1016/0092-8674(84)90259-9;;2432657;;10.1126/science.2432657;;10.1038/315115a0;;2986015;;16157683;;pmc2212952;;10.1084/jem.20050193;;10.1111/j.1749-6632.1995.tb55879.x;;7486582;;7584477;;10.1089/vim.2008.0014;;18570589;;pmc2570712;;pmc50453;;1438297;;10.1073/pnas.89.22.10915;;pmc2777488;;10.1093/rheumatology/kep293;;19815670;;10.1002/eji.200535239;;16482511;;8341653;;10.1073/pnas.90.14.6444;;pmc46948;;pmc148146;;9847191;;10.1093/nar/27.1.244;;18512248;;10.1002/ibd.20475;;11397087;;10.1006/jmbi.2001.4662;;10.1016/0022-2836(92)90894-p;;1404359;;10.1038/nbt1088-1204;;8187882;;10.1016/0014-5793(94)00383-1;;10.1073/pnas.85.16.5879;;3045807;;pmc281868;;10.1073/pnas.90.6.2551;;8460171;;pmc46126;;8459850;;10.1038/362255a0;;10.1038/321522a0;;3713831;;9204280;;10.1016/s0959-440x(97)80055-3;;17291186;;10.1146/annurev.immunol.22.012703.104758;;10.1101/gad.1.2.161;;3500093;;10.4049/jimmunol.175.2.788;;16002675;;10.3410/f.1026900.326466;;10.4049/jimmunol.137.11.3614;;2431039;;3719696;;10.1016/0092-8674(86)90862-7;;10.1002/prot.10497;;12945055;;11566601;;10.1016/s1389-0344(01)00090-9;;10.1093/protein/10.4.423;;9194168;;10.4049/jimmunol.148.5.1547;;1531669;;10.1016/s1389-0344(01)00083-1;;11535414;;10.1128/mcb.5.7.1639;;pmc367282;;2410773;;10.1128/mcb.5.7.1639-1648.1985;;10.2165/11538950-000000000-00000;;21348542;;7108955;;10.1016/0022-2836(82)90515-0;;16688182;;10.1038/nature04808;;11968500;;10.1385/1-59259-240-6:303;;10.1016/0092-8674(86)90280-1;;3011271;;1961196;;10.1016/0161-5890(91)90003-3;;15572068;;10.1016/j.dci.2004.07.003;;10.1016/j.intimp.2004.01.010;;15120653;;10.1093/rheumatology/kem055;;17569750,"The CCP4 Suite: Programs for Protein Crystallography, Acta Crystallogr D Biol Crystallogr, 50(Pt 5): p. 760-3 (1994).;;Adams et al., The c-myc oncogene driven by immunoglobulin enhancers induces lymphoid malignancy in transgenic mice, Nature, 318:533-538 (1985).;;Afzali et al., The role of T helper 17 (Th17) and regulatory T cells (Treg) in human organ transplantation and autoimmune disease, Clinical and Experimental Immunology, 148:32-46 (2007).;;Ahern et al., The interleukin-23 axis in intestinal inflammation, Immun. Rev., 226:147-159 (2008).;;Alexander et al., Expression of the c-myc Oncogene under control of an immunologulin enhancer in Emu-myc Transgenic Mice, Mol. Cell. Biol., 7:1436-1444 (1987).;;Amit et al., Three-dimensional structure of an antigen-antibody complex at 2.8 A resolution, Science, 233(4765):747-53 (1986).;;Aplin and Wriston, Preparation, Properties, and Applications of Carbohydrate Conjugates of Proteins and Lipids, CRC Crit. Rev, Biochem., pp. 259-306 (1981).;;Ashkenazi et al., Protection against endotoxic shock by a tumor necrosis factor receptor immunoadhesin, Proc. Natl. Acad. Sci. USA, 88:10535 (1991).;;Baum et al., Identification of ligands for OX40 receptor, EMBO J., 13:3992-4001 (1994).;;Belladonna et al., IL-23 and IL-12 have overlapping, but distinct, effects on murine dendritic cells, The Journal of Immunology, 168:5448-5454 (2002).;;Benoist and Chambon, In vivo sequence requirements of the SV40 early promoter region, Nature, 290:304-310 (1981).;;Beyer et al., Crystal structures of the pro-inflammatory cytokine interleukin-23 and its complex with a high-affinity neutralizing antibody, J. Mol. Biol., 382(4):942-55 (2008).;;Beyer, et al., Crystal Structures of the Pro-Inflammatory Cytokine Interleukin-23 and Its Complex with a High-Affinity Neutralizing Antibody, J Mol Biol, 382(4):942-55 (2008).;;Bianchi and McGrew, High-Level Expression of Full-Length Antibodies Using Trans-Complementing Expression Vectors, Biotech. Biotechnol. Bioeng. 84:439-44 (2003).;;Bird et al., Single-Chain Antigen-Binding Proteins, Science, 242:423 (1988).;;Blauvelt, In this Issue-Full Court Press on Psoriasis, The Journal of Investigative Dermatology, pp. vii-viii (2004).;;Bloom et al., Intrachain disulfide bond in the core hinge region of human IgG4, Protein Science, 6:407 (1997).;;Bowie et al., A method to identify protein sequences that fold into a known three-dimensional structure, Science, 253:164-170 (1991).;;Bowman et al., Rationale and safety of anti-interleukin-23 and anti-interleukin-17A therapy, Current Opinion in Infectious Diseases, 19:245-52 (2006).;;Brenner et al., Population statistics of protein structures: lessons from structural classifications, Curr. Op. Struct. Biol., 7:369-376 (1997).;;Brinster et al., Regulation of metallothionein-thymidine kinase fusion plasmids injected into mouse eggs, Nature, 296:39-42 (1982).;;Bruggermann et al., Designer mice: the production of human antibody repertoires in transgenic animals, Year in Immunol., 7:33-40 (1993).;;Brunger, et al., Crystallography & NMR System: A new software suite for macromolecular structure determination, Acta Crystallogr D Biol Crystallogr, 54(Pt 5): p. 905-21 (1998).;;Byrn et al., Biological properties of a CD4 immunoadhesin, Nature, 344:677 (1990).;;Carillo et al., The Multiple Sequence Alignment Problem in Biology, SIAM J. Applied Math., 48:1073 (1988).;;Chen et al., Anti-IL-23 therapy inhibits multiple inflammatory pathways and ameliorates autoimune encephalomyelitis, The Journal of Clinical Investigation, 116:1317-1326 (2006).;;Chen et al., Immunoglobulin gene rearrangement in B cell deficient mice generated by targeted deletion of the JH locus, International Immunology, 5:647-656 (1993).;;Cheung, et al., Epitope-Specific Antibody Response to the Surface Antigen of Duck Hepatitus B Virus in Infected Ducks, Virology, 176:546-552 (1990).;;Chothia & Lesk, Canonical Structures for the Hypervariable Regions of Immunoglobulins, J. Mol. Biol., 196:901-917 (1987).;;Chothia et al., Conformations of immunoglobulin hypervariable regions, Nature, 342:878-883 (1989).;;Chou et al., Conformational Parameters for Amino Acids in Helical, beta-Sheet, and Random Coil Regions Calculated from Proteins, Biochemistry, 113:211-222 (1974).;;Chou et al., Empirical Predictions of Proteins Conformation, Ann. Rev. Biochem., 47:251-276 (1979).;;Chou et al., Prediction of beta-Turns, Biophys. J., 26:367-384 (1979).;;Chou et al., Prediction of Protein Conformation, Biochem., 13:222-245 (1974).;;Chou et al., Prediction of the secondary structure of proteins from their amino acid sequence, Adv. Enzymol. Relat. Areas Mol. Biol., 47:45-148 (1978).;;Cosman et al., Cloning, sequence and expression of human interleukin-2 receptor, Nature, 312:768 (1984).;;Cua et al., Interleukin-23 rather than Interleukin-12 is the critical cytokine for autoimmune inflammation of the brain, Nature, 421:744-748 (2003).;;Dayhoff ef al., A model of evolutionary change in proteins, Atlas of Protein Sequence and Structure, 5:345-352 (1978).;;de Graaf et al., Expression of scFvs and scFv Fusion Proteins in Eukaryotic Cells, Methods Mol Biol., 178:379-387 (2002).;;DeBoer et al., The tac promoter: A functional hybrid derived from the trp and lac promoters, Proc. Natl. Acad. Sci. U.S.A., 80:21-25 (1983).;;Devereux et al., A comprehensive set of sequence analysis programs for the VAX, Nucl. Acid Res., 12:387 (1984).;;Duskin et al., Relationship of the structure and biological activity of the natural homologues of tunicamycin, J. Biol. Chem., 257:3105 (1982).;;Edge et al., Deglycosylation of Glycoproteins by Trifluoromethanesulfonic Acid, Anal. Biochem., 118:131 (1981).;;Evans et al., Design of Nonpeptidal Ligands for a Peptide Receptor: Cholecystokinin Antagonists, J. Med. Chem., 30:1229 (1987).;;Fanslow et al., Structural characteristics of CD40 ligand that determine biological function, Semin. Immunol., 6:267-278 (1994).;;Fauchere, Elements for the Rational Design of Peptide Drugs, Adv. Drug Res., 15:29 (1986).;;Fieschi and Casanova, Mini Review: The role of interleukin-12 in human infectious diseases: only a faint signature, Eur. J. Immunol., 33:1461-4 (2003).;;Fishwild et al., High-avidity human IgGk monoclonal antibodies from a novel strain of minilocus transgenic mice, Nature Biotechnology, 14:845-85 (1996).;;Fredericks et al, Identification of potent human anti-IL-IRI antagonist antibodies, Protein Engineering, Design & Selection, 17:95-106 (2004).;;GenBank Accession No. AB030000.;;GenBank Accession No. M65272.;;GenBank Accession No. NM 005535.;;GenBank Accession No. NM 144701.;;Ghilardi et al., Compromised Humoral and Delayed-Type Hypersensitivity Responses in IL-23-Deficient Mice, The Journal of Immunology, 172:2827-2833 (2004).;;Gribskov et al., Profile Analysis, Meth. Enzym., 183:146-159 (1990).;;Gribskov et al., Profile analysis: Detection of distantly related proteins, Proc. Nat. Acad. Sci., 84:4355-4358 (1987).;;Grosschedl et al., Introduction of a mu Immunoglobulin Gene into the Mouse Germ Line: Specific Expression in Lymphoid Cells and Synthesis of Functional Antibody, Cell, 38:647-658 (1984).;;Hammer et al., Diversity of alpha-fetoprotein gene expression in mice is generated by a combination of separate enhancer elements, Science, 253:53-58 (1987).;;Hanahan, Heritable formation of pancreatic beta-cell tumours in transgenic mice expressing recombinant insulin/simian virus 40 oncogenes, Nature, 315:115-122 (1985).;;Happel et al., Divergent roles of IL-23 and IL-12 in host defense against Klebsiella pneumoniae, The Journal of Experimental Medicine, 202:761-769 (2005).;;Harding et al., Class Switching in Human Immunoglobulin Transgenic Mice, Ann. N. Y Acad. Sci., 764:536-546 (1995).;;Hayden et al., Single-chain mono- and bispecific antibody derivatives with novel biological properties and antitumour activity from a COS cell transient expression system, Therapeutic Immunology, 1 :3-15 (1994).;;Held et al., Generation of a Protective T-Cell Response Following Coronavirus Infection of the Central Nervous System is Not Dependent on IL-12/23 Signaling, Viral Immunology, 21:173-187 (2008).;;Henikoff et al., Amino acid substitution matrices from protein blocks, Proc. Natl. Acad. Sci. U.S.A., 89:10915-10919 (1992).;;Hillyer et al., Investigating the role of the interleukin-23/-17A axis in rheumatoid arthritis, Rheumatology, 48:1581-1589 (2009).;;Hoeve et al., Divergent effects of IL-12 and IL-23 on the production of IL-17 by human T cells, Eur. J. Immunol., 36:1-10 (2006).;;Holliger et al., Diabodies: Small bivalent and bispecific antibody fragments, Proc. Natl. Acad. Sci. USA, 90:6444-48 (1993).;;Holm et al., Protein folds and families: sequence and structure alignments, Nucl. Acid. Res., 27:244-247 (1999).;;Holtta et al., IL-23/IL-17 Immunity as a Hallmark of Crohn's Disease, Inflamm Bowel Dis., 14:1175-1184 (2008).;;Honegger et al., Yet another numbering scheme for immunoglobulin variable domains: an automatic modeling and analysis tool, J. Mol. Biol., 309(3):657-670 (2001).;;Hoogenboom et al., By-passing Immunisation Human Antibodies from Synthetic Repertoires of Germline VH Gene Segments Rerranged in Vitro, J. Mol. Biol., 227:381 (1991).;;Hopp et al., A Short Polypeptide Marker Sequence Useful for Recombinant Protein Identification and Purification, Bio/Technology, 6:1204 (1988).;;Hoppe et al., A parallel three stranded alpha-helical bundle at the nucleation site of collagen triple-helix formation, FEBS Letters, 344:191 (1994).;;Huston et al., Protein engineering of antibody binding sites: recovery of specific activity in an anti-digoxin single-chain Fv analogue produced in Escherichia coli, Proc. Natl. Acad. Sci. U.S.A., 85:5879 (1988).;;Jakobovits et al., Analysis of homozygous mutant chimeric mice: Deletion of the immunoglobulin heavy-chain joining region blocks B-cell development and antibody production, Proc. Natl. Acad. Sci. USA, 90:2551-2555 (1993).;;Jakobovits et al., Germ-line transmission and expression of a human-derived yeast artificial chromosome, Nature, 362:255-258 (1993).;;Jones et al., Replacing the complementarity-determining regions in a human antibody with those from a mouse, Nature, 321 :522-525 (1986).;;Jones, Progress in protein structure prediction, Curr. Opin. Struct. Biol., 7:377-387 (1997).;;Kabat et al., Sequences of Proteins of Immunological Interest, 5th Ed., US Dept. of Health and Human Services, PHS, NIH, NIH Publication No. 91-3242 (1991).;;Kastelein, et al., Discovery and Biology of IL-23 and IL-27: Related but Functionally Distinct Regulators of Inflammation, Annual Review of Immunology, 25:221-42 (2007).;;Kelsey et al., Species- and tissue-specific expression of human alpha1-antitrypsin in transgenic mice, Genes and Devel., 1 :161-171 (1987).;;Khader et al., IL-23 Compensates for the Absence of IL-12p70 and is Essential for the IL-17 Response during Tuberculosis but is Dispensable for Protection and Antigen-Specific IFN-gamma Responses if IL-12p70 is Available, The Journal of Immunology, 175:788-795 (2005).;;Kirkland et al., Analysis of the fine specificity and cross-reactivity of monoclonal anti-lipid A antibodies, J. Immunol., 137:3614-3619 (1986).;;Kollias et al., Regulated Expression of Human Agamma-, beta-, and Hybrid gammabeta-Globin Genes in Transgenic Mice: Manipulation of the Developmental Expression Patterns, Cell, 46:89-94 (1986).;;Korndorfer et al., Crystallographic Analysis of an Anticalin With Tailored Specificity for fluorescein Reveals High Structural Plasticity of the Lipocalin Loop Region, Proteins: Structure, Function, and Bioinformatics, vol. 53, Issue 1:121-129 (2003).;;Kortt et ai, Dimeric and trimeric antibodies: high avidity scFvs for cancer targeting, Biomol. Eng., 18:95-108 (2001).;;Kortt et al., Single-chain Fv fragments of anti-neuraminidase antibody NC10 containing five- and ten-residue linkers form dimers and with zero-residue linker a trimer, Prot. Eng., 10:423 (1997).;;Kostelny et al., Formation of a bispecific antibody by the use of leucine zippers, J. Immunol., 148:1547-1553 (1992).;;Kriangkum et al., Bispecific and bifunctional single chain recombinant antibodies, Biomol. Eng., 18:31-40 (2001).;;Krumlauf et al., Developmental regulation of alpha-fetoprotein genes in transgenic mice, Mol. Cell. Biol., 5:1639-1648 (1985).;;Kurzeja et al., New Interleukin-23 pathway inhibitors in dermatology, Am. J. Clin. Dermatol., 12:113-125 (2011).;;Kyte et al., A simple method for displaying the hydropathic character of a protein, J. Mol. Biol., 157:105-131 (1982).;;Langowski et al., IL-23 promotes tumour incidence and growth, Nature, 442: 461-5 (2006).;;Lantto et al., Chain Shuffling to modify properties of recombinant immunoglobulins, Methods Mol. Biol., 178:303-316 (2002).;;Leder et al., Consequences of widespread deregulation of the c-myc gene in transgenic mice: multiple neoplasms and normal development, Cell, 45:485-495 (1986).;;Lederman et al., A single amino acid substitution in a common African allele of the CD4 molecule ablates binding of the monoclonal antibody, OKT4, Mol. Immunol., 28(11):1171-81 (1991).;;Lefranc et al, IMGT unique numbering for immunoglobulin and T cell receptor constant domain and Ig superfamily C-like domains, Dev. Comp. Immunol., 29:185-203 (2005).;;Li et al., Temporal associations between interleukin 22 and the extracellular domains of IL-22R and IL-10R2, Int. Immunopharmacol., 4(5):693-708 (2004).;;Liu, et al., Interleukin (IL)-23 p19 expression induced by IL-1beta in human fibroblast-like synoviocytes with rheumatoid arthritis via active nuclear factor-kB and AP-1 dependent pathway, Rheumatology, 46(8):1266-73 (2007).",ACTIVE
401,AU,A1,AU 2014/202591 A1,002-187-638-809-42X,2014-06-05,2014,AU 2014/202591 A,2014-05-13,AU 2010/315557 A;;AU 2014/202591 A,2010-10-26,Human IL-23 antigen binding proteins,"Antigen binding proteins that bind to human IL-23 protein are provided. Nucleic acids encoding the antigen binding protein, vectors, and cells encoding the same as well as use of IL-23 antigen binding proteins for diagnostic and therapeutic purposes are also provided.",AMGEN INC,TOWNE JENNIFER E;;CHENG JANET D;;O'NEILL JASON C;;ZHANG YU;;SUN YU;;CERNE HEATHER;;PIPER DEREK E;;KETCHEM RANDAL R,,https://lens.org/002-187-638-809-42X,Patent Application,no,0,0,2,2,0,,C07K16/24;;A61K39/395,,0,0,,,,DISCONTINUED
402,BR,B1,BR 112012009854 B1,016-034-944-376-926,2020-12-15,2020,BR 112012009854 A,2010-10-26,US 2010/0054148 W;;US 25498209 P;;US 38128710 P,2009-10-26,"proteínas de ligação de antígeno isolada recombinante que liga il-23, composição farmacêutica, molécula de ácido nucleico isolada recombinante, vetor recombinante, método de confecção da referida proteína de ligação e uso da mesma","proteínas de ligação de antígeno il-23 humano. são fornecidas proteínas de ligação de antígeno que se ligam a proteína de il-23 humana. ácidos nucleicos que codificam a proteína de ligação de antígeno, vetores, e células que codificam os mesmos bem como o uso de proteínas de ligação de antígeno de il-23 para objetivos diagnósticos e terapêuticos são também fornecidos.",AMGEN INC,DEREK E PIPER;;HEATHER CERNE;;JANET D CHENG;;JASON C O'NEILL;;JENNIFER E TOWNE;;RANDAL R KETCHEM;;YU SUN;;YU ZHANG,,https://lens.org/016-034-944-376-926,Granted Patent,no,0,0,86,87,0,A61K2039/505;;C07K2317/21;;C07K2317/55;;C07K2317/92;;A61K47/6845;;C07K16/244;;A61P37/00;;C07K16/244;;A61K2039/505;;C07K2317/626;;C07K2317/21;;C07K2317/76;;A61K47/6845;;C07K2317/54;;A61K39/395;;C07K2317/31;;C07K16/24;;A61P37/00;;C07K2317/92;;C07K2317/24;;C07K2317/622;;C07K2317/55;;C07K2317/565;;A61K39/00;;A61K39/395;;A61K39/39533;;A61K39/3955;;C07K16/18;;C07K16/24;;C07K16/244;;A61K2039/505;;C07K2317/21;;C07K2317/55;;C07K2317/92;;A61K47/6845;;C07K16/244;;A61K39/395;;C07K16/24;;C07K2317/24;;C07K2317/31;;C07K2317/54;;C07K2317/565;;C07K2317/622;;C07K2317/626;;C07K2317/76,A61K39/395;;C07K16/24,,0,0,,,,ACTIVE
403,US,A1,US 2017/0002070 A1,049-560-187-602-291,2017-01-05,2017,US 201615271315 A,2016-09-21,US 201615271315 A;;US 201414228556 A;;US 201213504449 A;;US 2010/0054148 W;;US 38128710 P;;US 25498209 P,2009-10-26,HUMAN IL-23 ANTIGEN BINDING PROTEINS,"Antigen binding proteins that bind to human IL-23 protein are provided. Nucleic acids encoding the antigen binding protein, vectors, and cells encoding the same as well as use of IL-23 antigen binding proteins for diagnostic and therapeutic purposes are also provided.",AMGEN INC,TOWNE JENNIFER E;;CHENG JANET D;;O'NEILL JASON C;;ZHANG YU;;SUN YU;;CERNE HEATHER;;PIPER DEREK E;;KETCHEM RANDAL R,AMGEN INC (2012-06-11),https://lens.org/049-560-187-602-291,Patent Application,yes,0,2,86,87,155,A61K2039/505;;C07K2317/21;;C07K2317/55;;C07K2317/92;;A61K47/6845;;C07K16/244;;A61P37/00;;C07K16/244;;A61K2039/505;;C07K2317/626;;C07K2317/21;;C07K2317/76;;A61K47/6845;;C07K2317/54;;A61K39/395;;C07K2317/31;;C07K16/24;;A61P37/00;;C07K2317/92;;C07K2317/24;;C07K2317/622;;C07K2317/55;;C07K2317/565;;A61K39/00;;A61K39/395;;A61K39/39533;;A61K39/3955;;C07K16/18;;C07K16/24;;C07K16/244;;A61K2039/505;;C07K2317/21;;C07K2317/55;;C07K2317/92;;A61K47/6845;;C07K16/244;;A61K39/395;;C07K16/24;;C07K2317/24;;C07K2317/31;;C07K2317/54;;C07K2317/565;;C07K2317/622;;C07K2317/626;;C07K2317/76,C07K16/24,,0,0,,,,ACTIVE
404,AU,A1,AU 2017/200537 A1,096-041-080-262-688,2017-02-16,2017,AU 2017/200537 A,2017-01-27,AU 2017/200537 A;;AU 2014/202591 A;;AU 2010/315557 A,2010-10-26,Human IL-23 antigen binding proteins,"Antigen binding proteins that bind to human IL-23 protein are provided. Nucleic acids encoding the antigen binding protein, vectors, and cells encoding the same as well as use of IL-23 antigen binding proteins for diagnostic and therapeutic purposes are also provided.",AMGEN INC,TOWNE JENNIFER E;;CHENG JANET D;;O'NEILL JASON C;;ZHANG YU;;SUN YU;;CERNE HEATHER;;PIPER DEREK E;;KETCHEM RANDAL R,,https://lens.org/096-041-080-262-688,Patent Application,no,0,0,2,2,0,,C07K16/24;;A61K39/395,,0,0,,,,DISCONTINUED
405,RS,B1,RS 55666 B1,115-250-304-509-060,2017-06-30,2017,RS P20170119 A,2010-10-26,US 25498209 P;;US 38128710 P;;US 2010/0054148 W,2009-10-26,HUMAN IL-23 ANTIGEN BINDING PROTEINS,,AMGEN INC,TOWNE JENNIFER E;;CHENG JANET D;;O'NEILL JASON C;;ZHANG YU;;SUN YU;;CERNE HEATHER;;PIPER DEREK E;;KETCHEM RANDAL R,,https://lens.org/115-250-304-509-060,Granted Patent,no,0,0,86,87,0,A61K2039/505;;C07K2317/21;;C07K2317/55;;C07K2317/92;;A61K47/6845;;C07K16/244;;A61P37/00;;C07K16/244;;A61K2039/505;;C07K2317/626;;C07K2317/21;;C07K2317/76;;A61K47/6845;;C07K2317/54;;A61K39/395;;C07K2317/31;;C07K16/24;;A61P37/00;;C07K2317/92;;C07K2317/24;;C07K2317/622;;C07K2317/55;;C07K2317/565;;A61K39/00;;A61K39/395;;A61K39/39533;;A61K39/3955;;C07K16/18;;C07K16/24;;C07K16/244;;A61K2039/505;;C07K2317/21;;C07K2317/55;;C07K2317/92;;A61K47/6845;;C07K16/244;;A61K39/395;;C07K16/24;;C07K2317/24;;C07K2317/31;;C07K2317/54;;C07K2317/565;;C07K2317/622;;C07K2317/626;;C07K2317/76,C07K16/24;;A61K39/395,,0,0,,,,ACTIVE
406,KR,A,KR 20160118278 A,158-606-216-289-971,2016-10-11,2016,KR 20167022998 A,2010-10-26,US 25498209 P;;US 38128710 P;;US 2010/0054148 W,2009-10-26,- HUMAN IL-23 ANTIGEN BINDING PROTEINS,"인간 IL-23 단백질에 결합하는 항원 결합 단백질이 제공된다. 항원 결합 단백질을 코딩하는 핵산, 벡터, 및 이를 코딩하는 세포 뿐만 아니라 진단 및 치료 목적을 위한 IL-23 항원 결합 단백질의 용도가 또한 제공된다.",AMGEN INC,TOWNE JENNIFER E;;CHENG JANET D;;O'NEILL JASON C;;ZHANG YU;;SUN YU;;CERNE HEATHER;;PIPER DEREK E;;KETCHEM RANDAL R,,https://lens.org/158-606-216-289-971,Patent Application,no,0,0,86,87,310,A61K2039/505;;C07K2317/21;;C07K2317/55;;C07K2317/92;;A61K47/6845;;C07K16/244;;A61P37/00;;C07K16/244;;A61K2039/505;;C07K2317/626;;C07K2317/21;;C07K2317/76;;A61K47/6845;;C07K2317/54;;A61K39/395;;C07K2317/31;;C07K16/24;;A61P37/00;;C07K2317/92;;C07K2317/24;;C07K2317/622;;C07K2317/55;;C07K2317/565;;A61K39/00;;A61K39/395;;A61K39/39533;;A61K39/3955;;C07K16/18;;C07K16/24;;C07K16/244;;A61K2039/505;;C07K2317/21;;C07K2317/55;;C07K2317/92;;A61K47/6845;;C07K16/244;;A61K39/395;;C07K16/24;;C07K2317/24;;C07K2317/31;;C07K2317/54;;C07K2317/565;;C07K2317/622;;C07K2317/626;;C07K2317/76,C07K16/24;;A61K39/00;;A61K39/395;;C07K16/18,,0,0,,,,DISCONTINUED
407,US,B1,US 7264924 B1,154-446-659-273-594,2007-09-04,2007,US 1070004 A,2004-12-02,US 1070004 A;;US 32822602 A;;US 38399902 P,2002-05-29,Methods for detecting bacteriophage MS2,The present invention relates to methods and assays for detecting bacteriophage MS2 in a sample.,US ARMY,O'CONNELL KEVIN P;;KHAN AKBAR S;;CAO CHENG J;;BUCHER JENNIFER R;;GOSTOMSKI MARK V;;VALDES JAMES J;;ANDERSON PATRICIA E,,https://lens.org/154-446-659-273-594,Granted Patent,yes,0,2,5,5,17,C12Q1/701;;C12Q1/701;;C12Q1/686;;C12Q1/686,C12Q1/70;;C12Q1/68,435/5,0,0,,,,INACTIVE
408,PT,T,PT 2493925 T,046-916-392-431-255,2017-02-14,2017,PT 10774095 T,2010-10-26,US 25498209 P;;US 38128710 P,2009-10-26,HUMAN IL-23 ANTIGEN BINDING PROTEINS,,AMGEN INC,JENNIFER E TOWNE;;JANET D CHENG;;JASON C O'NEILL;;YU ZHANG;;YU SUN;;HEATHER CERNE;;DEREK E PIPER;;RANDAL R KETCHEM,,https://lens.org/046-916-392-431-255,Patent Application,no,0,0,86,87,0,A61K2039/505;;C07K2317/21;;C07K2317/55;;C07K2317/92;;A61K47/6845;;C07K16/244;;A61P37/00;;C07K16/244;;A61K2039/505;;C07K2317/626;;C07K2317/21;;C07K2317/76;;A61K47/6845;;C07K2317/54;;A61K39/395;;C07K2317/31;;C07K16/24;;A61P37/00;;C07K2317/92;;C07K2317/24;;C07K2317/622;;C07K2317/55;;C07K2317/565;;A61K39/00;;A61K39/395;;A61K39/39533;;A61K39/3955;;C07K16/18;;C07K16/24;;C07K16/244;;A61K2039/505;;C07K2317/21;;C07K2317/55;;C07K2317/92;;A61K47/6845;;C07K16/244;;A61K39/395;;C07K16/24;;C07K2317/24;;C07K2317/31;;C07K2317/54;;C07K2317/565;;C07K2317/622;;C07K2317/626;;C07K2317/76,C07K16/24;;A61K39/395,,0,0,,,,PENDING
409,TW,A,TW 201903206 A,063-845-979-787-059,2019-01-16,2019,TW 107115900 A,2018-05-10,US 201762504471 P;;US 201815965794 A,2017-05-10,Multi-layer plasma erosion protection for chamber components,"A method of applying a multi-layer plasma resistant coating on an article comprises performing plating or ALD to form a conformal first plasma resistant layer on an article, wherein the conformal first plasma resistant layer is formed on a surface of the article and on walls of high aspect ratio features in the article. The conformal first plasma resistant coating has a porosity of approximately 0% and a thickness of approximately 200 nm to approximately 1 micron. One of electron beam ion assisted deposition (EB-IAD), plasma enhanced chemical vapor deposition (PECVD), aerosol deposition or plasma spraying is then performed to form a second plasma resistant layer that covers the conformal first plasma resistant layer at a region of the surface but not at the walls of the high aspect ratio features.",APPLIED MATERIALS INC,TRAN TOAN;;LAKSHESWAR KALITA;;KIM TAE-WON;;LUBOMIRSKY DMITRY;;WU XIAO-WEI;;HE XIAO-MING;;CHOU CHENG-HSUAN;;SUN JENNIFER Y,,https://lens.org/063-845-979-787-059,Patent of Addition,no,0,1,12,12,0,H01J37/32477;;H01J37/32495;;C23C16/04;;C23C16/40;;C23C16/4404;;C23C16/45544;;C23C16/45565;;C23C28/042;;C23C24/04;;C25D7/123;;C23C18/36;;H01J37/32495;;C23C16/403;;C23C16/0254;;H01J37/32477;;H01J37/32495;;C23C16/403;;H01J2237/0203;;C23C16/0254;;C23C16/45525;;C23C28/042;;C23C16/45544;;C23C18/36;;C23C16/04;;C23C16/4404;;C23C16/45565;;C25D7/123;;C23C16/40;;C23C24/04;;H01J37/32477,C23C28/04;;H01L21/3065;;H01L21/67,,0,0,,,,ACTIVE
410,EP,A1,EP 3539171 A1,135-873-387-195-779,2019-09-18,2019,EP 17808591 A,2017-11-09,CN 201610987137 A;;IB 2017056996 W,2016-11-09,BATTERY PACK,,JOHNSON CONTROLS TECH CO;;JOHNSON CONTROLS ADVANCED POWER SOLUTIONS GMBH,FAN BINBIN;;CHENG LIANG;;QU WEI;;SONG PENG;;FU YINGYAO;;LIU CHANG;;FUHR JASON;;WIEGMANN MARTIN;;ZHANG XUGANG;;CZARNECKI JENNIFER LYNN,CPS TECHNOLOGY HOLDINGS LLC (2020-10-28);;CLARIOS ADVANCED SOLUTIONS GMBH (2020-10-28);;JOHNSON CONTROLS TECHNOLOGY COMPANY (2020-09-23),https://lens.org/135-873-387-195-779,Patent Application,yes,0,0,9,9,0,H01M50/284;;H01M50/244;;H01M50/51;;H01M50/249;;H01M50/204;;H01M50/258;;H01M50/289;;H01M10/613;;H01M10/625;;H01M10/6563;;H01M10/6566;;H01M10/482;;H01M2010/4271;;H01M2200/103;;H01M2220/20;;H01M10/625;;H01M10/6563;;H01M10/613;;F04D25/0613;;F04D29/601;;H01M50/24;;H01M50/3425;;H01M50/553;;H01M50/507;;H01M50/367;;H01M50/284;;H01M50/55;;H01M50/51;;H01M50/583;;H01M50/244;;H01M50/271;;H01M50/298;;H01M50/209;;H01M50/517;;H01M50/296;;H01M50/242;;H01M50/227;;Y02E60/10;;B60L50/64;;B60L58/26;;F04D25/0673;;F04D29/601;;H01M10/425;;H01M2010/4271;;H01M2220/20;;H01M50/342;;H01M10/482;;H01M50/55;;H01M50/367;;H01M50/583;;H01M50/517;;H01M50/507;;H01M50/553;;H01M50/242;;H01M50/227;;H01M50/296;;H01M50/284;;H01M50/298;;H01M50/271;;H01M50/244;;H01M50/209;;H01M50/51,F04D29/60;;F04D29/64;;H01M10/42;;H01M10/48;;H01M10/613;;H01M10/625;;H01M10/6563;;H01M50/209;;H01M50/227;;H01M50/242;;H01M50/244;;H01M50/249;;H01M50/271;;H01M50/284;;H01M50/296;;H01M50/298;;H01M50/367;;H01M50/507;;H01M50/51;;H01M50/517;;H01M50/55;;H01M50/553;;H01M50/583;;H05K7/20,,0,0,,,,PENDING
411,MX,B,MX 358249 B,039-971-389-537-778,2018-08-10,2018,MX 2012004868 A,2010-10-26,US 25498209 P;;US 38128710 P;;US 2010/0054148 W,2009-10-26,HUMAN IL-23 ANTIGEN BINDING PROTEINS.,"Antigen binding proteins that bind to human IL-23 protein are provided. Nucleic acids encoding the antigen binding protein, vectors, and cells encoding the same as well as use of IL-23 antigen binding proteins for diagnostic and therapeutic purposes are also provided.",AMGEN INC STAR,RANDAL R KETCHEM;;JENNIFER E TOWNE;;JANET D CHENG;;JASON C O'NEILL;;YU ZHANG;;YU SUN;;HEATHER CERNE;;DEREK E PIPER,,https://lens.org/039-971-389-537-778,Granted Patent,no,0,0,86,87,0,A61K2039/505;;C07K2317/21;;C07K2317/55;;C07K2317/92;;A61K47/6845;;C07K16/244;;A61P37/00;;C07K16/244;;A61K2039/505;;C07K2317/626;;C07K2317/21;;C07K2317/76;;A61K47/6845;;C07K2317/54;;A61K39/395;;C07K2317/31;;C07K16/24;;A61P37/00;;C07K2317/92;;C07K2317/24;;C07K2317/622;;C07K2317/55;;C07K2317/565;;A61K39/00;;A61K39/395;;A61K39/39533;;A61K39/3955;;C07K16/18;;C07K16/24;;C07K16/244;;A61K2039/505;;C07K2317/21;;C07K2317/55;;C07K2317/92;;A61K47/6845;;C07K16/244;;A61K39/395;;C07K16/24;;C07K2317/24;;C07K2317/31;;C07K2317/54;;C07K2317/565;;C07K2317/622;;C07K2317/626;;C07K2317/76,C07K16/24;;A61K39/395,,0,0,,,,ACTIVE
412,US,A1,US 2019/0071498 A1,049-609-600-080-170,2019-03-07,2019,US 201816194896 A,2018-11-19,US 201816194896 A;;US 201815922675 A;;US 201615271315 A;;US 201414228556 A;;US 201213504449 A;;US 2010/0054148 W;;US 38128710 P;;US 25498209 P,2009-10-26,Human IL-23 Antigen Binding Proteins,"Antigen binding proteins that bind to human IL-23 protein arc provided. Nucleic acids encoding the antigen binding protein, vectors, and cells encoding the same as well as use of IL-23 antigen binding proteins for diagnostic and therapeutic purposes arc also provided.",AMGEN INC,TOWNE JENNIFER E;;CHENG JANET D;;O'NEILL JASON C;;ZHANG YU;;SUN YU;;CERNE HEATHER;;PIPER DEREK E;;KETCHEM RANDAL R,AMGEN INC (2012-06-11),https://lens.org/049-609-600-080-170,Patent Application,yes,0,1,86,87,155,A61K2039/505;;C07K2317/21;;C07K2317/55;;C07K2317/92;;A61K47/6845;;C07K16/244;;A61P37/00;;C07K16/244;;A61K2039/505;;C07K2317/626;;C07K2317/21;;C07K2317/76;;A61K47/6845;;C07K2317/54;;A61K39/395;;C07K2317/31;;C07K16/24;;A61P37/00;;C07K2317/92;;C07K2317/24;;C07K2317/622;;C07K2317/55;;C07K2317/565;;A61K39/00;;A61K39/395;;A61K39/39533;;A61K39/3955;;C07K16/18;;C07K16/24;;C07K16/244;;A61K2039/505;;C07K2317/21;;C07K2317/55;;C07K2317/92;;A61K47/6845;;C07K16/244;;A61K39/395;;C07K16/24;;C07K2317/24;;C07K2317/31;;C07K2317/54;;C07K2317/565;;C07K2317/622;;C07K2317/626;;C07K2317/76,C07K16/24;;A61K39/00;;A61K39/395;;A61K47/68,,0,0,,,,DISCONTINUED
413,HR,T1,HR P20170037 T1,058-904-289-694-265,2017-03-10,2017,HR P20170037 T,2017-01-10,US 25498209 P;;US 38128710 P;;EP 10774095 A;;US 2010/0054148 W,2009-10-26,HUMAN IL-23 ANTIGEN BINDING PROTEINS,,AMGEN INC,TOWNE JENNIFER E;;CHENG JANET D;;O'NEILL JASON C;;ZHANG YU;;SUN YU;;CERNE HEATHER;;PIPER DEREK E;;KETCHEM RANDAL R,,https://lens.org/058-904-289-694-265,Granted Patent,no,0,0,86,87,0,A61K2039/505;;C07K2317/21;;C07K2317/55;;C07K2317/92;;A61K47/6845;;C07K16/244;;A61P37/00;;C07K16/244;;A61K2039/505;;C07K2317/626;;C07K2317/21;;C07K2317/76;;A61K47/6845;;C07K2317/54;;A61K39/395;;C07K2317/31;;C07K16/24;;A61P37/00;;C07K2317/92;;C07K2317/24;;C07K2317/622;;C07K2317/55;;C07K2317/565;;A61K39/00;;A61K39/395;;A61K39/39533;;A61K39/3955;;C07K16/18;;C07K16/24;;C07K16/244;;A61K2039/505;;C07K2317/21;;C07K2317/55;;C07K2317/92;;A61K47/6845;;C07K16/244;;A61K39/395;;C07K16/24;;C07K2317/24;;C07K2317/31;;C07K2317/54;;C07K2317/565;;C07K2317/622;;C07K2317/626;;C07K2317/76,C07K16/24;;A61K39/395,,0,0,,,,ACTIVE
414,TW,A,TW 201121567 A,185-634-785-159-883,2011-07-01,2011,TW 99136594 A,2010-10-26,US 25498209 P;;US 38128710 P,2009-10-26,Human IL-23 antigen binding proteins,"Antigen binding proteins that bind to human IL-23 protein are provided. Nucleic acids encoding the antigen binding protein, vectors, and cells encoding the same as well as use of IL-23 antigen binding proteins for diagnostic and therapeutic purposes are also provided.",AMGEN INC,TOWNE JENNIFER E;;CHENG JANET D;;O'NEILL JASON C;;ZHANG YU;;SUN YU;;CERNE HEATHER;;PIPER DEREK E;;KETCHEM RANDAL R,,https://lens.org/185-634-785-159-883,Patent of Addition,no,0,0,86,87,0,A61K2039/505;;C07K2317/21;;C07K2317/55;;C07K2317/92;;A61K47/6845;;C07K16/244;;A61P37/00;;C07K16/244;;A61K2039/505;;C07K2317/626;;C07K2317/21;;C07K2317/76;;A61K47/6845;;C07K2317/54;;A61K39/395;;C07K2317/31;;C07K16/24;;A61P37/00;;C07K2317/92;;C07K2317/24;;C07K2317/622;;C07K2317/55;;C07K2317/565;;A61K39/00;;A61K39/395;;A61K39/39533;;A61K39/3955;;C07K16/18;;C07K16/24;;C07K16/244;;A61K2039/505;;C07K2317/21;;C07K2317/55;;C07K2317/92;;A61K47/6845;;C07K16/244;;A61K39/395;;C07K16/24;;C07K2317/24;;C07K2317/31;;C07K2317/54;;C07K2317/565;;C07K2317/622;;C07K2317/626;;C07K2317/76,A61K39/395;;A61P37/00;;C07K16/24,,0,0,,,,INACTIVE
415,US,B1,US 7235355 B1,086-430-148-072-570,2007-06-26,2007,US 161604 A,2004-11-29,US 161604 A;;US 32822602 A;;US 38399902 P,2002-05-29,Methods for detecting bacteriophage MS2,The present invention relates to methods and assays for detecting bacteriophage MS2 in a sample.,US ARMY,O'CONNELL KEVIN P;;KHAN AKBAR S;;CAO CHENG J;;BUCHER JENNIFER R;;GOSTOMSKI MARK V;;VALDES JAMES J;;ANDERSON PATRICIA E,,https://lens.org/086-430-148-072-570,Granted Patent,yes,0,1,5,5,17,C12Q1/701;;C12Q1/701;;C12Q1/686;;C12Q1/686,C12Q1/70;;C12Q1/68,435/5;;435/4;;435/7.1,3,3,000-738-663-236-606;;065-516-799-483-731;;013-046-609-139-586,pmc1352182;;10.1128/aem.72.1.478-483.2006;;16391081;;16145106;;pmc1234060;;10.1128/jcm.43.9.4551-4557.2005;;10489530;;10.1021/ac981425v,"O'Connell Kevin P; Bucher Jennifer R; Anderson Patricia E; Cao Cheng J; Khan Akbar S; Gostomski Mark V; Valdes James J Real-time fluorogenic transcription-PCR assays for detection of bacteriophage MS2. Applied and environmental microbiology. Jan. 2006, 72 (1) p. 478-83.;;Dreier, J., M. Störmer, and K. Kleesiek, 2005. Use of bacteriophage MS2 as an internal control in viral reverse transcription-PCR assays. J. Clin. Microbiol. 43:4551-4557.;;Rowe C A; Tender L M; Feldstein M J; Golden J P; Scruggs S B; MacCraith B D ; Cras J J; Ligler F S. Array biosensor for simultaneous identification of bacterial, viral, and protein analytes. Analytical chemistry. Sep. 1, 1999, 71 (17) p. 3846-52.",EXPIRED
416,JP,A,JP 2016102122 A,099-216-512-719-153,2016-06-02,2016,JP 2015236268 A,2015-12-03,US 25498209 P;;US 38128710 P,2009-10-26,HUMAN IL-23 ANTIGEN BINDING PROTEINS,"PROBLEM TO BE SOLVED: To provide interleukin 23 (IL-23) antagonists capable of inhibiting IL-23, which is a heterodimeric cytokine and a potent inducer of proinflammatory cytokines.SOLUTION: The present invention provides a monoclonal antibody, a recombinant antibody, a human antibody, a humanized antibody, a chimeric antibody, a multispecific antibody, or an antibody fragment thereof, which binds to IL-23 antigen and has specific amino acid sequences and properties of reducing human IL-23 activity and reducing production of a proinflammatory cytokine.SELECTED DRAWING: None",AMGEN INC,JENNIFER E TOWNE;;JANET D CHENG;;JASON C O'NEILL;;ZHANG YU;;SUN YU;;HEATHER CERNE;;DEREK E PIPER;;KETCHEM RANDAL R,,https://lens.org/099-216-512-719-153,Patent Application,no,2,0,86,87,155,A61K2039/505;;C07K2317/21;;C07K2317/55;;C07K2317/92;;A61K47/6845;;C07K16/244;;A61P37/00;;C07K16/244;;A61K2039/505;;C07K2317/626;;C07K2317/21;;C07K2317/76;;A61K47/6845;;C07K2317/54;;A61K39/395;;C07K2317/31;;C07K16/24;;A61P37/00;;C07K2317/92;;C07K2317/24;;C07K2317/622;;C07K2317/55;;C07K2317/565;;A61K39/00;;A61K39/395;;A61K39/39533;;A61K39/3955;;C07K16/18;;C07K16/24;;C07K16/244;;A61K2039/505;;C07K2317/21;;C07K2317/55;;C07K2317/92;;A61K47/6845;;C07K16/244;;A61K39/395;;C07K16/24;;C07K2317/24;;C07K2317/31;;C07K2317/54;;C07K2317/565;;C07K2317/622;;C07K2317/626;;C07K2317/76,C07K16/24;;A61K39/395;;A61K49/00;;A61K51/00;;A61P1/04;;A61P3/10;;A61P17/06;;A61P19/02;;A61P25/00;;A61P29/00;;A61P35/00;;A61P37/02;;A61P37/06;;A61P43/00;;C12N1/15;;C12N1/19;;C12N1/21;;C12N5/10;;C12N15/00;;C12N15/09;;C12P21/08,,1,0,,,"""Database DDBJ/EMBL/Genbank[online]"", ACCETION NO.AB114470, vol. [retrived on 2016-12-15], JPN6016049276, 10 July 2004 (2004-07-10), ISSN: 0003467775",PENDING
417,US,A1,US 2021/0230267 A1,156-359-725-992-86X,2021-07-29,2021,US 202117229607 A,2021-04-13,US 202117229607 A;;US 202017060905 A;;US 202016793610 A;;US 201916453482 A;;US 201816194896 A;;US 201815922675 A;;US 201615271315 A;;US 201414228556 A;;US 201213504449 A;;US 2010/0054148 W;;US 38128710 P;;US 25498209 P,2009-10-26,Human IL-23 Antigen Binding Proteins,"Antigen binding proteins that bind to human IL-23 protein are provided. Nucleic acids encoding the antigen binding protein, vectors, and cells encoding the same as well as use of IL-23 antigen binding proteins for diagnostic and therapeutic purposes are also provided.",AMGEN INC,TOWNE JENNIFER E;;CHENG JANET D;;O'NEILL JASON C;;ZHANG YU;;SUN YU;;CERNE HEATHER;;PIPER DEREK E;;KETCHEM RANDAL R,AMGEN INC (2012-06-11),https://lens.org/156-359-725-992-86X,Patent Application,yes,0,0,86,87,155,A61K2039/505;;C07K2317/21;;C07K2317/55;;C07K2317/92;;A61K47/6845;;C07K16/244;;A61P37/00;;C07K16/244;;A61K2039/505;;C07K2317/626;;C07K2317/21;;C07K2317/76;;A61K47/6845;;C07K2317/54;;A61K39/395;;C07K2317/31;;C07K16/24;;A61P37/00;;C07K2317/92;;C07K2317/24;;C07K2317/622;;C07K2317/55;;C07K2317/565;;A61K39/00;;A61K39/395;;A61K39/39533;;A61K39/3955;;C07K16/18;;C07K16/24;;C07K16/244;;A61K2039/505;;C07K2317/21;;C07K2317/55;;C07K2317/92;;A61K47/6845;;C07K16/244;;A61K39/395;;C07K16/24;;C07K2317/24;;C07K2317/31;;C07K2317/54;;C07K2317/565;;C07K2317/622;;C07K2317/626;;C07K2317/76,C07K16/24;;A61K39/395;;A61K47/68,,0,0,,,,DISCONTINUED
418,BR,B8,BR 112012009854 B8,198-922-989-561-776,2021-05-25,2021,BR 112012009854 A,2010-10-26,US 2010/0054148 W;;US 25498209 P;;US 38128710 P,2009-10-26,"proteína de ligação de antígeno isolada recombinante que liga il-23, composição farmacêutica, molécula de ácido nucleico isolada recombinante, vetor recombinante, método de confecção da referida proteína de ligação e uso da mesma","proteínas de ligação de antígeno il-23 humano. são fornecidas proteínas de ligação de antígeno que se ligam a proteína de il-23 humana. ácidos nucleicos que codificam a proteína de ligação de antígeno, vetores, e células que codificam os mesmos bem como o uso de proteínas de ligação de antígeno de il-23 para objetivos diagnósticos e terapêuticos são também fornecidos.",AMGEN INC,DEREK E PIPER;;HEATHER CERNE;;JANET D CHENG;;JASON C O'NEILL;;JENNIFER E TOWNE;;RANDAL R KETCHEM;;YU SUN;;YU ZHANG,,https://lens.org/198-922-989-561-776,Amended Patent,no,0,0,86,87,0,A61K2039/505;;C07K2317/21;;C07K2317/55;;C07K2317/92;;A61K47/6845;;C07K16/244;;A61P37/00;;C07K16/244;;A61K2039/505;;C07K2317/626;;C07K2317/21;;C07K2317/76;;A61K47/6845;;C07K2317/54;;A61K39/395;;C07K2317/31;;C07K16/24;;A61P37/00;;C07K2317/92;;C07K2317/24;;C07K2317/622;;C07K2317/55;;C07K2317/565;;A61K39/00;;A61K39/395;;A61K39/39533;;A61K39/3955;;C07K16/18;;C07K16/24;;C07K16/244;;A61K2039/505;;C07K2317/21;;C07K2317/55;;C07K2317/92;;A61K47/6845;;C07K16/244;;A61K39/395;;C07K16/24;;C07K2317/24;;C07K2317/31;;C07K2317/54;;C07K2317/565;;C07K2317/622;;C07K2317/626;;C07K2317/76,A61K39/395;;C07K16/24,,0,0,,,,ACTIVE
419,US,B2,US 11177525 B2,199-330-990-638-117,2021-11-16,2021,US 201716348447 A,2017-11-09,CN 201610987137 A;;IB 2017056996 W,2016-11-09,Battery pack,"The present disclosure provides a battery pack for a hybrid vehicle. The battery pack includes: multiple battery cells, a housing, a first end plate, a second end plate, a bearing plate and an upper cover, wherein the housing is provided with a bottom portion and side walls extending from the periphery of the bottom portion and forming an upper portion opening; the housing is configured for accommodating the multiple battery cells and the two end plates, when the multiple battery cells are sequentially arranged and mounted into the housing, the first end plate and the second end plate are located at two end sides of the sequentially arranged multiple battery cells to laterally fix the multiple battery cells; the bearing plate is mounted above the top portions of the multiple battery cells; and the upper cover is mounted above the housing to cover the upper portion opening of the housing.",CPS TECH HOLDINGS LLC;;CLARIOS ADVANCED SOLUTIONS GMBH,FAN BINBIN;;CHENG LIANG;;QU WEI;;SONG PENG;;FU YINGYAO;;LIU CHANG;;FUHR JASON D;;WIEGMANN MARTIN;;ZHANG XUGANG;;CZARNECKI JENNIFER L,CPS TECHNOLOGY HOLDINGS LLC (2019-04-30);;CLARIOS ADVANCED SOLUTIONS GMBH (2019-10-01);;JOHNSON CONTROLS TECHNOLOGY COMPANY (2019-09-09),https://lens.org/199-330-990-638-117,Granted Patent,yes,48,3,9,9,0,H01M50/284;;H01M50/244;;H01M50/51;;H01M50/249;;H01M50/204;;H01M50/258;;H01M50/289;;H01M10/613;;H01M10/625;;H01M10/6563;;H01M10/6566;;H01M10/482;;H01M2010/4271;;H01M2200/103;;H01M2220/20;;H01M10/625;;H01M10/6563;;H01M10/613;;F04D25/0613;;F04D29/601;;H01M50/24;;H01M50/3425;;H01M50/553;;H01M50/507;;H01M50/367;;H01M50/284;;H01M50/55;;H01M50/51;;H01M50/583;;H01M50/244;;H01M50/271;;H01M50/298;;H01M50/209;;H01M50/517;;H01M50/296;;H01M50/242;;H01M50/227;;Y02E60/10;;B60L50/64;;B60L58/26;;F04D25/0673;;F04D29/601;;H01M10/425;;H01M2010/4271;;H01M2220/20;;H01M50/342;;H01M10/482;;H01M50/55;;H01M50/367;;H01M50/583;;H01M50/517;;H01M50/507;;H01M50/553;;H01M50/242;;H01M50/227;;H01M50/296;;H01M50/284;;H01M50/298;;H01M50/271;;H01M50/244;;H01M50/209;;H01M50/51,H01M50/20;;B60L50/64;;B60L58/26;;F04D25/06;;F04D29/60;;H01M10/42;;H01M50/209;;H01M50/227;;H01M50/242;;H01M50/244;;H01M50/249;;H01M50/271;;H01M50/284;;H01M50/296;;H01M50/298;;H01M50/342;;H01M50/35;;H01M50/367;;H01M50/502;;H01M50/507;;H01M50/51;;H01M50/517;;H01M50/543;;H01M50/55;;H01M50/553;;H01M50/583,,4,0,,,"International Search Report and Written Opinion of the International Search Authority dated Apr. 4, 2018, for PCT/IB2017/056993 filed Nov. 9, 2017.;;International Search Report and Written Opinion of the International Search Authority dated Apr. 13, 2018, for PCT/IB2017/056994 filed Nov. 9, 2017.;;International Search Report and Written Opinion of the International Search Authority dated Jan. 18, 2018, for PCT/IB2017/056995 filed Nov. 9, 2017.;;International Search Report and Written Opinion of the International Search Authority dated Mar. 29, 2018, for PCT/IB2017/056996 filed Nov. 9, 2017.",ACTIVE
420,BR,B1,BR 122020002402 B1,019-636-946-257-047,2022-02-08,2022,BR 122020002402 A,2010-10-26,US 2010/0054148 W;;US 25498209 P;;US 38128710 P;;BR 112012009854 A,2009-10-26,"Proteína de ligação de antígeno isolada recombinante que liga il-23, composição farmacêutica, molécula de ácido nucleico isolada recombinante, vetor recombinante, célula hospedeira recombinante, métodos de confecção da referida proteína de ligação e uso da mesma","são fornecidas proteínas de ligação de antígeno que se ligam a proteína de il-23 humana. ácidos nucleicos que codificam a proteína de ligação de antígeno, vetores, e células que codificam os mesmos bem como o uso de proteínas de ligação de antígeno de il-23 para objetivos diagnósticos e terapêuticos são também fornecidos.",AMGEN INC,DEREK E PIPER;;CERNE HEATHER;;JANET D CHENG;;JASON C O?NEILL;;JENNIFER E TOWNE;;RANDAL R KETCHEM;;SUN YU;;ZHANG YU,,https://lens.org/019-636-946-257-047,Granted Patent,no,0,0,86,87,0,A61K2039/505;;C07K2317/21;;C07K2317/55;;C07K2317/92;;A61K47/6845;;C07K16/244;;A61P37/00;;C07K16/244;;A61K2039/505;;C07K2317/626;;C07K2317/21;;C07K2317/76;;A61K47/6845;;C07K2317/54;;A61K39/395;;C07K2317/31;;C07K16/24;;A61P37/00;;C07K2317/92;;C07K2317/24;;C07K2317/622;;C07K2317/55;;C07K2317/565;;A61K39/00;;A61K39/395;;A61K39/39533;;A61K39/3955;;C07K16/18;;C07K16/24;;C07K16/244;;A61K2039/505;;C07K2317/21;;C07K2317/55;;C07K2317/92;;A61K47/6845;;C07K16/244;;A61K39/395;;C07K16/24;;C07K2317/24;;C07K2317/31;;C07K2317/54;;C07K2317/565;;C07K2317/622;;C07K2317/626;;C07K2317/76,A61K39/395;;C07K16/24,,0,0,,,,ACTIVE
421,LT,T,LT 2493925 T,002-226-061-137-137,2017-04-25,2017,LT 10774095 T,2010-10-26,US 25498209 P;;US 38128710 P;;US 2010/0054148 W,2009-10-26,HUMAN IL-23 ANTIGEN BINDING PROTEINS,,AMGEN INC,TOWNE JENNIFER E;;CHENG JANET D;;O`NEILL JASON C;;ZHANG YU;;SUN YU;;CERNE HEATHER;;PIPER DEREK E;;KETCHEM RANDAL R,,https://lens.org/002-226-061-137-137,Unknown,no,0,0,86,87,0,A61K2039/505;;C07K2317/21;;C07K2317/55;;C07K2317/92;;A61K47/6845;;C07K16/244;;A61P37/00;;C07K16/244;;A61K2039/505;;C07K2317/626;;C07K2317/21;;C07K2317/76;;A61K47/6845;;C07K2317/54;;A61K39/395;;C07K2317/31;;C07K16/24;;A61P37/00;;C07K2317/92;;C07K2317/24;;C07K2317/622;;C07K2317/55;;C07K2317/565;;A61K39/00;;A61K39/395;;A61K39/39533;;A61K39/3955;;C07K16/18;;C07K16/24;;C07K16/244;;A61K2039/505;;C07K2317/21;;C07K2317/55;;C07K2317/92;;A61K47/6845;;C07K16/244;;A61K39/395;;C07K16/24;;C07K2317/24;;C07K2317/31;;C07K2317/54;;C07K2317/565;;C07K2317/622;;C07K2317/626;;C07K2317/76,C07K16/24;;A61K39/395,,0,0,,,,PENDING
422,UY,A,UY 32971 A,104-774-057-031-394,2010-11-30,2010,UY 32971 A,2010-10-26,US 25498209 P;;US 38128710 P,2009-10-26,PROTEÍNAS DE UNIÓN AL ANTÍGENO DE LA IL-23 HUMANA,"Se proporcionan proteínas de unión al antígeno que se unen a la IL-23 humana. Asimismo, se proporcionan ácidos nucleicos que codifican la proteína de unión al antígeno, vectores y células que los codifican, así como el uso de las proteínas de unión al antígeno de la IL-23 para fines de diagnóstico y terapia",AMGEN INC,TOWNE JENNIFER E;;CHENG JANET D;;YU ZHANG;;YU SUN;;HEATHER CERNE;;PIPER DEREK E;;KETCHEM RANDAL R;;NEILL JASON C O,,https://lens.org/104-774-057-031-394,Patent Application,no,0,0,86,87,0,A61K2039/505;;C07K2317/21;;C07K2317/55;;C07K2317/92;;A61K47/6845;;C07K16/244;;A61P37/00;;C07K16/244;;A61K2039/505;;C07K2317/626;;C07K2317/21;;C07K2317/76;;A61K47/6845;;C07K2317/54;;A61K39/395;;C07K2317/31;;C07K16/24;;A61P37/00;;C07K2317/92;;C07K2317/24;;C07K2317/622;;C07K2317/55;;C07K2317/565;;A61K39/00;;A61K39/395;;A61K39/39533;;A61K39/3955;;C07K16/18;;C07K16/24;;C07K16/244;;A61K2039/505;;C07K2317/21;;C07K2317/55;;C07K2317/92;;A61K47/6845;;C07K16/244;;A61K39/395;;C07K16/24;;C07K2317/24;;C07K2317/31;;C07K2317/54;;C07K2317/565;;C07K2317/622;;C07K2317/626;;C07K2317/76,A61K39/395;;A61P37/00;;C07K14/54;;C07K16/24;;C12N5/22;;C12N15/13;;C12N15/63;;C12N15/79;;G01N33/53,,0,0,,,,DISCONTINUED
423,CA,A1,CA 2335638 A1,028-321-614-094-122,1999-12-23,1999,CA 2335638 A,1999-06-18,US 8987998 P;;US 9913875 W,1998-06-19,CATIONIC AMPHIPHILE MICELLAR COMPLEXES,"The effective introduction of foreign genes and other biologically active molecules into targeted mammalian cells is a challenge still facing those skilled in the art. Gene therapy, for example, requires successful transfection of target cells in a patient. The present invention relates to novel micellar complexes of cationic amphiphilic compounds that facilitate delivery of biologically active molecules to the targeted cells of a mammal. The novel micellar complexes are comprised of a cationic amphiphile, a biologically active molecule, a derivative of polyethylene glycol (PEG), and optionally, a co-lipid. A further aspect of the invention is the use of targeting absents in any of the methods that effectuate the delivery of biologically active molecules into the cells of mammals. A targeting agent i s usually any molecule, peptide sequence, or large protein that preferentially targets or binds to specific mammalian cells.",GENZYME CORP,CHU QUIMING;;LEE EDWARD R;;EASTMAN SIMON J;;TOUSIGNANT JENNIFER D;;SCHEULE RONALD K;;NIETUPSKI JANNIFER B;;MARSHALL JOHN;;CHENG SENG H,,https://lens.org/028-321-614-094-122,Patent Application,no,0,0,7,7,0,A61K9/1272;;A61K47/6907;;A61K47/6911,C12N15/00;;A61K9/00;;A61K9/127;;A61K31/711;;A61K39/395;;A61K47/24;;A61K47/34;;A61K47/42;;A61K47/44;;A61K47/48;;A61K48/00,,0,0,,,,DISCONTINUED
424,US,A1,US 2020/0083502 A1,027-268-126-216-630,2020-03-12,2020,US 201716348447 A,2017-11-09,CN 201610987137 A;;IB 2017056996 W,2016-11-09,BATTERY PACK,"The present disclosure provides a battery pack for a hybrid vehicle. The battery pack includes: multiple battery cells, a housing, a first end plate, a second end plate, a bearing plate and an upper cover, wherein the housing is provided with a bottom portion and side walls extending from the periphery of the bottom portion and forming an upper portion opening; the housing is configured for accommodating the multiple battery cells and the two end plates, when the multiple battery cells are sequentially arranged and mounted into the housing, the first end plate and the second end plate are located at two end sides of the sequentially arranged multiple battery cells to laterally fix the multiple battery cells; the bearing plate is mounted above the top portions of the multiple battery cells; and the upper cover is mounted above the housing to cover the upper portion opening of the housing.",CPS TECH HOLDINGS LLC;;JOHNSON CONTROLS ADVANCED POWER SOLUTIONS GMBH,FAN BINBIN;;CHENG LIANG;;QU WEI;;SONG PENG;;FU YINGYAO;;LIU CHANG;;FUHR JASON D;;WIEGMANN MARTIN;;ZHANG XUGANG;;CZARNECKI JENNIFER L,CPS TECHNOLOGY HOLDINGS LLC (2019-04-30);;CLARIOS ADVANCED SOLUTIONS GMBH (2019-10-01);;JOHNSON CONTROLS TECHNOLOGY COMPANY (2019-09-09),https://lens.org/027-268-126-216-630,Patent Application,yes,0,19,9,9,0,H01M50/284;;H01M50/244;;H01M50/51;;H01M50/249;;H01M50/204;;H01M50/258;;H01M50/289;;H01M10/613;;H01M10/625;;H01M10/6563;;H01M10/6566;;H01M10/482;;H01M2010/4271;;H01M2200/103;;H01M2220/20;;H01M10/625;;H01M10/6563;;H01M10/613;;F04D25/0613;;F04D29/601;;H01M50/24;;H01M50/3425;;H01M50/553;;H01M50/507;;H01M50/367;;H01M50/284;;H01M50/55;;H01M50/51;;H01M50/583;;H01M50/244;;H01M50/271;;H01M50/298;;H01M50/209;;H01M50/517;;H01M50/296;;H01M50/242;;H01M50/227;;Y02E60/10;;B60L50/64;;B60L58/26;;F04D25/0673;;F04D29/601;;H01M10/425;;H01M2010/4271;;H01M2220/20;;H01M50/342;;H01M10/482;;H01M50/55;;H01M50/367;;H01M50/583;;H01M50/517;;H01M50/507;;H01M50/553;;H01M50/242;;H01M50/227;;H01M50/296;;H01M50/284;;H01M50/298;;H01M50/271;;H01M50/244;;H01M50/209;;H01M50/51,B60L50/64;;B60L58/26;;F04D25/06;;F04D29/60;;H01M10/42;;H01M50/209;;H01M50/227;;H01M50/242;;H01M50/244;;H01M50/249;;H01M50/271;;H01M50/284;;H01M50/296;;H01M50/298;;H01M50/367;;H01M50/507;;H01M50/51;;H01M50/517;;H01M50/55;;H01M50/553;;H01M50/583,,0,0,,,,ACTIVE
425,US,B2,US 11724606 B2,156-328-064-292-038,2023-08-15,2023,US 202117518179 A,2021-11-03,US 202117518179 A;;CN 201610987137 A;;US 201916348447 A;;IB 2017056996 W,2016-11-09,Battery pack,"The present disclosure provides a battery pack for a hybrid vehicle. The battery pack includes: multiple battery cells, a housing, a first end plate, a second end plate, a bearing plate and an upper cover, wherein the housing is provided with a bottom portion and side walls extending from the periphery of the bottom portion and forming an upper portion opening; the housing is configured for accommodating the multiple battery cells and the two end plates, when the multiple battery cells are sequentially arranged and mounted into the housing, the first end plate and the second end plate are located at two end sides of the sequentially arranged multiple battery cells to laterally fix the multiple battery cells; the bearing plate is mounted above the top portions of the multiple battery cells; and the upper cover is mounted above the housing to cover the upper portion opening of the housing.",CPS TECH HOLDINGS LLC;;CLARIOS ADVANCED SOLUTIONS GMBH,FAN BINBIN;;CHENG LIANG;;QU WEI;;SONG PENG;;FU YINGYAO;;LIU CHANG;;FUHR JASON D;;WIEGMANN MARTIN;;ZHANG XUGANG;;CZARNECKI JENNIFER L,CPS TECHNOLOGY HOLDINGS LLC (2019-04-30);;CLARIOS ADVANCED SOLUTIONS GMBH (2019-10-01);;JOHNSON CONTROLS TECHNOLOGY COMPANY (2019-09-09),https://lens.org/156-328-064-292-038,Granted Patent,yes,51,2,9,9,0,H01M50/284;;H01M50/244;;H01M50/51;;H01M50/249;;H01M50/204;;H01M50/258;;H01M50/289;;H01M10/613;;H01M10/625;;H01M10/6563;;H01M10/6566;;H01M10/482;;H01M2010/4271;;H01M2200/103;;H01M2220/20;;H01M10/625;;H01M10/6563;;H01M10/613;;F04D25/0613;;F04D29/601;;H01M50/24;;H01M50/3425;;H01M50/553;;H01M50/507;;H01M50/367;;H01M50/284;;H01M50/55;;H01M50/51;;H01M50/583;;H01M50/244;;H01M50/271;;H01M50/298;;H01M50/209;;H01M50/517;;H01M50/296;;H01M50/242;;H01M50/227;;Y02E60/10;;B60L50/64;;B60L58/26;;F04D25/0673;;F04D29/601;;H01M10/425;;H01M2010/4271;;H01M2220/20;;H01M50/342;;H01M10/482;;H01M50/55;;H01M50/367;;H01M50/583;;H01M50/517;;H01M50/507;;H01M50/553;;H01M50/242;;H01M50/227;;H01M50/296;;H01M50/284;;H01M50/298;;H01M50/271;;H01M50/244;;H01M50/209;;H01M50/51,B60L50/64;;B60L58/26;;F04D25/06;;F04D29/60;;H01M10/42;;H01M10/48;;H01M50/209;;H01M50/227;;H01M50/242;;H01M50/244;;H01M50/271;;H01M50/284;;H01M50/296;;H01M50/298;;H01M50/342;;H01M50/367;;H01M50/507;;H01M50/51;;H01M50/517;;H01M50/55;;H01M50/553;;H01M50/583,,6,0,,,"Machine Translation of DE-102020213987-B3 (Feb. 24, 2023) (Year: 2023).;;Machine Translation of CN-113574726-A (Feb. 24, 2023) (Year: 2023).;;International Search Report and Written Opinion of the International Search Authority dated Mar. 29, 2018, for PCT/IB2017/056996 filed Nov. 9, 2017.;;International Search Report and Written Opinion of the International Search Authority dated Apr. 4, 2018, for PCT/IB2017/056993 filed Nov. 9, 2017.;;International Search Report and Written Opinion of the International Search Authority dated Apr. 13, 2018, for PCT/IB2017/056994 filed Nov. 9, 2017.;;International Search Report and Written Opinion of the International Search Authority dated Jan. 18, 2018, for PCT/IB2017/056995 filed Nov. 9, 2017.",ACTIVE
426,WO,A3,WO 1999/065461 A3,178-763-753-296-637,1999-12-23,1999,US US9913875,1999-06-18,"US 60/0/089,879",1998-06-19,CATIONIC AMPHIPHILE MICELLAR COMPLEXES,"The effective introduction of foreign genes and other biologically active molecules into targeted mammalian cells is a challenge still facing those skilled in the art. Gene therapy, for example, requires successful transfection of target cells in a patient. The present invention relates to novel micellar complexes of cationic amphiphilic compounds that facilitate delivery of biologically active molecules to the targeted cells of a mammal. The novel micellar complexes are comprised of a cationic amphiphile, a biologically active molecule, a derivative of polyethylene glycol (PEG), and optionally, a co-lipid. A further aspect of the invention is the use of targeting absents in any of the methods that effectuate the delivery of biologically active molecules into the cells of mammals. A targeting agent is usually any molecule, peptide sequence, or large protein that preferentially targets or binds to specific mammalian cells.",GENZYME CORPORATION,"TOUSIGNANT, Jennifer, D.;;EASTMAN, Simon, J.;;CHU, Quiming;;LEE, Edward, R.;;FANG, Shaona, L.;;SCHEULE, Ronald, K.;;CHENG, Seng, H.;;NIETUPSKI, Jannifer, B.;;MARSHALL, John",,https://lens.org/178-763-753-296-637,Search Report,yes,0,0,1,1,0,,A61K9/127;;A61K47/48,,0,0,,,,UNKNOWN
427,WO,A9,WO 1999/065461 A9,047-681-151-042-892,2001-02-01,2001,US 9913875 W,1999-06-18,US 8987998 P,1998-06-19,CATIONIC AMPHIPHILE MICELLAR COMPLEXES,"The effective introduction of foreign genes and other biologically active molecules into targeted mammalian cells is a challenge still facing those skilled in the art. Gene therapy, for example, requires successful transfection of target cells in a patient. The present invention relates to novel micellar complexes of cationic amphiphilic compounds that facilitate delivery of biologically active molecules to the targeted cells of a mammal. The novel micellar complexes are comprised of a cationic amphiphile, a biologically active molecule, a derivative of polyethylene glycol (PEG), and optionally, a co-lipid. A further aspect of the invention is the use of targeting absents in any of the methods that effectuate the delivery of biologically active molecules into the cells of mammals. A targeting agent is usually any molecule, peptide sequence, or large protein that preferentially targets or binds to specific mammalian cells.",GENZYME CORP,TOUSIGNANT JENNIFER D;;EASTMAN SIMON J;;CHU QUIMING;;LEE EDWARD R;;FANG SHAONA L;;SCHEULE RONALD K;;CHENG SENG H;;NIETUPSKI JANNIFER B;;MARSHALL JOHN,,https://lens.org/047-681-151-042-892,Patent Application,no,0,0,7,7,0,A61K9/1272;;A61K47/6907;;A61K47/6911,C12N15/00;;A61K9/00;;A61K9/127;;A61K31/711;;A61K39/395;;A61K47/24;;A61K47/34;;A61K47/42;;A61K47/44;;A61K47/48;;A61K48/00,,0,0,,,,PENDING
428,US,B1,US 6415556 B1,016-501-789-444-772,2002-07-09,2002,US 60972800 A,2000-07-03,US 60972800 A,2000-07-03,Transport mechanism for large structures such as retractable stadium rooves,"
    An edifice such as a sports stadium is adapted for open use during good weather as well as for covered use during poor weather by having at least one movable roof member. Each movable roof member includes a transport mechanism that is constructed and arranged to permit the roof member to move in a predetermined path with respect to the underlying structure of the edifice. The transport mechanism includes structure for supporting both ends of the roof member, which bridges an otherwise open area of the edifice. In order to permit some flexure and movement of the roof member with respect to the underlying edifice, as will inevitably occur as a result of natural forces such as winds, orientation structure is provided for maintaining the transport mechanism in a predetermined orientation while simultaneously permitting a limited amount of movement of the roof member in a direction that is nonparallel to the predetermined path of movement. The orientation structure has been found to be most effective when it is provided at but one end of the roof member. 
",UNI SYSTEMS INC,SILBERMAN CYRIL J;;SADINSKY M DAVID;;RIBERICH BARTON L;;CHENG CHEUK A;;EIDE DICK;;NIELSEN LENNART;;BECKER MICHAEL JAMES;;KLINE TIMOTHY JOHN;;RIBERICH MICHAEL R;;MCLEISH JENNIFER ANN,UNI-SYSTEMS INC (2000-12-07);;C&F MANAGEMENT LLC (2013-12-30),https://lens.org/016-501-789-444-772,Granted Patent,yes,54,17,1,1,0,E04B7/166;;E04B7/166,E04B7/16,52/66;;52/6;;52/64;;52/83,0,0,,,,EXPIRED
429,US,B2,US 11661419 B2,045-410-197-493-026,2023-05-30,2023,US 202017126358 A,2020-12-18,US 202017126358 A;;US 202063108602 P;;US 201962951030 P,2019-12-20,Benzimidazole derivative compounds and uses thereof,"The invention relates to benzimidazoles of Formula (I) and pharmaceutically acceptable salts thereof, wherein R 1 to R 6 are as defined in the description; to their use in medicine; to compositions containing them; to processes for their preparation; and to intermediates used in such processes. The benzimidazoles of Formula (I) are ITK inhibitors and are therefore potentially useful in the treatment of a wide range of disorders including, atopic dermatitis.",PFIZER,BAGLEY SCOTT WILLIAM;;CASIMIRO-GARCIA AGUSTIN;;CHENG XIAYUN;;DAVOREN JENNIFER ELIZABETH;;DENNY RAJIAH ALDRIN;;GERSTENBERGER BRIAN STEPHEN;;LOVERING FRANK ELDRIDGE;;PARIKH MIHIR DINESHKUMAR;;STROHBACH JOSEPH WALTER;;TRUJILLO JOHN ISIDRO,,https://lens.org/045-410-197-493-026,Granted Patent,yes,53,0,24,29,0,A61P17/00;;C07D413/14;;C07D405/14;;C07D413/14;;C07D405/14;;A61P17/00;;A61K31/5377;;A61K31/4184;;C07D403/04;;A61K31/5377;;A61K9/0014;;A61K31/4184;;A61P17/00;;A61P29/00;;C07D405/14;;C07D413/14;;A61P17/00;;A61K45/06;;C07D413/14,C07D413/14;;A61K45/06;;A61P17/00,,13,7,019-971-337-924-914;;110-902-105-693-204;;028-414-487-236-185;;115-925-020-109-463;;093-054-601-588-266;;080-486-145-807-759;;021-758-616-191-580,10.1016/j.jmgm.2010.09.008;;21036641;;20363624;;10.1016/j.bmcl.2010.03.062;;10.1007/bf02256917;;10.1016/j.bmcl.2014.10.020;;25455497;;24918870;;10.1021/jm500550e;;10.1021/jm501998m;;25844760;;10.1517/13543771003674409;;20218931,"Overview of Atopic Dermatitis [online] retrieved from interneton Nov. 18, 2022 URL: https://www.niams.nih.gov/health-topics/atopic-dermatitis.;;Atopic Dermatitis Treatment Options [online] retrieved from internet on Nov. 18, 2022 URL: https://www.healthline.com/health/atopic-dermatitis/treatment-option.;;No new references cited by the Examiner.;;Podlipnik et al., “Structural elements of TRK receptors and directives for development of their inhibitors”, Slovenski Kemijski Dnevi, Maribor, Slovenia, Sep. 23-24, 2010 (2010), podi1/1-podi1/17.;;Podlipnik et al., “DFG-in and DFG-out homology models of TrkB kinase receptor Induced-fit and ensemble docking”, Journal of Molecular Graphics and Modelling, 2010, 309-320, 29, 3.;;Boatman et al., “Potent tricyclic pyrazole tetrazole agonists of the nicotinic acid receptor (GPR109a)”, Bioorganic & Medicinal Chemistry Letters, 2010, 2797-2800, 20, 9.;;Tonkikh et al., “4(3H)-Quinazolinones containing heterocyclic group in position 3”, Chemistry of Heterocyclic Compounds, 2000, 822-829, 36, 7.;;Trani et al., “Design, synthesis and structure-activity relationships of a novel class of sulfonylpyridine inhibitors of interleukin-2 inducible T-cell kinase (ITK)”, Bioorganic & Medicinal Chemistry Letters, 2014, 5818-5823, 24.;;Burch et al., “Property- and Structure-Guided Discovery of a Tetrahydroindazole Series of Interleukin-2 Inducible T-Cell Kinase Inhibitors”, Journal of Medicinal Chemistry, 2014, 5714-5727, 57.;;Burch et al., “Tetrahydroindazoles as Interleukin-2 Inducible T-Cell Kinase Inhibitors. Part II. Second-Generation Analogues with Enhanced Potency, Selectivity, and Pharmacodynamic Modulation in Vivo”, Journal of Medicinal Chemistry, 2015, 3806-3816, 58.;;Lo et al., “Itk inhibitors: a patent review”, Expert Opinion on Therapeutic Patents, 2010, 459-469, 20(4).;;International Search Report and Written Opinion dated Feb. 17, 2021 for International application No. PCT/IB2020/062036, filed Dec. 16, 2020.;;International Preliminary Report on Patentability, dated May 17, 2022; for International application No. PCT/IB2020/062036, filed Dec. 16, 2020, 7 pages.",ACTIVE
430,CR,A,CR 20220299 A,063-006-066-741-104,2022-08-05,2022,CR 20220299 A,2020-12-16,US 202063108602 P;;US 201962951030 P;;IB 2020062036 W,2019-12-20,BENZIMIDAZOLE DERIVATIVES,"The invention relates to benzimidazoles of Formula (I) and pharmaceutically acceptable salts thereof, wherein R<sup>1</sup> to R<sup>6</sup> are as defined in the description; to their use in medicine; to compositions containing them; to processes for their preparation; and to intermediates used in such processes. The benzimidazoles of Formula (I) are ITK inhibitors and are therefore potentially useful in the treatment of a wide range of disorders including, atopic dermatitis.",PFIZER,CHENG XIAYUN;;CASIMIRO-GARCIA AGUSTIN;;DAVOREN JENNIFER ELIZABETH;;PARIKH MIHIR DINESHKUMAR;;BAGLEY SCOTT WILLIAM;;DENNY RAJIAH ALDRIN;;STROHBACH JOSEPH WALTER;;GERSTENBERGER BRIAN STEPHEN;;LOVERING FRANK ELDRIDGE;;TRUJILLO JOHN ISIDRO,,https://lens.org/063-006-066-741-104,Patent Application,no,0,0,24,29,0,A61P17/00;;C07D413/14;;C07D405/14;;C07D413/14;;C07D405/14;;A61P17/00;;A61K31/5377;;A61K31/4184;;C07D403/04;;A61K31/5377;;A61K9/0014;;A61K31/4184;;A61P17/00;;A61P29/00;;C07D405/14;;C07D413/14;;A61P17/00;;A61K45/06;;C07D413/14,C07D413/14;;A61K31/4453;;A61K31/5377;;A61P17/00;;C07D405/14,,0,0,,,,PENDING
431,CL,A1,CL 2022001675 A1,075-209-421-398-853,2023-03-17,2023,CL 2022001675 A,2022-06-17,US 201962951030 P;;US 202063108602 P,2019-12-20,Derivados de benzimidazol,"La invención se refiere a bencimidazoles de la Fórmula (I) y sales de estos aceptables desde el punto de vista farmacéutico, en donde R1 a R6 son como se definen en la descripción; a su uso en la medicina; a composiciones que los contienen; a procesos para su preparación; y a intermediarios usados en dichos procesos. Los bencimidazoles de la Fórmula (I) son inhibidores de ITK y, por lo tanto, son potencialmente útiles en el tratamiento de diversos trastornos, que incluyen dermatitis atópica.",PFIZER,SCOTT WILLIAM BAGLEY;;AGUSTIN CASIMIRO-GARCIA;;XIAYUN CHENG;;JENNIFER ELIZABETH DAVOREN;;RAJIAH ALDRIN DENNY;;BRIAN STEPHEN GERSTENBERGER;;FRANK ELDRIDGE LOVERING;;MIHIR DINESHKUMAR PARIKH;;JOSEPH WALTER STROHBACH;;JOHN ISIDRO TRUJILLO,,https://lens.org/075-209-421-398-853,Patent Application,no,0,0,24,29,0,A61P17/00;;C07D413/14;;C07D405/14;;C07D413/14;;C07D405/14;;A61P17/00;;A61K31/5377;;A61K31/4184;;C07D403/04;;A61K31/5377;;A61K9/0014;;A61K31/4184;;A61P17/00;;A61P29/00;;C07D405/14;;C07D413/14;;A61P17/00;;A61K45/06;;C07D413/14,A61K31/4453;;A61K31/5377;;A61P17/00;;C07D405/14;;C07D413/14,,0,0,,,,PENDING
432,UY,A,UY 38998 A,179-483-902-948-839,2021-07-30,2021,UY 38998 A,2020-12-21,US 201962951030 P;;US 202063108602 P,2019-12-20,"DERIVADOS DE BENCIMIDAZOL, SU USO EN MEDICINA Y COMPOSICIONES QUE LOS CONTIENEN","La invención se refiere a bencimidazoles de la Fórmula (I) y sales de estos aceptables desde el punto de vista farmacéutico, en donde R1 a R6 son como se definen en la descripción; a su uso en la medicina; a composiciones que los contienen; a procesos para su preparación; y a intermediarios usados en dichos procesos. Los bencimidazoles de la Fórmula (I) son inhibidores de ITK y, por lo tanto, son potencialmente útiles en el tratamiento de diversos trastornos, que incluyen dermatitis atópica.",PFIZER,CASIMIRO-GARCIA AGUSTIN;;LOVERING FRANK ELDRIDGE;;GERSTENBERGER BRIAN STEPHEN;;TRUJILLO JOHN ISIDRO;;PARIKH MIHIR DINESHKUMAR;;BAGLEY SCOTT WILLIAM;;CHENG XIAYUN;;DENNY RAJIAH ALDRIN;;DAVOREN JENNIFER ELIZABETH;;STROHBACH JOSEPH WALTER,,https://lens.org/179-483-902-948-839,Patent Application,no,0,0,24,29,0,A61P17/00;;C07D413/14;;C07D405/14;;C07D413/14;;C07D405/14;;A61P17/00;;A61K31/5377;;A61K31/4184;;C07D403/04;;A61K31/5377;;A61K9/0014;;A61K31/4184;;A61P17/00;;A61P29/00;;C07D405/14;;C07D413/14;;A61P17/00;;A61K45/06;;C07D413/14,A61P17/00;;A61K31/351;;A61K31/416;;A61K31/4184;;A61K31/5377;;C07D403/04;;C07D403/14;;C07D405/14;;C07D413/14,,0,0,,,,PENDING
433,TW,B,TW I766484 B,034-388-871-281-547,2022-06-01,2022,TW 109144868 A,2020-12-18,US 201962951030 P;;US 202063108602 P,2019-12-20,CHEMICAL COMPOUNDS,,PFIZER,BAGLEY SCOTT WILLIAM;;CASIMIRO-GARCIA AGUSTIN;;CHENG XIAYUN;;DAVOREN JENNIFER ELIZABETH;;DENNY RAJIAH ALDRIN;;GERSTENBERGER BRIAN STEPHEN;;LOVERING FRANK ELDRIDGE;;PARIKH MIHIR DINESHKUMAR;;STROHBACH JOSEPH WALTER;;TRUJILLO JOHN ISIDRO,,https://lens.org/034-388-871-281-547,Granted Patent,no,3,0,24,29,0,A61P17/00;;C07D413/14;;C07D405/14;;C07D413/14;;C07D405/14;;A61P17/00;;A61K31/5377;;A61K31/4184;;C07D403/04;;A61K31/5377;;A61K9/0014;;A61K31/4184;;A61P17/00;;A61P29/00;;C07D405/14;;C07D413/14;;A61P17/00;;A61K45/06;;C07D413/14,,,0,0,,,,ACTIVE
434,PE,A1,PE 20221916 A1,177-647-535-749-816,2022-12-23,2022,PE 2022001143 A,2020-12-16,US 201962951030 P;;US 202063108602 P;;IB 2020062036 W,2019-12-20,COMPUESTOS QUIMICOS,"Referida a bencimidazoles de Formula (I) y sales de estos aceptables desde el punto de vista farmaceutico; en donde cada R1 es independientemente H o F; R2 es hidroxi(C1-C4)alquilo, (C1-C4)alcoxi(C1-C4)alquilo, entre otros; cada R3 puede ser (C1- C4)alquilo o pueden unirse para formar (C3-C5)cicloalquilo; R4 se selecciona de dos heterociclos, que se sustituyen con oxo, hidroxi(C1-C4)alquilo, entre otros; y R5 y R6 son independientemente hidroxi(C1- C6)alquilo, (C1-C6)alquilo sustituido con uno a tres F o (C1-C6)alcoxi sustituido con (C1-C4)alcoxi. Dichos compuestoss o sales se seleccionan del grupo de (S)-N-metil-N-(6-metil-2-((4aS,5aR)-5a-metil-1,4,4a,5,5a,6- hexahidrociclopropa[f]indazol-3-il)-1H-benzo[d]imidazol-5-il)-2-morfolinopropanamida y son inhibidores de ITK por lo que son utiles en el tratamiento de trastornos como la dermatitis atopica.",PFIZER,BAGLEY SCOTT WILLIAM;;CASIMIRO-GARCIA AGUSTIN;;CHENG XIAYUN;;DAVOREN JENNIFER ELIZABETH;;DENNY RAJIAH ALDRIN;;GERSTENBERGER BRIAN STEPHEN;;LOVERING FRANK ELDRIDGE;;PARIKH MIHIR DINESHKUMAR;;STROHBACH JOSEPH WALTER;;TRUJILLO JOHN ISIDRO,,https://lens.org/177-647-535-749-816,Patent Application,no,0,0,24,29,0,A61P17/00;;C07D413/14;;C07D405/14;;C07D413/14;;C07D405/14;;A61P17/00;;A61K31/5377;;A61K31/4184;;C07D403/04;;A61K31/5377;;A61K9/0014;;A61K31/4184;;A61P17/00;;A61P29/00;;C07D405/14;;C07D413/14;;A61P17/00;;A61K45/06;;C07D413/14,C07D405/14;;A61K31/4453;;A61K31/5377;;A61P17/00;;C07D413/14,,0,0,,,,PENDING
435,EC,A,EC SP22049160 A,194-765-199-421-187,2022-07-29,2022,EC DI202249160 A,2022-06-20,US 201962951030 P;;US 202063108602 P,2019-12-20,DERIVADOS DE BENCIMIDAZOL,"La invenci?n se refiere a bencimidazoles de la F?rmula (I) y sales de estos aceptables desde el punto de vista farmac?utico, en donde R1 a R6 son como se definen en la descripci?n; a su uso en la medicina; a composiciones que los contienen; a procesos para su preparaci?n; y a intermediarios usados en dichos procesos. Los bencimidazoles de la F?rmula (I) son inhibidores de ITK y, por lo tanto, son potencialmente ?tiles en el tratamiento de diversos trastornos, que incluyen dermatitis at?pica.",PFIZER,GERSTENBERGER BRIAN STEPHEN;;CHENG XIAYUN;;LOVERING FRANK ELDRIDGE;;CASIMIRO-GARCIA AGUSTIN;;PARIKH MIHIR DINESHKUMAR;;DENNY RAJIAH ALDRIN;;DAVOREN JENNIFER ELIZABETH;;BAGLEY SCOTT WILLIAM;;TRUJILLO JOHN ISIDRO;;STROHBACH JOSEPH WALTER,,https://lens.org/194-765-199-421-187,Patent Application,no,0,0,24,29,0,A61P17/00;;C07D413/14;;C07D405/14;;C07D413/14;;C07D405/14;;A61P17/00;;A61K31/5377;;A61K31/4184;;C07D403/04;;A61K31/5377;;A61K9/0014;;A61K31/4184;;A61P17/00;;A61P29/00;;C07D405/14;;C07D413/14;;A61P17/00;;A61K45/06;;C07D413/14,C07D405/14;;A61K31/4453;;A61K31/5377;;A61P17/00;;C07D413/14,,0,0,,,,PENDING
436,CO,A2,CO 2022008313 A2,061-939-873-729-162,2022-07-08,2022,CO 2022008313 A,2022-06-14,IB 2020062036 W;;US 201962951030 P;;US 202063108602 P,2019-12-20,Compuestos químicos,"La invención se refiere a bencimidazoles de la Fórmula (I) y sales de estos aceptables desde el punto de vista farmacéutico, en donde R1 a R6 son como se definen en la descripción; a su uso en la medicina; a composiciones que los contienen; a procesos para su preparación; y a intermediarios usados en dichos procesos. Los bencimidazoles de la Fórmula (I) son inhibidores de ITK y, por lo tanto, son potencialmente útiles en el tratamiento de diversos trastornos, que incluyen dermatitis atópica.",PFIZER,STROHBACH JOSEPH WALTER;;CASIMIRO-GARCIA AGUSTIN;;BAGLEY SCOTT WILLIAM;;CHENG XIAYUN;;DAVOREN JENNIFER ELIZABETH;;DENNY RAJIAH ALDRIN;;GERSTENBERGER BRIAN STEPHEN;;LOVERING FRANK ELDRIDGE;;PARIKH MIHIR DINESHKUMAR;;TRUJILLO JOHN ISIDRO,,https://lens.org/061-939-873-729-162,Patent Application,no,0,0,24,29,0,A61P17/00;;C07D413/14;;C07D405/14;;C07D413/14;;C07D405/14;;A61P17/00;;A61K31/5377;;A61K31/4184;;C07D403/04;;A61K31/5377;;A61K9/0014;;A61K31/4184;;A61P17/00;;A61P29/00;;C07D405/14;;C07D413/14;;A61P17/00;;A61K45/06;;C07D413/14,C07D405/14;;A61K31/4453;;A61K31/5377;;A61P17/00;;C07D413/14,,0,0,,,,PENDING
437,AU,B2,AU 2020/405536 B2,094-819-091-010-998,2023-09-07,2023,AU 2020/405536 A,2020-12-16,US 201962951030 P;;US 202063108602 P;;IB 2020062036 W,2019-12-20,Benzimidazole derivatives,"The invention relates to benzimidazoles of Formula (I) and pharmaceutically acceptable salts thereof, wherein R",PFIZER,BAGLEY SCOTT WILLIAM;;CASIMIRO-GARCIA AGUSTIN;;CHENG XIAYUN;;DAVOREN JENNIFER ELIZABETH;;DENNY RAJIAH ALDRIN;;GERSTENBERGER BRIAN STEPHEN;;LOVERING FRANK ELDRIDGE;;PARIKH MIHIR DINESHKUMAR;;STROHBACH JOSEPH WALTER;;TRUJILLO JOHN ISIDRO,,https://lens.org/094-819-091-010-998,Granted Patent,no,1,0,24,29,0,A61P17/00;;C07D413/14;;C07D405/14;;C07D413/14;;C07D405/14;;A61P17/00;;A61K31/5377;;A61K31/4184;;C07D403/04;;A61K31/5377;;A61K9/0014;;A61K31/4184;;A61P17/00;;A61P29/00;;C07D405/14;;C07D413/14;;A61P17/00;;A61K45/06;;C07D413/14,C07D405/14;;A61K31/4453;;A61K31/5377;;A61P17/00;;C07D413/14,,0,0,,,,ACTIVE
438,MX,A,MX 2022007518 A,058-290-036-214-258,2022-09-19,2022,MX 2022007518 A,2020-12-16,US 201962951030 P;;US 202063108602 P;;IB 2020062036 W,2019-12-20,BENZIMIDAZOLE DERIVATIVES.,"The invention relates to benzimidazoles of Formula (I) and pharmaceutically acceptable salts thereof, wherein R<sup>1</sup> to R<sup>6</sup> are as defined in the description; to their use in medicine; to compositions containing them; to processes for their preparation; and to intermediates used in such processes. The benzimidazoles of Formula (I) are ITK inhibitors and are therefore potentially useful in the treatment of a wide range of disorders including, atopic dermatitis.",PFIZER,CASIMIRO-GARCIA AGUSTIN;;LOVERING FRANK ELDRIDGE;;STROHBACH JOSEPH WALTER;;GERSTENBERGER BRIAN STEPHEN;;DENNY RAJIAH ALDRIN;;DAVOREN JENNIFER ELIZABETH;;TRUJILLO JOHN ISIDRO;;PARIKH MIHIR DINESHKUMAR;;BAGLEY SCOTT WILLIAM;;CHENG XIAYUN,,https://lens.org/058-290-036-214-258,Patent Application,no,0,0,24,29,0,A61P17/00;;C07D413/14;;C07D405/14;;C07D413/14;;C07D405/14;;A61P17/00;;A61K31/5377;;A61K31/4184;;C07D403/04;;A61K31/5377;;A61K9/0014;;A61K31/4184;;A61P17/00;;A61P29/00;;C07D405/14;;C07D413/14;;A61P17/00;;A61K45/06;;C07D413/14,A61P17/00;;A61K31/4453;;A61K31/5377;;C07D405/14;;C07D413/14,,0,0,,,,PENDING
439,AR,A1,AR 120835 A1,070-789-646-889-006,2022-03-23,2022,AR P200103572 A,2020-12-18,US 201962951030 P,2019-12-20,COMPUESTOS QUÍMICOS,"Bencimidazoles de la fórmula (1) y sales de estos aceptables desde el punto de vista farmacéutico, en donde R¹ a R⁶ son como se definen en la descripción; su uso en la medicina; composiciones que los contienen; procesos para su preparación; e intermediarios usados en dichos procesos. Los bencimidazoles de la fórmula (1) son inhibidores de ITK y, por lo tanto, son potencialmente útiles en el tratamiento de diversos trastornos, que incluyen dermatitis atópica. Reivindicación 1: Un compuesto caracterizado por la fórmula (1) o una sal de este aceptable desde el punto de vista farmacéutico, o un solvato de dicho compuesto o dicha sal aceptable desde el punto de vista farmacéutico, en donde: cada R¹ es independientemente H o F; R² es H, C₁₋₄alquilo, hidroxiC₁₋₄alquilo, C₁₋₄alcoxiC₁₋₄alquilo o C₁₋₄alquilo sustituido con uno, dos o tres F; cada R³ es independientemente H, F, C₃₋₅cicloalquilo, C₁₋₄alquilo o C₁₋₄alquilo sustituido con uno, dos o tres F; o ambos R³, junto con el átomo de carbono al que están unidos, forman C₃₋₅cicloalquilo; R⁴ se selecciona de los compuestos de fórmula (2) ó (3), en donde cada heterociclo se sustituye opcionalmente con uno o dos sustituyentes seleccionados independientemente de oxo, C₁₋₄alquilo, hidroxiC₁₋₄alquilo y C₁₋₄alquilo sustituido con uno, dos o tres F; y R⁵ y R⁶ son independientemente H; halógeno; OH; CN; C₁₋₆alquilo; hidroxiC₁₋₆alquilo; C₁₋₄alcoxiC₁₋₆alquilo; C₁₋₆alquilo sustituido con uno, dos o tres F; C₁₋₆alcoxi; o C₁₋₆alcoxi sustituido con C₁₋₄alcoxi.",PFIZER,BAGLEY SCOTT WILLIAM;;CASIMIRO-GARCIA AGUSTIN;;CHENG XIAYUN;;DAVOREN JENNIFER ELIZABETH;;DENNY RAJIAH ALDRIN;;GERSTENBERGER BRIAN STEPHEN;;LOVERING FRANK ELDRIDGE;;PARIKH MIHIR DINESHKUMAR;;STROHBACH JOSEPH WALTER;;TRUJILLO JOHN ISIDRO,,https://lens.org/070-789-646-889-006,Patent Application,no,0,0,1,29,0,,C07D405/14;;A61K31/4453;;A61K31/5377;;A61P17/00;;C07D413/14,,0,0,,,,PENDING
440,DO,A,DO P2022000130 A,110-526-435-339-447,2022-07-31,2022,DO 2022000130 A,2022-06-17,US 201962951030 P;;US 202063108602 P;;IB 2020062036 W,2019-12-20,DERIVADOS DE BENZIMIDAZOL,"La invención se refiere a bencimidazoles de la Fórmula (I) y sales de estos aceptables desde el punto de vista farmacéutico, en donde R1 a R6 son como se definen en la descripción; a su uso en la medicina; a composiciones que los contienen; a procesos para su preparación; y a intermediarios usados en dichos procesos. Los bencimidazoles de la Fórmula (I) son inhibidores de ITK y, por lo tanto, son potencialmente útiles en el tratamiento de diversos trastornos, que incluyen dermatitis atópica.",PFIZER,SCOTT WILLIAM BAGLEY;;JOHN ISIDRO TRUJILLO;;JENNIFER ELIZABETH DAVOREN;;RAJIAH ALDRIN DENNY;;AGUSTIN CASIMIRO-GARCIA;;MIHIR DINESHKUMAR PARIKH;;XIAYUN CHENG;;BRIAN STEPHEN GERSTENBERGER;;FRANK ELDRIDGE LOVERING;;JOSEPH WALTER STROHBARCH,,https://lens.org/110-526-435-339-447,Patent Application,no,0,0,24,29,0,A61P17/00;;C07D413/14;;C07D405/14;;C07D413/14;;C07D405/14;;A61P17/00;;A61K31/5377;;A61K31/4184;;C07D403/04;;A61K31/5377;;A61K9/0014;;A61K31/4184;;A61P17/00;;A61P29/00;;C07D405/14;;C07D413/14;;A61P17/00;;A61K45/06;;C07D413/14,A61K31/4453;;A61K31/5377;;A61P17/00;;C07D405/14;;C07D413/14,,0,0,,,,PENDING
441,KR,A,KR 20220118525 A,137-508-262-837-050,2022-08-25,2022,KR 20227025150 A,2020-12-16,US 201962951030 P;;US 202063108602 P;;IB 2020062036 W,2019-12-20,벤즈이미다졸 유도체,"본 발명은 하기 화학식 (I)의 벤즈이미다졸 및 이의 약학적으로 허용되는 염; 의약에서의 이의 용도; 이를 포함하는 조성물; 이의 제조 방법; 및 이러한 방법에 사용되는 중간체에 관한 것이다. 화학식 (I)의 벤즈이미다졸은 ITK 억제제이며, 따라서 아토피 피부염을 비롯한 광범위한 질환의 치료에 잠재적으로 유용하다: JPEGpct00308.jpg6284 상기 식에서, R1 내지 R6은 본 명세서에 정의된 바와 같다.",PFIZER,BAGLEY SCOTT WILLIAM;;CASIMIRO GARCIA AGUSTIN;;CHENG XIAYUN;;DAVOREN JENNIFER ELIZABETH;;DENNY RAJIAH ALDRIN;;GERSTENBERGER BRIAN STEPHEN;;LOVERING FRANK ELDRIDGE;;PARIKH MIHIR DINESHKUMAR;;STROHBACH JOSEPH WALTER;;TRUJILLO JOHN ISIDRO,,https://lens.org/137-508-262-837-050,Patent Application,no,0,0,24,29,0,A61P17/00;;C07D413/14;;C07D405/14;;C07D413/14;;C07D405/14;;A61P17/00;;A61K31/5377;;A61K31/4184;;C07D403/04;;A61K31/5377;;A61K9/0014;;A61K31/4184;;A61P17/00;;A61P29/00;;C07D405/14;;C07D413/14;;A61P17/00;;A61K45/06;;C07D413/14,C07D403/04;;A61K9/00;;A61K31/4184;;A61K31/5377;;A61P17/00;;A61P29/00;;C07D405/14;;C07D413/14,,0,0,,,,DISCONTINUED
442,EP,A1,EP 4077316 A1,050-785-056-911-580,2022-10-26,2022,EP 20828341 A,2020-12-16,US 201962951030 P;;US 202063108602 P;;IB 2020062036 W,2019-12-20,BENZIMIDAZOLE DERIVATIVES,,PFIZER,BAGLEY SCOTT WILLIAM;;CASIMIRO-GARCIA AGUSTIN;;CHENG XIAYUN;;DAVOREN JENNIFER ELIZABETH;;DENNY RAJIAH ALDRIN;;GERSTENBERGER BRIAN STEPHEN;;LOVERING FRANK ELDRIDGE;;PARIKH MIHIR DINESHKUMAR;;STROHBACH JOSEPH WALTER;;TRUJILLO JOHN ISIDRO,PFIZER INC. (2023-04-05),https://lens.org/050-785-056-911-580,Patent Application,yes,0,0,24,29,0,A61P17/00;;C07D413/14;;C07D405/14;;C07D413/14;;C07D405/14;;A61P17/00;;A61K31/5377;;A61K31/4184;;C07D403/04;;A61K31/5377;;A61K9/0014;;A61K31/4184;;A61P17/00;;A61P29/00;;C07D405/14;;C07D413/14;;A61P17/00;;A61K45/06;;C07D413/14,C07D405/14;;A61K31/4453;;A61K31/5377;;A61P17/00;;C07D413/14,,0,0,,,,PENDING
443,US,A1,US 2023/0280220 A1,085-776-681-106-654,2023-09-07,2023,US 202318301475 A,2023-04-17,US 202318301475 A;;US 202017126385 A;;US 202063108602 P;;US 201962951030 P,2019-12-20,Benzimidazole Derivative Compounds and Uses Thereof,"The invention relates to benzimidazoles of Formula (1) and pharmaceutically acceptable salts thereof, wherein R 1 to R 6 are as defined in the description; to their use in medicine; to compositions containing them; to processes for their preparation; and to intermediates used in such processes. The benzimidazoles of Formula (1) are ITK inhibitors and are therefore potentially useful in the treatment of a wide range of disorders including, atopic dermatitis.",PFIZER,BAGLEY SCOTT WILLIAM;;CASIMIRO GARCIA AGUSTIN;;CHENG XIAYUN;;DAVOREN JENNIFER ELIZABETH;;DENNY RAJIAH ALDRIN;;GERSTENBERGER BRIAN STEPHEN;;LOVERING FRANK ELDRIDGE;;PARIKH MIHIR DINESHKUMAR;;STROHBACH JOSEPH WALTER;;TRUJILLO JOHN ISIDRO,,https://lens.org/085-776-681-106-654,Patent Application,yes,0,0,1,29,0,G01N23/207;;G01N2223/62;;A61K31/5377;;A61K31/4184;;G01N23/207;;G01L1/25,G01N23/207;;G01L1/25,,0,0,,,,PENDING
444,BR,A2,BR 112022011838 A2,111-052-036-524-332,2022-08-30,2022,BR 112022011838 A,2020-12-16,IB 2020062036 W;;US 202063108602 P;;US 201962951030 P,2019-12-20,DERIVADOS DE BENZIMIDAZOL,"DERIVADOS DE BENZIMIDAZOL. A presente invenção refere-se a benzimidazóis de Fórmula (I) e sais farmaceuticamente aceitáveis dos mesmos, em que R1 a R6 são como definidos no relatório descritivo; ao seu uso em medicina; a composições contendo os mesmos, a processos para a preparação dos mesmos; e a intermediários usados em tais processos. Os benzimidazóis de Fórmula (I) são inibidores de ITK e são, portanto, potencialmente úteis no tratamento de uma ampla gama de distúrbios, incluindo dermatite atópica.",PFIZER,SCOTT WILLIAM BAGLEY;;AGUSTIN CASIMIRO-GARCIA;;XIAYUN CHENG;;JENNIFER ELIZABETH DAVOREN;;RAJIAH ALDRIN DENNY;;BRIAN STEPHEN GERSTENBERGER;;FRANK ELDRIDGE LOVERING;;MIHIR DINESHKUMAR PARIKH;;JOSEPH WALTER STROHBACH;;JOHN ISIDRO TRUJILLO,PFIZER INC. (US) (2023-07-25),https://lens.org/111-052-036-524-332,Patent Application,no,0,0,24,29,0,A61P17/00;;C07D413/14;;C07D405/14;;C07D413/14;;C07D405/14;;A61P17/00;;A61K31/5377;;A61K31/4184;;C07D403/04;;A61K31/5377;;A61K9/0014;;A61K31/4184;;A61P17/00;;A61P29/00;;C07D405/14;;C07D413/14;;A61P17/00;;A61K45/06;;C07D413/14,C07D405/14;;A61K31/4453;;A61K31/5377;;A61P17/00;;C07D413/14,,0,0,,,,DISCONTINUED
445,WO,A1,WO 2021/124155 A1,028-429-520-458-305,2021-06-24,2021,IB 2020062036 W,2020-12-16,US 201962951030 P;;US 202063108602 P,2019-12-20,BENZIMIDAZOLE DERIVATIVES,"The invention relates to benzimidazoles of Formula (I) and pharmaceutically acceptable salts thereof, wherein R 1 to R 6 are as defined in the description; to their use in medicine; to compositions containing them; to processes for their preparation; and to intermediates used in such processes. The benzimidazoles of Formula (I) are ITK inhibitors and are therefore potentially useful in the treatment of a wide range of disorders including, atopic dermatitis.",PFIZER,BAGLEY SCOTT WILLIAM;;CASIMIRO-GARCIA AGUSTIN;;CHENG XIAYUN;;DAVOREN JENNIFER ELIZABETH;;DENNY RAJIAH ALDRIN;;GERSTENBERGER BRIAN STEPHEN;;LOVERING FRANK ELDRIDGE;;PARIKH MIHIR DINESHKUMAR;;STROHBACH JOSEPH WALTER;;TRUJILLO JOHN ISIDRO,,https://lens.org/028-429-520-458-305,Patent Application,yes,2,1,24,29,0,A61P17/00;;C07D413/14;;C07D405/14;;C07D413/14;;C07D405/14;;A61P17/00;;A61K31/5377;;A61K31/4184;;C07D403/04;;A61K31/5377;;A61K9/0014;;A61K31/4184;;A61P17/00;;A61P29/00;;C07D405/14;;C07D413/14;;A61P17/00;;A61K45/06;;C07D413/14,C07D405/14;;A61K31/4453;;A61K31/5377;;A61P17/00;;C07D413/14,,33,20,021-758-616-191-580;;015-469-939-643-037;;010-459-799-559-27X;;150-211-289-209-998;;101-736-485-538-451;;018-213-579-233-535;;044-764-760-426-677;;005-704-796-152-875;;014-497-444-193-822;;112-690-224-017-752;;051-637-894-718-95X;;026-939-530-330-687;;106-352-306-591-089;;163-282-666-950-723;;057-764-157-227-018;;088-067-559-098-969;;072-311-552-536-365;;124-143-008-652-738;;018-540-614-214-259;;146-847-819-259-175,10.1517/13543771003674409;;20218931;;23815605;;10.1517/13543784.2013.813932;;10.1038/sj.jid.5700270;;16845411;;pmc5405702;;28390479;;10.1016/j.jaci.2017.03.001;;10.1016/j.jaci.2017.01.011;;pmc5360469;;10.4049/jimmunol.1601202;;28213500;;15323564;;10.1021/bi049428r;;28658541;;10.1111/imr.12545;;10.1002/art.30564;;21792838;;31028434;;10.1007/s00281-019-00742-7;;pmc6505509;;pmc2770952;;19689375;;10.2174/156802609789044443;;1151699;;10.1002/jps.2600640805;;2891813;;10.1111/j.2042-7158.1987.tb05117.x;;10.1016/b978-0-08-052349-1.00237-7;;10.1002/0471264180.or058.01;;16836305;;10.1021/cr040679f;;10.1016/0168-3659(84)90010-5;;10.1021/ja00316a077;;10.1021/acs.oprd.9b00195;;10.1021/acs.jmedchem.6b00850;;27766865;;29944371;;10.1021/acs.jmedchem.8b00633,"HO YIN LO: ""Itk inhibitors: a patent review"", EXPERT OPINION ON THERAPEUTIC PATENTS, vol. 20, no. 4, 1 April 2010 (2010-04-01), GB, pages 459 - 469, XP055227947, ISSN: 1354-3776, DOI: 10.1517/13543771003674409;;BENECKE H ET AL., EXPERT OPIN. INVEST. DRUGS., vol. 22, 2013, pages 1167 - 1179;;BISSONETTE RPAPP KA ET AL., BRIT. J. DERM., vol. 175, 2016, pages 902 - 911;;BOTCHKAREV VAYAAR MPETERS EMJ ET AL., J. INVEST. DERMATOLOGY., vol. 126, 2006, pages 1719 - 1727;;BRUNNER PM ET AL., J ALLERGY CLIN IMMUNOL, vol. 139, no. 4S, 2017, pages S65 - S76;;KAPNICK SMSTINCHCOMBE JC ET AL., IMMUNOL., vol. 198, 2017, pages 2699 - 2711;;LIN TAMCLNTYRE KW ET AL., BIOCHEMISTRY, vol. 43, 2004, pages 11056 - 11062;;MATSUMURA STERAO M ET AL., J. DERM. SCIENCE, vol. 78, 2015, pages 215 - 223;;OTSUKA ANOMURA T ET AL., IMMUNOLOGICAL REVIEWS, vol. 278, 2017, pages 246 - 262;;RAYCHAUDHURI SPRAYCHAUDHURI SK ET AL., ARTHRITIS & RHEUMATISM, vol. 63, 2011, pages 3243 - 3252;;SABAT RWOLK K ET AL., SEMINARS IN IMMUNOPATHOLOGY, vol. 41, 2019, pages 359 - 377;;SAHU NAUGUST A, CURR. TOP. MED. CHEM., vol. 9, 2009, pages 690 - 703;;VON BONIN ARAUSCH A ET AL., EXP. DERM., vol. 20, 2010, pages 41 - 47;;YAMAGUCHI JAIHARA M ET AL., J. DERMATOL. SCIENCE, vol. 53, 2008, pages 48 - 54;;STAHLWERMUTH: ""Handbook of Pharmaceutical Salts: Properties, Selection, and Use"", 2002, WILEY-VCH;;K. R. MORRIS: ""Polymorphism in Pharmaceutical Solids"", 1995, MACK PUBLISHING COMPANY;;O. ALMARSSONM. J. ZAWOROTKO, CHEM COMMUN, vol. 17, 2004, pages 1889 - 1896;;HALEBLIAN, J PHARM SCI, vol. 64, no. 8, August 1975 (1975-08-01), pages 1269 - 1288;;N. H. HARTSHORNEA. STUART: ""Crystals and the Polarizing Microscope"", 1970;;T HIGUCHIW STELLA: ""Pro-drugs as Novel Delivery Systems"", ACS SYMPOSIUM SERIES, vol. 14;;TAKEUCHI, H. ET AL.: ""Enhancement of the dissolution rate of a poorly water-soluble drug (tolbutamide) by a spray-drying solvent deposition method and disintegrants"", J. PHARM. PHARMACOL., vol. 39, 1987, pages 769 - 773;;H BUNDGAARD: ""Design of Prodrugs"", 1985, ELSEVIER;;SMITH, ROGER M.: ""Chromatographic Science Series"", vol. 75, 1998, LOUGHBOROUGH UNIVERSITY, article ""Supercritical Fluid Chromatography with Packed Columns"", pages: 223 - 249;;E. L. ELIELS. H. WILEN: ""Stereochemistry of Organic Compounds"", 1994, WILEY;;THEODORA W GREENEPETER G M WUTS: ""Greene's Protective Groups in Organic Synthesis"", 2014, JOHN WILEY AND SONS;;MANDER, L. N.: ""Comprehensive Organic Synthesis"", vol. 8, 1991, PERGAMON, pages: 489 - 521;;CHARETTE, A. B.BEAUCHEMIN, A: ""Simmons-Smith Cyclopropanation Reaction"", ORG. REACT., vol. 58, 2001, pages 1 - 415, XP002788506, DOI: 10.1002/0471264180.or058.01;;CARON, S.DUGGER, R. W.GUT RUGGERI, S.RAGAN, J. A.BROWN RIPIN, D. H., CHEM. REV., vol. 106, 2006, pages 2943 - 2989;;MERRITT ET AL.: ""Diffusion Apparatus for Skin Penetration"", J OF CONTROLLED RELEASE, vol. 1, 1984, pages 161 - 162, XP023843582, DOI: 10.1016/0168-3659(84)90010-5;;EVANS, D. A ET AL., J. AM. CHEM. SOC., vol. 106, 1984, pages 1154 - 1156;;BERNHARDSON, D. J.WIDLICKA, D. W.SINGER, R. A., ORG. PROCESS RES. DEV., vol. 23, 2019, pages 1538 - 1551;;SKERRATT SE ET AL., J. MED. CHEM., vol. 59, no. 22, 2016, pages 10084 - 10099;;BAGAL SK ET AL., J. MED. CHEM., vol. 61, no. 15, 2018, pages 6779 - 6800",PENDING
446,US,A1,US 2021/0188829 A1,014-083-674-293-44X,2021-06-24,2021,US 202017126358 A,2020-12-18,US 202017126358 A;;US 202063108602 P;;US 201962951030 P,2019-12-20,Chemical Compounds,"The invention relates to benzimidazoles of Formula (I) and pharmaceutically acceptable salts thereof, wherein R 1 to R 6 are as defined in the description; to their use in medicine; to compositions containing them; to processes for their preparation; and to intermediates used in such processes. The benzimidazoles of Formula (I) are ITK inhibitors and are therefore potentially useful in the treatment of a wide range of disorders including, atopic dermatitis.",PFIZER,BAGLEY SCOTT WILLIAM;;CASIMIRO-GARCIA AGUSTIN;;CHENG XIAYUN;;DAVOREN JENNIFER ELIZABETH;;DENNY RAJIAH ALDRIN;;GERSTENBERGER BRIAN STEPHEN;;LOVERING FRANK ELDRIDGE;;PARIKH MIHIR DINESHKUMAR;;STROHBACH JOSEPH WALTER;;TRUJILLO JOHN ISIDRO,,https://lens.org/014-083-674-293-44X,Patent Application,yes,0,1,24,29,0,A61P17/00;;C07D413/14;;C07D405/14;;C07D413/14;;C07D405/14;;A61P17/00;;A61K31/5377;;A61K31/4184;;C07D403/04;;A61K31/5377;;A61K9/0014;;A61K31/4184;;A61P17/00;;A61P29/00;;C07D405/14;;C07D413/14;;A61P17/00;;A61K45/06;;C07D413/14,C07D413/14;;A61K45/06;;A61P17/00,,1,0,,,no new references cited by the Examiner.,ACTIVE
447,AU,A1,AU 2020/405536 A1,006-797-283-131-229,2022-07-14,2022,AU 2020/405536 A,2020-12-16,US 201962951030 P;;US 202063108602 P;;IB 2020062036 W,2019-12-20,Benzimidazole derivatives,"The invention relates to benzimidazoles of Formula (I) and pharmaceutically acceptable salts thereof, wherein R",PFIZER,BAGLEY SCOTT WILLIAM;;CASIMIRO-GARCIA AGUSTIN;;CHENG XIAYUN;;DAVOREN JENNIFER ELIZABETH;;DENNY RAJIAH ALDRIN;;GERSTENBERGER BRIAN STEPHEN;;LOVERING FRANK ELDRIDGE;;PARIKH MIHIR DINESHKUMAR;;STROHBACH JOSEPH WALTER;;TRUJILLO JOHN ISIDRO,,https://lens.org/006-797-283-131-229,Patent Application,no,0,0,24,29,0,A61P17/00;;C07D413/14;;C07D405/14;;C07D413/14;;C07D405/14;;A61P17/00;;A61K31/5377;;A61K31/4184;;C07D403/04;;A61K31/5377;;A61K9/0014;;A61K31/4184;;A61P17/00;;A61P29/00;;C07D405/14;;C07D413/14;;A61P17/00;;A61K45/06;;C07D413/14,C07D405/14;;A61K31/4453;;A61K31/5377;;A61P17/00;;C07D413/14,,0,0,,,,ACTIVE
448,CN,A,CN 115087655 A,130-459-490-752-777,2022-09-20,2022,CN 202080096751 A,2020-12-16,US 201962951030 P;;US 202063108602 P;;IB 2020062036 W,2019-12-20,Benzimidazole derivatives,"The present invention relates to benzimidazoles of formula (I) and pharmaceutically acceptable salts thereof, wherein R1 to R6 are as defined in the specification; their use in medicine; compositions comprising them; processes for their preparation; and intermediates used in such processes. The benzimidazoles of formula (I) are ITK inhibitors, and thus may be useful in the treatment of various disorders, including atopic dermatitis.",PFIZER,BAGLEY SCOTT WILLIAM;;CASIMIRO-GARCIA AGUSTIN;;CHENG XU;;DAVOREN JENNIFER ELIZABETH;;DENNY RICHARD A;;GERSTENBERGER BRIAN S;;LOVERING FRANK ELDRIDGE;;PARIKH MIHIR D;;STROHBACH JOSEPH WALTER;;TRUJILLO JOHN I,,https://lens.org/130-459-490-752-777,Patent Application,no,2,0,24,29,0,A61P17/00;;C07D413/14;;C07D405/14;;C07D413/14;;C07D405/14;;A61P17/00;;A61K31/5377;;A61K31/4184;;C07D403/04;;A61K31/5377;;A61K9/0014;;A61K31/4184;;A61P17/00;;A61P29/00;;C07D405/14;;C07D413/14;;A61P17/00;;A61K45/06;;C07D413/14,C07D405/14;;A61K31/4453;;A61K31/5377;;A61P17/00;;C07D413/14,,1,1,021-758-616-191-580,10.1517/13543771003674409;;20218931,"HO YIN LO: ""Itk inhibitors: a patent review"", 《EXPERT OPIN. THER. PATENTS》, vol. 20, no. 4, pages 459 - 469, XP055227947, DOI: 10.1517/13543771003674409",PENDING
449,CA,A1,CA 3103120 A1,137-633-435-535-337,2021-06-20,2021,CA 3103120 A,2020-12-17,US 201962951030 P;;US 202063108602 P,2019-12-20,CHEMICAL COMPOUNDS,"Abstract The invention relates to benzimidazoles of Formula (I) R4 R3 -)r0 R3 R2 H-R5 R6 )CH3 R1 and pharmaceutically acceptable salts thereof, wherein R1 to R6 are as defined in the description; to their use in medicine; to compositions containing them; to processes for their preparation; and to intermediates used in such processes. The benzimidazoles of Formula (I) are ITK inhibitors and are therefore potentially useful in the treatment of a wide range of disorders including, atopic dermatitis. Date Recue/Date Received 2020-12-17",PFIZER,BAGLEY SCOTT WILLIAM;;CASIMIRO-GARCIA AGUSTIN;;CHENG XIAYUN;;DAVOREN JENNIFER ELIZABETH;;DENNY RAJIAH ALDRIN;;GERSTENBERGER BRIAN STEPHEN;;LOVERING FRANK ELDRIDGE;;PARIKH MIHIR DINESHKUMAR;;STROHBACH JOSEPH WALTER;;TRUJILLO JOHN ISIDRO,,https://lens.org/137-633-435-535-337,Patent Application,no,0,0,24,29,0,A61P17/00;;C07D413/14;;C07D405/14;;C07D413/14;;C07D405/14;;A61P17/00;;A61K31/5377;;A61K31/4184;;C07D403/04;;A61K31/5377;;A61K9/0014;;A61K31/4184;;A61P17/00;;A61P29/00;;C07D405/14;;C07D413/14;;A61P17/00;;A61K45/06;;C07D413/14,C07D403/04;;A61K31/4184;;A61K31/5377;;A61P17/00,,0,0,,,,PENDING
450,US,A1,US 2023/0316370 A1,183-757-209-992-292,2023-10-05,2023,US 202217656915 A,2022-03-29,US 202217656915 A,2022-03-29,SYSTEM AND METHOD FOR GENERATING PERSONALIZED EFFICIENCY RECOMMENDATIONS,"A system includes: a processor; and memory including instructions that, when executed by the processor, cause the processor to: receive personalization profile parameters from a user of a relevant resource device; calculate a representative utilization of the relevant resource device based on the personalization profile parameters; and generate the recommendation based on the representative utilization and the personalization profile parameters.",MICROSOFT TECHNOLOGY LICENSING LLC,KINI RITESH;;TIONG EDWARD;;THOMPSON DOUG;;BERG BRODY;;JANSKY MARTIN;;RIVERA MARK TIMOTHY CARREON;;VELAGIC JENNIFER TAMARA;;NEBOSHYNSKY LINDSAY;;TRAN TONY;;GYORKI EVA;;CHENG JULIA A;;CHOI LEENA;;SANDERS JAMES,MICROSOFT TECHNOLOGY LICENSING LLC (2022-03-29),https://lens.org/183-757-209-992-292,Patent Application,yes,0,0,2,2,0,G06Q30/0631;;G06Q30/0621;;G06F11/3006;;G06F3/0482;;G06Q30/0201;;G06Q30/0631,G06Q30/06;;G06F3/0482;;G06Q30/02,,0,0,,,,PENDING
451,WO,A1,WO 2023/191918 A1,086-219-842-497-911,2023-10-05,2023,US 2023/0010538 W,2023-01-11,US 202217656915 A,2022-03-29,SYSTEM AND METHOD FOR GENERATING PERSONALIZED EFFICIENCY RECOMMENDATIONS,"A system includes: a processor; and memory including instructions that, when executed by the processor, cause the processor to: receive personalization profile parameters from a user of a relevant resource device; calculate a representative utilization of the relevant resource device based on the personalization profile parameters; and generate the recommendation based on the representative utilization and the personalization profile parameters.",MICROSOFT TECHNOLOGY LICENSING LLC,KINI RITESH;;TIONG EDWARD;;THOMPSON DOUG;;BERG BRODY;;JANSKY MARTIN;;RIVERA MARK TIMOTHY CARREON;;VELAGIC JENNIFER TAMARA;;NEBOSHYNSKY LINDSAY;;TRAN TONY;;GYORKI EVA;;CHENG JULIA A;;CHOI LEENA;;SANDERS JAMES,,https://lens.org/086-219-842-497-911,Patent Application,yes,2,0,2,2,0,G06Q30/0631;;G06Q30/0621;;G06F11/3006;;G06F3/0482;;G06Q30/0201;;G06Q30/0631,G06F11/30;;G06Q30/0601,,1,1,105-764-571-398-057,10.1145/3419111.3421305,"BILAL MUHAMMAD ET AL: ""Finding the right cloud configuration for analytics clusters"", PROCEEDINGS OF THE 11TH ACM SYMPOSIUM ON CLOUD COMPUTING, ACMPUB27, NEW YORK, NY, USA, 12 October 2020 (2020-10-12), pages 208 - 222, XP058477973, ISBN: 978-1-4503-8137-6, DOI: 10.1145/3419111.3421305",PENDING
452,TW,A,TW 202130634 A,071-787-958-311-091,2021-08-16,2021,TW 109144868 A,2020-12-18,US 201962951030 P;;US 202063108602 P,2019-12-20,Chemical compounds,"The invention relates to benzimidazoles of Formula (I) and pharmaceutically acceptable salts thereof, wherein R1 to R6 are as defined in the description; to their use in medicine; to compositions containing them; to processes for their preparation; and to intermediates used in such processes. The benzimidazoles of Formula (I) are ITK inhibitors and are therefore potentially useful in the treatment of a wide range of disorders including, atopic dermatitis.",PFIZER,BAGLEY SCOTT WILLIAM;;CASIMIRO-GARCIA AGUSTIN;;CHENG XIA-YUN;;DAVOREN JENNIFER ELIZABETH;;DENNY RAJIAH ALDRIN;;GERSTENBERGER BRIAN STEPHEN;;LOVERING FRANK ELDRIDGE;;PARIKH MIHIR DINESHKUMAR;;STROHBACH JOSEPH WALTER;;TRUJILLO JOHN ISIDRO,,https://lens.org/071-787-958-311-091,Patent of Addition,no,0,0,24,29,0,A61P17/00;;C07D413/14;;C07D405/14;;C07D413/14;;C07D405/14;;A61P17/00;;A61K31/5377;;A61K31/4184;;C07D403/04;;A61K31/5377;;A61K9/0014;;A61K31/4184;;A61P17/00;;A61P29/00;;C07D405/14;;C07D413/14;;A61P17/00;;A61K45/06;;C07D413/14,C07D403/04;;A61K31/416;;A61K31/4184;;A61K31/5377;;A61P17/00;;C07D413/14,,0,0,,,,ACTIVE
453,EP,A2,EP 2212313 A2,118-370-865-604-821,2010-08-04,2010,EP 08841788 A,2008-10-20,US 2008/0011927 W;;US 15107 P,2007-10-24,SYNTHESIS AND CRYSTALLINE FORMS OF CB-1 ANTAGONIST/INVERSE AGONIST,,MERCK SHARP & DOHME,CAMPOS KEVIN R;;CHEN CHENG-YI;;FOLEY JENNIFER R;;HILLIER MICHAEL;;JEN WENDY S;;KASSIM AMUDE M;;KLAPARS ARTIS;;PERESYPKIN ANDREY V;;ROSNER THORSTEN;;SAVARIN CECILE G;;TUDGE MATTHEW;;VARIANKAVAL NARAYAN;;VYDRA VICKY;;ZHAO DALIAN,,https://lens.org/118-370-865-604-821,Patent Application,yes,0,0,7,7,0,A61P1/00;;A61P1/10;;A61P1/14;;A61P1/16;;A61P3/04;;A61P3/10;;A61P11/06;;A61P25/00;;A61P25/06;;A61P25/08;;A61P25/14;;A61P25/16;;A61P25/18;;A61P25/22;;A61P25/28;;A61P25/30;;A61P43/00;;C07D271/113;;C07D271/113;;C07C255/53;;C07C255/53;;C07D413/10;;C07D413/10,C07D413/10;;A61K31/4245;;A61P25/00;;C07D271/113,,1,0,,,See references of WO 2009054923A2,DISCONTINUED
454,WO,A3,WO 2009/054923 A3,068-949-954-772-297,2009-06-18,2009,US 2008/0011927 W,2008-10-20,US 15107 P,2007-10-24,SYNTHESIS AND CRYSTALLINE FORMS OF CB-1 ANTAGONIST/INVERSE AGONIST,"The present invention relates to a process for producing crystalline 3-[(1 S )-1-(1-{( S )-(4-chlorophenyl)[3-(5-oxo-4,5-dihydro-1,3,4-oxadiazol-2-yl)phenyl]methyl} azetidin-3-yl)-2-fluoro-2-methylpropyl]-5-fluorobenzonitrile, and novel salts, solvates, hydrates and polymorphs thereof.",MERCK & CO INC;;CAMPOS KEVIN R;;CHEN CHENG-YI;;FOLEY JENNIFER R;;HILLIER MICHAEL;;JEN WENDY S;;KASSIM AMUDE M;;KLAPARS ARTIS;;PERESYPKIN ANDREY V;;ROSNER THORSTEN;;SAVARIN CECILE G;;TUDGE MATTHEW;;VARIANKAVAL NARAYAN;;VYDRA VICKY;;ZHAO DALIAN,CAMPOS KEVIN R;;CHEN CHENG-YI;;FOLEY JENNIFER R;;HILLIER MICHAEL;;JEN WENDY S;;KASSIM AMUDE M;;KLAPARS ARTIS;;PERESYPKIN ANDREY V;;ROSNER THORSTEN;;SAVARIN CECILE G;;TUDGE MATTHEW;;VARIANKAVAL NARAYAN;;VYDRA VICKY;;ZHAO DALIAN,,https://lens.org/068-949-954-772-297,Search Report,yes,3,0,7,7,0,A61P1/00;;A61P1/10;;A61P1/14;;A61P1/16;;A61P3/04;;A61P3/10;;A61P11/06;;A61P25/00;;A61P25/06;;A61P25/08;;A61P25/14;;A61P25/16;;A61P25/18;;A61P25/22;;A61P25/28;;A61P25/30;;A61P43/00;;C07D271/113;;C07D271/113;;C07C255/53;;C07C255/53;;C07D413/10;;C07D413/10,C07D413/10;;A61K31/4245;;A61P25/00;;C07D271/113,,1,1,062-827-486-482-77X,16995705;;10.1021/jo061147x,"HILLIER, MICHAEL C. ET AL: ""A One-Pot Preparation of 1,3-Disubstituted Azetidines"", JOURNAL OF ORGANIC CHEMISTRY, vol. 71, no. 20, 29 September 2006 (2006-09-29), pages 7885 - 7887, XP002511522, ISSN: 0022-3263",PENDING
455,CA,A1,CA 2703465 A1,111-454-114-841-627,2009-04-30,2009,CA 2703465 A,2008-10-20,US 15107 P;;US 2008/0011927 W,2007-10-24,SYNTHESIS AND CRYSTALLINE FORMS OF CB-1 ANTAGONIST/INVERSE AGONIST,"The present invention relates to a process for producing crystalline 3-[(1S)-1-(1-{(S)-(4-chlorophenyl)[3-(5-oxo-4,5-dihydro-1,3,4-oxadiazol-2-yl)phenyl]methyl} azetidin-3-yl)-2-fluoro-2-methylpropyl]-5-fluorobenzonitrile, and novel salts, solvates, hydrates and polymorphs thereof.",MERCK SHARP & DOHME,CAMPOS KEVIN R;;CHEN CHENG-YI;;FOLEY JENNIFER R;;HILLIER MICHAEL;;JEN WENDY S;;KASSIM AMUDE M;;KLAPARS ARTIS;;PERESYPKIN ANDREY V;;ROSNER THORSTEN;;SAVARIN CECILE G;;TUDGE MATTHEW;;VARIANKAVAL NARAYAN;;VYDRA VICKY;;ZHAO DALIAN,,https://lens.org/111-454-114-841-627,Patent Application,no,0,0,7,7,0,A61P1/00;;A61P1/10;;A61P1/14;;A61P1/16;;A61P3/04;;A61P3/10;;A61P11/06;;A61P25/00;;A61P25/06;;A61P25/08;;A61P25/14;;A61P25/16;;A61P25/18;;A61P25/22;;A61P25/28;;A61P25/30;;A61P43/00;;C07D271/113;;C07D271/113;;C07C255/53;;C07C255/53;;C07D413/10;;C07D413/10,C07D413/10;;A61K31/4245;;A61P25/00;;C07D271/113,,0,0,,,,DISCONTINUED
456,AU,A1,AU 2008/317482 A1,173-812-109-788-08X,2009-04-30,2009,AU 2008/317482 A,2008-10-20,US 15107 P;;US 2008/0011927 W,2007-10-24,Synthesis and crystalline forms of CB-1 antagonist/inverse agonist,,MERCK SHARP & DOHME,JEN WENDY S;;TUDGE MATTHEW;;VYDRA VICKY;;SAVARIN CECILE G;;VARIANKAVAL NARAYAN;;HILLIER MICHAEL;;FOLEY JENNIFER R;;KASSIM AMUDE M;;KLAPARS ARTIS;;ROSNER THORSTEN;;CAMPOS KEVIN R;;PERESYPKIN ANDREY V;;ZHAO DALIAN;;CHEN CHENG-YI,,https://lens.org/173-812-109-788-08X,Patent Application,no,0,0,7,7,0,A61P1/00;;A61P1/10;;A61P1/14;;A61P1/16;;A61P3/04;;A61P3/10;;A61P11/06;;A61P25/00;;A61P25/06;;A61P25/08;;A61P25/14;;A61P25/16;;A61P25/18;;A61P25/22;;A61P25/28;;A61P25/30;;A61P43/00;;C07D271/113;;C07D271/113;;C07C255/53;;C07C255/53;;C07D413/10;;C07D413/10,A61K31/4245;;A61P25/00;;C07D271/113;;C07D413/10,,0,0,,,,DISCONTINUED
457,WO,A2,WO 2009/054923 A2,139-701-452-294-058,2009-04-30,2009,US 2008/0011927 W,2008-10-20,US 15107 P,2007-10-24,SYNTHESIS AND CRYSTALLINE FORMS OF CB-1 ANTAGONIST/INVERSE AGONIST,"The present invention relates to a process for producing crystalline 3-[(1 S )-1-(1-{( S )-(4-chlorophenyl)[3-(5-oxo-4,5-dihydro-1,3,4-oxadiazol-2-yl)phenyl]methyl} azetidin-3-yl)-2-fluoro-2-methylpropyl]-5-fluorobenzonitrile, and novel salts, solvates, hydrates and polymorphs thereof.",MERCK & CO INC;;CAMPOS KEVIN R;;CHEN CHENG-YI;;FOLEY JENNIFER R;;HILLIER MICHAEL;;JEN WENDY S;;KASSIM AMUDE M;;KLAPARS ARTIS;;PERESYPKIN ANDREY V;;ROSNER THORSTEN;;SAVARIN CECILE G;;TUDGE MATTHEW;;VARIANKAVAL NARAYAN;;VYDRA VICKY;;ZHAO DALIAN,CAMPOS KEVIN R;;CHEN CHENG-YI;;FOLEY JENNIFER R;;HILLIER MICHAEL;;JEN WENDY S;;KASSIM AMUDE M;;KLAPARS ARTIS;;PERESYPKIN ANDREY V;;ROSNER THORSTEN;;SAVARIN CECILE G;;TUDGE MATTHEW;;VARIANKAVAL NARAYAN;;VYDRA VICKY;;ZHAO DALIAN,,https://lens.org/139-701-452-294-058,Patent Application,yes,0,1,7,7,0,C07C255/53;;C07D271/113;;C07D413/10;;A61P1/00;;A61P1/10;;A61P1/14;;A61P1/16;;A61P11/06;;A61P25/00;;A61P25/06;;A61P25/08;;A61P25/14;;A61P25/16;;A61P25/18;;A61P25/22;;A61P25/28;;A61P25/30;;A61P3/04;;A61P43/00;;A61P3/10;;C07D271/113;;C07D413/10;;C07C255/53,C07D413/10;;A61K31/4245;;A61P25/00;;C07D271/113,,0,0,,,,PENDING
458,WO,A1,WO 2003/030909 A1,112-792-665-672-610,2003-04-17,2003,US 0230616 W,2002-09-25,US 32427601 P;;US 35250902 P,2001-09-25,2- AND 4-AMINOPYRIMIDINES N-SUBSTTITUDED BY A BICYCLIC RING FOR USE AS KINASE INHIBITORS IN THE TREATMENT OF CANCER,"A coumpound of the formula ࿈I&rpar; wherein each X is independently NR1R6, NR4R5, or R4, with the proviso that at least one X must be NR1R6&semi; each R1 is independently an optionally substituted fused bicyclic unsaturated ring containing 9 or 10 atoms optionally containing 1ᇁ4 heteroatoms selected from the group consisting of N, S and O, and the variables R2ᇁ6 are as defined in claim 1, are claimed&period; These compounds are kinase inhibitors useful in the treatment of cancer and viral infections&period;",BAYER AG;;NAGARATHNAM DHANAPALAN;;WANG CHUNGUANG;;CHEN YUANWEI;;YI LIN;;CHEN JIANQING;;WEBER OLAF;;BOYER STEPHEN;;CLARK ROGER B;;PHILLIPS BARTON;;MEAHL JENNIFER;;LADOUCEUR GAETAN;;BI CHENG;;BURKE MICHAEL J;;COOK JAMES;;VERMA SHARAD K;;FAN JIANMEI,NAGARATHNAM DHANAPALAN;;WANG CHUNGUANG;;CHEN YUANWEI;;YI LIN;;CHEN JIANQING;;WEBER OLAF;;BOYER STEPHEN;;CLARK ROGER B;;PHILLIPS BARTON;;MEAHL JENNIFER;;LADOUCEUR GAETAN;;BI CHENG;;BURKE MICHAEL J;;COOK JAMES;;VERMA SHARAD K;;FAN JIANMEI,,https://lens.org/112-792-665-672-610,Patent Application,yes,6,0,1,1,0,C07C45/45;;C07D231/12;;C07D233/56;;C07D239/42;;C07D249/08;;C07D317/54;;C07D401/12;;C07D401/14;;C07D403/12;;C07D403/14;;C07D405/14;;C07D409/12;;C07D409/14;;C07D417/12;;C07D417/14;;A61P31/12;;A61P35/00,A61P31/12;;A61P35/00;;C07C45/45;;C07D239/42;;C07D317/54;;C07D401/12;;C07D401/14;;C07D403/12;;C07D403/14;;C07D405/14;;C07D409/12;;C07D409/14;;C07D417/12;;C07D417/14;;C07D521/00,,1,1,185-420-093-141-646,10.1002/chin.197346260,"WERBEL ET AL.: ""Synthesis and antimalarial effects of 5,6-dichloro-2-[(4-[[4-(diethylamino)-1-methylbutyl]amino]-6-methyl-2-pyrimidinyl)amino]benzimidazole and related benzimidazoles and 1H-imidazo[4,5-b]pyridines (1,2)"", J. HETEROCYCL. CHEM., vol. 10, no. 3, 1973, pages 363-382, XP009001685",PENDING
459,US,A1,US 2010/0292282 A1,199-634-478-025-314,2010-11-18,2010,US 68179708 A,2008-10-20,US 68179708 A;;US 15107 P;;US 2008/0011927 W,2007-10-24,SYNTHESIS AND CRYSTALLINE FORMS OF CB-1 ANTAGONIST/INVERSE AGONIST,"The present invention relates to a process for producing crystalline 3-[(1S)-1-(1-{(S)-(4-chlorophenyl)[3-(5-oxo-4,5-dihydro-1,3,4-oxadiazol-2-yl)phenyl]methyl}azetidin-3-yl)-2-fluoro-2-methyl-propyl]-5-fluorobenzonitrile, and novel salts, solvates, hydrates and polymorphs thereof.",CAMPOS KEVIN R;;CHEN CHENG-YI;;FOLEY JENNIFER R;;HILLIER MICHAEL;;JEN WENDY S;;KASSIM AMUDE M;;KLAPARS ARTIS;;PERESYPKIN ANDREY V;;ROSNER THORSTEN;;SAVARIN CECILE G;;TUDGE MATTHEW;;VARIANKAVAL NARAYAN;;VYDRA VICKY;;ZHAO DALIAN,CAMPOS KEVIN R;;CHEN CHENG-YI;;FOLEY JENNIFER R;;HILLIER MICHAEL;;JEN WENDY S;;KASSIM AMUDE M;;KLAPARS ARTIS;;PERESYPKIN ANDREY V;;ROSNER THORSTEN;;SAVARIN CECILE G;;TUDGE MATTHEW;;VARIANKAVAL NARAYAN;;VYDRA VICKY;;ZHAO DALIAN,MERCK SHARP & DOHME CORP (2007-12-11),https://lens.org/199-634-478-025-314,Patent Application,yes,0,1,7,7,0,A61P1/00;;A61P1/10;;A61P1/14;;A61P1/16;;A61P3/04;;A61P3/10;;A61P11/06;;A61P25/00;;A61P25/06;;A61P25/08;;A61P25/14;;A61P25/16;;A61P25/18;;A61P25/22;;A61P25/28;;A61P25/30;;A61P43/00;;C07D271/113;;C07D271/113;;C07C255/53;;C07C255/53;;C07D413/10;;C07D413/10,A61K31/4245;;A61P3/04;;A61P3/10;;A61P25/28;;C07C255/53;;C07D271/113;;C07D413/10,514/364;;548/144;;558/423,0,0,,,,DISCONTINUED
460,EP,A1,EP 2961749 A1,043-134-284-968-076,2016-01-06,2016,EP 14712418 A,2014-02-27,US 201361771615 P;;US 201361826431 P;;US 201461928898 P;;US 2014/0019100 W,2013-03-01,"PERFLUORINATED 5,6-DIHYDRO-4H-1,3-OXAZIN-2-AMINE COMPOUNDS AS BETA-SECRETASE INHIBITORS AND METHODS OF USE",,AMGEN INC,MINATTI ANA ELENA;;LOW JONATHAN D;;ALLEN JENNIFER R;;CHEN JIAN;;CHEN NING;;CHENG YUAN;;JUDD TED;;LIU QINGYIAN;;LOPEZ PATRICIA;;QIAN WENYUAN;;RUMFELT SHANNON;;RZASA ROBERT M;;TAMAYO NURIA A;;XUE QIUFEN;;YANG BRYANT;;ZHONG WENGE,,https://lens.org/043-134-284-968-076,Patent Application,yes,0,1,17,18,0,A61P7/04;;A61P9/00;;A61P25/00;;A61P25/28;;A61P43/00;;C07D413/14;;C07D413/14;;C07D265/08;;C07D265/08;;C07D413/04;;C07D413/04;;C07D413/10;;C07D413/10;;C07D413/12;;C07D413/12;;C07D471/04;;C07D471/04;;C07D498/04;;C07D498/04;;C07D513/04;;C07D513/04;;C07F7/0812,C07D413/14;;A61K31/535;;A61K31/5355;;A61P25/00;;C07D265/08;;C07D413/04;;C07D413/10;;C07D413/12;;C07D471/04;;C07D498/04;;C07D513/04,,1,0,,,See references of WO 2014134341A1,ACTIVE
461,AR,A1,AR 095014 A1,152-148-365-923-397,2015-09-16,2015,AR P140100710 A,2014-03-05,US 201361771615 P,2013-03-01,"COMPUESTOS PERFLUORADOS DE 5,6-DIHIDRO-4H-1,3-OXAZIN-2-AMINA COMO INHIBIDORES DE b-SECRETASA Y MÉTODOS DE USO","Composiciones farmacéuticas que comprenden los compuestos, y los correspondientes usos de los compuestos y composiciones para el tratamiento de trastornos y/o condiciones asociadas con la formación y deposición de placa A-b que resulta de la actividad biológica de BACE. Dichos trastornos mediados por BACE incluyen, por ejemplo, la enfermedad de Alzheimer, déficits cognitivos, deterioro cognitivo, esquizofrenia y otras condiciones del sistema nervioso central. Procesos y métodos útiles para la preparación de los compuestos descritos en las reivindicaciones. Reivindicación 1: Un compuesto de fórmula (1), o un estereoisómero, tautómero, hidrato, solvato o sal farmacéuticamente aceptable del mismo, donde A⁴ es CR⁴ o N; A⁵ es CR⁵ o N; A⁶ es CR⁶ o N; A⁸ es CR⁸ o N, siempre y cuando no más de dos de A⁴, A⁵, A⁶ y A⁸ es N; un R¹ es haloalquilo C₁₋₃ y el otro R¹ es H, F, Cl, alquilo C₁₋₆, alquenilo C₂₋₄, alquinilo C₂₋₄, CN, -CH₂O-alquilo C₁₋₆, -O-alquilo C₁₋₆, -S(O)ₒ-alquilo C₁₋₆, -NH-alquilo C₁₋₆ o -C(O)-alquilo C₁₋₆, donde cada uno de alquilo C₁₋₆, alquenilo C₂₋₄, alquinilo C₂₋₄, y alquilo C₁₋₆ de -CH₂O-alquilo C₁₋₆, -O-alquilo C₁₋₆, -S(O)ₒ-alquilo C₁₋₆, -NH-alquilo C₁₋₆ y -C(O)-alquilo C₁₋₆ se sustituyen opcionalmente con 1 - 4 sustituyentes de F, oxo o OH; en forma alternativa, cada R¹ considerado en forma conjunta con el átomo de carbono al cual están unidos forman un anillo espirocarbocíclico C₃₋₆ que opcionalmente incluye un heteroátomo a seleccionar a partir de O y N y opcionalmente sustituido con 1 - 4 átomos de F en los átomos de carbono y opcionalmente sustituido con un sustituyente a seleccionar a partir de alquilo C₁₋₃, CH₂O-alquilo C₁₋₂ o haloalquilo C₁₋₃ en el átomo de nitrógeno; cada R², en forma independiente, es H, F, Cl, alquilo C₁₋₆, alquenilo C₂₋₄, alquinilo C₂₋₄, CN, -CH₂O-alquilo C₁₋₆, -O-alquilo C₁₋₆, -S(O)ₒ-alquilo C₁₋₆, -NH-alquilo C₁₋₆ o -C(O)-alquilo C₁₋₆, donde cada uno de alquilo C₁₋₆, alquenilo C₂₋₄, alquinilo C₂₋₄, y alquilo C₁₋₆ de -CH₂O-alquilo C₁₋₆, -O-alquilo C₁₋₆, -S(O)ₒ-alquilo C₁₋₆, -NH-alquilo C₁₋₆ y -C(O)-alquilo C₁₋₆ se sustituyen opcionalmente con 1 - 4 sustituyentes de F, oxo o OH; en forma alternativa, cada R² considerado en forma conjunta con el átomo de carbono al cual están unidos forman un anillo espirocarbocíclico C₃₋₆ que opcionalmente incluye un heteroátomo a seleccionar a partir de O y N y opcionalmente sustituido con 1 - 4 átomos de F en los átomos de carbono y opcionalmente sustituido con un sustituyente a seleccionar a partir de alquilo C₁₋₃, CH₂O-alquilo C₁₋₂ o haloalquilo C₁₋₃ en el átomo de nitrógeno; R³ es alquilo C₁₋₄, CH₂O-alquilo C₁₋₄, CH₂OH, haloalquilo C₁₋₄ o ciclopropilo, donde cada uno de alquilo C₁₋₄, CH₂O-alquilo C₁₋₄, haloalquilo C₁₋₄ y ciclopropilo opcionalmente se encuentra sustituido con 1 - 4 átomos de F; cada uno de R⁴, R⁵, R⁶ y R⁸, en forma independiente, es H, halo, haloalquilo, haloalcoxilo, alquilo C₁₋₄, CN, OH, O-alquilo C₁₋₄, S(O)ₒ-alquilo C₁₋₄, NH-alquilo C₁₋₄ o C(O)-alquilo C₁₋₄; R⁷ es -NH-R⁹, -NH-C(=O)-R⁹, -C(=O)NH-R⁹, -NH-C(=S)-R⁹, -O-R⁹ o -S-R⁹; R⁹ es acetilo, alquilo C₁₋₆, alquenilo C₂₋₄, alquinilo C₂₋₄ o un anillo monocíclico de 3, 4, 5, 6 ó 7 miembros o bicíclico de 8, 9 ó 10 miembros total o parcialmente insaturado formado de átomos de carbono, donde dicho anillo opcionalmente incluye 1 - 4 heteroátomos si es monocíclico o 1 - 5 heteroátomos si es bicíclico, dichos heteroátomos a seleccionar a partir de O, N o S, donde el alquilo C₁₋₆, alquenilo C₂₋₄, alquinilo C₂₋₄ y el anillo opcionalmente se encuentran sustituidos, en forma independiente, con 1 - 5 sustituyentes de R¹⁰; y cada R¹⁰, en forma independiente, es H, halo, haloalquilo, CN, OH, NO₂, NH₂, SF₅, acetilo, -C(O)NHCH₃, oxo, ciclopropilmetoxi, 2-propiniloxi, 2-butiniloxi, alquilo C₁₋₆, alquenilo C₂₋₆, alquinilo C₂₋₆, cicloalquilo C₃₋₆, alquil C₁₋₆amino-, dialquil C₁₋₆amino-, alcoxilo C₁₋₆, tioalcoxilo C₁₋₆, morfolinilo, pirazolilo, isoxazolilo, dihidropiranilo, pirrolilo, pirrolidinilo, tetrahidropirrolilo, piperazinilo, oxetan-3-ilo, imidazo-piridinilo o dioxolilo, donde cada uno de ciclopropilmetoxi, 2-butiniloxi, alquilo C₁₋₆, alquenilo C₂₋₆, alquinilo C₂₋₆, cicloalquilo C₃₋₆, alquil C₁₋₆amino-, dialquil C₁₋₆amino-, alcoxilo C₁₋₆, tioalcoxilo C₁₋₆, morfolinilo, pirazolilo, isoxazolilo, dihidropiranilo, pirrolidinilo, oxetan-3-ilo o dioxolilo, opcionalmente se encuentra sustituido en forma independiente con 1 - 5 sustituyentes de F, Cl, CN, NO₂, NH₂, OH, oxo, CF₃, CHF₂, CH₂F, metilo, metoxi, etilo, etoxi, CH₂CF₃, CH₂CHF₂, propilo, propoxi, isopropilo, isopropoxi, ciclopropilo, butilo, butoxilo, ciclobutilo, isobutoxi, ter-butoxi, isobutilo, sec-butilo, ter-butilo, alquil C₁₋₃amino-, dialquil C₁₋₃amino, tioalcoxil C₁₋₃ oxazolilo, o oxetan-3-ilo; siempre y cuando, si A⁴ es CR⁴, A⁵ es CR⁵, A⁶ es CR⁶ y A⁸ es CR⁸, y cada uno de R⁶ y R⁸, en forma independiente, es H, luego R⁵ no es H.",AMGEN INC,JENNIFER R ALLEN;;JONATHAN D LOW;;ANA ELENA MINATTI;;YUAN CHENG;;ROBERT M RZASA;;WENGE ZHONG;;NING CHEN;;QINGYIAN LIU;;QIUFEN XUE;;PATRICIA LOPEZ;;TED JUDD;;JIAN CHEN;;WENYUAN QIAN;;NURIA A TAMAYO;;SHANNON RUMFELT;;BRYANT YANG,,https://lens.org/152-148-365-923-397,Patent Application,no,0,0,1,18,0,,C07D413/12;;A61K31/5355;;A61P25/28,,0,0,,,,PENDING
462,US,A1,US 2014/0249104 A1,152-482-186-687-708,2014-09-04,2014,US 201414192710 A,2014-02-27,US 201414192710 A;;US 201461928898 P;;US 201361826431 P;;US 201361771615 P,2013-03-01,"PERFLUORINATED 5,6-DIHYDRO-4H-1,3-OXAZIN-2-AMINE COMPOUNDS AS BETA-SECRETASE INHIBITORS AND METHODS OF USE","The present invention provides a new class of compounds useful for the modulation of beta-secretase enzyme (BACE) activity. The compounds have a general Formula I: wherein variables A 4 , A 5 , A 6 , A 8 , each of R 1 and R 2 , R 3 and R 7 of Formula I, independently, are defined herein. The invention also provides pharmaceutical compositions comprising the compounds, and corresponding uses of the compounds and compositions for treatment of disorders and/or conditions related to A-beta plaque formation and deposition, resulting from the biological activity of BACE. Such BACE mediated disorders include, for example, Alzheimer's Disease, cognitive deficits, cognitive impairments, schizophrenia and other central nervous system conditions. The invention further provides compounds of Formulas II and III, and sub-formula embodiments thereof, intermediates and processes and methods useful for the preparation of compounds of Formulas I-III.",AMGEN INC,MINATTI ANA ELENA;;LOW JONATHAN D;;ALLEN JENNIFER R;;CHEN JIAN;;CHEN NING;;CHENG YUAN;;JUDD TED;;LIU QINGYIAN;;LOPEZ PATRICIA;;QIAN WENYUAN;;RUMFELT SHANNON;;RZASA ROBERT M;;TAMAYO NURIA A;;XUE QIUFEN;;YANG BRYANT;;ZHONG WENGE,AMGEN INC (2015-01-14),https://lens.org/152-482-186-687-708,Patent Application,yes,1,3,17,18,0,A61P7/04;;A61P9/00;;A61P25/00;;A61P25/28;;A61P43/00;;C07D413/14;;C07D413/14;;C07D265/08;;C07D265/08;;C07D413/04;;C07D413/04;;C07D413/10;;C07D413/10;;C07D413/12;;C07D413/12;;C07D471/04;;C07D471/04;;C07D498/04;;C07D498/04;;C07D513/04;;C07D513/04;;C07F7/0812,C07D413/14;;C07D413/12;;C07D471/04;;C07D513/04;;C07F7/08,514/63;;544/96;;514/228.8;;544/69,0,0,,,,ACTIVE
463,CA,A1,CA 2902212 A1,000-832-751-942-085,2014-09-04,2014,CA 2902212 A,2014-02-27,US 201361771615 P;;US 201361826431 P;;US 201461928898 P;;US 2014/0019100 W,2013-03-01,"PERFLUORINATED 5,6-DIHYDRO-4H-1,3-OXAZIN-2-AMINE COMPOUNDS AS BETA-SECRETASE INHIBITORS AND METHODS OF USE","The present invention provides a new class of compounds useful for the modulation of beta-secretase enzyme (BACE) activity. The compounds have a general Formula (I): wherein variables A4, A5, A6, A8, each of R1 and R2, R3 and R7 of Formula I, independently, are defined herein. The invention also provides pharmaceutical compositions comprising the compounds, and corresponding uses of the compounds and compositions for treatment of disorders and/or conditions related to A-beta plaque formation and deposition, resulting from the biological activity of BACE. Such BACE mediated disorders include, for example, Alzheimer's Disease, cognitive deficits, cognitive impairments, schizophrenia and other central nervous system conditions. The invention further provides compounds of Formulas II and III, and sub-formula embodiments thereof, intermediates and processes and methods useful for the preparation of compounds of Formulas I-III.",AMGEN INC,MINATTI ANA ELENA;;LOW JONATHAN D;;ALLEN JENNIFER R;;CHEN JIAN;;CHEN NING;;CHENG YUAN;;JUDD TED;;LIU QINGYIAN;;LOPEZ PATRICIA;;QIAN WENYUAN;;RUMFELT SHANNON;;RZASA ROBERT M;;TAMAYO NURIA A;;XUE QIUFEN;;YANG BRYANT;;ZHONG WENGE,,https://lens.org/000-832-751-942-085,Patent Application,no,0,0,17,18,0,A61P7/04;;A61P9/00;;A61P25/00;;A61P25/28;;A61P43/00;;C07D413/14;;C07D413/14;;C07D265/08;;C07D265/08;;C07D413/04;;C07D413/04;;C07D413/10;;C07D413/10;;C07D413/12;;C07D413/12;;C07D471/04;;C07D471/04;;C07D498/04;;C07D498/04;;C07D513/04;;C07D513/04;;C07F7/0812,C07D413/14;;A61K31/535;;A61K31/5355;;A61P25/00;;C07D265/08;;C07D413/04;;C07D413/10;;C07D413/12;;C07D471/04;;C07D498/04;;C07D513/04,,0,0,,,,ACTIVE
464,US,A1,US 2023/0297964 A1,149-432-758-700-629,2023-09-21,2023,US 202318121851 A,2023-03-15,US 202318121851 A;;US 202263320116 P,2022-03-15,PAY EQUITY FRAMEWORK,"A method, a system, and computer program product for managing pay equity cloud-based software applications are provided. A query for compensation data for an employment position associated with a macro-entity is received. The employment position is defined by parameters associated with a micro-entity. The compensation data for similar employment positions associated with the macro-entity is retrieved, from a database and by using the parameters. The compensation data is processed to generate grouped and ranked employment positions. Compensation gaps between the ranked employment positions are determined, by executing a multivariate regression analysis including an analysis of one or more cohorts of employment positions within the ranked employment positions. A recommendation for adjusting compensation associated with one or more employment positions is generated, by using a machine learning model. An instruction to display a notification including the recommendation is provided.",SALARY COM LLC,PLUNKETT GREGORY KENT;;ZHANG YONG;;AMBLER HEIDI;;AIKINS ALDEN;;CHENG LAN;;CROSS DAVID;;DEMORE JENNIFER;;FERRARI CAROL;;FUSCO CHRISTOPHER;;GOLD HELENE;;HIMSTEAD CONOR;;KNIZE CHRISTOPHER;;LINN ANDREW;;MULKEEN PATRICIA;;SCHIATTAREGGIA CAITLIN;;STRAKER GARRY;;SWEET JONATHAN;;TURETSKY DAVID,,https://lens.org/149-432-758-700-629,Patent Application,yes,0,0,1,1,0,H04L63/101;;G06Q10/1053;;H04L63/101;;G06Q10/1053,G06Q10/1053;;H04L9/40,,0,0,,,,PENDING
465,CA,C,CA 2902212 C,135-906-071-818-480,2020-10-13,2020,CA 2902212 A,2014-02-27,US 201361771615 P;;US 201361826431 P;;US 201461928898 P;;US 2014/0019100 W,2013-03-01,"PERFLUORINATED 5,6-DIHYDRO-4H-1,3-OXAZIN-2-AMINE COMPOUNDS AS BETA-SECRETASE INHIBITORS AND METHODS OF USE","The present invention provides a new class of compounds useful for the modulation of beta-secretase enzyme (BACE) activity. The compounds have a general Formula (I): wherein variables A4, A5, A6, A8, each of R1 and R2, R3 and R7 of Formula I, independently, are defined herein. The invention also provides pharmaceutical compositions comprising the compounds, and corresponding uses of the compounds and compositions for treatment of disorders and/or conditions related to A-beta plaque formation and deposition, resulting from the biological activity of BACE. Such BACE mediated disorders include, for example, Alzheimer's Disease, cognitive deficits, cognitive impairments, schizophrenia and other central nervous system conditions. The invention further provides compounds of Formulas II and III, and sub-formula embodiments thereof, intermediates and processes and methods useful for the preparation of compounds of Formulas I-III.",AMGEN INC,MINATTI ANA ELENA;;LOW JONATHAN D;;ALLEN JENNIFER R;;CHEN JIAN;;CHEN NING;;CHENG YUAN;;JUDD TED;;LIU QINGYIAN;;LOPEZ PATRICIA;;QIAN WENYUAN;;RUMFELT SHANNON;;RZASA ROBERT M;;TAMAYO NURIA A;;XUE QIUFEN;;YANG BRYANT;;ZHONG WENGE,,https://lens.org/135-906-071-818-480,Granted Patent,no,0,0,17,18,0,C07D413/04;;C07D413/10;;C07D265/08;;C07D498/04;;C07D413/14;;C07D413/12;;C07D471/04;;C07D513/04;;A61P25/00;;A61P25/28;;A61P43/00;;A61P7/04;;A61P9/00;;C07D413/14;;C07D413/12;;C07D471/04;;C07D513/04;;C07F7/0812;;C07D413/04;;C07D413/10;;C07D265/08;;C07D498/04,C07D413/14;;A61K31/535;;A61K31/5355;;A61P25/00;;C07D265/08;;C07D413/04;;C07D413/10;;C07D413/12;;C07D471/04;;C07D498/04;;C07D513/04,,0,0,,,,ACTIVE
466,US,B2,US 9296734 B2,065-157-486-323-903,2016-03-29,2016,US 201414192710 A,2014-02-27,US 201414192710 A;;US 201461928898 P;;US 201361826431 P;;US 201361771615 P,2013-03-01,"Perfluorinated 5,6-dihydro-4H-1,3-oxazin-2-amine compounds as beta-secretase inhibitors and methods of use","The present invention provides a new class of compounds useful for the modulation of beta-secretase enzyme (BACE) activity. The compounds have a general Formula I: wherein variables A 4 , A 5 , A 6 , A 8 , each of R 1 and R 2 , R 3 and R 7 of Formula I, independently, are defined herein. The invention also provides pharmaceutical compositions comprising the compounds, and corresponding uses of the compounds and compositions for treatment of disorders and/or conditions related to A-beta plaque formation and deposition, resulting from the biological activity of BACE. Such BACE mediated disorders include, for example, Alzheimer's Disease, cognitive deficits, cognitive impairments, schizophrenia and other central nervous system conditions. The invention further provides compounds of Formulas II and III, and sub-formula embodiments thereof, intermediates and processes and methods useful for the preparation of compounds of Formulas I-III.",AMGEN INC,MINATTI ANA ELENA;;LOW JONATHAN D;;ALLEN JENNIFER R;;CHEN JIAN;;CHEN NING;;CHENG YUAN;;JUDD TED;;LIU QINGYIAN;;LOPEZ PATRICIA;;QIAN WENYUAN;;RUMFELT SHANNON;;RZASA ROBERT M;;TAMAYO NURIA A;;XUE QIUFEN;;YANG BRYANT;;ZHONG WENGE,AMGEN INC (2015-01-14),https://lens.org/065-157-486-323-903,Granted Patent,yes,96,2,17,18,0,A61P7/04;;A61P9/00;;A61P25/00;;A61P25/28;;A61P43/00;;C07D413/14;;C07D413/14;;C07D265/08;;C07D265/08;;C07D413/04;;C07D413/04;;C07D413/10;;C07D413/10;;C07D413/12;;C07D413/12;;C07D471/04;;C07D471/04;;C07D498/04;;C07D498/04;;C07D513/04;;C07D513/04;;C07F7/0812,C07D413/14;;C07D265/08;;C07D413/04;;C07D413/10;;C07D413/12;;C07D471/04;;C07D498/04;;C07D513/04;;C07F7/08,,44,33,118-265-836-977-00X;;054-712-216-545-603;;064-204-983-655-362;;032-340-926-422-023;;044-407-914-794-953;;108-349-484-349-717;;061-138-525-636-453;;010-118-470-073-21X;;048-784-633-528-797;;013-801-653-376-729;;077-351-302-208-527;;003-778-511-848-73X;;035-920-450-620-162;;000-871-005-085-466;;013-369-899-259-645;;003-828-313-704-930;;023-381-578-379-560;;051-801-341-692-560;;117-896-947-554-821;;027-599-889-247-132;;008-314-583-015-610;;039-148-595-027-639;;082-722-733-297-69X;;106-260-003-796-433;;059-006-551-099-763;;015-982-248-847-361;;090-808-357-264-137;;065-576-541-132-98X;;064-327-872-895-873;;015-595-224-888-222;;005-277-927-658-347;;127-854-145-178-323;;010-016-516-394-602,10.1021/jm400225m;;23590342;;10.1016/s1474-4422(13)70276-x;;pmc4086426;;24556009;;15743924;;10.1124/jpet.104.081174;;15102495;;10.1016/j.tips.2003.12.004;;10.1186/1750-1326-2-22;;18005427;;pmc2211305;;10.1001/archneurol.2010.179;;20697045;;pmc2963067;;11145990;;10.1046/j.1471-4159.2001.00012.x;;21747967;;10.1371/journal.pone.0021908;;pmc3128622;;7845465;;10.1038/373523a0;;15052274;;10.1038/sj.mp.4001508;;10.1016/s0014-5793(97)00886-7;;9280316;;pmc3050043;;21040845;;10.1016/j.neuron.2010.10.020;;10.1517/14656560903044982;;19527190;;pmc15924;;10.1073/pnas.96.6.3228;;10077666;;8810256;;10.1126/science.274.5284.99;;1605946;;10.1097/00002093-199205000-00003;;21852788;;10.1038/nrd3505;;10.1016/s1044-7431(03)00035-6;;12676526;;11224535;;10.1038/85059;;pmc6633289;;10.1523/jneurosci.3647-11.2011;;22090477;;10.1038/nn.2583;;pmc3072750;;20581818;;pmc2601528;;18359102;;10.1016/j.bbr.2008.02.016;;10.1016/0896-6273(91)90052-2;;1673054;;10.1038/359325a0;;1406936;;17495518;;10.4161/auto.4341;;pmc2772133;;18568035;;10.1038/nm1782;;16505324;;10.1212/01.wnl.0000198762.41312.e1;;18090456;;10.1097/wnf.0b013e31805b7660;;10.1038/990114;;10591214;;10.1016/j.cell.2005.02.008;;15734686;;10.1523/jneurosci.3657-09.2009;;19828790;;pmc2879048;;10.1016/j.neuron.2004.09.010;;15450169;;10348917;;10.1093/oxfordjournals.jbchem.a022396,"International Search Report for analogous PCT Application No. /US2014/019100, mailed on May 8, 2014.;;Hilpert, H. et al., ""beta-Secretase (BACE1) Inhibitors with high in Vivo Efficacy Suitable for Clinical Evaluation in Alzheimer's Disease,"" Journal of Medicinal Chemistry, vol. 56, pp. 3980-3995 (2013).;;CAS Registry No. 145976-71-4, Oct. 14, 2013.;;Yan, R. et al., ""Targeting the beta Secretase BACE1 for Alzheimer's Disease Therapy,"" Lancet Neurol. vol. 13. pp. 319-329 (2014).;;Written Opinion of the International Searching Authority for International Patent Application No. PCT/US2014/019100, mailed May 8, 2014, pp. 1-7.;;U.S. Appl. No. 14/819,256, filed Aug. 5, 2015, Amgen Inc.;;U.S. Appl. No. 14/932,787, filed Nov. 4, 2015, Amgen Inc.;;Alzforum Networking For A Cure, ""Barcelona: Out of Left Field-Hit to The Eye Kills BACE Inhibitor,"" pp. 1-7 (Mar. 31, 2011); access online: www.alzforum.org/news/conference-coverage/barcelona-out-left-field-hit-eye-kills-bace-inhibitor (last accessed Dec. 16, 2015).;;Best, J. D. et al., ""Quantitative Measurement of Changes in Amyloid-beta(40) in the Rat Brain and Cerebrospinal Fluid Following Treatment with the gamma-Secretase Inhibitor LY-411575 [N2-[(2S)-2-(3,5-Difluoropheny1)-2-hydroxyethanoy1]-N1-[(7S)-5-methyl-6-oxo-6,7- dihydro-5H-dibenzo[b,d]azepin-7-yl1]L-alaninamide],"" Journal of Pharmacology and Experimental Therapeutics 313(2):902-908 (2005).;;Citron, M., ""beta-Secretase inhibition for the treatment of Alzheimer's disease-promise and challenge,"" TRENDS in Pharmacological Sciences 25(2):92-97 (2004).;;Cole, S.L. and Vassar, R., ""The Alzheimer's disease beta-secretase enzyme, BACE1,"" Molecular Neurodegeneration 2(22):1-25 (2007).;;De Meyer, G. et al., ""Diagnosis-Independent Alzheimer Disease Biomarker Signature in Cognitively Normal Elderly People,"" Arch. Neurol. 67(8):949-956 (2010).;;Dovey, H. F. et al., ""Functional gamma-secretasae inhibitors reduce beta-amyloid peptide levels in brain,"" Journal of Neurochemistry 76:173-181 (2001).;;Follo, C. et al., ""Knock-Down of Cathepsin D Affects the Retinal Pigment Epithelium, Impairs Swim-Bladder Ontogenesis and Causes Premature Death in Zebrafish,"" PLoS One 6(7):e21908, pp. 1-13 (2011).;;Games, D. et al., ""Alzheimer-type neuropathology in transgenic mice overexpressing V717F beta-amyloid precursor protein,"" Nature 373:523-527 (1995).;;Götz, J. et al., ""Transgenic animal models of Alzheimer's disease and related disorders: histopathology, behavior and therapy,"" Molecular Psychiatry 9:664-683 (2004).;;Gulnik, S. V. et al. ""Design of sensitive fluorogenic substrates for human cathespin D,"" FEBS Letters 413:379-384 (1997).;;Harris, J. A. et al, ""Transsynaptic Progression of Amyloid-beta-Induced Neuronal Dysfunction within the Entorhinal-Hippocampal Network,"" Neuron 68:428-441 (2010).;;Henley, D. B. et al., ""Development of semagacestat (LY450139), a functional g-secretase inhibitor, for the treatment of Alzheimer's disease,"" Expert Opin. Pharmacother. 10(10):1657-1664 (2009).;;Hsia, A. Y. et al., ""Plaque-independent disruption of neural circuits in Alzheimer's disease mouse models,"" Proc. Natl. Acad. Sci. USA 96:3228-3233 (1999).;;Hsiao, K. et al., ""Correlative Memory Deficits, Ab Elevation, and Amyloid Plaques in Transgenic Mice,"" Science 274:99-102 (1996).;;International Preliminary Report on Patentability and Written Opinion for International Patent Application No. PCT/US2014/021412, issued Sep. 8, 2015, pp. 1-7.;;International Search Report for International Patent Application No. PCT/US2014/019100, mailed Aug. 5, 2014, pp. 1-6.;;International Search Report for International Patent Application No. PCT/US2014/021412, mailed May 13, 2014, pp. 1-3.;;Joachim, C. L. and Selkoe, D. J., ""The Seminal Role of beta-Amyloid in the Pathogenesis of Alzheimer Disease,"" Alzheimer Disease and Associated Disorders 6(1):7-34 (1992).;;Karran, E. et al. ""The amyloid cascade hypothesis for Alzheimer's disease: an appraisal for the development of therapeutics,"" Nature Reviews Drug Discovery 10:698-712 (2011).;;Koike, M. et al., ""Involvement of two different cell death pathways in retinal atrophy of cathepsin D-deficient mice,"" Molecular and Cellular Neuroscience 22:146-161 (2003).;;Luo, Y et al., ""Mice deficient in BACE1, the Alzheimer's beta-secretase, have normal phenotype and abolished beta-amyloid generation,"" Nature Neuroscience 4:231-232 (2001).;;May, P. C. et al., ""Robust Central Reduction of Amyloid-beta in Humans with an Orally Available, Non-Peptidic beta-Secretase Inhibitor,"" Journal of Neuroscience 31(46):16507-16516 (2011).;;Office Action mailed May 22, 2015 for U.S. Appl. No. 14/691,715, filed Apr. 21, 2015, pp. 1-5.;;Palop, J. J. and Mucke, L., ""Amyloid-beta-induced neuronal in Alzheimer's disease: from synapses toward neural networks,"" Nature Neuroscience 13(7):812-818 (2010).;;Sabbagh, M. N. et al., ""beta-Amyloid and Treatment Opportunities for Alzheimer's Disease,"" Alzheimer's Disease Review 3:1-19 (1997).;;Selkoe, D. J., ""Soluble oligomers of the amyloid beta-protein impair synaptic plasticity and behavior,"" Behavioural Brain Research 192:106-113 (2008).;;Selkoe, D. J., ""The Molecular Pathology of Alzheimer's Disease,"" Neuron 6:487-498 (1991).;;Seubert, P. et al., ""Isolation and quantification of soluble Alzheimer's beta-peptide from biological fluids,"" Nature 359:325-327 (1992).;;Shacka, J. J. and Roth, K. A., ""Cathepsin D Deficiency and NCL/Batten Disease: There's More to Death than Apoptosis,"" Autophagy, 3(5):474-476 (2007).;;Shankar, G. M. et al., ""Amyloid-beta protein dimers isolated directly from Alzheimer's brains impair synaptic plasticity and memory,"" Nature Medicine 14(8):837-842 (2008).;;Siemers, E. R. et al., ""Effects of a gamma-secretase inhibitor in a randomized study of patients with Alzheimer's disease,"" Neurology 66:602-604 (2006).;;Siemers, E. R. et al., ""Safety, Tolerability, and Effects on Plasma and Cerebrospinal Fluid Amyloid-beta After Inhibition of gamma-Secretase,"" Clin. Neuropharmacol. 30(6):317-325 (2007).;;Sinha, S. et al., ""Purification and cloning of amyloid precursor protein beta-secretase from human brain,"" Nature 402:537-540 (1999).;;Tanzi, R. E. and Bertram, L., ""Twenty Years of the Alzheimer's Disease Amyloid Hypothesis: A Genetic Perspective,"" Cell 120(4): 545-555 (2005).;;Vassar, R. et al, ""The beta-Secretase Enzyme BACE in Health and Alzheimer's Disease: Regulation, Cell Biology, Function, and Therapeutic Potential,"" Journal of Neuroscience 29(41):12787-12794 (2009).;;Walsh, D. M. and Selkoe, D. J., ""Deciphering the Molecular Basis of Memory Failure in Alzheimer's Disease,"" Neuron 44(1):181-193 (2004).;;Yasuda, Y. et al., ""Characterization of New Fluorogenic Substrates for the Rapid and Sensitive Assay of Cathepsin E and Cathepsin D,"" J. Biochem. 125(6):1137-1143 (1999).",ACTIVE
467,TW,A,TW 200508228 A,074-497-334-409-131,2005-03-01,2005,TW 93115729 A,2004-06-02,US 47543003 P;;US 47545303 P;;US 49085503 P;;US 52973103 P;;US 53158403 P,2003-06-03,Biaryl heterocyclic compounds and methods of making and using the same,"The present invention relates generally to the field of anti-infective, anti-proliferative, anti-inflammatory, and prokinetic agents. More particularly, the invention relates to a family of compounds having both a biaryl moiety and at least one heterocylic moiety that are useful as such agents.",RIB X PHARMACEUTICALS INC,ZHOU JIA CHENG;;BHATTACHARJEE ASHOKE;;CHEN SHI-LI;;CHEN YI;;FARMER JAY J;;GOLDBERG JOEL A;;HANSELMANN ROGER;;LOU RONGLIANG;;ORBIN ALIA;;OYELERE ADEGBOYEGA K;;SALVINO JOSEPH M;;SPRINGER DANE M;;TRAN JENNIFER;;WANG DEPING;;WU YUSHENG,,https://lens.org/074-497-334-409-131,Patent of Addition,no,0,0,45,82,0,C07D263/20;;C07D263/32;;C07D413/12;;C07D413/14;;C07D417/10;;C07D417/12;;C07D417/14;;C07D453/02;;C07D473/00;;C07D413/10;;C07D487/04;;C07D263/26;;C07D471/04;;C07D263/24;;C07D473/34;;A61P1/00;;A61P1/04;;A61P11/00;;A61P13/02;;A61P17/00;;A61P19/02;;A61P19/08;;A61P29/00;;A61P31/00;;A61P31/02;;A61P31/04;;A61P31/10;;A61P31/12;;A61P33/00;;A61P35/00;;A61P41/00;;A61P9/00;;C07D263/20;;C07D263/32;;C07D413/12;;C07D413/14;;C07D417/10;;C07D417/12;;C07D417/14;;C07D453/02;;C07D473/00;;C07D413/10;;C07D487/04;;C07D263/24;;C07D473/34;;C07D263/26;;C07D471/04,A61K31/421;;A61K31/4439;;A61K31/497;;A61K31/501;;C07D255/02;;C07D257/04;;C07D263/20;;C07D263/32;;C07D263/38;;C07D403/10;;C07D413/02;;C07D413/10;;C07D413/12;;C07D413/14;;C07D417/10;;C07D417/12;;C07D417/14;;C07D453/02;;C07D473/00;;C07D487/04,,0,0,,,,INACTIVE
468,UY,A,UY 35361 A,130-334-725-931-683,2014-09-30,2014,UY 35361 A,2014-03-05,US 201361771615 P;;US 201361826431 P;;US 201461928898 P,2013-03-01,"COMPUESTOS PERFLUORADOS DE 5,6-DIHIDRO-4H-1,3-OXAZIN-2-AMINA COMO INHIBIDORES DE BETA-SECRETASA y MÉTODOS DE USO","La invención da a conocer una nueva clase de compuestos útiles para la modulación de la actividad d e la enzima beta-secretasa (BACE). Los compuestos poseen una Fórmula general I: donde las variables A4, A5, A6, A8, cada uno de R1 y R2, R3 y R7 de la Fórmula I, en forma independiente, se definen e n la memoria. También se dan a conocer composiciones farmacéuticas que comprenden los compuestos, y usos de los compuestos y composiciones para el t ratamiento de trastornos y/o condiciones asociadas con la formación y deposición de placa A-beta qu e resulta de la actividad biológica de BACE.",AMGEN INC,YUAN CHENG;;ALLEN JENNIFER R;;NING CHEN;;QINGYIAN LIU;;WENYUAN QIAN;;SHANNON RUMFELT;;WENGE ZHONG;;TAMAYO NURIA A;;LOW JONATHAN D;;ELENA MINATTI ANA;;RZASA ROBERT M;;QIUFEN XUE;;PATRICIA LOPEZ;;TED JUDD;;CHEN JIAN;;BRYANT YANG,,https://lens.org/130-334-725-931-683,Patent Application,no,0,0,17,18,0,A61P7/04;;A61P9/00;;A61P25/00;;A61P25/28;;A61P43/00;;C07D413/14;;C07D413/14;;C07D265/08;;C07D265/08;;C07D413/04;;C07D413/04;;C07D413/10;;C07D413/10;;C07D413/12;;C07D413/12;;C07D471/04;;C07D471/04;;C07D498/04;;C07D498/04;;C07D513/04;;C07D513/04;;C07F7/0812,A61K31/429;;A61K31/4375;;A61K31/495;;A61K31/535;;A61K31/5355;;A61P25/28;;C07D265/08;;C07D413/04;;C07D413/12;;C07D413/14;;C07D471/04;;C07D513/04,,0,0,,,,DISCONTINUED
469,EP,B1,EP 2961749 B1,068-122-671-737-955,2019-10-09,2019,EP 14712418 A,2014-02-27,US 201361771615 P;;US 201361826431 P;;US 201461928898 P;;US 2014/0019100 W,2013-03-01,"PERFLUORINATED 5,6-DIHYDRO-4H-1,3-OXAZIN-2-AMINE COMPOUNDS AS BETA-SECRETASE INHIBITORS AND METHODS OF USE",,AMGEN INC,MINATTI ANA ELENA;;LOW JONATHAN D;;ALLEN JENNIFER R;;CHEN JIAN;;CHEN NING;;CHENG YUAN;;JUDD TED;;LIU QINGYIAN;;LOPEZ PATRICIA;;QIAN WENYUAN;;RUMFELT SHANNON;;RZASA ROBERT M;;TAMAYO NURIA A;;XUE QIUFEN;;YANG BRYANT;;ZHONG WENGE,,https://lens.org/068-122-671-737-955,Granted Patent,yes,1,0,17,18,0,A61P7/04;;A61P9/00;;A61P25/00;;A61P25/28;;A61P43/00;;C07D413/14;;C07D413/14;;C07D265/08;;C07D265/08;;C07D413/04;;C07D413/04;;C07D413/10;;C07D413/10;;C07D413/12;;C07D413/12;;C07D471/04;;C07D471/04;;C07D498/04;;C07D498/04;;C07D513/04;;C07D513/04;;C07F7/0812,C07D413/14;;A61K31/535;;A61K31/5355;;A61P25/00;;C07D265/08;;C07D413/04;;C07D413/10;;C07D413/12;;C07D471/04;;C07D498/04;;C07D513/04,,0,0,,,,ACTIVE
470,TW,A,TW 201446758 A,121-372-422-416-730,2014-12-16,2014,TW 103106910 A,2014-02-27,US 201361771615 P;;US 201361826431 P;;US 201461928898 P,2013-03-01,"Perfluorinated 5,6-dihydro-4H-1,3-oxazin-2-amine compounds as beta-secretase inhibitors and methods of use","The present invention provides a new class of compounds useful for the modulation of beta-secretase enzyme (BACE) activity. The compounds have a general Formula I: wherein variables A4, A5, A6, A8, each of R1 and R2, R3 and R7 of Formula I, independently, are defined herein. The invention also provides pharmaceutical compositions comprising the compounds, and corresponding uses of the compounds and compositions for treatment of disorders and/or conditions related to A-beta plaque formation and deposition, resulting from the biological activity of BACE. Such BACE mediated disorders include, for example, Alzheimer's Disease, cognitive deficits, cognitive impairments, schizophrenia and other central nervous system conditions. The invention further provides compounds of Formulas II and III, and sub-formula embodiments thereof, intermediates and processes and methods useful for the preparation of compounds of Formulas I-III.",AMGEN INC,ALLEN JENNIFER R;;LOW JONATHAN D;;MINATTI ANA ELENA;;CHENG YUAN;;RZASA ROBERT M;;ZHONG WENGE;;CHEN NING;;LIU QINGYIAN;;XUE QIUFEN;;LOPEZ PATRICIA;;JUDD TED;;CHEN JIAN;;QIAN WEN-YUAN;;TAMAYO NURIA A;;RUMFELT SHANNON;;YANG BRYANT,,https://lens.org/121-372-422-416-730,Patent of Addition,no,0,1,17,18,0,A61P7/04;;A61P9/00;;A61P25/00;;A61P25/28;;A61P43/00;;C07D413/14;;C07D413/14;;C07D265/08;;C07D265/08;;C07D413/04;;C07D413/04;;C07D413/10;;C07D413/10;;C07D413/12;;C07D413/12;;C07D471/04;;C07D471/04;;C07D498/04;;C07D498/04;;C07D513/04;;C07D513/04;;C07F7/0812,C07D413/12;;A61K31/5355;;A61P25/28;;C07D413/14;;C07D471/04,,0,0,,,,PENDING
471,MX,B,MX 366855 B,086-243-830-704-338,2019-07-26,2019,MX 2015011313 A,2014-02-27,US 201361771615 P;;US 201361826431 P;;US 201461928898 P;;US 2014/0019100 W,2013-03-01,"PERFLUORINATED 5,6-DIHYDRO-4H-1,3-OXAZIN-2-AMINE COMPOUNDS AS BETA-SECRETASE INHIBITORS AND METHODS OF USE.","The present invention provides a new class of compounds useful for the modulation of beta-secretase enzyme (BACE) activity. The compounds have a general Formula (I): wherein variables A4, A5, A6, A8, each of R1 and R2, R3 and R7 of Formula I, independently, are defined herein. The invention also provides pharmaceutical compositions comprising the compounds, and corresponding uses of the compounds and compositions for treatment of disorders and/or conditions related to A-beta plaque formation and deposition, resulting from the biological activity of BACE. Such BACE mediated disorders include, for example, Alzheimer's Disease, cognitive deficits, cognitive impairments, schizophrenia and other central nervous system conditions. The invention further provides compounds of Formulas II and III, and sub-formula embodiments thereof, intermediates and processes and methods useful for the preparation of compounds of Formulas I-III.",AMGEN INC,JIAN J CHEN;;QINGYIAN LIU;;WENGE ZHONG;;YUAN CHENG;;JENNIFER R ALLEN;;NING CHEN;;SHANNON RUMFELT;;ROBERT M RZASA;;ANA ELENA MINATTI;;JONATHAN D LOW;;TED JUDD;;PATRICIA LOPEZ;;WENYUAN QIAN;;NURIA A TAMAYO;;QIUFEN XUE;;BRYANT YANG,,https://lens.org/086-243-830-704-338,Granted Patent,no,0,0,17,18,0,A61P7/04;;A61P9/00;;A61P25/00;;A61P25/28;;A61P43/00;;C07D413/14;;C07D413/14;;C07D265/08;;C07D265/08;;C07D413/04;;C07D413/04;;C07D413/10;;C07D413/10;;C07D413/12;;C07D413/12;;C07D471/04;;C07D471/04;;C07D498/04;;C07D498/04;;C07D513/04;;C07D513/04;;C07F7/0812,C07D413/14;;A61K31/535;;A61K31/5355;;A61P25/00;;C07D265/08;;C07D413/04;;C07D413/10;;C07D413/12;;C07D471/04;;C07D498/04;;C07D513/04,,0,0,,,,ACTIVE
472,MX,A,MX 2015011313 A,110-261-638-842-201,2015-12-03,2015,MX 2015011313 A,2014-02-27,US 201361771615 P;;US 201361826431 P;;US 201461928898 P;;US 2014/0019100 W,2013-03-01,"PERFLUORINATED 5,6-DIHYDRO-4H-1,3-OXAZIN-2-AMINE COMPOUNDS AS BETA-SECRETASE INHIBITORS AND METHODS OF USE.","The present invention provides a new class of compounds useful for the modulation of beta-secretase enzyme (BACE) activity. The compounds have a general Formula (I): wherein variables A4, A5, A6, A8, each of R1 and R2, R3 and R7 of Formula I, independently, are defined herein. The invention also provides pharmaceutical compositions comprising the compounds, and corresponding uses of the compounds and compositions for treatment of disorders and/or conditions related to A-beta plaque formation and deposition, resulting from the biological activity of BACE. Such BACE mediated disorders include, for example, Alzheimer's Disease, cognitive deficits, cognitive impairments, schizophrenia and other central nervous system conditions. The invention further provides compounds of Formulas II and III, and sub-formula embodiments thereof, intermediates and processes and methods useful for the preparation of compounds of Formulas I-III.",AMGEN INC,CHEN JIAN J;;LIU QINGYIAN;;ZHONG WENGE;;CHENG YUAN;;ALLEN JENNIFER R;;CHEN NING;;RUMFELT SHANNON;;RZASA ROBERT M;;MINATTI ANA ELENA;;LOW JONATHAN D;;JUDD TED;;LOPEZ PATRICIA;;QIAN WENYUAN;;TAMAYO NURIA A;;XUE QIUFEN;;YANG BRYANT,,https://lens.org/110-261-638-842-201,Patent Application,no,0,0,17,18,0,A61P7/04;;A61P9/00;;A61P25/00;;A61P25/28;;A61P43/00;;C07D413/14;;C07D413/14;;C07D265/08;;C07D265/08;;C07D413/04;;C07D413/04;;C07D413/10;;C07D413/10;;C07D413/12;;C07D413/12;;C07D471/04;;C07D471/04;;C07D498/04;;C07D498/04;;C07D513/04;;C07D513/04;;C07F7/0812,C07D413/14;;A61K31/535;;A61K31/5355;;A61P25/00;;C07D265/08;;C07D413/04;;C07D413/10;;C07D413/12;;C07D471/04;;C07D498/04;;C07D513/04,,0,0,,,,ACTIVE
473,DE,D1,DE 69533569 D1,017-353-204-265-440,2004-11-04,2004,DE 69533569 T,1995-03-07,US 20749494 A;;US 31653694 A;;US 9503045 W,1994-03-07,BIOAKTIVE UND/ODER GEZIELTE DENDRIMERE-KONJUGATE ENTHALTEND GENETISCHES MATERIAL,"Dendritic polymer conjugates which are composed of at least one dendrimer in association with at least one unit of a carried material, where the carrier material can be a biological response modifier, have been prepared. The conjugate can also have a target director present, and when it is present then the carried material may be a bioactive agent. Preferred dendritic polymers are dense star polymers, which have been complexed with biological response modifiers. These conjugates and complexes have particularly advantageous properties due to their unique characteristics.",DOW CHEMICAL CO;;UNIV MICHIGAN ANN ARBOR,TOMALIA DONALD A;;BAKER JAMES R;;BIELINSKA ANNA U;;BROTHERS II;;CHENG ROBERTA C;;FAZIO MICHAEL J;;HEDSTRAND DAVID M;;JOHNSON JENNIFER A;;KAPLAN DONALD A;;KLAKAMP SCOTT L;;KRUPER JR;;KUKOWSKA-LATALLO JOLANTA;;MAXON BARTLEY D;;PIEHLER LARS T;;TOMLINSON IAN A;;WILSON LARRY R;;YIN RUI,"DENDRITIC NANOTECHNOLOGIES, INC., MT. PLEASANT, MI (2005-12-08);;THE REGENTS OF THE UNIVERSITY OF MICHIGAN, ANN ARB (2005-12-08)",https://lens.org/017-353-204-265-440,Granted Patent,no,0,0,35,36,0,A01N25/10;;A61K49/085;;A61K49/124;;B82Y5/00;;C07C211/29;;C07C233/11;;C07C237/20;;C08G83/003;;C08L101/005;;C12N15/87;;Y10S424/16;;A61K47/59;;A61K47/595;;A61K47/61;;A61K47/6949;;A61K47/50;;A61K47/46;;A01N25/10;;A61K49/085;;C07C211/29;;C12N15/87;;C07C233/11;;A61K49/124;;B82Y5/00;;C08L101/005;;C07C237/20;;C08G83/003;;Y10S424/16;;A61K47/61;;A61K47/59;;A61K47/6949;;A61K47/595,C12N15/02;;A01N25/10;;A61K/;;A61K31/70;;A61K38/00;;A61K39/385;;A61K39/44;;A61K45/00;;A61K47/34;;A61K47/48;;A61K48/00;;A61K49/00;;A61K51/00;;C07C211/29;;C07C233/11;;C07C237/20;;C07K/;;C07K14/525;;C07K14/535;;C07K14/54;;C07K14/555;;C07K17/06;;C07K17/08;;C08G73/00;;C08G83/00;;C08L101/00;;C12N/;;C12N5/10;;C12N15/09;;C12N15/57;;C12N15/87;;C12P21/02;;C12P21/08;;C12R1/91,,0,0,,,,EXPIRED
474,DE,T2,DE 69533569 T2,111-081-214-474-378,2006-01-05,2006,DE 69533569 T,1995-03-07,US 20749494 A;;US 31653694 A;;US 9503045 W,1994-03-07,BIOAKTIVE UND/ODER GEZIELTE DENDRIMERE-KONJUGATE ENTHALTEND GENETISCHES MATERIAL,"Dendritic polymer conjugates which are composed of at least one dendrimer in association with at least one unit of a carried material, where the carrier material can be a biological response modifier, have been prepared. The conjugate can also have a target director present, and when it is present then the carried material may be a bioactive agent. Preferred dendritic polymers are dense star polymers, which have been complexed with biological response modifiers. These conjugates and complexes have particularly advantageous properties due to their unique characteristics.",DENDRITIC NANOTECHNOLOGIES INC;;UNIV MICHIGAN ANN ARBOR,TOMALIA DONALD A;;BAKER JAMES R;;BIELINSKA ANNA U;;BROTHERS II;;CHENG ROBERTA C;;FAZIO MICHAEL J;;HEDSTRAND DAVID M;;JOHNSON JENNIFER A;;KAPLAN DONALD A;;KLAKAMP SCOTT L;;KRUPER JR;;KUKOWSKA-LATALLO JOLANTA;;MAXON BARTLEY D;;PIEHLER LARS T;;TOMLINSON IAN A;;WILSON LARRY R;;YIN RUI,"DENDRITIC NANOTECHNOLOGIES, INC., MT. PLEASANT, MI (2005-12-08);;THE REGENTS OF THE UNIVERSITY OF MICHIGAN, ANN ARB (2005-12-08)",https://lens.org/111-081-214-474-378,Granted Patent,no,0,0,35,36,0,A01N25/10;;A61K49/085;;A61K49/124;;B82Y5/00;;C07C211/29;;C07C233/11;;C07C237/20;;C08G83/003;;C08L101/005;;C12N15/87;;Y10S424/16;;A61K47/59;;A61K47/595;;A61K47/61;;A61K47/6949;;A61K47/50;;A61K47/46;;A01N25/10;;A61K49/085;;C07C211/29;;C12N15/87;;C07C233/11;;A61K49/124;;B82Y5/00;;C08L101/005;;C07C237/20;;C08G83/003;;Y10S424/16;;A61K47/61;;A61K47/59;;A61K47/6949;;A61K47/595,C12N15/02;;A01N25/10;;A61K/;;A61K31/70;;A61K38/00;;A61K39/385;;A61K39/44;;A61K45/00;;A61K47/34;;A61K47/48;;A61K48/00;;A61K49/00;;A61K51/00;;C07C211/29;;C07C233/11;;C07C237/20;;C07K/;;C07K14/525;;C07K14/535;;C07K14/54;;C07K14/555;;C07K17/06;;C07K17/08;;C08G73/00;;C08G83/00;;C08L101/00;;C12N/;;C12N5/10;;C12N15/09;;C12N15/57;;C12N15/87;;C12P21/02;;C12P21/08;;C12R1/91,,0,0,,,,EXPIRED
475,PL,A1,PL 311633 A1,181-806-888-862-486,1996-03-04,1996,PL 31163395 A,1995-03-07,US 20749494 A;;US 31653694 A;;US 9503045 W,1994-03-07,BIOLOGICALLY ACTIVE AND/OR ORIENTED CONJUGATES OF DENDRIMERS,"Dendritic polymer conjugates which are composed of at least one dendrimer in association with at least one unit of a carried material, where the carrier material can be a biological response modifier, have been prepared. The conjugate can also have a target director present, and when it is present then the carried material may be a bioactive agent. Preferred dendritic polymers are dense star polymers, which have been complexed with biological response modifiers. These conjugates and complexes have particularly advantageous properties due to their unique characteristics.",DOW CHEMICAL CO;;DENDRITECH INC;;UNIV MICHIGAN,TOMALIA DONALD A;;BAKER JAMES R;;BIELINSKA ANNA;;BROTHERS HERBERT M;;CHENG ROBERTA C;;FAZIO MICHAEL J;;HEDSTRAND DAVID M;;JOHNSON JENNIFER A;;KAPLAN DONALD A;;KLAKAMP SCOTT L;;KRUPER WILLIAM J JR;;KUKOWSKA-LATALLO JOLANTA;;MAXON BARTLEY D;;PIEHLER LARS T;;TOMLINSON IAN A;;WILSON LARRY R;;YIN RUI,,https://lens.org/181-806-888-862-486,Patent Application,no,0,0,35,36,0,A01N25/10;;A61K49/085;;A61K49/124;;B82Y5/00;;C07C211/29;;C07C233/11;;C07C237/20;;C08G83/003;;C08L101/005;;C12N15/87;;Y10S424/16;;A61K47/59;;A61K47/595;;A61K47/61;;A61K47/6949;;A61K47/50;;A61K47/46;;A01N25/10;;A61K49/085;;C07C211/29;;C12N15/87;;C07C233/11;;A61K49/124;;B82Y5/00;;C08L101/005;;C07C237/20;;C08G83/003;;Y10S424/16;;A61K47/61;;A61K47/59;;A61K47/6949;;A61K47/595,A01N25/10;;C12N15/02;;A61K/;;A61K31/70;;A61K38/00;;A61K39/385;;A61K39/44;;A61K45/00;;A61K47/34;;A61K47/48;;A61K48/00;;A61K49/00;;A61K51/00;;C07C211/29;;C07C233/11;;C07C237/20;;C07K/;;C07K14/525;;C07K14/535;;C07K14/54;;C07K14/555;;C07K17/06;;C07K17/08;;C08G73/00;;C08G83/00;;C08L101/00;;C12N/;;C12N5/10;;C12N15/09;;C12N15/57;;C12N15/87;;C12P21/02;;C12P21/08;;C12R1/91,,0,0,,,,EXPIRED
476,PL,B1,PL 181064 B1,051-142-859-523-095,2001-05-31,2001,PL 31163395 A,1995-03-07,US 20749494 A;;US 31653694 A;;US 9503045 W,1994-03-07,BIOLOGICALLY ACTIVE AND/OR ORIENTED CONJUGATES OF DENDRIMERS,"Dendritic polymer conjugates which are composed of at least one dendrimer in association with at least one unit of a carried material, where the carrier material can be a biological response modifier, have been prepared. The conjugate can also have a target director present, and when it is present then the carried material may be a bioactive agent. Preferred dendritic polymers are dense star polymers, which have been complexed with biological response modifiers. These conjugates and complexes have particularly advantageous properties due to their unique characteristics.",DOW CHEMICAL CO;;DENDRITECH INC;;UNIV MICHIGAN,TOMALIA DONALD A;;BAKER JAMES R;;BIELINSKA ANNA;;BROTHERS HERBERT M;;CHENG ROBERTA C;;FAZIO MICHAEL J;;HEDSTRAND DAVID M;;JOHNSON JENNIFER A;;KAPLAN DONALD A;;KLAKAMP SCOTT L;;KRUPER WILLIAM J JR;;KUKOWSKA-LATALLO JOLANTA;;MAXON BARTLEY D;;PIEHLER LARS T;;TOMLINSON IAN A;;WILSON LARRY R;;YIN RUI,,https://lens.org/051-142-859-523-095,Granted Patent,no,0,0,35,36,0,A01N25/10;;A61K49/085;;A61K49/124;;B82Y5/00;;C07C211/29;;C07C233/11;;C07C237/20;;C08G83/003;;C08L101/005;;C12N15/87;;Y10S424/16;;A61K47/59;;A61K47/595;;A61K47/61;;A61K47/6949;;A61K47/50;;A61K47/46;;A01N25/10;;A61K49/085;;C07C211/29;;C12N15/87;;C07C233/11;;A61K49/124;;B82Y5/00;;C08L101/005;;C07C237/20;;C08G83/003;;Y10S424/16;;A61K47/61;;A61K47/59;;A61K47/6949;;A61K47/595,A01N25/10;;A61K/;;A61K31/70;;C12N15/02;;A61K38/00;;A61K39/385;;A61K39/44;;A61K45/00;;A61K47/34;;A61K47/48;;A61K48/00;;A61K49/00;;A61K51/00;;C07C211/29;;C07C233/11;;C07C237/20;;C07K/;;C07K14/525;;C07K14/535;;C07K14/54;;C07K14/555;;C07K17/06;;C07K17/08;;C08G73/00;;C08G83/00;;C08L101/00;;C12N/;;C12N5/10;;C12N15/09;;C12N15/57;;C12N15/87;;C12P21/02;;C12P21/08;;C12R1/91,,0,0,,,,EXPIRED
477,AU,A,AU 2002/029312 A,189-755-812-322-452,2002-05-23,2002,AU 2002/029312 A,2002-03-28,AU 2002/029312 A;;AU 1999/064440 A,1999-12-10,Bioactive and/or targeted dendrimer conjugates,,DOW CHEMICAL CO;;UNIV MICHIGAN,TOMALIA DONALD A;;YIN RUI;;WILSON LARRY R;;TOMLINSON IAN A;;PIEHLER LARS T;;MAXON BARTLEY D;;KUKOWSKA-LATALLO JOLANTA;;KRUPER WILLAM J JR;;KLAKAMP SCOTT L;;KAPLAN DONALD A;;JOHNSON JENNIFER A;;HEDSTRAND DAVID M;;FAZIO MICHAEL J;;CHENG ROBERTA C;;BROTHERS HERBERT M;;BIELINSKA ANNA U;;BAKER JAMES R,,https://lens.org/189-755-812-322-452,Patent Application,no,0,0,4,4,0,,A61K47/34;;C07K17/08;;C08G69/46;;C08G83/00;;C12N15/09;;C12N15/63,,0,0,,,,EXPIRED
478,AU,B2,AU 750411 B2,116-281-428-883-706,2002-07-18,2002,AU 1999/064440 A,1999-12-10,AU 1999/064440 A,1999-12-10,Bioactive and/or targeted dendrimer conjugates,,DOW CHEMICAL CO;;UNIV MICHIGAN,TOMALIA DONALD A;;BAKER JAMES R;;BIELINSKA ANNA U;;BROTHERS HERBERT M;;CHENG ROBERTA C;;FAZIO MICHAEL J;;HEDSTRAND DAVID M;;JOHNSON JENNIFER A;;KAPLAN DONALD A;;KLAKAMP SCOTT L;;KRUPER WILLAM J JR;;KUKOWSKA-LATALLO JOLANTA;;MAXON BARTLEY D;;PIEHLER LARS T;;TOMLINSON IAN A;;WILSON LARRY R;;YIN RUI,"THE DOW CHEMICAL COMPANY, REGENTS OF THE UNIVERSIT (2002-08-08)",https://lens.org/116-281-428-883-706,Granted Patent,no,0,0,4,4,0,,A61K47/34;;C07K17/08;;C08G69/46;;C08G83/00;;C12N15/09;;C12N15/63,,0,0,,,,EXPIRED
479,DE,T1,DE 699079 T1,132-897-733-802-402,1997-09-25,1997,DE 95914006 T,1995-03-07,US 20749494 A;;US 31653694 A;;US 9503045 W,1994-03-07,BIOAKTIVE UND/ODER GEZIELTE DENDRIMERE-KONJUGATE,"Dendritic polymer conjugates which are composed of at least one dendrimer in association with at least one unit of a carried material, where the carrier material can be a biological response modifier, have been prepared. The conjugate can also have a target director present, and when it is present then the carried material may be a bioactive agent. Preferred dendritic polymers are dense star polymers, which have been complexed with biological response modifiers. These conjugates and complexes have particularly advantageous properties due to their unique characteristics.",DOW CHEMICAL CO;;DENDRITECH INC;;UNIV MICHIGAN,TOMALIA DONALD A;;BAKER JAMES R;;BIELINSKA ANNA U;;BROTHERS HERBERT M;;CHENG ROBERTA C;;FAZIO MICHAEL J;;HEDSTRAND DAVID M;;JOHNSON JENNIFER A;;KAPLAN DONALD A;;KLAKAMP SCOTT L;;KRUPER WILLIAM J;;KUKOWSKA-LATALLO JOLANTA;;MAXON BARTLEY D;;PIEHLER LARS T;;TOMLINSON IAN A;;WILSON LARRY R;;YIN RUI,,https://lens.org/132-897-733-802-402,Granted Patent,no,0,0,35,36,0,A01N25/10;;A61K49/085;;A61K49/124;;B82Y5/00;;C07C211/29;;C07C233/11;;C07C237/20;;C08G83/003;;C08L101/005;;C12N15/87;;Y10S424/16;;A61K47/59;;A61K47/595;;A61K47/61;;A61K47/6949;;A61K47/50;;A61K47/46;;A01N25/10;;A61K49/085;;C07C211/29;;C12N15/87;;C07C233/11;;A61K49/124;;B82Y5/00;;C08L101/005;;C07C237/20;;C08G83/003;;Y10S424/16;;A61K47/61;;A61K47/59;;A61K47/6949;;A61K47/595,C12N15/02;;A01N25/10;;A61K/;;A61K31/70;;A61K38/00;;A61K39/385;;A61K39/44;;A61K45/00;;A61K47/34;;A61K47/48;;A61K48/00;;A61K49/00;;A61K51/00;;C07C211/29;;C07C233/11;;C07C237/20;;C07K/;;C07K14/525;;C07K14/535;;C07K14/54;;C07K14/555;;C07K17/06;;C07K17/08;;C08G73/00;;C08G83/00;;C08L101/00;;C12N/;;C12N5/10;;C12N15/09;;C12N15/57;;C12N15/87;;C12P21/02;;C12P21/08;;C12R1/91,,0,0,,,,EXPIRED
480,AU,A,AU 1999/064440 A,100-338-370-099-33X,2000-05-11,2000,AU 1999/064440 A,1999-12-10,AU 1999/064440 A,1999-12-10,Bioactive and/or targeted dendrimer conjugates,,DENDRITIC NANOTECHNOLOGIES INC;;REGENTS OF THE UNIVERSITY OF MICHIGAN THE,TOMALIA DONALD A;;YIN RUI;;WILSON LARRY R;;TOMLINSON IAN A;;PIEHLER LARS T;;MAXON BARTLEY D;;KUKOWSKA-LATALLO JOLANTA;;KRUPER WILLAM J JR;;KALKAMP SCL;;KAPLAN DONALD A;;JOHNSON JENNIFER A;;HEDSTRAND DAVID M;;FAZIO MICHAEL J;;CHENG ROBERTA C;;BROTHERS HERBERT M;;BIELINSKA ANNA U;;BAKER JAMES R,"THE DOW CHEMICAL COMPANY, REGENTS OF THE UNIVERSIT (2002-08-08)",https://lens.org/100-338-370-099-33X,Patent Application,no,0,0,4,4,0,,A61K47/34;;C07K17/08;;C08G69/46;;C08G83/00;;C12N15/09;;C12N15/63,,0,0,,,,EXPIRED
481,PL,B1,PL 182237 B1,114-959-061-124-298,2001-11-30,2001,PL 33598295 A,1995-03-07,US 9503045 W;;US 31653694 A;;US 20749494 A,1994-03-07,METHOD OF EFFECTUATING TRANSFECTION OF CELLS AND ACHIEVING BIOAVAILABILITY OF GENETIC MATERIAL IN VITRO AND EX VITRO,"1. Method of carrying out cell transfection and achieving bio-accessibility of genetic material in vitro and ex vivo - Characterized in that: The cells to be transfected are contacted with a dendritic polymer complex containing genetic material, where the ratio of the genetic material to the dendrimer is within the range between about 1:1 and about 1:100, while the process is carried out in the solution of DEAE-dextran or glycerine. The dendritic polymer constitutes at least one solvent-soluble radially-symmetrical dendrimer, which contains at least one branch leaving from the core and containing at least one final group, while (1) the ratio of final groups to core branches is equal to two or more; (2) the density of final groups per polymer volume unit is at least 1.5 times larger than the density of a conventional elongated star-shaped polymer with a similar core and monomer components, with a comparable molecular weight and number of branches, while each branch of the elongated conventional star-shaped polymer contains only one final group; and (3) the molecule volume, determined on the basis of dimension examination by means of scalable molecule models of Corey-Pauling, constitutes not more than about 80 percent of the volume of the elongated conventional star-shaped polymer, and the polymer contains regular dendritic branches. 3. The method of carrying out cell transfection and achieving bio-accessibility of genetic material in vitro and ex vivo - Characterized in that: A complex of genetic material with the first dendritic polymer is produced. The dendritic polymer constitutes at least one solvent-soluble radially-symmetrical dendrimer, which contains at least one branch leaving from the core and containing at least one final group, while (1) the ratio of final groups to core branches is equal to two or more; (2) the density of final groups per polymer volume unit is at least 1.5 times larger than the density of a conventional elongated star-shaped polymer with a similar core and monomer components, with a comparable molecular weight and number of branches, while each branch of the elongated conventional star-shaped polymer contains only one final group; and (3) the molecule volume, determined on the basis of dimension examination by means of scalable molecule models of Corey-Pauling, constitutes not more than about 80 percent of the volume of the elongated conventional star-shaped polymer, and the polymer contains regular dendritic branches. Then, the complex is placed in a solution containing the second dendritic polymer, as defined above, but with larger molecules than in the case of the first dendritic polymer. The obtained complex and the second dendritic polymer are contacted with the cells to be transfected.",DOW CHEMICAL CO;;UNIV,TOMALIA DONALD A;;BAKER JAMES R;;BIELINSKA ANNA;;BROTHERS HERBERT M;;CHENG ROBERTA C;;FAZIO MICHAEL J;;HEDSTRAND DAVID M;;JOHNSON JENNIFER A;;KAPLAN DONALD A;;KLAKAMP SCOTT L;;KRUPER WILLIAM J JR;;KUKOWSKA-LATALLO JOLANTA;;MAXON BARTLEY D;;PIEHLER LARS T;;TOMLINSON IAN A;;WILSON LARRY R;;YIN RUI,,https://lens.org/114-959-061-124-298,Granted Patent,no,0,0,35,36,0,A01N25/10;;A61K49/085;;A61K49/124;;B82Y5/00;;C07C211/29;;C07C233/11;;C07C237/20;;C08G83/003;;C08L101/005;;C12N15/87;;Y10S424/16;;A61K47/59;;A61K47/595;;A61K47/61;;A61K47/6949;;A61K47/50;;A61K47/46;;A01N25/10;;A61K49/085;;C07C211/29;;C12N15/87;;C07C233/11;;A61K49/124;;B82Y5/00;;C08L101/005;;C07C237/20;;C08G83/003;;Y10S424/16;;A61K47/61;;A61K47/59;;A61K47/6949;;A61K47/595,A01N25/10;;A61K/;;A61K31/70;;C12N15/02;;A61K38/00;;A61K39/385;;A61K39/44;;A61K45/00;;A61K47/34;;A61K47/48;;A61K48/00;;A61K49/00;;A61K51/00;;C07C211/29;;C07C233/11;;C07C237/20;;C07K/;;C07K14/525;;C07K14/535;;C07K14/54;;C07K14/555;;C07K17/06;;C07K17/08;;C08G73/00;;C08G83/00;;C08L101/00;;C12N/;;C12N5/10;;C12N15/09;;C12N15/57;;C12N15/87;;C12P21/02;;C12P21/08;;C12R1/91,,0,0,,,,EXPIRED
482,AU,B2,AU 768662 B2,169-917-048-836-59X,2003-12-18,2003,AU 2002/029312 A,2002-03-28,AU 2002/029312 A;;AU 1999/064440 A,1999-12-10,Bioactive and/or targeted dendrimer conjugates,,DOW CHEMICAL CO;;UNIV MICHIGAN,TOMALIA DONALD A;;BAKER JAMES R;;BIELINSKA ANNA U;;BROTHERS HERBERT M;;CHENG ROBERTA C;;FAZIO MICHAEL J;;HEDSTRAND DAVID M;;JOHNSON JENNIFER A;;KAPLAN DONALD A;;KLAKAMP SCOTT L;;KRUPER WILLAM J JR;;KUKOWSKA-LATALLO JOLANTA;;MAXON BARTLEY D;;PIEHLER LARS T;;TOMLINSON IAN A;;WILSON LARRY R;;YIN RUI,,https://lens.org/169-917-048-836-59X,Granted Patent,no,1,0,4,4,0,,A61K47/34;;C07K17/08;;C08G69/46;;C08G83/00;;C12N15/09;;C12N15/63,,0,0,,,,EXPIRED
483,FI,A0,FI 955320 A0,140-233-793-878-570,1995-11-06,1995,FI 955320 A,1995-11-06,US 20749494 A;;US 31653694 A;;US 9503045 W,1994-03-07,Bioaktiivisia ja/tai kohdennettuja dendriimikonjugaatteja,"Dendritic polymer conjugates which are composed of at least one dendrimer in association with at least one unit of a carried material, where the carrier material can be a biological response modifier, have been prepared. The conjugate can also have a target director present, and when it is present then the carried material may be a bioactive agent. Preferred dendritic polymers are dense star polymers, which have been complexed with biological response modifiers. These conjugates and complexes have particularly advantageous properties due to their unique characteristics.",DOW CHEMICAL CO;;DENDRITECH INC;;UNIV MICHIGAN,TOMALIA DONALD A;;BAKER JAMES R;;BIELINSKA ANNA U;;BROTHERS II HERBERT M;;CHENG ROBERTA C;;FAZIO MICHAEL J;;HEDSTRAND DAVID M;;JOHNSON JENNIFER A;;KAPLAN DONALD A;;KLAKAMP SCOTT L;;KRUPER JR WILLIAM J;;KUKOWSKA-LATALLO JOLANTA;;MAXON BARTELY D;;PIEHLER LARS T;;TOMLINSON IAN A;;WILSON LARRY R;;YIN RUI,"DENDRITIC NANOTECHNOLOGIES, INC. (2005-08-30);;REGENTS OF THE UNIVERSITY OF MICHIGAN (2005-08-30)",https://lens.org/140-233-793-878-570,Patent Application,no,0,0,35,36,0,A01N25/10;;A61K49/085;;A61K49/124;;B82Y5/00;;C07C211/29;;C07C233/11;;C07C237/20;;C08G83/003;;C08L101/005;;C12N15/87;;Y10S424/16;;A61K47/59;;A61K47/595;;A61K47/61;;A61K47/6949;;A61K47/50;;A61K47/46;;A01N25/10;;A61K49/085;;C07C211/29;;C12N15/87;;C07C233/11;;A61K49/124;;B82Y5/00;;C08L101/005;;C07C237/20;;C08G83/003;;Y10S424/16;;A61K47/61;;A61K47/59;;A61K47/6949;;A61K47/595,C12N15/02;;A01N25/10;;A61K/;;A61K31/70;;A61K38/00;;A61K39/385;;A61K39/44;;A61K45/00;;A61K47/34;;A61K47/48;;A61K48/00;;A61K49/00;;A61K51/00;;C07C211/29;;C07C233/11;;C07C237/20;;C07K/;;C07K14/525;;C07K14/535;;C07K14/54;;C07K14/555;;C07K17/06;;C07K17/08;;C08G73/00;;C08G83/00;;C08L101/00;;C12N/;;C12N5/10;;C12N15/09;;C12N15/57;;C12N15/87;;C12P21/02;;C12P21/08;;C12R1/91,,0,0,,,,PENDING
484,NO,B1,NO 317691 B1,095-308-321-480-162,2004-12-06,2004,NO 954434 A,1995-11-06,US 20749494 A;;US 31653694 A;;US 9503045 W,1994-03-07,"Tette stjernepolymerkonjugatsamt sammensetning og formulering derav, og fremgangsmate for fremstilling av et kompleks.","Dendritic polymer conjugates which are composed of at least one dendrimer in association with at least one unit of a carried material, where the carrier material can be a biological response modifier, have been prepared. The conjugate can also have a target director present, and when it is present then the carried material may be a bioactive agent. Preferred dendritic polymers are dense star polymers, which have been complexed with biological response modifiers. These conjugates and complexes have particularly advantageous properties due to their unique characteristics.",DOW CHEMICAL CO;;UNIV MICHIGAN,HEDSTRAND DAVID M;;TOMALIA DONALD A;;TOMLINSON IAN A;;FAZIO MICHAEL J;;CHENG ROBERTA C;;KRUPER JR WILLIAM J;;BAKER JAMES R;;BIELINSKA ANNA U;;BROTHERS II HERBERG M;;JOHNSON JENNIFER A;;KAPLAN DONALD A;;KLAKAMP SCOTT L;;KUKOWSKA-LATALLO JOLANTA;;MAXON BARTLEY D;;PIEHLER LARS T;;WILSON LARRY R;;YIN RUI,,https://lens.org/095-308-321-480-162,Granted Patent,no,0,0,35,36,0,A01N25/10;;A61K49/085;;A61K49/124;;B82Y5/00;;C07C211/29;;C07C233/11;;C07C237/20;;C08G83/003;;C08L101/005;;C12N15/87;;Y10S424/16;;A61K47/59;;A61K47/595;;A61K47/61;;A61K47/6949;;A61K47/50;;A61K47/46;;A01N25/10;;A61K49/085;;C07C211/29;;C12N15/87;;C07C233/11;;A61K49/124;;B82Y5/00;;C08L101/005;;C07C237/20;;C08G83/003;;Y10S424/16;;A61K47/61;;A61K47/59;;A61K47/6949;;A61K47/595,A01N25/10;;A61K/;;C12N15/02;;A61K31/70;;A61K38/00;;A61K39/385;;A61K39/44;;A61K45/00;;A61K47/34;;A61K47/48;;A61K48/00;;A61K49/00;;A61K51/00;;C07C211/29;;C07C233/11;;C07C237/20;;C07K/;;C07K14/525;;C07K14/535;;C07K14/54;;C07K14/555;;C07K17/06;;C07K17/08;;C08G73/00;;C08G83/00;;C08L101/00;;C12N/;;C12N5/10;;C12N15/09;;C12N15/57;;C12N15/87;;C12P21/02;;C12P21/08;;C12R1/91,,0,0,,,,EXPIRED
485,AT,T1,AT E277640 T1,125-892-892-490-219,2004-10-15,2004,AT 95914006 T,1995-03-07,US 20749494 A;;US 31653694 A;;US 9503045 W,1994-03-07,BIOAKTIVE UND/ODER GEZIELTE DENDRIMERE-KONJUGATE ENTHALTEND GENETISCHES MATERIAL,"Dendritic polymer conjugates which are composed of at least one dendrimer in association with at least one unit of a carried material, where the carrier material can be a biological response modifier, have been prepared. The conjugate can also have a target director present, and when it is present then the carried material may be a bioactive agent. Preferred dendritic polymers are dense star polymers, which have been complexed with biological response modifiers. These conjugates and complexes have particularly advantageous properties due to their unique characteristics.",DOW CHEMICAL CO;;UNIV MICHIGAN,TOMALIA DONALD A;;BAKER JAMES R;;BIELINSKA ANNA U;;BROTHERS HERBERT M II;;CHENG ROBERTA C;;FAZIO MICHAEL J;;HEDSTRAND DAVID M;;JOHNSON JENNIFER A;;KAPLAN DONALD A;;KLAKAMP SCOTT L;;KRUPER WILLIAM J JR;;KUKOWSKA-LATALLO JOLANTA;;MAXON BARTLEY D;;PIEHLER LARS T;;TOMLINSON IAN A;;WILSON LARRY R;;YIN RUI,,https://lens.org/125-892-892-490-219,Granted Patent,no,0,0,35,36,0,A01N25/10;;A61K49/085;;A61K49/124;;B82Y5/00;;C07C211/29;;C07C233/11;;C07C237/20;;C08G83/003;;C08L101/005;;C12N15/87;;Y10S424/16;;A61K47/59;;A61K47/595;;A61K47/61;;A61K47/6949;;A61K47/50;;A61K47/46;;A01N25/10;;A61K49/085;;C07C211/29;;C12N15/87;;C07C233/11;;A61K49/124;;B82Y5/00;;C08L101/005;;C07C237/20;;C08G83/003;;Y10S424/16;;A61K47/61;;A61K47/59;;A61K47/6949;;A61K47/595,C12N15/02;;A01N25/10;;A61K/;;A61K31/70;;A61K38/00;;A61K39/385;;A61K39/44;;A61K45/00;;A61K47/34;;A61K47/48;;A61K48/00;;A61K49/00;;A61K51/00;;C07C211/29;;C07C233/11;;C07C237/20;;C07K/;;C07K14/525;;C07K14/535;;C07K14/54;;C07K14/555;;C07K17/06;;C07K17/08;;C08G73/00;;C08G83/00;;C08L101/00;;C12N/;;C12N5/10;;C12N15/09;;C12N15/57;;C12N15/87;;C12P21/02;;C12P21/08;;C12R1/91,,0,0,,,,DISCONTINUED
486,CA,A1,CA 2161684 A1,102-699-715-296-23X,1995-09-14,1995,CA 2161684 A,1995-03-07,US 20749494 A;;US 31653694 A;;US 9503045 W,1994-03-07,BIOACTIVE AND/OR TARGETED DENDRIMER CONJUGATES,"Dendritic polymer conjugates which are composed of at least one dendrimer in association with at least one unit of a carried material, where the carrier material can be a biological response modifier, have been prepared. The conjugate can also have a target director present, and when it is present, then the carried material may be a bioactive agent. Preferred dendritic polymers are dense starr polymers, which have been complexed with biological response modifiers. These conjugates and complexes have particularly advantageous properties due to their unique characteristics.",DOW CHEMICAL CO;;DENDRITECH INC;;UNIV MICHIGAN,TOMALIA DONALD A;;BAKER JAMES R;;BIELINSKA ANNA U;;BROTHERS HERBERT M II;;CHENG ROBERTA C;;FAZIO MICHAEL J;;HEDSTRAND DAVID M;;JOHNSON JENNIFER A;;KAPLAN DONALD A;;KLAKAMP SCOTT L;;KRUPER WILLIAM J JR;;KUKOWSKA-LATALLO JOLANTA;;MAXON BARTLEY D;;PIEHLER LARS T;;TOMLINSON IAN A;;WILSON LARRY R;;YIN RUI,,https://lens.org/102-699-715-296-23X,Patent Application,no,0,0,35,36,0,A01N25/10;;A61K49/085;;A61K49/124;;B82Y5/00;;C07C211/29;;C07C233/11;;C07C237/20;;C08G83/003;;C08L101/005;;C12N15/87;;Y10S424/16;;A61K47/59;;A61K47/595;;A61K47/61;;A61K47/6949;;A61K47/50;;A61K47/46;;A01N25/10;;A61K49/085;;C07C211/29;;C12N15/87;;C07C233/11;;A61K49/124;;B82Y5/00;;C08L101/005;;C07C237/20;;C08G83/003;;Y10S424/16;;A61K47/61;;A61K47/59;;A61K47/6949;;A61K47/595,C12N15/02;;A01N25/10;;A61K/;;A61K31/70;;A61K38/00;;A61K39/385;;A61K39/44;;A61K45/00;;A61K47/34;;A61K47/48;;A61K48/00;;A61K49/00;;A61K51/00;;C07C211/29;;C07C233/11;;C07C237/20;;C07K/;;C07K14/525;;C07K14/535;;C07K14/54;;C07K14/555;;C07K17/06;;C07K17/08;;C08G73/00;;C08G83/00;;C08L101/00;;C12N/;;C12N5/10;;C12N15/09;;C12N15/57;;C12N15/87;;C12P21/02;;C12P21/08;;C12R1/91,,0,0,,,,EXPIRED
487,WO,A1,WO 1995/024221 A1,086-586-331-697-844,1995-09-14,1995,US 9503045 W,1995-03-07,US 89745586 A;;US 8726687 A;;US 38604989 A;;US 65485191 A;;US 4319893 A;;US 20749494 A;;US 31653694 A,1986-08-18,BIOACTIVE AND/OR TARGETED DENDRIMER CONJUGATES,"Dendritic polymer conjugates which are composed of at least one dendrimer in association with at least one unit of a carried material, where the carrier material can be a biological response modifier, have been prepared. The conjugate can also have a target director present, and when it is present, then the carried material may be a bioactive agent. Preferred dendritic polymers are dense starr polymers, which have been complexed with biological response modifiers. These conjugates and complexes have particularly advantageous properties due to their unique characteristics.",DOW CHEMICAL CO;;DENDRITECH INC;;UNIV MICHIGAN;;TOMALIA DONALD A;;BAKER JAMES R;;BIELINSKA ANNA U;;BROTHERS HERBERT M II;;CHENG ROBERTA C;;FAZIO MICHAEL J;;HEDSTRAND DAVID M;;JOHNSON JENNIFER A;;KAPLAN DONALD A;;KLAKAMP SCOTT L;;KRUPER WILLIAM J JR;;KUKOWSKA LATALLO JOLANTA;;MAXON BARTLEY D;;PIEHLER LARS T;;TOMLINSON IAN A;;WILSON LARRY R;;YIN RUI,TOMALIA DONALD A;;BAKER JAMES R;;BIELINSKA ANNA U;;BROTHERS HERBERT M II;;CHENG ROBERTA C;;FAZIO MICHAEL J;;HEDSTRAND DAVID M;;JOHNSON JENNIFER A;;KAPLAN DONALD A;;KLAKAMP SCOTT L;;KRUPER WILLIAM J JR;;KUKOWSKA-LATALLO JOLANTA;;MAXON BARTLEY D;;PIEHLER LARS T;;TOMLINSON IAN A;;WILSON LARRY R;;YIN RUI,,https://lens.org/086-586-331-697-844,Patent Application,yes,4,64,35,36,0,A01N25/10;;A61K49/085;;A61K49/124;;B82Y5/00;;C07C211/29;;C07C233/11;;C07C237/20;;C08G83/003;;C08L101/005;;C12N15/87;;Y10S424/16;;A61K47/59;;A61K47/595;;A61K47/61;;A61K47/6949;;A61K47/50;;A61K47/46;;A01N25/10;;A61K49/085;;C07C211/29;;C12N15/87;;C07C233/11;;A61K49/124;;B82Y5/00;;C08L101/005;;C07C237/20;;C08G83/003;;Y10S424/16;;A61K47/61;;A61K47/59;;A61K47/6949;;A61K47/595,A01N25/10;;A61K/;;C12N15/02;;A61K31/70;;A61K38/00;;A61K39/385;;A61K39/44;;A61K45/00;;A61K47/34;;A61K47/48;;A61K48/00;;A61K49/00;;A61K51/00;;C07C211/29;;C07C233/11;;C07C237/20;;C07K/;;C07K14/525;;C07K14/535;;C07K14/54;;C07K14/555;;C07K17/06;;C07K17/08;;C08G73/00;;C08G83/00;;C08L101/00;;C12N/;;C12N5/10;;C12N15/09;;C12N15/57;;C12N15/87;;C12P21/02;;C12P21/08;;C12R1/91,,3,1,014-433-203-356-042,8121264;;10.1002/mrm.1910310102,"DATABASE WPI Section Ch Week 9344, Derwent World Patents Index; Class A18, AN 93-351682;;CHEMICAL ABSTRACTS, vol. 121, no. 8, 22 August 1994, Columbus, Ohio, US; abstract no. 91405, AKIYOSHI, KAZUNARI: ""Cascade polymers as drug carriers"";;WIENER, E. C. ET AL: ""Dendrimer-based metal chelates: a new class of magnetic resonance imaging contrast agents"", MAGN. RESON. MED. (1994), 31(1), 1-8 CODEN: MRMEEN;ISSN: 0740-3194",PATENTED
488,NO,L,NO 954434 L,094-251-967-356-776,1996-01-05,1996,NO 954434 A,1995-11-06,US 20749494 A;;US 31653694 A;;US 9503045 W,1994-03-07,Bioaktive og/eller målsökende dendrimer-konjugater,"Dendritic polymer conjugates which are composed of at least one dendrimer in association with at least one unit of a carried material, where the carrier material can be a biological response modifier, have been prepared. The conjugate can also have a target director present, and when it is present then the carried material may be a bioactive agent. Preferred dendritic polymers are dense star polymers, which have been complexed with biological response modifiers. These conjugates and complexes have particularly advantageous properties due to their unique characteristics.",DOW CHEMICAL CO;;DENDRITECH INC;;UNIV MICHIGAN,TOMALIA DONALD A;;BAKER JAMES R;;BIELINSKA ANNA U;;BROTHERS II HERBERG M;;CHENG ROBERTA C;;FAZIO MICHAEL J;;HEDSTRAND DAVID M;;JOHNSON JENNIFER A;;KAPLAN DONALD A;;KLAKAMP SCOTT L;;KRUPER JR WILLIAM J;;KUKOWSKA-LATALLO JOLANTA;;MAXON BARTLEY D;;PIEHLER LARS T;;TOMLINSON IAN A;;WILSON LARRY R;;YIN RUI,,https://lens.org/094-251-967-356-776,Abstract,no,0,0,35,36,0,A01N25/10;;A61K49/085;;A61K49/124;;B82Y5/00;;C07C211/29;;C07C233/11;;C07C237/20;;C08G83/003;;C08L101/005;;C12N15/87;;Y10S424/16;;A61K47/59;;A61K47/595;;A61K47/61;;A61K47/6949;;A61K47/50;;A61K47/46;;A01N25/10;;A61K49/085;;C07C211/29;;C12N15/87;;C07C233/11;;A61K49/124;;B82Y5/00;;C08L101/005;;C07C237/20;;C08G83/003;;Y10S424/16;;A61K47/61;;A61K47/59;;A61K47/6949;;A61K47/595,A01N25/10;;A61K/;;C12N15/02;;A61K31/70;;A61K38/00;;A61K39/385;;A61K39/44;;A61K45/00;;A61K47/34;;A61K47/48;;A61K48/00;;A61K49/00;;A61K51/00;;C07C211/29;;C07C233/11;;C07C237/20;;C07K/;;C07K14/525;;C07K14/535;;C07K14/54;;C07K14/555;;C07K17/06;;C07K17/08;;C08G73/00;;C08G83/00;;C08L101/00;;C12N/;;C12N5/10;;C12N15/09;;C12N15/57;;C12N15/87;;C12P21/02;;C12P21/08;;C12R1/91,,0,0,,,,EXPIRED
489,FI,A,FI 955320 A,199-570-859-199-780,1995-11-24,1995,FI 955320 A,1995-11-06,US 20749494 A;;US 31653694 A;;US 9503045 W,1994-03-07,Bioaktiivisia ja/tai kohdennettuja dendriimikonjugaatteja,"Dendritic polymer conjugates which are composed of at least one dendrimer in association with at least one unit of a carried material, where the carrier material can be a biological response modifier, have been prepared. The conjugate can also have a target director present, and when it is present then the carried material may be a bioactive agent. Preferred dendritic polymers are dense star polymers, which have been complexed with biological response modifiers. These conjugates and complexes have particularly advantageous properties due to their unique characteristics.",DOW CHEMICAL CO;;DENDRITECH INC;;UNIV MICHIGAN,TOMALIA DONALD A;;BAKER JAMES R;;BIELINSKA ANNA U;;BROTHERS II HERBERT M;;CHENG ROBERTA C;;FAZIO MICHAEL J;;HEDSTRAND DAVID M;;JOHNSON JENNIFER A;;KAPLAN DONALD A;;KLAKAMP SCOTT L;;KRUPER JR WILLIAM J;;KUKOWSKA-LATALLO JOLANTA;;MAXON BARTELY D;;PIEHLER LARS T;;TOMLINSON IAN A;;WILSON LARRY R;;YIN RUI,"DENDRITIC NANOTECHNOLOGIES, INC. (2005-08-30);;REGENTS OF THE UNIVERSITY OF MICHIGAN (2005-08-30)",https://lens.org/199-570-859-199-780,Patent Application,no,0,0,35,36,0,A01N25/10;;A61K49/085;;A61K49/124;;B82Y5/00;;C07C211/29;;C07C233/11;;C07C237/20;;C08G83/003;;C08L101/005;;C12N15/87;;Y10S424/16;;A61K47/59;;A61K47/595;;A61K47/61;;A61K47/6949;;A61K47/50;;A61K47/46;;A01N25/10;;A61K49/085;;C07C211/29;;C12N15/87;;C07C233/11;;A61K49/124;;B82Y5/00;;C08L101/005;;C07C237/20;;C08G83/003;;Y10S424/16;;A61K47/61;;A61K47/59;;A61K47/6949;;A61K47/595,C12N15/02;;A01N25/10;;A61K/;;A61K31/70;;A61K38/00;;A61K39/385;;A61K39/44;;A61K45/00;;A61K47/34;;A61K47/48;;A61K48/00;;A61K49/00;;A61K51/00;;C07C211/29;;C07C233/11;;C07C237/20;;C07K/;;C07K14/525;;C07K14/535;;C07K14/54;;C07K14/555;;C07K17/06;;C07K17/08;;C08G73/00;;C08G83/00;;C08L101/00;;C12N/;;C12N5/10;;C12N15/09;;C12N15/57;;C12N15/87;;C12P21/02;;C12P21/08;;C12R1/91,,0,0,,,,PENDING
490,US,A,US 5714166 A,008-815-788-113-850,1998-02-03,1998,US 40020395 A,1995-03-07,US 40020395 A;;US 31653694 A;;US 20749494 A;;US 4319893 A;;US 65485191 A;;US 38604989 A;;US 8726687 A;;US 89745586 A,1986-08-18,Bioactive and/or targeted dendrimer conjugates,"Dendritic polymer conjugates which are composed of at least one dendrimer in association with at least one unit of a carried material, where the carrier material can be a biological response modifier, have been prepared. The conjugate can also have a target director present, and when it is present then the carried material may be a bioactive agent. Preferred dendritic polymers are dense star polymers, which have been complexed with biological response modifiers. These conjugates and complexes have particularly advantageous properties due to their unique characteristics.",DOW CHEMICAL CO;;DENDRITECH INC;;UNIV MICHIGAN,TOMALIA DONALD A;;BAKER JAMES R;;CHENG ROBERTA C;;BIELINSKA ANNA U;;FAZIO MICHAEL J;;HEDSTRAND DAVID M;;JOHNSON JENNIFER A;;KAPLAN DONALD A;;KLAKAMP SCOTT L;;KRUPER JR WILLIAM J;;KUKOWSKA-LATALLO JOLANTA;;MAXON BARTLEY D;;PIEHLER LARS T;;TOMLINSON IAN A;;WILSON LARRY R;;YIN RUI;;BROTHERS II HERBERT M,DENDRITIC NANOTECHNOLOGIES. INC (2005-02-15);;DOW CHEMICAL COMPANY THE (2001-07-02);;DENDRITECH INCORPORATED (1995-03-21);;REGENTS OF THE UNIVERSITY OF MICHIGAN THE (1995-05-12);;AVC HOLDINGS INC (2005-02-01),https://lens.org/008-815-788-113-850,Granted Patent,yes,66,499,35,36,0,A01N25/10;;A61K49/085;;A61K49/124;;B82Y5/00;;C07C211/29;;C07C233/11;;C07C237/20;;C08G83/003;;C08L101/005;;C12N15/87;;Y10S424/16;;A61K47/59;;A61K47/595;;A61K47/61;;A61K47/6949;;A61K47/50;;A61K47/46;;A01N25/10;;A61K49/085;;C07C211/29;;C12N15/87;;C07C233/11;;A61K49/124;;B82Y5/00;;C08L101/005;;C07C237/20;;C08G83/003;;Y10S424/16;;A61K47/61;;A61K47/59;;A61K47/6949;;A61K47/595,A01N25/10;;A61K/;;A61K31/70;;C12N15/02;;A61K38/00;;A61K39/385;;A61K39/44;;A61K45/00;;A61K47/34;;A61K47/48;;A61K48/00;;A61K49/00;;A61K51/00;;C07C211/29;;C07C233/11;;C07C237/20;;C07K/;;C07K14/525;;C07K14/535;;C07K14/54;;C07K14/555;;C07K17/06;;C07K17/08;;C08G73/00;;C08G83/00;;C08L101/00;;C12N/;;C12N5/10;;C12N15/09;;C12N15/57;;C12N15/87;;C12P21/02;;C12P21/08;;C12R1/91,424/486;;424/1.29;;424/1.33;;424/1.37;;424/1.41;;424/1.49;;424/9.3;;424/9.322;;424/9.32;;424/9.36;;424/9.4;;424/9.42;;424/9.6;;424/78.08;;424/93.1;;424/178.1;;424/193.1;;424/204.1;;424/234.1;;424/280;;X424DIG  16;;424/405;;424/417;;514/772;;523/105;;525/417;;935/52;;935/54,69,39,064-442-363-575-605;;025-826-573-344-520;;037-169-692-647-565;;197-698-560-021-363;;004-912-179-216-140;;058-429-436-163-000;;099-487-416-905-68X;;016-105-053-679-849;;145-596-669-249-560;;004-336-132-497-691;;110-509-109-698-351;;057-765-040-654-07X;;019-377-804-719-572;;016-928-022-550-951;;070-475-862-912-774;;058-614-758-287-617;;160-923-598-951-537;;070-913-313-442-527;;004-818-816-069-227;;009-881-818-536-152;;071-587-151-986-956;;035-240-148-017-355;;133-689-003-394-865;;166-549-653-488-882;;000-334-915-112-036;;124-254-252-973-260;;059-918-800-971-834;;122-809-255-733-370;;064-161-055-040-755;;045-857-392-228-624;;012-481-880-840-417;;064-161-055-040-755;;012-481-880-840-417;;160-217-204-333-800;;070-913-313-442-527;;021-917-483-303-942;;045-039-263-696-910;;114-517-649-646-486;;074-543-290-342-119,2835080;;10.1021/bi00403a008;;8274523;;10.1021/bc00023a012;;10.1021/ar00029a008;;2255890;;10.1038/scientificamerican1190-68;;10.1126/science.8493530;;8493530;;3049582;;10.1016/s0021-9258(18)68081-0;;7691415;;10.1016/0092-8674(93)80063-k;;16667645;;pmc1062700;;10.1104/pp.93.4.1492;;pmc47802;;8248135;;10.1073/pnas.90.22.10489;;3458887;;10.1073/pnas.85.15.5409;;pmc281766;;3399498;;10.1016/0304-5102(85)80002-x;;10.1016/0304-5102(85)80003-1;;2098106;;10.1021/bc00005a001;;10.1295/polymj.17.117;;10.1021/ma00163a029;;3730595;;10.1038/255487a0;;1138199;;10.1073/pnas.83.12.4277;;3459174;;pmc323715;;10.1295/polymj.24.573;;10.1021/jo00233a002;;10.1021/ma00171a051;;10.1021/ja00188a079;;10.1021/ja00167a094;;10.1021/ja00179a034;;10.1021/ja00019a034;;10.1021/ma00205a039;;10.1016/0014-5793(90)80417-h;;8305514;;10.1021/bc00024a006;;10.1021/ja00094a078;;10.1002/bip.360311210;;1840094;;8305514;;10.1021/bc00024a006;;10.1002/bip.360311210;;1840094;;10.1080/00397919308011178;;10.1038/255487a0;;1138199;;17788779;;10.1126/science.267.5197.458;;10.1016/s0021-9258(18)99963-1;;8175709;;10.1021/bc00029a002;;7849066;;pmc53961;;2339110;;10.1073/pnas.87.10.3655,"Wu, Biochemistry, vol. 27, pp. 887 892, 1988.;;Paul Communications In Mass Spectrometry, vol. 5, 323 386 (1991).;;Conjugate Chem., 1993, 372 379, Haensler et al.;;Acc. Chem. Res., 1993, 26, 274 278, Behr.;;Scientific American, Nov. 1990, 68 84 (Verma).;;Chemistry in Britain, Jun. 1993, 484 488, Brown et al.;;Science, vol. 260, May 14, 1993, 926 932, Mulligan.;;The Journal of Biological Chemistry, Oct. 15, 1988, vol. 263, No. 29, 14621 14624, Wu et al.;;Chem. & Eng. News, Aug. 16, 1993, pp. 20 23.;;Cell, vol. 75 (1993), 207 216, Zabner et al.;;Transfection reagent, Klakamp, Cat. No. 1202 375.;;Angewandte Chemie International Edition, vol. 29, Feb. 1990, 138 175.;;Plant Physical, (1990) 93, 1492 1496, Horn et al.;;Proc. Natl. Acad, Sci. USA, Nov. 1993, vol. 90, 10489 10493.;;Biconjugate Chemistry, Sep./Oct. 1993, V4, No. 5, pp. 372 379.;;J. Nucl. Med., 27, pp. 829 833 (1986), Anderson et al.;;Proc. Nat l Acad. Sci. (U.S.A.), 85, pp. 5409 5413 (1988), Tam.;;Journal of Molecular Catalysis, 32, pp. 149 158 (1985), Savinova et al.;;Journal of Molecular Catalysis, 32, pp. 159 175 (1985), Savinova et al.;;Bioconjugate Chemistry, 1, pp. 305 308 (1990), Roberts et al.;;Polymer Journal, 17(1), pp. 117 132 (Jan. 1985), Tomalia et al.;;Macromolecules, 19(9), pp. 2466 2468, Tomalia et al. 1986.;;Biochem. Biophys. Acta. 883, (1986), Manabe et al.;;Byull, Eksp. Biol. Med. (BEBMAE), 102(7), pp. 63 65 (1986), Torchilin et al.;;Nature, 225, pp. 487 488 (Jun. 5, 1975), Rowland et al.;;Proceedings Nat l Acad. Sc. (U.S.A.), 83, pp. 4277 4281 (1986), Curtet et al.;;Polymer Journal, 24,(6), pp. 573 581 (1992).;;J. Chem. Soc. Chem. Commun., 1992, pp. 608 610.;;The Chemical Society of Japan, Chemistry Letters, pp. 959 962, (1992).;;Angew. Chem. Int. Ed. Engl., 31,(12), (1992).;;J. Org. Chem., 52, pp. 5305 5312, (1987).;;J. Am. Chem. Soc., 109, pp. 1601 1603, (1987).;;Macromolecules, 20, pp. 1164 1167, (1987).;;Angew. Chem. Int. Ed. Engl., 31,(11), pp. 1493 1495, (1992).;;J. Am. Chem. Soc., 111, pp. 2339 2341, (1989).;;J. Am. Chem. Soc., 112, pp. 4592 4593, (1990).;;J. Macromol. Sci. Chem., A17,(4), pp. 689 703, (1982).;;J. Org. Chem., 50, pp. 2003 2004, (1985).;;J. Am. Chem. Soc. 112, pp. 8458 8465, (1990).;;Angew. Chem. Int. Ed. Engl., 30, pp. 1177 1180, (1991).;;Acc. Chem. Res., 24, pp. 332 340, (1991).;;J. Am. Chem. Soc., 113, pp. 7335 7342, 1991.;;Macromolecules, 23, pp. 910 912, (1990).;;Poly. Prep., 32, (31), pp. 602 603, (1991).;;J. Org. Chem., 57, p. 435, (1992).;;Progress in Neutron Capture Therapy for Cancer, Plenum Press, New York, 1992, pp. 265 268.;;Genes IV, Benjamin Lewin, Oxford University Press, 1990, pp. 409 430.;;Bioconjugate Chemistry, Kabanov et al., 1993, V 4, 448 454.;;Polymer Science, Kabanov et al., V 36, No. 2, 1994, pp. 157 168.;;J. Am. Chem. Soc., 1994, V 116, pp. 6975 6976.;;Biopolymers, Kabanov et al., V 31, pp. 1437 1443 1991.;;Kabanov s Lecture in MacroAkron Symposium (Jul. 11 15, 1994) supramolecular devices for targeting DNA into cells .;;Bioconjugate Chem., 1993, 4, 448 454, Kabanov et al.;;Biopolymers, vol. 31, 1437 1443 (1991), Kabanov et al.;;Polymer Science, vol. 16, No. 2 1994, pp. 157 168. Galligan. et al.;;Chem. & Eng. News, Jul. 24, 1995 pp. 37 40 Borman.;;Proceed. Intern. Symp. Sontrol. Rel. Bloact. Master. 22 (1985) 178 179, Mumper, R.J.;;Communications. Sep. 1984. pp. 782 784.;;Synthetic Communications. 23(22), 3191 3194 (1993), Cheng.;;J. Chem. Phys., 11,45 (1943), pp. 2719 2723 Stockmayer.;;Radio Communications in Mass Spect. vol. 5, pp. 383 386. (1991), Kallos.;;Sci. Chem., A17(4), pp. 689 703 (1982), Macromol.;;Nature., vol. 255, Jun. 5, 1975, pp. 487 488.;;Science, vol. 267, Jan. 27, 1995, pp. 458 459.;;Journal of Boiological Chemistry. vol. 269. No. 17 Apr. 29, 1994, pp. 12918 12924.;;Proc. Natl. Acad, Sci. USA, vol. 34. pp. 7413 7417.;;Bioconjugate Chem. 1994, vol. 5, pp. 382 389.;;Proc. Natl. Acad. Sci. USA 87 (1990) pp. 3655 3659. Zenke et al.;;Complexes of DNA with Skynthetic . . . Kabanov. Dept. of Polymer Science, Moscow State University, v 234, USSR and aboratory of Biopolymer Chemistry, Moscow 113149, USSR.",EXPIRED
491,EP,B1,EP 0699079 B1,190-105-203-042-042,2004-09-29,2004,EP 95914006 A,1995-03-07,US 9503045 W;;US 20749494 A;;US 31653694 A,1994-03-07,BIOACTIVE AND/OR TARGETED DENDRIMER CONJUGATES COMPRISING GENETIC MATERIALS,"Dendritic polymer conjugates which are composed of at least one dendrimer in association with at least one unit of a carried material, where the carrier material can be a biological response modifier, have been prepared. The conjugate can also have a target director present, and when it is present then the carried material may be a bioactive agent. Preferred dendritic polymers are dense star polymers, which have been complexed with biological response modifiers. These conjugates and complexes have particularly advantageous properties due to their unique characteristics.",DOW CHEMICAL CO;;UNIV MICHIGAN,TOMALIA DONALD A;;BAKER JAMES R;;BIELINSKA ANNA U;;BROTHERS HERBERT M II;;CHENG ROBERTA C;;FAZIO MICHAEL J;;HEDSTRAND DAVID M;;JOHNSON JENNIFER A;;KAPLAN DONALD A;;KLAKAMP SCOTT L;;KRUPER WILLIAM J JR;;KUKOWSKA-LATALLO JOLANTA;;MAXON BARTLEY D;;PIEHLER LARS T;;TOMLINSON IAN A;;WILSON LARRY R;;YIN RUI,"DENDRITIC NANOTECHNOLOGIES, INC. (2005-06-16);;THE REGENTS OF THE UNIVERSITY OF MICHIGAN TECHNOL (2001-10-10);;THE DOW CHEMICAL COMPANY (2001-10-10);;DENDRITECH INCORPORATED (1997-11-26);;THE REGENTS OF THE UNIVERSITY OF MICHIGAN (2005-06-16);;AVC HOLDINGS INC. (2005-06-16)",https://lens.org/190-105-203-042-042,Granted Patent,yes,0,0,35,36,0,A01N25/10;;A61K49/085;;A61K49/124;;B82Y5/00;;C07C211/29;;C07C233/11;;C07C237/20;;C08G83/003;;C08L101/005;;C12N15/87;;Y10S424/16;;A61K47/59;;A61K47/595;;A61K47/61;;A61K47/6949;;A61K47/50;;A61K47/46;;A01N25/10;;A61K49/085;;C07C211/29;;C12N15/87;;C07C233/11;;A61K49/124;;B82Y5/00;;C08L101/005;;C07C237/20;;C08G83/003;;Y10S424/16;;A61K47/61;;A61K47/59;;A61K47/6949;;A61K47/595,C12N15/02;;A01N25/10;;A61K/;;A61K31/70;;A61K38/00;;A61K39/385;;A61K39/44;;A61K45/00;;A61K47/34;;A61K47/48;;A61K48/00;;A61K49/00;;A61K51/00;;C07C211/29;;C07C233/11;;C07C237/20;;C07K/;;C07K14/525;;C07K14/535;;C07K14/54;;C07K14/555;;C07K17/06;;C07K17/08;;C08G73/00;;C08G83/00;;C08L101/00;;C12N/;;C12N5/10;;C12N15/09;;C12N15/57;;C12N15/87;;C12P21/02;;C12P21/08;;C12R1/91,,4,4,025-826-573-344-520;;052-923-517-523-448;;124-733-194-893-825;;063-384-088-949-756,8274523;;10.1021/bc00023a012;;8199235;;10.1021/bc00025a008;;10.1021/bc9600630;;8950489;;10.1002/anie.199001381,"HAENSLER J. et al: BIOCONJUGATE CHEM., 4, 1993, 372-379;;Barth R.F. et al: BIOCONJUGATE CHEM., 5(1), Jan./Feb. 1994, 58-66;;Tang M.X. et al: BIOCONJUGATE CHEM., 7, 1996, 703-714;;Tomalia D.A. et al: Angewandte Chemie, 1990, 29(2), 138-175",EXPIRED
492,NO,D0,NO 954434 D0,034-321-361-879-972,1995-11-06,1995,NO 954434 A,1995-11-06,US 20749494 A;;US 31653694 A;;US 9503045 W,1994-03-07,Bioaktive og/eller målsökende dendrimer-konjugater,"Dendritic polymer conjugates which are composed of at least one dendrimer in association with at least one unit of a carried material, where the carrier material can be a biological response modifier, have been prepared. The conjugate can also have a target director present, and when it is present then the carried material may be a bioactive agent. Preferred dendritic polymers are dense star polymers, which have been complexed with biological response modifiers. These conjugates and complexes have particularly advantageous properties due to their unique characteristics.",DOW CHEMICAL CO;;DENDRITECH INC;;UNIV MICHIGAN,TOMALIA DONALD A;;BAKER JAMES R;;BIELINSKA ANNA U;;BROTHERS II HERBERG M;;CHENG ROBERTA C;;FAZIO MICHAEL J;;HEDSTRAND DAVID M;;JOHNSON JENNIFER A;;KAPLAN DONALD A;;KLAKAMP SCOTT L;;KRUPER JR WILLIAM J;;KUKOWSKA-LATALLO JOLANTA;;MAXON BARTLEY D;;PIEHLER LARS T;;TOMLINSON IAN A;;WILSON LARRY R;;YIN RUI,,https://lens.org/034-321-361-879-972,Patent Application,no,0,0,35,36,0,A01N25/10;;A61K49/085;;A61K49/124;;B82Y5/00;;C07C211/29;;C07C233/11;;C07C237/20;;C08G83/003;;C08L101/005;;C12N15/87;;Y10S424/16;;A61K47/59;;A61K47/595;;A61K47/61;;A61K47/6949;;A61K47/50;;A61K47/46;;A01N25/10;;A61K49/085;;C07C211/29;;C12N15/87;;C07C233/11;;A61K49/124;;B82Y5/00;;C08L101/005;;C07C237/20;;C08G83/003;;Y10S424/16;;A61K47/61;;A61K47/59;;A61K47/6949;;A61K47/595,A01N25/10;;C12N15/02;;A61K/;;A61K31/70;;A61K38/00;;A61K39/385;;A61K39/44;;A61K45/00;;A61K47/34;;A61K47/48;;A61K48/00;;A61K49/00;;A61K51/00;;C07C211/29;;C07C233/11;;C07C237/20;;C07K/;;C07K14/525;;C07K14/535;;C07K14/54;;C07K14/555;;C07K17/06;;C07K17/08;;C08G73/00;;C08G83/00;;C08L101/00;;C12N/;;C12N5/10;;C12N15/09;;C12N15/57;;C12N15/87;;C12P21/02;;C12P21/08;;C12R1/91,,0,0,,,,EXPIRED
493,GR,T1,GR 970300044 T1,188-699-501-982-509,1997-11-28,1997,GR 970300044 T,1997-11-28,US 20749494 A;;US 31653694 A;;US 9503045 W,1994-03-07,BIOACTIVE AND/OR TARGETED DENDRIMER CONJUGATES,"Dendritic polymer conjugates which are composed of at least one dendrimer in association with at least one unit of a carried material, where the carrier material can be a biological response modifier, have been prepared. The conjugate can also have a target director present, and when it is present then the carried material may be a bioactive agent. Preferred dendritic polymers are dense star polymers, which have been complexed with biological response modifiers. These conjugates and complexes have particularly advantageous properties due to their unique characteristics.",DOW CHEMICAL CO;;DENDRITECH INC;;UNIV MICHIGAN,TOMALIA DONALD A;;BAKER JAMES R;;BIELINSKA ANNA U;;BROTHERS HERBERT M II;;CHENG ROBERTA C;;FAZIO MICHAEL J;;HEDSTRAND DAVID M;;JOHNSON JENNIFER A;;KAPLAN DONALD A;;KLAKAMP SCOTT L;;KRUPER WILLIAM J JR;;KUKOWSKA-LATALLO JOLANTA;;MAXON BARTLEY D;;PIEHLER LARS T;;TOMLINSON IAN A;;WILSON LARRY R;;YIN RUI,,https://lens.org/188-699-501-982-509,Granted Patent,no,0,0,35,36,0,A01N25/10;;A61K49/085;;A61K49/124;;B82Y5/00;;C07C211/29;;C07C233/11;;C07C237/20;;C08G83/003;;C08L101/005;;C12N15/87;;Y10S424/16;;A61K47/59;;A61K47/595;;A61K47/61;;A61K47/6949;;A61K47/50;;A61K47/46;;A01N25/10;;A61K49/085;;C07C211/29;;C12N15/87;;C07C233/11;;A61K49/124;;B82Y5/00;;C08L101/005;;C07C237/20;;C08G83/003;;Y10S424/16;;A61K47/61;;A61K47/59;;A61K47/6949;;A61K47/595,A01N25/10;;A61K/;;C12N15/02;;A61K31/70;;A61K38/00;;A61K39/385;;A61K39/44;;A61K45/00;;A61K47/34;;A61K47/48;;A61K48/00;;A61K49/00;;A61K51/00;;C07C211/29;;C07C233/11;;C07C237/20;;C07K/;;C07K14/525;;C07K14/535;;C07K14/54;;C07K14/555;;C07K17/06;;C07K17/08;;C08G73/00;;C08G83/00;;C08L101/00;;C12N/;;C12N5/10;;C12N15/09;;C12N15/57;;C12N15/87;;C12P21/02;;C12P21/08;;C12R1/91,,0,0,,,,EXPIRED
494,CA,C,CA 2161684 C,139-590-927-353-316,2010-11-09,2010,CA 2161684 A,1995-03-07,US 20749494 A;;US 31653694 A;;US 9503045 W,1994-03-07,BIOACTIVE AND/OR TARGETED DENDRIMER CONJUGATES,"Dendritic polymer conjugates which are composed of at least one dendrimer in association with at least one unit of a carried material, where the carrier material can be a biological response modifier, have been prepared. The conjugate can also have a target director present, and when it is present, then the carried material may be a bioactive agent. Preferred dendritic polymers are dense starr polymers, which have been complexed with biological response modifiers. These conjugates and complexes have particularly advantageous properties due to their unique characteristics.",,WILSON LARRY R;;YIN RUI;;TOMALIA DONALD A;;BAKER JAMES R;;BIELINSKA ANNA U;;BROTHERS HERBERT M II;;CHENG ROBERTA C;;FAZIO MICHAEL J;;HEDSTRAND DAVID M;;JOHNSON JENNIFER A;;KAPLAN DONALD A;;KLAKAMP SCOTT L;;KRUPER WILLIAM J JR;;KUKOWSKA-LATALLO JOLANTA;;MAXON BARTLEY D;;PIEHLER LARS T;;TOMLINSON IAN A,,https://lens.org/139-590-927-353-316,Granted Patent,no,0,1,35,36,0,A01N25/10;;A61K49/085;;A61K49/124;;B82Y5/00;;C07C211/29;;C07C233/11;;C07C237/20;;C08G83/003;;C08L101/005;;C12N15/87;;Y10S424/16;;A61K47/59;;A61K47/595;;A61K47/61;;A61K47/6949;;A61K47/50;;A61K47/46;;A01N25/10;;A61K49/085;;C07C211/29;;C12N15/87;;C07C233/11;;A61K49/124;;B82Y5/00;;C08L101/005;;C07C237/20;;C08G83/003;;Y10S424/16;;A61K47/61;;A61K47/59;;A61K47/6949;;A61K47/595,C12N15/02;;C12N15/87;;A01N25/10;;A61K/;;A61K31/70;;A61K38/00;;A61K39/385;;A61K39/44;;A61K45/00;;A61K47/34;;A61K47/48;;A61K48/00;;A61K49/00;;A61K51/00;;C07C211/29;;C07C233/11;;C07C237/20;;C07K/;;C07K14/525;;C07K14/535;;C07K14/54;;C07K14/555;;C07K17/06;;C07K17/08;;C08G73/00;;C08G83/00;;C08L101/00;;C12N/;;C12N5/10;;C12N15/09;;C12N15/57;;C12P21/02;;C12P21/08;;C12R1/91,,0,0,,,,EXPIRED
495,AU,A,AU 1995/021181 A,011-679-677-515-982,1995-09-25,1995,AU 1995/021181 A,1995-03-07,US 20749494 A;;US 31653694 A;;US 9503045 W,1994-03-07,Bioactive and/or targeted dendrimer conjugates,"Dendritic polymer conjugates which are composed of at least one dendrimer in association with at least one unit of a carried material, where the carrier material can be a biological response modifier, have been prepared. The conjugate can also have a target director present, and when it is present then the carried material may be a bioactive agent. Preferred dendritic polymers are dense star polymers, which have been complexed with biological response modifiers. These conjugates and complexes have particularly advantageous properties due to their unique characteristics.",DOW CHEMICAL CO;;UNIV MICHIGAN;;DENDRITECH INC,TOMALIA DONALD A;;BAKER JAMES R;;BIELINSKA ANNA U;;BROTHERS HERBERT M II;;CHENG ROBERTA C;;FAZIO MICHAEL J;;HEDSTRAND DAVID M;;JOHNSON JENNIFER A;;KAPLAN DONALD A;;KLAKAMP SCOTT L;;KRUPER WILLIAM J JR;;KUKOWSKA-LATALLO JOLANTA;;MAXON BARTLEY D;;PIEHLER LARS T;;TOMLINSON IAN A;;WILSON LARRY R;;YIN RUI,,https://lens.org/011-679-677-515-982,Patent Application,no,0,0,35,36,0,A01N25/10;;A61K49/085;;A61K49/124;;B82Y5/00;;C07C211/29;;C07C233/11;;C07C237/20;;C08G83/003;;C08L101/005;;C12N15/87;;Y10S424/16;;A61K47/59;;A61K47/595;;A61K47/61;;A61K47/6949;;A61K47/50;;A61K47/46;;A01N25/10;;A61K49/085;;C07C211/29;;C12N15/87;;C07C233/11;;A61K49/124;;B82Y5/00;;C08L101/005;;C07C237/20;;C08G83/003;;Y10S424/16;;A61K47/61;;A61K47/59;;A61K47/6949;;A61K47/595,C12N15/02;;A01N25/10;;A61K/;;A61K31/70;;A61K38/00;;A61K39/385;;A61K39/44;;A61K45/00;;A61K47/34;;A61K47/48;;A61K48/00;;A61K49/00;;A61K51/00;;C07C211/29;;C07C233/11;;C07C237/20;;C07K/;;C07K14/525;;C07K14/535;;C07K14/54;;C07K14/555;;C07K17/06;;C07K17/08;;C08G73/00;;C08G83/00;;C08L101/00;;C12N/;;C12N5/10;;C12N15/09;;C12N15/57;;C12N15/87;;C12P21/02;;C12P21/08;;C12R1/91,,0,0,,,,DISCONTINUED
496,EP,A1,EP 0699079 A1,156-118-452-003-255,1996-03-06,1996,EP 95914006 A,1995-03-07,US 9503045 W;;US 20749494 A;;US 31653694 A,1994-03-07,BIOACTIVE AND/OR TARGETED DENDRIMER CONJUGATES COMPRISING GENETIC MATERIALS,"Dendritic polymer conjugates which are composed of at least one dendrimer in association with at least one unit of a carried material, where the carrier material can be a biological response modifier, have been prepared. The conjugate can also have a target director present, and when it is present then the carried material may be a bioactive agent. Preferred dendritic polymers are dense star polymers, which have been complexed with biological response modifiers. These conjugates and complexes have particularly advantageous properties due to their unique characteristics.",DOW CHEMICAL CO;;DENDRITECH INC;;UNIV MICHIGAN,TOMALIA DONALD A;;BAKER JAMES R;;BIELINSKA ANNA U;;BROTHERS HERBERT M II;;CHENG ROBERTA C;;FAZIO MICHAEL J;;HEDSTRAND DAVID M;;JOHNSON JENNIFER A;;KAPLAN DONALD A;;KLAKAMP SCOTT L;;KRUPER WILLIAM J JR;;KUKOWSKA-LATALLO JOLANTA;;MAXON BARTLEY D;;PIEHLER LARS T;;TOMLINSON IAN A;;WILSON LARRY R;;YIN RUI,"DENDRITIC NANOTECHNOLOGIES, INC. (2005-06-16);;THE REGENTS OF THE UNIVERSITY OF MICHIGAN TECHNOL (2001-10-10);;THE DOW CHEMICAL COMPANY (2001-10-10);;DENDRITECH INCORPORATED (1997-11-26);;THE REGENTS OF THE UNIVERSITY OF MICHIGAN (2005-06-16);;AVC HOLDINGS INC. (2005-06-16)",https://lens.org/156-118-452-003-255,Patent Application,yes,0,0,35,36,0,A01N25/10;;A61K49/085;;A61K49/124;;B82Y5/00;;C07C211/29;;C07C233/11;;C07C237/20;;C08G83/003;;C08L101/005;;C12N15/87;;Y10S424/16;;A61K47/59;;A61K47/595;;A61K47/61;;A61K47/6949;;A61K47/50;;A61K47/46;;A01N25/10;;A61K49/085;;C07C211/29;;C12N15/87;;C07C233/11;;A61K49/124;;B82Y5/00;;C08L101/005;;C07C237/20;;C08G83/003;;Y10S424/16;;A61K47/61;;A61K47/59;;A61K47/6949;;A61K47/595,C12N15/02;;A01N25/10;;A61K/;;A61K31/70;;A61K38/00;;A61K39/385;;A61K39/44;;A61K45/00;;A61K47/34;;A61K47/48;;A61K48/00;;A61K49/00;;A61K51/00;;C07C211/29;;C07C233/11;;C07C237/20;;C07K/;;C07K14/525;;C07K14/535;;C07K14/54;;C07K14/555;;C07K17/06;;C07K17/08;;C08G73/00;;C08G83/00;;C08L101/00;;C12N/;;C12N5/10;;C12N15/09;;C12N15/57;;C12N15/87;;C12P21/02;;C12P21/08;;C12R1/91,,0,0,,,,EXPIRED
497,WO,A1,WO 2014/059185 A1,171-364-186-073-134,2014-04-17,2014,US 2013/0064400 W,2013-10-10,US 201261713413 P;;US 201361783656 P,2012-10-12,AMINO - DIHYDROTHIAZINE AND AMINO - DIOXIDO DIHYDROTHIAZINE COMPOUNDS AS BETA-SECRETASE ANTAGONISTS AND METHODS OF USE,"The present invention provides a new class of compounds useful for the modulation of beta-secretase enzyme (BACE) activity. The compounds have a general Formula I: wherein variables A 4 , A 5 , A 6 , A 8 , R 1 , R 2 , R 3 , R 7 and n of Formula I, independently, are defined herein. The invention also provides pharmaceutical compositions comprising the compounds, and corresponding uses of the compounds and compositions for treatment of disorders and/or conditions related to A-beta plaque formation and deposition, resulting from the biological activity of BACE. Such BACE mediated disorders include, for example, Alzheimer's Disease, cognitive deficits, cognitive impairments, schizophrenia and other central nervous system conditions. The invention further provides compounds of Formula II and sub-formula embodiments thereof, intermediates and processes and methods useful for the preparation of compounds of Formulas I-II.",AMGEN INC,LEWIS RICHARD T;;CHOQUETTE DEBORAH;;EPSTEIN OLEG;;GUZMAN-PEREZ ANGEL;;HUA ZIHAO;;HUMAN JASON BROOKS;;JUDD TED;;LIU QINGYIAN;;LOPEZ PATRICIA;;MINATTI ANA ELENA;;OLIVIERI PHILIP R;;ROMERO KARINA;;SCHENKEL LAURIE;;STELLWAGEN JOHN;;WHITE RYAN;;ZHENG XIAO MEI;;ALLEN JENNIFER R;;CHENG YUAN;;HARRINGTON PAUL E;;HUNGATE RANDALL W;;RUMFELT SHANNON;;RZASA ROBERT M;;XUE QIUFEN;;ZHONG WENGE,,https://lens.org/171-364-186-073-134,Patent Application,yes,34,24,4,4,0,A61P25/18;;A61P25/28;;C07D279/12;;C07D279/12;;C07D213/79;;C07D213/79;;C07D239/74;;C07D239/74;;C07D241/44;;C07D241/44;;C07D279/14;;C07D279/14;;C07D417/04;;C07D417/04;;C07D417/12;;C07D417/12;;C07D417/14;;C07D417/14;;C07D471/04;;C07D471/04;;C07D495/04;;C07D495/04;;C07D498/04;;C07D498/04;;C07D513/04;;C07D513/04;;C07D513/10;;C07D513/10;;C07D519/00;;C07D519/00,C07D417/12;;A61K31/54;;A61K31/541;;A61K31/547;;A61P25/18;;A61P25/28;;C07D279/12;;C07D279/14;;C07D417/14;;C07D471/04;;C07D495/04;;C07D498/04;;C07D513/04;;C07D513/10;;C07D519/00,,17,9,082-722-733-297-69X;;106-260-003-796-433;;032-340-926-422-023;;044-407-914-794-953;;117-896-947-554-821;;065-576-541-132-98X;;059-006-551-099-763;;010-118-470-073-21X;;007-364-858-655-289,10.1016/0896-6273(91)90052-2;;1673054;;10.1038/359325a0;;1406936;;15102495;;10.1016/j.tips.2003.12.004;;10.1186/1750-1326-2-22;;18005427;;pmc2211305;;11224535;;10.1038/85059;;18090456;;10.1097/wnf.0b013e31805b7660;;17495518;;10.4161/auto.4341;;21747967;;10.1371/journal.pone.0021908;;pmc3128622;;10.1002/jps.2600660104;;833720,"JOACHIM ET AL., ALZ. DIS. ASSOC. DIS., vol. 6, 1992, pages 7 - 34;;SELKOE, NEURON, vol. 6, 1991, pages 487;;SEUBERT ET AL., NATURE, vol. 359, 1992, pages 325 - 327;;CITRON, TRENDS IN PHARMACOLOGICAL SCIENCES, vol. 25, no. 2, 2004, pages 92 - 97;;SHANKAR, G.M., NATURE MEDICINE, 22 June 2008 (2008-06-22);;SINHA ET AL., NATURE, vol. 402, 1999, pages 537 - 554;;SABBAGH, M. ET AL., ALZ. DIS. REV., vol. 3, 1997, pages 1 - 19;;COLE, S.L.; VASSER, R., MOLECULAR DEGENERATION, vol. 2, 2007, pages 22;;LUO ET AL., NATURE NEUROSCIENCE, vol. 4, 2001, pages 231 - 232;;EXPERT OPIN. PHARMACOTHER, vol. 10, no. 10, 2009;;CLIN. NEUROPHARMACOL., vol. 30, 2007, pages 317 - 325;;NEUROLOGY, vol. 66, 2006, pages 602 - 624;;L. MOL. CELL. NEUROSCI, 22 February 2003 (2003-02-22), pages 146 - 161;;AUTOPHAGY, vol. 3, no. 5, September 2007 (2007-09-01), pages 474 - 476;;PLOS ONE, vol. 6, no. 7, 2011, pages E21908;;ALZHEIMER'S RESEARCH FORUM NEWS, 2011, pages 3 - 31;;BERGE ET AL., J. PHARM. SCI., vol. 66, 1977, pages 1",PENDING
498,US,A1,US 2014/0107109 A1,039-490-398-817-475,2014-04-17,2014,US 201314051339 A,2013-12-18,US 201314051339 A;;US 201361783656 P;;US 201261713413 P,2012-10-12,AMINO-DIHYDROTHIAZINE AND AMINO-DIOXIDO DIHYDROTHIAZINE COMPOUNDS AS BETA-SECRETASE ANTAGONISTS AND METHODS OF USE,"The present invention provides a new class of compounds useful for the modulation of beta-secretase enzyme (BACE) activity. The compounds have a general Formula I: wherein variables A 4 , A 5 , A 6 , A 8 , R 1 , R 2 , R 3 , R 7 and n of Formula I, independently, are defined herein. The invention also provides pharmaceutical compositions comprising the compounds, and corresponding uses of the compounds and compositions for treatment of disorders and/or conditions related to A-beta plaque formation and deposition, resulting from the biological activity of BACE. Such BACE mediated disorders include, for example, Alzheimer's Disease, cognitive deficits, cognitive impairments, schizophrenia and other central nervous system conditions. The invention further provides compounds of Formula II and sub-formula embodiments thereof, intermediates and processes and methods useful for the preparation of compounds of Formulas I-II.",AMGEN INC,LEWIS RICHARD T;;ALLEN JENNIFER R;;CHENG YUAN;;CHOQUETTE DEBORAH;;EPSTEIN OLEG;;GUZMAN-PEREZ ANGEL;;HARRINGTON PAUL E;;HUA ZIHAO;;HUNGATE RANDALL W;;HUMAN JASON BROOKS;;JUDD TED;;LIU QINGYIAN;;LOPEZ PATRICIA;;MINATTI ANA ELENA;;OLIVIERI PHILIP;;ROMERO KARINA;;RUMFELT SHANNON;;RZASA ROBERT M;;SCHENKEL LAURIE;;STELLWAGEN JOHN;;WHITE RYAN;;XUE QIUFEN;;ZHENG XIAO;;ZHONG WENGE,AMGEN INC (2013-10-23),https://lens.org/039-490-398-817-475,Patent Application,yes,1,9,4,4,0,A61P25/18;;A61P25/28;;C07D279/12;;C07D279/12;;C07D213/79;;C07D213/79;;C07D239/74;;C07D239/74;;C07D241/44;;C07D241/44;;C07D279/14;;C07D279/14;;C07D417/04;;C07D417/04;;C07D417/12;;C07D417/12;;C07D417/14;;C07D417/14;;C07D471/04;;C07D471/04;;C07D495/04;;C07D495/04;;C07D498/04;;C07D498/04;;C07D513/04;;C07D513/04;;C07D513/10;;C07D513/10;;C07D519/00;;C07D519/00,C07D513/04;;C07D279/12;;C07D279/14;;C07D417/04;;C07D417/12;;C07D417/14;;C07D471/04;;C07D495/04;;C07D498/04;;C07D513/10,514/224.2;;514/227.5;;514/227.8;;544/6;;544/47;;544/48;;544/58.2,0,0,,,,DISCONTINUED
499,US,B2,US 9556135 B2,009-358-731-102-814,2017-01-31,2017,US 201314433769 A,2013-10-10,US 201314433769 A;;US 201261713413 P;;US 201361783656 P;;US 2013/0064400 W,2012-10-12,Amino-dihydrothiazine and amino-dioxido dihydrothiazine compounds as beta-secretase antagonists and methods of use,"The present invention provides a new class of compounds useful for the modulation of beta-secretase enzyme (BACE) activity. The compounds have a general Formula I: wherein variables A 4 , A 5 , A 6 , A 8 , R 1 , R 2 , R 3 , R 7 and n of Formula I, independently, are defined herein. The invention also provides pharmaceutical compositions comprising the compounds, and corresponding uses of the compounds and compositions for treatment of disorders and/or conditions related to A-beta plaque formation and deposition, resulting from the biological activity of BACE. Such BACE mediated disorders include, for example, Alzheimer's Disease, cognitive deficits, cognitive impairments, schizophrenia and other central nervous system conditions. The invention further provides compounds of Formula II and sub-formula embodiments thereof, intermediates and processes and methods useful for the preparation of compounds of Formulas I-II.",AMGEN INC;;AMGEN INC,LEWIS RICHARD T;;ALLEN JENNIFER R;;CHENG YUAN;;CHOQUETTE DEBORAH;;EPSTEIN OLEG;;GUZMAN-PEREZ ANGEL;;HARRINGTON PAUL E;;HUA ZIHAO;;HUNGATE RANDALL W;;HUMAN JASON BROOKS;;JUDD TED;;LIU QINGYIAN;;LOPEZ PATRICIA;;MINATTI ANA ELENA;;OLIVIERI PHILIP;;ROMERO KARINA;;RUMFELT SHANNON;;RZASA ROBERT M;;SCHENKEL LAURIE;;STELLWAGEN JOHN;;WHITE RYAN;;XUE QIUFEN;;ZHENG XIAO MEI;;ZHONG WENGE,AMGEN INC (2013-10-23),https://lens.org/009-358-731-102-814,Granted Patent,yes,43,2,4,4,0,A61P25/18;;A61P25/28;;C07D279/12;;C07D279/12;;C07D213/79;;C07D213/79;;C07D239/74;;C07D239/74;;C07D241/44;;C07D241/44;;C07D279/14;;C07D279/14;;C07D417/04;;C07D417/04;;C07D417/12;;C07D417/12;;C07D417/14;;C07D417/14;;C07D471/04;;C07D471/04;;C07D495/04;;C07D495/04;;C07D498/04;;C07D498/04;;C07D513/04;;C07D513/04;;C07D513/10;;C07D513/10;;C07D519/00;;C07D519/00,C07D279/12;;C07D213/79;;C07D239/74;;C07D241/44;;C07D279/14;;C07D417/04;;C07D417/12;;C07D417/14;;C07D471/04;;C07D495/04;;C07D498/04;;C07D513/04;;C07D513/10;;C07D519/00,,36,31,010-239-412-120-058;;064-204-983-655-362;;032-340-926-422-023;;044-407-914-794-953;;108-349-484-349-717;;061-138-525-636-453;;010-118-470-073-21X;;048-784-633-528-797;;013-801-653-376-729;;077-351-302-208-527;;003-778-511-848-73X;;035-920-450-620-162;;000-871-005-085-466;;013-369-899-259-645;;003-828-313-704-930;;051-801-341-692-560;;117-896-947-554-821;;027-599-889-247-132;;008-314-583-015-610;;039-148-595-027-639;;082-722-733-297-69X;;106-260-003-796-433;;059-006-551-099-763;;015-982-248-847-361;;090-808-357-264-137;;065-576-541-132-98X;;064-327-872-895-873;;015-595-224-888-222;;005-277-927-658-347;;127-854-145-178-323;;010-016-516-394-602,10.1186/alzrt2;;19674435;;pmc2719107;;15743924;;10.1124/jpet.104.081174;;15102495;;10.1016/j.tips.2003.12.004;;10.1186/1750-1326-2-22;;18005427;;pmc2211305;;10.1001/archneurol.2010.179;;20697045;;pmc2963067;;11145990;;10.1046/j.1471-4159.2001.00012.x;;21747967;;10.1371/journal.pone.0021908;;pmc3128622;;7845465;;10.1038/373523a0;;15052274;;10.1038/sj.mp.4001508;;10.1016/s0014-5793(97)00886-7;;9280316;;pmc3050043;;21040845;;10.1016/j.neuron.2010.10.020;;10.1517/14656560903044982;;19527190;;pmc15924;;10.1073/pnas.96.6.3228;;10077666;;8810256;;10.1126/science.274.5284.99;;1605946;;10.1097/00002093-199205000-00003;;10.1016/s1044-7431(03)00035-6;;12676526;;11224535;;10.1038/85059;;pmc6633289;;10.1523/jneurosci.3647-11.2011;;22090477;;10.1038/nn.2583;;pmc3072750;;20581818;;pmc2601528;;18359102;;10.1016/j.bbr.2008.02.016;;10.1016/0896-6273(91)90052-2;;1673054;;10.1038/359325a0;;1406936;;17495518;;10.4161/auto.4341;;pmc2772133;;18568035;;10.1038/nm1782;;16505324;;10.1212/01.wnl.0000198762.41312.e1;;18090456;;10.1097/wnf.0b013e31805b7660;;10.1038/990114;;10591214;;10.1016/j.cell.2005.02.008;;15734686;;10.1523/jneurosci.3657-09.2009;;19828790;;pmc2879048;;10.1016/j.neuron.2004.09.010;;15450169;;10348917;;10.1093/oxfordjournals.jbchem.a022396,"Aisen, P. S., ""Alzheimer's disease therapeutic research: the path forward,"" Alzheimer's Research & Therapy, 1: 2, pp. 1-6 (2009).;;Alzforum Networking for a Cure, ""Barcelona: Out of Left Field-Hit to the Eye Kills BACE Inhibitor,"" pp 1-7 (Mar. 31, 2011); access online: www.alzforum.org/news/conference-coverage/barcelona-out-left-field-hit-eye-kills-bace-inhibitor (last accessed Oct. 21, 2015).;;Best, J. D. et al., ""Quantitative Measurement of Changes in Amyloid-beta(40) in the Rat Brain and Cerebrospinal Fluid following Treatment with the kappa-Secretase Inhibitor LY-411575 [N2-[(2S)-2-(3,5-Difluoropheny1)-2-hydroxyethanoy1]-N1-[(7S)-5-methyl-6-oxo-6,7-dihydro-5H-dibenzo[b,d]azepin-7-yl]-L-alaninamide],"" Journal of Pharmacology and Experimental Therapeutics, 313(2): 902-908 (2005).;;Citron, M., ""beta-Secretase inhibition for the treatment of Alzheimer's disease-promise and challenge,"" TRENDS in Pharmacological Sciences, 25(2): 92-97 (2004).;;Cole, S. L. and Vasser, R., ""The Alzheimer's disease beta-secretase enzyme, BACE1,"" Molecular Neurodegeneration, 2: 22, pp. 1-25 (2007).;;De Meyer, G. et al., ""Diagnosis-Independent Alzheimer Disease Biomarker Signature in Cognitively Normal Elderly People,"" Arch Neurol. 67(8): 949-956 (2010).;;Dovey, H. F. et al., ""Functional gamma-secretase inhibitors reduce beta-amyloid peptide levels in brain,"" Journal of Neurochemistry, 76: 173-181 (2001).;;Follo, C. et al., ""Knock-Down of Cathepsin D Affects the Retinal Pigment Epithelium, Impairs Swim-Bladder Ontogenesis and Causes Premature Death in Zebrafish,"" PLoS One. 6(7): e21908, pp. 1-13(2011).;;Games, D. et al., ""Alzheimer-type neuropathology in transgenic mice overexpressing V717F beta-amyloid precursor protein,"" Nature, 373: 523-527 (1995).;;Götz, J. et al., ""Transgenic animal models of Alzheimer's disease and related disorders: histopathology, behavior and therapy,"" Molecular Psychiatry, 9: 664-683 (2004).;;Gulnik, S. V. et al., ""Design of sensitive fluorogenic substrates for human cathepsin D,"" FEBS Letters, 413: 379-384 (1997).;;Harris, J. A. et al., ""Transsynaptic Progression of Amyloid-beta-Induced Neuronal Dysfunction within the Entorhinal-Hippocampal Network,"" Neuron, 68: 428-441 (2010).;;Henley, D. B., et al., ""Development of semagacestat (LY450139), a functional kappa-secretase inhibitor, for the treatment of Alzheimer's disease,"" Expert Opin. Pharmacother, 10(10): 1657-1664 (2009).;;Hsia, A. Y. et al., ""Plaque-independent disruption of neural circuits in Alzheimer's disease mouse models,"" PNAS USA, 96: 3228-3233 (1999).;;Hsiao, K. et al., ""Correlative Memory Deficits, Abeta Elevation, and Amyloid Plaques in Transgenic Mice,"" Science, 274: 99-102 (1996).;;International Search Report for International Patent Application No. PCT/US2013/064400, Applicant: Amgen Inc., mailed Dec. 9, 2013 from the International Searching Authority, pp. 5.;;Joachim, C. L. et al., ""The Seminal Role of beta-Amyloid in the Pathogenesis of Alzheimer Disease,"" Alzheimer Disease and Associated. Disorder, 6: 7-34 (1992).;;Koike, M. et al., ""Involvement of two different cell death pathways in retinal atrophy of cathepsin D-deficient mice,"" Molecular and Cellular Neuroscience, 22: 146-161 (2003).;;Luo, Y. et al., ""Mice deficient in BACE1, the Alzheimer's beta-secretase, have normal phenotype and abolished beta-amyloid generation,"" Nature Neuroscience, 4(3): 231-232 (2001).;;May, P. C. et al., ""Robust Central Reduction of Amyloid-beta in Humans with an Orally Available, Non-Peptidic beta-Secretase Inhibitor,"" Journal of Neuroscience, 31(46): 16507-16516 (2011).;;Office Action mailed Sep. 15, 2015 for U.S. Appl. No. 14/051,339, Applicant: Amgen Inc., pp. 5.;;Palop, J. J. and Mucke, L., ""Amyloid-beta-induced neuronal dysfunction in Alzheimer's disease: from synapses toward neural networks,"" Nature Neuroscience, 13(7): 812-818 (2010).;;Sabbagh, M. N. et al., ""beta-Amyloid and Treatment Opportunities for Alzheimer's Disease,"" Alzheimer's Disease Review, 3: 1-19 (1997).;;Selkoe, D. J., ""Soluble oligomers of the amyloid beta-protein impair synaptic plasticity and behavior,"" Behavioural Brain Research, 192(1): 106-113 (2008).;;Selkoe, D. J., ""The Molecular Pathology of Alzheimer's Disease,"" Neuron, 6: 487-498 (1991).;;Seubert, P. et al., ""Isolation and quantification of soluble Alzheimer's beta-peptide from biological fluids,"" Nature, 359: 325-327 (1992).;;Shacka, J. J. and Roth, K. A., ""Cathepsin D Deficiency and NCL/Batten Disease,"" Autophagy, 3(5): 474-476 (2007).;;Shankar, G.M. et al., ""Amyloid-beta protein dimers isolated directly from Alzheimer's brains impair synaptic plasticity and memory,"" Nature Medicine, 14: 837-842 (2008).;;Siemers, E. R et al., ""Effects of a kappa-secretase inhibitor in a randomized study of patients with Alzheimer disease,"" Neurology, 66: 602-604 (2006).;;Siemers, E. R. et al., ""Safety, Tolerability, and Effects on Plasma and Cerebrospinal Fluid Amyloid-beta After Inhibition of kappa-Secretase,"" Clinical Neuropharmacology, 30(6): 317-325 (2007).;;Sinha, S. et al., ""Purification and cloning of amyloid precursor protein beta-secretase from human brain,"" Nature, 402: 537-540 (1999).;;Tanzi, R. E. and Bertram, L., ""Twenty Years of the Alzheimer's Disease Amyloid Hypothesis: A Genetic Perspective,"" Cell, 120: 545-555 (2005).;;Vassar, R. et al., ""The beta-Secretase Enzyme BACE in Health and Alzheimer's Disease: Regulation, Cell Biology, Function, and Therapeutic Potential,"" Journal of Neuroscience, 29(41): 12787-12794 (2009).;;Walsh, D. M. and Selkoe, D. J., ""Deciphering the Molecular Basis of Memory Failure in Alzheimer's Disease,"" Neuron, 44: 181-193 (2004).;;Written Opinion for International Patent Application No. PCT/US2013/064400, Applicant: Amgen Inc., mailed Dec. 9, 2013 from the International Bureau of WIPO, pp. 6.;;Yasuda, Y. et al., ""Characterization of New Fluorogenic Substrates for the Rapid and Sensitive Assay of Cathepsin E and Cathepsin D,"" J. Biochem., 125: 1137-1143 (1999).",ACTIVE
500,US,A1,US 2015/0259308 A1,130-866-292-791-394,2015-09-17,2015,US 201314433769 A,2013-10-10,US 201314433769 A;;US 201261713413 P;;US 201361783656 P;;US 2013/0064400 W,2012-10-12,AMINO-DIHYDROTHIAZINE AND AMINO-DIOXIDO DIHYDROTHIAZINE COMPOUNDS AS BETA-SECRETASE ANTAGONISTS AND METHODS OF USE,"The present invention provides a new class of compounds useful for the modulation of beta-secretase enzyme (BACE) activity. The compounds have a general Formula I: wherein variables A 4 , A 5 , A 6 , A 8 , R 1 , R 2 , R 3 , R 7 and n of Formula I, independently, are defined herein. The invention also provides pharmaceutical compositions comprising the compounds, and corresponding uses of the compounds and compositions for treatment of disorders and/or conditions related to A-beta plaque formation and deposition, resulting from the biological activity of BACE. Such BACE mediated disorders include, for example, Alzheimer's Disease, cognitive deficits, cognitive impairments, schizophrenia and other central nervous system conditions. The invention further provides compounds of Formula II and sub-formula embodiments thereof, intermediates and processes and methods useful for the preparation of compounds of Formulas I-II.",AMGEN INC,LEWIS RICHARD T;;ALLEN JENNIFER R;;CHENG YUAN;;CHOQUETTE DEBORAH;;EPSTEIN OLEG;;GUZMAN-PEREZ ANGEL;;HARRINGTON PAUL E;;HUA ZIHAO;;HUNGATE RANDALL W;;HUMAN JASON BROOKS;;JUDD TED;;LIU QINGYIAN;;LOPEZ PATRICIA;;MINATTI ANA ELENA;;OLIVIERI PHILIP;;ROMERO KARINA;;RUMFELT SHANNON;;RZASA ROBERT M;;SCHENKEL LAURIE;;STELLWAGEN JOHN;;WHITE RYAN;;XUE QIUFEN;;ZHENG XIAO MEI;;ZHONG WENGE,AMGEN INC (2013-10-23),https://lens.org/130-866-292-791-394,Patent Application,yes,2,3,4,4,0,A61P25/18;;A61P25/28;;C07D279/12;;C07D279/12;;C07D213/79;;C07D213/79;;C07D239/74;;C07D239/74;;C07D241/44;;C07D241/44;;C07D279/14;;C07D279/14;;C07D417/04;;C07D417/04;;C07D417/12;;C07D417/12;;C07D417/14;;C07D417/14;;C07D471/04;;C07D471/04;;C07D495/04;;C07D495/04;;C07D498/04;;C07D498/04;;C07D513/04;;C07D513/04;;C07D513/10;;C07D513/10;;C07D519/00;;C07D519/00,C07D279/12;;C07D213/79;;C07D239/74;;C07D241/44;;C07D279/14;;C07D417/04;;C07D417/12;;C07D417/14;;C07D471/04;;C07D495/04;;C07D498/04;;C07D513/04;;C07D513/10,,0,0,,,,ACTIVE
501,CN,A,CN 106795147 A,106-644-550-666-120,2017-05-31,2017,CN 201580054674 A,2015-08-05,US 201462035269 P;;US 2015/0043868 W,2014-08-08,Cyclopropyl fused thiazin-2-amine compounds as beta-secretase inhibitors and methods of use,"The present invention provides a new class of compounds useful for the modulation of beta-secretase enzyme (BACE) activity. The compounds have a general Formula (I): wherein variables A4, A5, A6, A8, and each of Ra, Rb, R1, R2, R3 and R7 of Formula (I), independently, are defined herein. The invention also provides pharmaceutical compositions comprising the compounds, and uses of the compounds and compositions for treatment of disorders and/or conditions related to A-beta plaque formation and 15 deposition, resulting from the biological activity of BACE. Such BACE mediated disorders include, for example, Alzheimers Disease, cognitive deficits, cognitive impairments, schizophrenia and other central nervous system conditions. The invention further provides compounds of Formulas (II) and (III), and sub-formula embodiments thereof, intermediates and methods for preparing compounds of the invention.",AMGEN INC,ALLEN JENNIFER R;;AMEGADZIE ALBERT;;BOURBEAU MATTHEW P;;BROWN JAMES A;;CHEN JIAN J;;CHENG YUAN;;FROHN MICHAEL J;;GUZMAN-PEREZ ANGEL;;HARRINGTON PAUL E;;LIU LONGBIN;;LIU QINGYIAN;;LOW JONATHAN D;;MA VU VAN;;MANNING JAMES;;MINATTI ANA ELENA;;NGUYEN THOMAS T;;NISHMURA NOBUKO;;NORMAN MARK H;;PETTUS LIPING H;;PICKRELL ALEXANDER J;;QIAN WENYUAN;;RUMFELT SHANNON;;RZASA ROBERT M;;SIEGMUND AARON C;;STEC MARKIAN M;;WHITE RYAN;;XUE QIUFEN,,https://lens.org/106-644-550-666-120,Patent Application,no,5,2,19,19,0,C07D417/04;;C07D417/14;;C07D471/04;;C07D279/08;;C07D417/12;;C07D513/10;;A61P25/00;;A61P25/28;;A61P43/00;;A61P7/04;;A61P9/00;;C07D417/04;;C07D417/14;;C07D471/04;;C07D279/08;;C07D417/12;;C07D513/10,C07D417/04;;A61K31/5415;;A61K31/547;;A61P25/00;;A61P25/28;;C07D279/08;;C07D417/12;;C07D417/14;;C07D471/04;;C07D513/10,,0,0,,,,ACTIVE
502,WO,A1,WO 2016/022724 A1,034-200-627-994-409,2016-02-11,2016,US 2015/0043868 W,2015-08-05,US 201462035269 P,2014-08-08,CYCLOPROPYL FUSED THIAZIN-2-AMINE COMPOUNDS AS BETA-SECRETASE INHIBITORS AND METHODS OF USE,"The present invention provides a new class of compounds useful for the modulation of beta-secretase enzyme (BACE) activity. The compounds have a general Formula (I): wherein variables A 4 , A 5 , A 6 , A 8 , and each of R a , R b , R 1 , R 2 , R 3 and R 7 of Formula (I), independently, are defined herein. The invention also provides pharmaceutical compositions comprising the compounds, and uses of the compounds and compositions for treatment of disorders and/or conditions related to A-beta plaque formation and 15 deposition, resulting from the biological activity of BACE. Such BACE mediated disorders include, for example, Alzheimers Disease, cognitive deficits, cognitive impairments, schizophrenia and other central nervous system conditions. The invention further provides compounds of Formulas (II) and (III), and sub-formula embodiments thereof, intermediates and methods for preparing compounds of the invention.",AMGEN INC,ALLEN JENNIFER R;;AMEGADZIE ALBERT;;BOURBEAU MATTHEW P;;BROWN JAMES A;;CHEN JIAN J;;CHENG YUAN;;FROHN MICHAEL J;;GUZMAN-PEREZ ANGEL;;HARRINGTON PAUL E;;LIU LONGBIN;;LIU QINGYIAN;;LOW JONATHAN D;;MA VU VAN;;MANNING JAMES;;MINATTI ANA ELENA;;NGUYEN THOMAS T;;NISHMURA NOBUKO;;NORMAN MARK H;;PETTUS LIPING H;;PICKRELL ALEXANDER J;;QIAN WENYUAN;;RUMFELT SHANNON;;RZASA ROBERT M;;SIEGMUND AARON C;;STEC MARKIAN M;;WHITE RYAN;;XUE QIUFEN,,https://lens.org/034-200-627-994-409,Patent Application,yes,50,11,19,19,0,C07D417/04;;C07D417/14;;C07D471/04;;C07D279/08;;C07D417/12;;C07D513/10;;A61P25/00;;A61P25/28;;A61P43/00;;A61P7/04;;A61P9/00;;C07D417/04;;C07D417/14;;C07D471/04;;C07D279/08;;C07D417/12;;C07D513/10,A61K31/5415;;C07D417/04;;A61P25/28;;C07D279/08;;C07D417/14;;C07D471/04,,22,10,054-712-216-545-603;;082-722-733-297-69X;;106-260-003-796-433;;032-340-926-422-023;;044-407-914-794-953;;117-896-947-554-821;;065-576-541-132-98X;;059-006-551-099-763;;010-118-470-073-21X;;007-364-858-655-289,10.1016/s1474-4422(13)70276-x;;pmc4086426;;24556009;;10.1016/0896-6273(91)90052-2;;1673054;;10.1038/359325a0;;1406936;;15102495;;10.1016/j.tips.2003.12.004;;10.1186/1750-1326-2-22;;18005427;;pmc2211305;;11224535;;10.1038/85059;;18090456;;10.1097/wnf.0b013e31805b7660;;17495518;;10.4161/auto.4341;;21747967;;10.1371/journal.pone.0021908;;pmc3128622;;10.1002/jps.2600660104;;833720,"VASSAR; YAN, LANCET NEUROLOGY, vol. 13, 2014, pages 319 - 329;;JOACHIM ET AL., ALZ. DIS. ASSOC. DIS., vol. 6, 1992, pages 7 - 34;;SELKOE, NEURON, vol. 6, 1991, pages 487;;SEUBERT ET AL., NATURE, vol. 359, 1992, pages 325 - 327;;CITRON, TRENDS IN PHARMACOLOGICAL SCIENCES, vol. 25, no. 2, 2004, pages 92 - 97;;SHANKAR, G.M., NATURE MEDICINE, 22 June 2008 (2008-06-22);;SINHA ET AL., NATURE, vol. 402, 1999, pages 537 - 554;;SABBAGH, M. ET AL., ALZ. DIS. REV., vol. 3, 1997, pages 1 - 19;;COLE, S.L.; VASSER, R., MOLECULAR DEGENERATION, vol. 2, 2007, pages 22;;LUO ET AL., NATURE NEUROSCIENCE, vol. 4, 2001, pages 231 - 232;;EXPERT OPIN. PHARMACOTHER, vol. 10, no. 10, 2009;;CLIN. NEUROPHARMACOL, vol. 30, 2007, pages 317 - 325;;NEUROLOGY, vol. 66, 2006, pages 602 - 624;;MOL. CELL. NEUROSCI, vol. 22, no. 2, February 2003 (2003-02-01), pages 146 - 161;;AUTOPHAGY, vol. 3, no. 5, September 2007 (2007-09-01), pages 474 - 476;;PLOS ONE, vol. 6, no. 7, 7 January 2011 (2011-01-07), pages E21908;;ALZHEIMER'S RESEARCH FORUM NEWS, 31 March 2011 (2011-03-31);;JACQUES, J. ET AL.: ""Enantiomers, Racemates and Resolutions"", 1981, WILEY-INTERSCIENCE;;WILEN, S. H. ET AL., TETRAHEDRON, vol. 33, 1997, pages 2725;;ELIEL, E. L.: ""Stereochemistry of Carbon Compounds"", 1962, MCGRAW-HILL;;WILEN, S. H.: ""Tables of Resolving Agents and Optical Resolutions"", 1972, UNIV. OF NOTRE DAME PRESS, pages: 268;;BERGE ET AL., J. PHARM. SCI., vol. 66, no. 1, 1977",PENDING
503,AU,A1,AU 2015/301028 A1,132-995-523-744-426,2017-03-09,2017,AU 2015/301028 A,2015-08-05,US 201462035269 P;;US 2015/0043868 W,2014-08-08,Cyclopropyl fused thiazin-2-amine compounds as beta-secretase inhibitors and methods of use,The present invention provides a new class of compounds useful for the modulation of beta-secretase enzyme (BACE) activity. The compounds have a general Formula (I): wherein variables A,AMGEN INC,ALLEN JENNIFER R;;AMEGADZIE ALBERT;;BOURBEAU MATTHEW P;;BROWN JAMES A;;CHEN JIAN J;;CHENG YUAN;;FROHN MICHAEL J;;GUZMAN-PEREZ ANGEL;;HARRINGTON PAUL E;;LIU LONGBIN;;LIU QINGYIAN;;LOW JONATHAN D;;MA VU VAN;;MANNING JAMES;;MINATTI ANA ELENA;;NGUYEN THOMAS T;;NISHMURA NOBUKO;;NORMAN MARK H;;PETTUS LIPING H;;PICKRELL ALEXANDER J;;QIAN WENYUAN;;RUMFELT SHANNON;;RZASA ROBERT M;;SIEGMUND AARON C;;STEC MARKIAN M;;WHITE RYAN;;XUE QIUFEN,,https://lens.org/132-995-523-744-426,Patent Application,no,0,0,19,19,0,C07D417/04;;C07D417/14;;C07D471/04;;C07D279/08;;C07D417/12;;C07D513/10;;A61P25/00;;A61P25/28;;A61P43/00;;A61P7/04;;A61P9/00;;C07D417/04;;C07D417/14;;C07D471/04;;C07D279/08;;C07D417/12;;C07D513/10,C07D417/04;;A61K31/5415;;A61P25/28;;C07D279/08;;C07D417/14;;C07D471/04,,0,0,,,,ACTIVE
504,TW,A,TW 201619154 A,134-673-410-557-14X,2016-06-01,2016,TW 104125848 A,2015-08-07,US 201462035269 P,2014-08-08,Cyclopropyl fused thiazin-2-amine compounds as beta-secretase inhibitors and methods of use,"The present invention provides a new class of compounds useful for the modulation of beta-secretase enzyme (BACE) activity. The compounds have a general Formula I:wherein variables A4, A5, A6, A8, and each of R<SP>a</SP>, R<SP>b</SP>, R1, R2, R3 and R7 of Formula I, independently, are defined herein. The invention also provides pharmaceutical compositions comprising the compounds, and uses of the compounds and compositions for treatment of disorders and/or conditions related to A-beta plaque formation and deposition, resulting from the biological activity of BACE. Such BACE mediated disorders include, for example, Alzheimer's Disease, cognitive deficits, cognitive impairments, schizophrenia and other central nervous system conditions. The invention further provides compounds of Formulas II and III, and sub-formula embodiments thereof, intermediates and methods for preparing compounds of the invention.",AMGEN INC,ALLEN JENNIFER R;;AMEGADZIE ALBERT;;BOURBEAU MATTHEW P;;BROWN JAMES A;;CHEN JIAN J;;CHENG YUAN;;FROHN MICHAEL J;;GUZMAN-PEREZ ANGEL;;HARRINGTON PAUL E;;LIU LONGBIN;;LIU QINGYIAN;;LOW JONATHAN D;;MA VU VAN;;MANNING JAMES;;MINATTI ANA ELENA;;NGUYEN THOMAS T;;NISHIMURA NOBUKO;;NORMAN MARK H;;PETTUS LIPING H;;PICKRELL ALEXANDER J;;QIAN WENYUAN;;RUMFELT SHANNON;;RZASA ROBERT M;;SIEGMUND AARON C;;STEC MARKIAN M;;WHITE RYAN D;;XUE QIUFEN,,https://lens.org/134-673-410-557-14X,Patent of Addition,no,0,0,19,19,0,C07D417/04;;C07D417/14;;C07D471/04;;C07D279/08;;C07D417/12;;C07D513/10;;A61P25/00;;A61P25/28;;A61P43/00;;A61P7/04;;A61P9/00;;C07D417/04;;C07D417/14;;C07D471/04;;C07D279/08;;C07D417/12;;C07D513/10,C07D417/12;;A61K31/5415;;A61P25/28;;C07D417/14;;C07D471/04,,0,0,,,,ACTIVE
505,TW,B,TW I614250 B,124-099-629-271-780,2018-02-11,2018,TW 104125848 A,2015-08-07,US 201462035269 P,2014-08-08,Cyclopropyl fused thiazin-2-amine compounds as beta-secretase inhibitors and methods of use,,AMGEN INC,ALLEN JENNIFER R;;AMEGADZIE ALBERT;;BOURBEAU MATTHEW P;;BROWN JAMES A;;CHEN JIAN J;;CHENG YUAN;;FROHN MICHAEL J;;GUZMAN-PEREZ ANGEL;;HARRINGTON PAUL E;;LIU LONGBIN;;LIU QINGYIAN;;LOW JONATHAN D;;MA VU VAN;;MANNING JAMES R;;MINATTI ANA ELENA;;NGUYEN THOMAS T;;NISHIMURA NOBUKO;;NORMAN MARK H;;PETTUS LIPING H;;PICKRELL ALEXANDER J;;QIAN WENYUAN;;RUMFELT SHANNON;;RZASA ROBERT M;;SIEGMUND AARON C;;STEC MARKIAN M;;WHITE RYAN D;;XUE QIUFEN,,https://lens.org/124-099-629-271-780,Granted Patent,no,1,0,19,19,0,C07D417/04;;C07D417/14;;C07D471/04;;C07D279/08;;C07D417/12;;C07D513/10;;A61P25/00;;A61P25/28;;A61P43/00;;A61P7/04;;A61P9/00;;C07D417/04;;C07D417/14;;C07D471/04;;C07D279/08;;C07D417/12;;C07D513/10,,,0,0,,,,ACTIVE
506,CA,A1,CA 2957544 A1,082-557-201-057-998,2016-02-11,2016,CA 2957544 A,2015-08-05,US 201462035269 P;;US 2015/0043868 W,2014-08-08,CYCLOPROPYL FUSED THIAZIN-2-AMINE COMPOUNDS AS BETA-SECRETASE INHIBITORS AND METHODS OF USE,"The present invention provides a new class of compounds useful for the modulation of beta-secretase enzyme (BACE) activity. The compounds have a general Formula (I): wherein variables A4, A5, A6, A8, and each of Ra, Rb, R1, R2, R3 and R7 of Formula (I), independently, are defined herein. The invention also provides pharmaceutical compositions comprising the compounds, and uses of the compounds and compositions for treatment of disorders and/or conditions related to A-beta plaque formation and 15 deposition, resulting from the biological activity of BACE. Such BACE mediated disorders include, for example, Alzheimers Disease, cognitive deficits, cognitive impairments, schizophrenia and other central nervous system conditions. The invention further provides compounds of Formulas (II) and (III), and sub-formula embodiments thereof, intermediates and methods for preparing compounds of the invention.",AMGEN INC,ALLEN JENNIFER R;;AMEGADZIE ALBERT;;BOURBEAU MATTHEW P;;BROWN JAMES A;;CHEN JIAN J;;CHENG YUAN;;FROHN MICHAEL J;;GUZMAN-PEREZ ANGEL;;HARRINGTON PAUL E;;LIU LONGBIN;;LIU QINGYIAN;;LOW JONATHAN D;;MA VU VAN;;MANNING JAMES R;;MINATTI ANA ELENA;;NGUYEN THOMAS T;;NISHIMURA NOBUKO;;NORMAN MARK H;;PETTUS LIPING H;;PICKRELL ALEXANDER J;;QIAN WENYUAN;;RUMFELT SHANNON;;RZASA ROBERT M;;SIEGMUND AARON C;;STEC MARKIAN M;;WHITE RYAN D;;XUE QIUFEN,,https://lens.org/082-557-201-057-998,Patent Application,no,0,0,19,19,0,C07D417/04;;C07D417/14;;C07D471/04;;C07D279/08;;C07D417/12;;C07D513/10;;A61P25/00;;A61P25/28;;A61P43/00;;A61P7/04;;A61P9/00;;C07D417/04;;C07D417/14;;C07D471/04;;C07D279/08;;C07D417/12;;C07D513/10,C07D471/04;;A61K31/5415;;A61P25/28;;C07D417/14,,0,0,,,,PENDING
507,EP,A1,EP 3177618 A1,079-130-927-665-158,2017-06-14,2017,EP 15766951 A,2015-08-05,US 201462035269 P;;US 2015/0043868 W,2014-08-08,CYCLOPROPYL FUSED THIAZIN-2-AMINE COMPOUNDS AS BETA-SECRETASE INHIBITORS AND METHODS OF USE,,AMGEN INC,ALLEN JENNIFER R;;AMEGADZIE ALBERT;;BOURBEAU MATTHEW P;;BROWN JAMES A;;CHEN JIAN J;;CHENG YUAN;;FROHN MICHAEL J;;GUZMAN-PEREZ ANGEL;;HARRINGTON PAUL E;;LIU LONGBIN;;LIU QINGYIAN;;LOW JONATHAN D;;MA VU VAN;;MANNING JAMES R;;MINATTI ANA ELENA;;NGUYEN THOMAS T;;NISHIMURA NOBUKO;;NORMAN MARK H;;PETTUS LIPING H;;PICKRELL ALEXANDER J;;QIAN WENYUAN;;RUMFELT SHANNON;;RZASA ROBERT M;;SIEGMUND AARON C;;STEC MARKIAN M;;WHITE RYAN D;;XUE QIUFEN,,https://lens.org/079-130-927-665-158,Patent Application,yes,0,0,19,19,0,C07D417/04;;C07D417/14;;C07D471/04;;C07D279/08;;C07D417/12;;C07D513/10;;A61P25/00;;A61P25/28;;A61P43/00;;A61P7/04;;A61P9/00;;C07D417/04;;C07D417/14;;C07D471/04;;C07D279/08;;C07D417/12;;C07D513/10,C07D417/04;;A61K31/5415;;A61P25/28;;C07D279/08;;C07D417/14;;C07D471/04,,0,0,,,,DISCONTINUED
508,MX,A,MX 2017001794 A,015-532-394-311-356,2017-06-29,2017,MX 2017001794 A,2015-08-05,US 201462035269 P;;US 2015/0043868 W,2014-08-08,CYCLOPROPYL FUSED THIAZIN-2-AMINE COMPOUNDS AS BETA-SECRETASE INHIBITORS AND METHODS OF USE.,"The present invention provides a new class of compounds useful for the modulation of beta-secretase enzyme (BACE) activity. The compounds have a general Formula (I): wherein variables A4, A5, A6, A8, and each of Ra, Rb, R1, R2, R3 and R7 of Formula (I), independently, are defined herein. The invention also provides pharmaceutical compositions comprising the compounds, and uses of the compounds and compositions for treatment of disorders and/or conditions related to A-beta plaque formation and 15 deposition, resulting from the biological activity of BACE. Such BACE mediated disorders include, for example, Alzheimers Disease, cognitive deficits, cognitive impairments, schizophrenia and other central nervous system conditions. The invention further provides compounds of Formulas (II) and (III), and sub-formula embodiments thereof, intermediates and methods for preparing compounds of the invention.",AMGEN INC,LIPING H PETTUS;;MARK H NORMAN;;JIAN J CHEN;;QINGYIAN LIU;;THOMAS T NGUYEN;;VU VAN MA;;ANGEL GUZMAN-PEREZ;;YUAN CHENG;;JENNIFER R ALLEN;;ALBERT AMEGADZIE;;ALEXANDER J PICKRELL;;SHANNON RUMFELT;;ROBERT M RZASA;;MICHAEL J FROHN;;JONATHAN D LOW;;WENYUAN QIAN;;QIUFEN XUE;;PAUL E HARRINGTON;;AARON C SIEGMUND;;MATTHEW P BOURBEAU;;JAMES A BROWN;;LONGBIN LIU;;ANA ELENA MINATTI;;MARKIAN M STEC;;JAMES ROBERT MANNING;;RYAN D WHITE;;NOBUKO NISHIMURA,,https://lens.org/015-532-394-311-356,Patent Application,no,0,0,19,19,0,C07D417/04;;C07D417/14;;C07D471/04;;C07D279/08;;C07D417/12;;C07D513/10;;A61P25/00;;A61P25/28;;A61P43/00;;A61P7/04;;A61P9/00;;C07D417/04;;C07D417/14;;C07D471/04;;C07D279/08;;C07D417/12;;C07D513/10,C07D417/04;;A61K31/5415;;A61P25/28;;C07D279/08;;C07D417/14;;C07D471/04,,0,0,,,,PENDING
509,JO,B1,JO 3569 B1,033-004-870-796-598,2020-07-05,2020,JO P20150190 A,2015-08-09,US 201462035269 P,2014-08-08,CYCLOPROPYL FUSED THIAZIN-2-AMINE COMPOUNDS AS BETA-SECRETASE INHIBITORS AND METHODS OF USE,"<p>The present invention provides a new class of compounds useful for the modulation of beta-secretase enzyme (BACE) activity. The compounds have a general Formula I: I wherein variables A4, A5, A6, A8, and each of Ra, Rb, R1, R2, R3 and R7 of Formula I, independently, are defined herein. The invention also provides pharmaceutical compositions comprising the compounds, and uses of the compounds and compositions for treatment of disorders and/or conditions related to A-beta plaque formation and deposition, resulting from the biological activity of BACE. Such BACE mediated disorders include, for example, Alzheimer’s Disease, cognitive deficits, cognitive impairments, schizophrenia and other central nervous system conditions. The invention further provides compounds of Formulas II and III, and sub-formula embodiments thereof, intermediates and methods for preparing compounds of the invention.</p>",AMGEN INC,MICHAEL J FROHN;;SHANNON RUMFELT;;THOMAS T NGUYEN;;LONGBIN LIU;;ANGEL GUZMAN-PEREZ;;JONATHAN D LOW;;MATTHEW P BOURBEAU;;PAUL E HARRINGTON;;MARKIAN M STEC;;JENNIFER R ALLEN;;JAMES R MANNING;;RYAN D WHITE;;NOBUKO NISHIMURA;;ROBERT M RZASA;;VU VAN MA;;YUAN CHENG;;WENYUAN QIAN;;QINGYIAN LIU;;ALEXANDER J PICKRELL;;MARK H NORMAN;;AARON C SIEGMUND;;JIAN J CHEN;;ALBERT AMEGADZIE;;QIUFEN XUE;;LIPING H PETTUS;;JAMES A BROWN;;ANA ELENA MINATTI,,https://lens.org/033-004-870-796-598,Granted Patent,no,0,0,19,19,0,C07D417/04;;C07D417/14;;C07D471/04;;C07D279/08;;C07D417/12;;C07D513/10;;A61P25/00;;A61P25/28;;A61P43/00;;A61P7/04;;A61P9/00;;C07D417/04;;C07D417/14;;C07D471/04;;C07D279/08;;C07D417/12;;C07D513/10,A61K31/5415;;A61P25/28;;C07D279/08;;C07D417/04;;C07D417/14;;C07D471/04,,0,0,,,,ACTIVE
510,AU,B2,AU 2015/301028 B2,078-989-218-199-84X,2019-09-26,2019,AU 2015/301028 A,2015-08-05,US 201462035269 P;;US 2015/0043868 W,2014-08-08,Cyclopropyl fused thiazin-2-amine compounds as beta-secretase inhibitors and methods of use,The present invention provides a new class of compounds useful for the modulation of beta-secretase enzyme (BACE) activity. The compounds have a general Formula (I): wherein variables A,AMGEN INC,ALLEN JENNIFER R;;AMEGADZIE ALBERT;;BOURBEAU MATTHEW P;;BROWN JAMES A;;CHEN JIAN J;;CHENG YUAN;;FROHN MICHAEL J;;GUZMAN-PEREZ ANGEL;;HARRINGTON PAUL E;;LIU LONGBIN;;LIU QINGYIAN;;LOW JONATHAN D;;MA VU VAN;;MANNING JAMES R;;MINATTI ANA ELENA;;NGUYEN THOMAS T;;NISHIMURA NOBUKO;;NORMAN MARK H;;PETTUS LIPING H;;PICKRELL ALEXANDER J;;QIAN WENYUAN;;RUMFELT SHANNON;;RZASA ROBERT M;;SIEGMUND AARON C;;STEC MARKIAN M;;WHITE RYAN D;;XUE QIUFEN,,https://lens.org/078-989-218-199-84X,Granted Patent,no,2,0,19,19,0,C07D417/04;;C07D417/14;;C07D471/04;;C07D279/08;;C07D417/12;;C07D513/10;;A61P25/00;;A61P25/28;;A61P43/00;;A61P7/04;;A61P9/00;;C07D417/04;;C07D417/14;;C07D471/04;;C07D279/08;;C07D417/12;;C07D513/10,C07D417/04;;A61K31/5415;;A61P25/28;;C07D279/08;;C07D417/14;;C07D471/04,,0,0,,,,ACTIVE
511,AR,A1,AR 101483 A1,153-340-122-162-286,2016-12-21,2016,AR P150102557 A,2015-08-07,US 201462035269 P,2014-08-08,COMPUESTOS DE TIAZIN-2-AMINA FUSIONADOS CON CICLOPROPILO COMO INHIBIDORES DE b-SECRETASA Y MÉTODOS DE USO,"Reivindicación 1: Un compuesto de la fórmula (1), o un estereoisómero, tautómero, hidrato, solvato o sal farmacéuticamente aceptable del mismo, caracterizado porque A⁴ es CR⁴ o N; A⁵ es CR⁵ o N; A⁶ es CR⁶ o N; A⁸ es CR⁸ o N, con la condición de que no más de dos de A⁴, A⁵, A⁶ y A⁸ es N; cada uno de Rᵃ y Rᵇ, independientemente, es H, F, Cl, alquilo-C₁₋₆, alquenilo-C₂₋₄, alquinilo-C₂₋₄, CN, -CH₂O-alquilo-C₁₋₆, -O-alquilo-C₁₋₆, -S(O)ₒ-alquilo-C₁₋₆, -NH-alquilo-C₁₋₆ o -C(O)alquilo-C₁₋₆, en donde cada uno de la porción alquilo-C₁₋₆, alquenilo-C₂₋₄, alquinilo-C₂₋₄, y alquilo-C₁₋₆ de -CH₂O-alquilo-C₁₋₆, -O-alquilo-C₁₋₆, -S(O)ₒ-alquilo-C₁₋₆, -NH-alquilo-C₁₋₆ y -C(O)alquilo-C₁₋₆ están opcionalmente sustituidas con 1 - 4 sustituyentes de F, oxo u OH; R¹ y cualquiera de Rᵃ o Rᵇ puede unirse opcionalmente para formar un anillo saturado de 5 miembros que incluye un heteroátomo S; R¹ es H, F, Cl, alquilo-C₁₋₆, alquenilo-C₂₋₄, alquinilo-C₂₋₄,CN, -CH₂O-alquilo-C₁₋₆, -O-alquilo-C₁₋₆, -S(O)ₒ-alquilo-C₁₋₆, -NH-alquilo-C₁₋₆, -alquilo-C₁₋₆-NH₂, -alquilo-C₁₋₆-NH-alquilo-C₁₋₆, -alquilo-C₁₋₆-NHC(O)O-alquilo-C₁₋₆, -alquilo-C₁₋₆-NHC(O)NH-alquilo-C₁₋₆, -alquilo-C₁₋₆-NHC(O)alquilo-C₁₋₆, -C(O)NH₂, -CH=CHC(O)NH₂, -CH=CHC(O)NH-alquilo-C₁₋₆, -CH=CHC(O)N(alquilo-C₁₋₆)₂, -CH=CHC(O)NH-alquilo-C₁₋₆-O-alquilo-C₁₋₆, -CH=CHC(O)-heterociclilo, CH=C(CH₃)C(O)-heterociclilo, -CH=CHC(O)₂H, -CH=CHC(O)O-alquilo-C₁₋₆, -CH=CHCH₂OH, alquilo-C₁₋₆-C(O)NH-alquilo-C₁₋₆, alquilo-C₁₋₆-C(O)N(alquilo-C₁₋₆)₂, -C(O)alquilo-C₁₋₆, -C(O)alquenilo-C₁₋₆, -C(O)OH, -C(O)O-alquilo-C₁₋₆, -C(O)NH-alquilo-C₁₋₆, -C(O)N(alquilo-C₁₋₆)₂, -C(O)NH-cicloalquilo-C₃₋₆, -C(O)NHO-alquilo-C₁₋₆, -C(O)N(alquilo-C₁₋₆)O-alquilo-C₁₋₆, -C(O)-heterociclilo, -CH₂-heteroarilo, o heteroarilo, en donde los grupos heterociclilo de los grupos -CH=CHC(O)-heterociclilo, -CH=C(CH₃)C(O)-heterociclilo, y -C(O)-heterociclilo son anillos monocíclicos de 3, 4, 5, 6 ó 7 miembros completamente o parcialmente insaturados que incluye 1 heteroátomo seleccionado de N, O, o S si el anillo es un anillo de 3 miembros, que incluye 1 ó 2 heteroátomos independientemente seleccionados de N, O, o S si el anillo es un anillo de 4 ó 5 miembros, e incluye 1, 2, ó 3 heteroátomos independientemente seleccionados de N, O, o S si el anillo es un anillo de 6 ó 7 miembros, en donde el grupo heteroarilo de los grupos -CH₂-heteroarilo y heteroarilo es un anillo de 5 ó 6 que incluye 1, 2, 3 ó 4 heteroátomos seleccionados de N ,O, o S, en donde cada una de la porción alquilo-C₁₋₆, alquenilo-C₂₋₄, alquinilo-C₂₋₄ y cicloalquilo-C₃₋₆ de los grupos alquilo-C₁₋₆, alquenilo-C₂₋₄, alquinilo-C₂₋₄, -CH₂O-alquilo-C₁₋₆, -O-alquilo-C₁₋₆, -S(O)ₒ-alquilo-C₁₋₆, NH-alquilo-C₁₋₆, C₍O₎ₐₗqᵘⁱₗₒ₋C₁₋₆, -C(O)alquenilo-C₁₋₆, -C(O)NH-alquilo-C₁₋₆, -C(O)N(alquilo-C₁₋₆)₂, -C(O)NH-cicloalquilo-C₃₋₆, -CH=CHC(O)NH-alquilo-C₁₋₆ y alquilo-C₁₋₆-C(O)NH-alquilo-C₁₋₆, están opcionalmente sustituidas con 1 - 4 sustituyentes de F, CN, metilo, oxo u OH, y además en donde cada uno de los grupos heterociclilo de los grupos -CH=CHC(O)-heterociclilo, -CH=C(CH₃)C(O)-heterociclilo, y -C(O)heterociclilo está opcionalmente sustituido con 1 - 4 sustituyentes independientemente seleccionados de F, metilo, OH, o OCH₃ y además en donde cada uno de los grupos heteroarilo de los grupos -CH₂-heteroarilo y heteroarilo está opcionalmente sustituido con 1 - 3 sustituyentes independientemente seleccionados de halo, metilo, u OH; R² es H, F, Cl, alquilo-C₁₋₆, alquenilo-C₂₋₄, alquinilo-C₂₋₄, CN, -CH₂O-alquilo-C₁₋₆, -O-alquilo-C₁₋₆, -S(O)ₒ-alquilo-C₁₋₆, -NH-alquilo-C₁₋₆, -C(O)NH₂, -CH=CHC(O)NH-alquilo-C₁₋₆, -CH=CHC(O)₂H, CH=CHCH₂OH, alquilo-C₁₋₆-C(O)NH-alquilo-C₁₋₆, -C(O)alquilo-C₁₋₆ o -C(O)alquenilo-C₁₋₆, en donde cada una de la porción alquilo-C₁₋₆, alquenilo-C₂₋₄, alquinilo-C₂₋₄, y alquilo-C₁₋₆ de -CH₂O-alquilo-C₁₋₆, -O-alquilo-C₁₋₆, -S(O)ₒ-alquilo-C₁₋₆, -NH-alquilo-C₁₋₆, C₍O₎ₐₗqᵘⁱₗₒ₋C₁₋₆, -C(O)alquenilo-C₁₋₆, -CH=CHC(O)NH-alquilo-C₁₋₆ y alquilo-C₁₋₆-C(O)NH-alquilo-C₁₋₆, está opcionalmente sustituida con 1 - 4 sustituyentes de F, CN, oxo u OH; R³ es alquilo-C₁₋₄, CH₂O-alquilo-C₁₋₄, CH₂OH, haloalquilo-C₁₋₄ o ciclopropilo, en donde cada uno del alquilo-C₁₋₄, CH₂O-alquilo-C₁₋₄, haloalquilo-C₁₋₄ y ciclopropilo está opcionalmente sustituido con 1 - 4 átomos F; cada uno de R⁴, R⁵, R⁶ y R⁸, independientemente, es H halo, haloalquilo, haloalcoxilo, alquilo-C₁₋₄ CN, OH, O-alquilo-C₁₋₄, S(O)ₒ-alquilo-C₁₋₄, NH-alquilo-C₁₋₄, C₍O₎ₐₗqᵘⁱₗₒ₋C₁₋₄, C₍O₎O₋ₐₗqᵘⁱₗₒ₋C₁₋₄, o CH₂OH; R⁷ es -NH-R⁹ o-NH-C(=O)-R⁹; R⁹ es un anillo monocíclico de 3, 4, 5, 6 ó 7 miembros o bicíclico de 8, 9 ó 10 miembros completamente o parcialmente insaturado formado de átomos de carbono, el anillo incluye opcionalmente 1 - 4 heteroátomos si es monocíclico o 1 - 5 heteroátomos si es bicíclico, los heteroátomos seleccionados de O, N o S, en donde el anillo está opcionalmente sustituido, independientemente, con 1 - 5 sustituyentes de R¹⁰; cada R¹⁰, independientemente, es H, halo, haloalquilo, CN, OH, NO₂, NH₂, SF₅, acetilo, -C(O)NH-alquilo-C₁₋₆, -OCH₂C(O)NH-alquilo-C₁₋₆, -OCH₂C(O)N(alquilo-C₁₋₆)₂, -OCH₂CH₂-pirolidinonilo, oxo, ciclopropilmetoxi, 2-propiniloxi, 2-butiniloxi, 3-butiniloxi, 3-pentiniloxi, 2-pentiloxi, alquilo-C₁₋₆, alquenilo-C₂₋₆, alquinilo-C₂₋₆, cicloalquilo-C₃₋₆, alquilamino-C₁₋₆, dialquilamino-C₁₋₆, alcoxilo-C₁₋₆, -O-alquenilo-C₂₋₆, tioalcoxilo-C₁₋₆, -OCH₂-cicloalquilo-C₃₋₆, morfolinilo, pirazolilo, isoxazolilo, dihidropiranilo, pirrolilo, pirrolidinilo, tetrahidropirrolilo, piperazinilo, oxetan-3-ilo, imidazo-piridinilo, dioxolilo, -O-heterociclilo, o -OCH₂-heteroarilo, en donde el heterociclilo del grupo -O-heterociclilo es un anillo saturado monocíclico de 3, 4, 5, 6 ó 7 miembros que incluye 1 heteroátomo seleccionados de N, O, o S si el anillo heterociclilo es un anillo de 3 miembros, que incluye 1 ó 2 heteroátomos independientemente seleccionados de N, O, o S si el anillo heterociclilo es un anillo de 4 ó 5 miembros, e incluye 1, 2, ó 3 heteroátomos independientemente seleccionados de N, O, o S si el anillo heterociclilo es un anillo de 6 ó 7 miembros en donde el grupo heteroarilo del grupo -OCH₂-heteroarilo es un anillo de 5 ó 6 miembros que incluye 1, 2, 3, ó 4 heteroátomos seleccionados de N, O, o S, y además en donde cada uno del ciclopropilmetoxi, 2-propiniloxi, 2-butiniloxi, 2-pentiloxi, alquilo-C₁₋₆, alquenilo-C₂₋₆, alquinilo-C₂₋₆, cicloalquilo-C₃₋₆, alquilamino-C₁₋₆, dialquilamino-C₁₋₆, alcoxilo-C₁₋₆, tioalcoxilo-C₁₋₆, -OCH₂-cicloalquilo-C₃₋₆, morfolinilo, pirazolilo, isoxazolilo, dihidropiranilo, pirrolidinilo, oxetan-3-ilo, dioxolilo o -OCH₂-heteroarilo está opcionalmente sustituido independientemente con 1 - 5 sustituyentes de F, Cl, Br, CN, NO₂, NH₂, OH, oxo, CF₃, CHF₂, CH₂F, metilo, metoxi, etilo, etoxi, CH₂CF₃, CH₂CHF₂, propilo, propoxi, isopropilo, isopropoxi, ciclopropilo, butilo, butoxilo, ciclobutilo, isobutoxi, tert-butoxi, isobutilo, sec-butilo, tert-butilo, ciclopentilo, ciclohexilo, fenilo, alquilamino-C₁₋₃, dialquilamino-C₁₋₃, tioalcoxilo-C₁₋₃, oxazolilo, isoxazolilo, tiazolilo, isotiazolilo, tiadiazolilo, tienilo, furilo, pirrolilo, tetrahidropiranilo, tetrahidropirrolilo, oxetan-2-ilo, u oxetan-3-ilo; y el subíndice o se selecciona de 0, 1, ó 2.",AMGEN INC,QIUFEN XUE;;RYAN D WHITE;;MARKIAN M STEC;;AARON C SIEGMUND;;ROBERT M RZASA;;SHANNON RUMFELT;;WENYUAN QIAN;;ALEXANDER J PICKRELL;;LIPING H PETTUS;;MARK H NORMAN;;NOBUKO NISHIMURA;;THOMAS T NGUYEN;;ANA ELENA MINATTI;;JAMES MANNING;;VU VAN MA;;JONATHAN D LOW;;QINGYIAN LIU;;LONGBIN LIU;;PAUL E HARRINGTON;;ANGEL GUZMAN-PEREZ;;MICHAEL J FROHN;;YUAN CHENG;;JIAN J CHEN;;JAMES A BROWN;;MATTHEW P BOURBEAU;;ALBERT AMEGADZIE;;JENNIFER R ALLEN,,https://lens.org/153-340-122-162-286,Patent Application,no,0,0,19,19,0,C07D417/04;;C07D417/14;;C07D471/04;;C07D279/08;;C07D417/12;;C07D513/10;;A61P25/00;;A61P25/28;;A61P43/00;;A61P7/04;;A61P9/00;;C07D417/04;;C07D417/14;;C07D471/04;;C07D279/08;;C07D417/12;;C07D513/10,C07D417/06;;A61K31/497;;A61K31/4985;;A61K31/541;;A61K31/547;;A61P25/00;;A61P25/28;;C07D413/12;;C07D413/14;;C07D417/12;;C07D417/14;;C07D471/04;;C07D487/04,,0,0,,,,PENDING
512,US,A1,US 2017/0267673 A1,157-026-655-978-034,2017-09-21,2017,US 201615354877 A,2016-11-17,US 201615354877 A;;US 201514819256 A;;US 201462035269 P,2014-08-08,CYCLOPROPYL FUSED THIAZIN-2-AMINE COMPOUNDS AS BETA-SECRETASE INHIBITORS AND METHODS OF USE,"The present invention provides a new class of compounds useful for the modulation of beta-secretase enzyme (BACE) activity. The compounds have a general Formula I: wherein variables A 4 , A 5 , A 6 , A 8 , and each of R a , R b , R 1 , R 2 , R 3 and R 7 of Formula I, independently, are defined herein. The invention also provides pharmaceutical compositions comprising the compounds, and uses of the compounds and compositions for treatment of disorders and/or conditions related to A-beta plaque formation and deposition, resulting from the biological activity of BACE. Such BACE mediated disorders include, for example, Alzheimer's Disease, cognitive deficits, cognitive impairments, schizophrenia and other central nervous system conditions. The invention further provides compounds of Formulas II and III, and sub-formula embodiments thereof, intermediates and methods for preparing compounds of the invention.",AMGEN INC,ALLEN JENNIFER R;;AMEGADZIE ALBERT;;BOURBEAU MATTHEW P;;BROWN JAMES A;;CHEN JIAN J;;CHENG YUAN;;FROHN MICHAEL J;;GUZMAN-PEREZ ANGEL;;HARRINGTON PAUL E;;LIU LONGBIN;;LIU QINGYIAN;;LOW JONATHAN D;;MA VU VAN;;MANNING JAMES R;;MINATTI ANA ELENA;;NGUYEN THOMAS T;;NISHIMURA NOBUKO;;NORMAN MARK H;;PETTUS LIPING H;;PICKRELL ALEXANDER J;;QIAN WENYUAN;;RUMFELT SHANNON;;RZASA ROBERT M;;SIEGMUND AARON C;;STEC MARKIAN M;;WHITE RYAN D;;XUE QIUFEN,,https://lens.org/157-026-655-978-034,Patent Application,yes,0,1,19,19,0,C07D417/04;;C07D417/14;;C07D471/04;;C07D279/08;;C07D417/12;;C07D513/10;;A61P25/00;;A61P25/28;;A61P43/00;;A61P7/04;;A61P9/00;;C07D417/04;;C07D417/14;;C07D471/04;;C07D279/08;;C07D417/12;;C07D513/10,C07D417/12;;C07D279/08;;C07D417/04;;C07D417/14;;C07D471/04;;C07D513/10,,0,0,,,,DISCONTINUED
513,CA,C,CA 2957544 C,173-587-980-927-02X,2023-01-24,2023,CA 2957544 A,2015-08-05,US 201462035269 P;;US 2015/0043868 W,2014-08-08,CYCLOPROPYL FUSED THIAZIN-2-AMINE COMPOUNDS AS BETA-SECRETASE INHIBITORS AND METHODS OF USE,"The present invention provides a new class of compounds useful for the modulation of beta-secretase enzyme (BACE) activity. The compounds have a general Formula (I): wherein variables A4, A5, A6, A8, and each of Ra, Rb, R1, R2, R3 and R7 of Formula (I), independently, are defined herein. The invention also provides pharmaceutical compositions comprising the compounds, and uses of the compounds and compositions for treatment of disorders and/or conditions related to A-beta plaque formation and 15 deposition, resulting from the biological activity of BACE. Such BACE mediated disorders include, for example, Alzheimers Disease, cognitive deficits, cognitive impairments, schizophrenia and other central nervous system conditions. The invention further provides compounds of Formulas (II) and (III), and sub-formula embodiments thereof, intermediates and methods for preparing compounds of the invention.",AMGEN INC,ALLEN JENNIFER R;;AMEGADZIE ALBERT;;BOURBEAU MATTHEW P;;BROWN JAMES A;;CHEN JIAN J;;CHENG YUAN;;FROHN MICHAEL J;;GUZMAN-PEREZ ANGEL;;HARRINGTON PAUL E;;LIU LONGBIN;;LIU QINGYIAN;;LOW JONATHAN D;;MA VU VAN;;MANNING JAMES R;;MINATTI ANA ELENA;;NGUYEN THOMAS T;;NISHIMURA NOBUKO;;NORMAN MARK H;;PETTUS LIPING H;;PICKRELL ALEXANDER J;;QIAN WENYUAN;;RUMFELT SHANNON;;RZASA ROBERT M;;SIEGMUND AARON C;;STEC MARKIAN M;;WHITE RYAN D;;XUE QIUFEN,,https://lens.org/173-587-980-927-02X,Granted Patent,no,0,0,19,19,0,C07D417/04;;C07D417/14;;C07D471/04;;C07D279/08;;C07D417/12;;C07D513/10;;A61P25/00;;A61P25/28;;A61P43/00;;A61P7/04;;A61P9/00;;C07D417/04;;C07D417/14;;C07D471/04;;C07D279/08;;C07D417/12;;C07D513/10,C07D471/04;;A61K31/5415;;A61P25/28;;C07D417/14,,0,0,,,,PENDING
514,US,A1,US 2016/0046618 A1,144-094-552-370-547,2016-02-18,2016,US 201514819256 A,2015-08-05,US 201514819256 A;;US 201462035269 P,2014-08-08,Cyclopropyl Fused Thiazin-2-Amine Compounds as Beta-Secretase Inhibitors and Methods of Use,"The present invention provides a new class of compounds useful for the modulation of beta-secretase enzyme (BACE) activity. The compounds have a general Formula I: wherein variables A 4 , A 5 , A 6 , A 8 , and each of R a , R b , R 1 , R 2 , R 3 and R 7 of Formula I, independently, are defined herein. The invention also provides pharmaceutical compositions comprising the compounds, and uses of the compounds and compositions for treatment of disorders and/or conditions related to A-beta plaque formation and deposition, resulting from the biological activity of BACE. Such BACE mediated disorders include, for example, Alzheimer's Disease, cognitive deficits, cognitive impairments, schizophrenia and other central nervous system conditions. The invention further provides compounds of Formulas II and III, and sub-formula embodiments thereof, intermediates and methods for preparing compounds of the invention.",AMGEN INC,ALLEN JENNIFER R;;AMEGADZIE ALBERT;;BOURBEAU MATTHEW P;;BROWN JAMES A;;CHEN JIAN J;;CHENG YUAN;;FROHN MICHAEL J;;GUZMAN-PEREZ ANGEL;;HARRINGTON PAUL E;;LIU LONGBIN;;LIU QINGYIAN;;LOW JONATHAN D;;MA VU VAN;;MANNING JAMES;;MINATTI ANA ELENA;;NGUYEN THOMAS T;;NISHIMURA NOBUKO;;NORMAN MARK H;;PETTUS LIPING H;;PICKRELL ALEXANDER J;;QIAN WENYUAN;;RUMFELT SHANNON;;RZASA ROBERT M;;SIEGMUND AARON C;;STEC MARKIAN M;;WHITE RYAN D;;XUE QIUFEN,AMGEN INC (2015-09-22),https://lens.org/144-094-552-370-547,Patent Application,yes,0,9,19,19,0,C07D417/04;;C07D417/14;;C07D471/04;;C07D279/08;;C07D417/12;;C07D513/10;;A61P25/00;;A61P25/28;;A61P43/00;;A61P7/04;;A61P9/00;;C07D417/04;;C07D417/14;;C07D471/04;;C07D279/08;;C07D417/12;;C07D513/10,C07D417/12;;C07D417/14;;C07D471/04;;C07D513/10,,0,0,,,,ACTIVE
515,UY,A,UY 36263 A,070-587-083-874-701,2016-02-29,2016,UY 36263 A,2015-08-07,US 201462035269 P,2014-08-08,COMPUESTOS DE TIAZIN-2-AMINA FUSIONADOS CON CICLOPROPILO COMO INHIBIDORES DE BETA-SECRETASA Y MÉTODOS DE USO,"La presente invención proporciona una clase nueva de compuestos útiles para la modulación de la actividad de la enzima beta-secretase (BACE). Los compuestos tienen una Fórmula general I: en donde las variables A4, A5, A6, A8, y cada uno de Ra, Rb, R1, R2, R3 y R7 de la Fórmula I, independientemente, se definen en la presente. La invención también proporciona composiciones farmacéuticas que comprenden los compuestos, y usos de los compuestos y composiciones para el tratamiento de trastornos y/o afecciones relacionadas con la formación y deposición de placa A-beta, que resulta de la actividad biológica de BACE.",AMGEN INC,ALLEN JENNIFER R;;ALBERT AMEGADZIE;;BOURBEAU MATTHEW P;;BROWN JAMES A;;CHEN JIAN J;;YUAN CHENG;;FROHN MICHAEL J;;ANGEL GUZMAN-PEREZ;;HARRINGTON PAUL E;;LONGBIN LIU;;QINGYIAN LIU;;LOW JONATHAN D;;VAN MA VU;;JAMES MANNING;;ELENA MINATTI ANA;;NGUYEN THOMAS T;;NOBUKO NISHIMURA;;NORMAN MARK H;;PETTUS LIPING H;;PICKRELL ALEXANDER J;;WENYUAN QIAN;;SHANNON RUMFELT;;RZASA ROBERT M;;SIEGMUND AARON C;;STEC MARKIAN M;;WHITE RYAN D;;QIUFEN XUE,,https://lens.org/070-587-083-874-701,Patent Application,no,0,0,19,19,0,C07D417/04;;C07D417/14;;C07D471/04;;C07D279/08;;C07D417/12;;C07D513/10;;A61P25/00;;A61P25/28;;A61P43/00;;A61P7/04;;A61P9/00;;C07D417/04;;C07D417/14;;C07D471/04;;C07D279/08;;C07D417/12;;C07D513/10,A61P25/00;;A61K31/5415;;C07D213/60;;C07D213/78;;C07D213/81;;C07D213/84;;C07D241/24;;C07D249/04;;C07D263/32;;C07D271/02;;C07D279/08;;C07D417/04;;C07D417/12;;C07D417/14;;C07D471/04,,0,0,,,,DISCONTINUED
516,US,B2,US 9550762 B2,170-373-257-828-011,2017-01-24,2017,US 201514819256 A,2015-08-05,US 201514819256 A;;US 201462035269 P,2014-08-08,Cyclopropyl fused thiazin-2-amine compounds as beta-secretase inhibitors and methods of use,"The present invention provides a new class of compounds useful for the modulation of beta-secretase enzyme (BACE) activity. The compounds have a general Formula I: wherein variables A 4 , A 5 , A 6 , A 8 , and each of R a , R b , R 1 , R 2 , R 3 and R 7 of Formula I, independently, are defined herein. The invention also provides pharmaceutical compositions comprising the compounds, and uses of the compounds and compositions for treatment of disorders and/or conditions related to A-beta plaque formation and deposition, resulting from the biological activity of BACE. Such BACE mediated disorders include, for example, Alzheimer's Disease, cognitive deficits, cognitive impairments, schizophrenia and other central nervous system conditions. The invention further provides compounds of Formulas II and III, and sub-formula embodiments thereof, intermediates and methods for preparing compounds of the invention.",AMGEN INC;;AMGEN INC,ALLEN JENNIFER R;;AMEGADZIE ALBERT;;BOURBEAU MATTHEW P;;BROWN JAMES A;;CHEN JIAN J;;CHENG YUAN;;FROHN MICHAEL J;;GUZMAN-PEREZ ANGEL;;HARRINGTON PAUL E;;LIU LONGBIN;;LIU QINGYIAN;;LOW JONATHAN D;;MA VU VAN;;MANNING JAMES;;MINATTI ANA ELENA;;NGUYEN THOMAS T;;NISHIMURA NOBUKO;;NORMAN MARK H;;PETTUS LIPING H;;PICKRELL ALEXANDER J;;QIAN WENYUAN;;RUMFELT SHANNON;;RZASA ROBERT M;;SIEGMUND AARON C;;STEC MARKIAN M;;WHITE RYAN D;;XUE QIUFEN,AMGEN INC (2015-09-22),https://lens.org/170-373-257-828-011,Granted Patent,yes,99,1,19,19,0,C07D417/04;;C07D417/14;;C07D471/04;;C07D279/08;;C07D417/12;;C07D513/10;;A61P25/00;;A61P25/28;;A61P43/00;;A61P7/04;;A61P9/00;;C07D417/04;;C07D417/14;;C07D471/04;;C07D279/08;;C07D417/12;;C07D513/10,C07D417/12;;C07D279/08;;C07D417/04;;C07D417/14;;C07D471/04;;C07D513/10,,45,33,054-712-216-545-603;;003-828-313-704-930;;082-722-733-297-69X;;106-260-003-796-433;;032-340-926-422-023;;015-982-248-847-361;;064-327-872-895-873;;044-407-914-794-953;;117-896-947-554-821;;035-920-450-620-162;;065-576-541-132-98X;;090-808-357-264-137;;059-006-551-099-763;;010-118-470-073-21X;;023-381-578-379-560;;051-801-341-692-560;;118-265-836-977-00X;;077-351-302-208-527;;010-016-516-394-602;;013-369-899-259-645;;061-138-525-636-453;;064-204-983-655-362;;108-349-484-349-717;;015-595-224-888-222;;127-854-145-178-323;;008-314-583-015-610;;039-148-595-027-639;;048-784-633-528-797;;013-801-653-376-729;;000-871-005-085-466;;003-778-511-848-73X;;005-277-927-658-347;;027-599-889-247-132,10.1016/s1474-4422(13)70276-x;;pmc4086426;;24556009;;1605946;;10.1097/00002093-199205000-00003;;10.1016/0896-6273(91)90052-2;;1673054;;10.1038/359325a0;;1406936;;15102495;;10.1016/j.tips.2003.12.004;;pmc2772133;;18568035;;10.1038/nm1782;;10.1038/990114;;10591214;;10.1186/1750-1326-2-22;;18005427;;pmc2211305;;11224535;;10.1038/85059;;10.1517/14656560903044982;;19527190;;18090456;;10.1097/wnf.0b013e31805b7660;;16505324;;10.1212/01.wnl.0000198762.41312.e1;;17495518;;10.4161/auto.4341;;21747967;;10.1371/journal.pone.0021908;;pmc3128622;;21852788;;10.1038/nrd3505;;10.1016/s1044-7431(03)00035-6;;12676526;;10.1021/jm400225m;;23590342;;10.1016/s0014-5793(97)00886-7;;9280316;;10348917;;10.1093/oxfordjournals.jbchem.a022396;;8810256;;10.1126/science.274.5284.99;;11145990;;10.1046/j.1471-4159.2001.00012.x;;15743924;;10.1124/jpet.104.081174;;10.1001/archneurol.2010.179;;20697045;;pmc2963067;;10.1016/j.cell.2005.02.008;;15734686;;10.1016/j.neuron.2004.09.010;;15450169;;10.1038/nn.2583;;pmc3072750;;20581818;;pmc2601528;;18359102;;10.1016/j.bbr.2008.02.016;;7845465;;10.1038/373523a0;;15052274;;10.1038/sj.mp.4001508;;pmc15924;;10.1073/pnas.96.6.3228;;10077666;;pmc3050043;;21040845;;10.1016/j.neuron.2010.10.020;;10.1523/jneurosci.3657-09.2009;;19828790;;pmc2879048;;pmc6633289;;10.1523/jneurosci.3647-11.2011;;22090477,"U.S. Appl. No. 14/932,787, filed Nov. 4, 2012, Amgen Inc.;;Vassar, R. and Yan, R., ""Targeting the beta secretase BACE1 for Alzheimer's disease therapy,"" Lancet Neurology 13:319-329 (2014).;;Joachim, C. L. and Selkoe, D. J., ""The Seminal Role of beta-Amyloid in the Pathogenesis of Alzheimer Disease,"" Alzheimer Disease and Associated Disorders 6(1):7-34 (1992).;;Selkoe, D. J., ""The Molecular Pathology of Alzheimer's Disease,"" Neuron 6:487-498 (1991).;;Seubert, P. et al., ""Isolation and quantification of soluble Alzheimer's beta-peptide from biological fluids,"" Nature 359:325-327 (1992).;;Citron, M., ""beta-Secretase inhibition for the treatment of Alzheimer's disease-promise and challenge,"" TRENDS in Pharmacological Sciences 25(2):92-97 (2004).;;Shankar, G. M. et al., ""Amyloid-beta protein dimers isolated directly from Alzheimer's brains impair synaptic plasticity and memory,"" Nature Medicine 14(8):837-842 (2008).;;Sinha, S. et al., ""Purification and cloning of amyloid precursor protein beta-secretase from human brain,"" Nature 402:537-540 (1999).;;Sabbagh, M. N. et al., ""beta-Amyloid and Treatment Opportunities for Alzheimer's Disease,"" Alzheimer's Disease Review 3:1-19 (1997).;;Cole, S.L. and Vassar, R., ""The Alzheimer's disease beta-secretase enzyme, BACE1,"" Molecular Neurodegeneration 2(22):1-25 (2007).;;Luo, Y et al., ""Mice deficient in BACE1, the Alzheimer's beta-secretase, have normal phenotype and abolished beta-amyloid generation,"" Nature Neuroscience 4:231-232 (2001).;;Henley, D. B. et al., ""Development of semagacestat (LY450139), a functional gamma-secretase inhibitor, for the treatment of Alzheimer's disease,"" Expert Opin. Pharmacother. 10(10):1657-1664 (2009).;;Siemers, E. R. et al., ""Safety, Tolerability, and Effects on Plasma and Cerebrospinal Fluid Amyloid-beta After Inhibition of gamma-Secretase,"" Clin. Neuropharmacol. 30(6):317-325 (2007).;;Siemers, E. R. et al., ""Effects of a gamma-secretase inhibitor in a randomized study of patients with Alzheimer's disease,"" Neurology 66:602-604 (2006).;;Shacka, J. J. and Roth, K. A., ""Cathepsin D Deficiency and NCL/Batten Disease: There's More to Death than Apoptosis,"" Autophagy, 3(5):474-476 (2007).;;Follo, C. et al., ""Knock-Down of Cathepsin D Affects the Retinal Pigment Epithelium, Impairs Swim-Bladder Ontogenesis and Causes Premature Death in Zebrafish,"" PLoS One 6(7):e21908, pp. 1-13 (2011).;;Karran, E. et al. ""The amyloid cascade hypothesis for Alzheimer's disease: an appraisal for the development of therapeutics,"" Nature Reviews Drug Discovery 10:698-712 (2011).;;Office Action mailed May 22, 2015 for U.S. Appl. No. 14/691,715, filed Apr. 21, 2015, pp. 1-5.;;International Preliminary Report on Patentability and Written Opinion for International Patent Application No. PCT/US2014/021412, issued Sep. 8, 2015, pp. 1-7.;;International Search Report for International Patent Application No. PCT/US2014/021412, mailed May 13, 2014, pp. 1-3.;;Koike, M. et al., ""Involvement of two different cell death pathways in retinal atrophy of cathepsin D-deficient mice,"" Molecular and Cellular Neuroscience 22:146-161 (2003).;;Alzforum Networking for a Cure, ""Barcelona: Out of Left Field-Hit to the Eye Kills BACE Inhibitor,"" pp. 1-7 (Mar. 31, 2011); access online: www.alzforum.org/news/conference-coverage/barcelona-out-left-field-hit-eye-kills-bace-inhibitor (last accessed Dec. 16, 2015).;;Hilpert, H. et al., ""beta-Secretase (BACE1) Inhibitors with High in Vivo Efficacy Suitable for Clinical Evaluation in Alzheimer's Disease,"" J. Med. Chem. 56(10):3980-3995 (2013).;;Gulnik, S. V. et al. ""Design of sensitive fluorogenic substrates for human cathespin D,"" FEBS Letters 413:379-384 (1997).;;Yasuda, Y. et al., ""Characterization of New Fluorogenic Substrates for the Rapid and Sensitive Assay of Cathepsin E and Cathepsin D,"" J. Biochem. 125(6):1137-1143 (1999).;;Hsiao, K. et al., ""Correlative Memory Deficits, Abeta Elevation, and Amyloid Plaques in Transgenic Mice,"" Science 274:99-102 (1996).;;Dovey, H. F. et al., ""Functional gamma-secretasae inhibitors reduce beta-amyloid peptide levels in brain,"" Journal of Neurochemistry 76:173-181 (2001).;;Best, J. D. et al., ""Quantitative Measurement of Changes in Amyloid -beta(40) in the Rat Brain and Cerebrospinal Fluid Following Treatment with the gamma-Secretase Inhibitor LY-411575 [N2-[(2S)-2-(3,5-Difluoropheny1)-2-hydroxyethanoyl]-N1-[(7S)-5-methyl-6-oxo-6,7-dihydro-5H-dibenzo[b,d]azepin-7-yl]L-alaninamide],"" Journal of Pharmacology and Experimental Therapeutics 313(2):902-908 (2005).;;De Meyer, G. et al., ""Diagnosis-Independent Alzheimer Disease Biomarker Signature in Cognitively Normal Elderly People,"" Arch. Neurol. 67(8):949-956 (2010).;;Tanzi, R. E. and Bertram, L., ""Twenty Years of the Alzheimer's Disease Amyloid Hypothesis: A Genetic Perspective,"" Cell 120(4): 545-555 (2005).;;Walsh, D. M. and Selkoe, D. J., ""Deciphering the Molecular Basis of Memory Failure in Alzheimer's Disease,"" Neuron 44(1):181-193 (2004).;;Palop, J. J. and Mucke, L., ""Amyloid-beta-induced neuronal in Alzheimer's disease: from synapses toward neural networks,"" Nature Neuroscience 13(7):812-818 (2010).;;Selkoe, D. J., ""Soluble oligomers of the amyloid beta-protein impair synaptic plasticity and behavior,"" Behavioural Brain Research 192:106-113 (2008).;;Games, D. et al., ""Alzheimer-type neuropathology in transgenic mice overexpressing V717F beta-amyloid precursor protein,"" Nature 373:523-527 (1995).;;Götz, J. et al., ""Transgenic animal models of Alzheimer's disease and related disorders: histopahtology, behavior and therapy,"" Molecular Psychiatry 9:664-683 (2004).;;Hsia, A. Y. et al., ""Plaque-independent disruption of neural circuits in Alzheimer's disease mouse models,"" Proc. Natl. Acad. Sci. USA 96:3228-3233 (1999).;;Harris, J. A. et al, ""Transsynaptic Progression of Amyloid-beta-Induced Neuronal Dysfunction within the Entorhinal-Hippocampal Network,"" Neuron 68:428-441 (2010).;;Vassar, R. et al, ""The beta-Secretase Enzyme BACE in Health and Alzheimer's Disease: Regulation, Cell Biology, Function, and Therapeutic Potential,"" Journal of Neuroscience 29(41):12787-12794 (2009).;;May, P. C. et al., ""Robust Central Reduction of Amyloid-beta in Humans with an Orally Available, Non-Peptidic beta-Secretase Inhibitor,"" Journal of Neuroscience 31(46):16507-16516 (2011).;;International Preliminary Report on Patentability and Written Opinion for International Patent Application No. PCT/US2014/019100, issued Sep. 1, 2015, pp. 1-8.;;International Search Report for International Patent Application No. PCT/US2014/019100, mailed Aug. 5, 2014, pp. 1-6.;;""1,9-Dioxa-3-azaspiro[5.5]undec-2-en-2-amine, 4-[2-fluoro-5-[(3-methoxy-2-pyridinyl)amino]phenyl]-4-methyl-, (4S)"" CAS No. 1457976-71-4, Chemical Abstracts Service, Columbus, Ohio, USA, p. 1.;;Notice of Allowance mailed Oct. 15, 2015 for U.S. Appl. No. 14/192,710, filed Feb. 27, 2014, pp. 1-7.;;Written Opinion of the International Searching Authority mailed Nov. 13, 2015 for International Patent Application No. PCT/US2015/043868, pp. 1-6.;;International Search Report mailed Nov. 13, 2015 for International Patent Application No. PCT/US2015/043868, pp. 1-4.",ACTIVE
